Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
prerank,GO_Biological_Process_2021__GTP metabolic process (GO:0046039),0.9913847052871403,2.271957296791969,0.09243697478991597,0.1290395695466037,0.128,1/15,0.86%,RHOQ
prerank,GO_Biological_Process_2021__triglyceride catabolic process (GO:0019433),-0.9908444008018662,-2.2350942318851583,0.15267175572519084,0.22421033065644214,0.2,1/16,0.92%,LIPG
prerank,TRRUST_Transcription_Factors_2019__PML human,-0.9869619396324533,-2.136978563663798,0.23484848484848486,0.8545374866528549,0.812,2/18,1.31%,HCK;PML
prerank,GO_Biological_Process_2021__nitric oxide biosynthetic process (GO:0006809),-0.9873837658678103,-2.1364467636894866,0.1746031746031746,0.5767422970973889,0.812,1/15,1.27%,CYP1B1
prerank,GO_Biological_Process_2021__interleukin-27-mediated signaling pathway (GO:0070106),-0.991424580701983,-2.13257350250451,0.1440677966101695,0.46957257929934104,0.836,2/15,0.87%,OAS1;OASL
prerank,Elsevier_Pathway_Collection__VEGFR -> NFATC Signaling,-0.9969575748436275,-2.123328150456273,0.05128205128205128,0.44503635443505113,0.876,1/21,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__LH and FSH Signaling and Steroidogenesis,-0.9907276824409393,-2.120555215083976,0.14678899082568808,0.345682773950094,0.9,1/18,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__LH and FSH Signaling Impairment in Primary Ovarian Insufficiency,-0.9907276824409393,-2.120555215083976,0.14678899082568808,0.345682773950094,0.9,1/18,0.93%,CCND2
prerank,GO_Biological_Process_2021__nitric oxide metabolic process (GO:0046209),-0.9873825023037367,-2.118477734985067,0.18181818181818182,0.3178075677465135,0.908,1/16,1.27%,CYP1B1
prerank,GO_Biological_Process_2021__microglial cell activation (GO:0001774),-0.9965714167041818,-2.114252274538068,0.05454545454545454,0.31633868455300956,0.928,1/21,0.35%,APP
prerank,Elsevier_Pathway_Collection__NO Effect on Vasodilation and Vasoconstriction,-0.9903834530086932,-2.0877305157032384,0.17391304347826086,0.49114753564552693,0.992,1/16,0.97%,HRH2
prerank,Elsevier_Pathway_Collection__Proteins Involved in HPV Infection,-0.9869643839623343,-2.0808889560825623,0.21774193548387097,0.5034156480776719,0.996,2/15,1.31%,RB1;PML
prerank,Elsevier_Pathway_Collection__NO Synthesis in Early Vasospasm,-0.990424940413897,-2.0792035662044857,0.16535433070866143,0.482968794024097,0.996,2/15,0.97%,PDE5A;HRH2
prerank,GO_Biological_Process_2021__regulation of extracellular matrix organization (GO:1903053),-0.994846416723934,-2.0587575790721617,0.08870967741935484,0.6732818202150636,1.0,2/15,0.53%,SLC2A10;RB1
prerank,"Elsevier_Pathway_Collection__Hyperparathyroidism, Neonatal Severe",-0.9933438742571163,-2.0584209575053674,0.15625,0.6291184749686152,1.0,1/16,0.67%,PTK2B
prerank,GO_Biological_Process_2021__regulation of ERBB signaling pathway (GO:1901184),-0.9866115823840595,-2.055969995098191,0.22137404580152673,0.6111494170220252,1.0,1/16,1.34%,PTPN18
prerank,Reactome_2022__Regulation Of Signaling By CBL R-HSA-912631,-0.989193700661688,-2.0538081527199736,0.1746031746031746,0.5967484861929125,1.0,3/18,1.10%,PIK3CB;HCK;VAV1
prerank,WikiPathway_2021_Human__Fatty acid transporters WP5061,0.9882306617004532,2.0508044303272213,0.168,0.5560087334875718,0.668,1/15,1.18%,ACSL5
prerank,GO_Biological_Process_2021__organic cation transport (GO:0015695),-0.9994578811428281,-2.0502231226857117,0.017094017094017096,0.5927513958087071,1.0,1/20,0.06%,SLC22A1
prerank,GO_Biological_Process_2021__regulation of smooth muscle contraction (GO:0006940),-0.997958537500078,-2.04792374055202,0.01680672268907563,0.5805026380727589,1.0,1/17,0.21%,ZDHHC21
prerank,GO_Biological_Process_2021__neuron projection organization (GO:0106027),-0.9965747295240377,-2.046739738422804,0.06363636363636363,0.5588559383790166,1.0,1/15,0.35%,APP
prerank,GO_Biological_Process_2021__negative regulation of interleukin-10 production (GO:0032693),-0.9898438355068846,-2.0442830256603757,0.17073170731707318,0.5546032896048974,1.0,1/17,1.02%,CD274
prerank,GO_Biological_Process_2021__necroptotic process (GO:0070266),-0.9896914548503374,-2.035023823042105,0.16030534351145037,0.6097795785238547,1.0,1/16,1.04%,TICAM2
prerank,Reactome_2022__G Beta:Gamma Signaling Thru PLC Beta R-HSA-418217,0.9888818476925421,2.034253354892842,0.2231404958677686,0.6249563466276689,0.836,1/18,1.11%,GNB5
prerank,WikiPathway_2021_Human__Cell Differentiation - Index expanded WP2023,-0.9901530685221576,-2.0328806698339683,0.176,0.6043679839221249,1.0,1/15,0.99%,KLF4
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts Via 27-Hydroxycholesterol R-HSA-193807,-0.9960363832490926,-2.032839886233707,0.0782608695652174,0.5782750447775669,1.0,1/15,0.40%,NCOA1
prerank,Reactome_2022__Phase 4 - Resting Membrane Potential R-HSA-5576886,-0.9892670912896612,-2.02916923645439,0.2125984251968504,0.5971891511509637,1.0,1/16,1.08%,KCNK6
prerank,Elsevier_Pathway_Collection__ADRA1 -> Ion Channels,-0.9918830733366776,-2.0263773164426016,0.14414414414414414,0.6079907306027142,1.0,1/16,0.82%,KCNE1
prerank,GO_Biological_Process_2021__anterior/posterior axis specification (GO:0009948),0.9911160521712747,2.0263704222650927,0.14754098360655737,0.5484181705730657,0.872,1/15,0.89%,TBX3
prerank,Elsevier_Pathway_Collection__Familial Partial Lipodystrophy Type 2 Progression (Hypothesis),0.9921935695729428,2.025149014637926,0.11475409836065574,0.4501203808302118,0.872,2/15,0.79%,ACACA;PPARA
prerank,GO_Biological_Process_2021__positive regulation of positive chemotaxis (GO:0050927),-0.9917297826327299,-2.0231877811744163,0.16666666666666666,0.620076611126053,1.0,1/17,0.83%,NTF3
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation without Degranulation through IL1R1 and TLR Signaling,-0.9969591509157072,-2.0201375537366526,0.061068702290076333,0.630170475122439,1.0,1/17,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of transcription regulatory region DNA binding (GO:2000679),-0.9948038401656613,-2.0201161073727185,0.09923664122137404,0.607664386725209,1.0,1/19,0.53%,RB1
prerank,GO_Biological_Process_2021__regulation of cellular response to transforming growth factor beta stimulus (GO:1903844),-0.9886097008524464,-2.0138761851775495,0.21904761904761905,0.6590645893987024,1.0,1/21,1.15%,LTBP4
prerank,Reactome_2022__G Beta:Gamma Signaling Thru CDC42 R-HSA-8964616,0.9888815599389451,2.0134209631100224,0.20833333333333334,0.47820546361388433,0.928,1/18,1.11%,GNB5
prerank,Elsevier_Pathway_Collection__MacrophageR -> CEBPB -> NF-kB Signaling,-0.992039772560218,-2.013402311709712,0.14173228346456693,0.6400570382701828,1.0,2/15,0.81%,PTK2B;HCK
prerank,GO_Biological_Process_2021__glycerolipid catabolic process (GO:0046503),0.9963058144476425,2.010828998484564,0.056910569105691054,0.43483081838813525,0.932,1/18,0.37%,PNPLA6
prerank,GO_Biological_Process_2021__heart trabecula morphogenesis (GO:0061384),-0.9878077139625481,-2.0106654072007553,0.26605504587155965,0.6428818428012774,1.0,2/19,1.23%,TEK;S1PR1
prerank,TRRUST_Transcription_Factors_2019__NFE2L2 human,-0.9995748374853272,-2.01018983968459,0.008547008547008548,0.6279475652229364,1.0,1/16,0.05%,GSTA1
prerank,GO_Biological_Process_2021__regulation of nervous system process (GO:0031644),-0.9965749942508556,-2.0074277659778015,0.03968253968253968,0.6334037986126246,1.0,1/18,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of mRNA polyadenylation (GO:1900363),-0.9994202446596985,-2.004662171297988,0.007751937984496124,0.6376681157681829,1.0,1/18,0.07%,CPEB3
prerank,GO_Biological_Process_2021__leukotriene biosynthetic process (GO:0019370),-0.9962290020968187,-2.003003885103536,0.08196721311475409,0.6351618801076029,1.0,1/16,0.38%,GGT5
prerank,GO_Biological_Process_2021__purine ribonucleotide transport (GO:0015868),0.9949599353058798,2.0026971606336383,0.047619047619047616,0.43693177776625747,0.956,1/15,0.51%,SLC19A1
prerank,TRRUST_Transcription_Factors_2019__NRF1 human,-0.9916540584385627,-1.9985180675254237,0.15178571428571427,0.6528892018486333,1.0,1/15,0.84%,GALNT3
prerank,GO_Biological_Process_2021__positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050),-0.9963821229995157,-1.9977490963224676,0.05343511450381679,0.6416462904864626,1.0,1/17,0.37%,AKT3
prerank,GO_Biological_Process_2021__regulation of chromosome segregation (GO:0051983),0.9979591334429702,1.9966983453581684,0.022556390977443608,0.43434887788562687,0.968,1/17,0.21%,MKI67
prerank,Reactome_2022__Prostacyclin Signaling Thru Prostacyclin Receptor R-HSA-392851,0.9888829438514061,1.9962510436728598,0.1875,0.39508879970004257,0.968,1/17,1.11%,GNB5
prerank,GO_Biological_Process_2021__detection of chemical stimulus involved in sensory perception of taste (GO:0050912),-0.9867293623730508,-1.996153388587037,0.25806451612903225,0.6371180349289067,1.0,1/16,1.33%,RTP4
prerank,Reactome_2022__G Beta:Gamma Signaling Thru BTK R-HSA-8964315,0.9888830794584821,1.995087804023486,0.20754716981132076,0.3674522501794999,0.972,1/16,1.11%,GNB5
prerank,GO_Biological_Process_2021__negative regulation of interferon-gamma production (GO:0032689),-0.98983702556665,-1.9933142415020515,0.24,0.6401980510567592,1.0,1/27,1.02%,CD274
prerank,Elsevier_Pathway_Collection__STAT3 Inhibits Maturation of Dendritic Cells and Facilitates Cancer Progression,-0.9888838636690813,-1.9927660144191193,0.21008403361344538,0.628952281327293,1.0,1/16,1.12%,IL10RA
prerank,Elsevier_Pathway_Collection__TGFBR -> ATF/GADD/MAX/TP53 Signaling,-0.9969593030046476,-1.9914670689838962,0.05309734513274336,0.6223822892405241,1.0,1/17,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Nephrogenesis WP5052,-0.9915000254105598,-1.9873125043683697,0.14728682170542637,0.6409031149896411,1.0,1/15,0.86%,MEIS1
prerank,Elsevier_Pathway_Collection__T-Cell Genetic Rearrangements in Acute Lymphoblastic Leukemia,-0.9907298477009462,-1.987173976116015,0.18032786885245902,0.6272773445658073,1.0,1/16,0.93%,CCND2
prerank,TRRUST_Transcription_Factors_2019__NR0B2 mouse,-0.9918446516157049,-1.984016741599962,0.1452991452991453,0.641191550234911,1.0,1/17,0.82%,BHMT
prerank,GO_Biological_Process_2021__mitotic sister chromatid cohesion (GO:0007064),-0.994805823719869,-1.9825219860748728,0.10256410256410256,0.639728008434838,1.0,1/15,0.53%,RB1
prerank,GO_Biological_Process_2021__xenobiotic transport (GO:0042908),-0.9994578583153488,-1.9803102314053496,0.009345794392523364,0.6438459905355829,1.0,1/20,0.06%,SLC22A1
prerank,GO_Biological_Process_2021__intracellular estrogen receptor signaling pathway (GO:0030520),0.9894987701275844,1.9777448045515604,0.1693548387096774,0.4449967508629202,0.992,1/16,1.05%,PADI2
prerank,TRRUST_Transcription_Factors_2019__HDAC9 human,-0.9965753901142345,-1.9763256057839944,0.06976744186046512,0.6711008532213699,1.0,1/16,0.35%,APP
prerank,Elsevier_Pathway_Collection__PTGIR -> IL6 Production,-0.9966896144949714,-1.9753490198255885,0.07377049180327869,0.6660210175985586,1.0,1/17,0.34%,RAP1A
prerank,GO_Biological_Process_2021__regulation of establishment or maintenance of cell polarity (GO:0032878),-0.9880787724122045,-1.9738591202795306,0.26956521739130435,0.6656379088799262,1.0,3/18,1.21%,RAP1B;PTK2B;TEK
prerank,GO_Biological_Process_2021__regulation of ATP biosynthetic process (GO:2001169),0.9921542051729263,1.9735557779904687,0.17829457364341086,0.4428801515886829,0.996,1/15,0.79%,PPARA
prerank,GO_Biological_Process_2021__cellular modified amino acid catabolic process (GO:0042219),-0.996269071231023,-1.9714782943134375,0.08888888888888889,0.6738154993765678,1.0,2/16,0.38%,GGACT;GGT5
prerank,GO_Biological_Process_2021__regulation of calcium ion transmembrane transport (GO:1903169),-0.9933434379816078,-1.969915165119962,0.140625,0.6783544521303676,1.0,1/20,0.67%,PTK2B
prerank,GO_Biological_Process_2021__maintenance of gastrointestinal epithelium (GO:0030277),-0.9999213766944304,-1.969278639600607,0.0,0.6705158001706807,1.0,1/16,0.02%,MUC6
prerank,Elsevier_Pathway_Collection__PTPRC -> BCL6 Signaling,-0.989113038788699,-1.9691263706475646,0.225,0.6592214741514971,1.0,1/17,1.10%,VAV1
prerank,GO_Biological_Process_2021__linoleic acid metabolic process (GO:0043651),-0.9995736680679598,-1.9685598398769366,0.007751937984496124,0.6525758401006858,1.0,1/20,0.05%,GSTA1
prerank,Elsevier_Pathway_Collection__Frizzled Receptors -> ARRB1/ARRB2 Canonical Signaling,0.9959980691299868,1.9673190542835552,0.06976744186046512,0.4613977885889066,1.0,1/16,0.40%,LRP5
prerank,GO_Biological_Process_2021__regulation of establishment of cell polarity (GO:2000114),-0.993385305302084,-1.96672874385388,0.12844036697247707,0.6587091841309675,1.0,2/16,0.67%,RAP1B;PTK2B
prerank,"GO_Biological_Process_2021__RNA phosphodiester bond hydrolysis, endonucleolytic (GO:0090502)",-0.9880028195358593,-1.9663634704003652,0.23931623931623933,0.6508747334689707,1.0,2/15,1.21%,LACTB2;NYNRIN
prerank,Reactome_2022__Presynaptic Function Of Kainate Receptors R-HSA-500657,0.9888809666430682,1.9652362751391754,0.24369747899159663,0.4531566059960142,1.0,1/19,1.11%,GNB5
prerank,Reactome_2022__Activation Of G Protein Gated Potassium Channels R-HSA-1296041,0.9888753630802753,1.9645131022045914,0.21666666666666667,0.42839239448743804,1.0,1/26,1.11%,GNB5
prerank,GO_Biological_Process_2021__purine ribonucleoside bisphosphate metabolic process (GO:0034035),-0.9933088278238617,-1.9611707940492504,0.15789473684210525,0.6931149546509476,1.0,2/15,0.68%,TPST1;SULT1B1
prerank,GO_Biological_Process_2021__regulation of Arp2/3 complex-mediated actin nucleation (GO:0034315),0.992344951931511,1.9585540237948489,0.12582781456953643,0.44717345640457995,1.0,1/17,0.77%,ABI2
prerank,Elsevier_Pathway_Collection__IL33 Signaling Related Eosinophilia in Asthma,-0.9969593138203011,-1.9578323969542386,0.046511627906976744,0.7150807032386983,1.0,1/16,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of protein processing (GO:0010954),0.9890377605279531,1.957816683821591,0.1791044776119403,0.4271800129108156,1.0,1/17,1.10%,MELTF
prerank,GO_Biological_Process_2021__retinol metabolic process (GO:0042572),-0.987422527504006,-1.9565467368960914,0.2878787878787879,0.7159386477788854,1.0,2/20,1.27%,CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__calcium ion transport into cytosol (GO:0060402),-0.9999581350812384,-1.9560109072314884,0.0,0.7096468484456258,1.0,1/21,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__maintenance of protein location in nucleus (GO:0051457),-0.9869597655732776,-1.9549843662310267,0.2846153846153846,0.7098722377356453,1.0,2/20,1.31%,SYNE1;PML
prerank,Elsevier_Pathway_Collection__Histone Sumoylation,-0.9869154032761855,-1.9526261971460568,0.256,0.7245555390264026,1.0,1/19,1.31%,PML
prerank,GO_Biological_Process_2021__positive regulation of receptor internalization (GO:0002092),-0.9917679304950285,-1.9524698038893424,0.16,0.7146662321582848,1.0,2/21,0.83%,ATAD1;NTF3
prerank,GO_Biological_Process_2021__lipopolysaccharide-mediated signaling pathway (GO:0031663),-0.9919964787469978,-1.9506420892429575,0.21296296296296297,0.7228667971871613,1.0,1/20,0.81%,HCK
prerank,Reactome_2022__Expression And Translocation Of Olfactory Receptors R-HSA-9752946,-0.9953438705261873,-1.9501598630848473,0.0975609756097561,0.7176683065743359,1.0,1/17,0.47%,LDB2
prerank,Reactome_2022__NLRP3 Inflammasome R-HSA-844456,-0.9965747385367172,-1.9461691665147105,0.1111111111111111,0.7509571852403876,1.0,1/16,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of isotype switching (GO:0045191),-0.9869598307302002,-1.9452383862916987,0.2465753424657534,0.7498512776333164,1.0,1/15,1.31%,PARP3
prerank,GO_Biological_Process_2021__receptor catabolic process (GO:0032801),-0.993110696815412,-1.9448051742844639,0.16964285714285715,0.7430544365595295,1.0,1/24,0.70%,UVRAG
prerank,GO_Biological_Process_2021__adrenergic receptor signaling pathway (GO:0071875),-0.9979594623947622,-1.9442666971391,0.07575757575757576,0.7376808035160819,1.0,1/15,0.21%,ZDHHC21
prerank,WikiPathway_2021_Human__Vitamin D in inflammatory diseases WP4482,-0.9876151786499252,-1.9442283921040908,0.23770491803278687,0.727625978734114,1.0,3/22,1.25%,MAP2K6;NR3C1;VDR
prerank,GO_Biological_Process_2021__nucleotide catabolic process (GO:0009166),-0.9952693188834509,-1.9438965458122002,0.09302325581395349,0.7208335318314208,1.0,2/15,0.48%,DERA;NT5C1B
prerank,GO_Biological_Process_2021__histone H3 deacetylation (GO:0070932),0.9961139658707792,1.943226210613807,0.06153846153846154,0.5149597682525455,1.0,1/15,0.39%,HDAC8
prerank,GO_Biological_Process_2021__neuron maturation (GO:0042551),-0.9965745707578797,-1.943188911686069,0.08196721311475409,0.7176963283460274,1.0,1/16,0.35%,APP
prerank,Elsevier_Pathway_Collection__Estrogen Effects in Mitochondria in Alzheimer Disease,-0.987426181636478,-1.9430415374770644,0.26548672566371684,0.7091977323787899,1.0,2/15,1.27%,APP;CYP1B1
prerank,GO_Biological_Process_2021__regulation of transcription by RNA polymerase I (GO:0006356),0.9859570911292889,1.9425375330667805,0.275,0.4956637583172484,1.0,1/18,1.41%,FLNA
prerank,Elsevier_Pathway_Collection__PI3K/AKT/MTOR Signaling Activation in Cancer,-0.9963815460681078,-1.941880628544601,0.07692307692307693,0.711790623917226,1.0,1/17,0.37%,AKT3
prerank,GO_Biological_Process_2021__DNA conformation change (GO:0071103),0.9897679581274497,1.9413722328306526,0.20491803278688525,0.4801934681867312,1.0,1/15,1.03%,NAA10
prerank,GO_Biological_Process_2021__basement membrane organization (GO:0071711),-0.9967688923839337,-1.9401854750866308,0.04,0.7193908319980534,1.0,2/16,0.33%,FLRT2;NTN4
prerank,GO_Biological_Process_2021__copper ion homeostasis (GO:0055070),-0.9965744258333478,-1.9389995999797824,0.04,0.721280403338177,1.0,1/17,0.35%,APP
prerank,GO_Biological_Process_2021__T cell migration (GO:0072678),-0.9878085065992483,-1.937456635452023,0.2809917355371901,0.7279006789677045,1.0,2/17,1.23%,ZAP70;S1PR1
prerank,TRRUST_Transcription_Factors_2019__TRP73 mouse,-0.9959586723148983,-1.9361004375224569,0.08333333333333333,0.7313682411471025,1.0,1/18,0.41%,NR3C1
prerank,GO_Biological_Process_2021__cardiac muscle cell contraction (GO:0086003),-0.9918802619302629,-1.9353909614352052,0.10256410256410256,0.7297679451124894,1.0,1/18,0.82%,KCNE1
prerank,TRRUST_Transcription_Factors_2019__FOXO3 human,-0.990728226331,-1.9347766402704178,0.1796875,0.7265683828347911,1.0,1/18,0.93%,CCND2
prerank,MSigDB_Oncogenic_Signatures__HINATA NFKB IMMU INF,-0.9892326294821481,-1.934639133616349,0.21774193548387097,0.7193741193714963,1.0,2/16,1.09%,TNFAIP2;CD83
prerank,GO_Biological_Process_2021__peptidyl-tyrosine autophosphorylation (GO:0038083),-0.9933446785561976,-1.932900249964751,0.1349206349206349,0.7253044267599907,1.0,1/15,0.67%,PTK2B
prerank,GO_Biological_Process_2021__protein heterooligomerization (GO:0051291),-0.9999599451618734,-1.932385629860236,0.0,0.720745234328881,1.0,1/16,0.01%,GRIN2B
prerank,Reactome_2022__Synthesis Of Leukotrienes (LT) And Eoxins (EX) R-HSA-2142691,-0.9962266061446866,-1.9312766519608937,0.075,0.7217336587236011,1.0,1/20,0.38%,GGT5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Sleep Disorders,0.9998056829170264,1.928561548320324,0.017094017094017096,0.5723974488711646,1.0,1/16,0.02%,SLC6A4
prerank,GO_Biological_Process_2021__negative regulation of T cell receptor signaling pathway (GO:0050860),0.9993430377636576,1.9273366364014632,0.0,0.5628567413343545,1.0,1/18,0.07%,THY1
prerank,Reactome_2022__Response Of EIF2AK1 (HRI) To Heme Deficiency R-HSA-9648895,-0.986459950879881,-1.9266103210593646,0.2807017543859649,0.7542525107876538,1.0,1/15,1.36%,GRB10
prerank,GO_Biological_Process_2021__branching involved in ureteric bud morphogenesis (GO:0001658),0.9864608926129316,1.9264203237100288,0.25190839694656486,0.5495251276647646,1.0,1/15,1.36%,FGF1
prerank,WikiPathway_2021_Human__TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) WP2453,-0.9976516288799582,-1.92475692876382,0.040983606557377046,0.7603868563596494,1.0,1/16,0.24%,SUCLG2
prerank,GO_Biological_Process_2021__cellular response to interferon-beta (GO:0035458),-0.9961905534586282,-1.9246963136961635,0.061068702290076333,0.7520844034402928,1.0,1/16,0.39%,OAS1
prerank,Reactome_2022__Nicotinamide Salvaging R-HSA-197264,-0.9988823866868449,-1.9236584265586196,0.05,0.7513738139279996,1.0,1/17,0.12%,PARP8
prerank,Elsevier_Pathway_Collection__Complement Component GPCRs Signaling,-0.9969593177759232,-1.922641948113388,0.09649122807017543,0.7510594519191099,1.0,1/15,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__sodium ion import across plasma membrane (GO:0098719),-0.9902292163944867,-1.921425602821367,0.18181818181818182,0.7521622035984039,1.0,1/16,0.98%,SLC9A9
prerank,WikiPathway_2021_Human__TCA Cycle (aka Krebs or citric acid cycle) WP78,-0.9976507059185589,-1.9201819874315293,0.040983606557377046,0.7537985717591145,1.0,1/18,0.24%,SUCLG2
prerank,Elsevier_Pathway_Collection__Lipoxins and Resolvins in Inflammation Resolution,-0.9920328470901095,-1.9197785170630417,0.16666666666666666,0.7484100372773281,1.0,1/21,0.80%,GPR132
prerank,GO_Biological_Process_2021__programmed necrotic cell death (GO:0097300),-0.9896898268346971,-1.919700280963624,0.20454545454545456,0.740999449461035,1.0,1/18,1.04%,TICAM2
prerank,Elsevier_Pathway_Collection__BMP2 and Canonical WNT Signaling in Pulmonary Artery Endothelial Cells,0.9959966359458966,1.919090702607845,0.08759124087591241,0.6080040894519386,1.0,1/19,0.40%,LRP5
prerank,GO_Biological_Process_2021__positive regulation of TORC1 signaling (GO:1904263),0.9967666123110145,1.9183603658596577,0.041666666666666664,0.5927937691501783,1.0,1/16,0.33%,CLEC16A
prerank,GO_Biological_Process_2021__regulation of transferase activity (GO:0051338),-0.9900779553425951,-1.916164029131538,0.20388349514563106,0.7615140515932672,1.0,2/17,1.00%,LDB2;SMG6
prerank,GO_Biological_Process_2021__cell communication by electrical coupling involved in cardiac conduction (GO:0086064),0.9974966833191736,1.9148960766038339,0.05970149253731343,0.6108997486378428,1.0,1/16,0.25%,GJC1
prerank,GO_Biological_Process_2021__positive regulation of viral life cycle (GO:1903902),-0.9874918957349899,-1.9138093127894542,0.24812030075187969,0.7725125752190581,1.0,1/23,1.26%,TMPRSS2
prerank,GO_Biological_Process_2021__DNA packaging (GO:0006323),0.9897652512041727,1.9115841835187926,0.18461538461538463,0.6222906132231698,1.0,1/18,1.03%,NAA10
prerank,Elsevier_Pathway_Collection__Peroxisome Protein Import and Peroxisome Division,-0.9951470941458382,-1.9106948320505739,0.09917355371900827,0.7906410677354333,1.0,1/27,0.49%,ABCD3
prerank,GO_Biological_Process_2021__negative regulation of lipid biosynthetic process (GO:0051055),-0.9919192479697239,-1.9080693736953862,0.1796875,0.8049504129402746,1.0,1/21,0.81%,ASXL3
prerank,GO_Biological_Process_2021__adenine nucleotide transport (GO:0051503),0.994959473930991,1.907840092544257,0.056910569105691054,0.6400938485318852,1.0,1/16,0.51%,SLC19A1
prerank,Elsevier_Pathway_Collection__Macroautophagy Decline,-0.9931104942873764,-1.9067207538834663,0.1826086956521739,0.8077442640052647,1.0,1/23,0.70%,UVRAG
prerank,GO_Biological_Process_2021__negative regulation of synaptic transmission (GO:0050805),-0.9949969086872631,-1.906543445068343,0.16129032258064516,0.8011662834910678,1.0,1/20,0.51%,ATAD1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Friedreich Ataxia,-0.9968824839589421,-1.9058542138717098,0.05426356589147287,0.7993309807082025,1.0,1/17,0.32%,TTPA
prerank,GO_Biological_Process_2021__NLS-bearing protein import into nucleus (GO:0006607),-0.992151591075175,-1.9055524691879098,0.1875,0.794223106651869,1.0,1/18,0.79%,KPNA3
prerank,GO_Biological_Process_2021__contractile actin filament bundle assembly (GO:0030038),0.9866904265122965,1.9048992591330098,0.22727272727272727,0.6313634346791608,1.0,1/15,1.33%,ITGB5
prerank,GO_Biological_Process_2021__stress fiber assembly (GO:0043149),0.9866904265122965,1.9048992591330098,0.22727272727272727,0.6313634346791608,1.0,1/15,1.33%,ITGB5
prerank,Reactome_2022__Lewis Blood Group Biosynthesis R-HSA-9037629,0.9856901864107628,1.9048001615063404,0.2734375,0.6134123655285243,1.0,1/17,1.43%,FUT6
prerank,GO_Biological_Process_2021__myoblast differentiation (GO:0045445),-0.9948064649450409,-1.9039475763241094,0.09090909090909091,0.7994595511900809,1.0,1/15,0.53%,RB1
prerank,Reactome_2022__PD-1 Signaling R-HSA-389948,-0.989843171082023,-1.9033646639795714,0.24074074074074073,0.7972424855050739,1.0,1/18,1.02%,CD274
prerank,Reactome_2022__Metabolism Of Nitric Oxide: NOS3 Activation And Regulation R-HSA-202131,-0.9979596069487595,-1.9026068365961097,0.04225352112676056,0.7954341465868515,1.0,1/15,0.21%,ZDHHC21
prerank,Reactome_2022__Inflammasomes R-HSA-622312,-0.9965729109999703,-1.901347607383762,0.10344827586206896,0.7972862953028451,1.0,1/21,0.35%,APP
prerank,Elsevier_Pathway_Collection__P2RY11/13/14 -> IL8/10 Production,-0.9966886979660077,-1.9010296748253674,0.05504587155963303,0.7922790110700764,1.0,1/20,0.34%,RAP1A
prerank,Reactome_2022__Signaling By NTRK3 (TRKC) R-HSA-9034015,-0.991730223430576,-1.9008745147486839,0.16101694915254236,0.7861792320760628,1.0,1/16,0.83%,NTF3
prerank,Reactome_2022__Vitamin B5 (Pantothenate) Metabolism R-HSA-199220,-0.9989585854777518,-1.900476950955111,0.03571428571428571,0.7821117526584871,1.0,1/17,0.11%,VNN1
prerank,GO_Biological_Process_2021__regulation of cholesterol storage (GO:0010885),0.992154220418094,1.9004531125025697,0.13934426229508196,0.6366872165864511,1.0,1/16,0.79%,PPARA
prerank,KEGG_2021_Human__Pantothenate and CoA biosynthesis,-0.9989599057203787,-1.9000293837850075,0.025423728813559324,0.7789339339232808,1.0,2/21,0.12%,VNN1;DPYS
prerank,Elsevier_Pathway_Collection__NTRK1/2/3 -> Acetylcholine Production,-0.991771214534712,-1.8994376156974708,0.14655172413793102,0.7765830543645859,1.0,2/15,0.83%,PTK2B;NTF3
prerank,Elsevier_Pathway_Collection__Mitochondria Enlargement and Apoptosis in Alzheimer's Disease,-0.9965745806605641,-1.8992848863629426,0.1111111111111111,0.7709207153694562,1.0,1/15,0.35%,APP
prerank,Reactome_2022__Fertilization R-HSA-1187000,-0.9939620118945386,-1.8988646138069074,0.16101694915254236,0.7680790218832126,1.0,2/16,0.61%,ADAM20;CATSPER3
prerank,Reactome_2022__Sema3A PAK Dependent Axon Repulsion R-HSA-399954,0.9917299717079346,1.8986322330449301,0.1925925925925926,0.6345933848377526,1.0,1/16,0.83%,ARHGEF7
prerank,Reactome_2022__cGMP Effects R-HSA-418457,-0.9905404445807193,-1.896714880556305,0.1889763779527559,0.7783531448786254,1.0,2/15,0.96%,PDE5A;PDE11A
prerank,Elsevier_Pathway_Collection__TGFBR -> CREB/ELK-SRF Signaling,-0.9969581481993055,-1.8964632140314988,0.05042016806722689,0.7733066998592514,1.0,1/18,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__SWI/SNF BRG1/BAF in Chromatin Remodeling,-0.9959603975789297,-1.8964013058509812,0.07272727272727272,0.7670605110497345,1.0,1/15,0.41%,NR3C1
prerank,GO_Biological_Process_2021__phosphatidylethanolamine acyl-chain remodeling (GO:0036152),-0.9984579950000119,-1.8956536478760022,0.01818181818181818,0.7667570270090592,1.0,1/22,0.16%,PLAAT3
prerank,Elsevier_Pathway_Collection__Androgen Receptor and Cell Cycle in Prostate Cancer,-0.9948056697641998,-1.8955519182451794,0.10084033613445378,0.7611074762648131,1.0,1/16,0.53%,RB1
prerank,GO_Biological_Process_2021__T cell mediated immunity (GO:0002456),0.987499051661604,1.8939169106839933,0.2543859649122807,0.6549571429088121,1.0,1/15,1.25%,CTSH
prerank,Elsevier_Pathway_Collection__Epigenetic Alterations Triggers Genomic Instability,0.9949594781108504,1.8933425721525063,0.11811023622047244,0.6438273294290106,1.0,1/18,0.51%,SLC19A1
prerank,Elsevier_Pathway_Collection__IFN-gamma/TNF-alpha Mediated Cell Proliferation in Psoriasis,-0.990148495723667,-1.8925886370364189,0.24390243902439024,0.7798246102396752,1.0,1/21,0.99%,KLF4
prerank,GO_Biological_Process_2021__membrane repolarization (GO:0086009),-0.9918835049891268,-1.8924511438534095,0.1349206349206349,0.7739469016523547,1.0,1/15,0.82%,KCNE1
prerank,Elsevier_Pathway_Collection__EGFR and PTAFR Signaling in Ovarian Cancer,-0.9966872960683425,-1.8921497829874525,0.1,0.7700355742969599,1.0,1/21,0.34%,RAP1A
prerank,TRRUST_Transcription_Factors_2019__NRF1 mouse,-0.9959992696469899,-1.8918345946861361,0.11904761904761904,0.7658742403492937,1.0,2/18,0.41%,GRIN2B;NR3C1
prerank,GO_Biological_Process_2021__regulation of vascular endothelial cell proliferation (GO:1905562),-0.9963816001752606,-1.8917813279386875,0.064,0.7601167117723272,1.0,1/18,0.37%,AKT3
prerank,Reactome_2022__Mismatch Repair R-HSA-5358508,0.9848117041304109,1.8917758843070174,0.29457364341085274,0.6383253110401549,1.0,2/15,1.53%,MSH2;LRIG1
prerank,WikiPathway_2021_Human__GDNF/RET signaling axis WP4830,-0.9878775508380409,-1.8910058783822752,0.302158273381295,0.7601277063718404,1.0,1/20,1.22%,GLI3
prerank,Elsevier_Pathway_Collection__FBLN5 Potentiates Migration and Proliferation of Endothelial Cells in Cancer,-0.9879953056465411,-1.8905573724737608,0.26851851851851855,0.7567610399606206,1.0,1/19,1.21%,TEK
prerank,GO_Biological_Process_2021__mitotic intra-S DNA damage checkpoint signaling (GO:0031573),-0.9875747319275383,-1.8905013676157894,0.2537313432835821,0.751248440741389,1.0,1/15,1.25%,NEK11
prerank,GO_Biological_Process_2021__postsynaptic membrane organization (GO:0001941),0.9870344196611666,1.8895746053337341,0.23140495867768596,0.6385061672689146,1.0,1/18,1.30%,APOE
prerank,Elsevier_Pathway_Collection__P-cell Activation,-0.9903837402651707,-1.8893456628135579,0.2413793103448276,0.7540155145076933,1.0,1/15,0.97%,HRH2
prerank,GO_Biological_Process_2021__endoplasmic reticulum tubular network organization (GO:0071786),-0.9942674388773796,-1.8891544557918432,0.18421052631578946,0.7495107190760072,1.0,1/15,0.58%,ATL2
prerank,Elsevier_Pathway_Collection__Epithelial Cell in the Innate Immune Response in Ulcerative Colitis,-0.9969562421639758,-1.8877560284844228,0.06153846153846154,0.7539006268579158,1.0,1/22,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737),-0.9907282194607426,-1.8870897366725452,0.1623931623931624,0.7525491689197066,1.0,1/17,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__WHIM Syndrome,0.9884250686302991,1.8867587502389325,0.23008849557522124,0.6436408091864533,1.0,2/16,1.16%,PTK2;GRK3
prerank,GO_Biological_Process_2021__production of small RNA involved in gene silencing by RNA (GO:0070918),0.9953042336384008,1.886240865586661,0.11029411764705882,0.631060424304751,1.0,1/19,0.47%,DROSHA
prerank,GO_Biological_Process_2021__mitochondrial fusion (GO:0008053),-0.993304892151216,-1.8858544803937236,0.13675213675213677,0.7542773953970496,1.0,1/18,0.68%,CHCHD3
prerank,GO_Biological_Process_2021__serine family amino acid metabolic process (GO:0009069),-0.9883865854928157,-1.8845819723960546,0.23770491803278687,0.7583689190747351,1.0,2/16,1.17%,GLYAT;CDO1
prerank,GO_Biological_Process_2021__negative regulation of ATP metabolic process (GO:1903579),0.9921522023859132,1.8839856149370688,0.11538461538461539,0.6300167219040064,1.0,1/16,0.79%,PPARA
prerank,Reactome_2022__ADP Signaling Thru P2Y Purinoceptor 12 R-HSA-392170,0.9888810706220428,1.8829460203202535,0.21428571428571427,0.6222454313010596,1.0,1/19,1.11%,GNB5
prerank,TRRUST_Transcription_Factors_2019__AHR human,-0.9874227467939488,-1.8827362413831474,0.2905982905982906,0.7654750925856375,1.0,2/20,1.27%,CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__regulation of establishment of endothelial barrier (GO:1903140),-0.9979585468257438,-1.882649661263655,0.07407407407407407,0.7603557886710525,1.0,1/17,0.21%,ZDHHC21
prerank,Elsevier_Pathway_Collection__NCAM1 -> CREB/ELK/SRF/MYC Signaling,0.9974584521730308,1.8809224281902432,0.03305785123966942,0.6233970449436813,1.0,1/15,0.26%,PTK2
prerank,GO_Biological_Process_2021__response to progesterone (GO:0032570),-0.9939208825680803,-1.880633950586089,0.22522522522522523,0.7682881733110638,1.0,1/18,0.61%,CATSPER3
prerank,WikiPathway_2021_Human__Phytochemical activity on NRF2 transcriptional activation WP3,-0.9999982582600602,-1.8801293380377073,0.0,0.7662008099064522,1.0,1/15,0.01%,GSTA2
prerank,Reactome_2022__Constitutive Signaling By AKT1 E17K In Cancer R-HSA-5674400,-0.9963783662914945,-1.8796445791177159,0.09009009009009009,0.7637708738815592,1.0,1/26,0.37%,AKT3
prerank,"Reactome_2022__GABA Synthesis, Release, Reuptake And Degradation R-HSA-888590",0.9880750450339347,1.8782529682537723,0.21875,0.6312243114585869,1.0,1/16,1.20%,STX1A
prerank,GO_Biological_Process_2021__regulation of protein kinase A signaling (GO:0010738),-0.9980741889735851,-1.8778092313547594,0.008928571428571428,0.7712267206273651,1.0,1/17,0.20%,AKAP7
prerank,Reactome_2022__Gluconeogenesis R-HSA-70263,-0.9992258995419923,-1.8774169754788932,0.008403361344537815,0.7686116517020746,1.0,1/27,0.08%,ALDOB
prerank,KEGG_2021_Human__Other glycan degradation,0.9933053874326567,1.8770366396030569,0.1111111111111111,0.6290046468487389,1.0,1/17,0.67%,MANBA
prerank,GO_Biological_Process_2021__prostanoid metabolic process (GO:0006692),-0.9995745146359307,-1.8767163480244793,0.008620689655172414,0.7676472336293525,1.0,1/17,0.05%,GSTA1
prerank,GO_Biological_Process_2021__protein autoprocessing (GO:0016540),-0.9874981006011937,-1.8764620296066024,0.31896551724137934,0.7641885798249893,1.0,1/16,1.26%,TMPRSS2
prerank,GO_Biological_Process_2021__regulation of calcium ion import (GO:0090279),-0.9957269118168963,-1.876417718445019,0.088,0.7591888407507843,1.0,1/21,0.43%,WNK3
prerank,GO_Biological_Process_2021__oligodendrocyte development (GO:0014003),0.9953440083026641,1.876269253824709,0.08943089430894309,0.6206110243795097,1.0,1/16,0.47%,CNTNAP1
prerank,Elsevier_Pathway_Collection__Neurofibrillary Tangle Formation,0.9958050083795432,1.8751785185123648,0.06818181818181818,0.6170966148154854,1.0,1/16,0.42%,TNFRSF10A
prerank,Reactome_2022__FRS-mediated FGFR3 Signaling R-HSA-5654706,0.9864620474660125,1.8746100619825719,0.2814814814814815,0.607956648433723,1.0,1/15,1.36%,FGF1
prerank,GO_Biological_Process_2021__endoplasmic reticulum calcium ion homeostasis (GO:0032469),-0.9869182242730508,-1.8736305710336334,0.3233082706766917,0.7731472895556717,1.0,1/20,1.31%,PML
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hutchinson-Gilford Progeria Sindrome,-0.9948056842285252,-1.8734186616995114,0.08771929824561403,0.769633983686238,1.0,1/16,0.53%,RB1
prerank,Reactome_2022__Gap Junction Trafficking R-HSA-190828,-0.9984958278340206,-1.8732871624331906,0.03225806451612903,0.7655525427903859,1.0,1/21,0.16%,GJB5
prerank,GO_Biological_Process_2021__positive regulation of cyclin-dependent protein kinase activity (GO:1904031),-0.9907264770915876,-1.872914205168215,0.17355371900826447,0.7630736757734865,1.0,1/20,0.93%,CCND2
prerank,GO_Biological_Process_2021__regulation of phospholipase C activity (GO:1900274),-0.9917307690737632,-1.872218155298692,0.16666666666666666,0.7628308833280113,1.0,1/15,0.83%,NTF3
prerank,Reactome_2022__Activation Of Kainate Receptors Upon Glutamate Binding R-HSA-451326,0.9889187648909983,1.871310454395418,0.26785714285714285,0.6214967023060913,1.0,2/27,1.11%,DLG1;GNB5
prerank,GO_Biological_Process_2021__RNA interference (GO:0016246),0.9953052727380712,1.8710658603089887,0.09448818897637795,0.6110403146177411,1.0,1/17,0.47%,DROSHA
prerank,GO_Biological_Process_2021__nitric oxide mediated signal transduction (GO:0007263),0.9870361950423636,1.869581568336092,0.20512820512820512,0.6108170627673145,1.0,1/16,1.30%,APOE
prerank,GO_Biological_Process_2021__regulation of delayed rectifier potassium channel activity (GO:1902259),-0.9918825613423028,-1.8695247974890048,0.21052631578947367,0.7767214509584613,1.0,1/17,0.82%,KCNE1
prerank,Reactome_2022__Other Semaphorin Interactions R-HSA-416700,-0.9904592640498043,-1.869320530102005,0.17886178861788618,0.7727024309836307,1.0,1/19,0.96%,SEMA4D
prerank,Elsevier_Pathway_Collection__Proteins Involved in Follicular Lymphoma,-0.9891141072008902,-1.8668742331197978,0.21487603305785125,0.7841825164911904,1.0,1/16,1.10%,VAV1
prerank,GO_Biological_Process_2021__dorsal/ventral pattern formation (GO:0009953),-0.988574309732483,-1.8668116356214746,0.2727272727272727,0.7793212662930143,1.0,1/18,1.15%,DSCAML1
prerank,Elsevier_Pathway_Collection__FPR1 -> Cytoskeleton Signaling,-0.9891095080969735,-1.8663435878521304,0.21008403361344538,0.777045824201809,1.0,1/22,1.10%,VAV1
prerank,GO_Biological_Process_2021__glycogen catabolic process (GO:0005980),0.9935762062493988,1.8663396841555793,0.09219858156028368,0.6266593575379749,1.0,1/15,0.65%,PHKA2
prerank,GO_Biological_Process_2021__cellular response to copper ion (GO:0071280),-0.9923440121956824,-1.8662408379605335,0.11363636363636363,0.7725738044553349,1.0,1/17,0.77%,AOC1
prerank,GO_Biological_Process_2021__negative regulation of calcium ion transport (GO:0051926),0.9891919278257414,1.8653789255545468,0.232,0.6240015588396809,1.0,1/15,1.08%,PACSIN3
prerank,"Elsevier_Pathway_Collection__Hypoparathyroidism, Primary",-0.9933428923095492,-1.8650475177923942,0.18699186991869918,0.7761233174899902,1.0,1/18,0.67%,PTK2B
prerank,GO_Biological_Process_2021__purinergic nucleotide receptor signaling pathway (GO:0035590),-0.9965728340537365,-1.8646080273497145,0.0703125,0.7735009177437022,1.0,1/21,0.35%,APP
prerank,Elsevier_Pathway_Collection__Sperm Motility Impairement in Testicular Male Infertility,-0.9939214759413799,-1.8645305619818295,0.13274336283185842,0.7691929091771769,1.0,1/15,0.61%,CATSPER3
prerank,GO_Biological_Process_2021__protein O-linked mannosylation (GO:0035269),-0.9971896526209159,-1.863245825032749,0.058333333333333334,0.7731568380921409,1.0,1/18,0.29%,CRPPA
prerank,GO_Biological_Process_2021__regulation of Golgi organization (GO:1903358),0.9895739576389937,1.8631190907374078,0.183206106870229,0.6328983244919207,1.0,1/17,1.05%,CAMSAP3
prerank,GO_Biological_Process_2021__regulation of viral release from host cell (GO:1902186),-0.9869144093033191,-1.8617842948621532,0.28225806451612906,0.7782019660724318,1.0,1/22,1.31%,PML
prerank,Elsevier_Pathway_Collection__Keratinocyte Proliferation in Acne Vulgaris,-0.9969581296159925,-1.8615334130856482,0.07142857142857142,0.7748295627975613,1.0,1/19,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Response to Self-Determinants in Diabetes,-0.9887664445391324,-1.861188031282925,0.2713178294573643,0.7723243714602114,1.0,2/23,1.13%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__response to ketone (GO:1901654),-0.9939172747372683,-1.8609753812828327,0.16806722689075632,0.7692423773724678,1.0,1/25,0.61%,CATSPER3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy,0.9871504277296663,1.8607681383763506,0.26666666666666666,0.6456118784374462,1.0,1/18,1.29%,PPP1R13L
prerank,GO_Biological_Process_2021__nucleobase-containing small molecule catabolic process (GO:0034656),-0.9883104716730435,-1.860062302287296,0.24031007751937986,0.7709282903386864,1.0,2/15,1.18%,ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__regulation of keratinocyte proliferation (GO:0010837),-0.9875329317497903,-1.8594961919519768,0.2702702702702703,0.769903701228032,1.0,1/22,1.25%,VDR
prerank,WikiPathway_2021_Human__Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.9987661310100462,1.8591343513373315,0.03571428571428571,0.6500774953209154,1.0,1/19,0.13%,ACACA
prerank,Elsevier_Pathway_Collection__NPY1R -> CRH/POMC Production,-0.9966878464862756,-1.8582752355119396,0.09821428571428571,0.7738747122946859,1.0,1/21,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__HPV E1 and E2 Expression in Early Phase of Cancer,-0.994805120778909,-1.8582573881522202,0.15384615384615385,0.76928493915866,1.0,1/16,0.53%,RB1
prerank,Elsevier_Pathway_Collection__Mutations in Krebs Cycle Enzymes in Cancer,-0.9928026633221717,-1.8581008984113305,0.17796610169491525,0.7658276245520784,1.0,1/24,0.73%,DEPTOR
prerank,TRRUST_Transcription_Factors_2019__IRF8 mouse,-0.9890762414111586,-1.8572688852686836,0.3064516129032258,0.7661326631648806,1.0,2/21,1.10%,GAS2;SPI1
prerank,GO_Biological_Process_2021__potassium ion homeostasis (GO:0055075),-0.9889541753310195,-1.8568908669284723,0.2540983606557377,0.7637235633217799,1.0,1/21,1.11%,SLC12A8
prerank,WikiPathway_2021_Human__Fatty Acid Omega Oxidation WP206,-0.9911147395602786,-1.855904468895675,0.20869565217391303,0.7649188246126171,1.0,1/15,0.90%,CYP1A2
prerank,Elsevier_Pathway_Collection__IFNLR1-> STAT/NFKB Signaling,-0.9888842650677814,-1.8552708226996155,0.23387096774193547,0.7645980294631042,1.0,1/16,1.12%,IL10RA
prerank,Elsevier_Pathway_Collection__Chromosome Condensation,0.9992294479731842,1.8549513983216759,0.007751937984496124,0.6811531457491001,1.0,1/15,0.08%,NCAPG
prerank,GO_Biological_Process_2021__cellular response to glucocorticoid stimulus (GO:0071385),-0.9959587066644919,-1.8545533496183049,0.11666666666666667,0.7641565853271947,1.0,1/16,0.41%,NR3C1
prerank,GO_Biological_Process_2021__cellular response to nitrogen compound (GO:1901699),-0.9923433318092538,-1.8539823464568457,0.20155038759689922,0.7631760444025799,1.0,1/19,0.77%,AOC1
prerank,GO_Biological_Process_2021__positive regulation of excitatory postsynaptic potential (GO:2000463),-0.9933445372466678,-1.8530722075251904,0.15267175572519084,0.7641745253944335,1.0,1/16,0.67%,PTK2B
prerank,WikiPathway_2021_Human__Immune response to tuberculosis WP4197,-0.9961873961249145,-1.8530586359525112,0.07874015748031496,0.7598062377747812,1.0,1/23,0.39%,OAS1
prerank,GO_Biological_Process_2021__establishment of epithelial cell polarity (GO:0090162),0.9896150222652016,1.8521973693231184,0.22131147540983606,0.696761326841905,1.0,2/20,1.05%,SIPA1L3;CAMSAP3
prerank,GO_Biological_Process_2021__regulation of spindle organization (GO:0090224),-0.986955451879347,-1.8518437069858458,0.30327868852459017,0.7630979883228961,1.0,1/18,1.31%,PARP3
prerank,WikiPathway_2021_Human__Estrogen metabolism WP697,-0.9875029826068747,-1.8495720479912188,0.28846153846153844,0.7737008995137559,1.0,4/17,1.27%,GSTA1;STS;CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__glycerophospholipid catabolic process (GO:0046475),0.9963026877776499,1.8488432264048942,0.07246376811594203,0.7178871366600685,1.0,1/25,0.37%,PNPLA6
prerank,GO_Biological_Process_2021__dendrite self-avoidance (GO:0070593),-0.9885765606011754,-1.8486031902213504,0.24060150375939848,0.7751216491218853,1.0,1/15,1.15%,DSCAML1
prerank,GO_Biological_Process_2021__carbohydrate derivative transport (GO:1901264),-0.9877269421820586,-1.8485993297445498,0.29133858267716534,0.7707424307652644,1.0,1/18,1.23%,SLC15A3
prerank,MSigDB_Oncogenic_Signatures__GLI1 UP.V1 DN,-0.9993826072984785,-1.8479545797125811,0.016666666666666666,0.7708329303064494,1.0,2/24,0.07%,SLC22A1;CYP3A7
prerank,GO_Biological_Process_2021__leukotriene metabolic process (GO:0006691),-0.9962261688717063,-1.8478158277995405,0.1,0.7673301376360665,1.0,1/23,0.38%,GGT5
prerank,Elsevier_Pathway_Collection__Macrophage Related Iron Uptake and Release,-0.9908038362624817,-1.8477287349116365,0.23357664233576642,0.7635607371799945,1.0,1/19,0.93%,CD163
prerank,GO_Biological_Process_2021__establishment of apical/basal cell polarity (GO:0035089),0.9895771916681905,1.8476382164998921,0.19858156028368795,0.7186365439308651,1.0,1/15,1.05%,CAMSAP3
prerank,GO_Biological_Process_2021__phosphatidylinositol acyl-chain remodeling (GO:0036149),-0.9984593997293899,-1.8470200323730281,0.03305785123966942,0.7633388303178775,1.0,1/15,0.16%,PLAAT3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Bronchitis,-0.9873768623767892,-1.84663486341835,0.2962962962962963,0.761352828182849,1.0,1/22,1.27%,CYP1B1
prerank,WikiPathway_2021_Human__Drug Induction of Bile Acid Pathway WP2289,-0.9875345215123678,-1.8465178084332556,0.2773109243697479,0.7579090525726477,1.0,1/17,1.25%,VDR
prerank,Elsevier_Pathway_Collection__ADRA2C/ADRB2 -> Vasoconstriction,-0.9966869601065599,-1.846305376158295,0.05454545454545454,0.754893559964481,1.0,1/24,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__GLP1R -> ARRB1 Signaling,-0.9966900429944784,-1.846189397267917,0.06666666666666667,0.751636264016038,1.0,1/15,0.34%,RAP1A
prerank,Reactome_2022__Biosynthesis Of DHA-derived SPMs R-HSA-9018677,-0.9911554287535359,-1.846013348010038,0.20168067226890757,0.7485959447378916,1.0,2/16,0.90%,CYP2C8;CYP1A2
prerank,GO_Biological_Process_2021__maintenance of protein localization in organelle (GO:0072595),-0.986916494044922,-1.8455026017392329,0.3305084745762712,0.7476241557394913,1.0,1/19,1.31%,PML
prerank,GO_Biological_Process_2021__protein localization to Golgi apparatus (GO:0034067),-0.9929581322215142,-1.8451582550539776,0.12612612612612611,0.7454025906589021,1.0,2/26,0.71%,VPS13D;VPS13C
prerank,Elsevier_Pathway_Collection__Aldosterone Renal Effects,-0.9957681335021736,-1.8448059559269385,0.09836065573770492,0.7399386215199146,1.0,2/17,0.43%,NR3C1;WNK3
prerank,Elsevier_Pathway_Collection__Aldosterone Signaling in Arterial Hypertension,-0.9957681335021736,-1.8448059559269385,0.09836065573770492,0.7399386215199146,1.0,2/17,0.43%,NR3C1;WNK3
prerank,GO_Biological_Process_2021__regulation of centriole replication (GO:0046599),0.9976891052949024,1.8446389629731592,0.06015037593984962,0.7367823445375512,1.0,1/17,0.23%,CEP295
prerank,Elsevier_Pathway_Collection__Leukotriene Effect on Airway Smooth Muscle Response,-0.9969582374251399,-1.8444210137982946,0.09482758620689655,0.7379472287672961,1.0,1/19,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of response to cytokine stimulus (GO:0060760),-0.9965356613972992,-1.8437922267770799,0.09917355371900827,0.7373206078112401,1.0,1/15,0.35%,TRIM44
prerank,Reactome_2022__Nuclear Events Stimulated By ALK Signaling In Cancer R-HSA-9725371,0.9849182892331806,1.8427896768527994,0.3392857142857143,0.7430181665828635,1.0,1/18,1.51%,FN1
prerank,Elsevier_Pathway_Collection__ADRA1 -> Prostaglandin Generation,-0.9969567462159059,-1.8427178718677182,0.09523809523809523,0.739506123344124,1.0,1/22,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of small molecule metabolic process (GO:0062013),0.9921539005086347,1.8425272939871937,0.168,0.734417083259872,1.0,1/15,0.79%,PPARA
prerank,Reactome_2022__Recycling Of Bile Acids And Salts R-HSA-159418,-0.994461748717155,-1.8424989403830465,0.12605042016806722,0.7371116326764942,1.0,2/16,0.56%,NCOA1;SLCO1A2
prerank,WikiPathway_2021_Human__Regulation of sister chromatid separation at the metaphase-anaphase transition WP4240,0.9993824578412712,1.8419248622168498,0.02054794520547945,0.7282196296104291,1.0,1/15,0.07%,CENPE
prerank,GO_Biological_Process_2021__positive regulation of triglyceride metabolic process (GO:0090208),-0.9952660812504719,-1.8416700165268354,0.104,0.7385165047127821,1.0,1/19,0.48%,AADAC
prerank,TRRUST_Transcription_Factors_2019__ARNT human,-0.9873787156856308,-1.8416672794252784,0.29914529914529914,0.7347485633622066,1.0,1/20,1.27%,CYP1B1
prerank,GO_Biological_Process_2021__regulation of fibroblast migration (GO:0010762),0.9917683541324371,1.8415922205488344,0.15,0.719468586404186,1.0,2/21,0.83%,PTK2;ARHGEF7
prerank,GO_Biological_Process_2021__epithelial cilium movement involved in extracellular fluid movement (GO:0003351),0.990461190196876,1.8414211222137253,0.1893939393939394,0.7097176325063205,1.0,1/17,0.96%,CCDC40
prerank,GO_Biological_Process_2021__platelet-derived growth factor receptor signaling pathway (GO:0048008),0.9851523076861123,1.8414049715553653,0.32575757575757575,0.6992381240049501,1.0,1/16,1.49%,BCAR1
prerank,Reactome_2022__Hyaluronan Metabolism R-HSA-2142845,0.9866154509324248,1.8410487279117698,0.2692307692307692,0.6921923622478284,1.0,1/15,1.34%,HAS3
prerank,GO_Biological_Process_2021__negative regulation of chemokine production (GO:0032682),-0.9901937480576488,-1.8404880379013313,0.2076923076923077,0.7381482526563108,1.0,2/17,0.99%,OAS1;KLF4
prerank,Elsevier_Pathway_Collection__Frizzled Receptors -> ARRB1/ARRB2 non-Canonical Signaling,0.9959980741330016,1.8403974256926052,0.07333333333333333,0.6876059927118896,1.0,1/17,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Oxidized LDL/OLR1 Activates Cell Proliferation in Cancer,-0.9907274076068395,-1.8396779223849136,0.208,0.7393770442821456,1.0,1/18,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__TGFBR -> MEF/MYOD/MYOG Signaling,-0.9969560877391799,-1.8395278305939275,0.032,0.7367244921996452,1.0,1/25,0.31%,MAP2K6
prerank,Reactome_2022__SUMOylation Of DNA Methylation Proteins R-HSA-4655427,0.9898077446508937,1.8391229044104895,0.2032520325203252,0.6891146760240896,1.0,1/15,1.02%,CBX2
prerank,Reactome_2022__Effects Of PIP2 Hydrolysis R-HSA-114508,-0.9907613152372907,-1.8385236752998315,0.23529411764705882,0.7389845586928413,1.0,1/25,0.93%,RASGRP2
prerank,Elsevier_Pathway_Collection__IL1R -> NF-kB Signaling,-0.996958001118198,-1.8370344090508708,0.07407407407407407,0.744168672801134,1.0,1/19,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Hedgehog Signaling Pathway Netpath WP47,-0.9878818058834405,-1.8369235584446648,0.3,0.7414480241510065,1.0,1/16,1.22%,GLI3
prerank,Elsevier_Pathway_Collection__WNT Signaling in Hepatocellular Carcinoma,0.9959980444316208,1.8366011168239422,0.09243697478991597,0.7012183402288101,1.0,1/15,0.40%,LRP5
prerank,GO_Biological_Process_2021__microtubule depolymerization (GO:0007019),0.9934237507389844,1.8359245251199934,0.13970588235294118,0.6975411044976337,1.0,2/17,0.66%,CCSAP;STMN3
prerank,GO_Biological_Process_2021__steroid hormone mediated signaling pathway (GO:0043401),-0.9959602947465614,-1.8349457344059386,0.09375,0.7494447552186659,1.0,1/15,0.41%,NR3C1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Bronchiectasis,0.9849183485371703,1.834213837390817,0.3387096774193548,0.701867118807071,1.0,1/17,1.51%,FN1
prerank,GO_Biological_Process_2021__cellular response to gamma radiation (GO:0071480),0.9950366770029502,1.8337296607478364,0.07692307692307693,0.697357323976618,1.0,1/17,0.50%,ATR
prerank,GO_Biological_Process_2021__negative regulation of dephosphorylation (GO:0035305),0.9877312402897145,1.8337075813726484,0.23931623931623933,0.6882110375818865,1.0,2/19,1.23%,PPP1R16B;SH3RF2
prerank,GO_Biological_Process_2021__regulation of phosphate metabolic process (GO:0019220),-0.9900367223005724,-1.8327674603855548,0.20833333333333334,0.7591050096198408,1.0,1/15,1.00%,SMG6
prerank,WikiPathway_2021_Human__Metabolism of Spingolipids in ER and Golgi apparatus WP4142,-0.9949208451114806,-1.832416114562486,0.152,0.7573624800204402,1.0,1/19,0.51%,SGPP1
prerank,"GO_Biological_Process_2021__positive regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043517)",0.9905404438280887,1.8321902290330896,0.11023622047244094,0.6923891763791257,1.0,2/15,0.95%,ATR;MSX1
prerank,Elsevier_Pathway_Collection__Alternative Lengthening of Telomeres in Cancer,0.9950365565356946,1.8319489807733886,0.0967741935483871,0.6855165520451354,1.0,1/16,0.50%,ATR
prerank,TRRUST_Transcription_Factors_2019__BCL6 human,-0.9907290790036438,-1.8314638150090687,0.2265625,0.7596002858262629,1.0,1/17,0.93%,CCND2
prerank,GO_Biological_Process_2021__regulation of protein targeting to membrane (GO:0090313),-0.9918758377320438,-1.831394315442651,0.14285714285714285,0.756298578671311,1.0,1/28,0.82%,KCNE1
prerank,GO_Biological_Process_2021__acylglycerol catabolic process (GO:0046464),-0.9908374763288816,-1.8313149231437547,0.2231404958677686,0.7531506489966173,1.0,1/27,0.92%,LIPG
prerank,TRRUST_Transcription_Factors_2019__RB1 mouse,-0.989035028029227,-1.8290871432940365,0.27941176470588236,0.7628049581221158,1.0,1/17,1.10%,SPI1
prerank,KEGG_2021_Human__alpha-Linolenic acid metabolism,-0.9984574618983512,-1.827763160926593,0.032520325203252036,0.767331150497263,1.0,1/21,0.16%,PLAAT3
prerank,GO_Biological_Process_2021__regulation of brown fat cell differentiation (GO:0090335),-0.9918055637143226,-1.8275541006981655,0.2230769230769231,0.7646167736962114,1.0,1/16,0.83%,FNDC5
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Noise-Induced),-0.9918800313272742,-1.8269032940444307,0.19672131147540983,0.7650209733630009,1.0,1/20,0.82%,KCNE1
prerank,Elsevier_Pathway_Collection__Mitochondrial Dysfunction in Alzheimer's Disease,-0.9874188950012919,-1.826425914856975,0.3333333333333333,0.7641701375088374,1.0,2/26,1.27%,APP;CYP1B1
prerank,Reactome_2022__Signaling By Cytosolic FGFR1 Fusion Mutants R-HSA-1839117,0.9984969978443817,1.8255290493392478,0.032520325203252036,0.7328785808864801,1.0,1/17,0.15%,TRIM24
prerank,TRRUST_Transcription_Factors_2019__AHR mouse,-0.9874633296104997,-1.8252640358332215,0.30578512396694213,0.767814622908382,1.0,3/19,1.27%,GSTA1;CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__Aqueous Humor Production,-0.9876046861378209,-1.8250732656995752,0.3125,0.7652272022430618,1.0,1/22,1.24%,KCNS3
prerank,GO_Biological_Process_2021__regulation of lipopolysaccharide-mediated signaling pathway (GO:0031664),-0.9906114352815247,-1.8246932541730596,0.2196969696969697,0.7641913776977389,1.0,1/19,0.95%,SCIMP
prerank,GO_Biological_Process_2021__negative regulation of anoikis (GO:2000811),0.9925392742972662,1.8241879988445446,0.19117647058823528,0.7358041873327559,1.0,2/16,0.75%,PTK2;ZNF304
prerank,WikiPathway_2021_Human__RAS and bradykinin pathways in COVID-19 WP4969,-0.9875286394766324,-1.8239916797774944,0.31496062992125984,0.7648221626218186,1.0,1/25,1.25%,VDR
prerank,GO_Biological_Process_2021__regulation of leukocyte migration (GO:0002685),-0.9904202545189379,-1.823937886538299,0.26666666666666666,0.7617213180939347,1.0,1/16,0.96%,RHOH
prerank,Elsevier_Pathway_Collection__Ethanol Induced Hepatotoxicity,0.9849214901300527,1.8230112341103157,0.3089430894308943,0.7358576335431508,1.0,1/17,1.51%,FN1
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Prostaglandin Generation,-0.99695568458969,-1.8227901812994027,0.0962962962962963,0.7643472537042094,1.0,1/26,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__ROS and RNS in Vasoconstriction and Vasodilation Regulation,-0.9891501921246315,-1.8224834433027362,0.26851851851851855,0.7624497273463624,1.0,2/26,1.10%,PTK2B;VAV1
prerank,Elsevier_Pathway_Collection__KIT -> MITF Signaling,-0.9933413956894175,-1.821980551082262,0.2033898305084746,0.7618518876569962,1.0,1/21,0.67%,PTK2B
prerank,Elsevier_Pathway_Collection__Microglia and Motor Neuron Interaction Dysregulation,-0.9933812838065511,-1.8216608116671391,0.17886178861788618,0.7602113659024393,1.0,2/26,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__glucan catabolic process (GO:0009251),0.9935761474645896,1.8212434836867237,0.09420289855072464,0.7420946632095532,1.0,1/15,0.65%,PHKA2
prerank,TRRUST_Transcription_Factors_2019__TCF4 mouse,0.9849176330939324,1.820920905811337,0.3358208955223881,0.7365160223081438,1.0,1/19,1.51%,FN1
prerank,WikiPathway_2021_Human__Cells and molecules involved in local acute inflammatory response  WP4493,0.9890749922284262,1.820804033665712,0.19047619047619047,0.7293342077492307,1.0,1/16,1.10%,ITGAL
prerank,GO_Biological_Process_2021__gliogenesis (GO:0042063),0.9981128174759997,1.8207699526422811,0.06870229007633588,0.7213293864886303,1.0,1/15,0.19%,CDK6
prerank,Reactome_2022__PI3K Events In ERBB2 Signaling R-HSA-1963642,0.9904206896278396,1.820730729305421,0.2196969696969697,0.7130664102627202,1.0,1/16,0.96%,ERBB3
prerank,Elsevier_Pathway_Collection__Apoptosis of Chondrocyte,-0.9969561709650198,-1.820690309845456,0.07142857142857142,0.7621140387335567,1.0,1/22,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__diol metabolic process (GO:0034311),-0.9949207536578738,-1.8204281299433764,0.09701492537313433,0.7603170234078254,1.0,1/19,0.51%,SGPP1
prerank,Elsevier_Pathway_Collection__TGFBR -> AP-1 Signaling,-0.9969593940686573,-1.819539434724311,0.03333333333333333,0.7614126423978144,1.0,1/16,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__acetyl-CoA metabolic process (GO:0006084),0.9987660427112178,1.8192779476617578,0.05737704918032787,0.7192499673291886,1.0,1/15,0.13%,ACACA
prerank,Reactome_2022__MET Activates PTK2 Signaling R-HSA-8874081,0.996306686182713,1.8187569802758845,0.058333333333333334,0.7158686059025582,1.0,2/17,0.38%,PTK2;ITGA2
prerank,GO_Biological_Process_2021__regulation of superoxide anion generation (GO:0032928),0.9972663197943985,1.818686335960728,0.045112781954887216,0.7083375301582284,1.0,1/15,0.28%,AATF
prerank,GO_Biological_Process_2021__nucleoside diphosphate metabolic process (GO:0009132),-0.9883101085734041,-1.817909133714465,0.2815533980582524,0.7672530675636088,1.0,2/16,1.18%,ENTPD8;ENTPD3
prerank,Elsevier_Pathway_Collection__IL1B Induced Arthralgia,-0.9969570093774424,-1.817743868188184,0.07801418439716312,0.7649353530150713,1.0,1/21,0.31%,MAP2K6
prerank,Reactome_2022__ERBB2 Regulates Cell Motility R-HSA-6785631,0.9904222763661853,1.8176205598803687,0.21374045801526717,0.7092059091637695,1.0,1/15,0.96%,ERBB3
prerank,GO_Biological_Process_2021__positive regulation of p38MAPK cascade (GO:1900745),-0.989033401839855,-1.8174823645545353,0.27586206896551724,0.7627121865519997,1.0,1/24,1.10%,SPI1
prerank,Reactome_2022__RHO GTPases Activate PAKs R-HSA-5627123,0.9859991934341163,1.8172500744375486,0.3203125,0.7050367853757084,1.0,2/21,1.41%,ARHGEF7;FLNA
prerank,Reactome_2022__Aflatoxin Activation And Detoxification R-HSA-5423646,-0.9900009278927387,-1.8168387887100752,0.24812030075187969,0.7632055368493244,1.0,3/19,1.01%,GGT5;CYP1A2;AKR7A3
prerank,TRRUST_Transcription_Factors_2019__RFX1 human,0.986502892350134,1.8167318733547084,0.31007751937984496,0.702627546267496,1.0,2/15,1.36%,ITGAL;FGF1
prerank,GO_Biological_Process_2021__long-term synaptic potentiation (GO:0060291),-0.993384145663337,-1.8150737381261812,0.17557251908396945,0.7687158785443268,1.0,2/20,0.67%,GRIN2B;PTK2B
prerank,Elsevier_Pathway_Collection__Complement Activation in Glomerulonephritis,-0.9894955492375528,-1.8149369337991927,0.28346456692913385,0.7661023247856688,1.0,1/20,1.06%,C1R
prerank,GO_Biological_Process_2021__epithelial structure maintenance (GO:0010669),-0.9999211302190886,-1.8148701629165118,0.0,0.7632560198940593,1.0,1/15,0.02%,MUC6
prerank,Reactome_2022__JNK (c-Jun Kinases) Phosphorylation And Activation Mediated By Activated Human TAK1 R-HSA-450321,0.9990356564295372,1.8148058868547203,0.022058823529411766,0.7130178772517579,1.0,1/18,0.10%,IRAK2
prerank,GO_Biological_Process_2021__regulation of presynapse assembly (GO:1905606),-0.9914623759267062,-1.814364377094776,0.22900763358778625,0.7591369129652202,1.0,2/16,0.86%,APP;SLITRK3
prerank,GO_Biological_Process_2021__regulation of presynapse organization (GO:0099174),-0.9914623759267062,-1.814364377094776,0.22900763358778625,0.7591369129652202,1.0,2/16,0.86%,APP;SLITRK3
prerank,Elsevier_Pathway_Collection__SWI/SNF BRG1/PBAF in Chromatin Remodeling,-0.9959599243622268,-1.8128869264538334,0.07692307692307693,0.7632512091130059,1.0,1/16,0.41%,NR3C1
prerank,GO_Biological_Process_2021__ruffle organization (GO:0031529),-0.9977281198058026,-1.8124655291202598,0.00847457627118644,0.762024733493445,1.0,1/17,0.23%,CARMIL1
prerank,GO_Biological_Process_2021__regulation of SMAD protein signal transduction (GO:0060390),-0.9973410246570489,-1.812081206144111,0.07086614173228346,0.7607015095601937,1.0,1/23,0.27%,SLC2A10
prerank,GO_Biological_Process_2021__3'-UTR-mediated mRNA destabilization (GO:0061158),-0.9994203201464892,-1.8116381733578393,0.014925373134328358,0.7596027018077575,1.0,1/15,0.07%,CPEB3
prerank,GO_Biological_Process_2021__regulation of voltage-gated calcium channel activity (GO:1901385),0.9870404213674627,1.8111325051013272,0.24444444444444444,0.7419979296319889,1.0,3/18,1.31%,GPR35;GNB5;DRD4
prerank,WikiPathway_2021_Human__Triacylglyceride synthesis WP325,-0.9906132276348917,-1.8108678662908364,0.248,0.7604424272252361,1.0,2/22,0.95%,MOGAT1;AGPAT4
prerank,TRRUST_Transcription_Factors_2019__PITX2 mouse,0.9958444999178289,1.8106186773394515,0.07758620689655173,0.7390301254634025,1.0,1/17,0.42%,DEPDC1B
prerank,Reactome_2022__LDL Clearance R-HSA-8964038,0.9864980292385614,1.8105971096879787,0.3181818181818182,0.7313707119782273,1.0,1/17,1.35%,SOAT2
prerank,GO_Biological_Process_2021__retrograde axonal transport (GO:0008090),-0.9896141075918168,-1.8100862070093224,0.28688524590163933,0.7610460091527157,1.0,1/16,1.05%,DLG2
prerank,Reactome_2022__Translesion Synthesis By REV1 R-HSA-110312,0.9949590006051775,1.8100371704844365,0.12307692307692308,0.7290498474292032,1.0,1/16,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__ethanol metabolic process (GO:0006067),-0.9932665885647424,-1.809389757020032,0.1721311475409836,0.7617323493960937,1.0,1/18,0.68%,SULT1B1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Fragile X Syndrome,-0.9965740371721554,-1.809000754957447,0.06363636363636363,0.7600880545199407,1.0,1/18,0.35%,APP
prerank,GO_Biological_Process_2021__toll-like receptor 4 signaling pathway (GO:0034142),-0.9897694280627378,-1.8082500844207428,0.2734375,0.760650825170582,1.0,3/20,1.04%,OAS1;SCIMP;TICAM2
prerank,GO_Biological_Process_2021__positive regulation of endopeptidase activity (GO:0010950),-0.9999582314113108,-1.8082232080218985,0.0,0.7577067801328866,1.0,1/27,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__heme catabolic process (GO:0042167),-0.9995737969746075,-1.8075251667154382,0.024,0.7551406687977976,1.0,1/16,0.05%,GSTA1
prerank,GO_Biological_Process_2021__porphyrin-containing compound catabolic process (GO:0006787),-0.9995737969746075,-1.8075251667154382,0.024,0.7551406687977976,1.0,1/16,0.05%,GSTA1
prerank,GO_Biological_Process_2021__miRNA metabolic process (GO:0010586),0.991347410660553,1.8074996542158255,0.19047619047619047,0.7452837236882073,1.0,3/18,0.88%,DIS3L2;DROSHA;PARN
prerank,GO_Biological_Process_2021__peptide cross-linking (GO:0018149),0.9849153389087091,1.806881652021111,0.35398230088495575,0.7434491646417022,1.0,1/21,1.51%,FN1
prerank,WikiPathway_2021_Human__Serotonin Receptor 4/6/7 and NR3C Signaling WP734,-0.9959989008061688,-1.8066804203363207,0.1015625,0.7561939133101545,1.0,2/18,0.41%,RAP1A;NR3C1
prerank,Reactome_2022__CD28 Dependent PI3K/Akt Signaling R-HSA-389357,-0.9963799995106467,-1.8064867182448487,0.11965811965811966,0.7542023402041944,1.0,1/22,0.37%,AKT3
prerank,Reactome_2022__Activation Of IRF3/IRF7 Mediated By TBK1/IKK Epsilon R-HSA-936964,0.9956134506976061,1.8064464377659213,0.112,0.7398498671063295,1.0,1/16,0.44%,TRAF3
prerank,GO_Biological_Process_2021__transition metal ion homeostasis (GO:0055076),-0.994378415246064,-1.8062016307387012,0.1322314049586777,0.7524985955471042,1.0,1/29,0.57%,NEO1
prerank,GO_Biological_Process_2021__synaptic vesicle membrane organization (GO:0048499),0.988073959741668,1.8060818263773446,0.2109375,0.7355255464156412,1.0,1/17,1.20%,STX1A
prerank,GO_Biological_Process_2021__cellular polysaccharide catabolic process (GO:0044247),0.9935758075590061,1.8056948407045166,0.09090909090909091,0.7308359313080651,1.0,1/16,0.65%,PHKA2
prerank,Reactome_2022__Common Pathway Of Fibrin Clot Formation R-HSA-140875,-0.9957660258990405,-1.8056459943676728,0.12037037037037036,0.7518237729106205,1.0,1/22,0.43%,PROS1
prerank,Reactome_2022__ABC Transporters In Lipid Homeostasis R-HSA-1369062,-0.9951917436414782,-1.8054526813033702,0.13157894736842105,0.7496543108522806,1.0,2/18,0.49%,ABCA6;ABCD3
prerank,Reactome_2022__Citric Acid Cycle (TCA Cycle) R-HSA-71403,-0.9976499460631956,-1.8051136899706897,0.025,0.7479721093687057,1.0,1/21,0.24%,SUCLG2
prerank,GO_Biological_Process_2021__negative regulation of platelet activation (GO:0010544),0.9870361059713071,1.805071721678036,0.30714285714285716,0.7292521694186523,1.0,1/16,1.30%,APOE
prerank,Reactome_2022__Basigin Interactions R-HSA-210991,-0.9980324865204713,-1.805042242579825,0.03361344537815126,0.7453501155448999,1.0,1/25,0.20%,SLC7A8
prerank,Reactome_2022__Translesion Synthesis By POLI R-HSA-5656121,0.9949587143479773,1.804731513990932,0.11450381679389313,0.7252672322632212,1.0,1/17,0.51%,SLC19A1
prerank,Elsevier_Pathway_Collection__Retinal Ganglion and Suprachiasmatic Nucleus in Melatonin Synthesis Regulation,0.985115583924076,1.8040844248379597,0.32167832167832167,0.7247892790625273,1.0,1/15,1.49%,GLS
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance (GO:0032205),-0.9900382062960025,-1.8039785795067522,0.25,0.7475287677056226,1.0,1/15,1.00%,SMG6
prerank,Reactome_2022__TRAF6 Mediated NF-kB Activation R-HSA-933542,-0.9965712084941554,-1.8036676723878042,0.07692307692307693,0.7459078717702516,1.0,1/24,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of cysteine-type endopeptidase activity (GO:2000116),-0.9999584339826577,-1.8032073444705112,0.0,0.7447788622262563,1.0,1/23,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__positive regulation of translational initiation (GO:0045948),0.993651032832933,1.8029721395766907,0.0975609756097561,0.7273205093604369,1.0,1/16,0.64%,YTHDF3
prerank,GO_Biological_Process_2021__negative regulation of double-strand break repair via homologous recombination (GO:2000042),0.9918448047280688,1.802444972255194,0.2032520325203252,0.7246481265409859,1.0,1/18,0.82%,SMCHD1
prerank,GO_Biological_Process_2021__negative regulation of proteolysis involved in cellular protein catabolic process (GO:1903051),-0.9869127527437473,-1.8023626213777648,0.3333333333333333,0.7461606555066823,1.0,1/25,1.31%,PML
prerank,GO_Biological_Process_2021__cellular modified amino acid biosynthetic process (GO:0042398),0.9923049288727883,1.8017266621303645,0.2033898305084746,0.7242602997724302,1.0,1/20,0.77%,PLOD2
prerank,TRRUST_Transcription_Factors_2019__FOXM1 human,0.9870792209256253,1.8015821418470037,0.2682926829268293,0.71864357222986,1.0,2/17,1.30%,BRIP1;APOE
prerank,GO_Biological_Process_2021__negative regulation of amyloid-beta formation (GO:1902430),0.9870376412692509,1.801323238191149,0.27906976744186046,0.7142789340742117,1.0,1/17,1.30%,APOE
prerank,TRRUST_Transcription_Factors_2019__NR2F2 mouse,0.9921539533738538,1.8011632275579932,0.1984126984126984,0.7091310890083813,1.0,1/15,0.79%,PPARA
prerank,WikiPathway_2021_Human__Small Ligand GPCRs WP247,-0.9877670150866373,-1.8006849855232605,0.2980769230769231,0.7516637397946921,1.0,1/16,1.23%,S1PR1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Myeloid Leukemia,-0.9948019953033244,-1.8001978887744607,0.1557377049180328,0.7510809240843472,1.0,1/23,0.53%,RB1
prerank,Reactome_2022__Translesion Synthesis By POLK R-HSA-5655862,0.994958496600869,1.799421281260293,0.1297709923664122,0.7173081954208267,1.0,1/17,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__aortic valve morphogenesis (GO:0003180),-0.9948003114440087,-1.7990715231256313,0.0975609756097561,0.7538218156250336,1.0,1/31,0.53%,RB1
prerank,GO_Biological_Process_2021__embryonic axis specification (GO:0000578),0.9911156293957637,1.79877443571518,0.2033898305084746,0.7162238292901829,1.0,1/16,0.89%,TBX3
prerank,Reactome_2022__Metabolism Of Cofactors R-HSA-8978934,-0.9974971057449625,-1.7983047665771466,0.04065040650406504,0.7551315762996443,1.0,1/19,0.26%,PDSS2
prerank,Reactome_2022__Nephrin Family Interactions R-HSA-373753,-0.9927652637132244,-1.7982202374064373,0.13392857142857142,0.7524915922449106,1.0,1/21,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030947),-0.9864515369232967,-1.797808834486591,0.3779527559055118,0.7514801949880421,1.0,1/23,1.36%,GRB10
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Congenital Deafness),-0.9918778231171691,-1.7975670218430646,0.1864406779661017,0.7500438069636997,1.0,1/23,0.82%,KCNE1
prerank,Elsevier_Pathway_Collection__beta-Cell Function Inhibition by Ciclosporine and Tacrolimus (Rodent Model),-0.9907254428141391,-1.797454394943667,0.24615384615384617,0.7475965820556668,1.0,1/22,0.93%,CCND2
prerank,Reactome_2022__Signaling By FGFR3 In Disease R-HSA-5655332,0.9864597565556399,1.797173448755344,0.28776978417266186,0.7234209496263136,1.0,1/17,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Axonal Transport Impairment in Hungtington Disease,0.9954206909064848,1.797082785069877,0.08270676691729323,0.7177076987321164,1.0,1/19,0.46%,SORT1
prerank,WikiPathway_2021_Human__Cancer immunotherapy by PD-1 blockade WP4585,-0.9887660919135804,-1.7967741291178843,0.2975206611570248,0.7476964452746467,1.0,2/23,1.13%,CD274;ZAP70
prerank,Reactome_2022__TP53 Regulates Transcription Of Genes Involved In G2 Cell Cycle Arrest R-HSA-6804114,0.9971506096556235,1.7960365189916143,0.033112582781456956,0.7198493838748133,1.0,1/18,0.29%,RBL1
prerank,GO_Biological_Process_2021__protein localization to centrosome (GO:0071539),0.9960746185526208,1.7960316387981623,0.08661417322834646,0.7136765036815585,1.0,1/18,0.40%,NUDCD3
prerank,GO_Biological_Process_2021__negative regulation of antigen receptor-mediated signaling pathway (GO:0050858),0.9993416450644487,1.7955287142312708,0.0,0.7116639306895272,1.0,1/24,0.07%,THY1
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies and Endothelial Cell Interaction,-0.9969567021904426,-1.7950969059907569,0.0873015873015873,0.7511456487339802,1.0,1/23,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies in Endothelial Cell,-0.9969567021904426,-1.7950969059907569,0.0873015873015873,0.7511456487339802,1.0,1/23,0.31%,MAP2K6
prerank,Reactome_2022__Tie2 Signaling R-HSA-210993,-0.9880397506684717,-1.7949176296135108,0.33043478260869563,0.7492968657120601,1.0,2/17,1.21%,PIK3CB;TEK
prerank,GO_Biological_Process_2021__regulation of phosphatase activity (GO:0010921),0.9876831166420393,1.7945142964617458,0.2564102564102564,0.7137380577788343,1.0,1/24,1.23%,SH3RF2
prerank,GO_Biological_Process_2021__negative regulation of DNA recombination at telomere (GO:0048239),0.9859158451863027,1.7928326045100103,0.2926829268292683,0.714524989018841,1.0,1/21,1.41%,ACD
prerank,GO_Biological_Process_2021__regulation of DNA recombination at telomere (GO:0072695),0.9859158451863027,1.7928326045100103,0.2926829268292683,0.714524989018841,1.0,1/21,1.41%,ACD
prerank,Elsevier_Pathway_Collection__HPV E6 and E7 Induced Block of Apoptosis in Keratinocytes,-0.9948036611349783,-1.7927308070300692,0.19327731092436976,0.7578810554984459,1.0,1/19,0.53%,RB1
prerank,Elsevier_Pathway_Collection__Mevalonate Kinase Deficiency,-0.9896812469223661,-1.7918869307122527,0.28440366972477066,0.7592679992201272,1.0,1/28,1.04%,TICAM2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Polycystic Ovary Syndrome,0.9905372567388905,1.7918215619038744,0.23015873015873015,0.716241752697301,1.0,1/17,0.95%,AMH
prerank,Reactome_2022__Activation Of SMO R-HSA-5635838,0.9970731506954372,1.791646103128215,0.021739130434782608,0.7117397086925619,1.0,1/18,0.30%,SMOX
prerank,GO_Biological_Process_2021__positive regulation of axon extension (GO:0045773),0.9985345210519376,1.7910923666621557,0.02962962962962963,0.7101187598148105,1.0,1/21,0.15%,MEGF8
prerank,GO_Biological_Process_2021__negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902176),-0.9989585255441717,-1.7907307061818936,0.024,0.7618889752959996,1.0,1/18,0.11%,VNN1
prerank,Elsevier_Pathway_Collection__CFTR Expression in Epithelial Cells (Class I Mutations),-0.9969573333473136,-1.790585030486913,0.07894736842105263,0.7596715218813613,1.0,1/22,0.31%,MAP2K6
prerank,Reactome_2022__CRMPs In Sema3A Signaling R-HSA-399956,0.986768040664948,1.7905152982410069,0.2809917355371901,0.7081566699714825,1.0,1/15,1.33%,DPYSL3
prerank,Elsevier_Pathway_Collection__G2/M Damage Checkpoint,0.9950369461225214,1.7904065163426268,0.07971014492753623,0.7034630086647674,1.0,1/17,0.50%,ATR
prerank,KEGG_2021_Human__Mannose type O-glycan biosynthesis,-0.9971881247381265,-1.790370406257656,0.03937007874015748,0.7577944807381553,1.0,1/22,0.29%,CRPPA
prerank,GO_Biological_Process_2021__epoxygenase P450 pathway (GO:0019373),-0.9874637566763009,-1.7902307648683666,0.31932773109243695,0.7558387915247772,1.0,3/18,1.27%,CYP2C8;CYP1A2;CYP1B1
prerank,Reactome_2022__Activation Of BAD And Translocation To Mitochondria R-HSA-111447,-0.9963828489634776,-1.7899613788555087,0.08928571428571429,0.7544643906140313,1.0,1/15,0.37%,AKT3
prerank,GO_Biological_Process_2021__protein alkylation (GO:0008213),-0.9918429088018852,-1.788308864336419,0.192,0.759941833217394,1.0,1/21,0.82%,BHMT
prerank,GO_Biological_Process_2021__regulation of fatty acid oxidation (GO:0046320),0.9921532981423452,1.788099146187052,0.16260162601626016,0.7147177652198442,1.0,1/16,0.79%,PPARA
prerank,Reactome_2022__Interleukin-37 Signaling R-HSA-9008059,-0.9866103454481249,-1.7878649275538245,0.336,0.7596125482359357,1.0,1/20,1.34%,PTPN18
prerank,GO_Biological_Process_2021__fluid transport (GO:0042044),-0.9883821235059317,-1.7876296481029987,0.3225806451612903,0.7581029358328798,1.0,1/16,1.17%,AQP3
prerank,GO_Biological_Process_2021__autonomic nervous system development (GO:0048483),0.9849659490953078,1.787558871932039,0.3220338983050847,0.7127359272085453,1.0,2/16,1.51%,ISX;FN1
prerank,GO_Biological_Process_2021__negative regulation of interleukin-8 production (GO:0032717),-0.990152646423984,-1.7872823370602713,0.23893805309734514,0.7570724702738315,1.0,1/17,0.99%,KLF4
prerank,Elsevier_Pathway_Collection__Vitamin K Metabolism,-0.9888100960119872,-1.7866829005538627,0.25862068965517243,0.757374156628234,1.0,2/16,1.13%,PROS1;PRRG4
prerank,GO_Biological_Process_2021__regulation of hippo signaling (GO:0035330),0.9924995085268054,1.7859751777917352,0.17424242424242425,0.7195912944224553,1.0,2/19,0.76%,VGLL4;NEK8
prerank,KEGG_2021_Human__Steroid biosynthesis,0.986537106895564,1.7859461108279928,0.3308270676691729,0.7142778544123222,1.0,2/19,1.35%,CYP27B1;SOAT2
prerank,GO_Biological_Process_2021__regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903587),0.9990738760626262,1.7857404381841258,0.008547008547008548,0.710155549597542,1.0,1/15,0.10%,PPP1R16B
prerank,"Reactome_2022__Synthesis, Secretion, And Deacylation Of Ghrelin R-HSA-422085",-0.990150346482949,-1.7855543427118885,0.2719298245614035,0.7595488733973623,1.0,1/17,0.99%,KLF4
prerank,TRRUST_Transcription_Factors_2019__E2F4 human,-0.9886069530033144,-1.7842509618084745,0.27692307692307694,0.7626051222594206,1.0,1/23,1.15%,LTBP4
prerank,GO_Biological_Process_2021__positive regulation of nitrogen compound metabolic process (GO:0051173),-0.9901921121330572,-1.7837460668521434,0.23809523809523808,0.7621691462063628,1.0,2/20,0.99%,APP;KLF4
prerank,GO_Biological_Process_2021__regulation of monocyte differentiation (GO:0045655),0.9981127222899016,1.7836694195365,0.0625,0.7203502149094645,1.0,1/15,0.19%,CDK6
prerank,GO_Biological_Process_2021__endoplasmic reticulum mannose trimming (GO:1904380),-0.9928430127711907,-1.7835486646886045,0.2,0.7605339100856752,1.0,1/19,0.72%,AMFR
prerank,Elsevier_Pathway_Collection__Scavenger Receptors in Platelet Activation,-0.9891521470423309,-1.7835303514865768,0.2781954887218045,0.757993033018167,1.0,2/22,1.10%,MAP2K6;VAV1
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte differentiation (GO:0045621),-0.98880934778996,-1.7834674658601846,0.3228346456692913,0.7558236227118784,1.0,3/18,1.13%,CD27;RHOH;ZAP70
prerank,GO_Biological_Process_2021__water transport (GO:0006833),-0.9883824120256026,-1.7833979065649685,0.3225806451612903,0.7534783229397833,1.0,1/16,1.17%,AQP3
prerank,KEGG_2021_Human__Primary bile acid biosynthesis,-0.999766485933187,-1.7829011570919653,0.0,0.753388868461563,1.0,1/17,0.03%,CYP39A1
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Age-Related),-0.991879515778853,-1.782849373300707,0.20512820512820512,0.7510827264046124,1.0,1/21,0.82%,KCNE1
prerank,GO_Biological_Process_2021__N-terminal protein amino acid acetylation (GO:0006474),0.9898093682087674,1.78282950308948,0.19327731092436976,0.721678519523118,1.0,2/15,1.03%,NAA60;NAA10
prerank,Elsevier_Pathway_Collection__Dopamine Synthesis and Release in Migraine,-0.9876490164750507,-1.7824977363655476,0.3050847457627119,0.7475319618254781,1.0,1/18,1.24%,MAOB
prerank,Elsevier_Pathway_Collection__Dopamine Synthesis and Release,-0.9876490164750507,-1.7824977363655476,0.3050847457627119,0.7475319618254781,1.0,1/18,1.24%,MAOB
prerank,GO_Biological_Process_2021__regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090092),-0.9886037803467017,-1.782472998447961,0.30097087378640774,0.7450528490478705,1.0,1/28,1.15%,LTBP4
prerank,Elsevier_Pathway_Collection__TNFRSF5/6 -> RB1/E2F Signaling,-0.9948457637825473,-1.7817964371822024,0.09166666666666666,0.7452669661160161,1.0,2/16,0.53%,MAP2K6;RB1
prerank,WikiPathway_2021_Human__Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex WP4884,-0.9887683120006316,-1.781770985944741,0.32432432432432434,0.7428553596843629,1.0,2/20,1.13%,CD2;ZAP70
prerank,Reactome_2022__Scavenging By Class A Receptors R-HSA-3000480,0.9870357065185542,1.7812779405931758,0.30935251798561153,0.7288081835958113,1.0,1/18,1.30%,APOE
prerank,Reactome_2022__Signaling By NTRK2 (TRKB) R-HSA-9006115,-0.991768645177849,-1.7808734486199895,0.1896551724137931,0.7449048090352127,1.0,2/22,0.83%,GRIN2B;NTF3
prerank,GO_Biological_Process_2021__negative regulation of interleukin-2 production (GO:0032703),0.9877633030245329,1.780691489607376,0.2440944881889764,0.7286373938006865,1.0,1/22,1.23%,HOMER3
prerank,Reactome_2022__Transcription Of E2F Targets Under Negative Control By P107 (RBL1) And P130 (RBL2) In Complex With HDAC1 R-HSA-1362300,0.9971514547176532,1.7806832748368133,0.029411764705882353,0.7232963061644925,1.0,1/16,0.29%,RBL1
prerank,GO_Biological_Process_2021__positive regulation of glucose import (GO:0046326),0.9913799936589476,1.7803953323034305,0.20161290322580644,0.720210469476373,1.0,1/23,0.86%,RHOQ
prerank,Elsevier_Pathway_Collection__HTR7 -> IL6 Production,-0.9959990353952586,-1.77885890905501,0.10852713178294573,0.7507007983557034,1.0,2/18,0.41%,RAP1A;NR3C1
prerank,Elsevier_Pathway_Collection__NMDA Receptors -> Ca2+/CREB Activation/PGE2 Synthesis,-0.9967301054924002,-1.7781616520659236,0.13178294573643412,0.7510066558641103,1.0,2/17,0.34%,GRIN2B;RAP1A
prerank,GO_Biological_Process_2021__regulation of telomere maintenance via telomere lengthening (GO:1904356),-0.9900369185966059,-1.7777958316168776,0.2396694214876033,0.749881475050299,1.0,1/17,1.00%,SMG6
prerank,GO_Biological_Process_2021__positive regulation of cellular response to transforming growth factor beta stimulus (GO:1903846),-0.9973409368244303,-1.7777154035538731,0.08208955223880597,0.7451940169288456,1.0,1/22,0.27%,SLC2A10
prerank,GO_Biological_Process_2021__positive regulation of transforming growth factor beta receptor signaling pathway (GO:0030511),-0.9973409368244303,-1.7777154035538731,0.08208955223880597,0.7451940169288456,1.0,1/22,0.27%,SLC2A10
prerank,GO_Biological_Process_2021__endocrine system development (GO:0035270),0.9996516073052648,1.7770228684173044,0.016129032258064516,0.7441798962495525,1.0,1/19,0.04%,HOXD3
prerank,Elsevier_Pathway_Collection__DNA Replication in DNA Machinery,0.999113197714003,1.7765817667139494,0.023255813953488372,0.7426650758816041,1.0,1/15,0.09%,CDC45
prerank,Reactome_2022__Defective B3GAT3 Causes JDSSDHD R-HSA-3560801,-0.9884946640277129,-1.7764819658032245,0.3111111111111111,0.7475592100551258,1.0,1/20,1.16%,SDC3
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies in Platelets and Coagulation Cascade,-0.9957643966738838,-1.7759028589920296,0.08849557522123894,0.7450067323953539,1.0,1/23,0.43%,PROS1
prerank,Elsevier_Pathway_Collection__Platelet and Coagulation Cascade Activation by Antiphospholipid Antibodies,-0.9957643966738838,-1.7759028589920296,0.08849557522123894,0.7450067323953539,1.0,1/23,0.43%,PROS1
prerank,Reactome_2022__CD209 (DC-SIGN) Signaling R-HSA-5621575,0.9917295253732346,1.7756727212773116,0.21212121212121213,0.7457864584417974,1.0,1/18,0.83%,ARHGEF7
prerank,GO_Biological_Process_2021__protein localization to chromatin (GO:0071168),0.9983044154462054,1.775523714038904,0.041666666666666664,0.7416522150537782,1.0,1/21,0.17%,MSH2
prerank,KEGG_2021_Human__One carbon pool by folate,-0.9881880746506255,-1.775457339608925,0.312,0.7444504223521942,1.0,1/19,1.19%,MTHFD2L
prerank,Elsevier_Pathway_Collection__Apoptosis of Melanocyte in Vitiligo,-0.9933365062481707,-1.7754013642492927,0.2066115702479339,0.7423217230606522,1.0,1/29,0.67%,PTK2B
prerank,WikiPathway_2021_Human__NRF2-ARE regulation WP4357,-0.9999969789050179,-1.7751053762806306,0.0,0.7411714740961252,1.0,1/23,0.01%,GSTA2
prerank,Elsevier_Pathway_Collection__NGFR -> MEF Signaling,-0.991767358499275,-1.7749537360453047,0.15748031496062992,0.7394792938135376,1.0,2/22,0.83%,MAP2K6;NTF3
prerank,Elsevier_Pathway_Collection__Adiponectin in Insulin Resistance Prevention,0.9921493905550092,1.7748545906117457,0.17829457364341086,0.742233235345765,1.0,1/23,0.79%,PPARA
prerank,GO_Biological_Process_2021__negative regulation of amyloid precursor protein catabolic process (GO:1902992),0.9870359651132345,1.7745965328840851,0.27692307692307694,0.7394384281434008,1.0,1/19,1.30%,APOE
prerank,Elsevier_Pathway_Collection__CD46/CD55/CD59 Inhibit Complement Mediated Lysis of Cancer Cells,-0.9894988571043202,-1.7740699875400554,0.2916666666666667,0.7404814162676304,1.0,1/15,1.06%,C1R
prerank,Reactome_2022__Heme Degradation R-HSA-189483,-0.9995740650655505,-1.7738069719892207,0.0234375,0.739198124832511,1.0,1/16,0.05%,GSTA1
prerank,"Reactome_2022__Defective B4GALT7 Causes EDS, Progeroid Type R-HSA-3560783",-0.9884945571823481,-1.7737822053939527,0.31297709923664124,0.7369845122226556,1.0,1/20,1.16%,SDC3
prerank,Elsevier_Pathway_Collection__EphrinB -> Cytoskeleton Signaling,0.9851927414281696,1.7727550999368868,0.36764705882352944,0.749475196303279,1.0,2/20,1.49%,PTK2;BCAR1
prerank,Elsevier_Pathway_Collection__Thymic Follicular Hyperplasia,-0.9875268245299545,-1.7724577699480881,0.3181818181818182,0.7399917154031196,1.0,1/27,1.25%,VDR
prerank,GO_Biological_Process_2021__peptide hormone secretion (GO:0030072),-0.988609222278983,-1.7715385025886083,0.3643410852713178,0.7413443153195796,1.0,1/21,1.15%,LTBP4
prerank,KEGG_2021_Human__Linoleic acid metabolism,-0.9911907588199875,-1.77073214030074,0.23076923076923078,0.7423245408508174,1.0,3/25,0.90%,CYP2C8;PLAAT3;CYP1A2
prerank,Elsevier_Pathway_Collection__B-Cell Activation in Crohn's Disease,-0.988720448879993,-1.7704532171876328,0.2605042016806723,0.7411094870886554,1.0,1/27,1.13%,ZAP70
prerank,Reactome_2022__Signaling By Hippo R-HSA-2028269,0.9955358364759667,1.7702995387625216,0.08527131782945736,0.7658825268494194,1.0,1/20,0.45%,TJP1
prerank,GO_Biological_Process_2021__RNA destabilization (GO:0050779),0.9936508742819286,1.770291041144732,0.14615384615384616,0.7606005783883889,1.0,1/17,0.64%,YTHDF3
prerank,GO_Biological_Process_2021__negative regulation of receptor-mediated endocytosis (GO:0048261),-0.996570857269093,-1.7701617497021171,0.06956521739130435,0.7399021235401778,1.0,1/25,0.35%,APP
prerank,Elsevier_Pathway_Collection__Cochlear Hair Cell Stereocilia Proteins Mutations (Age-Related),0.9885786200678546,1.770104766780665,0.20863309352517986,0.7565347688385995,1.0,2/16,1.15%,MYO7A;ESPN
prerank,GO_Biological_Process_2021__defense response to fungus (GO:0050832),-0.9874576370618401,-1.7699296118876926,0.3333333333333333,0.738488856488673,1.0,1/17,1.26%,HRG
prerank,GO_Biological_Process_2021__positive regulation of protein targeting to mitochondrion (GO:1903955),-0.9864824786363284,-1.7697316068864606,0.3629032258064516,0.7370179624438237,1.0,1/31,1.36%,ABLIM3
prerank,GO_Biological_Process_2021__negative regulation of lymphocyte activation (GO:0051250),-0.9945341784077182,-1.7696622396233144,0.11864406779661017,0.734906482166443,1.0,1/21,0.55%,FGL1
prerank,Reactome_2022__Cell-extracellular Matrix Interactions R-HSA-446353,0.9860020675150578,1.7696138610502905,0.3089430894308943,0.7554159194405919,1.0,2/16,1.41%,FBLIM1;FLNA
prerank,GO_Biological_Process_2021__cardiac epithelial to mesenchymal transition (GO:0060317),0.9911140605288318,1.7680872226325821,0.27007299270072993,0.7629797918760136,1.0,1/19,0.89%,TBX3
prerank,Elsevier_Pathway_Collection__IL36 Receptor Antagonist (IL1F5) Deficiency (DITRA),-0.996955810430875,-1.7678388389686357,0.09016393442622951,0.7401452701923481,1.0,1/26,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of amyloid-beta clearance (GO:1900221),0.9870371450751109,1.7675784794137122,0.29457364341085274,0.7618836487778256,1.0,1/15,1.30%,APOE
prerank,GO_Biological_Process_2021__hepaticobiliary system development (GO:0061008),0.9930736691142843,1.767538000894946,0.10273972602739725,0.7572345563511286,1.0,1/20,0.70%,PHF2
prerank,Elsevier_Pathway_Collection__BMP2 and WNT Signaling in Pulmonary Artery Smooth Muscle Cells,0.9849626895380039,1.7675258449450963,0.3358208955223881,0.7524459667932752,1.0,2/19,1.51%,LRP5;FN1
prerank,Elsevier_Pathway_Collection__Ca2+ Overload in Muscular Dystrophies,0.9974566397326126,1.7668772508864852,0.029197080291970802,0.7518152939334826,1.0,1/21,0.26%,PTK2
prerank,GO_Biological_Process_2021__negative regulation of cell communication (GO:0010648),0.9904211274127368,1.7667856515349059,0.22900763358778625,0.7476208355565339,1.0,1/18,0.96%,ERBB3
prerank,Reactome_2022__Inwardly Rectifying K+ Channels R-HSA-1296065,0.9888699911662783,1.7662678374298397,0.23770491803278687,0.746709304372144,1.0,1/32,1.11%,GNB5
prerank,GO_Biological_Process_2021__stress granule assembly (GO:0034063),0.9936496333902947,1.7656172301877133,0.17829457364341086,0.7466910196060115,1.0,1/20,0.64%,YTHDF3
prerank,"Reactome_2022__Adrenaline,noradrenaline Inhibits Insulin Secretion R-HSA-400042",0.9888752132948982,1.7652506862614479,0.27419354838709675,0.7446050274403003,1.0,1/26,1.11%,GNB5
prerank,GO_Biological_Process_2021__phosphatidylserine acyl-chain remodeling (GO:0036150),-0.9984590909603808,-1.7651599247891494,0.034782608695652174,0.748606572774263,1.0,1/19,0.16%,PLAAT3
prerank,GO_Biological_Process_2021__positive regulation of blood coagulation (GO:0030194),-0.9874591056013664,-1.7648847763303224,0.3305785123966942,0.7473590102966345,1.0,1/17,1.26%,HRG
prerank,WikiPathway_2021_Human__miR-509-3p alteration of YAP1/ECM axis WP3967,0.985002726768047,1.7646977197724971,0.3684210526315789,0.7444553360354456,1.0,3/17,1.51%,TEAD4;BCAR1;FN1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Prostate Cancer,-0.9959539054367217,-1.7642475009179701,0.14782608695652175,0.7474681804365797,1.0,1/27,0.41%,NR3C1
prerank,Elsevier_Pathway_Collection__HTR5 -> TNF Production,-0.99672917567769,-1.7639046457081846,0.11475409836065574,0.7465451942664448,1.0,2/19,0.34%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__proteoglycan metabolic process (GO:0006029),0.9980718292020998,1.763454705358409,0.03816793893129771,0.748823443977257,1.0,1/24,0.20%,FAM20B
prerank,TRRUST_Transcription_Factors_2019__PPARGC1A mouse,0.9921531818818644,1.7619399406875091,0.16176470588235295,0.7551894009092579,1.0,1/16,0.79%,PPARA
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Action Impairment in HIV Type 1 Infection,-0.988764192359125,-1.7618946440431769,0.28,0.75184980604045,1.0,2/27,1.13%,PTK2B;ZAP70
prerank,Elsevier_Pathway_Collection__TRPM8 Effects in Prostate Cancer (Hypothesis),-0.9933450617315438,-1.7613748377024934,0.23333333333333334,0.7515289437224904,1.0,1/15,0.67%,PTK2B
prerank,GO_Biological_Process_2021__very long-chain fatty acid metabolic process (GO:0000038),-0.9951456026781336,-1.7612296963230194,0.12931034482758622,0.7499422224812932,1.0,1/32,0.49%,ABCD3
prerank,GO_Biological_Process_2021__epithelial cell development (GO:0002064),0.9929200048392365,1.7609164734030651,0.13821138211382114,0.7586056017775614,1.0,1/20,0.71%,SIPA1L3
prerank,Reactome_2022__Caspase Activation Via Death Receptors In Presence Of Ligand R-HSA-140534,0.9958051095241732,1.7604181758921493,0.06837606837606838,0.7575004617849038,1.0,1/15,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__aromatic amino acid family catabolic process (GO:0009074),-0.9939972021494138,-1.7603104845289304,0.1322314049586777,0.7512800138482371,1.0,1/16,0.61%,AADAT
prerank,Reactome_2022__Deregulated CDK5 Triggers Neurodegenerative Pathways In Alzheimers Disease Models R-HSA-8862803,-0.996573269436185,-1.7595048755815015,0.11904761904761904,0.7516452995843884,1.0,1/20,0.35%,APP
prerank,GO_Biological_Process_2021__cardiac muscle tissue morphogenesis (GO:0055008),-0.9877582544437754,-1.7585988728025486,0.2975206611570248,0.7525339645811963,1.0,1/25,1.23%,S1PR1
prerank,Reactome_2022__PI-3K cascade:FGFR1 R-HSA-5654689,0.9864600220963977,1.7580351262599585,0.3178294573643411,0.7712621040384424,1.0,1/16,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Dentin and Enamel Dysruprion in Bloch-Sulzberger Syndrome,0.9887663081724429,1.75801463657193,0.2647058823529412,0.7668098419123602,1.0,1/18,1.13%,TUFT1
prerank,Elsevier_Pathway_Collection__POMC Secretion in adenohypophysis,-0.9966887368853876,-1.757456636841041,0.09022556390977443,0.7547847858164226,1.0,1/18,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__Oxytocin Signaling in Brain Nerve Cell (Hypothesis),-0.9991506408421392,-1.7573265290839823,0.01639344262295082,0.7529955381985932,1.0,1/17,0.09%,FOSB
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer Metabolic Reprogramming,-0.9948050681678061,-1.7571134145512235,0.16964285714285715,0.7515981524520984,1.0,1/19,0.53%,RB1
prerank,Elsevier_Pathway_Collection__Complement Cascade Activation by Pentraxins,-0.996574134587899,-1.7568908993249368,0.09448818897637795,0.7501204735508489,1.0,1/18,0.35%,APP
prerank,GO_Biological_Process_2021__monovalent inorganic cation homeostasis (GO:0055067),-0.9889521098629328,-1.7559703329134542,0.3063063063063063,0.751619199136662,1.0,1/23,1.11%,SLC12A8
prerank,GO_Biological_Process_2021__protein mannosylation (GO:0035268),-0.9971884194306262,-1.755733362937703,0.05128205128205128,0.7504146522790467,1.0,1/22,0.29%,CRPPA
prerank,Reactome_2022__FRS-mediated FGFR1 Signaling R-HSA-5654693,0.9864600655611633,1.7556821768003616,0.32558139534883723,0.7803931786676058,1.0,1/17,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__EGFR -> SMAD1 Signaling,-0.989107106396962,-1.7550423590975284,0.2890625,0.7508114935833636,1.0,1/23,1.10%,VAV1
prerank,WikiPathway_2021_Human__Regulation of apoptosis by parathyroid hormone-related protein WP3872,0.9849534914103641,1.7548931882261154,0.33858267716535434,0.7824260245449682,1.0,1/22,1.51%,BOK
prerank,GO_Biological_Process_2021__negative regulation of cellular carbohydrate metabolic process (GO:0010677),0.9921484556851993,1.7548888461794614,0.12121212121212122,0.7777354778998616,1.0,1/22,0.79%,PPARA
prerank,GO_Biological_Process_2021__protein insertion into mitochondrial membrane (GO:0051204),-0.9922255601722262,-1.7544478600507383,0.23728813559322035,0.7507804451689928,1.0,1/24,0.78%,TOMM70
prerank,GO_Biological_Process_2021__regulation of histone H3-K4 methylation (GO:0051569),0.9969198477043104,1.754447821465923,0.04065040650406504,0.7766691245606169,1.0,1/19,0.31%,BCOR
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Activation,-0.9969498750635204,-1.7543235674512938,0.058823529411764705,0.7490524348891267,1.0,1/42,0.31%,MAP2K6
prerank,Reactome_2022__Acetylcholine Neurotransmitter Release Cycle R-HSA-264642,0.9881177061396612,1.7541620992149833,0.28,0.7741470534354019,1.0,2/15,1.20%,PPFIA4;STX1A
prerank,Elsevier_Pathway_Collection__Cryopyrin (NLPR3) Associated Periodic Syndromes,-0.9896826604598776,-1.754143064794478,0.3247863247863248,0.7476207623836647,1.0,1/26,1.04%,TICAM2
prerank,Reactome_2022__TRAF6-mediated Induction Of TAK1 Complex Within TLR4 Complex R-HSA-937072,0.9990361522175945,1.753968961189935,0.014492753623188406,0.7711832262844364,1.0,1/15,0.10%,IRAK2
prerank,GO_Biological_Process_2021__negative regulation of mRNA processing (GO:0050686),0.9881522397548378,1.7539173886555401,0.28225806451612906,0.7670487076958843,1.0,1/15,1.19%,PCBP4
prerank,Elsevier_Pathway_Collection__Bone Resorption in Hyperparathyroidism,0.9959964276430555,1.7525763546191742,0.07352941176470588,0.772861350318513,1.0,1/21,0.40%,LRP5
prerank,GO_Biological_Process_2021__regulation of cell-cell adhesion mediated by cadherin (GO:2000047),0.9955359641887495,1.7524730356467175,0.07936507936507936,0.769140266020172,1.0,1/19,0.45%,TJP1
prerank,Elsevier_Pathway_Collection__Thyrotropin Releasing Hormone (TRH) Hypothalamic Release in non-Autoimmune Hypothyroidism,-0.9898826090575676,-1.751880136439719,0.31092436974789917,0.7539759340439289,1.0,1/18,1.02%,SLC16A2
prerank,GO_Biological_Process_2021__C21-steroid hormone metabolic process (GO:0008207),0.9878401090055532,1.7517525099388427,0.2814814814814815,0.769696242356782,1.0,1/21,1.22%,FDXR
prerank,TRRUST_Transcription_Factors_2019__CREBBP human,0.9921489946897586,1.7517171140066425,0.14285714285714285,0.7654908203580217,1.0,1/22,0.79%,PPARA
prerank,GO_Biological_Process_2021__negative regulation of ion transmembrane transporter activity (GO:0032413),0.9918821258939132,1.7516850235865908,0.1484375,0.7613551476475748,1.0,1/19,0.81%,CAB39
prerank,GO_Biological_Process_2021__rRNA transcription (GO:0009303),0.9861551531784281,1.7516727835203076,0.3089430894308943,0.7571370866227947,1.0,2/18,1.39%,TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-lysine acetylation (GO:2000758),0.9996893564334745,1.7513016246218698,0.008064516129032258,0.7556898553557585,1.0,1/20,0.03%,PRKAA2
prerank,"GO_Biological_Process_2021__negative regulation of gene expression, epigenetic (GO:0045814)",-0.9890246678943895,-1.7511095298123784,0.2926829268292683,0.7549008203482294,1.0,1/30,1.10%,SPI1
prerank,GO_Biological_Process_2021__peptidyl-threonine dephosphorylation (GO:0035970),-0.987415432513856,-1.7508280133431393,0.3656716417910448,0.7540319591475275,1.0,1/22,1.26%,DUSP4
prerank,GO_Biological_Process_2021__negative regulation of protein transport (GO:0051224),0.9870773850876502,1.7506328408523046,0.28,0.756348422096278,1.0,4/21,1.31%,WWP2;PKDCC;APOE;DRD4
prerank,GO_Biological_Process_2021__regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060211),-0.9994209778253392,-1.7504607141868909,0.016666666666666666,0.7532665304793247,1.0,1/15,0.07%,CPEB3
prerank,Reactome_2022__Processive Synthesis On Lagging Strand R-HSA-69183,0.9847680150904166,1.7496294844690832,0.33587786259541985,0.7590986968300207,1.0,1/15,1.53%,LRIG1
prerank,TRRUST_Transcription_Factors_2019__ETV4 human,-0.9907247919187012,-1.7495136626427379,0.20155038759689922,0.7550805551814629,1.0,1/21,0.93%,CCND2
prerank,GO_Biological_Process_2021__positive regulation of cellular protein catabolic process (GO:1903364),0.9870777805263367,1.748783824859502,0.28688524590163933,0.7611436962520993,1.0,2/19,1.30%,VGLL4;APOE
prerank,GO_Biological_Process_2021__DNA replication checkpoint signaling (GO:0000076),0.9991123663297715,1.7487428353081107,0.029850746268656716,0.7571481665190629,1.0,1/17,0.09%,CDC45
prerank,TRRUST_Transcription_Factors_2019__GATA2 human,-0.9890362831110827,-1.7486798303356725,0.2900763358778626,0.7563583528775669,1.0,1/17,1.10%,SPI1
prerank,GO_Biological_Process_2021__modified amino acid transport (GO:0072337),0.994959218098681,1.7484819391938717,0.13953488372093023,0.7547605333176752,1.0,1/17,0.51%,SLC19A1
prerank,TRRUST_Transcription_Factors_2019__WT1 mouse,0.9905375317742666,1.748125474953519,0.23741007194244604,0.7530833894850971,1.0,1/16,0.95%,AMH
prerank,Reactome_2022__Inactivation Of CSF3 (G-CSF) Signaling R-HSA-9705462,-0.9919933655085387,-1.7475674545859552,0.19469026548672566,0.7588479164651318,1.0,1/25,0.81%,HCK
prerank,Reactome_2022__Removal Of Flap Intermediate From C-strand R-HSA-174437,0.9859197253090615,1.7470777003261952,0.32231404958677684,0.7568079997177808,1.0,1/17,1.41%,ACD
prerank,GO_Biological_Process_2021__inositol phosphate-mediated signaling (GO:0048016),0.9973814228520935,1.7464609403949787,0.024193548387096774,0.7574766337629967,1.0,1/17,0.27%,GPR62
prerank,KEGG_2021_Human__Protein export,-0.9929940573954802,-1.7462862564527892,0.18110236220472442,0.761724329281247,1.0,1/23,0.71%,SEC61A2
prerank,GO_Biological_Process_2021__regulation of RIG-I signaling pathway (GO:0039535),-0.9913822043873555,-1.7462827673972539,0.21052631578947367,0.7595538595228402,1.0,1/18,0.87%,OASL
prerank,GO_Biological_Process_2021__regulation of B cell differentiation (GO:0045577),-0.9915734220608047,-1.7459640194734198,0.21739130434782608,0.758435258132673,1.0,1/17,0.85%,CD27
prerank,GO_Biological_Process_2021__cellular response to acid chemical (GO:0071229),-0.9994178052851895,-1.745901581420622,0.01652892561983471,0.7564432071703637,1.0,1/26,0.07%,CPEB3
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> STAT Signaling,-0.9887258401916214,-1.7458345657006047,0.2972972972972973,0.754606692302066,1.0,1/19,1.13%,ZAP70
prerank,GO_Biological_Process_2021__negative regulation of cation transmembrane transport (GO:1904063),0.991882268662843,1.745752322916241,0.16793893129770993,0.7589950772335576,1.0,1/17,0.81%,CAB39
prerank,GO_Biological_Process_2021__modulation of excitatory postsynaptic potential (GO:0098815),-0.9933818592085291,-1.7453992239025666,0.15555555555555556,0.7543265301640435,1.0,2/25,0.67%,APP;PTK2B
prerank,Reactome_2022__Defective B3GALT6 Causes EDSP2 And SEMDJL1 R-HSA-4420332,-0.9884946321835786,-1.7448099876863772,0.31297709923664124,0.754705213851239,1.0,1/20,1.16%,SDC3
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (JAMs),0.995533879304518,1.7443936110921512,0.10077519379844961,0.7640693102738266,1.0,1/23,0.45%,TJP1
prerank,GO_Biological_Process_2021__cellular response to steroid hormone stimulus (GO:0071383),-0.9959574400788651,-1.7442446621739194,0.0873015873015873,0.7545693514481302,1.0,1/21,0.41%,NR3C1
prerank,GO_Biological_Process_2021__negative regulation of intracellular protein transport (GO:0090317),-0.9918807878832869,-1.7438492186222485,0.16393442622950818,0.7541609410171242,1.0,1/20,0.82%,KCNE1
prerank,GO_Biological_Process_2021__sphingosine metabolic process (GO:0006670),-0.9949204913249305,-1.7435449160750827,0.11678832116788321,0.7532926758538145,1.0,1/19,0.51%,SGPP1
prerank,Elsevier_Pathway_Collection__HRH2/4 -> IL6/10 Production,-0.9904207817170028,-1.7432640194353968,0.2980769230769231,0.7522520106244918,1.0,2/23,0.97%,RAP1A;HRH2
prerank,GO_Biological_Process_2021__establishment of protein localization to endoplasmic reticulum (GO:0072599),0.9916910305297525,1.7432047006941922,0.21897810218978103,0.769049186776888,1.0,1/17,0.83%,RAB3GAP1
prerank,GO_Biological_Process_2021__positive regulation of macrophage migration (GO:1905523),0.997458449749531,1.7431378066391316,0.01639344262295082,0.7655624882344724,1.0,1/19,0.26%,PTK2
prerank,GO_Biological_Process_2021__regulation of cholesterol biosynthetic process (GO:0045540),0.9865016650946907,1.7424552106164308,0.2682926829268293,0.7663072765505199,1.0,2/17,1.36%,APOE;FGF1
prerank,GO_Biological_Process_2021__mycotoxin metabolic process (GO:0043385),-0.9899633857684736,-1.7416214320684895,0.26229508196721313,0.7521997028435876,1.0,2/15,1.01%,CYP1A2;AKR7A3
prerank,GO_Biological_Process_2021__organic heteropentacyclic compound metabolic process (GO:1901376),-0.9899633857684736,-1.7416214320684895,0.26229508196721313,0.7521997028435876,1.0,2/15,1.01%,CYP1A2;AKR7A3
prerank,GO_Biological_Process_2021__aflatoxin metabolic process (GO:0046222),-0.9899633857684736,-1.7416214320684895,0.26229508196721313,0.7521997028435876,1.0,2/15,1.01%,CYP1A2;AKR7A3
prerank,TRRUST_Transcription_Factors_2019__NKX2-5 mouse,0.9903480427415225,1.741501043242223,0.2903225806451613,0.768852489138703,1.0,2/15,0.97%,GJC1;MYCN
prerank,GO_Biological_Process_2021__myoblast fusion (GO:0007520),-0.995497646471833,-1.7414781740450485,0.1574074074074074,0.75051913195813,1.0,1/15,0.46%,ADAMTS5
prerank,Elsevier_Pathway_Collection__Immune System Role in Otitis Media,-0.9969513225159352,-1.7408353178921876,0.10483870967741936,0.7509105694431722,1.0,1/37,0.31%,MAP2K6
prerank,Reactome_2022__HS-GAG Degradation R-HSA-2024096,-0.9884945250849434,-1.740028866121606,0.2857142857142857,0.7521831230777312,1.0,1/21,1.16%,SDC3
prerank,GO_Biological_Process_2021__aspartate family amino acid catabolic process (GO:0009068),-0.9939974436577633,-1.7396794230435357,0.13675213675213677,0.7513393070630404,1.0,1/19,0.61%,AADAT
prerank,GO_Biological_Process_2021__cAMP-mediated signaling (GO:0019933),0.997842163233951,1.7396442390751186,0.05223880597014925,0.7775582885547186,1.0,1/23,0.22%,KSR1
prerank,GO_Biological_Process_2021__lipid catabolic process (GO:0016042),-0.9909601429835331,-1.7394286529109215,0.27611940298507465,0.7502573751371098,1.0,4/25,0.92%,PLAAT3;STS;CYP1A2;LIPG
prerank,GO_Biological_Process_2021__negative regulation of signaling (GO:0023057),0.9904188629133865,1.7393190138495596,0.23308270676691728,0.7761645550143933,1.0,1/22,0.96%,ERBB3
prerank,GO_Biological_Process_2021__peptidyl-glutamic acid modification (GO:0018200),0.9897646756113084,1.7392658066544415,0.232,0.7725158463093219,1.0,1/22,1.03%,NAA10
prerank,GO_Biological_Process_2021__negative regulation of cytokine production involved in inflammatory response (GO:1900016),0.9921515081272454,1.7391856264340773,0.21052631578947367,0.7691575790214529,1.0,1/19,0.79%,PPARA
prerank,Elsevier_Pathway_Collection__Histone Acetylation,-0.9960349275581625,-1.7387764071596383,0.12295081967213115,0.7505760979226892,1.0,1/20,0.40%,NCOA1
prerank,Reactome_2022__VxPx Cargo-Targeting To Cilium R-HSA-5620916,-0.99338212173792,-1.7385818204361105,0.18691588785046728,0.7492377210246242,1.0,1/20,0.67%,EXOC2
prerank,GO_Biological_Process_2021__polyol biosynthetic process (GO:0046173),0.9869978754566081,1.7375188410269575,0.33064516129032256,0.7771806967770838,1.0,1/16,1.30%,CYP27B1
prerank,TRRUST_Transcription_Factors_2019__POU2F1 mouse,-0.9990739884272777,-1.7372106420542752,0.01652892561983471,0.7531114604056011,1.0,1/18,0.10%,ATP11C
prerank,GO_Biological_Process_2021__gastrulation (GO:0007369),0.9960383971891994,1.7371495907133025,0.09154929577464789,0.7758942406569003,1.0,2/17,0.40%,MEGF8;LRP5
prerank,KEGG_2021_Human__Phenylalanine metabolism,-0.9876948921156888,-1.7370603757197751,0.325,0.7515905301393104,1.0,2/15,1.24%,GLYAT;MAOB
prerank,Elsevier_Pathway_Collection__Proteins Involved in Vasospasm,-0.9968049219373488,-1.7368910459718778,0.06818181818181818,0.7501804228188642,1.0,1/17,0.33%,PDE5A
prerank,GO_Biological_Process_2021__organelle fusion (GO:0048284),-0.9933024909176679,-1.736598692658898,0.16260162601626016,0.7493806126631956,1.0,1/22,0.68%,CHCHD3
prerank,Reactome_2022__Blood Group Systems Biosynthesis R-HSA-9033658,0.9856865784725701,1.736556423540736,0.3225806451612903,0.7763842431544321,1.0,1/21,1.43%,FUT6
prerank,GO_Biological_Process_2021__regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061178),0.9959927625544228,1.7365077831646265,0.12781954887218044,0.7727879630547418,1.0,1/27,0.40%,LRP5
prerank,GO_Biological_Process_2021__long-chain fatty-acyl-CoA biosynthetic process (GO:0035338),0.9882703877183909,1.735410622662637,0.24369747899159663,0.7769130907069857,1.0,2/18,1.18%,ACSF3;ACSL5
prerank,Reactome_2022__Lagging Strand Synthesis R-HSA-69186,0.9848077286407075,1.735279636957817,0.35507246376811596,0.7739164233255263,1.0,2/20,1.53%,SLC19A1;LRIG1
prerank,Reactome_2022__CTLA4 Inhibitory Signaling R-HSA-389513,-0.9963813009821361,-1.7352614122370351,0.07142857142857142,0.7531103539167244,1.0,1/21,0.37%,AKT3
prerank,GO_Biological_Process_2021__regulation of protein-containing complex disassembly (GO:0043244),0.9967665963428639,1.7352547228186395,0.06153846153846154,0.7703294046899757,1.0,1/17,0.33%,CLEC16A
prerank,Reactome_2022__Nitric Oxide Stimulates Guanylate Cyclase R-HSA-392154,-0.9905380719666679,-1.7352105010004624,0.2542372881355932,0.751402091893222,1.0,2/20,0.96%,PDE5A;PDE11A
prerank,GO_Biological_Process_2021__positive regulation of cartilage development (GO:0061036),0.9896521752690125,1.7352086047965456,0.1935483870967742,0.7669459898494316,1.0,1/17,1.04%,PKDCC
prerank,Elsevier_Pathway_Collection__Histone Phosphorylation,0.9950372064233981,1.7351300563421097,0.08270676691729323,0.763707371667832,1.0,1/16,0.50%,ATR
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via LTB4/Polyisoprenyl Phosphate Signaling,-0.9891067559404816,-1.7348338211091296,0.3283582089552239,0.7508874480077534,1.0,1/23,1.10%,VAV1
prerank,GO_Biological_Process_2021__membrane lipid metabolic process (GO:0006643),-0.9873789207972933,-1.7345760190463027,0.3305084745762712,0.7498917477209215,1.0,1/21,1.27%,CYP1B1
prerank,WikiPathway_2021_Human__Nanoparticle triggered autophagic cell death WP2509,-0.9931112829881111,-1.7344596209200245,0.1794871794871795,0.7483739343611477,1.0,1/22,0.70%,UVRAG
prerank,Reactome_2022__Class I Peroxisomal Membrane Protein Import R-HSA-9603798,-0.995037284227739,-1.7343481498782884,0.10077519379844961,0.7468641517598914,1.0,2/20,0.51%,ABCD3;ATAD1
prerank,Reactome_2022__Signaling By CSF3 (G-CSF) R-HSA-9674555,-0.9919907757190738,-1.733955260621801,0.20909090909090908,0.746489694510954,1.0,1/30,0.81%,HCK
prerank,TRRUST_Transcription_Factors_2019__TWIST1 mouse,-0.9880329471895188,-1.7339238550204175,0.33620689655172414,0.7447145019494884,1.0,2/26,1.21%,IL12RB2;TEK
prerank,GO_Biological_Process_2021__regulation of metal ion transport (GO:0010959),0.9852720296529152,1.7337601878422262,0.33088235294117646,0.7692942946011513,1.0,2/16,1.48%,DLG1;SLC30A10
prerank,Reactome_2022__Signaling By PDGFR In Disease R-HSA-9671555,-0.9898073244282655,-1.7336907338745717,0.25,0.743637036863495,1.0,2/19,1.03%,PIK3CB;BIN2
prerank,GO_Biological_Process_2021__regulation of leukocyte chemotaxis (GO:0002688),-0.9933441833816044,-1.7330459370109799,0.1349206349206349,0.7438055348483619,1.0,1/18,0.67%,PTK2B
prerank,GO_Biological_Process_2021__calcium-ion regulated exocytosis (GO:0017156),-0.9913010073909978,-1.7329021726301914,0.25384615384615383,0.7423715716907301,1.0,1/24,0.88%,SYT7
prerank,Reactome_2022__Telomere Extension By Telomerase R-HSA-171319,0.9854987587299898,1.7324685004740292,0.3504273504273504,0.7735925879058171,1.0,3/22,1.46%,PIF1;ACD;WRAP53
prerank,Reactome_2022__Early Phase Of HIV Life Cycle R-HSA-162594,0.9847698002966786,1.732139123476835,0.35555555555555557,0.7720372541159973,1.0,1/15,1.53%,LRIG1
prerank,GO_Biological_Process_2021__epiboly involved in wound healing (GO:0090505),0.9860026752967703,1.7318957963222936,0.3333333333333333,0.7698764929128749,1.0,2/16,1.41%,MRTFA;FLNA
prerank,Reactome_2022__SHC-mediated cascade:FGFR1 R-HSA-5654688,0.9864616128779508,1.7317151647549527,0.30158730158730157,0.7675184979533849,1.0,1/15,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Apoptosis Block by Inhibitor of Apoptosis Proteins (IAPs) in Cancer,-0.9938819128952752,-1.7311682093219014,0.1773049645390071,0.747367768854807,1.0,1/19,0.62%,BIRC6
prerank,KEGG_2021_Human__Galactose metabolism,-0.9944548748424351,-1.7307547097269933,0.11904761904761904,0.7468440070760948,1.0,1/26,0.56%,GANC
prerank,GO_Biological_Process_2021__positive regulation of glucose transmembrane transport (GO:0010828),0.9913774615905947,1.7305336729353316,0.234375,0.7720144667118026,1.0,1/28,0.86%,RHOQ
prerank,TRRUST_Transcription_Factors_2019__HIF1A mouse,0.9887660852688903,1.730427413813708,0.30656934306569344,0.7690751150131218,1.0,1/19,1.13%,TUFT1
prerank,GO_Biological_Process_2021__response to gamma radiation (GO:0010332),0.9950335868934493,1.7302970149721049,0.10483870967741936,0.7663067112156455,1.0,1/24,0.50%,ATR
prerank,Reactome_2022__RAF-independent MAPK1/3 Activation R-HSA-112409,-0.9874146972636096,-1.730082943120481,0.34545454545454546,0.7476600233347581,1.0,1/23,1.26%,DUSP4
prerank,GO_Biological_Process_2021__protein import into peroxisome membrane (GO:0045046),-0.9950365948762077,-1.7297712445445101,0.11023622047244094,0.7468430701140578,1.0,2/22,0.51%,ABCD3;ATAD1
prerank,GO_Biological_Process_2021__N-glycan processing (GO:0006491),-0.9944587101733244,-1.7295935448967081,0.13445378151260504,0.745506981568026,1.0,1/18,0.56%,GANC
prerank,Reactome_2022__Na+/Cl- Dependent Neurotransmitter Transporters R-HSA-442660,-0.9994597060163788,-1.7294632994824775,0.024193548387096774,0.7442212624602493,1.0,1/15,0.06%,SLC22A1
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR3 R-HSA-5654708,0.9864568445617712,1.7294219032079605,0.3284671532846715,0.7686068588735567,1.0,1/20,1.36%,FGF1
prerank,GO_Biological_Process_2021__positive regulation of heterotypic cell-cell adhesion (GO:0034116),0.9993445727493844,1.7293264535842516,0.014705882352941176,0.765955190921972,1.0,1/15,0.07%,THY1
prerank,GO_Biological_Process_2021__regulation of tissue remodeling (GO:0034103),-0.9913055724394523,-1.7290757800953944,0.21367521367521367,0.7439400734272582,1.0,1/18,0.88%,SYT7
prerank,Reactome_2022__Defective Intrinsic Pathway For Apoptosis R-HSA-9734009,-0.9965721514276015,-1.7286306202172532,0.096,0.7438983493999101,1.0,1/23,0.35%,APP
prerank,TRRUST_Transcription_Factors_2019__NR1I2 human,-0.9997270364585149,-1.7285360556389182,0.0,0.7423028197859411,1.0,1/26,0.03%,CYP2C8
prerank,GO_Biological_Process_2021__purine ribonucleoside monophosphate metabolic process (GO:0009167),0.9848804113167693,1.7284828957870495,0.384,0.7679178323414987,1.0,1/20,1.51%,HPRT1
prerank,GO_Biological_Process_2021__positive regulation of monocyte chemotaxis (GO:0090026),0.9894223651291204,1.728460661613813,0.232,0.7645910769091041,1.0,1/16,1.06%,MOSPD2
prerank,Elsevier_Pathway_Collection__Familial Partial Lipodystrophy Type 4 Progression (Hypothesis),0.9921927201590691,1.7283967308939363,0.19166666666666668,0.7615923090142124,1.0,2/17,0.79%,ACACA;PPARA
prerank,GO_Biological_Process_2021__regulation of mitotic spindle assembly (GO:1901673),0.9966888502591643,1.727911600279388,0.07462686567164178,0.7609887512751747,1.0,1/19,0.33%,CCSAP
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Histone Deacetylation,0.9961139396496672,1.7278083780843263,0.11965811965811966,0.7580511484162691,1.0,1/15,0.39%,HDAC8
prerank,Reactome_2022__SHC1 Events In ERBB2 Signaling R-HSA-1250196,0.9904185330396825,1.7278081912870964,0.23255813953488372,0.7546054613780133,1.0,1/21,0.96%,ERBB3
prerank,GO_Biological_Process_2021__hyaluronan metabolic process (GO:0030212),0.9866089951438488,1.7272856384173034,0.34558823529411764,0.7543336561531233,1.0,1/22,1.34%,HAS3
prerank,GO_Biological_Process_2021__histone H2A monoubiquitination (GO:0035518),0.9969204035310278,1.7272606210181223,0.03875968992248062,0.7510725237004428,1.0,1/17,0.31%,BCOR
prerank,Reactome_2022__Acyl Chain Remodelling Of PS R-HSA-1482801,-0.9984590908200356,-1.7269554775168032,0.03389830508474576,0.7468833737864149,1.0,1/19,0.16%,PLAAT3
prerank,Elsevier_Pathway_Collection__HMGB1 and IL1B in Neuroinflammation,-0.9896862938177945,-1.7267795822231984,0.3103448275862069,0.7458037437854192,1.0,1/23,1.04%,TICAM2
prerank,Reactome_2022__PINK1-PRKN Mediated Mitophagy R-HSA-5205685,-0.9922258390440694,-1.7262756885814563,0.22807017543859648,0.7461111485794935,1.0,1/21,0.78%,TOMM70
prerank,Reactome_2022__RNA Pol II CTD Phosphorylation And Interaction With CE R-HSA-77075,-0.99226142992855,-1.7261602665006943,0.21774193548387097,0.7448466311554112,1.0,1/27,0.78%,RNGTT
prerank,GO_Biological_Process_2021__regulation of telomerase RNA localization to Cajal body (GO:1904872),0.991267026230793,1.725853744628111,0.22764227642276422,0.7551418755978379,1.0,1/18,0.88%,PARN
prerank,TRRUST_Transcription_Factors_2019__NFYA human,-0.9907279855811731,-1.7257948690227842,0.23275862068965517,0.7442491485370725,1.0,1/19,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__SCF/BTRC Complex,-0.9928393131234218,-1.725676947371437,0.19130434782608696,0.7428149690872028,1.0,2/34,0.73%,RB1;DEPTOR
prerank,GO_Biological_Process_2021__positive regulation of small GTPase mediated signal transduction (GO:0051057),-0.9891040011152149,-1.7256134554483566,0.28346456692913385,0.7412819538551949,1.0,1/28,1.10%,VAV1
prerank,GO_Biological_Process_2021__protein import into mitochondrial matrix (GO:0030150),-0.992227628788783,-1.7255374874535676,0.21481481481481482,0.7397354517813605,1.0,1/19,0.78%,TOMM70
prerank,KEGG_2021_Human__Pentose and glucuronate interconversions,-0.9971846908721858,-1.7254963810535673,0.05384615384615385,0.73808061749949,1.0,1/30,0.29%,CRPPA
prerank,GO_Biological_Process_2021__female gonad development (GO:0008585),0.9865746937716173,1.7253322835350384,0.325,0.7546171676032873,1.0,1/17,1.34%,COL9A3
prerank,Reactome_2022__Biosynthesis Of Specialized Proresolving Mediators (SPMs) R-HSA-9018678,-0.9911545432886012,-1.72521252361173,0.23008849557522124,0.7373074536333878,1.0,2/18,0.90%,CYP2C8;CYP1A2
prerank,GO_Biological_Process_2021__negative regulation of protein tyrosine kinase activity (GO:0061099),0.9944210497492496,1.7250844865185857,0.128,0.7526296148496616,1.0,2/24,0.56%,THY1;ZGPAT
prerank,Elsevier_Pathway_Collection__ADRA2C/ADRB2 -> Synaptic Endocytosis,-0.9966862436512083,-1.7247377060796933,0.1322314049586777,0.7373254190415512,1.0,1/26,0.34%,RAP1A
prerank,TRRUST_Transcription_Factors_2019__NR1H3 mouse,0.9870379393227997,1.7246710125806068,0.29133858267716534,0.7517344210286528,1.0,1/16,1.30%,APOE
prerank,GO_Biological_Process_2021__response to axon injury (GO:0048678),0.9867658898196068,1.7244404766224817,0.33076923076923076,0.7495764474582643,1.0,1/18,1.33%,DPYSL3
prerank,Elsevier_Pathway_Collection__Enterocyte Mediated Mucosal Damage in Celiac Disease,0.9955334309565743,1.7242679688264588,0.10256410256410256,0.7470711921119163,1.0,1/24,0.45%,TJP1
prerank,GO_Biological_Process_2021__modulation by symbiont of entry into host (GO:0052372),-0.9933812964026866,-1.7242648734887098,0.1308411214953271,0.7373956517446902,1.0,1/18,0.67%,EXOC2
prerank,GO_Biological_Process_2021__positive regulation of regulated secretory pathway (GO:1903307),0.9880749486106871,1.7239987853714067,0.2992125984251969,0.7457313731465425,1.0,1/17,1.20%,STX1A
prerank,GO_Biological_Process_2021__positive regulation of receptor signaling pathway via STAT (GO:1904894),-0.9874184277239662,-1.7235054449805844,0.3252032520325203,0.7383011689475258,1.0,2/25,1.27%,IL10RA;CYP1B1
prerank,GO_Biological_Process_2021__purine ribonucleotide catabolic process (GO:0009154),0.9848776434366054,1.7231529616596881,0.37777777777777777,0.7477529531974869,1.0,1/22,1.51%,HPRT1
prerank,Elsevier_Pathway_Collection__OPTN Associated Glaucoma,-0.9917269838742517,-1.722834407645949,0.22321428571428573,0.7390667698420597,1.0,1/21,0.83%,NTF3
prerank,GO_Biological_Process_2021__regulation of T cell migration (GO:2000404),-0.9965728754461428,-1.7226674562247088,0.11214953271028037,0.7380096475638291,1.0,1/19,0.35%,APP
prerank,"Elsevier_Pathway_Collection__Overt Hypothyroidism, Primary",-0.9966843738508366,-1.7226382117368904,0.08088235294117647,0.7362630119119171,1.0,1/31,0.34%,RAP1A
prerank,GO_Biological_Process_2021__cellular response to inorganic substance (GO:0071241),-0.9923429448392236,-1.7222463512612598,0.21897810218978103,0.7359729703307256,1.0,1/20,0.77%,AOC1
prerank,Elsevier_Pathway_Collection__DRD1/5 Expression Targets,-0.996688569053527,-1.7222358577100383,0.10606060606060606,0.7341985503230765,1.0,1/17,0.34%,RAP1A
prerank,GO_Biological_Process_2021__apoptotic cell clearance (GO:0043277),-0.9904104389746172,-1.7215517616200628,0.2032520325203252,0.7350162838992118,1.0,1/32,0.96%,RHOH
prerank,Reactome_2022__Xenobiotics R-HSA-211981,-0.9911532743739736,-1.7214960283148184,0.25396825396825395,0.7333862826129501,1.0,2/21,0.90%,CYP2C8;CYP1A2
prerank,TRRUST_Transcription_Factors_2019__STAT5A mouse,-0.9864986349333339,-1.720983732618597,0.36666666666666664,0.7336796269326593,1.0,2/22,1.36%,NR3C1;GRB10
prerank,GO_Biological_Process_2021__cellular response to topologically incorrect protein (GO:0035967),-0.9938367730436278,-1.7208785748211626,0.20967741935483872,0.7321935668210445,1.0,1/32,0.62%,DNAJB14
prerank,Reactome_2022__Processive Synthesis On C-strand Of Telomere R-HSA-174414,0.9848068734228645,1.7208222424923016,0.38333333333333336,0.757807627421384,1.0,2/19,1.53%,ACD;LRIG1
prerank,GO_Biological_Process_2021__ERK1 and ERK2 cascade (GO:0070371),0.9874925270434461,1.7208057843449143,0.3333333333333333,0.7547048049522079,1.0,1/21,1.25%,CTSH
prerank,GO_Biological_Process_2021__cellular response to nerve growth factor stimulus (GO:1990090),-0.9917682467069406,-1.720277093011408,0.15454545454545454,0.7326310831829576,1.0,2/21,0.83%,RAP1A;NTF3
prerank,GO_Biological_Process_2021__cardiac muscle cell action potential (GO:0086001),-0.9918738000553595,-1.7200751437775914,0.16393442622950818,0.7317038244613108,1.0,1/28,0.82%,KCNE1
prerank,Reactome_2022__PI-3K cascade:FGFR2 R-HSA-5654695,0.9864594590270797,1.7194166071104515,0.3308270676691729,0.7598707295315656,1.0,1/17,1.36%,FGF1
prerank,GO_Biological_Process_2021__actin filament capping (GO:0051693),0.9934968321382472,1.7192773218548592,0.17796610169491525,0.7540982003553902,1.0,1/19,0.65%,SVIL
prerank,GO_Biological_Process_2021__barbed-end actin filament capping (GO:0051016),0.9934968321382472,1.7192773218548592,0.17796610169491525,0.7540982003553902,1.0,1/19,0.65%,SVIL
prerank,GO_Biological_Process_2021__peroxisome organization (GO:0007031),-0.9951896851344167,-1.7191920954688733,0.14953271028037382,0.7326578019097891,1.0,2/25,0.49%,PLAAT3;ABCD3
prerank,Elsevier_Pathway_Collection__Hodgkin and Reed-Sternberg Cells Reprogramming,-0.9890753982556415,-1.718759604328292,0.26717557251908397,0.7324838354965538,1.0,2/21,1.10%,IL21R;SPI1
prerank,GO_Biological_Process_2021__positive regulation of phospholipase activity (GO:0010518),-0.9917267305177592,-1.7186870661681,0.1885245901639344,0.7309779771930656,1.0,1/23,0.83%,NTF3
prerank,Elsevier_Pathway_Collection__CHRM1 -> IL2 Production,-0.9934203485151047,-1.7184020497822425,0.2558139534883721,0.7304160174399467,1.0,3/27,0.67%,MAP2K6;RAP1A;PTK2B
prerank,TRRUST_Transcription_Factors_2019__FOXM1 mouse,0.9903844858977224,1.7182867817561236,0.28,0.7568530984012725,1.0,3/22,0.97%,AXIN2;BRIP1;MYCN
prerank,Elsevier_Pathway_Collection__EGFR -> NCOR2 Signaling,-0.993337570003746,-1.7176738789826764,0.19658119658119658,0.7313639898937159,1.0,1/28,0.67%,PTK2B
prerank,GO_Biological_Process_2021__fatty acid transport (GO:0015908),0.987034548397287,1.717470513449772,0.3225806451612903,0.7586399314595191,1.0,1/18,1.30%,APOE
prerank,WikiPathway_2021_Human__Purine metabolism and related disorders WP4224,0.9848801520364707,1.7170621469467937,0.3939393939393939,0.7580357115629455,1.0,1/20,1.51%,HPRT1
prerank,GO_Biological_Process_2021__histone H2A ubiquitination (GO:0033522),0.9969212767997587,1.7167687681572972,0.05185185185185185,0.7563725987046863,1.0,1/17,0.31%,BCOR
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (Claudins),0.9886908281781943,1.7167675176960056,0.26515151515151514,0.7532210462100836,1.0,2/23,1.14%,TJP1;CRB3
prerank,GO_Biological_Process_2021__mismatch repair (GO:0006298),0.9983026267207333,1.7159703623854978,0.028985507246376812,0.7545208513689136,1.0,1/27,0.17%,MSH2
prerank,GO_Biological_Process_2021__positive regulation of response to wounding (GO:1903036),0.9974549059126429,1.7159671241544636,0.05426356589147287,0.7514186795924191,1.0,1/27,0.26%,PTK2
prerank,WikiPathway_2021_Human__Cysteine and methionine catabolism WP4504,-0.9883867955473722,-1.7158559017677089,0.30701754385964913,0.7359263522378042,1.0,2/15,1.17%,BHMT;CDO1
prerank,GO_Biological_Process_2021__regulation of supramolecular fiber organization (GO:1902903),0.987073604869555,1.7157479747027309,0.34532374100719426,0.7494665679331065,1.0,2/22,1.30%,CAMSAP3;APOE
prerank,Reactome_2022__Translesion Synthesis By POLH R-HSA-110320,0.9949578474506855,1.7156007025144977,0.1171875,0.7472504774094009,1.0,1/19,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__regulation of cytokine production involved in immune response (GO:0002718),-0.9906088421306328,-1.7154348813970126,0.2558139534883721,0.7356967105615706,1.0,1/23,0.95%,SCIMP
prerank,GO_Biological_Process_2021__chaperone cofactor-dependent protein refolding (GO:0051085),-0.9938411347633185,-1.7153729291110995,0.1487603305785124,0.7342110098053695,1.0,1/25,0.62%,DNAJB14
prerank,GO_Biological_Process_2021__aortic valve development (GO:0003176),-0.9947983435789634,-1.7150492805363857,0.10344827586206896,0.7336181926766302,1.0,1/35,0.53%,RB1
prerank,Elsevier_Pathway_Collection__PPARGC1A Repression in Huntington Disease,0.9921522646348132,1.7149450434654057,0.19708029197080293,0.7476859380235745,1.0,1/18,0.79%,PPARA
prerank,Elsevier_Pathway_Collection__ALK Associated Neuroblastoma,-0.9966867498500049,-1.7145018400757037,0.10483870967741936,0.7338126664832044,1.0,1/24,0.34%,RAP1A
prerank,Reactome_2022__Acyl Chain Remodelling Of PE R-HSA-1482839,-0.9984572335792018,-1.71349625537349,0.034782608695652174,0.7355319415224947,1.0,1/25,0.16%,PLAAT3
prerank,Elsevier_Pathway_Collection__Deacetylases Activation in Histone Deacetylation in Cancer,0.9961135853488573,1.7134877024363955,0.09917355371900827,0.7525302587009433,1.0,1/15,0.39%,HDAC8
prerank,Reactome_2022__Ephrin Signaling R-HSA-3928664,0.991728107720745,1.7134068393110418,0.2108843537414966,0.7498677152909448,1.0,1/18,0.83%,ARHGEF7
prerank,Reactome_2022__Dectin-2 Family R-HSA-5621480,-0.9886918796654275,-1.7133308102816958,0.368,0.7343965693045452,1.0,2/22,1.14%,MUC6;CLEC10A
prerank,WikiPathway_2021_Human__SREBF and miR33 in cholesterol and lipid homeostasis WP2011,0.9921527692771452,1.7131714720878715,0.21238938053097345,0.7482672856951126,1.0,1/16,0.79%,PPARA
prerank,WikiPathway_2021_Human__Tamoxifen metabolism WP691,-0.9874628492401368,-1.7122774847062519,0.3611111111111111,0.7362149393710389,1.0,3/19,1.27%,CYP2C8;CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__nuclear-transcribed mRNA poly(A) tail shortening (GO:0000289),0.9912654619107352,1.7122438354798086,0.21374045801526717,0.7500786979633729,1.0,1/21,0.88%,PARN
prerank,GO_Biological_Process_2021__telomere capping (GO:0016233),0.9859630497274476,1.7119084378527998,0.3484848484848485,0.7489152993968299,1.0,2/17,1.41%,DCLRE1C;ACD
prerank,GO_Biological_Process_2021__determination of bilateral symmetry (GO:0009855),0.9865306254897032,1.7116246127596495,0.2978723404255319,0.7475343612895471,1.0,1/21,1.35%,KIF3B
prerank,Elsevier_Pathway_Collection__Il17 Signaling Related Neutrophilia in Asthma,-0.9881420857051565,-1.711327694323206,0.3333333333333333,0.7378084136717804,1.0,1/26,1.19%,IL12RB2
prerank,TRRUST_Transcription_Factors_2019__CEBPA mouse,-0.9890315580462218,-1.7109248290613026,0.30158730158730157,0.7374903302776821,1.0,1/21,1.10%,SPI1
prerank,GO_Biological_Process_2021__entrainment of circadian clock by photoperiod (GO:0043153),-0.9869107836328184,-1.7109207534908732,0.36585365853658536,0.7357831767353725,1.0,1/26,1.31%,PML
prerank,Reactome_2022__Growth Hormone Receptor Signaling R-HSA-982772,0.9860706250078127,1.7105781768204098,0.31932773109243695,0.7506223326567144,1.0,1/20,1.39%,PRLR
prerank,GO_Biological_Process_2021__regulation of dopamine secretion (GO:0014059),-0.9913019534880647,-1.7104496585972675,0.29545454545454547,0.7357643379409123,1.0,1/22,0.88%,SYT7
prerank,GO_Biological_Process_2021__lipid droplet organization (GO:0034389),0.9916884261702231,1.7099867604546433,0.20863309352517986,0.7509106873743713,1.0,1/22,0.83%,RAB3GAP1
prerank,Reactome_2022__Olfactory Signaling Pathway R-HSA-381753,-0.9953409316211883,-1.7098542265586756,0.12931034482758622,0.7360575036457662,1.0,1/23,0.47%,LDB2
prerank,Reactome_2022__KSRP (KHSRP) Binds And Destabilizes mRNA R-HSA-450604,0.9912676787159584,1.7095849031377839,0.2109375,0.7499715232379729,1.0,1/17,0.88%,PARN
prerank,Elsevier_Pathway_Collection__Familial Cold Autoinflammatory Syndrome 2,-0.9896808896559137,-1.7093108555350274,0.31896551724137934,0.7361450960472802,1.0,1/28,1.04%,TICAM2
prerank,GO_Biological_Process_2021__endosome transport via multivesicular body sorting pathway (GO:0032509),0.9954169740083559,1.7092270537405754,0.1450381679389313,0.7491290258349718,1.0,1/25,0.46%,SORT1
prerank,GO_Biological_Process_2021__detection of mechanical stimulus (GO:0050982),0.9974592649688326,1.7092186110588747,0.031746031746031744,0.7462027405778039,1.0,1/16,0.26%,PTK2
prerank,Reactome_2022__PI-3K cascade:FGFR4 R-HSA-5654720,0.9865016739567589,1.7090880726438709,0.3511450381679389,0.7439785390465036,1.0,2/16,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__mammary gland development (GO:0030879),0.9861544979802624,1.7090309649817421,0.371900826446281,0.741330267590184,1.0,3/21,1.39%,GPAT4;TBX3;PRLR
prerank,Elsevier_Pathway_Collection__Insulin Secretion,0.9869204018487538,1.7087016892275113,0.3181818181818182,0.7402264201279454,1.0,1/18,1.31%,CPE
prerank,Elsevier_Pathway_Collection__EZH2 Methyltransferase Role in Cancer,-0.9947998040322537,-1.708553741038298,0.15966386554621848,0.7369890983932565,1.0,1/28,0.53%,RB1
prerank,GO_Biological_Process_2021__cortical actin cytoskeleton organization (GO:0030866),0.9876163018836989,1.7078454153902853,0.304,0.7420213166020935,1.0,3/20,1.25%,DLG1;RHOQ;FMNL2
prerank,GO_Biological_Process_2021__adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460),0.9983037153014289,1.7074705503830367,0.04065040650406504,0.7412286475173065,1.0,1/20,0.17%,MSH2
prerank,GO_Biological_Process_2021__activation of NF-kappaB-inducing kinase activity (GO:0007250),0.995805670808184,1.7072779419560393,0.0847457627118644,0.7396308241445935,1.0,1/16,0.42%,TNFRSF10A
prerank,Elsevier_Pathway_Collection__GUCY2C Signaling in Colorectal Cancer,-0.996802053802481,-1.7072535332804541,0.09482758620689655,0.7395330080811812,1.0,1/26,0.33%,PDE5A
prerank,Elsevier_Pathway_Collection__Hutchinson-Gilford Progeria Syndrome,-0.9889210762678077,-1.7071247612112534,0.3416666666666667,0.7383178386478163,1.0,1/16,1.11%,SYNE1
prerank,KEGG_2021_Human__Fatty acid biosynthesis,0.988309552511496,1.7053761243866181,0.2740740740740741,0.7480600767341583,1.0,3/18,1.18%,ACACA;ACSF3;ACSL5
prerank,Elsevier_Pathway_Collection__Nuclear Lamina Cleavage,-0.98896086585054,-1.7051231303399426,0.28688524590163933,0.7430345968937243,1.0,2/20,1.11%,RB1;SYNE1
prerank,GO_Biological_Process_2021__aminoglycan catabolic process (GO:0006026),-0.9884859075013176,-1.7050957979647727,0.3170731707317073,0.7414324124743649,1.0,1/31,1.16%,SDC3
prerank,GO_Biological_Process_2021__organophosphate ester transport (GO:0015748),0.9944563223490973,1.704473890608046,0.10743801652892562,0.7503443953782792,1.0,1/24,0.56%,PRELID3A
prerank,GO_Biological_Process_2021__immune response-activating cell surface receptor signaling pathway (GO:0002429),0.9851464706826968,1.7040417272030786,0.38461538461538464,0.7498330414186443,1.0,1/22,1.49%,BCAR1
prerank,GO_Biological_Process_2021__granulocyte differentiation (GO:0030851),-0.9869592767216518,-1.7037643109604024,0.390625,0.743597835172867,1.0,2/20,1.31%,SPI1;PML
prerank,WikiPathway_2021_Human__Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,-0.9948022322835671,-1.7037630090749056,0.2076923076923077,0.7419250581331034,1.0,1/22,0.53%,RB1
prerank,GO_Biological_Process_2021__positive regulation of nuclear division (GO:0051785),0.9959947490435832,1.7034225329793806,0.08264462809917356,0.7508664735691692,1.0,1/21,0.40%,LRP5
prerank,GO_Biological_Process_2021__meiosis I (GO:0007127),0.9967282483271884,1.7030948283905414,0.08870967741935484,0.7498026276728135,1.0,1/19,0.33%,SYCP3
prerank,Reactome_2022__TNF Receptor Superfamily (TNFSF) Members Mediating Non-Canonical NF-kB Pathway R-HSA-5676594,0.9956126894531002,1.7028347759892408,0.046511627906976744,0.7487608824229126,1.0,1/17,0.44%,TRAF3
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte chemotaxis (GO:0140131),-0.9933446911654369,-1.7024065207571304,0.19130434782608696,0.7442801299613739,1.0,1/15,0.67%,PTK2B
prerank,Elsevier_Pathway_Collection__TLR -> AP-1 Signaling,-0.9969571866542949,-1.7017047317857028,0.07633587786259542,0.7446142083601737,1.0,1/23,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902175),-0.9989589253034579,-1.7010204989672133,0.02830188679245283,0.7451844472828716,1.0,1/17,0.11%,VNN1
prerank,TRRUST_Transcription_Factors_2019__ATM human,0.9906493310222577,1.7010090215053957,0.19083969465648856,0.7574760999145047,1.0,1/22,0.94%,PBK
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway in absence of ligand (GO:0097192),0.9849993725217425,1.7006167186505077,0.3798449612403101,0.756793179174248,1.0,2/20,1.51%,ERBB3;BOK
prerank,Elsevier_Pathway_Collection__Cathepsins Role in Periodontitis,0.9849222425663673,1.7003619462188755,0.3949579831932773,0.7554150620082272,1.0,1/15,1.51%,FN1
prerank,Elsevier_Pathway_Collection__Hedgehog Family Signaling,-0.987872005895763,-1.6997380489620055,0.3902439024390244,0.7474499736182821,1.0,1/25,1.22%,GLI3
prerank,TRRUST_Transcription_Factors_2019__NOTCH1 mouse,-0.9890332741079867,-1.6996527068708474,0.30952380952380953,0.746023888606898,1.0,1/20,1.10%,SPI1
prerank,WikiPathway_2021_Human__Transcription factor regulation in adipogenesis WP3599,-0.9959580176503691,-1.698461912417433,0.096,0.7477864005649556,1.0,1/21,0.41%,NR3C1
prerank,GO_Biological_Process_2021__acyl-CoA biosynthetic process (GO:0071616),0.9987661954720648,1.6978124518848956,0.023622047244094488,0.7678607863018111,1.0,1/17,0.13%,ACACA
prerank,GO_Biological_Process_2021__negative regulation of insulin receptor signaling pathway (GO:0046627),-0.986447283056769,-1.6974698241446327,0.3783783783783784,0.7491170811515341,1.0,1/27,1.36%,GRB10
prerank,GO_Biological_Process_2021__regulation of nuclear division (GO:0051783),0.988499523557975,1.697111258422253,0.3230769230769231,0.7693577696917254,1.0,2/20,1.16%,MKI67;PKMYT1
prerank,Reactome_2022__Plasma Lipoprotein Assembly R-HSA-8963898,0.987039628014889,1.6971046810522168,0.31451612903225806,0.7665498946198579,1.0,1/15,1.30%,APOE
prerank,GO_Biological_Process_2021__cellular biogenic amine biosynthetic process (GO:0042401),0.9970754216106698,1.6969271313848802,0.05714285714285714,0.7648527213125965,1.0,1/15,0.30%,SMOX
prerank,Elsevier_Pathway_Collection__Nicotine anti-Inflammatory Effect in Ulcerative Colitis,-0.9896819252143694,-1.6958768293317565,0.3548387096774194,0.7524254274666798,1.0,1/28,1.04%,TICAM2
prerank,Elsevier_Pathway_Collection__Hyperseborrhea in Acne Vulgaris,0.9921478890321276,1.69581287264028,0.16535433070866143,0.7682419726587443,1.0,1/26,0.79%,PPARA
prerank,Elsevier_Pathway_Collection__Familial Mediterranean Fever,-0.9896836488861094,-1.6954604945328071,0.3220338983050847,0.7520327594883316,1.0,1/25,1.04%,TICAM2
prerank,GO_Biological_Process_2021__exogenous drug catabolic process (GO:0042738),-0.9911530225469077,-1.695400358963803,0.2459016393442623,0.7504812812663828,1.0,2/21,0.90%,CYP2C8;CYP1A2
prerank,TRRUST_Transcription_Factors_2019__YY1 mouse,-0.9948446760590192,-1.695177484820743,0.11811023622047244,0.7495063071412965,1.0,2/20,0.53%,NR3C1;RB1
prerank,Elsevier_Pathway_Collection__Primary Mediastinal B-cell Lymphoma (PMBL) Subtype,-0.9898368921446438,-1.694947924323715,0.2831858407079646,0.7484890379286853,1.0,1/28,1.02%,CD274
prerank,GO_Biological_Process_2021__glutamine family amino acid catabolic process (GO:0009065),0.9851136356006113,1.6949145499936262,0.3644067796610169,0.7699625876237993,1.0,1/16,1.49%,GLS
prerank,KEGG_2021_Human__Citrate cycle (TCA cycle),-0.9976480083790338,-1.694541042810854,0.05128205128205128,0.7481921512994074,1.0,1/29,0.24%,SUCLG2
prerank,GO_Biological_Process_2021__artery development (GO:0060840),-0.9973420371705086,-1.6943983278060477,0.058394160583941604,0.7469874054173312,1.0,1/23,0.27%,SLC2A10
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Infected Cells,-0.9969522081874662,-1.694363772971861,0.05511811023622047,0.7454084008137567,1.0,1/31,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Toll-like Receptors (TLR) in Antiviral Innate Immune Response,-0.9896877762835069,-1.6943278759927467,0.3125,0.743919421235472,1.0,1/20,1.04%,TICAM2
prerank,Reactome_2022__Apoptotic Factor-Mediated Response R-HSA-111471,0.9845312539655239,1.6941834339934265,0.38461538461538464,0.7716435198807804,1.0,1/20,1.55%,UACA
prerank,TRRUST_Transcription_Factors_2019__NANOG human,0.9981115265839607,1.6940611528979317,0.045454545454545456,0.7695851367836347,1.0,1/21,0.19%,CDK6
prerank,GO_Biological_Process_2021__negative regulation of protein dephosphorylation (GO:0035308),0.9990725153781753,1.6936165811653967,0.022556390977443608,0.7690731235824315,1.0,1/21,0.10%,PPP1R16B
prerank,Elsevier_Pathway_Collection__ER Associated Protein Degradation in Vesicular Transport,-0.992842881439353,-1.693463257397702,0.18461538461538463,0.7451005044431868,1.0,1/19,0.72%,AMFR
prerank,WikiPathway_2021_Human__Resistin as a regulator of inflammation WP4481,-0.9928019153013478,-1.6930298005239799,0.12931034482758622,0.7448969795943601,1.0,2/33,0.73%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__hippo signaling (GO:0035329),0.9888812049602365,1.692687984666633,0.2727272727272727,0.7714416049605783,1.0,2/26,1.12%,TJP1;TEAD4
prerank,Elsevier_Pathway_Collection__MUC5AC Expression by NTHi and S. Pneumoniae,-0.9969573414245758,-1.6925511201011478,0.12096774193548387,0.7447493969392023,1.0,1/21,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance via telomerase (GO:0032211),0.9859615350781963,1.6924731539934808,0.35,0.7698634226923625,1.0,2/19,1.41%,PIF1;ACD
prerank,GO_Biological_Process_2021__drug catabolic process (GO:0042737),-0.9911526263424488,-1.6922848553856515,0.24806201550387597,0.7440072693305518,1.0,2/22,0.90%,CYP2C8;CYP1A2
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transmembrane transport (GO:1904427),0.9993415016733255,1.6922775623827397,0.023809523809523808,0.7682159283244753,1.0,1/25,0.07%,THY1
prerank,GO_Biological_Process_2021__long-chain fatty-acyl-CoA metabolic process (GO:0035336),0.9882664041862996,1.6918786187576036,0.2796610169491525,0.7676090383965326,1.0,2/24,1.18%,ACSF3;ACSL5
prerank,WikiPathway_2021_Human__MAPK pathway in congenital thyroid cancer WP4928,0.9978432255981632,1.6917728689795344,0.016260162601626018,0.7652752263296878,1.0,1/16,0.22%,KSR1
prerank,GO_Biological_Process_2021__regulation of execution phase of apoptosis (GO:1900117),0.984955930720835,1.6912791638688365,0.392,0.7653065626616807,1.0,1/18,1.51%,BOK
prerank,GO_Biological_Process_2021__release of cytochrome c from mitochondria (GO:0001836),0.984957519882683,1.6908948500779204,0.4028776978417266,0.7650996490323684,1.0,1/18,1.51%,BOK
prerank,KEGG_2021_Human__Terpenoid backbone biosynthesis,-0.9974952823240728,-1.6907692189283532,0.07017543859649122,0.7471972134325979,1.0,1/21,0.26%,PDSS2
prerank,GO_Biological_Process_2021__nucleotide biosynthetic process (GO:0009165),0.9849252470426306,1.690187303116042,0.3669064748201439,0.7663437589709605,1.0,2/17,1.51%,RRM2;HPRT1
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> CREBBP Signaling,-0.9887235544148711,-1.6897113807127333,0.3162393162393162,0.7490240612833443,1.0,1/22,1.13%,ZAP70
prerank,Reactome_2022__Synthesis Of Very Long-Chain Fatty acyl-CoAs R-HSA-75876,0.9882682192603764,1.689687083742772,0.2734375,0.76639733759111,1.0,2/22,1.18%,ACSF3;ACSL5
prerank,GO_Biological_Process_2021__actin nucleation (GO:0045010),0.9892642861600274,1.6895355278354187,0.22962962962962963,0.7645921675072241,1.0,1/21,1.08%,SPIRE2
prerank,GO_Biological_Process_2021__regulation of cholesterol transport (GO:0032374),-0.9908391639052694,-1.6891776597392598,0.27049180327868855,0.7490963126902594,1.0,1/25,0.92%,LIPG
prerank,KEGG_2021_Human__Selenocompound metabolism,0.9894634091575845,1.6891142728421904,0.25984251968503935,0.7641688355442293,1.0,3/17,1.06%,SCLY;PAPSS1;TXNRD2
prerank,GO_Biological_Process_2021__regulation of cellular protein catabolic process (GO:1903362),0.9969593848755213,1.688984402049868,0.06837606837606838,0.7622536861029533,1.0,1/17,0.31%,VGLL4
prerank,Elsevier_Pathway_Collection__ER Stress (Unfolded Protein Response),-0.9969548741129809,-1.688928784553046,0.0975609756097561,0.7482513682900066,1.0,1/31,0.31%,MAP2K6
prerank,Reactome_2022__Post-chaperonin Tubulin Folding Pathway R-HSA-389977,0.9869229941080031,1.688879485561877,0.348993288590604,0.7602350307427945,1.0,2/20,1.31%,TBCD;TUBA1A
prerank,GO_Biological_Process_2021__regulation of gluconeogenesis (GO:0006111),-0.9925298620988933,-1.6887271288227068,0.23484848484848486,0.7473103974855361,1.0,1/27,0.75%,SDHAF3
prerank,Reactome_2022__Signaling By FGFR2 IIIa TM R-HSA-8851708,0.9864574347413726,1.6883932543267905,0.30434782608695654,0.7598953842897987,1.0,1/19,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__IL4R -> ELK/SRF/HMGY Signaling,0.9884553455064908,1.6883330770221638,0.3130434782608696,0.7577054285590454,1.0,1/21,1.16%,PKMYT1
prerank,GO_Biological_Process_2021__oligosaccharide biosynthetic process (GO:0009312),0.9856861797490903,1.686986627217729,0.3644067796610169,0.7620950809957755,1.0,1/22,1.43%,FUT6
prerank,"Reactome_2022__Inactivation, Recovery And Regulation Of Phototransduction Cascade R-HSA-2514859",0.9888779349801241,1.6868589783202523,0.304,0.7602702703679133,1.0,1/25,1.11%,GNB5
prerank,WikiPathway_2021_Human__Glutathione metabolism WP100,-0.996268184967049,-1.6868119850943657,0.10185185185185185,0.7522218628542632,1.0,2/20,0.38%,GSTA1;GGT5
prerank,Elsevier_Pathway_Collection__CCR1 Expression Targets,-0.9991886331995632,-1.6867306557552169,0.043859649122807015,0.7507983784386801,1.0,1/26,0.09%,CCL23
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Docking,0.988115882152445,1.6864252037166976,0.32061068702290074,0.7602407249255247,1.0,2/19,1.20%,RHOQ;STX1A
prerank,GO_Biological_Process_2021__diacylglycerol metabolic process (GO:0046339),-0.990878380023249,-1.686021446889265,0.2809917355371901,0.751343129327439,1.0,1/22,0.92%,MOGAT1
prerank,GO_Biological_Process_2021__cellular response to virus (GO:0098586),-0.9922639622958376,-1.6858026929871168,0.24107142857142858,0.7503137684724536,1.0,2/31,0.78%,OAS1;TOMM70
prerank,GO_Biological_Process_2021__response to nutrient levels (GO:0031667),0.9996898456001836,1.6855881441392073,0.0,0.7618995792312946,1.0,1/15,0.03%,PRKAA2
prerank,Reactome_2022__RAS Processing R-HSA-9648002,0.9877281031536159,1.6855067348277073,0.31654676258992803,0.7597773949274882,1.0,1/17,1.23%,ZDHHC9
prerank,GO_Biological_Process_2021__mRNA polyadenylation (GO:0006378),-0.9965718971651965,-1.685478337199996,0.0975609756097561,0.7481876106372278,1.0,1/25,0.35%,APP
prerank,GO_Biological_Process_2021__RNA polyadenylation (GO:0043631),-0.9965718971651965,-1.685478337199996,0.0975609756097561,0.7481876106372278,1.0,1/25,0.35%,APP
prerank,GO_Biological_Process_2021__response to glucocorticoid (GO:0051384),-0.9959540494996824,-1.6853574530895858,0.1,0.7470464738980507,1.0,1/25,0.41%,NR3C1
prerank,Reactome_2022__Impaired BRCA2 Binding To PALB2 R-HSA-9709603,0.9962258943308061,1.6853484561448138,0.07692307692307693,0.7580854054964292,1.0,1/24,0.38%,BRIP1
prerank,WikiPathway_2021_Human__Transcription co-factors SKI and SKIL protein partners WP4533,0.9888436093180081,1.684967693415829,0.2595419847328244,0.7575105311219937,1.0,1/18,1.12%,TEAD4
prerank,Elsevier_Pathway_Collection__PI3K/AKT/MTOR Signaling Activation by Blocking of Tumor Suppressors,-0.9963790276430117,-1.6849327106898424,0.1282051282051282,0.7469966825743429,1.0,1/25,0.37%,AKT3
prerank,Reactome_2022__SHC-mediated cascade:FGFR2 R-HSA-5654699,0.9864610498485544,1.6847937554563734,0.328125,0.7560000251946044,1.0,1/16,1.36%,FGF1
prerank,Reactome_2022__Role Of Nef In HIV-1 Replication And Disease Pathogenesis R-HSA-164952,-0.9919922198331375,-1.684754551737043,0.22627737226277372,0.7460939138500204,1.0,1/27,0.81%,HCK
prerank,GO_Biological_Process_2021__mesoderm formation (GO:0001707),0.9962668184183656,1.6846433562976493,0.08695652173913043,0.7541623758873102,1.0,1/18,0.38%,ITGA2
prerank,GO_Biological_Process_2021__gluconeogenesis (GO:0006094),-0.9992236717018991,-1.6845131315340791,0.008130081300813009,0.7453368299789586,1.0,1/36,0.08%,ALDOB
prerank,GO_Biological_Process_2021__regulation of mitotic sister chromatid separation (GO:0010965),0.990656023277205,1.684445512653326,0.25396825396825395,0.7525980912003991,1.0,2/16,0.94%,CENPE;UBE2C
prerank,Reactome_2022__Defective HDR Thru Homologous Recombination (HRR) Due To BRCA1 Loss-Of-Function R-HSA-9701192,0.9962256934292943,1.6844051078515931,0.08148148148148149,0.750312260642233,1.0,1/25,0.38%,BRIP1
prerank,GO_Biological_Process_2021__regulation of transcription regulatory region DNA binding (GO:2000677),-0.9948020027556765,-1.6836599711286482,0.14285714285714285,0.7466892554465943,1.0,1/25,0.53%,RB1
prerank,TRRUST_Transcription_Factors_2019__STAT6 human,-0.9991475963454732,-1.6833720852880407,0.0743801652892562,0.7462431992416092,1.0,1/33,0.09%,FOSB
prerank,Reactome_2022__Resolution Of D-loop Structures Thru Synthesis-Dependent Strand Annealing (SDSA) R-HSA-5693554,0.9962253500992613,1.6831331829618863,0.08029197080291971,0.7549890354263878,1.0,1/27,0.38%,BRIP1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Ovarian Cancer,0.9957249578838819,1.682026663789404,0.07692307692307693,0.7584524966733198,1.0,1/28,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__negative regulation of ubiquitin-dependent protein catabolic process (GO:2000059),-0.986902201681862,-1.6819931894328195,0.3565217391304348,0.7497649862266055,1.0,1/36,1.31%,PML
prerank,GO_Biological_Process_2021__photoperiodism (GO:0009648),-0.9869093877381241,-1.6819167056010451,0.3790322580645161,0.7484788675265834,1.0,1/27,1.31%,PML
prerank,GO_Biological_Process_2021__cellular nitrogen compound biosynthetic process (GO:0044271),-0.9873686874151413,-1.6817922565044465,0.3412698412698413,0.7474262803845066,1.0,1/31,1.27%,CYP1B1
prerank,GO_Biological_Process_2021__regulation of ubiquitin protein ligase activity (GO:1904666),0.9906108665217217,1.680744067056971,0.2536231884057971,0.7621146250520858,1.0,1/21,0.94%,UBE2C
prerank,Reactome_2022__FCERI Mediated Ca+2 Mobilization R-HSA-2871809,-0.989105558888432,-1.680126315916196,0.2890625,0.7514492569631668,1.0,1/29,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Apoptosis of Myocyte,0.9958035212373798,1.6801151317427125,0.1111111111111111,0.7623863448582644,1.0,1/19,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__negative regulation of toll-like receptor signaling pathway (GO:0034122),-0.9896778461217457,-1.6796972231693104,0.25210084033613445,0.7512514474603094,1.0,1/34,1.04%,TICAM2
prerank,Elsevier_Pathway_Collection__Thyroid Stimulating Hormone (TSH) Resistance in Congenital Hypothyroidism,-0.9966841500277362,-1.678686766690854,0.07462686567164178,0.75309550472193,1.0,1/31,0.34%,RAP1A
prerank,Reactome_2022__Cyclin A/B1/B2 Associated Events During G2/M Transition R-HSA-69273,0.9884544639478089,1.6785003878888851,0.30935251798561153,0.7671594004140057,1.0,1/24,1.16%,PKMYT1
prerank,Reactome_2022__Sema4D Induced Cell Migration And Growth-Cone Collapse R-HSA-416572,-0.9904574473238923,-1.6782842726625913,0.26229508196721313,0.7528341904578914,1.0,1/20,0.96%,SEMA4D
prerank,WikiPathway_2021_Human__SARS coronavirus and innate immunity WP4912,0.9956127660344092,1.6780194475981287,0.06504065040650407,0.7666346900014711,1.0,1/17,0.44%,TRAF3
prerank,GO_Biological_Process_2021__acylglycerol homeostasis (GO:0055090),0.9870287059288377,1.6779178969399082,0.371900826446281,0.7646582723875139,1.0,1/24,1.30%,APOE
prerank,WikiPathway_2021_Human__Constitutive Androstane Receptor Pathway WP2875,-0.9960731689479468,-1.6779094142111626,0.11009174311926606,0.752669502165307,1.0,2/32,0.40%,GSTA2;NCOA1
prerank,Elsevier_Pathway_Collection__Hypothalamic-Pituitary-Adrenal Axis in Acute Phase Response,-0.9959971860666808,-1.6776832809185862,0.13793103448275862,0.7518726650489171,1.0,2/26,0.41%,RAP1A;NR3C1
prerank,Elsevier_Pathway_Collection__ICAM1 -> AP-1/CREB/ELK/SRF Signaling,-0.9969559114903871,-1.6773100483659424,0.125,0.7515895013608974,1.0,1/23,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Congenital Hypothyroidism,0.9856507898996528,1.677183422650623,0.3897058823529412,0.7658491200460759,1.0,1/18,1.44%,SERPINA7
prerank,Elsevier_Pathway_Collection__EctodysplasinR -> AP-1 Signaling,0.9880328595270296,1.6770945903968653,0.3017241379310345,0.7638997935008186,1.0,1/19,1.20%,EDA2R
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Medulloblastoma,-0.9907246253676703,-1.6767613248940614,0.24444444444444444,0.751834133033716,1.0,1/23,0.93%,CCND2
prerank,KEGG_2021_Human__Carbohydrate digestion and absorption,-0.9927997296954357,-1.676727406292306,0.13675213675213677,0.7503804452930681,1.0,2/37,0.73%,AKT3;PIK3CB
prerank,Elsevier_Pathway_Collection__Nuclear Envelope in Cell Division,-0.9889598834137091,-1.6765129110179433,0.3023255813953488,0.7496205341037712,1.0,2/21,1.11%,RB1;SYNE1
prerank,Elsevier_Pathway_Collection__RET1 Mutation in Hyperparathyroidism,0.9974567444184537,1.6762192857497673,0.04838709677419355,0.7654217951605599,1.0,1/21,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__HTR1 -> IL6 Production,-0.9967276119990508,-1.6760510901694163,0.125,0.7496274057999457,1.0,2/26,0.34%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__DNA geometric change (GO:0032392),0.9887224002464188,1.6758840805833999,0.2672413793103448,0.7648629523552402,1.0,1/26,1.13%,PIF1
prerank,Elsevier_Pathway_Collection__CHRM1/2/3/5 -> Ion Channels,0.9998427390688093,1.6757043726845273,0.0,0.7632812274124577,1.0,1/23,0.02%,KCNC1
prerank,Reactome_2022__MicroRNA (miRNA) Biogenesis R-HSA-203927,0.9953021502626183,1.675404981002504,0.08130081300813008,0.7622210089039936,1.0,1/24,0.47%,DROSHA
prerank,WikiPathway_2021_Human__Interactions between immune cells and microRNAs in tumor microenvironment WP4559,-0.989839469512566,-1.6752978394809552,0.3135593220338983,0.7506361826327413,1.0,1/27,1.02%,CD274
prerank,Elsevier_Pathway_Collection__CD38/CD3 -> JUN/FOS/NF-kB Signaling in T-cell Proliferation,-0.9887628659315164,-1.675196936526294,0.336283185840708,0.7495128724566659,1.0,2/29,1.13%,PTK2B;ZAP70
prerank,Elsevier_Pathway_Collection__FcIgER -> ELK-SRF Signaling,-0.9887630820202651,-1.6751781614289545,0.32061068702290074,0.7480444027903953,1.0,2/27,1.13%,VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__ActivinR/BMPR -> SMAD1/5/9 Signaling,0.9905328613661535,1.6751279439056332,0.26717557251908397,0.7612385782885307,1.0,1/25,0.95%,AMH
prerank,Reactome_2022__Defects In Vitamin And Cofactor Metabolism R-HSA-3296482,0.9987661229248553,1.6750728878420682,0.03968253968253968,0.7590917613707714,1.0,1/19,0.13%,ACACA
prerank,Reactome_2022__ER Quality Control Compartment (ERQC) R-HSA-901032,-0.9928420325261581,-1.6750105199983725,0.20909090909090908,0.7470840409140095,1.0,1/21,0.72%,AMFR
prerank,GO_Biological_Process_2021__peptidyl-tyrosine dephosphorylation (GO:0035335),-0.9866415316056432,-1.6749652114264673,0.373015873015873,0.7456943038574849,1.0,2/34,1.34%,DUSP4;PTPN18
prerank,GO_Biological_Process_2021__regulation of bicellular tight junction assembly (GO:2000810),0.9955353032566079,1.6745842677428486,0.07971014492753623,0.7593038098065179,1.0,1/19,0.45%,TJP1
prerank,Reactome_2022__Resolution Of AP Sites Via Multiple-Nucleotide Patch Replacement Pathway R-HSA-110373,0.9848441199162636,1.674399600259101,0.376,0.7578342813219591,1.0,3/25,1.53%,SLC19A1;POLE4;LRIG1
prerank,Reactome_2022__Interleukin Receptor SHC Signaling R-HSA-912526,-0.99276298304133,-1.6743068428984116,0.21487603305785125,0.7464041343814094,1.0,1/25,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__carbohydrate biosynthetic process (GO:0016051),0.9856848424209772,1.6738403828644624,0.3770491803278688,0.7582597508978532,1.0,1/23,1.43%,FUT6
prerank,Reactome_2022__Cristae Formation R-HSA-8949613,-0.9933001127566407,-1.6738054804007254,0.21428571428571427,0.746645783387536,1.0,1/29,0.68%,CHCHD3
prerank,GO_Biological_Process_2021__aspartate family amino acid metabolic process (GO:0009066),0.9848415081249469,1.673672329885363,0.38524590163934425,0.7566857002634644,1.0,1/19,1.52%,SMS
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> NFATC Signaling,-0.9887222047572282,-1.6736692958008845,0.32456140350877194,0.7455776664144363,1.0,1/24,1.13%,ZAP70
prerank,GO_Biological_Process_2021__regulation of transmembrane transport (GO:0034762),0.9941068647584018,1.673566221505648,0.14035087719298245,0.7547953312869456,1.0,1/30,0.59%,WWP2
prerank,GO_Biological_Process_2021__interleukin-6-mediated signaling pathway (GO:0070102),-0.9890363490335777,-1.6733068513797487,0.3,0.7452806672526905,1.0,1/18,1.10%,SPI1
prerank,Elsevier_Pathway_Collection__PAPA Syndrome,-0.9896827586523632,-1.673269405302692,0.3445378151260504,0.7438915093050116,1.0,1/26,1.04%,TICAM2
prerank,GO_Biological_Process_2021__regulation of mononuclear cell migration (GO:0071675),0.9974576204514187,1.6728681112044264,0.05343511450381679,0.7558761473549303,1.0,1/22,0.26%,PTK2
prerank,GO_Biological_Process_2021__positive regulation of synapse assembly (GO:0051965),-0.9904524570975453,-1.672788147561344,0.27927927927927926,0.7440103215553694,1.0,1/26,0.96%,SEMA4D
prerank,Elsevier_Pathway_Collection__Double Strand DNA non-Homologous Repair,0.9924211406292803,1.672528054504776,0.18548387096774194,0.7530115270627663,1.0,1/20,0.76%,DCLRE1C
prerank,Elsevier_Pathway_Collection__Persistent Double Strand DNA non-Homologous Repair in Cancer,0.9924211406292803,1.672528054504776,0.18548387096774194,0.7530115270627663,1.0,1/20,0.76%,DCLRE1C
prerank,Reactome_2022__PCNA-Dependent Long Patch Base Excision Repair R-HSA-5651801,0.9848467281829811,1.6717114548688636,0.3875968992248062,0.7547434716128226,1.0,3/21,1.53%,SLC19A1;POLE4;LRIG1
prerank,GO_Biological_Process_2021__cellular response to cAMP (GO:0071320),-0.9919575659912984,-1.6715529280820398,0.23846153846153847,0.7465077304733115,1.0,3/31,0.82%,RAP1A;RAP1B;KCNE1
prerank,GO_Biological_Process_2021__regulation of toll-like receptor 4 signaling pathway (GO:0034143),-0.9896851976446154,-1.671344587360278,0.30973451327433627,0.7456761727786833,1.0,1/23,1.04%,TICAM2
prerank,Reactome_2022__Negative Regulation Of FGFR3 Signaling R-HSA-5654732,0.9864517044218806,1.67106817504643,0.3779527559055118,0.755410069385938,1.0,1/25,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cryptorchidism,0.9905386185158478,1.6708058745864887,0.248,0.7541864423518457,1.0,1/15,0.95%,AMH
prerank,Elsevier_Pathway_Collection__Myocyte Dysfunction in Hypoparathyroidism,0.9974590498008198,1.6707517602843522,0.03731343283582089,0.7520697823416128,1.0,1/15,0.26%,PTK2
prerank,GO_Biological_Process_2021__cristae formation (GO:0042407),-0.993300151840297,-1.6705982203426917,0.1951219512195122,0.7463831825343329,1.0,1/28,0.68%,CHCHD3
prerank,GO_Biological_Process_2021__positive regulation of fatty acid metabolic process (GO:0045923),0.9921519965741015,1.670271356480864,0.20869565217391303,0.7522725099237237,1.0,1/17,0.79%,PPARA
prerank,GO_Biological_Process_2021__positive regulation of toll-like receptor signaling pathway (GO:0034123),-0.9896833730928266,-1.6696177085928403,0.3697478991596639,0.747903506410107,1.0,1/24,1.04%,TICAM2
prerank,KEGG_2021_Human__Maturity onset diabetes of the young,0.9845380451345465,1.6693520706002352,0.3828125,0.7540487857667121,1.0,2/20,1.55%,PKLR;FOXA3
prerank,WikiPathway_2021_Human__MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.9955763223146232,1.669313774874629,0.13709677419354838,0.7519853206403707,1.0,2/17,0.45%,PTK2;TJP1
prerank,GO_Biological_Process_2021__negative regulation of plasma membrane bounded cell projection assembly (GO:0120033),-0.9874491609772258,-1.6692626932117112,0.3826086956521739,0.7474564212943049,1.0,1/27,1.26%,HRG
prerank,Elsevier_Pathway_Collection__Mitochondrial Protein Transport,-0.9922275635068469,-1.669260537060486,0.2196969696969697,0.7459908204682376,1.0,1/19,0.78%,TOMM70
prerank,GO_Biological_Process_2021__retinoic acid metabolic process (GO:0042573),-0.9993824798862689,-1.669085307399753,0.02459016393442623,0.7450359527167044,1.0,2/25,0.07%,CYP2C8;CYP3A7
prerank,Elsevier_Pathway_Collection__TNF-alpha/TNFRSF1B Signaling,0.9956103836834753,1.6688340698029982,0.10483870967741936,0.7519725168612565,1.0,1/22,0.44%,TRAF3
prerank,GO_Biological_Process_2021__regulation of cholesterol metabolic process (GO:0090181),0.9870343219858202,1.6682892987087852,0.35772357723577236,0.7522405049282651,1.0,1/21,1.30%,APOE
prerank,Reactome_2022__Signaling By Erythropoietin R-HSA-9006335,-0.9891508351618122,-1.6682677105032482,0.28695652173913044,0.7457373085100176,1.0,2/24,1.10%,PIK3CB;VAV1
prerank,GO_Biological_Process_2021__positive regulation of membrane protein ectodomain proteolysis (GO:0051044),0.9870797540226597,1.6680289081750073,0.390625,0.7512418181256466,1.0,2/15,1.30%,PACSIN3;APOE
prerank,GO_Biological_Process_2021__DNA strand elongation involved in DNA replication (GO:0006271),0.9974199291492893,1.6674959881907216,0.09022556390977443,0.751566191868796,1.0,1/18,0.26%,GINS1
prerank,Elsevier_Pathway_Collection__Goblet-Cell Exocytosis in Asthma,0.9974586819494552,1.666579681282051,0.045112781954887216,0.7536471806347009,1.0,1/18,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Fusion,0.9880757467049901,1.6665565026777938,0.304,0.7515656043639264,1.0,1/16,1.20%,STX1A
prerank,GO_Biological_Process_2021__negative regulation of cellular response to insulin stimulus (GO:1900077),-0.9864461205361945,-1.666488668128528,0.3963963963963964,0.7492479393424921,1.0,1/28,1.36%,GRB10
prerank,WikiPathway_2021_Human__Dopaminergic Neurogenesis WP2855,0.9904949455593111,1.6664364731439938,0.2153846153846154,0.7499830238268564,1.0,1/23,0.95%,MSX1
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell apoptotic process (GO:2000352),-0.9879907596704167,-1.6663117913489833,0.36134453781512604,0.7482923079418934,1.0,1/25,1.21%,TEK
prerank,Reactome_2022__Regulation Of FZD By Ubiquitination R-HSA-4641263,0.9959968870941875,1.6660343203348889,0.09022556390977443,0.7497335797314857,1.0,1/19,0.40%,LRP5
prerank,Reactome_2022__Polo-like Kinase Mediated Events R-HSA-156711,0.9884606605573089,1.6650978400296579,0.3458646616541353,0.7519607652479195,1.0,1/16,1.16%,PKMYT1
prerank,GO_Biological_Process_2021__regulation of muscle contraction (GO:0006937),0.9879153826307611,1.66501161090378,0.25,0.7501275079066679,1.0,1/24,1.21%,TNNC2
prerank,Reactome_2022__TP53 Regulates Transcription Of Genes Involved In Cytochrome C Release R-HSA-6803204,0.994458019319822,1.6646659930444494,0.14393939393939395,0.7496501183865247,1.0,1/20,0.56%,PRELID3A
prerank,GO_Biological_Process_2021__negative regulation of lipid metabolic process (GO:0045833),-0.9919191028610895,-1.6646123223545866,0.23893805309734514,0.7510121964069072,1.0,1/21,0.81%,ASXL3
prerank,GO_Biological_Process_2021__regulation of cell size (GO:0008361),-0.989152095672955,-1.6636376992121,0.29770992366412213,0.7520654622680784,1.0,2/23,1.10%,DEPTOR;VAV1
prerank,GO_Biological_Process_2021__peptidyl-lysine dimethylation (GO:0018027),0.9972282473920376,1.6634079569492328,0.06779661016949153,0.7533524632835314,1.0,1/18,0.28%,ASH1L
prerank,GO_Biological_Process_2021__histone lysine demethylation (GO:0070076),0.9930713557733432,1.6633278257913142,0.21641791044776118,0.7515527263918577,1.0,1/25,0.70%,PHF2
prerank,GO_Biological_Process_2021__regulation of cell migration involved in sprouting angiogenesis (GO:0090049),-0.9901859872910846,-1.663262984482172,0.23478260869565218,0.7516417927728958,1.0,2/31,0.99%,AKT3;KLF4
prerank,GO_Biological_Process_2021__regulation of histone acetylation (GO:0035065),-0.9890233519530435,-1.6618437148749192,0.312,0.7542577951641664,1.0,1/32,1.10%,SPI1
prerank,GO_Biological_Process_2021__tail-anchored membrane protein insertion into ER membrane (GO:0071816),0.9968055373760419,1.6612972066166876,0.12781954887218044,0.7588285745631749,1.0,1/17,0.32%,GET3
prerank,GO_Biological_Process_2021__positive regulation of response to endoplasmic reticulum stress (GO:1905898),0.9849568164713959,1.6607783832656242,0.4230769230769231,0.7590130403798722,1.0,1/18,1.51%,BOK
prerank,GO_Biological_Process_2021__bile acid biosynthetic process (GO:0006699),-0.9997646450352413,-1.6602955013233274,0.0,0.7570022840995052,1.0,1/27,0.03%,CYP39A1
prerank,"GO_Biological_Process_2021__protein localization to chromosome, telomeric region (GO:0070198)",0.9859648116981572,1.6601235653470552,0.36363636363636365,0.7600266759141123,1.0,2/15,1.41%,ATR;ACD
prerank,Reactome_2022__Sema4D In Semaphorin Signaling R-HSA-400685,-0.9904548929975229,-1.6600473162916143,0.2796610169491525,0.7561078498381852,1.0,1/24,0.96%,SEMA4D
prerank,GO_Biological_Process_2021__microtubule polymerization (GO:0046785),-0.9868007869813076,-1.659361215426366,0.3821138211382114,0.7565972045980979,1.0,2/30,1.33%,TPPP2;HDGFL3
prerank,TRRUST_Transcription_Factors_2019__RARA human,-0.9876909816728328,-1.6591144301597645,0.38461538461538464,0.7557069733023412,1.0,2/21,1.24%,HCK;MAOB
prerank,GO_Biological_Process_2021__peroxisomal membrane transport (GO:0015919),-0.9950351275712526,-1.6591118909001394,0.12096774193548387,0.7542701155782398,1.0,2/27,0.51%,ABCD3;ATAD1
prerank,KEGG_2021_Human__Arginine biosynthesis,0.9851072669128718,1.658515343098808,0.4065040650406504,0.7649803710056992,1.0,1/21,1.49%,GLS
prerank,Reactome_2022__mRNA Capping R-HSA-72086,-0.9922603392880189,-1.6581206962708837,0.23770491803278687,0.7555109881712215,1.0,1/29,0.78%,RNGTT
prerank,GO_Biological_Process_2021__regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901028),0.9849573430791624,1.657924077154782,0.41605839416058393,0.7652209435351313,1.0,1/18,1.51%,BOK
prerank,GO_Biological_Process_2021__amyloid precursor protein metabolic process (GO:0042982),0.9870368612893253,1.657708204176474,0.3582089552238806,0.7640061937455626,1.0,1/17,1.30%,APOE
prerank,Elsevier_Pathway_Collection__Osteoblast Function Decline in Gout,-0.9875748667123382,-1.6575876128263207,0.4,0.7553934108793826,1.0,2/24,1.25%,MAP2K6;VDR
prerank,GO_Biological_Process_2021__regulation of vasculature development (GO:1901342),-0.9911844016535403,-1.6567254962461133,0.28695652173913044,0.7562253020648517,1.0,1/26,0.89%,ADGRA2
prerank,WikiPathway_2021_Human__Globo Sphingolipid Metabolism WP1424,0.9964971725910888,1.65657603317732,0.06896551724137931,0.7662737227611729,1.0,1/20,0.35%,ST3GAL1
prerank,GO_Biological_Process_2021__positive regulation of immune system process (GO:0002684),-0.9884228656217864,-1.6564166197209174,0.3770491803278688,0.7555288504308594,1.0,2/20,1.17%,PIK3CB;AQP3
prerank,Reactome_2022__Phosphorylation Of APC/C R-HSA-176412,0.9906118544070233,1.6557304840781264,0.2824427480916031,0.7674335513618578,1.0,1/20,0.94%,UBE2C
prerank,"GO_Biological_Process_2021__base-excision repair, AP site formation (GO:0006285)",0.9859187856738684,1.6555602886831613,0.3644067796610169,0.7661697938467464,1.0,1/19,1.41%,ACD
prerank,Reactome_2022__Formation Of Tubulin Folding Intermediates By CCT/TriC R-HSA-389960,0.9868775460381255,1.6547305996853268,0.3541666666666667,0.7675877458684464,1.0,1/23,1.31%,TUBA1A
prerank,Reactome_2022__Keratan Sulfate Biosynthesis R-HSA-2022854,0.994535859804357,1.6543829443169955,0.1259259259259259,0.765038327874923,1.0,2/26,0.55%,ST3GAL1;SLC35D2
prerank,GO_Biological_Process_2021__keratan sulfate biosynthetic process (GO:0018146),0.994535859804357,1.6543829443169955,0.1259259259259259,0.765038327874923,1.0,2/26,0.55%,ST3GAL1;SLC35D2
prerank,Elsevier_Pathway_Collection__Werner Syndrome (Adult Progeria),0.9950346632371923,1.654229280112992,0.10655737704918032,0.7637322459531926,1.0,1/21,0.50%,ATR
prerank,Elsevier_Pathway_Collection__Estrogens/ESR1 Genomic Canonical Signaling,-0.9960341836476743,-1.6539974361887628,0.1111111111111111,0.7604034395229757,1.0,1/22,0.40%,NCOA1
prerank,GO_Biological_Process_2021__positive regulation of ion transmembrane transporter activity (GO:0032414),-0.9957250055634095,-1.6534577572874396,0.0782608695652174,0.76034947529388,1.0,1/25,0.43%,WNK3
prerank,WikiPathway_2021_Human__Nucleotide metabolism WP404,0.984923707374039,1.6527754773459142,0.3597122302158273,0.7678805822217439,1.0,2/18,1.51%,RRM2;HPRT1
prerank,Reactome_2022__Role Of Phospholipids In Phagocytosis R-HSA-2029485,-0.9927652633215023,-1.6523563453060464,0.23,0.7619240132955497,1.0,1/24,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of TORC1 signaling (GO:1903432),0.9967612943405132,1.6520117864687112,0.061068702290076333,0.7690241185746044,1.0,1/34,0.33%,CLEC16A
prerank,Reactome_2022__FRS-mediated FGFR2 Signaling R-HSA-5654700,0.9864595024517795,1.6516641317735479,0.3629032258064516,0.7681545689166277,1.0,1/18,1.36%,FGF1
prerank,GO_Biological_Process_2021__cellular response to hexose stimulus (GO:0071331),0.9996889636757488,1.6515575097824549,0.016260162601626018,0.7664394619357581,1.0,1/24,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__response to copper ion (GO:0046688),-0.992342348440675,-1.6512910556850608,0.17647058823529413,0.7633332843519292,1.0,1/20,0.77%,AOC1
prerank,Reactome_2022__Activation Of GABAB Receptors R-HSA-991365,0.9888663845403723,1.650835825338639,0.27350427350427353,0.7672466536144914,1.0,1/38,1.11%,GNB5
prerank,Reactome_2022__Aspirin ADME R-HSA-9749641,-0.9947247277145658,-1.6503405350623657,0.12307692307692308,0.7645543648728754,1.0,3/41,0.54%,CYP2C8;GLYAT;ACSM2B
prerank,Reactome_2022__Glucagon-type Ligand Receptors R-HSA-420092,0.9888728659330103,1.6489860010846045,0.2956521739130435,0.7729895122352537,1.0,1/30,1.11%,GNB5
prerank,WikiPathway_2021_Human__Complement Activation WP545,-0.9894942826959765,-1.6488768126191358,0.3389830508474576,0.7672788801451227,1.0,1/22,1.06%,C1R
prerank,Reactome_2022__Triglyceride Metabolism R-HSA-8979227,-0.9908736862346412,-1.648850475123674,0.2833333333333333,0.7659133269095993,1.0,1/30,0.92%,MOGAT1
prerank,GO_Biological_Process_2021__hydrogen peroxide metabolic process (GO:0042743),-0.98764401616236,-1.6481418604284115,0.38095238095238093,0.7668064473781864,1.0,1/24,1.24%,MAOB
prerank,GO_Biological_Process_2021__vesicle transport along actin filament (GO:0030050),0.9897255312950364,1.6475984443436493,0.24390243902439024,0.7771070203326673,1.0,1/19,1.03%,MYO7A
prerank,GO_Biological_Process_2021__regulation of monooxygenase activity (GO:0032768),-0.9875748215619704,-1.646481986044685,0.352,0.7704507201499777,1.0,2/23,1.25%,ZDHHC21;VDR
prerank,GO_Biological_Process_2021__regulation of receptor internalization (GO:0002090),-0.9917616513334934,-1.6462986540114484,0.25396825396825395,0.7696304579534018,1.0,2/34,0.83%,ATAD1;NTF3
prerank,TRRUST_Transcription_Factors_2019__SOX2 human,0.9979590155048497,1.6462552131232753,0.031746031746031744,0.7803714127159393,1.0,1/17,0.21%,MKI67
prerank,GO_Biological_Process_2021__cellular polysaccharide biosynthetic process (GO:0033692),0.9866076261935506,1.6459027508068766,0.3793103448275862,0.779720627147783,1.0,1/21,1.34%,HAS3
prerank,Elsevier_Pathway_Collection__Dentin Formation Disruption,0.9880703905658136,1.645635257006964,0.28378378378378377,0.7787978764500312,1.0,2/30,1.20%,MSX1;EDA2R
prerank,Elsevier_Pathway_Collection__DNA Repair and Chromatin Remodeling Block in Pancreatic Neoplasms,0.996265479097111,1.6450435787966895,0.05384615384615385,0.7792333507796525,1.0,2/33,0.38%,MSH2;BRIP1
prerank,Reactome_2022__GAG Synthesis Requires Tetrasaccharide Linker Sequence R-HSA-1971475,-0.9884899353252715,-1.6447145806668153,0.34782608695652173,0.7729020916582844,1.0,1/26,1.16%,SDC3
prerank,Elsevier_Pathway_Collection__AGTR1 -> ARRB1/ARRB2 Signaling,-0.9891047941105101,-1.6442552856583486,0.3140495867768595,0.7728259400268801,1.0,1/25,1.10%,VAV1
prerank,GO_Biological_Process_2021__regulation of lymphocyte differentiation (GO:0045619),-0.9899939737672401,-1.6441100109745286,0.3305785123966942,0.7718334873258087,1.0,1/19,1.01%,CD2
prerank,Elsevier_Pathway_Collection__Diabetes Induced Periodontitis,-0.9969541149927168,-1.6440263005714577,0.08181818181818182,0.7707117710096693,1.0,1/30,0.31%,MAP2K6
prerank,Reactome_2022__Defects Of Contact Activation System (CAS) And Kallikrein/Kinin System (KKS) R-HSA-9651496,-0.9953064433030576,-1.6438491687535932,0.1388888888888889,0.7697737119912605,1.0,1/15,0.48%,TPST1
prerank,Elsevier_Pathway_Collection__Low-Density Lipoproteins and Chemokines in Atherosclerosis,0.9890710555295378,1.6438348994711085,0.28125,0.7822034492153004,1.0,1/22,1.10%,ITGAL
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Psoriasis,-0.9901463881021351,-1.6438037678382549,0.3037037037037037,0.7685586406497104,1.0,1/24,0.99%,KLF4
prerank,Elsevier_Pathway_Collection__MIF Role in Cholesteatoma,-0.99668630484326,-1.6432797543127782,0.07692307692307693,0.7688411130459599,1.0,1/26,0.34%,RAP1A
prerank,GO_Biological_Process_2021__natural killer cell activation (GO:0030101),-0.9894595666262536,-1.643116546733391,0.3140495867768595,0.7680513691463956,1.0,4/25,1.07%,RABL3;PBX1;CD2;IL21R
prerank,GO_Biological_Process_2021__regulation of reactive oxygen species biosynthetic process (GO:1903426),0.9852646628114444,1.6429665081452491,0.3923076923076923,0.7839634585607428,1.0,2/26,1.48%,PPARA;SLC30A10
prerank,TRRUST_Transcription_Factors_2019__TCF4 human,-0.990148164523001,-1.6428330792804604,0.26956521739130435,0.7677758831318501,1.0,1/23,0.99%,KLF4
prerank,GO_Biological_Process_2021__zinc ion transport (GO:0006829),0.9852251468917174,1.6424340547754053,0.38848920863309355,0.7843110632752035,1.0,1/20,1.48%,SLC30A10
prerank,GO_Biological_Process_2021__cellular response to misfolded protein (GO:0071218),-0.9938421778954237,-1.6407569862395746,0.22857142857142856,0.7729537269310512,1.0,1/20,0.62%,DNAJB14
prerank,GO_Biological_Process_2021__regulation of peptidase activity (GO:0052547),0.9874945973592971,1.640443450696059,0.3228346456692913,0.7912104797117938,1.0,1/19,1.25%,CTSH
prerank,WikiPathway_2021_Human__Type II diabetes mellitus WP1584,0.9935738955308411,1.6401823987419057,0.16279069767441862,0.7903824241136511,1.0,1/20,0.65%,PHKA2
prerank,GO_Biological_Process_2021__'de novo' posttranslational protein folding (GO:0051084),-0.9938388370887389,-1.6398978468043546,0.15789473684210525,0.7745230231748896,1.0,1/30,0.62%,DNAJB14
prerank,KEGG_2021_Human__Nicotine addiction,-0.999957398892253,-1.6390679765398348,0.0,0.7756782048046221,1.0,1/30,0.01%,GRIN2B
prerank,WikiPathway_2021_Human__Sphingolipid pathway WP1422,0.9845633347255187,1.638972965497215,0.4049586776859504,0.7934141032707558,1.0,1/28,1.54%,CERS4
prerank,TRRUST_Transcription_Factors_2019__POU5F1 human,0.999343363875193,1.638750357536039,0.008695652173913044,0.7923249296982678,1.0,1/20,0.07%,THY1
prerank,"GO_Biological_Process_2021__regulation of DNA-templated transcription, elongation (GO:0032784)",0.9895306758798035,1.6387347514688166,0.2898550724637681,0.7903349890248216,1.0,1/26,1.05%,HTATSF1
prerank,WikiPathway_2021_Human__Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668,0.98599785479432,1.6387259452400187,0.35384615384615387,0.7882859198465223,1.0,2/24,1.41%,FBN3;FLNA
prerank,Elsevier_Pathway_Collection__Protein Degradation Dysregulation in Dementia (Hypothesis),-0.9928431220588066,-1.6386211581111887,0.183206106870229,0.7755293042685332,1.0,1/19,0.72%,AMFR
prerank,GO_Biological_Process_2021__regulation of regulated secretory pathway (GO:1903305),-0.9912957750486407,-1.6383035253921527,0.325,0.7753809442062596,1.0,1/32,0.88%,SYT7
prerank,GO_Biological_Process_2021__histone monoubiquitination (GO:0010390),0.9969179828921118,1.6380696962327859,0.02142857142857143,0.7890221690661016,1.0,1/24,0.31%,BCOR
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (Occludin),0.9955333331213699,1.637857030581929,0.07936507936507936,0.7879261277439333,1.0,1/24,0.45%,TJP1
prerank,GO_Biological_Process_2021__regulation of lipoprotein lipase activity (GO:0051004),0.9954196150946142,1.6377652214134966,0.13043478260869565,0.7863428864471723,1.0,1/21,0.46%,SORT1
prerank,GO_Biological_Process_2021__regulation of postsynapse organization (GO:0099175),0.992338066323475,1.6376222453140319,0.2014388489208633,0.7850726508700183,1.0,1/28,0.77%,ABI2
prerank,GO_Biological_Process_2021__vesicle transport along microtubule (GO:0047496),0.9865753204850821,1.6372792738751833,0.3709677419354839,0.7843777816899572,1.0,2/23,1.35%,KIF13A;KIF3B
prerank,Elsevier_Pathway_Collection__Proteins Involved in Autistic Disorder,0.999804881907411,1.636788969802625,0.0,0.7845081531819823,1.0,1/21,0.02%,SLC6A4
prerank,GO_Biological_Process_2021__regulation of monocyte chemotaxis (GO:0090025),0.9894174371696061,1.6363331609058152,0.2595419847328244,0.7846280978759578,1.0,1/23,1.06%,MOSPD2
prerank,Elsevier_Pathway_Collection__TNFR/NF-kB Alternative Pathway in Multiple Myeloma Plasma Cells,0.9956114931383118,1.6362933577499585,0.13008130081300814,0.7827427403402356,1.0,1/21,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__Axonal Transport,0.9954183782458086,1.6362243130012446,0.07086614173228346,0.7810999850296937,1.0,1/25,0.46%,SORT1
prerank,Elsevier_Pathway_Collection__EGFR/ERBB2 -> HIF1A Signaling,-0.9890994781904593,-1.635960258303608,0.3488372093023256,0.782099831287641,1.0,1/32,1.10%,VAV1
prerank,Reactome_2022__Deadenylation Of mRNA R-HSA-429947,0.9912645250071964,1.6357802696765449,0.25210084033613445,0.780975978234337,1.0,1/24,0.88%,PARN
prerank,GO_Biological_Process_2021__regulation of multicellular organismal development (GO:2000026),0.9966878816413989,1.6355382036023896,0.08088235294117647,0.7800124257056715,1.0,1/26,0.33%,CCSAP
prerank,GO_Biological_Process_2021__positive regulation of mitotic cell cycle (GO:0045931),-0.9965703905912875,-1.6354286826992075,0.14035087719298245,0.7824297185008324,1.0,1/27,0.35%,APP
prerank,GO_Biological_Process_2021__cardiac conduction system development (GO:0003161),0.9904944797531726,1.635357942619501,0.23357664233576642,0.7789285392838918,1.0,1/23,0.95%,MSX1
prerank,Reactome_2022__Pre-NOTCH Processing In Golgi R-HSA-1912420,0.9957282200240338,1.6352575034826913,0.17557251908396945,0.777369725520292,1.0,1/18,0.43%,NOTCH3
prerank,Elsevier_Pathway_Collection__Lipolysis Regulation in Adipocyte,-0.9959945936547376,-1.6352327989499822,0.1328125,0.7816206401356434,1.0,2/34,0.41%,PLAAT3;NR3C1
prerank,Elsevier_Pathway_Collection__SPP1 Induced Survival of Myelin Specific T-Cells in Multiple Sclerosis,-0.9933384304348086,-1.6352170305506588,0.20168067226890757,0.7802504262218609,1.0,1/29,0.67%,PTK2B
prerank,GO_Biological_Process_2021__regulation of cellular component size (GO:0032535),-0.9891017451431366,-1.6350533146725554,0.33076923076923076,0.7792960057290882,1.0,1/31,1.10%,VAV1
prerank,GO_Biological_Process_2021__response to alcohol (GO:0097305),-0.9999576646703124,-1.635017263092167,0.008620689655172414,0.7779500751715512,1.0,1/27,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__zinc ion transmembrane transport (GO:0071577),0.9852252244590096,1.6349983218146784,0.3969465648854962,0.7765855080801956,1.0,1/21,1.48%,SLC30A10
prerank,Reactome_2022__Prefoldin Mediated Transfer Of Substrate To CCT/TriC R-HSA-389957,0.9868753030243643,1.6349767837541944,0.3515625,0.774734532231202,1.0,1/25,1.31%,TUBA1A
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Breast Cancer,0.9958004433471915,1.6341454611220323,0.12857142857142856,0.7762971680202421,1.0,1/28,0.42%,TNFRSF10A
prerank,Elsevier_Pathway_Collection__Myeloid Cell Differentiation Block in Leukemia,-0.9890296961452614,-1.634090687972276,0.3656716417910448,0.7793913178063459,1.0,1/25,1.10%,SPI1
prerank,"GO_Biological_Process_2021__protein alpha-1,2-demannosylation (GO:0036508)",-0.9928401983769666,-1.6334380859613429,0.21621621621621623,0.7801690079219386,1.0,1/24,0.72%,AMFR
prerank,GO_Biological_Process_2021__protein localization to cell surface (GO:0034394),0.9859474866029952,1.6330233380532582,0.3870967741935484,0.7793073045395619,1.0,1/28,1.41%,FLNA
prerank,WikiPathway_2021_Human__Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,-0.9927942995175868,-1.6327352998182116,0.2109375,0.7814953812917652,1.0,1/37,0.73%,DEPTOR
prerank,GO_Biological_Process_2021__regulation of transforming growth factor beta production (GO:0071634),0.984918215441842,1.6324063801613848,0.4222222222222222,0.7800062450946469,1.0,1/18,1.51%,FN1
prerank,GO_Biological_Process_2021__negative regulation of lipid storage (GO:0010888),0.9921513692166942,1.6323702657692323,0.2153846153846154,0.7782030604980489,1.0,1/20,0.79%,PPARA
prerank,Reactome_2022__Chaperone Mediated Autophagy R-HSA-9613829,0.9852636424893992,1.6316512298029084,0.40458015267175573,0.7793449975492092,1.0,1/19,1.48%,LAMP2
prerank,Elsevier_Pathway_Collection__B-Cell Mediated IgE Production in Asthma,0.9956096575755815,1.6315837322707696,0.08527131782945736,0.7777125012938316,1.0,1/28,0.44%,TRAF3
prerank,KEGG_2021_Human__Glyoxylate and dicarboxylate metabolism,-0.9892978350652145,-1.6315820946247013,0.358974358974359,0.7840914196904736,1.0,1/29,1.08%,HAO1
prerank,TRRUST_Transcription_Factors_2019__HDAC4 human,-0.990147588614705,-1.6299127895290206,0.3153153153153153,0.7880707835139176,1.0,1/22,0.99%,KLF4
prerank,GO_Biological_Process_2021__negative regulation of vascular associated smooth muscle cell proliferation (GO:1904706),0.9981905801136017,1.6297834520377956,0.038461538461538464,0.7831619652607867,1.0,1/16,0.18%,TAFA5
prerank,Elsevier_Pathway_Collection__MicroRNAs Role in Melanoma,0.9981110028221437,1.6289726961949353,0.040983606557377046,0.7846299287267671,1.0,1/22,0.19%,CDK6
prerank,Elsevier_Pathway_Collection__Local Estrogen Production in Endometriosis,-0.9974169892592935,-1.6289364894940983,0.11009174311926606,0.7898344082225246,1.0,1/25,0.27%,STS
prerank,GO_Biological_Process_2021__positive regulation of lipid metabolic process (GO:0045834),0.9870738522853763,1.6285277418764592,0.3828125,0.7846884632628954,1.0,2/23,1.30%,PPARA;APOE
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hashimoto's Thyroiditis,-0.9891842009575932,-1.6283651231548173,0.3333333333333333,0.790286660598958,1.0,1/22,1.09%,CD83
prerank,Elsevier_Pathway_Collection__Dopamine Mediated Glutamate Release and Glutamate Uptake Circle,0.9847325908269058,1.6281155650299703,0.4263565891472868,0.7843737095254063,1.0,3/18,1.54%,STX1A;GLS;SLC38A1
prerank,GO_Biological_Process_2021__striated muscle cell differentiation (GO:0051146),0.9954215740692957,1.6280029075520825,0.11290322580645161,0.7830465632110405,1.0,1/18,0.46%,SORT1
prerank,Elsevier_Pathway_Collection__IGF1R -> MEF/MYOD/MYOG Signaling,-0.9892274178042927,-1.627683013716354,0.2781954887218045,0.7911191697164693,1.0,4/29,1.10%,MAP2K6;PTK2B;PAK2;VAV1
prerank,Elsevier_Pathway_Collection__High Level of Homocystine Effects (Methylation Cycle),0.9949564129616406,1.6275678909526494,0.13138686131386862,0.7830250249569294,1.0,1/23,0.51%,SLC19A1
prerank,Elsevier_Pathway_Collection__ADRA1A -> IL6 Production,-0.9969535084533413,-1.626912002409714,0.0916030534351145,0.791963685457584,1.0,1/30,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Synaptic Potentiation by PKMZ in LTP Maintenance - Active State,0.9886875804665666,1.6268390671862434,0.3284671532846715,0.7839200133876386,1.0,1/22,1.13%,IQSEC1
prerank,Reactome_2022__Signaling By ERBB2 TMD/JMD Mutants R-HSA-9665686,0.9904185629916274,1.6264837924124018,0.26229508196721313,0.7836563639618561,1.0,1/21,0.96%,ERBB3
prerank,Reactome_2022__Negative Regulation Of FGFR1 Signaling R-HSA-5654726,0.9864490351864083,1.6264099065506639,0.3875968992248062,0.782113547488242,1.0,1/28,1.36%,FGF1
prerank,Reactome_2022__ERK/MAPK Targets R-HSA-198753,-0.9874163816062903,-1.626236591032899,0.38016528925619836,0.7926634634212194,1.0,1/22,1.26%,DUSP4
prerank,Reactome_2022__Intrinsic Pathway Of Fibrin Clot Formation R-HSA-140837,-0.9957650625915518,-1.6256740989890175,0.13513513513513514,0.7931447894830086,1.0,1/21,0.43%,PROS1
prerank,Elsevier_Pathway_Collection__HIF1A as Master Regulator of Angiogenesis in Cancer,-0.98797293112801,-1.6254997484520013,0.3389830508474576,0.7921969480530515,1.0,1/44,1.21%,TEK
prerank,Elsevier_Pathway_Collection__Autocrine Cytokine/Chemokine Loops in Systemic Scleroderma,-0.9969546583114302,-1.6252313992195002,0.088,0.7915641448580878,1.0,1/32,0.31%,MAP2K6
prerank,"WikiPathway_2021_Human__Relationship between inflammation, COX-2 and EGFR WP4483",-0.9928049057669793,-1.6251533843684238,0.256198347107438,0.7905557130167635,1.0,2/25,0.73%,AKT3;PIK3CB
prerank,Reactome_2022__Condensation Of Prophase Chromosomes R-HSA-2299718,-0.9947997472836356,-1.6250815493987427,0.13513513513513514,0.7894546620791416,1.0,1/32,0.53%,RB1
prerank,Elsevier_Pathway_Collection__Thyroid Stimulating Hormone (TSH) Secretion in Overt Hypothyroidism,-0.9898749930870085,-1.6248132741439423,0.3418803418803419,0.7889554665922279,1.0,1/27,1.02%,SLC16A2
prerank,Elsevier_Pathway_Collection__Amyloid beta Traffic and Degradation in Extracellular Matrix in Alzheimer's Disease,0.9870725252615105,1.6247767976300402,0.36220472440944884,0.7871579154125468,1.0,2/24,1.30%,A2M;APOE
prerank,GO_Biological_Process_2021__negative regulation of RNA splicing (GO:0033119),0.9881487348943853,1.6244122727610295,0.3140495867768595,0.7868516860844054,1.0,1/19,1.19%,PCBP4
prerank,GO_Biological_Process_2021__response to interferon-beta (GO:0035456),-0.9961877775197648,-1.6239788143699752,0.088,0.7901678519163692,1.0,1/24,0.39%,OAS1
prerank,GO_Biological_Process_2021__positive regulation of lamellipodium assembly (GO:0010592),0.9923411904473195,1.6238802114738415,0.1773049645390071,0.7873517151343232,1.0,1/23,0.77%,ABI2
prerank,TRRUST_Transcription_Factors_2019__ERG human,-0.987535053095075,-1.6231211755057844,0.4166666666666667,0.7915525927808352,1.0,2/26,1.26%,KCNN2;TMPRSS2
prerank,GO_Biological_Process_2021__myeloid cell development (GO:0061515),-0.9965726855026698,-1.623019134089521,0.08333333333333333,0.7905602791597905,1.0,1/20,0.35%,APP
prerank,GO_Biological_Process_2021__cellular response to amino acid stimulus (GO:0071230),-0.9994167367519855,-1.6229592941657158,0.0,0.7893587861677245,1.0,1/32,0.07%,CPEB3
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR2 R-HSA-5654696,0.9864542989522528,1.6225176527431575,0.3795620437956204,0.7907870340187018,1.0,1/23,1.36%,FGF1
prerank,GO_Biological_Process_2021__epithelial cell morphogenesis (GO:0003382),0.9929215647726514,1.6225120745107857,0.15447154471544716,0.7889179664176299,1.0,1/16,0.71%,SIPA1L3
prerank,Elsevier_Pathway_Collection__AngiopoietinR -> AP-1 Signaling,-0.9880713153565266,-1.6223597461928052,0.38738738738738737,0.7898521402292198,1.0,3/31,1.21%,MAP2K6;PTK2B;TEK
prerank,GO_Biological_Process_2021__axonemal dynein complex assembly (GO:0070286),0.9904987604732333,1.622233296032609,0.2647058823529412,0.7882291127954764,1.0,2/22,0.96%,DNAAF5;CCDC40
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor signaling pathway (GO:1900746),-0.9875006318525119,-1.6220631138943415,0.3949579831932773,0.7894889457777512,1.0,2/19,1.26%,PIK3CB;HRG
prerank,GO_Biological_Process_2021__regulation of cell-substrate junction assembly (GO:0090109),0.9896148469434112,1.6220602854383552,0.2814814814814815,0.7871087656107836,1.0,2/21,1.05%,PTK2;CAMSAP3
prerank,Reactome_2022__SHC-mediated cascade:FGFR4 R-HSA-5654719,0.9865027141038045,1.622037933360205,0.366412213740458,0.7853612065031426,1.0,2/15,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__regulation of granulocyte chemotaxis (GO:0071622),0.9974582768719562,1.6212579876935176,0.01694915254237288,0.7867320968514816,1.0,1/19,0.26%,PTK2
prerank,Reactome_2022__Laminin Interactions R-HSA-3000157,0.9962645926337511,1.6209484222548687,0.0859375,0.78591105550596,1.0,1/22,0.38%,ITGA2
prerank,Reactome_2022__Assembly Of ORC Complex At Origin Of Replication R-HSA-68616,-0.9926855341348112,-1.620485114625875,0.1640625,0.7929854053122656,1.0,1/27,0.74%,ORC4
prerank,Elsevier_Pathway_Collection__beta-Catenin/Androgen Receptor Signaling in Prostate Cancer,0.9960365200744132,1.6202612116926007,0.11811023622047244,0.7869152723602336,1.0,2/23,0.40%,AXIN2;LRP5
prerank,Reactome_2022__DNA Strand Elongation R-HSA-69190,0.9848793324146752,1.6196119924586296,0.3888888888888889,0.787359781940785,1.0,4/31,1.53%,CDC45;GINS1;SLC19A1;LRIG1
prerank,WikiPathway_2021_Human__TLR4 Signaling and Tolerance WP3851,0.9956100455707965,1.6195321756812526,0.12949640287769784,0.7857393526136034,1.0,1/27,0.44%,TRAF3
prerank,Reactome_2022__E2F Mediated Regulation Of DNA Replication R-HSA-113510,-0.9927297348162658,-1.6195141863189395,0.1724137931034483,0.7946131200337362,1.0,2/21,0.74%,RB1;ORC4
prerank,GO_Biological_Process_2021__regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903798),0.990306285512359,1.6193410592139528,0.2540983606557377,0.7847145322883771,1.0,1/17,0.97%,MYCN
prerank,GO_Biological_Process_2021__positive regulation of DNA binding (GO:0043388),-0.9947973731835759,-1.6192811055188452,0.13934426229508196,0.793981944128741,1.0,1/33,0.53%,RB1
prerank,Reactome_2022__Serotonin Neurotransmitter Release Cycle R-HSA-181429,0.9881165713962754,1.6191585736750973,0.3162393162393162,0.7835967413416538,1.0,2/17,1.20%,PPFIA4;STX1A
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by NO,0.9892180593633961,1.6191196987773944,0.27692307692307694,0.7819077875144912,1.0,1/31,1.08%,SLC7A1
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Arterial Hypertension,-0.9933359784646053,-1.6190453721220306,0.18032786885245902,0.7931787839106665,1.0,1/32,0.67%,PTK2B
prerank,Elsevier_Pathway_Collection__WNT Canonical Signaling,0.9959944013528902,1.618716837221716,0.04878048780487805,0.7817837461445101,1.0,1/26,0.40%,LRP5
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts Via 7Alpha-Hydroxycholesterol R-HSA-193368,-0.9960332766031614,-1.6187071356643805,0.12962962962962962,0.7927695398478831,1.0,1/24,0.40%,NCOA1
prerank,Elsevier_Pathway_Collection__CD4+ T-Cell Death in HIV,-0.9887178972060384,-1.6183189555470276,0.3333333333333333,0.792614794783443,1.0,1/28,1.13%,ZAP70
prerank,GO_Biological_Process_2021__production of miRNAs involved in gene silencing by miRNA (GO:0035196),0.9953013143417507,1.6182252452690506,0.16546762589928057,0.7819780262052292,1.0,1/26,0.47%,DROSHA
prerank,TRRUST_Transcription_Factors_2019__CTNNB1 human,-0.9948039082408716,-1.618133192903945,0.17391304347826086,0.7917025739722678,1.0,1/21,0.53%,RB1
prerank,WikiPathway_2021_Human__Mitochondrial CIV Assembly WP4922,0.9926446171595258,1.6175550660436901,0.183206106870229,0.783007951691279,1.0,1/32,0.74%,CMC1
prerank,WikiPathway_2021_Human__Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670,0.9849206179080989,1.6174727093972687,0.3880597014925373,0.7815819897293064,1.0,1/18,1.51%,FN1
prerank,Reactome_2022__Mitochondrial tRNA Aminoacylation R-HSA-379726,0.984723332251198,1.6174223067778444,0.4533333333333333,0.7799960775969785,1.0,1/21,1.53%,SARS2
prerank,Reactome_2022__Tight Junction Interactions R-HSA-420029,0.9886446736671265,1.617396090175589,0.2809917355371901,0.7782513209406342,1.0,1/27,1.14%,CRB3
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Retinitis Pigmentosa,-0.9983350851645737,-1.6173509023837902,0.017094017094017096,0.7923140931622014,1.0,1/50,0.17%,CYP4V2
prerank,Elsevier_Pathway_Collection__PHOX2B Effects in Neuroblastoma,0.9905355032600676,1.6169983941547887,0.28368794326241137,0.7781112218015082,1.0,2/26,0.95%,NOTCH3;MSX1
prerank,GO_Biological_Process_2021__bile acid and bile salt transport (GO:0015721),-0.9944583210353068,-1.6165904348667088,0.14049586776859505,0.7931609518424934,1.0,2/27,0.56%,NCOA1;SLCO1A2
prerank,Elsevier_Pathway_Collection__G1/S Damage Checkpoint,0.9950754370784215,1.615980468135553,0.10218978102189781,0.7802263017809757,1.0,2/22,0.50%,CDK6;ATR
prerank,Elsevier_Pathway_Collection__RNA and DNA Metabolism Dysregulation,0.9953062236899533,1.615888336824799,0.16806722689075632,0.7786406385584033,1.0,1/15,0.47%,DROSHA
prerank,WikiPathway_2021_Human__miRNA targets in ECM and membrane receptors WP2911,0.9849597741952032,1.615860576904323,0.42857142857142855,0.7769669005194274,1.0,2/22,1.51%,ITGB5;FN1
prerank,Elsevier_Pathway_Collection__FGFR -> RUNX2 Signaling,0.9864536896737343,1.6153892109952008,0.3484848484848485,0.7770644264744326,1.0,1/22,1.36%,FGF1
prerank,GO_Biological_Process_2021__actin filament-based transport (GO:0099515),0.9897245498406565,1.61480740283993,0.26229508196721313,0.7772563911660736,1.0,1/21,1.03%,MYO7A
prerank,GO_Biological_Process_2021__regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902235),0.9849527043777874,1.6143136673351661,0.4166666666666667,0.7774733035107497,1.0,1/22,1.51%,BOK
prerank,Reactome_2022__Initial Triggering Of Complement R-HSA-166663,-0.9894956784632668,-1.6141325732421863,0.29838709677419356,0.7985154288279437,1.0,1/21,1.06%,C1R
prerank,Reactome_2022__Phototransduction Cascade R-HSA-2514856,0.9888773289516578,1.6137798575904037,0.32,0.7778781397635031,1.0,1/26,1.11%,GNB5
prerank,Elsevier_Pathway_Collection__Tumor Infiltrating Macrophages in Cancer Progression and Immune Escape,-0.9898323463176601,-1.6136600365341203,0.2830188679245283,0.7984669786345185,1.0,1/34,1.02%,CD274
prerank,Reactome_2022__FCERI Mediated MAPK Activation R-HSA-2871796,-0.9891037438940518,-1.613658619386547,0.3700787401574803,0.7971302506963799,1.0,1/29,1.10%,VAV1
prerank,GO_Biological_Process_2021__regulation of microtubule polymerization or depolymerization (GO:0031110),0.9896103316085032,1.6129352997926405,0.2814814814814815,0.7792321104840885,1.0,2/27,1.05%,STMN3;CAMSAP3
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Dysregulated DNA Repair,0.9983037483153052,1.6127035191287484,0.03007518796992481,0.7783746159852766,1.0,1/25,0.17%,MSH2
prerank,GO_Biological_Process_2021__positive regulation of interleukin-10 production (GO:0032733),-0.9898351731309245,-1.6118458619865699,0.3053435114503817,0.8009073702716527,1.0,1/29,1.02%,CD274
prerank,TRRUST_Transcription_Factors_2019__MTA1 human,0.9855280584731986,1.6117418938543435,0.3951612903225806,0.7802757527217238,1.0,1/24,1.45%,RNF144A
prerank,Elsevier_Pathway_Collection__Vascular Reactivity in Raynaud Disease,-0.9968010248628454,-1.6115683758934851,0.09917355371900827,0.8002558866666999,1.0,1/30,0.33%,PDE5A
prerank,GO_Biological_Process_2021__lymphocyte chemotaxis (GO:0048247),-0.999185719370395,-1.6115523220844028,0.025,0.7989656293975274,1.0,1/37,0.09%,CCL23
prerank,WikiPathway_2021_Human__Cell migration and invasion through p75NTR WP4561,-0.996377113472701,-1.6106995957225572,0.1092436974789916,0.8002819282815432,1.0,1/30,0.37%,AKT3
prerank,Elsevier_Pathway_Collection__Glucocorticoids in Insulin Resistance in Skeletal Muscles,-0.9928796522556533,-1.6101541976381604,0.18333333333333332,0.8004510386472169,1.0,3/34,0.73%,NCOA1;NR3C1;DEPTOR
prerank,GO_Biological_Process_2021__regulation of telomere capping (GO:1904353),-0.990031510776992,-1.6097686877526773,0.2975206611570248,0.8002156765074016,1.0,1/23,1.00%,SMG6
prerank,TRRUST_Transcription_Factors_2019__HSF1 human,-0.9893725622450816,-1.609711500595328,0.36036036036036034,0.7990826755840137,1.0,1/29,1.07%,HSD17B6
prerank,GO_Biological_Process_2021__regulation of chondrocyte differentiation (GO:0032330),0.9896477365170521,1.6095626147622495,0.2734375,0.7864146544216158,1.0,1/24,1.04%,PKDCC
prerank,GO_Biological_Process_2021__negative regulation of B cell activation (GO:0050869),-0.9869546399251993,-1.6093530080409948,0.40186915887850466,0.798716197916643,1.0,1/22,1.31%,PARP3
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transport (GO:0051928),-0.9957211179838836,-1.6093147473583298,0.07086614173228346,0.7974766625647232,1.0,1/36,0.43%,WNK3
prerank,Elsevier_Pathway_Collection__CD19 -> JUN/ELK Signaling,-0.989106976217736,-1.6088817296433209,0.37398373983739835,0.797374516280803,1.0,1/22,1.10%,VAV1
prerank,Reactome_2022__FLT3 Signaling R-HSA-9607240,-0.9865284413339536,-1.608859512154273,0.4032258064516129,0.7961272732630114,1.0,3/37,1.36%,AKT3;HCK;GRB10
prerank,GO_Biological_Process_2021__macrophage activation (GO:0042116),-0.9965675591003813,-1.6087192942156308,0.11811023622047244,0.7952138984294788,1.0,1/34,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of calcineurin-NFAT signaling cascade (GO:0070884),0.9877583440395592,1.6086411141265027,0.38405797101449274,0.7878647701630477,1.0,1/26,1.23%,HOMER3
prerank,GO_Biological_Process_2021__negative regulation of organelle assembly (GO:1902116),-0.9956446972048835,-1.6079507523465093,0.0967741935483871,0.7961245740677388,1.0,1/34,0.44%,FEZ1
prerank,GO_Biological_Process_2021__regulation of intracellular pH (GO:0051453),-0.9871832822964381,-1.6079461766306775,0.423728813559322,0.7948576122679264,1.0,2/32,1.29%,SLC9A9;SLC4A5
prerank,TRRUST_Transcription_Factors_2019__RUNX1 human,-0.9891062743291096,-1.6076868745895576,0.319672131147541,0.7942929149620555,1.0,3/37,1.10%,CCND2;KLF4;SPI1
prerank,Reactome_2022__FGFR1 Mutant Receptor Activation R-HSA-1839124,0.9864963236067114,1.6075193754196355,0.3488372093023256,0.7901725164338477,1.0,2/26,1.36%,TRIM24;FGF1
prerank,GO_Biological_Process_2021__MyD88-dependent toll-like receptor signaling pathway (GO:0002755),0.9990328161256511,1.607464032123409,0.014814814814814815,0.788666249011317,1.0,1/28,0.10%,IRAK2
prerank,GO_Biological_Process_2021__negative regulation of T cell proliferation (GO:0042130),-0.9898351854059286,-1.6072711844717813,0.31746031746031744,0.7940646061360556,1.0,1/33,1.02%,CD274
prerank,WikiPathway_2021_Human__DNA Mismatch Repair WP531,0.9928443401319781,1.6072355973322459,0.1694915254237288,0.7877401853086493,1.0,2/23,0.72%,MSH2;POLE4
prerank,GO_Biological_Process_2021__negative regulation of signaling receptor activity (GO:2000272),0.9921888758824333,1.6072286415233874,0.2109375,0.7860103635295048,1.0,2/26,0.79%,ZGPAT;PPARA
prerank,GO_Biological_Process_2021__Golgi to plasma membrane protein transport (GO:0043001),0.9925296830866128,1.607063691857874,0.12403100775193798,0.784943133779617,1.0,1/30,0.75%,KIF13A
prerank,GO_Biological_Process_2021__positive regulation of G1/S transition of mitotic cell cycle (GO:1900087),-0.990722565437449,-1.6067875014202797,0.29464285714285715,0.7941710259783485,1.0,1/26,0.93%,CCND2
prerank,KEGG_2021_Human__Mismatch repair,0.9983030939788959,1.606424723993124,0.0603448275862069,0.7855143462894736,1.0,1/23,0.17%,MSH2
prerank,Elsevier_Pathway_Collection__Thyroid Dysfunction,-0.9966832875031948,-1.606177236902018,0.10144927536231885,0.7948189188598929,1.0,1/34,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__Bradykinin Effects in Inflammation,-0.9969512638299799,-1.6058634700027556,0.07874015748031496,0.7943828189103872,1.0,1/37,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__proteoglycan biosynthetic process (GO:0030166),0.9980694631350734,1.6058025094477424,0.032520325203252036,0.7863589109206287,1.0,1/30,0.20%,FAM20B
prerank,Elsevier_Pathway_Collection__RARA Signaling in Acute Myeloid Leukemia (M3),-0.9890259003442634,-1.6057726839154411,0.34108527131782945,0.7934080974867574,1.0,1/27,1.10%,SPI1
prerank,GO_Biological_Process_2021__keratan sulfate metabolic process (GO:0042339),0.9945341147560391,1.6056235503095486,0.13970588235294118,0.7851644913653398,1.0,2/31,0.55%,ST3GAL1;SLC35D2
prerank,Elsevier_Pathway_Collection__Estrogen Effects on Pregnancy Gingivitis,-0.9960278070489511,-1.6054958421345107,0.1,0.7928305677426914,1.0,1/34,0.40%,NCOA1
prerank,Reactome_2022__Negative Regulation Of FGFR2 Signaling R-HSA-5654727,0.9864491582166046,1.6053981399057722,0.39097744360902253,0.7842582920044747,1.0,1/28,1.36%,FGF1
prerank,WikiPathway_2021_Human__PPAR-alpha pathway WP2878,0.9921478448676541,1.6052798688371037,0.20454545454545456,0.7829823437008202,1.0,1/25,0.79%,PPARA
prerank,Reactome_2022__HDMs Demethylate Histones R-HSA-3214842,0.9930717607159868,1.6051809195961817,0.22758620689655173,0.7816788206608738,1.0,1/25,0.70%,PHF2
prerank,Elsevier_Pathway_Collection__Th17-Cell Numbers Reduction in HIV,-0.9881868607329032,-1.605173131399666,0.421875,0.7924757579571922,1.0,2/27,1.19%,IL21R;IL12RB2
prerank,Reactome_2022__Transcriptional Regulation Of Pluripotent Stem Cells R-HSA-452723,-0.9901885500436867,-1.6051467495981526,0.352,0.7912953188360187,1.0,2/25,0.99%,PBX1;KLF4
prerank,GO_Biological_Process_2021__telomere maintenance via telomerase (GO:0007004),0.9854936872088411,1.6050348077220604,0.36607142857142855,0.7805959607232554,1.0,3/29,1.46%,PIF1;ACD;WRAP53
prerank,GO_Biological_Process_2021__regulation of toll-like receptor signaling pathway (GO:0034121),0.998840582647294,1.6045491631948543,0.023622047244094488,0.780862658606088,1.0,1/25,0.12%,GFI1
prerank,Reactome_2022__TGF-beta Receptor Signaling In EMT (Epithelial To Mesenchymal Transition) R-HSA-2173791,0.9885755881252261,1.604366098851316,0.30714285714285716,0.7799509212521465,1.0,1/16,1.15%,ARHGEF18
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance via telomere lengthening (GO:1904357),0.9859580163276228,1.6041261648984793,0.3902439024390244,0.7792895776610306,1.0,2/24,1.41%,PIF1;ACD
prerank,Reactome_2022__FRS-mediated FGFR4 Signaling R-HSA-5654712,0.9865014296451571,1.6036480823198334,0.3953488372093023,0.7794999889762885,1.0,2/17,1.36%,KLB;FGF1
prerank,Elsevier_Pathway_Collection__Endothelin Signaling in Arterial Hypertension,-0.9933391142976344,-1.6036284000720582,0.256198347107438,0.7944454035537697,1.0,1/26,0.67%,PTK2B
prerank,Reactome_2022__FCGR3A-mediated IL10 Synthesis R-HSA-9664323,-0.9919896836806626,-1.6034471911940609,0.2033898305084746,0.7935265647724385,1.0,1/35,0.81%,HCK
prerank,GO_Biological_Process_2021__positive regulation of alpha-beta T cell activation (GO:0046635),-0.9878802108079598,-1.6029901292758884,0.38738738738738737,0.7937008680811105,1.0,1/19,1.22%,GLI3
prerank,Elsevier_Pathway_Collection__TNFRSF1A -> AP-1/ATF/TP53 Signaling,-0.9969533661923643,-1.6028186870467407,0.10344827586206896,0.7928751962897471,1.0,1/28,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell contraction (GO:0086004),0.9926085157634605,1.6027984830842699,0.16030534351145037,0.7816234930466471,1.0,1/26,0.74%,DLG1
prerank,GO_Biological_Process_2021__regulation of epidermal cell differentiation (GO:0045604),-0.9884222955502492,-1.6027484898474285,0.36923076923076925,0.7918198287007664,1.0,2/22,1.17%,SGPP1;AQP3
prerank,Elsevier_Pathway_Collection__CFTR Related Ion-Channel Dysfunction in Cystic Fibrosis Airway Epithelium (Class III Mutations),-0.9883717292102191,-1.6026500099908323,0.38636363636363635,0.7909179759090732,1.0,1/28,1.17%,AQP3
prerank,Elsevier_Pathway_Collection__Mast-Cell Related Chemokines Signaling in Asthma,-0.9891471157177718,-1.6025412202564728,0.2867647058823529,0.7899509055161086,1.0,2/30,1.10%,GNA14;VAV1
prerank,Elsevier_Pathway_Collection__WNT Canonical Signaling Activation in Cancer,0.9960356103323291,1.602305231659036,0.06666666666666667,0.7818687896721633,1.0,2/26,0.40%,AXIN2;LRP5
prerank,GO_Biological_Process_2021__positive regulation of peptidase activity (GO:0010952),0.9874920907251208,1.6021846179179893,0.30952380952380953,0.7805248792645993,1.0,1/21,1.25%,CTSH
prerank,GO_Biological_Process_2021__positive regulation of signal transduction by p53 class mediator (GO:1901798),0.9905367800237652,1.6018041206482028,0.15384615384615385,0.780275734458935,1.0,2/22,0.95%,ATR;MSX1
prerank,GO_Biological_Process_2021__positive regulation of fibroblast proliferation (GO:0048146),0.9849563753627029,1.6017059640848503,0.39568345323741005,0.7789815191011886,1.0,2/27,1.51%,CDK6;FN1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell proliferation (GO:0060043),0.996958267705936,1.6016559300751074,0.09923664122137404,0.7775067002406675,1.0,1/20,0.31%,VGLL4
prerank,Elsevier_Pathway_Collection__Cancer Cells Inhibit Adipocyte Differentiation,0.9988024054307676,1.6012072610409007,0.049586776859504134,0.7776854708588714,1.0,1/25,0.12%,AXIN2
prerank,Reactome_2022__Lysosome Vesicle Biogenesis R-HSA-432720,-0.9965692537348075,-1.600092161668653,0.12,0.795305315030973,1.0,1/34,0.35%,APP
prerank,GO_Biological_Process_2021__7-methylguanosine RNA capping (GO:0009452),-0.9922587317675435,-1.5991156503357948,0.24166666666666667,0.7955968536482858,1.0,1/32,0.78%,RNGTT
prerank,GO_Biological_Process_2021__7-methylguanosine mRNA capping (GO:0006370),-0.9922587317675435,-1.5991156503357948,0.24166666666666667,0.7955968536482858,1.0,1/32,0.78%,RNGTT
prerank,Elsevier_Pathway_Collection__Toll-like Receptors Act through MYD88-TIRAP Signaling,-0.9969517466977409,-1.5988197106949475,0.0743801652892562,0.7952985790632644,1.0,1/38,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Peripheral Tolerance to Autoantigens Recession in Diabetes Mellitus Type 1,-0.988710475091849,-1.5984068358615928,0.29411764705882354,0.7952310226754923,1.0,1/38,1.13%,ZAP70
prerank,GO_Biological_Process_2021__regulation of vasoconstriction (GO:0019229),-0.997954482483863,-1.5982525432880534,0.03968253968253968,0.7943472919615691,1.0,1/29,0.21%,ZDHHC21
prerank,Elsevier_Pathway_Collection__Immunoglobulin Class-Switch Recombination Activation,0.9956101801198826,1.5982387103420412,0.08029197080291971,0.7883146077378411,1.0,1/26,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__Thrombophilia Hereditary,-0.9957645199615142,-1.598120836181107,0.11570247933884298,0.7908870007501171,1.0,1/23,0.43%,PROS1
prerank,Elsevier_Pathway_Collection__Coagulation Cascade,-0.9957645199615142,-1.598120836181107,0.11570247933884298,0.7908870007501171,1.0,1/23,0.43%,PROS1
prerank,Elsevier_Pathway_Collection__Hereditary Thrombophilia and Pregnancy Complications,-0.9957645199615142,-1.598120836181107,0.11570247933884298,0.7908870007501171,1.0,1/23,0.43%,PROS1
prerank,GO_Biological_Process_2021__positive regulation of axonogenesis (GO:0050772),-0.9904431661546812,-1.5977358528875014,0.211864406779661,0.7906392520002654,1.0,1/41,0.96%,SEMA4D
prerank,GO_Biological_Process_2021__negative regulation of axonogenesis (GO:0050771),0.9860336401304645,1.597523375724218,0.36879432624113473,0.7896838911766204,1.0,2/28,1.40%,THY1;SEMA3G
prerank,GO_Biological_Process_2021__regulation of cellular pH (GO:0030641),-0.9871860928090309,-1.5973924805382165,0.42105263157894735,0.79037889997558,1.0,2/27,1.29%,SLC9A9;SLC4A5
prerank,GO_Biological_Process_2021__regulation of small molecule metabolic process (GO:0062012),0.9870717779552453,1.597142176005045,0.3629032258064516,0.7896592586344646,1.0,2/27,1.30%,PPARA;APOE
prerank,GO_Biological_Process_2021__calcium ion transmembrane import into cytosol (GO:0097553),-0.9999568379982524,-1.5970717718774678,0.0,0.7899723429981441,1.0,1/38,0.01%,GRIN2B
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Age-Related Macular Degeneration,0.9870307546789867,1.596187913285745,0.366412213740458,0.7920287999758592,1.0,1/23,1.30%,APOE
prerank,WikiPathway_2021_Human__Amyotrophic lateral sclerosis (ALS) WP2447,-0.9969505717988006,-1.595886962584087,0.09090909090909091,0.7919291439188094,1.0,1/36,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__MAPK Cascade WP422,-0.9969526820248859,-1.5955520918407675,0.088,0.7914881159996809,1.0,1/33,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__TNFRSF1A -> CREB/ELK-SRF Signaling,-0.9969523564717648,-1.5954158221349921,0.10236220472440945,0.7906028213428477,1.0,1/29,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__AHR Signaling in Tr1 Cells Function,-0.9893368570719052,-1.5947172248760666,0.35344827586206895,0.7911946314708062,1.0,1/28,1.07%,IL21R
prerank,Elsevier_Pathway_Collection__CFTR Misfolding and Degradation (Class II Mutations),0.9913738654038357,1.5943834132619277,0.16541353383458646,0.797576400725172,1.0,1/30,0.86%,RHOQ
prerank,WikiPathway_2021_Human__NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,-0.9948037541344305,-1.5941689017091791,0.12,0.7911745624275943,1.0,1/23,0.53%,RB1
prerank,Reactome_2022__Resolution Of D-Loop Structures R-HSA-5693537,0.9962230396373145,1.593903221556705,0.08888888888888889,0.7979419798267091,1.0,1/33,0.38%,BRIP1
prerank,GO_Biological_Process_2021__ncRNA catabolic process (GO:0034661),0.9913031372448105,1.5936600708198063,0.26153846153846155,0.7973273686191367,1.0,2/28,0.88%,DIS3L2;PARN
prerank,Reactome_2022__Calnexin/calreticulin Cycle R-HSA-901042,-0.9928386478655868,-1.5935246915998378,0.22018348623853212,0.7916047378643546,1.0,1/26,0.72%,AMFR
prerank,WikiPathway_2021_Human__Nicotine Activity on Dopaminergic Neurons WP1602,0.9869560665986966,1.5927168465978438,0.3769230769230769,0.7992878628813657,1.0,1/19,1.31%,DRD4
prerank,WikiPathway_2021_Human__1q21.1 copy number variation syndrome WP4905,0.995574791135047,1.5925105368844694,0.13559322033898305,0.7983798444200191,1.0,2/25,0.45%,PRKAA2;TJP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteopetrosis,-0.9890645867558323,-1.5922859266686842,0.2459016393442623,0.793738942390533,1.0,2/40,1.10%,PTK2B;SPI1
prerank,GO_Biological_Process_2021__response to organonitrogen compound (GO:0010243),0.9869437636916961,1.5922422451109308,0.3125,0.7977365349691141,1.0,1/34,1.31%,DRD4
prerank,GO_Biological_Process_2021__response to amino acid (GO:0043200),-0.9994168208197043,-1.5920707498926028,0.015748031496062992,0.7929362378273984,1.0,1/29,0.07%,CPEB3
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell action potential (GO:0098901),0.9926097662381516,1.591880633880221,0.17094017094017094,0.7974904203035822,1.0,1/24,0.74%,DLG1
prerank,GO_Biological_Process_2021__positive regulation of nitric oxide biosynthetic process (GO:0045429),-0.9901456989521051,-1.5916595746499664,0.3050847457627119,0.7928872235122661,1.0,1/26,0.99%,KLF4
prerank,GO_Biological_Process_2021__cholesterol efflux (GO:0033344),0.9865351327412608,1.5914332510144025,0.37593984962406013,0.7978280049267803,1.0,2/24,1.35%,APOE;SOAT2
prerank,GO_Biological_Process_2021__positive regulation of granulocyte chemotaxis (GO:0071624),0.9894192153991033,1.5913527592006,0.3162393162393162,0.7964276343298968,1.0,1/20,1.06%,MOSPD2
prerank,Reactome_2022__Signaling By ERBB2 KD Mutants R-HSA-9664565,0.990416202757451,1.5912334095879832,0.2713178294573643,0.7951663557288133,1.0,1/24,0.96%,ERBB3
prerank,WikiPathway_2021_Human__T-Cell Receptor and Co-stimulatory Signaling WP2583,-0.9887194650225046,-1.5911625361706259,0.36363636363636365,0.7929831026151286,1.0,1/28,1.13%,ZAP70
prerank,Reactome_2022__Sulfur Amino Acid Metabolism R-HSA-1614635,-0.9883812570405486,-1.5911185178599805,0.35454545454545455,0.7918765718476338,1.0,2/25,1.17%,BHMT;CDO1
prerank,Elsevier_Pathway_Collection__EGFR/ERBB2 -> TP53 Signaling,-0.9891816495520255,-1.5905755669333113,0.3140495867768595,0.7920261904268332,1.0,3/41,1.10%,MAP2K6;PTK2B;VAV1
prerank,GO_Biological_Process_2021__smoothened signaling pathway (GO:0007224),-0.9879128743139566,-1.5904879535230048,0.3709677419354839,0.7910293440421249,1.0,2/35,1.22%,TTBK2;GLI3
prerank,Elsevier_Pathway_Collection__Central Hypothyroidism,-0.9898783793730687,-1.5902915548623842,0.3418803418803419,0.7891166933990635,1.0,1/24,1.02%,SLC16A2
prerank,Elsevier_Pathway_Collection__Tertiary Hypothyroidism,-0.9898783793730687,-1.5902915548623842,0.3418803418803419,0.7891166933990635,1.0,1/24,1.02%,SLC16A2
prerank,Reactome_2022__tRNA Modification In Nucleus And Cytosol R-HSA-6782315,-0.988486406685513,-1.5900896237786213,0.35772357723577236,0.7883635971617887,1.0,2/42,1.16%,TYW1;TRMT9B
prerank,Reactome_2022__Endogenous Sterols R-HSA-211976,-0.8527334343279012,-1.5900105015093113,0.3557692307692308,0.7873394702804959,1.0,4/23,1.27%,CYP39A1;CYP4V2;NCOA1;CYP1B1
prerank,Elsevier_Pathway_Collection__PARK2/PINK1/UCHL1 in Young Onset Parkinson's Disease,0.9852679671963688,1.5899939891975132,0.4166666666666667,0.7979481447342135,1.0,1/18,1.48%,LAMP2
prerank,GO_Biological_Process_2021__regulation of extracellular matrix disassembly (GO:0010715),0.989039350764485,1.5895695744602871,0.3358208955223881,0.797985258661323,1.0,1/15,1.10%,MELTF
prerank,GO_Biological_Process_2021__negative regulation of protein localization to cell periphery (GO:1904376),0.9890384579615107,1.589522390709032,0.2786885245901639,0.7964557898353276,1.0,2/20,1.10%,RHOQ;SAPCD2
prerank,Elsevier_Pathway_Collection__mRNA Degradation,0.9912633327330013,1.588968600299153,0.24427480916030533,0.7969235566460304,1.0,1/26,0.88%,PARN
prerank,GO_Biological_Process_2021__zinc ion homeostasis (GO:0055069),0.985217612670129,1.5887022178057255,0.4172661870503597,0.7966443243697849,1.0,1/28,1.48%,SLC30A10
prerank,TRRUST_Transcription_Factors_2019__PARP1 human,0.9849136062783703,1.5885882642066875,0.4444444444444444,0.7954212841889838,1.0,1/24,1.51%,FN1
prerank,WikiPathway_2021_Human__NO/cGMP/PKG mediated Neuroprotection WP4008,-0.9999557696780101,-1.587275350669186,0.0,0.792907750805372,1.0,1/43,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__positive regulation of cholesterol efflux (GO:0010875),0.9870324132291259,1.5864012262310128,0.408,0.8020179499830185,1.0,1/22,1.30%,APOE
prerank,Elsevier_Pathway_Collection__Toll-like Receptors (TLR) in Periodontitis,-0.9896842584510175,-1.5863783176734692,0.3963963963963964,0.7940079642922243,1.0,1/26,1.04%,TICAM2
prerank,GO_Biological_Process_2021__response to estradiol (GO:0032355),-0.9962229822038086,-1.5863107341165892,0.11382113821138211,0.7929345500117468,1.0,1/32,0.38%,GGT5
prerank,GO_Biological_Process_2021__NAD biosynthetic process (GO:0009435),0.9914984027664205,1.5857112902628796,0.29133858267716534,0.8029488757834755,1.0,1/19,0.85%,QPRT
prerank,Reactome_2022__Signaling By ERBB2 In Cancer R-HSA-1227990,0.9904157010923532,1.585675893212647,0.2734375,0.8014587463523338,1.0,1/25,0.96%,ERBB3
prerank,GO_Biological_Process_2021__protein ADP-ribosylation (GO:0006471),-0.9869952626202695,-1.585570971245799,0.43846153846153846,0.7936949971786614,1.0,2/28,1.31%,PARP8;PARP3
prerank,"Elsevier_Pathway_Collection__Lymphoma, GCB Subtype",0.9950341481561773,1.585450224865815,0.1015625,0.8006968288965849,1.0,1/22,0.50%,ATR
prerank,Elsevier_Pathway_Collection__Complement System Defects in Systemic Lupus Erythematosis,-0.9894928564921646,-1.5853985320582866,0.35964912280701755,0.7929095167515507,1.0,1/23,1.06%,C1R
prerank,"GO_Biological_Process_2021__wound healing, spreading of cells (GO:0044319)",0.985997947337427,1.5848065003005547,0.40476190476190477,0.8017091212419205,1.0,2/23,1.41%,MRTFA;FLNA
prerank,Reactome_2022__Resolution Of D-loop Structures Thru Holliday Junction Intermediates R-HSA-5693568,0.996223207839404,1.5847631599650776,0.08888888888888889,0.8002764148583161,1.0,1/32,0.38%,BRIP1
prerank,WikiPathway_2021_Human__Type II interferon signaling (IFNG) WP619,-0.9890692566046121,-1.5841049328375865,0.35294117647058826,0.7949187422062716,1.0,2/34,1.10%,OAS1;SPI1
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR4 R-HSA-5654716,0.9864975680087866,1.5839746334592109,0.41007194244604317,0.8018429353238271,1.0,2/22,1.36%,KLB;FGF1
prerank,WikiPathway_2021_Human__Gastric Cancer Network 2 WP2363,0.9866477733481916,1.5839028612593655,0.3609022556390977,0.8004385772194536,1.0,3/31,1.34%,CEBPZ;UBE2C;COL9A3
prerank,TRRUST_Transcription_Factors_2019__MITF human,0.9947257294343603,1.5835869949506982,0.13008130081300814,0.8000894446808311,1.0,1/24,0.53%,HERC2
prerank,Reactome_2022__HIV Elongation Arrest And Recovery R-HSA-167287,0.9919522882592432,1.5832503393262993,0.12781954887218044,0.7997492992352773,1.0,1/31,0.81%,TCEA1
prerank,GO_Biological_Process_2021__positive regulation of phosphate metabolic process (GO:0045937),-0.9965716149386586,-1.5832427763900345,0.0859375,0.7960010828735918,1.0,1/26,0.35%,APP
prerank,"Reactome_2022__Interleukin-3, Interleukin-5 And GM-CSF Signaling R-HSA-512988",-0.9891815187191622,-1.5828857776432046,0.35537190082644626,0.7956528614741443,1.0,3/42,1.10%,PIK3CB;HCK;VAV1
prerank,Reactome_2022__Negative Regulation Of MET Activity R-HSA-6807004,0.9847611157124592,1.5828253936835306,0.453125,0.7996756510789351,1.0,1/21,1.53%,LRIG1
prerank,Elsevier_Pathway_Collection__Replication Stress Triggers Genomic Instability,0.9950729921412267,1.5825825030300202,0.1484375,0.7989294277166511,1.0,2/29,0.50%,MMS22L;ATR
prerank,GO_Biological_Process_2021__positive regulation of smoothened signaling pathway (GO:0045880),0.9942651528423676,1.582543680253592,0.15748031496062992,0.7974693687843583,1.0,1/21,0.58%,TTC23
prerank,GO_Biological_Process_2021__hexose biosynthetic process (GO:0019319),-0.9992229683305237,-1.5824254673875024,0.024193548387096774,0.7955239564405642,1.0,1/39,0.08%,ALDOB
prerank,Elsevier_Pathway_Collection__VEGFR -> ATF/CREB/ELK-SRF Signaling,-0.9969512171958265,-1.5823945568672662,0.13559322033898305,0.794369894489561,1.0,1/37,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Intracellular trafficking proteins involved in CMT neuropathy WP4856,-0.9930686866735259,-1.5822384631539657,0.1885245901639344,0.7935329231893431,1.0,1/27,0.70%,SBF2
prerank,Elsevier_Pathway_Collection__Ketogenic Diet Mechanism (Hypothesis),0.992147827423858,1.581833460959546,0.26153846153846155,0.7984022152882037,1.0,1/25,0.79%,PPARA
prerank,GO_Biological_Process_2021__regulation of cellular biosynthetic process (GO:0031326),0.9996878002937487,1.5817335126470426,0.0,0.7971969912437968,1.0,1/30,0.03%,PRKAA2
prerank,Elsevier_Pathway_Collection__Extracellular Matrix Turnover,0.984962844851744,1.581665274928135,0.4344262295081967,0.7959140248121545,1.0,2/18,1.51%,A2M;FN1
prerank,Elsevier_Pathway_Collection__NF-kB non-Canonical Signaling,0.9956096254280243,1.5807190117592138,0.08888888888888889,0.7978549971566112,1.0,1/28,0.44%,TRAF3
prerank,WikiPathway_2021_Human__NAD+ biosynthetic pathways WP3645,0.9914961468804541,1.5806790025876774,0.23770491803278687,0.7964039528773974,1.0,1/22,0.85%,QPRT
prerank,GO_Biological_Process_2021__positive regulation of receptor-mediated endocytosis (GO:0048260),-0.9917594350650547,-1.5803910306968363,0.22764227642276422,0.7970119380987508,1.0,2/41,0.83%,ATAD1;NTF3
prerank,Elsevier_Pathway_Collection__Th17-Cell Activation in Crohn's Disease,-0.9882228903419901,-1.580035775622429,0.33076923076923076,0.7966775794730085,1.0,3/34,1.19%,IL21R;ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__response to steroid hormone (GO:0048545),-0.9939569319289396,-1.5797354987187915,0.21929824561403508,0.7962422909974092,1.0,2/31,0.61%,NR3C1;CATSPER3
prerank,Reactome_2022__RAF Activation R-HSA-5673000,0.9978408533536443,1.5795743664391804,0.03125,0.7985451138427754,1.0,1/30,0.22%,KSR1
prerank,GO_Biological_Process_2021__regulation of T cell differentiation (GO:0045580),-0.9888007757128472,-1.5794597850021401,0.3560606060606061,0.7957319739109581,1.0,3/34,1.13%,RHOH;CD2;ZAP70
prerank,GO_Biological_Process_2021__cellular response to amyloid-beta (GO:1904646),-0.9965679766928746,-1.5794023430241058,0.09259259259259259,0.7946769235584498,1.0,1/34,0.35%,APP
prerank,GO_Biological_Process_2021__heterochromatin assembly (GO:0031507),0.991841174988831,1.578970289715054,0.19083969465648856,0.7990481395903707,1.0,1/24,0.82%,SMCHD1
prerank,GO_Biological_Process_2021__regulation of spindle assembly (GO:0090169),0.9966869558249862,1.5789592465502535,0.07407407407407407,0.7975067260967922,1.0,1/25,0.33%,CCSAP
prerank,Reactome_2022__Polymerase Switching On C-strand Of Telomere R-HSA-174411,0.985957853299262,1.5787076529121398,0.34375,0.7966681237047154,1.0,2/25,1.41%,SLC19A1;ACD
prerank,GO_Biological_Process_2021__negative regulation of reactive oxygen species metabolic process (GO:2000378),0.9853072781964198,1.5785787792785793,0.43548387096774194,0.7954258891969183,1.0,3/22,1.48%,AATF;PPARA;SLC30A10
prerank,Elsevier_Pathway_Collection__Immune Sustem Activation in Hashimoto's Thyroiditis,-0.9875690311034044,-1.5776815917952307,0.39823008849557523,0.7974939033334568,1.0,2/30,1.25%,ZAP70;VDR
prerank,Reactome_2022__Gap-filling DNA Repair Synthesis And Ligation In GG-NER R-HSA-5696397,0.9848436820486887,1.577672971770506,0.4580152671755725,0.7970017222070759,1.0,3/25,1.53%,SLC19A1;POLE4;LRIG1
prerank,WikiPathway_2021_Human__Urea cycle and metabolism of amino groups WP497,0.9848824219553468,1.5773552102523518,0.40310077519379844,0.796603784702463,1.0,2/21,1.52%,PYCR1;SMS
prerank,Elsevier_Pathway_Collection__T-Cell Positive Selection and Neglect Induced Death,-0.9887188167228075,-1.5770861585896596,0.3983050847457627,0.797762952296991,1.0,1/30,1.13%,ZAP70
prerank,GO_Biological_Process_2021__regulation of DNA biosynthetic process (GO:2000278),-0.990028670929516,-1.577007662802513,0.2982456140350877,0.796817095806703,1.0,1/28,1.00%,SMG6
prerank,Reactome_2022__NOTCH3 Activation And Transmission Of Signal To Nucleus R-HSA-9013507,0.994151046213856,1.5767883132748821,0.17164179104477612,0.7969649748434051,1.0,2/25,0.59%,NOTCH3;WWP2
prerank,GO_Biological_Process_2021__positive regulation of neutrophil chemotaxis (GO:0090023),0.9894198951835598,1.5766205001464275,0.3217391304347826,0.7960400979915015,1.0,1/19,1.06%,MOSPD2
prerank,GO_Biological_Process_2021__RNA-dependent DNA biosynthetic process (GO:0006278),0.9854930708436973,1.575443682758201,0.36607142857142855,0.7985990212282059,1.0,3/30,1.46%,PIF1;ACD;WRAP53
prerank,Elsevier_Pathway_Collection__Complement Activation in Macular Degeneration,-0.9894887673328209,-1.5753508054359178,0.3445378151260504,0.7999529102370581,1.0,1/29,1.06%,C1R
prerank,GO_Biological_Process_2021__negative regulation of calcium ion transmembrane transporter activity (GO:1901020),0.9870381239025047,1.5748794931632712,0.37606837606837606,0.7988811523681442,1.0,3/22,1.31%,GPR35;GNB5;DRD4
prerank,TRRUST_Transcription_Factors_2019__LEF1 mouse,0.995994593230051,1.574431320190412,0.1417910447761194,0.798892149515393,1.0,1/23,0.40%,LRP5
prerank,GO_Biological_Process_2021__positive regulation of cytokine production (GO:0001819),-0.9874221942169024,-1.574194394126403,0.01020408163265306,0.8016923669621004,1.0,6/312,1.27%,APP;SCIMP;CD2;CD274;IL12RB2;CYP1B1
prerank,Reactome_2022__Energy Dependent Regulation Of mTOR By LKB1-AMPK R-HSA-380972,0.991919276083002,1.5741687352370222,0.21323529411764705,0.7982984818733013,1.0,2/29,0.81%,PRKAA2;CAB39
prerank,TRRUST_Transcription_Factors_2019__SMAD3 human,-0.9876091703723984,-1.5736201093114113,0.39285714285714285,0.8019095002341706,1.0,3/31,1.25%,CCND2;LTBP4;VDR
prerank,Elsevier_Pathway_Collection__Gap Junction Assembly,0.9955757200345172,1.5734058220749445,0.1889763779527559,0.7993429859997273,1.0,2/19,0.45%,GJC1;TJP1
prerank,GO_Biological_Process_2021__positive regulation of neutrophil migration (GO:1902624),0.9894181404152577,1.5725938541942355,0.3114754098360656,0.800296414818811,1.0,1/22,1.06%,MOSPD2
prerank,Reactome_2022__Packaging Of Telomere Ends R-HSA-171306,0.9859138187819553,1.5725810775235616,0.4224137931034483,0.7988198319092346,1.0,1/23,1.41%,ACD
prerank,GO_Biological_Process_2021__prostaglandin metabolic process (GO:0006693),-0.9995715467641534,-1.5725062740830411,0.01652892561983471,0.8035968794129601,1.0,1/29,0.05%,GSTA1
prerank,GO_Biological_Process_2021__dicarboxylic acid transport (GO:0006835),0.9910729668949141,1.5724187897212893,0.20714285714285716,0.7978115369598171,1.0,2/27,0.90%,SLC19A1;SLC13A3
prerank,Elsevier_Pathway_Collection__GABA(B)R -> Postsynaptic Inhibition,-0.996686031698635,-1.5723263229464628,0.08527131782945736,0.8028062973221791,1.0,1/25,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__PDGFR -> AP-1/MYC Signaling,-0.9933773251917485,-1.5717187733000657,0.2413793103448276,0.8031398927545045,1.0,2/37,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__regulation of receptor-mediated endocytosis (GO:0048259),-0.9927571230799805,-1.5716739400595034,0.21929824561403508,0.8020769752681012,1.0,1/37,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__DNA strand elongation (GO:0022616),0.9974198240352766,1.5714242452919744,0.08396946564885496,0.7995200526906769,1.0,1/18,0.26%,GINS1
prerank,GO_Biological_Process_2021__positive regulation of extrinsic apoptotic signaling pathway (GO:2001238),-0.9869545876028554,-1.5702555331866634,0.45794392523364486,0.8043352683062687,1.0,2/28,1.31%,PAK2;PML
prerank,Reactome_2022__Transcription Of E2F Targets Under Negative Control By DREAM Complex R-HSA-1362277,0.9971501301244919,1.5702189799296902,0.056,0.8018054199710163,1.0,1/19,0.29%,RBL1
prerank,WikiPathway_2021_Human__G13 Signaling Pathway WP524,-0.9927580900025074,-1.5694535856293224,0.15789473684210525,0.8049646287170439,1.0,1/37,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__positive regulation of nitric oxide metabolic process (GO:1904407),-0.9901452571677245,-1.5694361780405863,0.325,0.8038164956873924,1.0,1/27,0.99%,KLF4
prerank,KEGG_2021_Human__Proximal tubule bicarbonate reclamation,0.985105867176194,1.5690284975195257,0.4244604316546763,0.8043049595820646,1.0,1/22,1.49%,GLS
prerank,WikiPathway_2021_Human__Statin inhibition of cholesterol production WP430,0.9870258324807175,1.5689518008415793,0.3875968992248062,0.8030643376865083,1.0,1/29,1.30%,APOE
prerank,WikiPathway_2021_Human__Base Excision Repair WP4752,0.9927994129980539,1.5688490921032328,0.17142857142857143,0.8019214891923399,1.0,1/31,0.72%,POLE4
prerank,Reactome_2022__Plasma Lipoprotein Clearance R-HSA-8964043,0.9865272443630877,1.5686643685650359,0.38686131386861317,0.8010045153161811,1.0,2/34,1.35%,APOE;SOAT2
prerank,Reactome_2022__Disassembly Of Destruction Complex And Recruitment Of AXIN To Membrane R-HSA-4641262,0.9959947345775824,1.5686253461158866,0.09090909090909091,0.799684351411242,1.0,1/27,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Lamellipodia and Filopodia Formation in Cancer,-0.9891046625829254,-1.5683746303894075,0.33070866141732286,0.8052535177444105,1.0,1/29,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Macrophage Function in Diabetes Mellitus Type 1,-0.9891884052250137,-1.5683032914563142,0.3305785123966942,0.8042698448477421,1.0,3/28,1.10%,PTK2B;HCK;VAV1
prerank,GO_Biological_Process_2021__negative regulation of transferase activity (GO:0051348),0.9887186804246036,1.5682405312590861,0.33064516129032256,0.7994087492709723,1.0,1/29,1.13%,PIF1
prerank,"GO_Biological_Process_2021__regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043516)",0.9905346858262654,1.5678989663823863,0.23741007194244604,0.7993047537959734,1.0,2/27,0.95%,ATR;MSX1
prerank,Elsevier_Pathway_Collection__Glycolysis Activation in Cancer (Warburg Effect),-0.9992234532988725,-1.56766126523438,0.008849557522123894,0.804548247047912,1.0,1/40,0.08%,ALDOB
prerank,GO_Biological_Process_2021__cellular zinc ion homeostasis (GO:0006882),0.9852196782861081,1.5672430631814978,0.4326241134751773,0.8001801168855558,1.0,1/26,1.48%,SLC30A10
prerank,GO_Biological_Process_2021__RNA biosynthetic process (GO:0032774),0.9926839622854826,1.5671039148816028,0.17293233082706766,0.799211218958226,1.0,1/31,0.73%,TAF4
prerank,GO_Biological_Process_2021__regulation of JUN kinase activity (GO:0043506),0.985058366230992,1.567097427027613,0.40310077519379844,0.7977441325995919,1.0,1/32,1.49%,MAPK8IP1
prerank,Reactome_2022__Caspase Activation Via Extrinsic Apoptotic Signaling Pathway R-HSA-5357769,0.995801160215039,1.5669121109546664,0.056,0.7968750719196316,1.0,1/25,0.42%,TNFRSF10A
prerank,KEGG_2021_Human__Aldosterone-regulated sodium reabsorption,-0.9927569776858332,-1.5668890329360912,0.17094017094017094,0.8053399216260828,1.0,1/33,0.73%,PIK3CB
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through ITSM-Containing Receptors,-0.9890964227908983,-1.5668433558521877,0.3671875,0.804267665192644,1.0,1/33,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Congenital Deafness,-0.991879188385242,-1.5666899670628502,0.2702702702702703,0.8034393933915573,1.0,1/23,0.82%,KCNE1
prerank,GO_Biological_Process_2021__cellular response to interleukin-6 (GO:0071354),-0.9890289282233325,-1.5659426520737663,0.3140495867768595,0.803976385903304,1.0,1/28,1.10%,SPI1
prerank,GO_Biological_Process_2021__establishment of protein localization to plasma membrane (GO:0061951),0.9925267073741193,1.565798214349849,0.13709677419354838,0.7991778382844282,1.0,1/35,0.75%,KIF13A
prerank,WikiPathway_2021_Human__Urea cycle and associated pathways WP4595,0.9862208971828152,1.5656916483309709,0.375,0.7980914640683573,1.0,1/24,1.38%,PYCR1
prerank,GO_Biological_Process_2021__phosphatidylserine metabolic process (GO:0006658),-0.9984562671135252,-1.5653673171909614,0.03361344537815126,0.8040930871928682,1.0,1/29,0.16%,PLAAT3
prerank,Elsevier_Pathway_Collection__Focal Junction Assembly,0.9850333315436475,1.5651070019466327,0.44881889763779526,0.7986226267905494,1.0,4/30,1.51%,PTK2;FBLIM1;BCAR1;FN1
prerank,Reactome_2022__Conversion From APC/C:Cdc20 To APC/C:Cdh1 In Late Anaphase R-HSA-176407,0.9906118084381327,1.5650423516356768,0.3181818181818182,0.7973592242387544,1.0,1/20,0.94%,UBE2C
prerank,GO_Biological_Process_2021__negative regulation of cation channel activity (GO:2001258),0.987037412378863,1.5650343746056279,0.376,0.7959187489193994,1.0,3/23,1.31%,GPR35;GNB5;DRD4
prerank,Elsevier_Pathway_Collection__Sialophorin -> CTNNB/MYC/TP53 Signaling,-0.9969567301173162,-1.5646482590342734,0.10077519379844961,0.8047075031173182,1.0,1/25,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__monocarboxylic acid catabolic process (GO:0072329),-0.989296875783288,-1.5641983628097567,0.3333333333333333,0.8046938668519676,1.0,1/27,1.08%,HAO1
prerank,GO_Biological_Process_2021__axoneme assembly (GO:0035082),0.9904544180254629,1.5641563603576587,0.2992125984251969,0.7976370018524656,1.0,1/27,0.96%,CCDC40
prerank,GO_Biological_Process_2021__nucleobase-containing compound catabolic process (GO:0034655),-0.9882963930584111,-1.5639513041978208,0.3709677419354839,0.8041284809471598,1.0,2/39,1.18%,ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__positive regulation of interferon-beta production (GO:0032728),-0.9922624799582831,-1.5637638655709876,0.22608695652173913,0.8032831140384941,1.0,2/35,0.78%,OAS1;TOMM70
prerank,GO_Biological_Process_2021__protein targeting to peroxisome (GO:0006625),-0.9950345301698387,-1.5636926939908606,0.1111111111111111,0.8023179249649027,1.0,2/29,0.51%,ABCD3;ATAD1
prerank,Reactome_2022__Signaling By WNT In Cancer R-HSA-4791275,0.9959929971369454,1.5634484700431939,0.09230769230769231,0.7987222055432953,1.0,1/32,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Enamel Formation Disruption,0.9888039760999584,1.5634250502226512,0.29770992366412213,0.7973497082052017,1.0,2/27,1.13%,DLX6;TUFT1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Rheumatoid Arthritis,0.9849158393694171,1.5626877930518828,0.4452054794520548,0.7984037158456412,1.0,1/20,1.51%,FN1
prerank,KEGG_2021_Human__Circadian rhythm,0.9996879559687786,1.5626156920240135,0.015503875968992248,0.797272282474556,1.0,1/30,0.03%,PRKAA2
prerank,TRRUST_Transcription_Factors_2019__CEBPB mouse,-0.999995667389614,-1.5625102540390772,0.0,0.8040475837189489,1.0,1/37,0.01%,GSTA2
prerank,GO_Biological_Process_2021__positive regulation of viral genome replication (GO:0045070),0.9921454408713322,1.562330512882592,0.20491803278688525,0.7966911042981248,1.0,1/28,0.79%,PPARA
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor superfamily cytokine production (GO:1903556),-0.9898246578788025,-1.562013054741403,0.29411764705882354,0.8040593792044834,1.0,1/43,1.02%,CD274
prerank,Reactome_2022__Recognition Of DNA Damage By PCNA-containing Replication Complex R-HSA-110314,0.992840813682528,1.5615221416050888,0.1956521739130435,0.798064884319431,1.0,2/30,0.72%,SLC19A1;POLE4
prerank,GO_Biological_Process_2021__regulation of cardiac conduction (GO:1903779),-0.9914402518509127,-1.5615171023005783,0.1694915254237288,0.8042233128180197,1.0,1/49,0.86%,FXYD6
prerank,GO_Biological_Process_2021__oxoacid metabolic process (GO:0043436),-0.9893805608582227,-1.5614238265145588,0.3644859813084112,0.8033656482827457,1.0,3/30,1.08%,TPST1;SULT1B1;HAO1
prerank,Elsevier_Pathway_Collection__AXL Receptor Tyrosine Kinase Signaling,-0.9957544897453141,-1.5609560491175603,0.07258064516129033,0.8031902194604805,1.0,1/46,0.43%,PROS1
prerank,Elsevier_Pathway_Collection__T-Cells Differentiation Block in Psoriasis,-0.9881354817554621,-1.560950069409735,0.4083333333333333,0.8020576993047949,1.0,1/37,1.19%,IL12RB2
prerank,KEGG_2021_Human__ABC transporters,-0.9951836243321588,-1.5601897736439347,0.14814814814814814,0.8026774622677479,1.0,2/43,0.49%,ABCA6;ABCD3
prerank,GO_Biological_Process_2021__positive regulation of pri-miRNA transcription by RNA polymerase II (GO:1902895),-0.9891087943249307,-1.559936704734049,0.3445378151260504,0.8021713811235268,1.0,3/33,1.10%,NR3C1;KLF4;SPI1
prerank,Elsevier_Pathway_Collection__EGFR -> AP-1/ATF2 Signaling,-0.9891812181650029,-1.5597179220454458,0.31932773109243695,0.8014555264220776,1.0,3/42,1.10%,MAP2K6;PTK2B;VAV1
prerank,GO_Biological_Process_2021__response to estrogen (GO:0043627),0.9870702484291959,1.5597034789692719,0.33884297520661155,0.8026641442743289,1.0,3/32,1.30%,TRIM24;GSTM3;CYP27B1
prerank,TRRUST_Transcription_Factors_2019__EZH2 human,-0.9875145552205169,-1.559545084854568,0.4188034188034188,0.8007537635676335,1.0,1/38,1.25%,VDR
prerank,GO_Biological_Process_2021__positive regulation of T cell migration (GO:2000406),-0.9965710658078114,-1.559467156677198,0.125,0.79979523973314,1.0,1/23,0.35%,APP
prerank,WikiPathway_2021_Human__TP53 network WP1742,0.9849584866616661,1.5592963171728256,0.44360902255639095,0.8026263976002705,1.0,1/18,1.51%,BOK
prerank,GO_Biological_Process_2021__metal ion export (GO:0070839),-0.9919182540901003,-1.5587444421441006,0.1743119266055046,0.8002395517308026,1.0,2/29,0.82%,KCNT2;KCNE1
prerank,TRRUST_Transcription_Factors_2019__SNAI1 mouse,0.9849592245610863,1.558361899969127,0.4645669291338583,0.8044349550950174,1.0,2/23,1.51%,TJP1;FN1
prerank,WikiPathway_2021_Human__Microglia Pathogen Phagocytosis Pathway WP3937,-0.9866816852976548,-1.5579981039177775,0.38524590163934425,0.8009946315625984,1.0,4/40,1.35%,PIK3CB;HCK;VAV1;PIK3R6
prerank,Reactome_2022__Cooperation Of Prefoldin And TriC/CCT In Actin And Tubulin Folding R-HSA-389958,0.9868720426057775,1.5577579025369708,0.3769230769230769,0.8051203212675225,1.0,1/29,1.31%,TUBA1A
prerank,MSigDB_Oncogenic_Signatures__GLI1 UP.V1 UP,-0.9907234470880913,-1.5574997306405007,0.3,0.8009086860922915,1.0,1/23,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__CagA Phosphorylation Dependent Signaling,0.9851789400691812,1.5574617388822445,0.39849624060150374,0.8046748907322949,1.0,2/39,1.49%,PTK2;BCAR1
prerank,GO_Biological_Process_2021__organophosphate biosynthetic process (GO:0090407),-0.9905597708047119,-1.5571343820930559,0.25862068965517243,0.8006255259575292,1.0,1/38,0.95%,AGPAT4
prerank,Reactome_2022__Glycogen Metabolism R-HSA-8982491,0.9935724575962036,1.557087193179224,0.1702127659574468,0.8045518866171417,1.0,1/24,0.65%,PHKA2
prerank,Reactome_2022__Adherens Junctions Interactions R-HSA-418990,0.9878740953476328,1.556857524019424,0.3435114503816794,0.8039932415593783,1.0,1/26,1.21%,CDH15
prerank,GO_Biological_Process_2021__regulation of cell development (GO:0060284),-0.9911777256225677,-1.5563701571725033,0.25833333333333336,0.8012812592479708,1.0,1/36,0.89%,ADGRA2
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transport into cytosol (GO:0010524),0.9993399369678925,1.5563279375786634,0.03076923076923077,0.8043888199677993,1.0,1/32,0.07%,THY1
prerank,GO_Biological_Process_2021__striated muscle tissue development (GO:0014706),0.9934938319652005,1.5560473203624214,0.1388888888888889,0.8039071488864128,1.0,1/29,0.65%,SVIL
prerank,GO_Biological_Process_2021__positive regulation of gene silencing by miRNA (GO:2000637),0.9902999018680423,1.5558005945220053,0.24087591240875914,0.8033458705990899,1.0,1/26,0.97%,MYCN
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Cyclin B R-HSA-174048,0.990608557593625,1.5556525502805532,0.29545454545454547,0.8025024545851539,1.0,1/24,0.94%,UBE2C
prerank,Reactome_2022__Mitophagy R-HSA-5205647,-0.9922227554768294,-1.5554906522992737,0.2818181818181818,0.8022454107055186,1.0,1/27,0.78%,TOMM70
prerank,GO_Biological_Process_2021__lytic vacuole organization (GO:0080171),0.9897191827109629,1.5548152227260512,0.3076923076923077,0.8042214914258919,1.0,1/33,1.03%,MYO7A
prerank,Reactome_2022__G0 And Early G1 R-HSA-1538133,0.9971478735081132,1.5547376789539487,0.05426356589147287,0.8030761634148418,1.0,1/26,0.29%,RBL1
prerank,WikiPathway_2021_Human__Ethanol effects on histone modifications WP3996,0.9949961794089188,1.5546709434735397,0.1349206349206349,0.8018877922935456,1.0,2/31,0.51%,HDAC8;SLC19A1
prerank,TRRUST_Transcription_Factors_2019__HNF1A human,-0.9911519030034603,-1.5545864077424603,0.2702702702702703,0.8032128045302241,1.0,2/23,0.90%,GPR39;CYP1A2
prerank,Reactome_2022__GPER1 Signaling R-HSA-9634597,0.9888658779193764,1.5543812281355096,0.3360655737704918,0.8015365745225894,1.0,1/39,1.11%,GNB5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Stem Cell Exhaustion in Aging,-0.9869496864031765,-1.553711843898045,0.4036697247706422,0.8041239279751478,1.0,2/36,1.31%,RB1;PML
prerank,WikiPathway_2021_Human__miRNA regulation of prostate cancer signaling pathways WP3981,-0.9963762859938289,-1.553557822661262,0.08870967741935484,0.8033153841356515,1.0,1/33,0.37%,AKT3
prerank,Reactome_2022__Keratan Sulfate/Keratin Metabolism R-HSA-1638074,0.9945339851090401,1.5533784107968296,0.1386861313868613,0.8035603250756781,1.0,2/31,0.55%,ST3GAL1;SLC35D2
prerank,GO_Biological_Process_2021__regulation of protein targeting to mitochondrion (GO:1903214),-0.9864747964880156,-1.5532357438140638,0.4274193548387097,0.8029481663464756,1.0,1/38,1.36%,ABLIM3
prerank,Reactome_2022__Activation Of BH3-only Proteins R-HSA-114452,-0.9963773151730292,-1.5532127791375843,0.12389380530973451,0.8018709883386771,1.0,1/30,0.37%,AKT3
prerank,Elsevier_Pathway_Collection__IL17 Signaling in Psoriasis,-0.9890664164344916,-1.5531581978181461,0.36220472440944884,0.8009092392041152,1.0,2/36,1.10%,MAP2K6;SPI1
prerank,GO_Biological_Process_2021__protein transmembrane import into intracellular organelle (GO:0044743),-0.9922203187003401,-1.5525580404041501,0.20967741935483872,0.8012322899841918,1.0,1/32,0.78%,TOMM70
prerank,GO_Biological_Process_2021__primary alcohol metabolic process (GO:0034308),-0.9874168105728589,-1.5523199834979426,0.423728813559322,0.8007992247224089,1.0,2/30,1.27%,CYP1A2;CYP1B1
prerank,TRRUST_Transcription_Factors_2019__LEF1 human,0.9947251079491486,1.5522762145145919,0.17557251908396945,0.8062663798421547,1.0,1/25,0.53%,HERC2
prerank,GO_Biological_Process_2021__lipid translocation (GO:0034204),-0.9990721949007135,-1.5522543123673294,0.025,0.7998312029469352,1.0,1/24,0.10%,ATP11C
prerank,GO_Biological_Process_2021__negative regulation of protein localization to plasma membrane (GO:1903077),0.9896922846593252,1.551713075279876,0.28346456692913385,0.8069516743477754,1.0,2/20,1.04%,RHOQ;PKDCC
prerank,Reactome_2022__Regulation Of TP53 Degradation R-HSA-6804757,-0.9963748333803265,-1.5517053026145704,0.1206896551724138,0.8000484984824581,1.0,1/35,0.37%,AKT3
prerank,KEGG_2021_Human__Gastric acid secretion,-0.9903492476748995,-1.551648430288967,0.19047619047619047,0.7990783327989199,1.0,1/64,0.97%,HRH2
prerank,GO_Biological_Process_2021__response to cAMP (GO:0051591),-0.9919552434551924,-1.5514632093337875,0.27692307692307694,0.7984276969983509,1.0,3/37,0.82%,RAP1A;RAP1B;KCNE1
prerank,GO_Biological_Process_2021__regulation of activated T cell proliferation (GO:0046006),-0.9898308239065451,-1.5513585573671358,0.34057971014492755,0.7975737895159204,1.0,1/33,1.02%,CD274
prerank,GO_Biological_Process_2021__divalent inorganic cation homeostasis (GO:0072507),0.9869916454907991,1.5511613993529894,0.3953488372093023,0.8075345087288441,1.0,1/21,1.30%,CYP27B1
prerank,GO_Biological_Process_2021__regulation of striated muscle contraction (GO:0006942),0.9916096644482792,1.550664022934469,0.208,0.8080154222491743,1.0,1/24,0.84%,ASB3
prerank,Reactome_2022__Diseases Associated With TLR Signaling Cascade R-HSA-5602358,0.9956073824335916,1.5505656248871957,0.11403508771929824,0.8069393170513999,1.0,1/31,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__Plasmacytoid Dendritic Cell in Diabetes Mellitus Type 1,-0.989830189534637,-1.550360484622936,0.3333333333333333,0.7991504726390789,1.0,1/34,1.02%,CD274
prerank,GO_Biological_Process_2021__positive regulation of DNA recombination (GO:0045911),0.9854083601385831,1.5503489866600353,0.4166666666666667,0.8063977830546321,1.0,1/28,1.46%,WRAP53
prerank,Elsevier_Pathway_Collection__Thrombopoietin Receptors Signaling in Platelet Maturation,-0.9890698830015235,-1.5502343746617386,0.36283185840707965,0.7984498455611424,1.0,2/30,1.10%,MAP2K6;SPI1
prerank,Elsevier_Pathway_Collection__Estrogens/ESR1 non-Genomic Signaling,-0.9933367910011939,-1.5498791375091188,0.1937984496124031,0.7981946121487923,1.0,1/31,0.67%,PTK2B
prerank,Reactome_2022__Pausing And Recovery Of Tat-mediated HIV Elongation R-HSA-167238,0.9919534288570147,1.5498609703624648,0.14728682170542637,0.8066728331542613,1.0,1/29,0.81%,TCEA1
prerank,Reactome_2022__SIRT1 Negatively Regulates rRNA Expression R-HSA-427359,0.9941475204922403,1.5498280967509575,0.17391304347826086,0.805419555524231,1.0,1/27,0.59%,TAF1B
prerank,Reactome_2022__BBSome-mediated Cargo-Targeting To Cilium R-HSA-5620922,0.9970718404464662,1.549409774249945,0.07142857142857142,0.8054049286555334,1.0,1/23,0.30%,SMOX
prerank,Elsevier_Pathway_Collection__NOTCH Signaling Deregulation in Cancer,0.9957244772833515,1.549336641988611,0.17424242424242425,0.8042833954828758,1.0,1/28,0.43%,NOTCH3
prerank,TRRUST_Transcription_Factors_2019__CREBBP mouse,-0.9991473261844358,-1.5491807626270129,0.04201680672268908,0.7988257820058815,1.0,1/34,0.09%,FOSB
prerank,WikiPathway_2021_Human__Pregnane X receptor pathway WP2876,-0.9961125508017067,-1.5486062112229022,0.10483870967741936,0.7991817243955883,1.0,3/33,0.40%,GSTA2;CYP3A7;NCOA1
prerank,GO_Biological_Process_2021__negative regulation of cold-induced thermogenesis (GO:0120163),-0.9948775105606263,-1.5485432933291305,0.14545454545454545,0.7982001666312343,1.0,3/44,0.53%,MAP2K6;ADAMTS5;RB1
prerank,WikiPathway_2021_Human__TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition WP3859,0.9849180348763727,1.5485037616993067,0.4596774193548387,0.8059678119932943,1.0,1/18,1.51%,FN1
prerank,Elsevier_Pathway_Collection__Hyperglycemia and Hyperlipidemia Trigger beta-Cell Apoptosis,0.986913288814065,1.5482743940213253,0.3543307086614173,0.8054335802612992,1.0,1/26,1.31%,CPE
prerank,GO_Biological_Process_2021__positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway (GO:0051482),0.9984565225053575,1.5481484025468357,0.06201550387596899,0.8045079004740863,1.0,1/25,0.16%,GPR35
prerank,Elsevier_Pathway_Collection__TNF-alpha/TNFRSF1A Signaling,-0.9969532099865512,-1.5477833023067373,0.128,0.7990492452848164,1.0,1/32,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of neurotransmitter secretion (GO:0046928),0.9900292855179551,1.5476454462857898,0.30985915492957744,0.8049399355510556,1.0,1/29,1.00%,MCTP1
prerank,WikiPathway_2021_Human__Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,0.9961079526705858,1.5474978116805147,0.08264462809917356,0.8041489384375599,1.0,1/30,0.39%,HDAC8
prerank,GO_Biological_Process_2021__bile acid metabolic process (GO:0008206),-0.9997641146843391,-1.547408284854488,0.0,0.7989629952856985,1.0,1/32,0.03%,CYP39A1
prerank,Elsevier_Pathway_Collection__Aldosterone Synthesis Chronic Regulation,-0.9933368196098215,-1.5472469264324522,0.2727272727272727,0.7982982694182756,1.0,1/29,0.67%,PTK2B
prerank,GO_Biological_Process_2021__actin filament polymerization (GO:0030041),0.989259364427743,1.5470183108335505,0.2814814814814815,0.8046257533462877,1.0,1/29,1.08%,SPIRE2
prerank,Reactome_2022__RUNX2 Regulates Osteoblast Differentiation R-HSA-8940973,-0.9879217695762007,-1.5462622003776,0.4396551724137931,0.7997678891780868,1.0,2/21,1.22%,RB1;GLI3
prerank,WikiPathway_2021_Human__Selective expression of chemokine receptors during T-cell polarization WP4494,-0.9881425583380512,-1.546103365565245,0.3739130434782609,0.798982681049135,1.0,1/27,1.19%,IL12RB2
prerank,GO_Biological_Process_2021__positive regulation of Rho protein signal transduction (GO:0035025),0.9984545193749329,1.5458689682491804,0.056451612903225805,0.8070539075472254,1.0,1/30,0.16%,GPR35
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: Anterograde Transport,0.986515247004252,1.5454092636745784,0.3656716417910448,0.807218673093936,1.0,1/37,1.35%,KIF3B
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Testicular Male Infertility,0.9898425356408513,1.5451561111922012,0.25190839694656486,0.8068249365271131,1.0,2/26,1.02%,AMH;CBX2
prerank,GO_Biological_Process_2021__positive regulation of cytokinesis (GO:0032467),0.9897276735022366,1.545125983978502,0.3409090909090909,0.8055776339547887,1.0,2/25,1.03%,SVIL;KIF23
prerank,GO_Biological_Process_2021__positive regulation of interleukin-12 production (GO:0032735),-0.9906041391768726,-1.5450619457458865,0.33035714285714285,0.8006317948470427,1.0,1/31,0.95%,SCIMP
prerank,Elsevier_Pathway_Collection__NFKB Non-Canonical Signaling Activation in Cancer,0.9956088094233168,1.5450553658203625,0.0851063829787234,0.8045026855954682,1.0,1/29,0.44%,TRAF3
prerank,GO_Biological_Process_2021__positive regulation of release of sequestered calcium ion into cytosol (GO:0051281),0.9993410215753851,1.5446484609264226,0.03389830508474576,0.8046319417391541,1.0,1/31,0.07%,THY1
prerank,Reactome_2022__RET Signaling R-HSA-8853659,-0.9864869654981683,-1.5443795506875202,0.45161290322580644,0.8013440101818796,1.0,2/38,1.36%,PIK3CB;GRB10
prerank,GO_Biological_Process_2021__regulation of heart rate by cardiac conduction (GO:0086091),-0.9918692710440774,-1.5441117487690053,0.192,0.8009564596230313,1.0,1/37,0.82%,KCNE1
prerank,GO_Biological_Process_2021__negative regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043124),-0.9904061824179728,-1.5437616789407076,0.29310344827586204,0.8008971410399813,1.0,1/39,0.96%,RHOH
prerank,KEGG_2021_Human__Starch and sucrose metabolism,-0.9944543203835038,-1.543233791016247,0.12844036697247707,0.8010844689770528,1.0,1/30,0.56%,GANC
prerank,Elsevier_Pathway_Collection__Immune System Activation in Hyperthyroidism,-0.9887099045516945,-1.5430053709856748,0.3333333333333333,0.8005385577310017,1.0,1/41,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__PTPN22 Role in Rheumatoid Arthritis,-0.9887128478575661,-1.5428443500492288,0.3793103448275862,0.799811186413841,1.0,1/35,1.13%,ZAP70
prerank,Reactome_2022__Diseases Associated With Glycosaminoglycan Metabolism R-HSA-3560782,-0.9884791569675447,-1.542573488639854,0.37209302325581395,0.7994511555728759,1.0,1/39,1.16%,SDC3
prerank,Reactome_2022__Processing Of Capped Intronless Pre-mRNA R-HSA-75067,0.9975705542116496,1.5423843310660643,0.07142857142857142,0.8112236915829033,1.0,1/29,0.25%,ZNF473
prerank,Elsevier_Pathway_Collection__Vitamin A (Retinol) Metabolism and Visual Cycle,-0.9874987211233698,-1.5419990363501799,0.38235294117647056,0.7999016834010447,1.0,4/25,1.27%,CYP2C8;CYP3A7;CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__BMP/TGF-beta Signaling Impairment in Pulmonary Hypertension,0.9870279190430353,1.5418378886548292,0.4028776978417266,0.8119136265934038,1.0,1/27,1.30%,APOE
prerank,GO_Biological_Process_2021__negative regulation of G protein-coupled receptor signaling pathway (GO:0045744),0.9883789177079974,1.5416147362005912,0.29457364341085274,0.8113810855516217,1.0,1/22,1.16%,GRK3
prerank,Reactome_2022__Azathioprine ADME R-HSA-9748787,-0.8741437501762985,-1.5415679723709421,0.3858267716535433,0.7999182809343945,1.0,3/21,1.10%,GSTA2;GSTA1;VAV1
prerank,GO_Biological_Process_2021__response to amyloid-beta (GO:1904645),-0.9965653612580201,-1.541562570093271,0.07272727272727272,0.7988544939535613,1.0,1/41,0.35%,APP
prerank,MSigDB_Oncogenic_Signatures__BCAT GDS748 DN,-0.9892562924331305,-1.541047233360393,0.3652173913043478,0.7990711954067582,1.0,2/41,1.08%,EXOC2;BASP1
prerank,GO_Biological_Process_2021__triglyceride homeostasis (GO:0070328),0.9870225552579204,1.5410405226146682,0.3769230769230769,0.8122799851298581,1.0,1/30,1.30%,APOE
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Trafficking,0.9865349997112031,1.540946938818329,0.43089430894308944,0.8111726100111692,1.0,1/18,1.35%,KIF3B
prerank,GO_Biological_Process_2021__regulation of T cell receptor signaling pathway (GO:0050856),0.9993394651413574,1.540562234181416,0.0,0.8113532253354858,1.0,1/34,0.07%,THY1
prerank,Elsevier_Pathway_Collection__NOD-like Receptors,0.9956068163660924,1.5404963532836504,0.05185185185185185,0.8102256155683982,1.0,1/32,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__IgE Induces Airway Smooth Muscle Cell Proliferation,-0.993375880523085,-1.540456276820382,0.19469026548672566,0.7994517678001896,1.0,2/41,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__termination of RNA polymerase II transcription (GO:0006369),0.9975690763786104,1.5403953181639871,0.0625,0.809165468945785,1.0,1/34,0.25%,ZNF473
prerank,Elsevier_Pathway_Collection__Megakaryocyte -> Platelet Precursor Cell Surface Expression Markers,-0.9877426762725993,-1.540161043413922,0.4065040650406504,0.7989931729684724,1.0,1/40,1.23%,S1PR1
prerank,Elsevier_Pathway_Collection__Cardiomyocyte Dysfunction,-0.9969501344148786,-1.539886451268297,0.06611570247933884,0.7985301487331004,1.0,1/42,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__TNF and IL1B Induce Metalloproteinase Synthesis in Osteoarthritis,-0.9969503256836487,-1.5398536986088884,0.07874015748031496,0.797514852743304,1.0,1/37,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Fas ligand pathway and stress induction of heat shock proteins WP314,-0.9929903002213206,-1.5396541499030527,0.16666666666666666,0.7968745379660421,1.0,2/41,0.71%,RB1;PAK2
prerank,Elsevier_Pathway_Collection__OipA Signaling in Helicobacter Pylori Infection,0.9974527203578756,1.5396223307238652,0.058394160583941604,0.8104483438801472,1.0,1/32,0.26%,PTK2
prerank,WikiPathway_2021_Human__Endothelin Pathways WP2197,0.9888734333325077,1.5395452081046979,0.36585365853658536,0.8093342508224474,1.0,1/29,1.11%,GNB5
prerank,Elsevier_Pathway_Collection__non-Hereditary Genetic Rearrangements in Neuroblastoma,0.9902983006534319,1.539376125972924,0.23931623931623933,0.8086547275898035,1.0,1/29,0.97%,MYCN
prerank,GO_Biological_Process_2021__regulation of natural killer cell mediated cytotoxicity (GO:0042269),-0.9865623927741919,-1.5391762983675144,0.47244094488188976,0.7968330265055144,1.0,1/28,1.35%,PIK3R6
prerank,GO_Biological_Process_2021__renal water homeostasis (GO:0003091),-0.9883736585922658,-1.5389123977897488,0.38571428571428573,0.7964315928012292,1.0,1/26,1.17%,AQP3
prerank,Reactome_2022__Regulation Of MECP2 Expression And Activity R-HSA-9022692,0.9957277754188594,1.5385616642118898,0.0782608695652174,0.8099320393850873,1.0,2/30,0.43%,SLC6A4;TBL1X
prerank,GO_Biological_Process_2021__termination of RNA polymerase I transcription (GO:0006363),0.9861467620260058,1.5383986302305905,0.4230769230769231,0.8091337988649473,1.0,2/30,1.39%,TAF1B;CAVIN1
prerank,Reactome_2022__Regulation Of TP53 Expression And Degradation R-HSA-6806003,-0.9963742589925412,-1.5382511660505367,0.12173913043478261,0.7970200002397487,1.0,1/36,0.37%,AKT3
prerank,GO_Biological_Process_2021__positive regulation of filopodium assembly (GO:0051491),0.9859208565092299,1.537735726437541,0.4344262295081967,0.8099773684111299,1.0,3/25,1.42%,RHOQ;DPYSL3;DOCK11
prerank,Reactome_2022__MAPK Targets/ Nuclear Events Mediated By MAP Kinases R-HSA-450282,-0.9874085378174892,-1.5377120541261147,0.4112903225806452,0.7972533798513366,1.0,1/30,1.26%,DUSP4
prerank,Elsevier_Pathway_Collection__Persisted DNA Repair Triggers Genomic Instability,0.9924559383104039,1.537478464028828,0.1652892561983471,0.8095404582310856,1.0,2/32,0.76%,ATR;DCLRE1C
prerank,Elsevier_Pathway_Collection__Kidney Cells Cilia Organization,0.984996754039359,1.5374297666333827,0.44696969696969696,0.80835724892347,1.0,3/26,1.51%,LRP5;KIF3B;FN1
prerank,GO_Biological_Process_2021__cyclic-nucleotide-mediated signaling (GO:0019935),0.9870697741754159,1.5370240124886765,0.37404580152671757,0.8084012235873911,1.0,2/32,1.30%,KSR1;APOE
prerank,GO_Biological_Process_2021__positive regulation of leukocyte mediated cytotoxicity (GO:0001912),-0.9890150459464069,-1.5367487832847009,0.33076923076923076,0.7984050590003186,1.0,1/41,1.10%,SPI1
prerank,Reactome_2022__Metabolism Of Steroid Hormones R-HSA-196071,0.9878787626949105,1.5363141023810236,0.3888888888888889,0.8094471076305738,1.0,2/29,1.22%,HSD17B11;FDXR
prerank,Elsevier_Pathway_Collection__WNT Signaling in Breast Cancer,0.99598985054298,1.5362525449329343,0.10294117647058823,0.80831366759598,1.0,1/35,0.40%,LRP5
prerank,WikiPathway_2021_Human__FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.9971478001324249,1.5361294944414725,0.07258064516129033,0.8074274033128698,1.0,1/27,0.29%,RBL1
prerank,GO_Biological_Process_2021__positive regulation of exocytosis (GO:0045921),-0.9934496875011334,-1.5359364268306182,0.20168067226890757,0.7992067551581234,1.0,1/37,0.66%,STXBP5
prerank,GO_Biological_Process_2021__glial cell differentiation (GO:0010001),0.9904157230444306,1.5358308048120426,0.25806451612903225,0.8072046404468942,1.0,1/27,0.96%,ERBB3
prerank,GO_Biological_Process_2021__cytoskeleton-dependent intracellular transport (GO:0030705),0.9868769866166145,1.535684797604769,0.4189189189189189,0.8064724225747503,1.0,1/23,1.31%,TUBA1A
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Psoriatic Arthritis,-0.9933314478716861,-1.5353388049528613,0.1693548387096774,0.7996151484835293,1.0,1/45,0.67%,PTK2B
prerank,MSigDB_Hallmark_2020__Oxidative Phosphorylation,-0.9875763836717791,-1.5351497754582104,0.06593406593406594,0.7989899827691597,1.0,2/200,1.24%,TOMM70;MAOB
prerank,GO_Biological_Process_2021__DNA damage checkpoint signaling (GO:0000077),0.9935343907424068,1.5351288516276826,0.184,0.8068793224479771,1.0,3/32,0.66%,BRIP1;ATR;CDC5L
prerank,GO_Biological_Process_2021__protein depolymerization (GO:0051261),0.9859183952275192,1.5351278963469601,0.43548387096774194,0.8055608921825392,1.0,2/27,1.41%,STMN3;MICAL3
prerank,WikiPathway_2021_Human__Gastric Cancer Network 1 WP2361,0.9906072376300857,1.5349886510932231,0.2631578947368421,0.8046863474701125,1.0,1/26,0.94%,UBE2C
prerank,Elsevier_Pathway_Collection__Proteins Involved in Acne Vulgaris,-0.9891691595293428,-1.5345884659785585,0.3467741935483871,0.7992080822123918,1.0,1/40,1.09%,CD83
prerank,Elsevier_Pathway_Collection__CD38/CD19 -> JUN/FOS/NF-kB Signaling in B-cell Proliferation,-0.9887577431364671,-1.5344244207144329,0.34959349593495936,0.7985572658134348,1.0,2/39,1.13%,PTK2B;ZAP70
prerank,WikiPathway_2021_Human__Genes controlling nephrogenesis WP4823,-0.9878652491866707,-1.5340562950790722,0.4426229508196721,0.7982250216849686,1.0,1/36,1.22%,GLI3
prerank,GO_Biological_Process_2021__regulation of steroid metabolic process (GO:0019218),0.9870321037253219,1.533960796279471,0.4,0.8064540409851645,1.0,1/22,1.30%,APOE
prerank,GO_Biological_Process_2021__negative regulation of JNK cascade (GO:0046329),0.9851056533317275,1.5339095258385036,0.45185185185185184,0.8053093557142061,1.0,2/32,1.49%,SH3RF2;MAPK8IP1
prerank,WikiPathway_2021_Human__mBDNF and proBDNF regulation of GABA neurotransmission WP4829,-0.9927583200255082,-1.5337532777862293,0.21238938053097345,0.7978159260051831,1.0,1/34,0.73%,PIK3CB
prerank,Reactome_2022__Deactivation Of Beta-Catenin Transactivating Complex R-HSA-3769402,-0.9976820625279076,-1.533731756429949,0.10852713178294573,0.7968091065545617,1.0,1/40,0.24%,TLE4
prerank,GO_Biological_Process_2021__positive regulation of wound healing (GO:0090303),0.9974518163941917,1.5333554120100845,0.04132231404958678,0.8059058372313767,1.0,1/39,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: Retrograde Transport,0.9865161834592369,1.5333292696178509,0.3939393939393939,0.8047042390912502,1.0,1/36,1.35%,KIF3B
prerank,GO_Biological_Process_2021__transcription initiation from RNA polymerase I promoter (GO:0006361),0.9861454420239095,1.5332034365792717,0.421875,0.8038504386176064,1.0,2/32,1.39%,TAF1B;CAVIN1
prerank,KEGG_2021_Human__Ovarian steroidogenesis,-0.9873545207283034,-1.5331138760737562,0.34782608695652173,0.7971061533137109,1.0,1/44,1.27%,CYP1B1
prerank,Reactome_2022__Cholesterol Biosynthesis R-HSA-191273,0.9864882310846885,1.5329800364945627,0.4666666666666667,0.8032998310233694,1.0,1/25,1.35%,SOAT2
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance (GO:0032206),-0.9869058411302228,-1.5328161244224914,0.4083333333333333,0.7967333039829376,1.0,1/31,1.31%,PML
prerank,KEGG_2021_Human__Histidine metabolism,-0.9876905499874757,-1.5326572475344282,0.43333333333333335,0.7960632026735847,1.0,2/22,1.24%,AOC1;MAOB
prerank,"Reactome_2022__FOXO-mediated Transcription Of Oxidative Stress, Metabolic And Neuronal Genes R-HSA-9615017",-0.9960366273726641,-1.5324131318075673,0.15789473684210525,0.7955934064647808,1.0,3/26,0.41%,GLYAT;ABCA6;NR3C1
prerank,GO_Biological_Process_2021__negative regulation of protein secretion (GO:0050709),0.9869887604390504,1.5323625195573343,0.4297520661157025,0.8039936481888272,1.0,2/34,1.31%,APOE;DRD4
prerank,Reactome_2022__Inactivation Of APC/C Via Direct Inhibition Of APC/C Complex R-HSA-141430,0.9906105060923058,1.5323599685520888,0.2923076923076923,0.8026989724268484,1.0,1/21,0.94%,UBE2C
prerank,GO_Biological_Process_2021__telomere maintenance via telomere lengthening (GO:0010833),0.9854893837733436,1.5319187087983182,0.38181818181818183,0.8028301647212426,1.0,3/35,1.46%,PIF1;ACD;WRAP53
prerank,Reactome_2022__Glutamate Neurotransmitter Release Cycle R-HSA-210500,0.9881137478360598,1.531460306661737,0.3181818181818182,0.8031071425218731,1.0,2/21,1.20%,PPFIA4;STX1A
prerank,TRRUST_Transcription_Factors_2019__NFE2L2 mouse,-0.9996120913395683,-1.5312772790515823,0.0,0.7969480849475408,1.0,2/45,0.05%,GSTA2;GSTA1
prerank,WikiPathway_2021_Human__Bladder cancer WP2828,-0.9947944830730052,-1.531145447569262,0.21428571428571427,0.7961923001341654,1.0,1/40,0.53%,RB1
prerank,Elsevier_Pathway_Collection__Thyroid Hormones in Adipose Tissue Metabolism,0.9987642174809334,1.530976035120298,0.03968253968253968,0.8034379722095452,1.0,1/29,0.13%,ACACA
prerank,Reactome_2022__Regulation Of Necroptotic Cell Death R-HSA-5675482,0.9958000406715267,1.5309190118174367,0.11627906976744186,0.8023953694672742,1.0,1/29,0.42%,TNFRSF10A
prerank,Reactome_2022__Resolution Of Abasic Sites (AP Sites) R-HSA-73933,0.9848355478317714,1.530594938352036,0.42857142857142855,0.8021927572147562,1.0,3/38,1.53%,SLC19A1;POLE4;LRIG1
prerank,KEGG_2021_Human__Bladder cancer,-0.9947940615143414,-1.5304011637993924,0.20689655172413793,0.7969713057016614,1.0,1/41,0.53%,RB1
prerank,GO_Biological_Process_2021__phosphatidylethanolamine metabolic process (GO:0046337),-0.9984557715210348,-1.5302949764968938,0.0423728813559322,0.7961570956344631,1.0,1/30,0.16%,PLAAT3
prerank,GO_Biological_Process_2021__cellular lipid catabolic process (GO:0044242),-0.9874173950500422,-1.529793682478895,0.45045045045045046,0.7962272381311225,1.0,2/26,1.27%,LIPG;CYP1B1
prerank,GO_Biological_Process_2021__positive regulation of innate immune response (GO:0045089),-0.9890219347105821,-1.5293934665233901,0.37606837606837606,0.7961111279404582,1.0,1/33,1.10%,SPI1
prerank,Elsevier_Pathway_Collection__Dopamine Receptors Signaling,-0.9967251088591572,-1.5292038394907252,0.1557377049180328,0.7954706190353772,1.0,2/35,0.34%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__protein destabilization (GO:0031648),0.9874839740307181,1.5288399513530497,0.3358208955223881,0.806482176965088,1.0,1/33,1.25%,CTSH
prerank,TRRUST_Transcription_Factors_2019__YBX1 human,0.990381190921657,1.5287414386674922,0.24615384615384617,0.8055303589765274,1.0,3/28,0.97%,SLC6A4;ERBB3;MYCN
prerank,Elsevier_Pathway_Collection__Proteins Involved in Prolactinoma,0.9860644083815268,1.5285307834267443,0.4305555555555556,0.8049737666329562,1.0,1/27,1.39%,PRLR
prerank,Reactome_2022__Formation Of Fibrin Clot (Clotting Cascade) R-HSA-140877,-0.9957595425918815,-1.528468501178864,0.14285714285714285,0.7960271875827051,1.0,1/37,0.43%,PROS1
prerank,GO_Biological_Process_2021__negative regulation of cellular protein localization (GO:1903828),-0.9890687682556198,-1.5281832691851183,0.36,0.7956828200080642,1.0,2/34,1.10%,TTBK2;SPI1
prerank,GO_Biological_Process_2021__protein K11-linked ubiquitination (GO:0070979),0.9906488972890322,1.5281244423953724,0.2676056338028169,0.8050695609275923,1.0,2/29,0.94%,UBE2H;UBE2C
prerank,GO_Biological_Process_2021__lymphocyte migration (GO:0072676),-0.9878392672880453,-1.5280445480477756,0.41228070175438597,0.7950235573066619,1.0,3/34,1.23%,CCL23;ZAP70;S1PR1
prerank,GO_Biological_Process_2021__regulation of macrophage derived foam cell differentiation (GO:0010743),0.9921457826484777,1.5278918066043452,0.2619047619047619,0.8045575659737786,1.0,1/29,0.79%,PPARA
prerank,GO_Biological_Process_2021__organic cyclic compound biosynthetic process (GO:1901362),0.986147470224376,1.527547820778075,0.38235294117647056,0.8043474508661204,1.0,3/30,1.39%,FDXR;PYCR1;PRLR
prerank,MSigDB_Hallmark_2020__Notch Signaling,0.9957220085791835,1.527332798500137,0.1171875,0.8038022401322523,1.0,1/32,0.43%,NOTCH3
prerank,Reactome_2022__HDR Thru Single Strand Annealing (SSA) R-HSA-5685938,0.9962206553007177,1.526912359330333,0.10655737704918032,0.8040369615922496,1.0,1/37,0.38%,BRIP1
prerank,Reactome_2022__Signaling To ERKs R-HSA-187687,-0.9966831301720751,-1.5267150074023443,0.10606060606060606,0.7971336824926942,1.0,1/32,0.34%,RAP1A
prerank,GO_Biological_Process_2021__bicarbonate transport (GO:0015701),-0.9871351440152477,-1.5266967541054959,0.43103448275862066,0.7961429875236199,1.0,1/32,1.29%,SLC4A5
prerank,WikiPathway_2021_Human__PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,-0.9864925735924855,-1.5266165913589922,0.47368421052631576,0.7953555048404917,1.0,2/30,1.36%,PIK3CB;GRB10
prerank,Elsevier_Pathway_Collection__GFs/TNF -> Ion Channels,-0.9918023183935835,-1.5262886181158546,0.25663716814159293,0.7950737848205058,1.0,3/34,0.83%,MAP2K6;APP;NTF3
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902042),0.9957979218165615,1.5259655893342268,0.10317460317460317,0.8055559603284507,1.0,1/33,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__positive regulation of phospholipase C activity (GO:0010863),-0.9917153554237641,-1.525022531149643,0.22608695652173913,0.7970107613669261,1.0,1/40,0.83%,NTF3
prerank,GO_Biological_Process_2021__DNA recombination (GO:0006310),0.998299348304846,1.5245961071854113,0.03816793893129771,0.8084665594789988,1.0,1/38,0.17%,MSH2
prerank,WikiPathway_2021_Human__Canonical and non-canonical Notch signaling WP3845,0.9957263699076201,1.5240395346316506,0.1171875,0.808770307901661,1.0,1/26,0.43%,NOTCH3
prerank,Reactome_2022__Dopamine Neurotransmitter Release Cycle R-HSA-212676,0.9881533136461895,1.5240111398075993,0.3524590163934426,0.8075740274464657,1.0,3/22,1.20%,LIN7A;PPFIA4;STX1A
prerank,GO_Biological_Process_2021__negative regulation of T cell activation (GO:0050868),-0.9898740447601809,-1.5236237556451953,0.3050847457627119,0.7989860126460225,1.0,2/41,1.02%,FGL1;CD274
prerank,GO_Biological_Process_2021__positive regulation of dephosphorylation (GO:0035306),0.9990717088046203,1.5235266440209043,0.015037593984962405,0.8077297367435502,1.0,1/29,0.10%,PPP1R16B
prerank,Elsevier_Pathway_Collection__Alveolar Macrophage Negative Regulation Declined in COPD,-0.9889101921646014,-1.5235125520972177,0.3983739837398374,0.7982043173215769,1.0,2/42,1.12%,RASA2;IL10RA
prerank,Reactome_2022__HSP90 Chaperone Cycle For Steroid Hormone Receptors (SHR) In Presence Of Ligand R-HSA-3371497,-0.9871031378232751,-1.523443398359955,0.4596774193548387,0.7973976684591219,1.0,2/38,1.30%,NR3C1;DNAJA4
prerank,Elsevier_Pathway_Collection__Circadian Clock Genes in Suprachiasmatic Nuclei Neurons,-0.9969498818332009,-1.5234249965678557,0.07377049180327869,0.7964262249480777,1.0,1/39,0.31%,MAP2K6
prerank,Reactome_2022__Sealing Of Nuclear Envelope (NE) By ESCRT-III R-HSA-9668328,0.9868754029960536,1.5231719695301853,0.4460431654676259,0.8075350819397408,1.0,1/27,1.31%,TUBA1A
prerank,GO_Biological_Process_2021__negative regulation of lymphocyte proliferation (GO:0050672),-0.9898340731176625,-1.5226001676993994,0.33035714285714285,0.7972526099103721,1.0,1/36,1.02%,CD274
prerank,GO_Biological_Process_2021__regulation of glucose metabolic process (GO:0010906),-0.9925277327213888,-1.5220818960917515,0.26356589147286824,0.7972394103408108,1.0,1/33,0.75%,SDHAF3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Acute Myeloid Leukemia,-0.9891085396258747,-1.5218261712476795,0.32,0.796808031403126,1.0,3/34,1.10%,RB1;MEIS1;SPI1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cystic Kidney Disease,0.9924532138613305,1.521540459993426,0.2734375,0.811029740174116,1.0,1/30,0.76%,NEK8
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to WNT Signaling Pathway,0.9960331446195849,1.520830914983729,0.11450381679389313,0.811936030757664,1.0,2/33,0.40%,AXIN2;LRP5
prerank,GO_Biological_Process_2021__negative regulation of wound healing (GO:0061045),0.9870256657174068,1.5207044155319236,0.4068965517241379,0.8110923743855135,1.0,1/29,1.30%,APOE
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced unfolded protein response WP3613,0.9918004774627828,1.5205870286426117,0.21212121212121213,0.8102513380642083,1.0,1/25,0.82%,EIF2A
prerank,GO_Biological_Process_2021__sprouting angiogenesis (GO:0002040),-0.9880599347560335,-1.5202275006497408,0.37815126050420167,0.7993443679980674,1.0,3/52,1.21%,PTK2B;ADGRA2;TEK
prerank,Elsevier_Pathway_Collection__Mucin Production in Goblet Airway Epithelial Cells,-0.9897175416689918,-1.5201250164735696,0.38016528925619836,0.7985530928520382,1.0,2/44,1.04%,MAP2K6;TICAM2
prerank,Reactome_2022__Nucleotide Catabolism R-HSA-8956319,-0.988340646387849,-1.519752616839061,0.39669421487603307,0.7982765896449383,1.0,3/32,1.18%,DPYS;ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__positive regulation of defense response to virus by host (GO:0002230),-0.9922659055075376,-1.519609175701028,0.20869565217391303,0.7975686765198479,1.0,2/27,0.78%,TRIM44;TOMM70
prerank,Elsevier_Pathway_Collection__Lipogenesis Regulation in Adipocyte,0.9921895984977054,1.5195466837131286,0.24242424242424243,0.8118136457850765,1.0,2/24,0.79%,ACACA;PPARA
prerank,WikiPathway_2021_Human__Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.9923406551636009,1.5194864706609945,0.19658119658119658,0.8107508449217704,1.0,2/31,0.77%,LRP5;PLOD2
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Vitiligo,-0.9875276081189943,-1.5194764437751405,0.4297520661157025,0.7968732024293228,1.0,1/26,1.25%,VDR
prerank,GO_Biological_Process_2021__cellular response to ketone (GO:1901655),-0.9884506366701064,-1.5194132758155459,0.373134328358209,0.7960198408422724,1.0,2/38,1.16%,NR3C1;MAP4K1
prerank,KEGG_2021_Human__Tyrosine metabolism,-0.9876361661998797,-1.5192351763958565,0.4198473282442748,0.7954662383062551,1.0,1/32,1.24%,MAOB
prerank,Reactome_2022__Antigen Activates B Cell Receptor Leading To Second Messenger Generation R-HSA-983695,-0.9891035819738662,-1.5192195274835425,0.36065573770491804,0.794510625797437,1.0,1/31,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Hippo/YAP1 Signaling,0.9926484124696342,1.5188339974766383,0.19708029197080293,0.8114335219480018,1.0,2/31,0.74%,TJP1;DLG1
prerank,Elsevier_Pathway_Collection__Gluten Impact on Neuronal System (Hypothesis),-0.9887526111134587,-1.5187388555862849,0.33076923076923076,0.7946971733117209,1.0,2/46,1.13%,IL10RA;ZAP70
prerank,GO_Biological_Process_2021__negative regulation of endocytosis (GO:0045806),0.9892280341588655,1.5181637426528745,0.3357664233576642,0.8123073701687348,1.0,2/25,1.08%,MCTP1;PACSIN3
prerank,GO_Biological_Process_2021__negative regulation of stress-activated MAPK cascade (GO:0032873),0.9877201266364255,1.5178508002691142,0.31690140845070425,0.8118744457216572,1.0,2/37,1.23%,DLG1;SH3RF2
prerank,GO_Biological_Process_2021__glycogen metabolic process (GO:0005977),0.993570723134485,1.5177125034875474,0.12413793103448276,0.8110399696258777,1.0,1/27,0.65%,PHKA2
prerank,Elsevier_Pathway_Collection__CNR1/2 -> IL1B/2/4/6/10 Production,-0.9967249932769375,-1.5176052285552508,0.11666666666666667,0.7961698411252703,1.0,2/37,0.34%,MAP2K6;RAP1A
prerank,Reactome_2022__RIPK1-mediated Regulated Necrosis R-HSA-5213460,0.9957991710918109,1.5175261688920145,0.11538461538461539,0.8103829549677466,1.0,1/31,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__regulation of membrane protein ectodomain proteolysis (GO:0051043),0.9870752524635963,1.5169203074978166,0.4186046511627907,0.810729164910787,1.0,2/22,1.30%,PACSIN3;APOE
prerank,KEGG_2021_Human__Tryptophan metabolism,-0.9875282051150565,-1.516666421214688,0.4,0.7972052129505636,1.0,5/41,1.27%,AADAT;AOC1;CYP1A2;MAOB;CYP1B1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction (GO:0055117),0.9916047843699393,1.5165482028004673,0.22962962962962963,0.8106558454743352,1.0,1/31,0.84%,ASB3
prerank,GO_Biological_Process_2021__presynaptic endocytosis (GO:0140238),0.9880660516503421,1.5162178721169164,0.3858267716535433,0.81028678794087,1.0,1/27,1.20%,STX1A
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Blood Coagulation Factors,-0.9957505614414001,-1.5153719802807153,0.1,0.7989668297106578,1.0,1/57,0.43%,PROS1
prerank,Reactome_2022__Negative Regulation Of FGFR4 Signaling R-HSA-5654733,0.9864937364237236,1.5151738526639913,0.45384615384615384,0.8121322886237978,1.0,2/27,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__regulation of endothelial cell apoptotic process (GO:2000351),-0.987976201122575,-1.515089843410737,0.42105263157894735,0.798519190140094,1.0,1/42,1.21%,TEK
prerank,Elsevier_Pathway_Collection__Osteoblast Function Decline in Osteoporosis,0.9849047084740348,1.514886284460043,0.5,0.8117910330403381,1.0,1/30,1.51%,FN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Psoriasis,-0.9875029602903161,-1.5144296666842578,0.3465346534653465,0.7992369429159092,1.0,1/49,1.25%,VDR
prerank,Elsevier_Pathway_Collection__DRD2 Expression Targets,-0.9969502566253508,-1.5143773555841282,0.11570247933884298,0.7983428388679398,1.0,1/38,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Monoamine Transport WP727,0.9881089906818962,1.5136736832548032,0.3458646616541353,0.8139232370837752,1.0,2/32,1.20%,SLC6A4;STX1A
prerank,Reactome_2022__RHO GTPase Effectors R-HSA-195258,0.9862599805063148,1.513300947525166,0.0472972972972973,0.8137129587590143,1.0,12/252,1.41%,CENPA;CENPE;NDC80;PTK2;MRTFA;ABI2;ARHGEF7;RHOQ;IQGAP3;ERCC6L;FMNL2;FLNA
prerank,WikiPathway_2021_Human__The influence of laminopathies on Wnt signaling WP4844,0.9981073245091167,1.5131770600072878,0.06956521739130435,0.8127776654009233,1.0,1/33,0.19%,CDK6
prerank,TRRUST_Transcription_Factors_2019__MEF2C mouse,0.9995736385822485,1.5129941834932656,0.0,0.8120177190586413,1.0,1/24,0.05%,DLX6
prerank,GO_Biological_Process_2021__regulation of exocytosis (GO:0017157),-0.9934416238832644,-1.5129228887116555,0.17094017094017094,0.8005199549801121,1.0,1/50,0.66%,STXBP5
prerank,Elsevier_Pathway_Collection__Kinetochore Assembly,0.999227871682516,1.5128660996399628,0.034482758620689655,0.8111854296509133,1.0,3/40,0.09%,CENPA;CENPE;NDC80
prerank,GO_Biological_Process_2021__monocyte chemotaxis (GO:0002548),-0.9991861944497599,-1.5124034842051313,0.023809523809523808,0.8006342117841423,1.0,1/36,0.09%,CCL23
prerank,Elsevier_Pathway_Collection__Macrophage M2-Related Phagocytosis,-0.9891027383043701,-1.5123252944261212,0.39090909090909093,0.7998255738834249,1.0,1/31,1.10%,VAV1
prerank,GO_Biological_Process_2021__positive regulation of neuron death (GO:1901216),-0.999955311209111,-1.5121461489935555,0.0,0.7991655350130609,1.0,1/46,0.01%,GRIN2B
prerank,Elsevier_Pathway_Collection__Lipid Metabolism Impairement in non-Alcoholic Fatty Liver Disease,0.9987621261867403,1.5119520984973776,0.015503875968992248,0.8123851556732201,1.0,1/31,0.13%,ACACA
prerank,GO_Biological_Process_2021__B cell receptor signaling pathway (GO:0050853),0.9851371178929779,1.5118415473121127,0.5,0.811463232236661,1.0,1/34,1.49%,BCAR1
prerank,GO_Biological_Process_2021__positive regulation of locomotion (GO:0040017),0.9861013388322797,1.5111982433492759,0.4057971014492754,0.8121559371401896,1.0,1/30,1.39%,CAVIN1
prerank,Reactome_2022__Gene And Protein Expression By JAK-STAT Signaling After Interleukin-12 Stimulation R-HSA-8950505,-0.9958804747536318,-1.5109781402635853,0.07142857142857142,0.8007504338942157,1.0,2/35,0.42%,GSTA2;RAP1B
prerank,Elsevier_Pathway_Collection__Dendritic Cells Function in Atherosclerosis,-0.9897192613804908,-1.5109083474226852,0.3620689655172414,0.7999446474645998,1.0,2/42,1.04%,MAP2K6;TICAM2
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced AP-1 survival signaling. WP3611,-0.994835499954229,-1.510707520735704,0.10852713178294573,0.7994068772326669,1.0,2/49,0.53%,MAP2K6;RB1
prerank,TRRUST_Transcription_Factors_2019__MYB human,-0.9883765587818959,-1.5106548660275008,0.4344262295081967,0.7985161629808425,1.0,2/33,1.17%,NR3C1;CDO1
prerank,"KEGG_2021_Human__Alanine, aspartate and glutamate metabolism",0.9851423199362436,1.5104159569483195,0.4444444444444444,0.8130862607074743,1.0,2/35,1.49%,ASRGL1;GLS
prerank,GO_Biological_Process_2021__negative regulation of double-strand break repair (GO:2000780),0.9918370592042672,1.510357982659907,0.20588235294117646,0.8120306704695656,1.0,1/32,0.82%,SMCHD1
prerank,Reactome_2022__Metabolism Of Porphyrins R-HSA-189445,-0.9995713250865609,-1.5095435606895449,0.008333333333333333,0.7998703155911783,1.0,1/28,0.05%,GSTA1
prerank,GO_Biological_Process_2021__establishment of spindle orientation (GO:0051294),0.9890733505605486,1.5095016346373271,0.34710743801652894,0.8131177144271637,1.0,3/29,1.10%,CENPA;NDC80;SAPCD2
prerank,Reactome_2022__RHO GTPases Activate WASPs And WAVEs R-HSA-5663213,0.9923784539594542,1.509469685620681,0.1984732824427481,0.8119856957257141,1.0,2/34,0.77%,PTK2;ABI2
prerank,GO_Biological_Process_2021__establishment of mitotic spindle orientation (GO:0000132),0.9890758104943809,1.5093469538749482,0.31896551724137934,0.8110272532292278,1.0,3/24,1.10%,CENPA;NDC80;SAPCD2
prerank,Reactome_2022__Sialic Acid Metabolism R-HSA-4085001,0.9964928002436273,1.5093386915775708,0.16793893129770993,0.8098394231883319,1.0,1/31,0.35%,ST3GAL1
prerank,GO_Biological_Process_2021__female gamete generation (GO:0007292),0.9912647402971804,1.509327275979936,0.25,0.8086777582531154,1.0,1/24,0.88%,PARN
prerank,GO_Biological_Process_2021__positive regulation of cellular component movement (GO:0051272),0.9861036312846334,1.5091679072207274,0.4094488188976378,0.8079713698751171,1.0,1/26,1.39%,CAVIN1
prerank,Elsevier_Pathway_Collection__Autophagic-Lysosomal System Decline Associated with Aging,0.9852539151139926,1.5091126236692314,0.44274809160305345,0.8069230804686841,1.0,1/29,1.48%,LAMP2
prerank,Elsevier_Pathway_Collection__Clozapine Induced Granulocytopenia,-0.9911833744876954,-1.5089745333583322,0.29838709677419356,0.8001817347559624,1.0,3/41,0.90%,MAP2K6;RAP1A;CYP1A2
prerank,Elsevier_Pathway_Collection__HGFR -> AP-1/CREB/MYC Signaling,-0.9933767891037699,-1.5083814740307282,0.29310344827586204,0.8006481093435555,1.0,2/38,0.67%,MAP2K6;PTK2B
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts R-HSA-192105,-0.9960722281383514,-1.5083723986905446,0.16964285714285715,0.7996721072286704,1.0,2/34,0.40%,CYP39A1;NCOA1
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Gout,-0.993369721264355,-1.508291214249999,0.15966386554621848,0.7988382989465352,1.0,2/58,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__mitochondrial gene expression (GO:0140053),0.9921766141531244,1.507972161416452,0.1640625,0.8085244629668832,1.0,1/42,0.78%,QRSL1
prerank,GO_Biological_Process_2021__regulation of trans-synaptic signaling (GO:0099177),-0.9917201736618945,-1.5076113192429157,0.2972972972972973,0.7995269850337985,1.0,1/32,0.83%,NTF3
prerank,GO_Biological_Process_2021__phosphatidylcholine biosynthetic process (GO:0006656),0.9968761034700548,1.5072575012931306,0.06722689075630252,0.8090584218200195,1.0,1/32,0.32%,GPAT4
prerank,Elsevier_Pathway_Collection__EDNRA/B -> Vascular Motility,-0.9967249215723858,-1.5072311919289803,0.11666666666666667,0.7994340285137777,1.0,2/39,0.34%,MAP2K6;RAP1A
prerank,Elsevier_Pathway_Collection__Acute Cytotoxic CD8+T-Cell Response against Melanocytes,-0.988751428478932,-1.5068041954157043,0.29133858267716534,0.7994238427871675,1.0,2/49,1.13%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__axonal transport (GO:0098930),0.9865182530158743,1.5067205389704903,0.42735042735042733,0.8091809554304256,1.0,1/36,1.35%,KIF3B
prerank,Reactome_2022__Transcriptional Regulation By AP-2 (TFAP2) Family Of Transcription Factors R-HSA-8864260,0.9870208964025026,1.5066072531550365,0.35251798561151076,0.8082435876189089,1.0,1/30,1.30%,APOE
prerank,WikiPathway_2021_Human__Oxidative Stress WP408,0.9893731961438126,1.5062570780144466,0.31756756756756754,0.8077232191635275,1.0,1/32,1.06%,TXNRD2
prerank,Elsevier_Pathway_Collection__Hypertrophic Cardiomyopathy,-0.9933602941823174,-1.5057328442349287,0.10810810810810811,0.8009646507685207,1.0,2/81,0.67%,MAP2K6;PTK2B
prerank,WikiPathway_2021_Human__CAMKK2  Pathway WP4874,0.991718036215236,1.5054178779503868,0.25196850393700787,0.8087191423308654,1.0,1/34,0.83%,ARHGEF7
prerank,WikiPathway_2021_Human__Renin-angiotensin-aldosterone system (RAAS) WP4756,-0.9889815106805091,-1.5052041155140046,0.3684210526315789,0.8011790716446835,1.0,1/39,1.11%,CREB5
prerank,GO_Biological_Process_2021__negative regulation of type I interferon production (GO:0032480),-0.9895179277296027,-1.5050905314285832,0.32231404958677684,0.8004677356687626,1.0,1/43,1.05%,HERC5
prerank,GO_Biological_Process_2021__positive regulation of mononuclear cell migration (GO:0071677),0.9894145262381934,1.5050061883099748,0.296,0.8086237835415871,1.0,1/27,1.06%,MOSPD2
prerank,GO_Biological_Process_2021__chloride transmembrane transport (GO:1902476),-0.9889381743990273,-1.5049131320721076,0.3524590163934426,0.7999326808994679,1.0,1/43,1.11%,SLC12A8
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> AP-1 Signaling,-0.9887157988517404,-1.5039982366949924,0.3790322580645161,0.80103467155693,1.0,1/31,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__Hemapoietic Stem Cell -> Lymphoid Multipotent Progenitor Surface Expression Markers,-0.9899107125843902,-1.503703396180577,0.3333333333333333,0.8006436287905099,1.0,3/45,1.02%,CD27;CD2;CD274
prerank,Reactome_2022__Downregulation Of TGF-beta Receptor Signaling R-HSA-2173788,0.9852946979439474,1.503627985264776,0.46153846153846156,0.8112093661598231,1.0,1/26,1.47%,ZFYVE9
prerank,WikiPathway_2021_Human__Alpha 6 Beta 4 signaling pathway WP244,0.9974536286238024,1.5035806218295336,0.06299212598425197,0.8101423380453066,1.0,1/33,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__anti-Inflammatory Function of Macrophage M2 Lineage,-0.988941120707359,-1.5034743101170018,0.3018867924528302,0.8001716863239401,1.0,3/61,1.12%,NR3C1;CD163;IL10RA
prerank,Elsevier_Pathway_Collection__Transcytosis,0.9852923825756441,1.5032969864924959,0.452991452991453,0.8097952592195379,1.0,2/37,1.48%,CLCN4;LAMP2
prerank,Elsevier_Pathway_Collection__RAS/RAF/MAPK Signaling Activation by Blocking of Tumor Suppressors,-0.9887842506211715,-1.5032522210767814,0.38596491228070173,0.7997877395168956,1.0,1/41,1.13%,RASSF5
prerank,GO_Biological_Process_2021__cognition (GO:0050890),-0.9965668769318001,-1.503093818070268,0.09734513274336283,0.7991801871794934,1.0,1/40,0.35%,APP
prerank,KEGG_2021_Human__Endocrine and other factor-regulated calcium reabsorption,-0.9875092341583444,-1.5030270340530787,0.37719298245614036,0.7983702249153237,1.0,1/47,1.25%,VDR
prerank,GO_Biological_Process_2021__heterotypic cell-cell adhesion (GO:0034113),-0.9899870292877241,-1.502634164576897,0.336283185840708,0.7982189141656895,1.0,1/30,1.01%,CD2
prerank,GO_Biological_Process_2021__positive regulation of proteolysis involved in cellular protein catabolic process (GO:1903052),0.9974560056325971,1.5026164131248028,0.08064516129032258,0.8104590508365637,1.0,1/29,0.26%,PTK2
prerank,GO_Biological_Process_2021__action potential (GO:0001508),-0.9896028822691466,-1.5024650247417297,0.288,0.7976967916599221,1.0,2/41,1.05%,KCNE1;GNA14
prerank,GO_Biological_Process_2021__regulation of myelination (GO:0031641),0.9982638851526136,1.5020989213353657,0.030303030303030304,0.8107663087360739,1.0,1/25,0.18%,NKX6-2
prerank,GO_Biological_Process_2021__regulation of dendritic spine morphogenesis (GO:0061001),0.9923372695237238,1.5017824512093556,0.21705426356589147,0.810502825373345,1.0,1/31,0.77%,ABI2
prerank,GO_Biological_Process_2021__positive regulation of cytokine production involved in immune response (GO:0002720),-0.9906024219701223,-1.5015382694708528,0.3548387096774194,0.7988467465233265,1.0,1/32,0.95%,SCIMP
prerank,Reactome_2022__DAP12 Signaling R-HSA-2424491,-0.9927626012010456,-1.5014909508824983,0.17592592592592593,0.7980157067672222,1.0,1/27,0.73%,PIK3CB
prerank,Elsevier_Pathway_Collection__TSLP Signaling in Bronchial Epithelial Cell in Asthma,-0.9875229142523948,-1.5010028738592285,0.4700854700854701,0.7982049893854505,1.0,1/33,1.25%,VDR
prerank,KEGG_2021_Human__Steroid hormone biosynthesis,-0.9875211175795512,-1.5008855722120549,0.38392857142857145,0.7975133326362563,1.0,5/55,1.27%,CYP3A7;STS;CYP1A2;HSD17B6;CYP1B1
prerank,Elsevier_Pathway_Collection__T-Cell Central Tolerance,-0.9887562727622503,-1.499977879734789,0.36666666666666664,0.7987388786312339,1.0,2/39,1.13%,CD274;ZAP70
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Postmenopause,-0.9933751963822066,-1.4999259054862728,0.21929824561403508,0.7978765970394917,1.0,2/41,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__positive regulation of developmental growth (GO:0048639),-0.9904391339788788,-1.499617846984645,0.2857142857142857,0.7975054617792404,1.0,1/45,0.96%,SEMA4D
prerank,GO_Biological_Process_2021__regulation of plasma membrane bounded cell projection organization (GO:0120035),0.9871896339533932,1.4995307751140823,0.38028169014084506,0.8153557286134424,1.0,3/26,1.29%,BRSK1;FRMD7;ULK4
prerank,GO_Biological_Process_2021__carbohydrate derivative biosynthetic process (GO:1901137),0.988259372611965,1.4991943282636404,0.3384615384615385,0.8151415044969645,1.0,1/26,1.18%,RRM2
prerank,Elsevier_Pathway_Collection__IL6 Promotes Inflammation in Muscular Dystrophies,-0.9891039281845958,-1.49918411155658,0.368,0.7975229953374555,1.0,1/29,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Majeed Syndrome,-0.9896806377847012,-1.4989450480922044,0.42857142857142855,0.7971481329530961,1.0,1/29,1.04%,TICAM2
prerank,Elsevier_Pathway_Collection__NOTCH Receptors Signaling,0.9945349306085822,1.4988670720545838,0.1864406779661017,0.8147846840529746,1.0,2/29,0.55%,NOTCH3;SLC35D2
prerank,GO_Biological_Process_2021__regulation of receptor signaling pathway via JAK-STAT (GO:0046425),-0.9874088174785011,-1.4984406685703613,0.4098360655737705,0.7973670175868472,1.0,2/38,1.27%,IL10RA;CYP1B1
prerank,Elsevier_Pathway_Collection__TLR2 Induced Synovial Fibroblast Activation in Rheumatoid Arthritis,-0.9896779313496715,-1.498343508002299,0.4065040650406504,0.7966118426866221,1.0,1/33,1.04%,TICAM2
prerank,GO_Biological_Process_2021__protein N-linked glycosylation via asparagine (GO:0018279),0.9896477678519685,1.4980766955024998,0.29770992366412213,0.8155509810845899,1.0,2/30,1.04%,DAD1;ASGR2
prerank,GO_Biological_Process_2021__phospholipid translocation (GO:0045332),-0.9990707887264181,-1.4980719757073382,0.008771929824561403,0.7962444046190889,1.0,1/29,0.10%,ATP11C
prerank,GO_Biological_Process_2021__histone mRNA metabolic process (GO:0008334),0.9975717934171758,1.4979973198214611,0.1079136690647482,0.814584939110275,1.0,1/28,0.25%,ZNF473
prerank,GO_Biological_Process_2021__regulation of cholesterol efflux (GO:0010874),0.9870241616173436,1.4979520180105674,0.416,0.8135174834600362,1.0,1/32,1.30%,APOE
prerank,WikiPathway_2021_Human__IL-7 signaling pathway WP205,-0.9933397407757797,-1.4978691435535558,0.23622047244094488,0.7957476705783074,1.0,1/25,0.67%,PTK2B
prerank,GO_Biological_Process_2021__glycosaminoglycan catabolic process (GO:0006027),-0.9884677954073614,-1.4977692195125156,0.32231404958677684,0.7950420918058424,1.0,1/54,1.16%,SDC3
prerank,Reactome_2022__NGF-stimulated Transcription R-HSA-9031628,-0.9991464466525972,-1.4976693486426553,0.025,0.7943182009001489,1.0,1/37,0.09%,FOSB
prerank,GO_Biological_Process_2021__long-chain fatty acid biosynthetic process (GO:0042759),-0.9911495649473826,-1.4974541336839495,0.2846153846153846,0.7938753822388656,1.0,2/29,0.90%,CYP2C8;CYP1A2
prerank,GO_Biological_Process_2021__peptidyl-asparagine modification (GO:0018196),0.9896472365265204,1.497037419717173,0.302158273381295,0.814901147178762,1.0,2/31,1.04%,DAD1;ASGR2
prerank,GO_Biological_Process_2021__positive regulation of cell cycle G1/S phase transition (GO:1902808),-0.9907166954512344,-1.4968075790476547,0.3508771929824561,0.7946095437498829,1.0,1/33,0.93%,CCND2
prerank,GO_Biological_Process_2021__response to growth factor (GO:0070848),-0.9901352185483165,-1.4967775943827504,0.36134453781512604,0.7938041089613884,1.0,1/40,0.99%,KLF4
prerank,Reactome_2022__Processing Of Capped Intron-Containing Pre-mRNA R-HSA-72203,0.9902516135994942,1.4965648068939288,0.006666666666666667,0.8150448960029975,1.0,4/239,0.98%,NUP210;CDC5L;PRPF40A;SF3A2
prerank,WikiPathway_2021_Human__Tryptophan metabolism WP465,-0.9875299991713704,-1.496198416769421,0.4090909090909091,0.7941588272254742,1.0,5/39,1.27%,AADAT;AOC1;CYP1A2;MAOB;CYP1B1
prerank,GO_Biological_Process_2021__regulation of cellular localization (GO:0060341),0.9960305723991221,1.495843552735863,0.06976744186046512,0.8158926790867105,1.0,2/47,0.40%,BRSK1;LRP5
prerank,Reactome_2022__Carboxyterminal Post-Translational Modifications Of Tubulin R-HSA-8955332,0.9868655471452018,1.495750704585445,0.41304347826086957,0.8149930690202966,1.0,1/36,1.31%,TUBA1A
prerank,KEGG_2021_Human__Fructose and mannose metabolism,-0.9992246844546692,-1.4951570208672793,0.017094017094017096,0.7959923540288378,1.0,1/33,0.08%,ALDOB
prerank,KEGG_2021_Human__Various types of N-glycan biosynthesis,0.9953732928722786,1.4948843233849691,0.11267605633802817,0.8163394491698384,1.0,1/38,0.46%,DAD1
prerank,GO_Biological_Process_2021__negative regulation of Notch signaling pathway (GO:0045746),0.994149204629436,1.4946451840435404,0.1259259259259259,0.8160072627733442,1.0,2/29,0.59%,NOTCH3;WWP2
prerank,GO_Biological_Process_2021__replication fork processing (GO:0031297),0.9950704101995986,1.4942997067200536,0.15328467153284672,0.8157900481699765,1.0,2/38,0.50%,MMS22L;ATR
prerank,Elsevier_Pathway_Collection__EGFR -> AP-1/CREB/ELK/SRF/MYC Signaling,-0.9933720016884598,-1.4942856583633806,0.2601626016260163,0.7970479126085388,1.0,2/49,0.67%,MAP2K6;PTK2B
prerank,Elsevier_Pathway_Collection__TRPM4/6/7/8 Signaling in Arterial Hypertension (Hypothesis),-0.9933314485385315,-1.4941207091358144,0.26605504587155965,0.7964861220431857,1.0,1/39,0.67%,PTK2B
prerank,GO_Biological_Process_2021__TOR signaling (GO:0031929),0.9931082634098504,1.4937385562883678,0.16546762589928057,0.8161752773822686,1.0,1/26,0.69%,FNIP1
prerank,Elsevier_Pathway_Collection__Th2-Cell Function in Systemic Lupus Erythematosus,-0.9887009415117723,-1.4936007336096144,0.336283185840708,0.7968657308516525,1.0,1/50,1.13%,ZAP70
prerank,GO_Biological_Process_2021__positive regulation of protein dephosphorylation (GO:0035307),0.9990709100288643,1.49294138892773,0.013513513513513514,0.817154958095093,1.0,1/33,0.10%,PPP1R16B
prerank,TRRUST_Transcription_Factors_2019__ATF2 human,0.9849072398654974,1.4929404433673086,0.4883720930232558,0.8159963260770903,1.0,1/28,1.51%,FN1
prerank,GO_Biological_Process_2021__negative regulation of protein polymerization (GO:0032272),0.996839792176137,1.4928288188268373,0.07692307692307693,0.8151649119132431,1.0,1/27,0.32%,TBCD
prerank,TRRUST_Transcription_Factors_2019__HNF4A mouse,0.9888414177440937,1.4927608428885693,0.375,0.8142226482007101,1.0,2/27,1.12%,PPARA;PKLR
prerank,GO_Biological_Process_2021__cellular response to glucose stimulus (GO:0071333),0.9996875645051105,1.4926464365069845,0.01652892561983471,0.8133153578444449,1.0,1/31,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__nucleobase-containing small molecule interconversion (GO:0015949),0.9882604622491974,1.4924730340989694,0.3597122302158273,0.8127009283655225,1.0,1/27,1.18%,RRM2
prerank,GO_Biological_Process_2021__response to glucose (GO:0009749),0.9996855194368997,1.4923518492168384,0.008547008547008548,0.8119057199465879,1.0,1/45,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__skeletal muscle tissue development (GO:0007519),0.9934922113027532,1.4922468983742216,0.14925373134328357,0.8110216282396088,1.0,1/31,0.65%,SVIL
prerank,GO_Biological_Process_2021__fatty-acyl-CoA metabolic process (GO:0035337),0.9987644846801323,1.4920752828442492,0.029850746268656716,0.810338091676963,1.0,1/22,0.13%,ACACA
prerank,Reactome_2022__COPI-independent Golgi-to-ER Retrograde Traffic R-HSA-6811436,0.9916807894240002,1.4913296232474662,0.22950819672131148,0.8115006666296378,1.0,1/34,0.83%,RAB3GAP1
prerank,GO_Biological_Process_2021__positive regulation of cell division (GO:0051781),0.9865317430543639,1.4912547581623736,0.46153846153846156,0.8106101990654484,1.0,3/32,1.36%,SVIL;KIF23;FGF1
prerank,Reactome_2022__Ion Transport By P-type ATPases R-HSA-936837,-0.9990670727329408,-1.4912311999002945,0.045454545454545456,0.8014550681732913,1.0,1/47,0.10%,ATP11C
prerank,GO_Biological_Process_2021__negative regulation of DNA biosynthetic process (GO:2000279),0.9859531722082007,1.4909635007157755,0.4166666666666667,0.8103618869928301,1.0,2/30,1.41%,PIF1;ACD
prerank,Elsevier_Pathway_Collection__VEGFA/NOTCH1/WNT Cross-talk in Blood Vessel Sprouting and Branching in Cancer,0.9959900105068763,1.4906935307218991,0.1,0.809943936235097,1.0,1/38,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Mucin Hyperproduction in Goblet and Mucous Cells,-0.9897124427816741,-1.49066562588797,0.352,0.8019810173875559,1.0,2/52,1.04%,MAP2K6;TICAM2
prerank,Reactome_2022__Signaling By FGFR1 In Disease R-HSA-5655302,0.9864926336485198,1.4905633035182628,0.39705882352941174,0.8092348025941238,1.0,2/32,1.36%,TRIM24;FGF1
prerank,GO_Biological_Process_2021__regulation of nitric oxide biosynthetic process (GO:0045428),-0.9901367202119747,-1.490404009620624,0.3103448275862069,0.8017069968568444,1.0,1/39,0.99%,KLF4
prerank,Elsevier_Pathway_Collection__Monocytes Function in Gout,-0.9896765828802769,-1.4903823501321591,0.3983050847457627,0.8008229419547677,1.0,1/34,1.04%,TICAM2
prerank,WikiPathway_2021_Human__Cardiac Hypertrophic Response WP2795,-0.9884409912287854,-1.4898826641836864,0.37168141592920356,0.8010674056033698,1.0,2/54,1.16%,MAP2K6;MAP4K1
prerank,Reactome_2022__Interactions Of Rev With Host Cellular Proteins R-HSA-177243,0.9952212848011763,1.4897973614430444,0.144,0.8102421643069614,1.0,1/37,0.48%,NUP210
prerank,GO_Biological_Process_2021__protein localization to lysosome (GO:0061462),-0.9926466477068266,-1.489715753743344,0.302158273381295,0.8005497340778984,1.0,1/28,0.74%,ZFYVE16
prerank,GO_Biological_Process_2021__protein methylation (GO:0006479),-0.9918326085424103,-1.4896317571504734,0.2796610169491525,0.7998467734182668,1.0,1/39,0.82%,BHMT
prerank,Reactome_2022__Interconversion Of Nucleotide Di- And Triphosphates R-HSA-499943,0.9882600922512352,1.4895962867226447,0.3732394366197183,0.8096618111047929,1.0,1/28,1.18%,RRM2
prerank,GO_Biological_Process_2021__regulation of microtubule cytoskeleton organization (GO:0070507),0.9896472944561886,1.4895019939205243,0.3,0.8088184127611205,1.0,3/36,1.05%,PRKAA2;STMN3;CAMSAP3
prerank,GO_Biological_Process_2021__negative regulation of developmental growth (GO:0048640),0.9860316674074365,1.4893237705065698,0.4186046511627907,0.8081782281946945,1.0,2/32,1.40%,SLC6A4;SEMA3G
prerank,GO_Biological_Process_2021__regulation of axon extension (GO:0030516),0.9860245183361618,1.4881425238783024,0.4233576642335766,0.8102952304013129,1.0,2/37,1.40%,APOE;SEMA3G
prerank,Elsevier_Pathway_Collection__ERBB2/3 -> EP300/ETS/ETV/SP1 Signaling,0.9904132754095558,1.4879307535237727,0.291970802919708,0.8097074852321998,1.0,1/28,0.96%,ERBB3
prerank,GO_Biological_Process_2021__bone development (GO:0060348),0.9959907188416164,1.4876008739076316,0.125,0.8095688030508879,1.0,1/35,0.40%,LRP5
prerank,GO_Biological_Process_2021__regulation of neutrophil chemotaxis (GO:0090022),0.9894158603073003,1.4874985151006528,0.358974358974359,0.8087313742359858,1.0,1/25,1.06%,MOSPD2
prerank,GO_Biological_Process_2021__alpha-amino acid catabolic process (GO:1901606),-0.9939902888508951,-1.4873142547023195,0.16666666666666666,0.8045915092799676,1.0,1/30,0.61%,AADAT
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell/Pericyte Migration and Proliferation,-0.9890874621582894,-1.4873070323066337,0.33043478260869563,0.8036749579391249,1.0,1/48,1.10%,VAV1
prerank,GO_Biological_Process_2021__regulation of insulin receptor signaling pathway (GO:0046626),-0.9864317212134147,-1.4872369725666597,0.4496124031007752,0.8029512598502776,1.0,1/43,1.36%,GRB10
prerank,Reactome_2022__Notch-HLH Transcription Pathway R-HSA-350054,0.9957670545481169,1.4870776871251636,0.13709677419354838,0.8088883894778622,1.0,3/28,0.43%,HDAC8;NOTCH3;TBL1X
prerank,GO_Biological_Process_2021__determination of left/right symmetry (GO:0007368),0.9866095178631358,1.4869050087208664,0.3851851851851852,0.8083058346700748,1.0,3/31,1.35%,MEGF8;CCDC40;KIF3B
prerank,Elsevier_Pathway_Collection__Neutrophil Recruitment and Priming,-0.9969397262362174,-1.4867421504764222,0.07692307692307693,0.8034260506500147,1.0,1/64,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__sulfur compound catabolic process (GO:0044273),-0.9962192171484554,-1.486138759966795,0.12295081967213115,0.8040070915737898,1.0,1/39,0.38%,GGT5
prerank,GO_Biological_Process_2021__neurogenesis (GO:0022008),0.9981055160933828,1.4860987632132252,0.044444444444444446,0.8093529317834202,1.0,1/43,0.19%,CDK6
prerank,Reactome_2022__Defective TPR May Confer Susceptibility Towards Thyroid Papillary Carcinoma (TPC) R-HSA-5619107,0.9926104841353024,1.4859848290305637,0.23015873015873015,0.8085413248863641,1.0,2/32,0.75%,NUP210;MAP4K5
prerank,Reactome_2022__Impaired BRCA2 Binding To RAD51 R-HSA-9709570,0.9962213961873649,1.485960386582229,0.0975609756097561,0.8075022500796448,1.0,1/35,0.38%,BRIP1
prerank,Elsevier_Pathway_Collection__Airway Epithelial Cell Dysfunction,-0.9884462084083953,-1.4852901910857703,0.358974358974359,0.8052349976318878,1.0,3/49,1.17%,MAP2K6;TICAM2;AQP3
prerank,GO_Biological_Process_2021__ion homeostasis (GO:0050801),-0.9872270745036336,-1.4850027763489524,0.4358974358974359,0.8050191184691405,1.0,3/28,1.29%,KLHL3;WNK3;SLC4A5
prerank,Elsevier_Pathway_Collection__Androgen Receptor/Akt Signaling,-0.9960290887668686,-1.4847494540226325,0.1282051282051282,0.8047940105605668,1.0,1/35,0.40%,NCOA1
prerank,TRRUST_Transcription_Factors_2019__GATA3 human,-0.9880270095092326,-1.48472815127412,0.4107142857142857,0.8039768744280522,1.0,2/35,1.21%,IL12RB2;TEK
prerank,GO_Biological_Process_2021__histone H4 acetylation (GO:0043967),0.9934508130295647,1.4846111617222055,0.13846153846153847,0.8103551507079865,1.0,2/47,0.66%,ING5;NAA60
prerank,TRRUST_Transcription_Factors_2019__KLF4 human,-0.9875158838189444,-1.4845746990279998,0.4406779661016949,0.8035303156185414,1.0,1/38,1.25%,VDR
prerank,GO_Biological_Process_2021__protein acetylation (GO:0006473),0.9898422067914778,1.4840870464504756,0.3008849557522124,0.8107897782005739,1.0,3/29,1.03%,ING5;NAA60;NAA10
prerank,Elsevier_Pathway_Collection__CD4+ T-Cell Function Decline in HIV,-0.9887009192529714,-1.4840578358167358,0.3305785123966942,0.8038504162889744,1.0,1/51,1.13%,ZAP70
prerank,Reactome_2022__FGFR2 Mutant Receptor Activation R-HSA-1839126,0.9864505523841822,1.4840577168672198,0.4344262295081967,0.8097414954598704,1.0,1/27,1.36%,FGF1
prerank,KEGG_2021_Human__Homologous recombination,0.9962626580318025,1.4839954616636835,0.075,0.8087739593502753,1.0,2/40,0.38%,SYCP3;BRIP1
prerank,Elsevier_Pathway_Collection__Androgens Promote Scalp Dermal Papilla Regression,0.9950734240909302,1.483659784264265,0.18796992481203006,0.8085193858525146,1.0,2/29,0.50%,AXIN2;ATR
prerank,Elsevier_Pathway_Collection__ROS in Triggering Vascular Inflammation,-0.9890997235608868,-1.483343142773437,0.4090909090909091,0.804648969790976,1.0,1/32,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Skin Aging,-0.9969462157938921,-1.4830759564527087,0.07142857142857142,0.804396562895702,1.0,1/49,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of osteoblast differentiation (GO:0045669),0.9959889795095559,1.4826369227290557,0.056910569105691054,0.810253758093609,1.0,1/42,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Th1-Cell Activation in Crohn's Disease,-0.9881818865113416,-1.4821398422578216,0.3790322580645161,0.8057528575434516,1.0,2/34,1.19%,ZAP70;IL12RB2
prerank,Elsevier_Pathway_Collection__Sertoli Cells Dysfunction Causes Male Infertility,0.9955317892307171,1.4819391465314853,0.11764705882352941,0.8110113160861396,1.0,1/27,0.45%,TJP1
prerank,GO_Biological_Process_2021__melanosome organization (GO:0032438),0.9925314671798505,1.481591645822631,0.21804511278195488,0.8108528469576922,1.0,1/27,0.75%,KIF13A
prerank,Reactome_2022__RNA Polymerase I Transcription Termination R-HSA-73863,0.9861469406387007,1.4814363146086826,0.44,0.8102100850048903,1.0,2/30,1.39%,TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__regulation of protein import into nucleus (GO:0042306),0.9859372962061915,1.4814095610369389,0.46923076923076923,0.8092085928239988,1.0,1/36,1.41%,FLNA
prerank,Elsevier_Pathway_Collection__Cochlear Hair Cell Stereocilia Proteins Mutations (Congenital Deafness),0.9885695859112502,1.480902397188375,0.3356643356643357,0.8093823406927217,1.0,2/33,1.15%,MYO7A;ESPN
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor production (GO:0010574),-0.9873730731333227,-1.4803187703054934,0.42857142857142855,0.8097108563568131,1.0,1/25,1.27%,CYP1B1
prerank,Reactome_2022__GABA Receptor Activation R-HSA-977443,0.9888566973200085,1.480031618019537,0.30434782608695654,0.8105622153136559,1.0,1/50,1.11%,GNB5
prerank,Elsevier_Pathway_Collection__CCR5 Signaling in Macrophages,-0.9933782830772967,-1.4798845356567518,0.25,0.8099112760855285,1.0,2/34,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__negative regulation of protein catabolic process (GO:0042177),0.9859393965080276,1.4794345018457629,0.3925925925925926,0.8109798447928126,1.0,1/37,1.41%,FLNA
prerank,Reactome_2022__Synthesis Of Active Ubiquitin: Roles Of E1 And E2 Enzymes R-HSA-8866652,0.9906481503378559,1.4788768051676437,0.27586206896551724,0.8113809815549247,1.0,2/30,0.94%,UBE2H;UBE2C
prerank,GO_Biological_Process_2021__signal transduction by p53 class mediator (GO:0072331),0.9849446775471622,1.4788570948292457,0.496,0.8103386255347328,1.0,1/31,1.51%,BOK
prerank,Elsevier_Pathway_Collection__Serotonin Receptors Signaling,-0.9967246455481806,-1.478826732341782,0.11504424778761062,0.8118149437709943,1.0,2/37,0.34%,MAP2K6;RAP1A
prerank,WikiPathway_2021_Human__Endoplasmic reticulum stress response in coronavirus infection WP4861,0.9979553733887605,1.4786663762725933,0.022388059701492536,0.8097383676536583,1.0,2/46,0.21%,PPP1R16B;PPP1R9A
prerank,GO_Biological_Process_2021__positive regulation of response to stimulus (GO:0048584),-0.9912511217319617,-1.4786551523062226,0.3047619047619048,0.8112577781001116,1.0,1/44,0.88%,ECHDC3
prerank,Reactome_2022__Nuclear Import Of Rev Protein R-HSA-180746,0.995222756755131,1.4786052028007846,0.144,0.8088336522837758,1.0,1/34,0.48%,NUP210
prerank,KEGG_2021_Human__Vasopressin-regulated water reabsorption,-0.9884090784675813,-1.478507883788805,0.3629032258064516,0.8107258862650156,1.0,2/40,1.17%,CREB5;AQP3
prerank,GO_Biological_Process_2021__establishment of mitotic spindle localization (GO:0040001),0.9890734450340061,1.4784813029059891,0.312,0.8079975920678316,1.0,3/29,1.10%,CENPA;NDC80;SAPCD2
prerank,Elsevier_Pathway_Collection__Mast-Cells Activation in Atopic Dermatitis,-0.9891348861039968,-1.478071675768842,0.3524590163934426,0.8108570972871718,1.0,2/52,1.10%,MAP2K6;VAV1
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Growth Factors,-0.9957966245591879,-1.4780578635092692,0.09302325581395349,0.8099675448571567,1.0,2/51,0.43%,MAP2K6;PROS1
prerank,GO_Biological_Process_2021__positive regulation of protein import (GO:1904591),0.985943312105404,1.4780239104731563,0.4728682170542636,0.808201625065978,1.0,1/30,1.41%,FLNA
prerank,GO_Biological_Process_2021__inner mitochondrial membrane organization (GO:0007007),-0.9922562033717973,-1.477831380763877,0.2892561983471074,0.8096016246861514,1.0,2/49,0.78%,CHCHD3;TOMM70
prerank,GO_Biological_Process_2021__CENP-A containing chromatin organization (GO:0061641),0.9994946081271892,1.4776871288885136,0.0234375,0.8068271135362217,1.0,1/30,0.05%,CENPA
prerank,GO_Biological_Process_2021__CENP-A containing nucleosome assembly (GO:0034080),0.9994946081271892,1.4776871288885136,0.0234375,0.8068271135362217,1.0,1/30,0.05%,CENPA
prerank,WikiPathway_2021_Human__IL17 signaling pathway WP2112,0.9956093497533904,1.4774839132445188,0.12698412698412698,0.8063275607626444,1.0,1/27,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__P38 MAPK/MAPK14 Signaling,-0.9969516064231942,-1.477173293351361,0.09166666666666666,0.8103837541238376,1.0,1/37,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__negative regulation of cellular metabolic process (GO:0031324),0.9870657214261397,1.476819185373145,0.3969465648854962,0.8070134679444597,1.0,2/36,1.30%,AATF;APOE
prerank,Reactome_2022__Association Of TriC/CCT With Target Proteins During Biosynthesis R-HSA-390471,0.9854508614801074,1.4767316644699893,0.45390070921985815,0.8061814573479266,1.0,2/36,1.46%,KIF13A;WRAP53
prerank,GO_Biological_Process_2021__positive regulation of production of molecular mediator of immune response (GO:0002702),-0.9906030611781869,-1.4762853537262928,0.2809917355371901,0.8119519434200765,1.0,1/34,0.95%,SCIMP
prerank,Elsevier_Pathway_Collection__Cardiomyocyte Hypertrophy,-0.9933678653997574,-1.4759552822834785,0.12727272727272726,0.8118234894743414,1.0,2/61,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__intracellular protein transmembrane transport (GO:0065002),-0.992258400312425,-1.4756452261281572,0.18253968253968253,0.8116333935478931,1.0,2/44,0.78%,SEC61A2;TOMM70
prerank,Elsevier_Pathway_Collection__Th1-Cell Function in Systemic Lupus Erythematosus,-0.9881700107516318,-1.4754373128609113,0.3504273504273504,0.8113675878962437,1.0,2/51,1.19%,ZAP70;IL12RB2
prerank,Elsevier_Pathway_Collection__Blau Syndrome,-0.9896739438086195,-1.4753985897617248,0.38095238095238093,0.8105557569610156,1.0,1/38,1.04%,TICAM2
prerank,GO_Biological_Process_2021__lysosome organization (GO:0007040),0.9897167903394852,1.4753944450910066,0.31746031746031744,0.8089046889948766,1.0,1/37,1.03%,MYO7A
prerank,Elsevier_Pathway_Collection__TNF Receptor Associated Periodic Syndrome,-0.9896752130296076,-1.4750319862193686,0.4,0.810505413160958,1.0,1/37,1.04%,TICAM2
prerank,Reactome_2022__Telomere C-strand (Lagging Strand) Synthesis R-HSA-174417,0.9848378287380606,1.474889865082666,0.4566929133858268,0.8092114651307231,1.0,3/33,1.53%,SLC19A1;ACD;LRIG1
prerank,Reactome_2022__Striated Muscle Contraction R-HSA-390522,0.987912620552924,1.4743321341031959,0.3643410852713178,0.8095778298941764,1.0,1/29,1.21%,TNNC2
prerank,Reactome_2022__Surfactant Metabolism R-HSA-5683826,0.9875335827073013,1.4742431230001438,0.3821138211382114,0.8087317502063381,1.0,2/27,1.25%,CKAP4;CTSH
prerank,Elsevier_Pathway_Collection__Eosinophil Activation and Degranulation in Asthma,-0.9891382404151123,-1.4735031296494998,0.36363636363636365,0.8131679394340515,1.0,2/43,1.10%,GNA14;VAV1
prerank,Elsevier_Pathway_Collection__Genes with Mutation in Cancer-Associated Dysregulated DNA Repair,0.9983012876153728,1.4733309857009091,0.03278688524590164,0.8101118634350857,1.0,1/34,0.17%,MSH2
prerank,GO_Biological_Process_2021__acute inflammatory response (GO:0002526),-0.9989573830752798,-1.4732474651251721,0.06060606060606061,0.8128305469097943,1.0,1/25,0.11%,VNN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Vitiligo,-0.9875162365274995,-1.473092734313673,0.4351851851851852,0.8122667744888685,1.0,1/38,1.25%,VDR
prerank,GO_Biological_Process_2021__intra-Golgi vesicle-mediated transport (GO:0006891),0.9919145997221699,1.4730323173684217,0.2764227642276423,0.8098889977849413,1.0,1/31,0.81%,COG5
prerank,GO_Biological_Process_2021__positive regulation of vascular endothelial growth factor production (GO:0010575),-0.987375091236186,-1.4730008469297227,0.43956043956043955,0.8115813680694092,1.0,1/23,1.27%,CYP1B1
prerank,WikiPathway_2021_Human__Zinc homeostasis WP3529,0.9852118852279157,1.4724645569746202,0.4594594594594595,0.8103226329292565,1.0,1/34,1.48%,SLC30A10
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance via telomerase (GO:0032212),0.985992926660183,1.4723239218037438,0.47540983606557374,0.8096750453264634,1.0,3/33,1.41%,ATR;PARN;ACD
prerank,Reactome_2022__Other Interleukin Signaling R-HSA-449836,0.9880710716183143,1.4720542754126438,0.371900826446281,0.8093138080108664,1.0,1/24,1.20%,STX1A
prerank,WikiPathway_2021_Human__Neovascularisation processes WP4331,0.9957206902206965,1.471986650977669,0.10638297872340426,0.8084298609996313,1.0,1/37,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__organic hydroxy compound transport (GO:0015850),-0.9944545325779013,-1.4718381792674693,0.16666666666666666,0.8134942672206519,1.0,2/39,0.56%,NCOA1;SLCO1A2
prerank,TRRUST_Transcription_Factors_2019__ETS2 human,-0.9908396228330394,-1.4714653632740888,0.3474576271186441,0.8135777524917895,1.0,2/31,0.93%,APP;CD163
prerank,GO_Biological_Process_2021__neurotransmitter secretion (GO:0007269),0.9881449928690488,1.4709367786384553,0.3684210526315789,0.8091808671317884,1.0,3/38,1.20%,BRSK1;LIN7A;STX1A
prerank,GO_Biological_Process_2021__signal release from synapse (GO:0099643),0.9881449928690488,1.4709367786384553,0.3684210526315789,0.8091808671317884,1.0,3/38,1.20%,BRSK1;LIN7A;STX1A
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> NF-kB Signaling,-0.9887567059203068,-1.4708658938787875,0.3467741935483871,0.8140285016271217,1.0,2/39,1.13%,VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Dilated Cardiomyopathy,-0.9969423290271048,-1.470403855955429,0.04854368932038835,0.8142053200094909,1.0,1/63,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of sodium ion transmembrane transporter activity (GO:2000649),-0.9914923148209123,-1.4702202503288426,0.2713178294573643,0.8136954832341163,1.0,2/36,0.86%,WNK3;FXYD6
prerank,GO_Biological_Process_2021__heart looping (GO:0001947),0.9904916732155351,1.47015968107623,0.21804511278195488,0.8103025264152991,1.0,2/36,0.96%,TBX3;CCDC40
prerank,GO_Biological_Process_2021__positive regulation of ubiquitin-protein transferase activity (GO:0051443),0.9906057112005432,1.469325316714363,0.31851851851851853,0.8114708647785558,1.0,1/29,0.94%,UBE2C
prerank,GO_Biological_Process_2021__mitochondrial membrane organization (GO:0007006),-0.9932987352731073,-1.4691605479183976,0.22764227642276422,0.8155484684598387,1.0,1/31,0.68%,CHCHD3
prerank,TRRUST_Transcription_Factors_2019__HNF1A mouse,-0.7835749814158947,-1.468604165747629,0.32231404958677684,0.8160700739422299,1.0,2/19,0.90%,CYP39A1;CYP1A2
prerank,GO_Biological_Process_2021__mRNA catabolic process (GO:0006402),0.996023986517585,1.4683714065339974,0.09166666666666666,0.8129928892882821,1.0,1/43,0.40%,DIS3L2
prerank,"Reactome_2022__Glutamate Binding, Activation Of AMPA Receptors And Synaptic Plasticity R-HSA-399721",0.9926098811814916,1.467410454632355,0.2578125,0.81429322353316,1.0,1/26,0.74%,DLG1
prerank,WikiPathway_2021_Human__Histone Modifications WP2369,0.9972207090754991,1.4671147427712854,0.0916030534351145,0.8140285713080098,1.0,1/38,0.28%,ASH1L
prerank,Elsevier_Pathway_Collection__WNT in Epithelial to Mesenchymal Transition in Cancer,0.9850251765920903,1.467103546304598,0.40601503759398494,0.8129798872918934,1.0,4/43,1.51%,LRP5;TJP1;CRB3;FN1
prerank,GO_Biological_Process_2021__respiratory tube development (GO:0030323),0.9864950774861652,1.4670888057671343,0.45806451612903226,0.8119536428781942,1.0,2/28,1.36%,CCDC40;FGF1
prerank,GO_Biological_Process_2021__positive regulation of TOR signaling (GO:0032008),0.993145579878088,1.466954993278333,0.145985401459854,0.8112303357637425,1.0,2/39,0.69%,CLEC16A;FNIP1
prerank,GO_Biological_Process_2021__positive regulation of protein import into nucleus (GO:0042307),0.9859452511208525,1.4665444529463798,0.48412698412698413,0.8113004055001285,1.0,1/28,1.41%,FLNA
prerank,GO_Biological_Process_2021__JNK cascade (GO:0007254),0.9990297242704164,1.4664727016657328,0.014925373134328358,0.8104128814155092,1.0,1/41,0.10%,IRAK2
prerank,GO_Biological_Process_2021__positive regulation of response to biotic stimulus (GO:0002833),-0.9906428816362415,-1.4658568650906065,0.3333333333333333,0.8220436432078793,1.0,2/40,0.95%,OASL;SCIMP
prerank,Elsevier_Pathway_Collection__Arterial Hypertension,-0.9957994521183804,-1.4658307007522877,0.08256880733944955,0.8211951380569467,1.0,2/43,0.43%,NCOA1;PROS1
prerank,Elsevier_Pathway_Collection__Cortisol in Resolving Inflammation,-0.9897573248465601,-1.4653864032347408,0.2777777777777778,0.821339492942398,1.0,3/45,1.04%,NCOA1;NR3C1;TICAM2
prerank,GO_Biological_Process_2021__regulation of defense response to virus by host (GO:0050691),-0.9922625984508937,-1.4647826902250254,0.18803418803418803,0.8217310019347874,1.0,2/34,0.78%,TRIM44;TOMM70
prerank,Reactome_2022__Defective Homologous Recombination Repair (HRR) Due To BRCA2 Loss Of Function R-HSA-9701190,0.9962192719228976,1.464506457786268,0.08661417322834646,0.8145193774493041,1.0,1/41,0.38%,BRIP1
prerank,Elsevier_Pathway_Collection__Hair Follicle Keratinocyte Apoptosis,0.9987995610224288,1.4644254696928565,0.035211267605633804,0.813708344435054,1.0,1/37,0.12%,AXIN2
prerank,GO_Biological_Process_2021__cellular defense response (GO:0006968),-0.9933747910282561,-1.4643774296538323,0.22522522522522523,0.8216692251202063,1.0,2/44,0.67%,ZNF148;PTK2B
prerank,GO_Biological_Process_2021__potassium ion import across plasma membrane (GO:1990573),-0.9889386447144499,-1.4642680641699086,0.373015873015873,0.8210578208707671,1.0,1/39,1.11%,SLC12A8
prerank,Elsevier_Pathway_Collection__Th17-Cell Function in Systemic Lupus Erythematosus,-0.9882168194985184,-1.463992905195759,0.39669421487603307,0.8208619578189711,1.0,3/45,1.19%,IL21R;ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__establishment of protein localization to mitochondrion (GO:0072655),-0.9922102744928765,-1.4636998176070672,0.2462686567164179,0.8206386325963179,1.0,1/48,0.78%,TOMM70
prerank,Reactome_2022__GPVI-mediated Activation Cascade R-HSA-114604,-0.9866466046505489,-1.4636440920927076,0.5263157894736842,0.8198492698891156,1.0,3/32,1.35%,PIK3CB;VAV1;PIK3R6
prerank,GO_Biological_Process_2021__positive regulation of bone mineralization (GO:0030501),0.989640875250876,1.463559517228875,0.34459459459459457,0.8147530250011227,1.0,1/34,1.04%,PKDCC
prerank,WikiPathway_2021_Human__White fat cell differentiation WP4149,-0.9901864747542252,-1.463207349694132,0.3484848484848485,0.8200032696771594,1.0,2/31,0.99%,NR3C1;KLF4
prerank,Elsevier_Pathway_Collection__HIF1A in Vasculogenic Mimicry of Cancer,0.9974498318603742,1.4631269655589914,0.08,0.8148034565363619,1.0,1/42,0.26%,PTK2
prerank,GO_Biological_Process_2021__regulation of fatty acid biosynthetic process (GO:0042304),0.9996883841529537,1.4618717681331832,0.0,0.8169221380392164,1.0,1/28,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__transcription by RNA polymerase I (GO:0006360),0.9861441107675373,1.4618364254504965,0.4444444444444444,0.8160001292842092,1.0,2/34,1.39%,TAF1B;CAVIN1
prerank,KEGG_2021_Human__Long-term potentiation,-0.9959140303131109,-1.4616855302753953,0.08064516129032258,0.8224412465888491,1.0,3/59,0.42%,GRIN2B;RAP1A;RAP1B
prerank,Elsevier_Pathway_Collection__IL1 Receptor Antagonist (IL1RN) Deficiency (DIRA),-0.9897190840484171,-1.461447045268241,0.421875,0.8220829464075518,1.0,2/39,1.04%,MAP2K6;TICAM2
prerank,GO_Biological_Process_2021__negative regulation of smooth muscle cell proliferation (GO:0048662),0.9981850621382498,1.461266434564854,0.015625,0.8163699072005892,1.0,1/32,0.18%,TAFA5
prerank,GO_Biological_Process_2021__regulation of neuron migration (GO:2001222),0.9871025631711375,1.4612223752818962,0.45,0.8154461071099756,1.0,1/28,1.29%,ULK4
prerank,Elsevier_Pathway_Collection__Ras Signaling,0.9877135817926489,1.461212784747577,0.4411764705882353,0.8144227503564193,1.0,1/33,1.23%,ZDHHC9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypertrophic Cardiomyopathy,-0.9991395800288249,-1.4610227866032253,0.019230769230769232,0.8221091691103394,1.0,1/57,0.09%,FOSB
prerank,Elsevier_Pathway_Collection__Adipocyte Hypertrophy and Hyperplasia,0.9921878462486651,1.4604603089272032,0.25190839694656486,0.8152972247181799,1.0,2/28,0.79%,ACACA;PPARA
prerank,Reactome_2022__mRNA Splicing R-HSA-72172,0.99023067667138,1.4603563603263008,0.02702702702702703,0.8145526009224838,1.0,3/188,0.98%,CDC5L;PRPF40A;SF3A2
prerank,GO_Biological_Process_2021__protein targeting to mitochondrion (GO:0006626),-0.9922060153597282,-1.4601537994111216,0.21804511278195488,0.8232622052982073,1.0,1/55,0.78%,TOMM70
prerank,Reactome_2022__PLC Beta Mediated Events R-HSA-112043,-0.9895557335983386,-1.4601445355685603,0.36363636363636365,0.8223967205434449,1.0,1/45,1.05%,GNA14
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through C-Type Lectin-like Receptors,-0.9890962233952585,-1.4600478148378035,0.4132231404958678,0.8217404931213487,1.0,1/34,1.10%,VAV1
prerank,Elsevier_Pathway_Collection__Treg Cells Promote Immunosuppression in Cancer Immune Escape,-0.9887552931248346,-1.4598576888409929,0.36065573770491804,0.821306649668256,1.0,2/43,1.13%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__regulation of cellular amino acid metabolic process (GO:0006521),-0.9918234915443724,-1.459400355960325,0.3277310924369748,0.8214853156774958,1.0,1/51,0.82%,BHMT
prerank,GO_Biological_Process_2021__regulation of viral entry into host cell (GO:0046596),-0.987480183841278,-1.459321099791355,0.42105263157894735,0.8207311638775406,1.0,1/36,1.26%,TMPRSS2
prerank,Elsevier_Pathway_Collection__VEGFR -> AP-1/CREB/MYC Signaling,-0.9933750226600115,-1.4591231079465492,0.28448275862068967,0.8202768854370472,1.0,2/43,0.67%,MAP2K6;PTK2B
prerank,WikiPathway_2021_Human__Translation inhibitors in chronically activated PDGFRA cells WP4566,-0.9928368101513406,-1.459073208933403,0.26495726495726496,0.819521093713195,1.0,3/46,0.73%,MAP2K6;AKT3;PIK3CB
prerank,KEGG_2021_Human__Glycosaminoglycan biosynthesis,0.996484269545318,1.4587172124357852,0.04580152671755725,0.8181031353199495,1.0,1/51,0.35%,ST3GAL1
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Dysfunction in COPD,-0.9934086723906714,-1.458649284325352,0.11206896551724138,0.8196917620219192,1.0,3/67,0.67%,GSTA2;MAP2K6;PTK2B
prerank,Elsevier_Pathway_Collection__EPCAM in Cancer Cell Motility and Proliferation,0.9959904861829603,1.4584979439717696,0.09219858156028368,0.8176272381127978,1.0,1/35,0.40%,LRP5
prerank,GO_Biological_Process_2021__regulation of microtubule polymerization (GO:0031113),0.9896046325904198,1.4582491065801462,0.34074074074074073,0.8172248873049764,1.0,2/39,1.05%,TBCD;CAMSAP3
prerank,TRRUST_Transcription_Factors_2019__PAX6 mouse,0.9981088344447728,1.4575015992195888,0.043795620437956206,0.8180131954077605,1.0,1/32,0.19%,CDK6
prerank,GO_Biological_Process_2021__T cell differentiation (GO:0030217),-0.9880300559367557,-1.4574451276153644,0.4122137404580153,0.8215039074926003,1.0,5/39,1.22%,RABL3;RHOH;SPI1;ZAP70;GLI3
prerank,GO_Biological_Process_2021__negative regulation of autophagy (GO:0010507),-0.988851094346285,-1.457193951026486,0.28225806451612906,0.8211878103459143,1.0,1/57,1.12%,IL10RA
prerank,Elsevier_Pathway_Collection__Macrophage Dysfunction,0.9852441486976478,1.4563157470793007,0.47058823529411764,0.8198769996198212,1.0,1/37,1.48%,LAMP2
prerank,GO_Biological_Process_2021__cellular response to peptide (GO:1901653),-0.9965607778626439,-1.4561589536796897,0.1,0.8229214159278984,1.0,1/54,0.35%,APP
prerank,GO_Biological_Process_2021__negative regulation of neurogenesis (GO:0050768),0.9993398568745275,1.4555244537850494,0.0072992700729927005,0.8209674207412685,1.0,1/33,0.07%,THY1
prerank,Elsevier_Pathway_Collection__Hashimoto's Thyroiditis,-0.9887058050494237,-1.4554406844840424,0.37168141592920356,0.8239720534418219,1.0,1/46,1.13%,ZAP70
prerank,KEGG_2021_Human__Renal cell carcinoma,-0.9929081341697266,-1.4551771232265158,0.19130434782608696,0.8237727163801957,1.0,5/68,0.73%,RAP1A;AKT3;RAP1B;PAK2;PIK3CB
prerank,Reactome_2022__Arachidonic Acid Metabolism R-HSA-2142753,-0.9874816113960224,-1.4549339390123488,0.41732283464566927,0.8234373440134128,1.0,4/56,1.27%,CYP2C8;GGT5;CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__Centriole Duplication and Separation,0.9932201508935277,1.4548488413782579,0.21830985915492956,0.8217096230167421,1.0,1/33,0.68%,CEP164
prerank,Elsevier_Pathway_Collection__Neutrophil Degranulation via FPR1 Signaling,-0.9891713332588458,-1.4548467475490796,0.35294117647058826,0.8227891620617971,1.0,3/62,1.10%,MAP2K6;HCK;VAV1
prerank,GO_Biological_Process_2021__positive regulation of leukocyte cell-cell adhesion (GO:1903039),0.9993414326939475,1.4547840595447024,0.0364963503649635,0.8208350396158959,1.0,1/31,0.07%,THY1
prerank,Reactome_2022__RUNX1 Interacts With Co-Factors Whose Precise Effect On RUNX1 Targets Is Not Known R-HSA-8939243,0.9897958626505012,1.4547300464066135,0.2814814814814815,0.819943518057386,1.0,1/34,1.02%,CBX2
prerank,Reactome_2022__EGFR Downregulation R-HSA-182971,0.9917209152571683,1.4546162888994274,0.2857142857142857,0.8191976406888442,1.0,1/30,0.83%,ARHGEF7
prerank,Elsevier_Pathway_Collection__non-Suppressive Treg-Cell in Diabetes Mellitus Type 1,-0.9887045104264872,-1.4546123238732314,0.3482142857142857,0.8224101743120519,1.0,1/46,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__Th17-Cell Differentiation,-0.9882098996712663,-1.4543763110397907,0.358974358974359,0.8220546698350677,1.0,3/57,1.19%,IL21R;ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__regulation of amyloid-beta formation (GO:1902003),0.9870217761498751,1.4543603679817565,0.39552238805970147,0.8188641984901902,1.0,1/34,1.30%,APOE
prerank,GO_Biological_Process_2021__transition metal ion transport (GO:0000041),0.9852580672054633,1.4542075057473218,0.49624060150375937,0.818164462588256,1.0,2/34,1.48%,MELTF;SLC30A10
prerank,Reactome_2022__M Phase R-HSA-68886,0.9186222556534526,1.4540111050170346,0.006329113924050633,0.8176807707733733,1.0,13/360,1.31%,CENPA;CENPE;NCAPG;NDC80;HDAC8;NUP210;CEP164;HAUS8;HAUS2;UBE2C;KIF23;ERCC6L;TUBA1A
prerank,GO_Biological_Process_2021__negative regulation of metabolic process (GO:0009892),-0.9948751070828211,-1.4539461474148072,0.1346153846153846,0.8222525034820917,1.0,3/53,0.53%,MAP2K6;ADAMTS5;RB1
prerank,GO_Biological_Process_2021__positive regulation of epithelial to mesenchymal transition (GO:0010718),0.9988003961494754,1.4535200319940276,0.02158273381294964,0.8180068098248602,1.0,1/40,0.12%,AXIN2
prerank,GO_Biological_Process_2021__positive regulation of phagocytosis (GO:0050766),0.9898997803165852,1.4533123935063474,0.20175438596491227,0.8175910266167294,1.0,1/51,1.01%,TUB
prerank,GO_Biological_Process_2021__regulation of filopodium assembly (GO:0051489),0.9859508391132995,1.4532138778741228,0.4230769230769231,0.8168109870263583,1.0,4/40,1.42%,PPP1R16B;RHOQ;DPYSL3;DOCK11
prerank,GO_Biological_Process_2021__connective tissue development (GO:0061448),0.9960335017660433,1.4531044538632454,0.125,0.816075538712262,1.0,2/37,0.40%,HOXD3;LRP5
prerank,GO_Biological_Process_2021__synaptic vesicle endocytosis (GO:0048488),0.988057576676334,1.4529382554254684,0.41353383458646614,0.8154696957547419,1.0,1/37,1.20%,STX1A
prerank,TRRUST_Transcription_Factors_2019__ESR1 mouse,0.9892223891593646,1.4528070123028778,0.32786885245901637,0.8147613814321599,1.0,1/27,1.08%,SLC7A1
prerank,KEGG_2021_Human__Inflammatory mediator regulation of TRP channels,-0.9927805574633479,-1.4527954719718514,0.1282051282051282,0.8241692142410693,1.0,2/89,0.73%,MAP2K6;PIK3CB
prerank,Reactome_2022__Intra-Golgi Traffic R-HSA-6811438,0.9919072596853591,1.4527330177557074,0.21641791044776118,0.8138990526077817,1.0,1/41,0.81%,COG5
prerank,Elsevier_Pathway_Collection__Dedifferentiation and Metastatic Progression in Melanoma,0.9974522340339921,1.4524288224873634,0.027972027972027972,0.8138120664127678,1.0,1/37,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Proteins Involved in B-Cell Chronic Lymphocytic Leukemia,-0.9887497472737006,-1.4515127986348666,0.4,0.8263032918534114,1.0,2/51,1.13%,CCND2;ZAP70
prerank,GO_Biological_Process_2021__histone exchange (GO:0043486),0.9994934151621966,1.4509612511187926,0.015267175572519083,0.8167718805592337,1.0,1/38,0.05%,CENPA
prerank,GO_Biological_Process_2021__negative regulation of cytoskeleton organization (GO:0051494),0.9955309064530309,1.45069699427341,0.14173228346456693,0.8165310556254421,1.0,1/29,0.45%,TJP1
prerank,Elsevier_Pathway_Collection__Th2-Cell Function in Ulcerative Colitis,-0.9887003322118579,-1.450454962354403,0.36885245901639346,0.8278458881179707,1.0,1/52,1.13%,ZAP70
prerank,Reactome_2022__RHOV GTPase Cycle R-HSA-9013424,0.9917621646184891,1.449563418993865,0.2781954887218045,0.8185266609187796,1.0,2/36,0.83%,DEPDC1B;ARHGEF7
prerank,Reactome_2022__Dual Incision In GG-NER R-HSA-5696400,0.9928366151322088,1.4495373438055015,0.1732283464566929,0.8175571069907158,1.0,2/41,0.72%,SLC19A1;POLE4
prerank,Elsevier_Pathway_Collection__CDH1 Down regulation Promotes Cancer Cell Migration and Metastases,0.995986743370287,1.4485837526758905,0.0703125,0.8190217384752083,1.0,1/44,0.40%,LRP5
prerank,Reactome_2022__Cleavage Of Damaged Purine R-HSA-110331,0.9859109199529702,1.448471930898479,0.4864864864864865,0.8183207111480856,1.0,1/27,1.41%,ACD
prerank,Reactome_2022__Mitotic Metaphase And Anaphase R-HSA-2555396,0.9870091026686739,1.448446363860955,0.06962025316455696,0.8174064068599045,1.0,7/224,1.31%,CENPA;CENPE;NDC80;HDAC8;UBE2C;ERCC6L;TUBA1A
prerank,Reactome_2022__G Alpha (Z) Signaling Events R-HSA-418597,0.9888631398112226,1.4484109018322013,0.3208955223880597,0.816541034211513,1.0,1/43,1.11%,GNB5
prerank,KEGG_2021_Human__Fatty acid degradation,0.9882080914817973,1.4481097527546694,0.31654676258992803,0.8165030516899404,1.0,1/43,1.18%,ACSL5
prerank,TRRUST_Transcription_Factors_2019__SREBF1 mouse,0.9987636346208102,1.4480969873423777,0.015151515151515152,0.8155384617512509,1.0,1/31,0.13%,ACACA
prerank,WikiPathway_2021_Human__PDGF Pathway WP2526,-0.9890941891113476,-1.4480293188609277,0.35344827586206895,0.8328263281908498,1.0,1/39,1.10%,VAV1
prerank,GO_Biological_Process_2021__regulation of cell-cell adhesion (GO:0022407),0.9974507771976817,1.4475270872977823,0.07407407407407407,0.816301786764177,1.0,1/42,0.26%,PTK2
prerank,Reactome_2022__PERK Regulates Gene Expression R-HSA-381042,0.9912596030060052,1.4474003584039365,0.26666666666666666,0.8157021446816305,1.0,1/32,0.88%,PARN
prerank,TRRUST_Transcription_Factors_2019__FOS mouse,-0.9890628354930204,-1.4473626710680754,0.37815126050420167,0.8335837975037577,1.0,2/45,1.10%,NR3C1;SPI1
prerank,Reactome_2022__Mitotic Anaphase R-HSA-68882,0.9870096671959364,1.447119770181039,0.06962025316455696,0.8155772189717062,1.0,7/223,1.31%,CENPA;CENPE;NDC80;HDAC8;UBE2C;ERCC6L;TUBA1A
prerank,Elsevier_Pathway_Collection__APC/C-CDC20 Complex,0.9993785847097886,1.446855490170582,0.027586206896551724,0.8154201600276173,1.0,1/33,0.07%,CENPE
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell proliferation (GO:0001937),0.9870195796733454,1.4468304490851978,0.3851851851851852,0.8145044278626731,1.0,1/35,1.30%,APOE
prerank,Elsevier_Pathway_Collection__WNT Signaling in Cystic Kidney Disease,0.9959875403890408,1.4468068162463428,0.0763888888888889,0.8136094174884215,1.0,1/43,0.40%,LRP5
prerank,GO_Biological_Process_2021__nucleus organization (GO:0006997),-0.988896374112235,-1.4466117472810065,0.3893805309734513,0.8344971694627075,1.0,1/46,1.11%,SYNE1
prerank,WikiPathway_2021_Human__Wnt signaling in kidney disease WP4150,0.9959910265147973,1.4463371927244035,0.088,0.8138847188288096,1.0,1/35,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__DREAM Complex and FOXM1/MYBL2 Promote Cell Cycle Progression in Cancer,0.997189325261236,1.4460969886381823,0.0948905109489051,0.8136659184454954,1.0,2/28,0.29%,CDK6;RBL1
prerank,GO_Biological_Process_2021__regulation of fibroblast proliferation (GO:0048145),0.984942982591606,1.4460126956182622,0.4393939393939394,0.8129363915561273,1.0,2/45,1.51%,CDK6;FN1
prerank,GO_Biological_Process_2021__amyloid fibril formation (GO:1990000),-0.9965588432286256,-1.4456973154736799,0.07142857142857142,0.8357322851783917,1.0,1/60,0.35%,APP
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: BBSome Interaction,0.9868686141174501,1.4456672063143088,0.43356643356643354,0.8128296792734355,1.0,1/30,1.31%,TUBA1A
prerank,Elsevier_Pathway_Collection__NGFR -> AP-1/CEBPB/CREB/ELK/SRF/TP53 Signaling,-0.991762066609596,-1.4456642493475713,0.3203125,0.8349169495652052,1.0,2/33,0.83%,MAP2K6;NTF3
prerank,MSigDB_Hallmark_2020__Interferon Gamma Response,-0.9870229776896777,-1.4454431286695875,0.10576923076923077,0.8345429800853813,1.0,11/199,1.33%,APOL6;OASL;TNFAIP2;GBP4;CD274;C1R;EPSTI1;IL10RA;HERC6;PML;RTP4
prerank,GO_Biological_Process_2021__amide transport (GO:0042886),0.9949541773395675,1.4452966971415304,0.17037037037037037,0.8129529639609955,1.0,1/28,0.51%,SLC19A1
prerank,KEGG_2021_Human__Cocaine addiction,-0.9877579828659563,-1.4447722174710564,0.4032258064516129,0.8352991002300034,1.0,4/44,1.24%,GRIN2B;FOSB;CREB5;MAOB
prerank,Elsevier_Pathway_Collection__TAM Receptor Signaling Activation in Cancer,-0.9891236497499095,-1.4446115274397868,0.2818181818181818,0.8347912199357627,1.0,2/72,1.10%,PROS1;VAV1
prerank,Elsevier_Pathway_Collection__Myocardial Remodeling,-0.9933249628046699,-1.4444613617047355,0.23931623931623933,0.8342441666058059,1.0,1/51,0.67%,PTK2B
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance via telomere lengthening (GO:1904358),0.9859912316760829,1.4441081807365879,0.46875,0.8153751476095091,1.0,3/36,1.41%,ATR;PARN;ACD
prerank,Elsevier_Pathway_Collection__Atopic Dermatitis Onset,-0.9887014019272654,-1.443995452885295,0.3870967741935484,0.8335953028742806,1.0,1/50,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__T-Cell Receptor Signaling,-0.9887014019272654,-1.443995452885295,0.3870967741935484,0.8335953028742806,1.0,1/50,1.13%,ZAP70
prerank,GO_Biological_Process_2021__regulation of embryonic development (GO:0045995),0.9966857586367033,1.443947252862808,0.07518796992481203,0.8148900154008509,1.0,1/32,0.33%,CCSAP
prerank,Reactome_2022__Transcriptional Regulation By VENTX R-HSA-8853884,0.9906013309853698,1.4437428876843963,0.33587786259541985,0.8145388197744337,1.0,1/39,0.94%,UBE2C
prerank,Elsevier_Pathway_Collection__Proteins Involved in Erectile Dysfunction,-0.9877953645687194,-1.4435255281852972,0.4396551724137931,0.8338803764422665,1.0,2/40,1.23%,PDE5A;S1PR1
prerank,Reactome_2022__G1/S-Specific Transcription R-HSA-69205,0.988342732611687,1.4434216315455126,0.37404580152671757,0.8144674007265045,1.0,3/28,1.18%,CDC45;RBL1;RRM2
prerank,Elsevier_Pathway_Collection__Cytokines Trigger Otitis Media,-0.9891695471710744,-1.4432847035608747,0.2818181818181818,0.8336215795407733,1.0,3/66,1.10%,MAP2K6;NR3C1;VAV1
prerank,GO_Biological_Process_2021__positive regulation of leukocyte migration (GO:0002687),0.999341414986847,1.4432761167475059,0.015503875968992248,0.8139348738698071,1.0,1/27,0.07%,THY1
prerank,Reactome_2022__APC-Cdc20 Mediated Degradation Of Nek2A R-HSA-179409,0.9906068807230503,1.442512697717745,0.265625,0.8150230080359919,1.0,1/26,0.94%,UBE2C
prerank,GO_Biological_Process_2021__cellular response to ionizing radiation (GO:0071479),0.9902938641637447,1.442440639892697,0.24806201550387597,0.8142496162683334,1.0,2/48,0.98%,ATR;PRAP1
prerank,Reactome_2022__Chondroitin Sulfate/Dermatan Sulfate Metabolism R-HSA-1793185,-0.988470481924194,-1.4420733224722546,0.392,0.8356942638157084,1.0,1/49,1.16%,SDC3
prerank,WikiPathway_2021_Human__Splicing factor NOVA regulated synaptic proteins WP4148,-0.9921474437881026,-1.4418155449467427,0.2366412213740458,0.8354296615810556,1.0,3/39,0.80%,GRIN2B;NEO1;DAB1
prerank,Reactome_2022__Inhibition Of DNA Recombination At Telomere R-HSA-9670095,0.9858993569758372,1.4414278646719918,0.415929203539823,0.8163177142043453,1.0,1/38,1.41%,ACD
prerank,GO_Biological_Process_2021__ncRNA metabolic process (GO:0034660),0.9913009812875775,1.4412920233919473,0.26153846153846155,0.8158309749027631,1.0,2/33,0.88%,DROSHA;PARN
prerank,GO_Biological_Process_2021__regulation of interleukin-10 production (GO:0032653),-0.9898243670337695,-1.441272492402714,0.34959349593495936,0.835791516105781,1.0,1/45,1.02%,CD274
prerank,GO_Biological_Process_2021__positive regulation of chemotaxis (GO:0050921),0.9985292580917163,1.4410052769918544,0.027972027972027972,0.815576930377405,1.0,1/44,0.15%,MEGF8
prerank,GO_Biological_Process_2021__glutathione derivative biosynthetic process (GO:1901687),-0.8329557206585396,-1.4402345134650474,0.376,0.8366059758655926,1.0,2/20,0.05%,GSTA2;GSTA1
prerank,GO_Biological_Process_2021__glutathione derivative metabolic process (GO:1901685),-0.8329557206585396,-1.4402345134650474,0.376,0.8366059758655926,1.0,2/20,0.05%,GSTA2;GSTA1
prerank,GO_Biological_Process_2021__protein localization to cilium (GO:0061512),0.9899097242872973,1.4398620033689937,0.27205882352941174,0.8180667966891899,1.0,1/33,1.01%,TUB
prerank,GO_Biological_Process_2021__establishment of protein localization to extracellular region (GO:0035592),-0.9873685086385212,-1.4390878854940936,0.43478260869565216,0.8386735481630122,1.0,2/44,1.27%,TANGO6;OLFM2
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Resisting to Cell Death,0.9958000619227338,1.4389845379561645,0.10317460317460317,0.8196585124285374,1.0,1/31,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__negative regulation of myeloid leukocyte differentiation (GO:0002762),0.9981114906491554,1.4389133954768465,0.05737704918032787,0.8188534613951012,1.0,1/25,0.19%,CDK6
prerank,WikiPathway_2021_Human__Notch Signaling WP268,0.9957191177157179,1.4388864504390404,0.10869565217391304,0.8179509269211976,1.0,1/43,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__tRNA export from nucleus (GO:0006409),0.9952229009171696,1.4387280820091775,0.15503875968992248,0.816526408528967,1.0,1/34,0.48%,NUP210
prerank,GO_Biological_Process_2021__tRNA-containing ribonucleoprotein complex export from nucleus (GO:0071431),0.9952229009171696,1.4387280820091775,0.15503875968992248,0.816526408528967,1.0,1/34,0.48%,NUP210
prerank,KEGG_2021_Human__Acute myeloid leukemia,-0.9870135233042213,-1.4380512251289235,0.344,0.8402372871364102,1.0,4/65,1.31%,AKT3;PIK3CB;SPI1;PML
prerank,GO_Biological_Process_2021__muscle filament sliding (GO:0030049),0.9879106413287764,1.4378898524939794,0.3474576271186441,0.817105211274875,1.0,1/31,1.21%,TNNC2
prerank,GO_Biological_Process_2021__actin-myosin filament sliding (GO:0033275),0.9879106413287764,1.4378898524939794,0.3474576271186441,0.817105211274875,1.0,1/31,1.21%,TNNC2
prerank,Reactome_2022__RNA Polymerase I Promoter Escape R-HSA-73772,0.9941373047789686,1.4371526560420207,0.14634146341463414,0.818644456058156,1.0,1/49,0.59%,TAF1B
prerank,Elsevier_Pathway_Collection__SIRT1 Signaling in Aging,-0.9868982536719889,-1.4370010432289808,0.49074074074074076,0.8419655637911758,1.0,1/40,1.31%,PML
prerank,WikiPathway_2021_Human__Target Of Rapamycin (TOR) Signaling WP1471,0.9996869083127832,1.4369348564998683,0.0,0.8183227965709056,1.0,1/36,0.03%,PRKAA2
prerank,Reactome_2022__Mitotic G2-G2/M Phases R-HSA-453274,0.9869501746801346,1.4369098856810827,0.07096774193548387,0.817401462471734,1.0,5/181,1.31%,CEP164;HAUS8;HAUS2;PKMYT1;TUBA1A
prerank,Reactome_2022__Kinesins R-HSA-983189,0.986604511596643,1.4367241138883193,0.46853146853146854,0.816996991622306,1.0,3/40,1.35%,CENPE;KIF23;KIF3B
prerank,Reactome_2022__TP53 Regulates Transcription Of Cell Cycle Genes R-HSA-6791312,0.9882168680088882,1.4366669988816048,0.3103448275862069,0.8162000875260704,1.0,3/48,1.19%,ARID3A;RBL1;PCBP4
prerank,Reactome_2022__Glutathione Conjugation R-HSA-156590,-0.8646886067479002,-1.4366298011239333,0.40310077519379844,0.8419566169766557,1.0,3/33,0.38%,GSTA2;GSTA1;GGT5
prerank,KEGG_2021_Human__HIF-1 signaling pathway,-0.9880730017656838,-1.4364059428073674,0.16071428571428573,0.8416436299802773,1.0,4/104,1.21%,ALDOB;AKT3;PIK3CB;TEK
prerank,Reactome_2022__mRNA Splicing - Major Pathway R-HSA-72163,0.9902343411992522,1.4361817080243768,0.03355704697986577,0.8167133143417967,1.0,3/180,0.98%,CDC5L;PRPF40A;SF3A2
prerank,TRRUST_Transcription_Factors_2019__FOXO1 mouse,-0.9907134381724759,-1.4360614278673471,0.2755905511811024,0.8416658512330006,1.0,1/42,0.93%,CCND2
prerank,Reactome_2022__Interleukin-10 Signaling R-HSA-6783783,-0.9888611691613208,-1.435638887880859,0.38392857142857145,0.8418903107424494,1.0,1/43,1.12%,IL10RA
prerank,Reactome_2022__Cleavage Of Damaged Pyrimidine R-HSA-110329,0.9859051124604299,1.435435304125691,0.4957983193277311,0.8179834993174544,1.0,1/32,1.41%,ACD
prerank,Elsevier_Pathway_Collection__Treg-Cell Differentiation,-0.9886981782182971,-1.4352118647096797,0.3305084745762712,0.8420264456506888,1.0,1/55,1.13%,ZAP70
prerank,Reactome_2022__ATF4 Activates Genes In Response To Endoplasmic Reticulum Stress R-HSA-380994,0.9912626328860065,1.4351801911928612,0.2619047619047619,0.8178207902582183,1.0,1/27,0.88%,PARN
prerank,GO_Biological_Process_2021__regulation of interleukin-2 production (GO:0032663),0.9877455552998572,1.4349809390787545,0.3467741935483871,0.8174671413577824,1.0,1/46,1.23%,HOMER3
prerank,GO_Biological_Process_2021__mRNA splice site selection (GO:0006376),0.9902206780110165,1.4346839049577829,0.31297709923664124,0.8175409565295916,1.0,1/29,0.98%,SF3A2
prerank,Elsevier_Pathway_Collection__TLR2 Signaling in Treg-Cell in Type 1 Diabetes (Animal Model),-0.9886961050457216,-1.4346158232457649,0.33035714285714285,0.8424256000050081,1.0,1/56,1.13%,ZAP70
prerank,Reactome_2022__Vpr-mediated Nuclear Import Of PICs R-HSA-180910,0.9952227485766784,1.4342568570201935,0.15267175572519084,0.8180362969740268,1.0,1/35,0.48%,NUP210
prerank,Reactome_2022__Rev-mediated Nuclear Export Of HIV RNA R-HSA-165054,0.9952220889484769,1.4341439704418626,0.16101694915254236,0.8174530812560773,1.0,1/35,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__Lymphocyte Mediated Myocardial Injury in Myocarditis,-0.988203703607387,-1.4337348844717495,0.3392857142857143,0.843862891772643,1.0,3/68,1.19%,IL21R;ZAP70;IL12RB2
prerank,Reactome_2022__Antimicrobial Peptides R-HSA-6803157,-0.9897882950970633,-1.433585102344531,0.3416666666666667,0.8434184970529347,1.0,1/42,1.03%,PGLYRP2
prerank,GO_Biological_Process_2021__regulation of vascular associated smooth muscle cell proliferation (GO:1904705),0.9981836339323739,1.4332161120630285,0.043478260869565216,0.819546080744215,1.0,1/36,0.18%,TAFA5
prerank,Elsevier_Pathway_Collection__Th17-Cell Differentiation in Asthma,-0.9882086771853634,-1.4331702612033856,0.3620689655172414,0.8436181097564337,1.0,3/59,1.19%,IL21R;ZAP70;IL12RB2
prerank,WikiPathway_2021_Human__Fatty acid beta-oxidation WP143,0.9882160436979857,1.4327252754594468,0.3533834586466165,0.8199488841552085,1.0,1/32,1.18%,ACSL5
prerank,GO_Biological_Process_2021__positive regulation of response to external stimulus (GO:0032103),-0.9875178605083093,-1.4327110201015627,0.17391304347826086,0.8439658978906154,1.0,4/128,1.26%,APP;OASL;SCIMP;HRG
prerank,"GO_Biological_Process_2021__retrograde transport, endosome to Golgi (GO:0042147)",-0.9971271492323687,-1.4320388516193108,0.023255813953488372,0.8450813350824389,1.0,1/87,0.29%,EVI5
prerank,Elsevier_Pathway_Collection__Th2-Cells Function in Systemic Scleroderma,-0.9886980487235656,-1.4318632145117318,0.34710743801652894,0.8445764597083049,1.0,1/55,1.13%,ZAP70
prerank,WikiPathway_2021_Human__TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.9956024223169413,1.431745801572918,0.10317460317460317,0.8219987590175799,1.0,1/42,0.44%,TRAF3
prerank,GO_Biological_Process_2021__positive regulation of B cell activation (GO:0050871),-0.9915571218766999,-1.4316625429375038,0.21008403361344538,0.8442338232052811,1.0,1/48,0.85%,CD27
prerank,Elsevier_Pathway_Collection__Nociception Expression Targets Signaling,-0.9905351673794115,-1.4316065315310913,0.11009174311926606,0.8435654732281929,1.0,6/128,0.97%,GRIN2B;CCL23;MAP2K6;RAP1A;PTK2B;HRH2
prerank,Elsevier_Pathway_Collection__mTOR/NF-kB/BCR Signaling Disregulation in Mantle Cell Lymphoma,0.9955999065513241,1.4315133732991185,0.10526315789473684,0.8217093273211004,1.0,1/49,0.44%,TRAF3
prerank,GO_Biological_Process_2021__mitotic G2 DNA damage checkpoint signaling (GO:0007095),0.9973001229776131,1.4314563291005982,0.06944444444444445,0.8209312807833176,1.0,1/32,0.27%,BRSK1
prerank,WikiPathway_2021_Human__Interleukin-11 Signaling Pathway WP2332,0.9962570062463457,1.4314123107902923,0.09302325581395349,0.8200933991558295,1.0,1/43,0.38%,ITGA2
prerank,GO_Biological_Process_2021__positive regulation of intrinsic apoptotic signaling pathway (GO:2001244),0.9849847785044162,1.431388756634248,0.4489795918367347,0.8192222771014547,1.0,2/40,1.51%,MSX1;BOK
prerank,GO_Biological_Process_2021__chromatin remodeling at centromere (GO:0031055),0.9994943652363337,1.4312716058829165,0.023255813953488372,0.8186123400587545,1.0,1/32,0.05%,CENPA
prerank,GO_Biological_Process_2021__regulation of cilium assembly (GO:1902017),-0.9971823114479997,-1.4312714800550213,0.08396946564885496,0.8435767497065327,1.0,2/59,0.29%,CEP120;EVI5
prerank,Elsevier_Pathway_Collection__DNA Damage Checkpoint Impairment in Cancer,0.9951121437402923,1.431108129738343,0.11347517730496454,0.8181880928371991,1.0,3/32,0.50%,CDK6;AATF;ATR
prerank,Reactome_2022__Signaling By NTRKs R-HSA-166520,-0.9875618210493746,-1.4305536183069036,0.1864406779661017,0.8447302934673477,1.0,6/128,1.26%,GRIN2B;FOSB;RAP1A;PIK3CB;NTF3;DUSP4
prerank,Elsevier_Pathway_Collection__Th2-Cell Differentiation,-0.9886999584127649,-1.4303176636481283,0.36666666666666664,0.8436277781340203,1.0,1/52,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__Th2-Cell Response in Asthma,-0.9886999584127649,-1.4303176636481283,0.36666666666666664,0.8436277781340203,1.0,1/52,1.13%,ZAP70
prerank,GO_Biological_Process_2021__positive regulation of lipid biosynthetic process (GO:0046889),0.9870680181763091,1.4301655474925534,0.46616541353383456,0.8202497267711925,1.0,2/33,1.30%,PPARA;APOE
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Immune Escape,-0.989819533425356,-1.4300958775599921,0.2833333333333333,0.8433748163214145,1.0,1/46,1.02%,CD274
prerank,GO_Biological_Process_2021__regulation of muscle cell differentiation (GO:0051147),0.9878691221473264,1.4299886958585832,0.3821138211382114,0.8198420795883447,1.0,1/32,1.21%,CDH15
prerank,GO_Biological_Process_2021__tRNA processing (GO:0008033),-0.9884209897492489,-1.429972279543726,0.2966101694915254,0.8428974434419029,1.0,1/62,1.16%,TRMT9B
prerank,Reactome_2022__G-protein Mediated Events R-HSA-112040,-0.9895526948660769,-1.4296695828710253,0.35294117647058826,0.8428531585148815,1.0,1/49,1.05%,GNA14
prerank,WikiPathway_2021_Human__Trans-sulfuration and one-carbon metabolism WP2525,-0.9882640582813281,-1.429582423206755,0.4205607476635514,0.8422348404770587,1.0,3/31,1.19%,AHCYL2;BHMT;MTHFD2L
prerank,Reactome_2022__Presynaptic Phase Of Homologous DNA Pairing And Strand Exchange R-HSA-5693616,0.9962194906570386,1.429264628974287,0.09016393442622951,0.8209963342195579,1.0,1/40,0.38%,BRIP1
prerank,Elsevier_Pathway_Collection__Vascular Motility,-0.9904367169075218,-1.4292443925403593,0.2523364485981308,0.8423465647063282,1.0,3/76,0.97%,PDE5A;RAP1A;HRH2
prerank,GO_Biological_Process_2021__regulation of dendrite development (GO:0050773),-0.9904453668685512,-1.4289628262326182,0.344,0.8422125095939438,1.0,1/38,0.96%,SEMA4D
prerank,Elsevier_Pathway_Collection__Th17-Cell and Th1 Immune Responsein Psoriatic Arthritis,-0.9882086355400049,-1.4284889503081362,0.36752136752136755,0.8424660461743173,1.0,3/59,1.19%,IL21R;ZAP70;IL12RB2
prerank,Elsevier_Pathway_Collection__Acute Phase in Atopic Dermatitis,-0.9887140343382472,-1.4282430318542503,0.448,0.8422676545525809,1.0,1/36,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__mTOR Signaling Hyperfunction,-0.9907076597195587,-1.4280024609069,0.3,0.8419751800314567,1.0,1/46,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__Lysophosphatidic Acid/LPARs Signaling,-0.9966821991784285,-1.4278437568255977,0.15454545454545454,0.8414387431208765,1.0,1/36,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__Airway Smooth Muscle Cell Contraction,-0.9890949233457319,-1.4277756111037674,0.41228070175438597,0.8407919545388596,1.0,1/40,1.10%,VAV1
prerank,GO_Biological_Process_2021__cellular response to organic cyclic compound (GO:0071407),-0.9875144426000719,-1.4277078624731483,0.18269230769230768,0.8400694034795274,1.0,6/143,1.27%,RAP1A;NR3C1;RAP1B;AOC1;KCNE1;CYP1B1
prerank,WikiPathway_2021_Human__Development and heterogeneity of the ILC family WP3893,0.9988404823626725,1.427696216123888,0.031496062992125984,0.8245543766225594,1.0,1/26,0.12%,GFI1
prerank,GO_Biological_Process_2021__positive regulation of establishment of protein localization to mitochondrion (GO:1903749),-0.986457849610444,-1.4276553229957734,0.42990654205607476,0.8393568684660124,1.0,1/56,1.36%,ABLIM3
prerank,GO_Biological_Process_2021__regulation of purine nucleotide metabolic process (GO:1900542),0.9855997862467432,1.427144230344412,0.4263565891472868,0.8252686845059971,1.0,2/43,1.44%,NUP210;SLC2A6
prerank,WikiPathway_2021_Human__Interferon type I signaling pathways WP585,-0.9888308003885348,-1.4270577814586336,0.3629032258064516,0.840158455536809,1.0,4/54,1.13%,MAP2K6;RAP1A;VAV1;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of chemokine production (GO:0032722),-0.9962226629165555,-1.4268808990621213,0.09836065573770492,0.8397716976891507,1.0,2/46,0.39%,APP;OAS1
prerank,WikiPathway_2021_Human__TYROBP causal network in microglia WP3945,-0.9888959851775142,-1.4263430783151698,0.30434782608695654,0.8404603734929165,1.0,2/61,1.12%,BIN2;IL10RA
prerank,GO_Biological_Process_2021__regulation of cell morphogenesis (GO:0022604),0.9875227923995425,1.4262091475951741,0.4224137931034483,0.8271186294096143,1.0,1/32,1.25%,FMNL2
prerank,Reactome_2022__Intraflagellar Transport R-HSA-5620924,0.9865142588016248,1.4261558943950496,0.3969465648854962,0.8263354895770065,1.0,1/38,1.35%,KIF3B
prerank,MSigDB_Oncogenic_Signatures__BCAT BILD ET AL UP,0.9861789796823419,1.426045702909619,0.42424242424242425,0.8257497769439882,1.0,2/41,1.39%,AXIN2;SLC35C2
prerank,WikiPathway_2021_Human__miRNAs involvement in the immune response in sepsis WP4329,0.9956066057775802,1.4253632065696367,0.136,0.8268676361147561,1.0,1/36,0.44%,TRAF3
prerank,GO_Biological_Process_2021__epithelial tube morphogenesis (GO:0060562),0.9985323273983203,1.4253280516527005,0.05737704918032787,0.8260484310017796,1.0,1/33,0.15%,MEGF8
prerank,GO_Biological_Process_2021__regulation of protein dephosphorylation (GO:0035304),0.999069474650118,1.4252560505599707,0.021897810218978103,0.8253524065863248,1.0,1/39,0.10%,PPP1R16B
prerank,Reactome_2022__Transport Of Ribonucleoproteins Into Host Nucleus R-HSA-168271,0.9952225496412482,1.4250259635495082,0.1297709923664122,0.8251383300506718,1.0,1/35,0.48%,NUP210
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte activation (GO:0051251),0.9993401665206738,1.4249243813886732,0.007874015748031496,0.8245875749266424,1.0,1/34,0.07%,THY1
prerank,Reactome_2022__N-glycan Trimming In ER And Calnexin/Calreticulin Cycle R-HSA-532668,-0.9928339201093429,-1.4249164668487961,0.2777777777777778,0.8436015403343785,1.0,1/35,0.72%,AMFR
prerank,TRRUST_Transcription_Factors_2019__RELA mouse,0.9849432495207457,1.4246407512657382,0.2014388489208633,0.8243575846923565,1.0,3/103,1.51%,PPARA;APOE;FN1
prerank,GO_Biological_Process_2021__negative regulation of DNA metabolic process (GO:0051053),0.9983001448545785,1.424615147885877,0.058823529411764705,0.8235070711065073,1.0,1/30,0.17%,MSH2
prerank,GO_Biological_Process_2021__iron ion homeostasis (GO:0055072),-0.9943641439991263,-1.4245035897980947,0.1926605504587156,0.8437785231378122,1.0,1/59,0.57%,NEO1
prerank,MSigDB_Hallmark_2020__E2F Targets,0.9884953731954085,1.4242977879252154,0.04516129032258064,0.823515765281345,1.0,9/199,1.18%,MELK;CENPE;MSH2;MKI67;GINS1;MMS22L;DEPDC1;POLE4;RRM2
prerank,GO_Biological_Process_2021__inorganic anion transport (GO:0015698),0.9871976643959198,1.4241043893794894,0.3561643835616438,0.8231414691636144,1.0,1/52,1.28%,CLCN4
prerank,Reactome_2022__SUMOylation Of SUMOylation Proteins R-HSA-4085377,0.9952224391798429,1.4240548395610242,0.176,0.8223253096281469,1.0,1/35,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through ITAM-Containing Receptors,-0.9887475131577567,-1.4236799814248753,0.36936936936936937,0.8450945902010116,1.0,2/55,1.13%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__ribosome biogenesis (GO:0042254),0.9917050314943471,1.4236371670420271,0.014084507042253521,0.8225929094210715,1.0,1/191,0.82%,EIF2A
prerank,GO_Biological_Process_2021__regulation of nervous system development (GO:0051960),0.9982608847445801,1.4233274785991814,0.0136986301369863,0.8226454817875007,1.0,1/37,0.18%,NKX6-2
prerank,GO_Biological_Process_2021__actin filament bundle assembly (GO:0051017),0.986839749948,1.4231623637342738,0.391304347826087,0.8221839018744681,1.0,4/33,1.33%,BAIAP2L2;ESPN;DPYSL3;SHROOM1
prerank,Reactome_2022__Separation Of Sister Chromatids R-HSA-2467813,0.9892441827747828,1.4227524164609995,0.08053691275167785,0.8226219073795292,1.0,6/165,1.09%,CENPA;CENPE;NDC80;HDAC8;UBE2C;ERCC6L
prerank,WikiPathway_2021_Human__Neural Crest Cell Migration during Development WP4564,-0.9866825939296147,-1.42239031902782,0.509090909090909,0.8474995894433048,1.0,4/39,1.35%,AKT3;PAK2;PIK3CB;PIK3R6
prerank,WikiPathway_2021_Human__Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,-0.9919821922163136,-1.4218046789580754,0.2711864406779661,0.8481685741357692,1.0,1/47,0.81%,HCK
prerank,KEGG_2021_Human__GnRH secretion,-0.9928315549947689,-1.421469709601089,0.25,0.848247016454077,1.0,3/63,0.73%,KCNN2;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__cellular response to alcohol (GO:0097306),-0.988396641943155,-1.4213851325457183,0.42857142857142855,0.847588478161208,1.0,1/44,1.16%,MAP4K1
prerank,Reactome_2022__G2/M Transition R-HSA-69275,0.9869512934012508,1.4212166082012003,0.07741935483870968,0.8262686745550712,1.0,5/179,1.31%,CEP164;HAUS8;HAUS2;PKMYT1;TUBA1A
prerank,Elsevier_Pathway_Collection__Treg-Cell Activation in Diabetes Mellitus,-0.9886985192832011,-1.4203448651318185,0.3577981651376147,0.8493214236773945,1.0,1/54,1.13%,ZAP70
prerank,WikiPathway_2021_Human__Oxysterols derived from cholesterol WP4545,-0.9997621046423018,-1.4203220225228441,0.0,0.8485236646159461,1.0,1/41,0.03%,CYP39A1
prerank,GO_Biological_Process_2021__phospholipid biosynthetic process (GO:0008654),-0.9905647873919114,-1.4202589400802366,0.3925233644859813,0.8478034928028751,1.0,1/36,0.95%,AGPAT4
prerank,GO_Biological_Process_2021__negative regulation of immune response (GO:0050777),-0.9891714548464507,-1.4200588360538142,0.11538461538461539,0.8474137399969973,1.0,6/152,1.10%,GPR39;GGT5;HCK;CD163;HRH2;SPI1
prerank,TRRUST_Transcription_Factors_2019__EGR1 mouse,-0.9906969461071276,-1.41996756309054,0.23728813559322035,0.8468225141761213,1.0,1/66,0.93%,CCND2
prerank,Elsevier_Pathway_Collection__Treg-Cell Function in Diabetes Mellitus Type 1,-0.9886971476144643,-1.4196126073102802,0.3389830508474576,0.8469354241884686,1.0,1/56,1.13%,ZAP70
prerank,GO_Biological_Process_2021__embryonic heart tube morphogenesis (GO:0003143),0.9905302113392881,1.4195117168439821,0.22627737226277372,0.8310641793465463,1.0,3/40,0.96%,MEGF8;TBX3;CCDC40
prerank,Elsevier_Pathway_Collection__Leukocyte Migration toward the Endothelial Cell in Ulcerative Colitis,0.9890640039794406,1.419448022668869,0.34375,0.8303052381784572,1.0,1/31,1.10%,ITGAL
prerank,Reactome_2022__Ca2+ Pathway R-HSA-4086398,0.9889021618739904,1.4189008455035783,0.31007751937984496,0.8313114646934647,1.0,2/59,1.11%,AXIN2;GNB5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Periodontitis,-0.9875535756460844,-1.4188977543779302,0.38461538461538464,0.8478092423629282,1.0,2/56,1.25%,NR3C1;VDR
prerank,Elsevier_Pathway_Collection__Myeloid Derived Suppressor Cells in Cancer Immune Escape,-0.9888550804719429,-1.4186314736518424,0.336,0.847706698441141,1.0,1/50,1.12%,IL10RA
prerank,WikiPathway_2021_Human__IL-4 signaling pathway WP395,0.9859229327027936,1.418525035569535,0.3787878787878788,0.8315495711240153,1.0,1/53,1.41%,FLNA
prerank,Elsevier_Pathway_Collection__TGFB Signaling activation by Blocking of Tumor Suppressors,-0.9907428829380811,-1.4183644867148735,0.21818181818181817,0.8475833739338946,1.0,2/72,0.93%,MAP2K6;CCND2
prerank,Elsevier_Pathway_Collection__Dendritic Cell Function in Ulcerative Colitis,-0.989669611480244,-1.4183563600979316,0.415929203539823,0.8467559287176987,1.0,1/44,1.04%,TICAM2
prerank,GO_Biological_Process_2021__protein K63-linked ubiquitination (GO:0070534),0.9941454898067081,1.4182819431103615,0.11363636363636363,0.8313281404770245,1.0,2/43,0.59%,TRAF3;WWP2
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation without Degranulation,-0.99694908706234,-1.4179411256470553,0.11764705882352941,0.8469730581610646,1.0,1/45,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Peutz-Jeghers Syndrome,0.9918635765139551,1.4177195334005999,0.2366412213740458,0.8322279594564419,1.0,1/52,0.81%,CAB39
prerank,Elsevier_Pathway_Collection__Basophil Activation in Asthma,-0.9891313835935994,-1.4172707579046846,0.33636363636363636,0.8478801767584032,1.0,2/60,1.10%,MAP2K6;VAV1
prerank,WikiPathway_2021_Human__Glucocorticoid Receptor Pathway WP2880,-0.9887788835361213,-1.417216233513887,0.3119266055045872,0.8471719373461083,1.0,2/67,1.13%,NR3C1;PRRG4
prerank,Reactome_2022__Regulation Of Complement Cascade R-HSA-977606,-0.9895242235321242,-1.417078081767989,0.39344262295081966,0.8467073097082138,1.0,2/45,1.06%,PROS1;C1R
prerank,WikiPathway_2021_Human__Striated Muscle Contraction Pathway WP383,0.987909254040329,1.4169945098783354,0.35833333333333334,0.8335074160818858,1.0,1/33,1.21%,TNNC2
prerank,GO_Biological_Process_2021__regulation of dendrite morphogenesis (GO:0048814),-0.9904486287632425,-1.4168841538347339,0.43410852713178294,0.846406305557075,1.0,1/32,0.96%,SEMA4D
prerank,WikiPathway_2021_Human__DNA IR-double strand breaks and cellular response via ATM WP3959,0.9924475678784821,1.4168185324691394,0.1643835616438356,0.8330854588930338,1.0,2/54,0.76%,ATR;DCLRE1C
prerank,Reactome_2022__Signaling By SCF-KIT R-HSA-1433557,-0.9864821086854239,-1.4165209705985011,0.504,0.8465393525413255,1.0,2/42,1.36%,VAV1;GRB10
prerank,Elsevier_Pathway_Collection__Donohue Syndrome Progression (Hypothesis),0.9987611693849806,1.416425249082295,0.024,0.8334091131321127,1.0,1/35,0.13%,ACACA
prerank,GO_Biological_Process_2021__sensory perception (GO:0007600),0.9897171879642728,1.416354015287788,0.2746478873239437,0.8326881328183858,1.0,1/36,1.03%,MYO7A
prerank,Elsevier_Pathway_Collection__Subepithelial Fibroblasts in Middle Ear Cholesteatoma,-0.9969473755571291,-1.416291755442233,0.08943089430894309,0.8462724163372807,1.0,1/45,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__oligosaccharide metabolic process (GO:0009311),0.9857161860405398,1.4162190550751705,0.4915254237288136,0.8322009483230975,1.0,2/42,1.43%,MANBA;FUT6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Dilated Cardiomyopathy,0.9893519611133814,1.4159279431905785,0.039473684210526314,0.8322124500288611,1.0,2/151,1.06%,PTK2;TXNRD2
prerank,"Elsevier_Pathway_Collection__Hyaluronic Acid, CD44 and HMMR in Cancer Cell Invasion and Survival",0.9849363050801722,1.4158709016163886,0.4461538461538462,0.8314909861663964,1.0,2/50,1.51%,HAS3;FN1
prerank,GO_Biological_Process_2021__positive regulation of endocytosis (GO:0045807),0.9870104599503075,1.4158591891655758,0.375,0.8306238549832233,1.0,1/47,1.30%,APOE
prerank,GO_Biological_Process_2021__neutral amino acid transport (GO:0015804),-0.8110823766032064,-1.4158418343490933,0.36893203883495146,0.8466216361261631,1.0,2/24,0.41%,SLC7A8;SLC36A4
prerank,GO_Biological_Process_2021__negative regulation of Ras protein signal transduction (GO:0046580),0.9933734196340872,1.4154955579353536,0.2054794520547945,0.830813589700534,1.0,1/34,0.66%,STMN3
prerank,GO_Biological_Process_2021__negative regulation of mitochondrion organization (GO:0010823),0.9950676170770276,1.415095468356157,0.109375,0.8311666391384179,1.0,1/33,0.50%,ADCK1
prerank,Elsevier_Pathway_Collection__Suppression of Caspase Activity in Cancer,-0.9939538421158156,-1.41474464927176,0.17557251908396945,0.8485700693191511,1.0,3/45,0.62%,APP;GAS2;BIRC6
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Inhibitory Receptor Signaling,-0.9887930043497921,-1.414706080884523,0.3543307086614173,0.8478701696192437,1.0,3/50,1.13%,RAP1A;VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Polycystins Mutation Effects in Cystic Kidney Disease,-0.9928362412053735,-1.4146366546546016,0.21705426356589147,0.8472545909696748,1.0,3/47,0.73%,RAP1A;DEPTOR;PIK3CB
prerank,GO_Biological_Process_2021__negative regulation of cellular catabolic process (GO:0031330),-0.9888464047146945,-1.4139434589150324,0.3119266055045872,0.8481691227066874,1.0,1/65,1.12%,IL10RA
prerank,Reactome_2022__TP53 Regulates Transcription Of Cell Death Genes R-HSA-5633008,0.9885650602005873,1.4139427328307401,0.362962962962963,0.8339722118399676,1.0,3/44,1.15%,TNFRSF10A;PRELID3A;TNFRSF10D
prerank,GO_Biological_Process_2021__regulation of myoblast differentiation (GO:0045661),0.9911066352964917,1.4139315874831102,0.3409090909090909,0.8330894141813311,1.0,1/30,0.89%,TBX3
prerank,GO_Biological_Process_2021__positive regulation of biomineral tissue development (GO:0070169),0.9896394646788433,1.4139230217278065,0.34965034965034963,0.8321918254195946,1.0,1/36,1.04%,PKDCC
prerank,GO_Biological_Process_2021__ncRNA processing (GO:0034470),0.9952274267993523,1.4136929196522219,0.007246376811594203,0.8320026042171081,1.0,1/199,0.47%,DROSHA
prerank,GO_Biological_Process_2021__positive regulation of interleukin-1 beta production (GO:0032731),-0.9965618167991637,-1.4134546580654577,0.10256410256410256,0.8484733849209254,1.0,1/54,0.35%,APP
prerank,GO_Biological_Process_2021__liver development (GO:0001889),0.9904947369384715,1.4130620897034958,0.3007518796992481,0.8329077088498312,1.0,2/30,0.96%,PHF2;CCDC40
prerank,MSigDB_Oncogenic_Signatures__WNT UP.V1 DN,-0.9883965783803089,-1.4129524670410303,0.13274336283185842,0.8489838159088056,1.0,4/147,1.17%,OAS1;NEO1;GBP4;CDO1
prerank,GO_Biological_Process_2021__regulation of immune effector process (GO:0002697),-0.9895199764783373,-1.4127470014807835,0.3902439024390244,0.8487165779725976,1.0,2/53,1.06%,PROS1;C1R
prerank,Reactome_2022__Signaling By FGFR2 In Disease R-HSA-5655253,0.986442072809598,1.4126677422295275,0.45038167938931295,0.8331643752021809,1.0,1/36,1.36%,FGF1
prerank,GO_Biological_Process_2021__RNA catabolic process (GO:0006401),0.9960249992818442,1.4126183236700596,0.11382113821138211,0.8324289555835857,1.0,1/46,0.40%,DIS3L2
prerank,Reactome_2022__Telomere Maintenance R-HSA-157579,0.9848847840538939,1.412126897989127,0.3114754098360656,0.8331058947953041,1.0,5/81,1.53%,SLC19A1;PIF1;ACD;WRAP53;LRIG1
prerank,Elsevier_Pathway_Collection__DNA Persistent Repair Inhibits mTOR Signaling,0.9950278988572723,1.4118036381488845,0.16279069767441862,0.8332575773344731,1.0,1/40,0.50%,ATR
prerank,Elsevier_Pathway_Collection__Lipoxin A4/FPR2-Related Neutrophil Depression,-0.9890959292233727,-1.4114553584363965,0.464,0.8511655613855506,1.0,1/36,1.10%,VAV1
prerank,GO_Biological_Process_2021__T cell activation (GO:0042110),-0.9887794708100075,-1.4112576925055538,0.24107142857142858,0.8508761020189418,1.0,3/73,1.13%,RHOH;CD2;ZAP70
prerank,GO_Biological_Process_2021__blood circulation (GO:0008015),0.9874345104181627,1.4112120212500705,0.3488372093023256,0.8343930436157546,1.0,1/45,1.26%,MYOF
prerank,GO_Biological_Process_2021__positive regulation of interleukin-1 production (GO:0032732),-0.9965597781319716,-1.4109795743794618,0.08695652173913043,0.85066547050733,1.0,1/59,0.35%,APP
prerank,GO_Biological_Process_2021__limb morphogenesis (GO:0035108),0.7754543531866918,1.4109352735261853,0.34782608695652173,0.8342941169731379,1.0,2/18,0.89%,MEGF8;TBX3
prerank,Elsevier_Pathway_Collection__ESR1 Signaling in Breast Cancer,-0.9960213926836865,-1.4109177304239462,0.08661417322834646,0.8499778903242567,1.0,1/51,0.40%,NCOA1
prerank,Reactome_2022__RND2 GTPase Cycle R-HSA-9696270,0.990912166517267,1.4106331325003165,0.2571428571428571,0.8343818557441258,1.0,2/42,0.91%,DEPDC1B;CKAP4
prerank,GO_Biological_Process_2021__regulation of epithelial to mesenchymal transition (GO:0010717),0.9987927892248255,1.4105578853819782,0.014184397163120567,0.8336871695718611,1.0,1/73,0.12%,AXIN2
prerank,Elsevier_Pathway_Collection__Th1-Cell Differentiation,-0.9881635317825289,-1.4104549362243288,0.3652173913043478,0.8502947695756881,1.0,2/62,1.19%,ZAP70;IL12RB2
prerank,KEGG_2021_Human__Spliceosome,0.9902562957861984,1.4104209861528274,0.10256410256410256,0.83325445736926,1.0,3/134,0.98%,CDC5L;PRPF40A;SF3A2
prerank,WikiPathway_2021_Human__Phosphodiesterases in neuronal function WP4222,-0.9905644081853975,-1.4103344814040164,0.319672131147541,0.8497854926508488,1.0,3/50,0.96%,GRIN2B;PDE5A;PDE11A
prerank,GO_Biological_Process_2021__negative regulation of transport (GO:0051051),0.9892952847481231,1.4102986161364772,0.31343283582089554,0.8327648697412003,1.0,4/49,1.08%,WWP2;ERBB3;MCTP1;PACSIN3
prerank,GO_Biological_Process_2021__cellular glucose homeostasis (GO:0001678),0.9845245826869917,1.4101874520230817,0.5259259259259259,0.832202090927299,1.0,2/41,1.55%,PRKAA2;FOXA3
prerank,GO_Biological_Process_2021__regulation of carbohydrate catabolic process (GO:0043470),0.9855997878011373,1.409695894651329,0.453125,0.8328644197685898,1.0,2/43,1.44%,NUP210;SLC2A6
prerank,Reactome_2022__Interferon Alpha/Beta Signaling R-HSA-909733,-0.9914056763925435,-1.4096310592671102,0.23684210526315788,0.8507338342816726,1.0,2/58,0.87%,OAS1;OASL
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cystic Fibrosis,0.9880138093696753,1.409528178862877,0.3146853146853147,0.8325291534142867,1.0,2/57,1.20%,STX1A;GSTM3
prerank,Elsevier_Pathway_Collection__beta-Cell Destruction through Cytokines in Diabetes Mellitus,-0.9969450162613365,-1.409096277401661,0.06666666666666667,0.8511843337627537,1.0,1/57,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of viral process (GO:0048524),0.992128811856555,1.4090297559560303,0.1015625,0.8333747281335914,1.0,1/60,0.79%,PPARA
prerank,GO_Biological_Process_2021__signal transduction in response to DNA damage (GO:0042770),0.9935278121274995,1.4087266859765544,0.15384615384615385,0.8333559086370284,1.0,3/52,0.66%,BRIP1;ATR;CDC5L
prerank,Reactome_2022__Ovarian Tumor Domain Proteases R-HSA-5689896,0.9956043328658686,1.4086430746170873,0.061068702290076333,0.8327586058469739,1.0,1/38,0.44%,TRAF3
prerank,Reactome_2022__Bile Acid And Bile Salt Metabolism R-HSA-194068,-0.994493230779648,-1.4083747676189045,0.2072072072072072,0.8523915805492918,1.0,3/43,0.56%,CYP39A1;NCOA1;SLCO1A2
prerank,GO_Biological_Process_2021__positive regulation of ossification (GO:0045778),0.9896388881923878,1.4083535164830214,0.3673469387755102,0.8329044353996224,1.0,1/37,1.04%,PKDCC
prerank,Reactome_2022__Interleukin-12 Signaling R-HSA-9020591,-0.9882193211924131,-1.408080366607089,0.3949579831932773,0.8522954651718919,1.0,3/44,1.19%,GSTA2;RAP1B;IL12RB2
prerank,Reactome_2022__Transport Of SLBP Independent Mature mRNA R-HSA-159227,0.9952226525080559,1.4080763183454035,0.16260162601626016,0.832775641956865,1.0,1/35,0.48%,NUP210
prerank,Reactome_2022__Formation Of HIV-1 Elongation Complex Containing HIV-1 Tat R-HSA-167200,0.9919461886368268,1.4078412251585979,0.2074074074074074,0.8326225876284851,1.0,1/41,0.81%,TCEA1
prerank,TRRUST_Transcription_Factors_2019__ATF4 human,0.9870685721953101,1.4078137073916803,0.37681159420289856,0.8318366350038535,1.0,2/34,1.30%,NDC80;APOE
prerank,GO_Biological_Process_2021__positive regulation of type I interferon production (GO:0032481),-0.9922452874443743,-1.4077103389896404,0.19672131147540983,0.8526532288380226,1.0,2/76,0.78%,OAS1;TOMM70
prerank,GO_Biological_Process_2021__positive regulation of stress fiber assembly (GO:0051496),-0.9977208384858506,-1.4075886076228,0.0743801652892562,0.852152791652065,1.0,1/43,0.23%,CARMIL1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Presbycusis,0.9870106469998116,1.4074227620676365,0.38686131386861317,0.832174633245882,1.0,1/43,1.30%,APOE
prerank,Reactome_2022__Diseases Of DNA Repair R-HSA-9675135,0.9962604301219338,1.4074125104915889,0.07377049180327869,0.8313297017144546,1.0,2/51,0.38%,MSH2;BRIP1
prerank,GO_Biological_Process_2021__membrane fusion (GO:0061025),0.987442863678062,1.4071468826106202,0.4380165289256198,0.8313091658025852,1.0,1/35,1.26%,MYOF
prerank,Reactome_2022__Mitotic Prometaphase R-HSA-68877,0.9871491203925152,1.4066602996791502,0.06382978723404255,0.8319883399469551,1.0,10/183,1.31%,CENPA;CENPE;NCAPG;NDC80;HDAC8;CEP164;HAUS8;HAUS2;ERCC6L;TUBA1A
prerank,"Reactome_2022__Base-Excision Repair, AP Site Formation R-HSA-73929",0.9859039750454852,1.4065194648091903,0.5,0.8316176843651367,1.0,1/34,1.41%,ACD
prerank,GO_Biological_Process_2021__cilium movement (GO:0003341),0.989646128476914,1.4064807035124864,0.36,0.8308419091741611,1.0,3/37,1.05%,DNAAF5;CCDC40;CAMSAP3
prerank,Reactome_2022__Nuclear Pore Complex (NPC) Disassembly R-HSA-3301854,0.9952219823410853,1.4062099270813293,0.15,0.8308909135624638,1.0,1/36,0.48%,NUP210
prerank,Reactome_2022__Fatty acyl-CoA Biosynthesis R-HSA-75105,0.9883007905294079,1.4061750968433615,0.36363636363636365,0.8300892166542886,1.0,3/35,1.18%,ACACA;ACSF3;ACSL5
prerank,GO_Biological_Process_2021__ncRNA export from nucleus (GO:0097064),0.9952211357341302,1.4059491041185692,0.16793893129770993,0.8299366118857475,1.0,1/38,0.48%,NUP210
prerank,Reactome_2022__DAP12 Interactions R-HSA-2172127,-0.9927578037572532,-1.405455896767546,0.1810344827586207,0.8570789803665603,1.0,1/38,0.73%,PIK3CB
prerank,WikiPathway_2021_Human__Heart Development WP1591,0.9904103080798519,1.4054135930945928,0.3046875,0.8308392506421054,1.0,1/36,0.96%,ERBB3
prerank,Reactome_2022__Homologous DNA Pairing And Strand Exchange R-HSA-5693579,0.9962188527574867,1.4051380872705324,0.08943089430894309,0.8308315238608096,1.0,1/43,0.38%,BRIP1
prerank,GO_Biological_Process_2021__SRP-dependent cotranslational protein targeting to membrane (GO:0006614),-0.992959520343872,-1.4050527055317774,0.1619047619047619,0.8573414403281308,1.0,1/90,0.71%,SEC61A2
prerank,GO_Biological_Process_2021__spermatid development (GO:0007286),0.9967234050959414,1.4048764534821472,0.09285714285714286,0.8307794478314082,1.0,1/31,0.33%,SYCP3
prerank,"Elsevier_Pathway_Collection__EDN, NRG, NRTN, and GDNF/RET Signaling in Hirschsprung Disease",0.9904077380378595,1.4047135146124814,0.3333333333333333,0.8303930785866213,1.0,1/37,0.96%,ERBB3
prerank,KEGG_2021_Human__Regulation of lipolysis in adipocytes,-0.9928359443761618,-1.4046104374003372,0.2809917355371901,0.8577336860021078,1.0,3/49,0.73%,PLAAT3;AKT3;PIK3CB
prerank,KEGG_2021_Human__Spinocerebellar ataxia,-0.9921931408194637,-1.4044422425247756,0.09574468085106383,0.8573197774033812,1.0,5/131,0.80%,GRIN2B;AKT3;PIK3CB;ATXN10;DAB1
prerank,WikiPathway_2021_Human__Copper homeostasis WP3286,-0.9965606242637597,-1.4040741327579538,0.07,0.8575081018398097,1.0,1/51,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of synapse assembly (GO:0051963),-0.9914492914814607,-1.4038477364367703,0.29133858267716534,0.8573387963286043,1.0,2/43,0.86%,APP;SLITRK3
prerank,Reactome_2022__Nuclear Signaling By ERBB4 R-HSA-1251985,0.9870212700835462,1.403721819084963,0.4393939393939394,0.8326155270754393,1.0,1/32,1.30%,APOE
prerank,Elsevier_Pathway_Collection__NF-kB Canonical Signaling,0.9956010490941838,1.4036116577339985,0.11363636363636363,0.8320913369510962,1.0,1/50,0.44%,TRAF3
prerank,GO_Biological_Process_2021__intraciliary transport involved in cilium assembly (GO:0035735),0.9865122290830187,1.4034491940955363,0.4076923076923077,0.8316686604951976,1.0,1/40,1.35%,KIF3B
prerank,GO_Biological_Process_2021__cellular response to heat (GO:0034605),0.9864402283350049,1.403293477412815,0.4696969696969697,0.8313070565284856,1.0,1/35,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__B-Cell Activation in Systemic Lupus Erythematosus,-0.9890770934248866,-1.403115709967805,0.29838709677419356,0.8586096871626157,1.0,1/62,1.10%,VAV1
prerank,Reactome_2022__MTOR Signaling R-HSA-165159,0.9919147052341611,1.4026892968162903,0.25757575757575757,0.832469138054582,1.0,2/41,0.81%,PRKAA2;CAB39
prerank,WikiPathway_2021_Human__IL-2 signaling pathway WP49,-0.9907580085382187,-1.4026676495611639,0.336,0.8590555687514946,1.0,2/41,0.93%,PTK2B;CCND2
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, exonucleolytic (GO:0000291)",0.9960286783962621,1.4025588447250565,0.12121212121212122,0.8320273833507698,1.0,1/35,0.40%,DIS3L2
prerank,Reactome_2022__Transport Of Mature mRNA Derived From An Intronless Transcript R-HSA-159231,0.9952196927798014,1.4023208926645203,0.14173228346456693,0.8319024998213839,1.0,1/42,0.48%,NUP210
prerank,WikiPathway_2021_Human__Regulation of Microtubule Cytoskeleton WP2038,-0.9984124907944592,-1.4020925071658004,0.01834862385321101,0.8598487433797889,1.0,1/45,0.17%,TESK2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Systemic Scleroderma,0.9848922723266378,1.402025627960199,0.4689655172413793,0.8320934868206102,1.0,1/44,1.51%,FN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Multiple Sclerosis,-0.9875076767197611,-1.4019429966734562,0.4336283185840708,0.8594270982868178,1.0,1/47,1.25%,VDR
prerank,GO_Biological_Process_2021__mitochondrial transport (GO:0006839),-0.9922074516208274,-1.4018504533055896,0.23255813953488372,0.8588365584269885,1.0,1/55,0.78%,TOMM70
prerank,GO_Biological_Process_2021__positive regulation of interferon-gamma production (GO:0032729),-0.9881696221112363,-1.401623922282946,0.4074074074074074,0.85853778259266,1.0,2/53,1.19%,CD2;IL12RB2
prerank,Reactome_2022__Diseases Of Programmed Cell Death R-HSA-9645723,-0.9965582774697943,-1.4013978896770085,0.08403361344537816,0.8583121663926687,1.0,1/60,0.35%,APP
prerank,GO_Biological_Process_2021__branching morphogenesis of an epithelial tube (GO:0048754),0.995988148769233,1.4011044920190165,0.14728682170542637,0.8340560016779042,1.0,1/41,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Dendritic Cell Dysfunction in Psoriatic Arthritis,-0.9969430546991945,-1.4009018038765861,0.11304347826086956,0.8588242753647768,1.0,1/62,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__IL1B Expression Targets -> Nociception,-0.9969488058212589,-1.4008035047016225,0.09401709401709402,0.8583170586774566,1.0,1/45,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__B-Cells Function in Systemic Scleroderma,-0.9888946299270684,-1.4007879564715575,0.3305785123966942,0.8575655083722088,1.0,2/65,1.12%,VAV1;IL10RA
prerank,KEGG_2021_Human__Phospholipase D signaling pathway,-0.9866646606217052,-1.4006680009688646,0.2033898305084746,0.8571006250527333,1.0,5/139,1.35%,AKT3;PTK2B;PIK3CB;AGPAT4;PIK3R6
prerank,GO_Biological_Process_2021__mitotic G2/M transition checkpoint (GO:0044818),0.9972964492544731,1.400650092688725,0.06535947712418301,0.8345512966564936,1.0,1/43,0.27%,BRSK1
prerank,Elsevier_Pathway_Collection__Inflammatory Reaction in Acne Vulgaris,-0.9969454370257996,-1.400460306394307,0.08,0.856837306198631,1.0,1/49,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Hippo/YAP1 Signaling Deregulation in Cancer,0.9888735027841591,1.400291917923167,0.344,0.8349300609402063,1.0,2/40,1.12%,LRP5;TEAD4
prerank,MSigDB_Hallmark_2020__Interferon Alpha Response,-0.986920890092984,-1.3999833776866877,0.26605504587155965,0.8571478939721313,1.0,7/97,1.33%,OAS1;OASL;GBP4;EPSTI1;GMPR;HERC6;RTP4
prerank,GO_Biological_Process_2021__interleukin-12-mediated signaling pathway (GO:0035722),-0.9882586701256213,-1.3992876691608556,0.43859649122807015,0.8582470843906311,1.0,4/44,1.19%,GSTA2;RAP1B;PAK2;IL12RB2
prerank,Reactome_2022__Deposition Of New CENPA-containing Nucleosomes At Centromere R-HSA-606279,0.9994921172628937,1.3989785269870445,0.0,0.8384588308691778,1.0,1/43,0.05%,CENPA
prerank,Elsevier_Pathway_Collection__Muscular Dystrophies,0.9974472557980043,1.3985745833339995,0.027777777777777776,0.8388923220210358,1.0,1/49,0.26%,PTK2
prerank,Reactome_2022__Cell Cycle Checkpoints R-HSA-69620,0.9056237205646904,1.398448774845643,0.0472972972972973,0.8384276953992087,1.0,10/258,1.19%,CENPA;CENPE;NDC80;CDC45;BRIP1;HERC2;UBE2C;ERCC6L;PKMYT1;PCBP4
prerank,GO_Biological_Process_2021__regulation of humoral immune response (GO:0002920),-0.9895196888630592,-1.3981083402019345,0.4,0.8607970135650248,1.0,2/53,1.06%,PROS1;C1R
prerank,GO_Biological_Process_2021__cell junction assembly (GO:0034329),0.9850308902771828,1.3978899028534544,0.2903225806451613,0.8393838002454488,1.0,5/95,1.51%,GJC1;TJP1;FBLIM1;FLNA;FN1
prerank,GO_Biological_Process_2021__regulation of generation of precursor metabolites and energy (GO:0043467),0.9855952485216483,1.3978096401509255,0.44715447154471544,0.8387136236645841,1.0,2/50,1.44%,NUP210;SLC2A6
prerank,KEGG_2021_Human__Adrenergic signaling in cardiomyocytes,-0.986625336283014,-1.3976288286400667,0.22413793103448276,0.8613908680193552,1.0,4/136,1.35%,AKT3;KCNE1;CREB5;PIK3R6
prerank,KEGG_2021_Human__SNARE interactions in vesicular transport,0.9880603723977142,1.3971282792021582,0.4,0.8401067234052946,1.0,1/33,1.20%,STX1A
prerank,WikiPathway_2021_Human__Spinal Cord Injury WP2431,-0.9947648427002199,-1.3965914616347441,0.025423728813559324,0.8635814795369602,1.0,1/110,0.53%,RB1
prerank,GO_Biological_Process_2021__cellular response to hydrogen peroxide (GO:0070301),-0.9873651043268955,-1.3965313845086629,0.4838709677419355,0.862926417144842,1.0,1/35,1.27%,CYP1B1
prerank,Reactome_2022__IRE1alpha Activates Chaperones R-HSA-381070,0.9858925322069465,1.3962850117787584,0.4782608695652174,0.8420820267462051,1.0,1/48,1.41%,ACD
prerank,GO_Biological_Process_2021__interstrand cross-link repair (GO:0036297),0.9911397496743997,1.396227061223634,0.24060150375939848,0.8414032359513212,1.0,3/54,0.90%,ATR;DCLRE1C;FANCL
prerank,KEGG_2021_Human__DNA replication,0.9927955246898668,1.3961901273865929,0.17518248175182483,0.8406548427815506,1.0,1/35,0.72%,POLE4
prerank,KEGG_2021_Human__Fc epsilon RI signaling pathway,-0.989210908703343,-1.3961494318454408,0.36283185840707965,0.8632933041643082,1.0,4/63,1.10%,MAP2K6;AKT3;PIK3CB;VAV1
prerank,TRRUST_Transcription_Factors_2019__NFKB1 mouse,0.9850974465598087,1.396132295536048,0.11764705882352941,0.8399316505204855,1.0,8/179,1.51%,UBE2H;PPARA;TNFRSF25;AMH;MSX1;PPP1R13L;APOE;FN1
prerank,GO_Biological_Process_2021__unsaturated fatty acid metabolic process (GO:0033559),-0.9874037079924756,-1.396088906416458,0.48360655737704916,0.862651696999072,1.0,2/52,1.27%,GSTA1;CYP1B1
prerank,KEGG_2021_Human__Pancreatic secretion,-0.9958671299797768,-1.3960639139590658,0.07547169811320754,0.8618998663847354,1.0,2/78,0.42%,RAP1A;RAP1B
prerank,Reactome_2022__Intra-Golgi And Retrograde Golgi-to-ER Traffic R-HSA-6811442,0.9866045935008756,1.39589370527306,0.14184397163120568,0.8398044477662326,1.0,5/178,1.35%,CENPE;COG5;RAB3GAP1;KIF23;KIF3B
prerank,GO_Biological_Process_2021__regulation of complement activation (GO:0030449),-0.989521432605375,-1.3956704616596523,0.38524590163934425,0.8623064429960008,1.0,2/50,1.06%,PROS1;C1R
prerank,GO_Biological_Process_2021__regulation of cytokine production (GO:0001817),0.9903756357179988,1.3956277576152134,0.08695652173913043,0.8397483014593778,1.0,3/136,0.97%,IGF2BP1;TRAF3;IGF2BP3
prerank,Reactome_2022__Mitotic Spindle Checkpoint R-HSA-69618,0.9892310543734234,1.3955174405339268,0.15172413793103448,0.8392522387647396,1.0,5/107,1.09%,CENPA;CENPE;NDC80;UBE2C;ERCC6L
prerank,Elsevier_Pathway_Collection__Norepinephrine Neuronal Release,0.9866017739018387,1.3954673378741473,0.416,0.8385805860595669,1.0,3/43,1.35%,RHOQ;STX1A;KIF3B
prerank,Reactome_2022__Formation Of HIV Elongation Complex In Absence Of HIV Tat R-HSA-167152,0.9919450474712347,1.3954292820019236,0.19852941176470587,0.8378867965947525,1.0,1/43,0.81%,TCEA1
prerank,MSigDB_Oncogenic_Signatures__BCAT.100 UP.V1 DN,0.7610247451369836,1.3949574210845088,0.3656716417910448,0.8387493686546635,1.0,2/21,0.95%,ZNF749;AMH
prerank,GO_Biological_Process_2021__ion transport (GO:0006811),-0.9877639095224168,-1.394857478734269,0.25688073394495414,0.863800636464013,1.0,4/103,1.24%,KCNN2;SLC9A9;SLC15A3;SLC17A4
prerank,Reactome_2022__Deadenylation-dependent mRNA Decay R-HSA-429914,0.991247485132593,1.3946917984137528,0.203125,0.8388002413271817,1.0,1/52,0.88%,PARN
prerank,KEGG_2021_Human__Inflammatory bowel disease,-0.9881689144419863,-1.3946152120578474,0.43,0.8637403567861744,1.0,2/55,1.19%,IL21R;IL12RB2
prerank,TRRUST_Transcription_Factors_2019__EP300 human,-0.9873463363238422,-1.3944297180097402,0.3893805309734513,0.8634700585785318,1.0,1/54,1.27%,CYP1B1
prerank,TRRUST_Transcription_Factors_2019__CEBPB human,0.994944405352773,1.3934440418709924,0.11940298507462686,0.8421420771733992,1.0,1/51,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__protein deacetylation (GO:0006476),0.9860630995738782,1.3929792375645171,0.46153846153846156,0.84268524026897,1.0,4/45,1.41%,MIER2;TBL1X;RCOR2;FLNA
prerank,Elsevier_Pathway_Collection__Splenic Marginal Zone Lymphoma,0.9956025986005771,1.3928425024343705,0.13636363636363635,0.8422521374955743,1.0,1/45,0.44%,TRAF3
prerank,GO_Biological_Process_2021__hexose metabolic process (GO:0019318),-0.996225096377777,-1.3928342935294127,0.13559322033898305,0.8670860402448203,1.0,2/38,0.39%,ALDOB;OAS1
prerank,GO_Biological_Process_2021__tRNA aminoacylation (GO:0043039),0.9847552827689692,1.3927575408533035,0.528169014084507,0.841601714849428,1.0,2/38,1.53%,QRSL1;SARS2
prerank,GO_Biological_Process_2021__apoptotic mitochondrial changes (GO:0008637),0.9849408091127414,1.3924800842084533,0.5151515151515151,0.8416532937495358,1.0,1/33,1.51%,BOK
prerank,Reactome_2022__Transport Of Mature mRNAs Derived From Intronless Transcripts R-HSA-159234,0.9952193196770573,1.3920651689555887,0.140625,0.8421208480165757,1.0,1/43,0.48%,NUP210
prerank,GO_Biological_Process_2021__glutamate receptor signaling pathway (GO:0007215),-0.8516785996499179,-1.3914070073376683,0.4322033898305085,0.870362841195014,1.0,3/31,0.67%,GRIN2B;APP;PTK2B
prerank,GO_Biological_Process_2021__positive regulation of catalytic activity (GO:0043085),0.9982994910038849,1.3913608729371267,0.015873015873015872,0.8436829102287653,1.0,1/38,0.17%,MSH2
prerank,Reactome_2022__Signaling By FGFR4 R-HSA-5654743,0.9864871439523202,1.3913211065674949,0.48148148148148145,0.8429327877870798,1.0,2/36,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__regulation of epithelial cell migration (GO:0010632),0.9875211267739925,1.391015586058464,0.390625,0.8430797136206842,1.0,2/50,1.25%,PTK2;CTSH
prerank,GO_Biological_Process_2021__regulation of interleukin-12 production (GO:0032655),-0.9905930565780445,-1.3909878577258479,0.30973451327433627,0.8707038778017562,1.0,1/48,0.95%,SCIMP
prerank,GO_Biological_Process_2021__cellular response to type I interferon (GO:0071357),-0.9914082007562441,-1.3909663201178215,0.26548672566371684,0.8691307315621677,1.0,2/52,0.87%,OAS1;OASL
prerank,GO_Biological_Process_2021__type I interferon signaling pathway (GO:0060337),-0.9914082007562441,-1.3909663201178215,0.26548672566371684,0.8691307315621677,1.0,2/52,0.87%,OAS1;OASL
prerank,GO_Biological_Process_2021__adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193),0.9859773183627951,1.3909607802697528,0.47368421052631576,0.8423782103820381,1.0,2/47,1.41%,DRD4;FLNA
prerank,WikiPathway_2021_Human__Nucleotide Excision Repair WP4753,0.9927909471116596,1.390930565204878,0.16176470588235295,0.8416665309579744,1.0,1/44,0.72%,POLE4
prerank,Elsevier_Pathway_Collection__Alveolar Macrophages Dysfunction in COPD,-0.9897037731239307,-1.3908692111587637,0.29245283018867924,0.8686400795023527,1.0,2/69,1.04%,MAP2K6;TICAM2
prerank,GO_Biological_Process_2021__DNA replication-independent nucleosome assembly (GO:0006336),0.9940702235341969,1.3907364514402498,0.12408759124087591,0.8414510016208523,1.0,2/39,0.60%,CENPA;HIRA
prerank,GO_Biological_Process_2021__DNA duplex unwinding (GO:0032508),0.9887020917439832,1.3904936532029462,0.31343283582089554,0.841374903810826,1.0,1/51,1.13%,PIF1
prerank,GO_Biological_Process_2021__arachidonic acid metabolic process (GO:0019369),-0.9874427459126707,-1.390483677131397,0.453781512605042,0.8689893278246071,1.0,3/54,1.27%,CYP2C8;CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__AXL Receptor Inhibits Macrophages and Dendritic Cells Function,-0.9897203697118634,-1.390220080733771,0.42727272727272725,0.8689758842514241,1.0,2/39,1.04%,PROS1;TICAM2
prerank,Reactome_2022__Interleukin-2 Family Signaling R-HSA-451927,-0.9894134913475122,-1.3901769667500703,0.42857142857142855,0.868305891260396,1.0,3/40,1.07%,PTK2B;PIK3CB;IL21R
prerank,WikiPathway_2021_Human__Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.9955977743810378,1.3900762247597975,0.08148148148148149,0.8418505107203194,1.0,1/55,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__NFKB Signaling Activation by Blocking of Tumor Suppressors,0.9955992727911077,1.390036369335058,0.07194244604316546,0.8411576694111664,1.0,1/53,0.44%,TRAF3
prerank,Reactome_2022__Regulation Of Apoptosis R-HSA-169911,-0.9996823586376212,-1.3900330357778123,0.01639344262295082,0.8679120977473554,1.0,1/50,0.04%,ARHGAP10
prerank,GO_Biological_Process_2021__glycosphingolipid metabolic process (GO:0006687),-0.9902168787938439,-1.3898652039412362,0.31896551724137934,0.8676053691936528,1.0,2/46,0.99%,STS;GALC
prerank,Reactome_2022__Signaling By NTRK1 (TRKA) R-HSA-187037,-0.987490526259657,-1.3897327416842333,0.24347826086956523,0.867209034184315,1.0,4/111,1.26%,FOSB;RAP1A;PIK3CB;DUSP4
prerank,Reactome_2022__RND3 GTPase Cycle R-HSA-9696264,0.9901836333442253,1.3896566365421954,0.3235294117647059,0.8416055877307815,1.0,3/40,0.99%,DEPDC1B;CKAP4;PLEKHG5
prerank,GO_Biological_Process_2021__regulation of neuron death (GO:1901214),-0.9999498400503117,-1.3895379797454934,0.0,0.8669622799589735,1.0,1/82,0.01%,GRIN2B
prerank,KEGG_2021_Human__Adherens junction,0.995512796641675,1.3895285669144373,0.072,0.8411528052422542,1.0,1/71,0.45%,TJP1
prerank,GO_Biological_Process_2021__positive regulation of protein tyrosine kinase activity (GO:0061098),0.9904067772113799,1.3891872384885648,0.3153846153846154,0.8413501321983147,1.0,1/40,0.96%,ERBB3
prerank,Reactome_2022__Transport Of SLBP Dependant Mature mRNA R-HSA-159230,0.9952222795036083,1.3891260512340113,0.16260162601626016,0.8406605990223858,1.0,1/36,0.48%,NUP210
prerank,Reactome_2022__Fanconi Anemia Pathway R-HSA-6783310,0.991062700417946,1.3891015690277566,0.34074074074074073,0.8398842856371993,1.0,1/36,0.90%,FANCL
prerank,KEGG_2021_Human__GABAergic synapse,0.9846904540302774,1.3888359717661976,0.3161764705882353,0.8400133597905418,1.0,3/77,1.54%,GNB5;GLS;SLC38A1
prerank,MSigDB_Oncogenic_Signatures__RAPA EARLY UP.V1 DN,0.9850263087669198,1.3887350181517144,0.16783216783216784,0.8394802949918565,1.0,12/173,1.53%,NUP210;SNTB1;ZNF175;YTHDF3;TAF4;COG5;MYCN;SF3A2;PCBP4;MID1;LRIG1;SNTA1
prerank,GO_Biological_Process_2021__positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901030),0.9849408768616483,1.3886282210513905,0.5373134328358209,0.8389635919811133,1.0,1/34,1.51%,BOK
prerank,GO_Biological_Process_2021__negative regulation of cellular biosynthetic process (GO:0031327),0.9988352574440891,1.388618421724874,0.03355704697986577,0.8381386551755852,1.0,1/50,0.12%,GFI1
prerank,Reactome_2022__Interleukin-12 Family Signaling R-HSA-447115,-0.9882141472482272,-1.388207780792741,0.38333333333333336,0.8700619378373644,1.0,3/54,1.19%,GSTA2;RAP1B;IL12RB2
prerank,GO_Biological_Process_2021__negative regulation of BMP signaling pathway (GO:0030514),0.9891300595793424,1.3881765652551195,0.22580645161290322,0.8386275140433296,1.0,1/46,1.09%,CHRD
prerank,Reactome_2022__Nuclear Envelope Breakdown R-HSA-2980766,0.9952147117552497,1.3881399209985676,0.13138686131386862,0.8378922132067429,1.0,1/53,0.48%,NUP210
prerank,Reactome_2022__NEP/NS2 Interacts With Cellular Export Machinery R-HSA-168333,0.9952223912307231,1.3880920801817755,0.15079365079365079,0.837207874517215,1.0,1/35,0.48%,NUP210
prerank,GO_Biological_Process_2021__DNA integrity checkpoint signaling (GO:0031570),0.9935714014592701,1.3878411126405812,0.22556390977443608,0.8372056240623839,1.0,4/39,0.66%,CDC45;BRIP1;ATR;CDC5L
prerank,Reactome_2022__SRP-dependent Cotranslational Protein Targeting To Membrane R-HSA-1799339,-0.9929495990640869,-1.3871382753779202,0.11428571428571428,0.8724090979497298,1.0,1/106,0.71%,SEC61A2
prerank,GO_Biological_Process_2021__negative regulation of secretion by cell (GO:1903531),0.9869873448981331,1.3871085848105058,0.45,0.8386280333146393,1.0,2/35,1.31%,APOE;DRD4
prerank,WikiPathway_2021_Human__Glycogen Synthesis and Degradation WP500,0.9935654045819415,1.38708035936469,0.16279069767441862,0.8378729014733841,1.0,1/40,0.65%,PHKA2
prerank,WikiPathway_2021_Human__FOXA2 pathway WP5066,-0.7312991231620947,-1.3869924411771812,0.328,0.8720136973770299,1.0,2/20,0.05%,GSTA2;GSTA1
prerank,Elsevier_Pathway_Collection__Skin Fibrosis,-0.9933654697935652,-1.386892989323231,0.1574074074074074,0.8714902415851739,1.0,2/67,0.67%,MAP2K6;PTK2B
prerank,KEGG_2021_Human__Type I diabetes mellitus,0.9868999549579974,1.3868702656763552,0.4453125,0.837706959331986,1.0,1/37,1.31%,CPE
prerank,TRRUST_Transcription_Factors_2019__SPI1 human,-0.9908248423823932,-1.386493535984375,0.22580645161290322,0.871977584192656,1.0,2/61,0.93%,HCK;CD163
prerank,GO_Biological_Process_2021__mitotic cytokinesis (GO:0000281),0.9887187385086432,1.3863421974005266,0.3458646616541353,0.8384428224511755,1.0,4/47,1.14%,CENPA;ANLN;KIF23;SEPTIN6
prerank,Reactome_2022__RHOJ GTPase Cycle R-HSA-9013409,0.9854811858899504,1.3861796069491035,0.4429530201342282,0.8381858286730186,1.0,5/54,1.47%,DEPDC1B;WWP2;ARHGEF7;IQGAP3;CDC42EP1
prerank,GO_Biological_Process_2021__positive regulation of T cell differentiation (GO:0045582),-0.987990200092901,-1.3860730769524607,0.4700854700854701,0.8723783309213581,1.0,4/41,1.22%,VNN1;RHOH;ZAP70;GLI3
prerank,Reactome_2022__Transcriptional Regulation By E2F6 R-HSA-8953750,0.9882546689568319,1.3860683589904028,0.39416058394160586,0.8376911967033771,1.0,1/33,1.18%,RRM2
prerank,Reactome_2022__Synthesis Of Substrates In N-glycan Biosythesis R-HSA-446219,0.9964821990356465,1.385969039806095,0.1349206349206349,0.8372013254754234,1.0,1/61,0.35%,ST3GAL1
prerank,GO_Biological_Process_2021__cartilage development (GO:0051216),0.9996467482496343,1.3859637837333034,0.014705882352941176,0.8364030712086638,1.0,1/48,0.04%,HOXD3
prerank,Reactome_2022__Mitochondrial Protein Import R-HSA-1268020,-0.9922508982162817,-1.3858832219507646,0.248,0.8721478691530787,1.0,2/62,0.78%,CHCHD3;TOMM70
prerank,GO_Biological_Process_2021__amino acid import across plasma membrane (GO:0089718),-0.6977980582204382,-1.38544871143454,0.3103448275862069,0.8726138224467956,1.0,2/20,1.02%,SLC7A8;SLC16A2
prerank,MSigDB_Oncogenic_Signatures__CTIP DN.V1 UP,-0.987988278479823,-1.3853370387691406,0.25663716814159293,0.8721388347514105,1.0,2/101,1.21%,ZNF528;TEK
prerank,GO_Biological_Process_2021__cellular response to light stimulus (GO:0071482),0.9950181943254532,1.385156183055674,0.12949640287769784,0.838248400665904,1.0,1/60,0.50%,ATR
prerank,GO_Biological_Process_2021__positive regulation of RNA metabolic process (GO:0051254),0.9902890931312752,1.384902513338196,0.203125,0.8382413751088331,1.0,1/43,0.97%,MYCN
prerank,GO_Biological_Process_2021__endodermal cell differentiation (GO:0035987),0.9849920065539841,1.3848462389906095,0.5333333333333333,0.8375836363297697,1.0,3/32,1.51%,COL12A1;ITGB5;FN1
prerank,Reactome_2022__Interactions Of Vpr With Host Cellular Proteins R-HSA-176033,0.9952213190021169,1.384820126969083,0.17829457364341086,0.8368482882110582,1.0,1/38,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__WNT Signaling Activation by Blocking of Tumor Suppressors,0.9960730907581989,1.3847888296284727,0.144,0.8361219027621313,1.0,3/35,0.40%,AXIN2;AATF;LRP5
prerank,GO_Biological_Process_2021__regulation of osteoclast differentiation (GO:0045670),0.9849837241563174,1.3847351228289861,0.5343511450381679,0.8354682081418462,1.0,1/31,1.50%,PRXL2A
prerank,Elsevier_Pathway_Collection__Steroidogenesis Impairement in Polycystic Ovary Syndrome,0.9905237543084012,1.3846577450197721,0.3484848484848485,0.8348832425003085,1.0,1/38,0.95%,AMH
prerank,Elsevier_Pathway_Collection__Telomer Attrition Triggers Genomic Instability,0.9903360945744681,1.3846420909516062,0.31007751937984496,0.8340935721754712,1.0,2/39,0.97%,ATR;MYCN
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in beta-Cell,-0.9881255294510889,-1.3843071321624798,0.4523809523809524,0.8746259871111852,1.0,1/45,1.19%,IL12RB2
prerank,Reactome_2022__Signaling By Interleukins R-HSA-449147,-0.8268576133755076,-1.3841465349014288,0.009900990099009901,0.8742896168495572,1.0,15/421,1.34%,GSTA2;MAP2K6;APP;RAP1B;PTK2B;PIK3CB;HCK;PELI2;IL21R;VAV1;IL10RA;IL12RB2;S1PR1;DUSP4;PTPN18
prerank,GO_Biological_Process_2021__negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059),0.9917579447461066,1.3837678485477938,0.23622047244094488,0.8361285489845017,1.0,2/43,0.83%,ZGPAT;ARHGEF7
prerank,Elsevier_Pathway_Collection__Apoptosis Block by BCL2 Family Proteins in Cancer,0.9849375876031823,1.3836303284608862,0.5135135135135135,0.8357314363242087,1.0,1/39,1.51%,BOK
prerank,Reactome_2022__Cyclin E Associated Events During G1/S Transition R-HSA-69202,-0.9948249810817653,-1.3829021990691013,0.07692307692307693,0.877149894214567,1.0,2/81,0.53%,AKT3;RB1
prerank,GO_Biological_Process_2021__positive regulation of transport (GO:0051050),0.9849929179249921,1.3826783351263279,0.3925925925925926,0.838100398182249,1.0,3/87,1.51%,TUB;APOE;BOK
prerank,Reactome_2022__B-WICH Complex Positively Regulates rRNA Expression R-HSA-5250924,0.9941372462606981,1.382668838293087,0.1391304347826087,0.8373181267655964,1.0,1/48,0.59%,TAF1B
prerank,Reactome_2022__Metabolism Of Polyamines R-HSA-351202,0.9846664242889505,1.3826460214403895,0.43661971830985913,0.8365560132980304,1.0,2/55,1.54%,SMOX;SLC38A1
prerank,WikiPathway_2021_Human__Hepatitis C and Hepatocellular Carcinoma WP3646,0.9874801477804508,1.3826032235616006,0.3448275862068966,0.8359107409599844,1.0,2/49,1.26%,RRM2;MYOF
prerank,GO_Biological_Process_2021__positive regulation of interleukin-6 production (GO:0032755),-0.9906288864928062,-1.3825525924675512,0.2857142857142857,0.8774930265572785,1.0,2/70,0.95%,APP;SCIMP
prerank,Reactome_2022__Export Of Viral Ribonucleoproteins From Nucleus R-HSA-168274,0.9952221439367092,1.382486091419396,0.15267175572519084,0.8354786141535145,1.0,1/36,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__Ependymoma,0.997450463484202,1.3822854601894656,0.04895104895104895,0.8353555603554254,1.0,1/42,0.26%,PTK2
prerank,WikiPathway_2021_Human__Kit receptor signaling pathway WP304,-0.9864701363307701,-1.3816946524313547,0.42063492063492064,0.8791232077786121,1.0,2/59,1.36%,VAV1;GRB10
prerank,GO_Biological_Process_2021__neutrophil migration (GO:1990266),-0.9991782395275899,-1.3816049727769755,0.009009009009009009,0.8785444306469813,1.0,1/70,0.09%,CCL23
prerank,KEGG_2021_Human__Cortisol synthesis and secretion,-0.9890138866900737,-1.381539335819008,0.35185185185185186,0.8779744293560967,1.0,2/60,1.11%,PBX1;CREB5
prerank,Reactome_2022__RHOD GTPase Cycle R-HSA-9013405,0.9894851796949112,1.381518778915325,0.2677165354330709,0.8372620911758244,1.0,3/51,1.06%,DEPDC1B;ARHGAP39;MOSPD2
prerank,KEGG_2021_Human__Nucleotide excision repair,0.9927904457151456,1.3813458335531936,0.15671641791044777,0.8370078145062215,1.0,1/45,0.72%,POLE4
prerank,KEGG_2021_Human__RNA transport,0.9927124888180657,1.3812042274184861,0.02040816326530612,0.8366429525777129,1.0,2/163,0.73%,NUP210;UPF2
prerank,GO_Biological_Process_2021__regulation of NMDA receptor activity (GO:2000310),-0.8098865143864781,-1.3809531601720475,0.39316239316239315,0.8787397541611507,1.0,4/28,1.05%,GRIN2B;APP;PTK2B;DLG2
prerank,GO_Biological_Process_2021__homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156),-0.9885402079033508,-1.3809230215421207,0.38461538461538464,0.8780010896651539,1.0,1/58,1.15%,DSCAML1
prerank,Elsevier_Pathway_Collection__Neutrophil Chemotaxis,-0.9891300392855162,-1.3806132157409277,0.36936936936936937,0.8779989862210904,1.0,2/56,1.10%,GNA14;VAV1
prerank,Reactome_2022__RNA Polymerase I Transcription Initiation R-HSA-73762,0.9941382573119886,1.3803100364904817,0.11363636363636363,0.8386092378635576,1.0,1/46,0.59%,TAF1B
prerank,Reactome_2022__Nuclear Events (Kinase And Transcription Factor Activation) R-HSA-198725,-0.9874376632519675,-1.3802079396162337,0.3951612903225806,0.8783314714859837,1.0,2/59,1.26%,FOSB;DUSP4
prerank,Reactome_2022__EML4 And NUDC In Mitotic Spindle Formation R-HSA-9648025,0.9891977776835583,1.3801921686982541,0.17647058823529413,0.8381215755576491,1.0,4/94,1.09%,CENPA;CENPE;NDC80;ERCC6L
prerank,GO_Biological_Process_2021__protein N-linked glycosylation (GO:0006487),0.9896707630406344,1.380158668628079,0.2518518518518518,0.8373985798970204,1.0,3/66,1.04%,ST3GAL1;DAD1;ASGR2
prerank,GO_Biological_Process_2021__positive regulation of actin filament bundle assembly (GO:0032233),-0.9977182613514269,-1.3800580544827012,0.06504065040650407,0.8779294715214377,1.0,1/50,0.23%,CARMIL1
prerank,Reactome_2022__HDR Thru Homologous Recombination (HRR) Or Single Strand Annealing (SSA) R-HSA-5693567,0.9928948901356204,1.3800305795492256,0.10273972602739725,0.8370347565324798,1.0,4/106,0.72%,BRIP1;SLC19A1;HERC2;POLE4
prerank,GO_Biological_Process_2021__negative regulation of hydrolase activity (GO:0051346),0.9876569564764814,1.3799461104745185,0.3968253968253968,0.8365463584855922,1.0,1/53,1.23%,SH3RF2
prerank,Reactome_2022__Clathrin-mediated Endocytosis R-HSA-8856828,0.9883494774146435,1.379939022380394,0.12598425196850394,0.8357680958033707,1.0,2/136,1.16%,PACSIN3;GRK3
prerank,Elsevier_Pathway_Collection__Clear Cell Ovarian Carcinoma,-0.9960116284070181,-1.3799132100544753,0.022900763358778626,0.8776126552584068,1.0,1/81,0.40%,NCOA1
prerank,WikiPathway_2021_Human__Hematopoietic Stem Cell Differentiation WP2849,-0.9891395039735004,-1.3798733725789096,0.34210526315789475,0.8769320558501207,1.0,4/51,1.10%,FOSB;RHOH;VAV1;SPI1
prerank,GO_Biological_Process_2021__vesicle cytoskeletal trafficking (GO:0099518),0.9897123971010676,1.3794458538140149,0.24793388429752067,0.8364587031083669,1.0,1/39,1.03%,MYO7A
prerank,KEGG_2021_Human__Fanconi anemia pathway,0.9911414394265002,1.3793921538253338,0.34108527131782945,0.8358436897628936,1.0,3/50,0.90%,BRIP1;ATR;FANCL
prerank,GO_Biological_Process_2021__negative regulation of viral genome replication (GO:0045071),-0.9914085812843597,-1.3792408748826623,0.28448275862068967,0.8780574998051867,1.0,2/50,0.87%,OAS1;OASL
prerank,GO_Biological_Process_2021__translation (GO:0006412),0.9846771590315697,1.3791752303437221,0.16025641025641027,0.8356960175893371,1.0,3/210,1.53%,QRSL1;IGF2BP3;SARS2
prerank,KEGG_2021_Human__Estrogen signaling pathway,-0.9890703031161191,-1.3791183629724422,0.14285714285714285,0.8776150905664045,1.0,4/116,1.11%,AKT3;NCOA1;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__cellular response to decreased oxygen levels (GO:0036294),-0.9883382743251687,-1.3789942199731318,0.34210526315789475,0.8771620065244448,1.0,1/67,1.17%,AQP3
prerank,Reactome_2022__Amino Acids Regulate mTORC1 R-HSA-9639288,0.9930962427675653,1.378974579443748,0.1015625,0.8356366372991828,1.0,1/52,0.69%,FNIP1
prerank,GO_Biological_Process_2021__regulation of double-strand break repair via homologous recombination (GO:0010569),0.9854440958976691,1.3789215245973128,0.47619047619047616,0.8349875643893011,1.0,2/45,1.46%,SMCHD1;WRAP53
prerank,"Elsevier_Pathway_Collection__BSG (CD147) in Cancer Cells Motility, Invasion and Survival",0.9851730757208372,1.3787651162473522,0.45864661654135336,0.8346910904820388,1.0,2/46,1.49%,PTK2;BCAR1
prerank,KEGG_2021_Human__Bile secretion,-0.987236154247147,-1.3786364834055147,0.3739130434782609,0.8773135356500152,1.0,4/83,1.29%,KCNN2;SLC22A1;SLCO1A2;SLC4A5
prerank,GO_Biological_Process_2021__regulation of cell communication (GO:0010646),0.9883694114490174,1.3785582543744117,0.3879310344827586,0.8344829399878676,1.0,1/34,1.16%,GRK3
prerank,Reactome_2022__Pre-NOTCH Transcription And Translation R-HSA-1912408,0.995714905023455,1.378274926586836,0.09302325581395349,0.8346039440963345,1.0,1/52,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__cellular response to lectin (GO:1990858),-0.9886887414952351,-1.3782614020612678,0.25862068965517243,0.8767880074129994,1.0,3/105,1.14%,MUC6;PAK2;CLEC10A
prerank,GO_Biological_Process_2021__stimulatory C-type lectin receptor signaling pathway (GO:0002223),-0.9886887414952351,-1.3782614020612678,0.25862068965517243,0.8767880074129994,1.0,3/105,1.14%,MUC6;PAK2;CLEC10A
prerank,KEGG_2021_Human__N-Glycan biosynthesis,0.9953691128199521,1.3782498279479378,0.12408759124087591,0.8338853744130849,1.0,1/49,0.46%,DAD1
prerank,Reactome_2022__SUMOylation Of DNA Replication Proteins R-HSA-4615885,0.9952176004951666,1.3781884652537397,0.175,0.8333322464252655,1.0,1/45,0.48%,NUP210
prerank,GO_Biological_Process_2021__actin filament bundle organization (GO:0061572),0.9868396896170581,1.3779693024012876,0.3968253968253968,0.8332463951001181,1.0,4/33,1.33%,BAIAP2L2;ESPN;DPYSL3;SHROOM1
prerank,Reactome_2022__Extension Of Telomeres R-HSA-180786,0.9849057243540671,1.3776503230504384,0.4603174603174603,0.8336155599636639,1.0,5/49,1.53%,SLC19A1;PIF1;ACD;WRAP53;LRIG1
prerank,Elsevier_Pathway_Collection__Th1-Cells Activation and Proliferation in Atherosclerosis,-0.9881597784388955,-1.3775297647230036,0.3652173913043478,0.8781857120773529,1.0,2/68,1.19%,ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__determination of heart left/right asymmetry (GO:0061371),0.990530549006607,1.3775127588913298,0.24031007751937986,0.833275128836892,1.0,3/39,0.96%,MEGF8;TBX3;CCDC40
prerank,GO_Biological_Process_2021__positive regulation of NIK/NF-kappaB signaling (GO:1901224),-0.9916414177030458,-1.3770098093418321,0.2545454545454545,0.8788422017757268,1.0,3/51,0.85%,APP;TRIM44;CD27
prerank,Reactome_2022__Loss Of Nlp From Mitotic Centrosomes R-HSA-380259,0.9869742026456791,1.3769690665287269,0.3006993006993007,0.8343372426907453,1.0,4/69,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,KEGG_2021_Human__GnRH signaling pathway,-0.9933587808639868,-1.3767046092567181,0.13761467889908258,0.8789078439588337,1.0,2/87,0.67%,MAP2K6;PTK2B
prerank,Reactome_2022__Degradation Of AXIN R-HSA-4641257,0.9987957252311889,1.3765939030335326,0.014598540145985401,0.834715191017188,1.0,1/52,0.12%,AXIN2
prerank,GO_Biological_Process_2021__response to light stimulus (GO:0009416),0.9972926488172548,1.3765733654847339,0.0763888888888889,0.8339723199864734,1.0,1/50,0.27%,BRSK1
prerank,Elsevier_Pathway_Collection__Scavenger Receptor OLR1 in Inflammation Related Endothelial Dysfunction,0.9848805238947599,1.3764210495245275,0.4744525547445255,0.8337125197342663,1.0,1/51,1.51%,FN1
prerank,GO_Biological_Process_2021__heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0007157),0.9890599628735166,1.3763938093113086,0.35384615384615387,0.8330045828755817,1.0,1/38,1.10%,ITGAL
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Activation in Psoriatic Arthritis,-0.9969473645240855,-1.3761862582071467,0.1,0.8796195184215212,1.0,1/47,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of microtubule-based process (GO:0032886),0.989608248900991,1.3761762970089986,0.3787878787878788,0.8329956033454372,1.0,2/36,1.05%,PRKAA2;CAMSAP3
prerank,KEGG_2021_Human__Retrograde endocannabinoid signaling,0.9888637131694087,1.375785475763065,0.10606060606060606,0.8334958080631832,1.0,2/124,1.11%,NDUFA10;GNB5
prerank,GO_Biological_Process_2021__tRNA transport (GO:0051031),0.9952215571356641,1.3757072963025772,0.16,0.8330137723191344,1.0,1/37,0.48%,NUP210
prerank,KEGG_2021_Human__Other types of O-glycan biosynthesis,-0.9916358745295764,-1.375650205802513,0.2564102564102564,0.8804590292337443,1.0,1/46,0.84%,GALNT3
prerank,Elsevier_Pathway_Collection__Humoral Immunity in Vitiligo,-0.9888927494951362,-1.3752463893778553,0.33613445378151263,0.880784835286094,1.0,2/68,1.12%,VAV1;IL10RA
prerank,GO_Biological_Process_2021__innate immune response activating cell surface receptor signaling pathway (GO:0002220),-0.988687312243161,-1.3751873363212268,0.25217391304347825,0.8801737628790928,1.0,3/108,1.14%,MUC6;PAK2;CLEC10A
prerank,Elsevier_Pathway_Collection__Cortisol Signaling in Arterial Hypertension,-0.647935682270839,-1.3749548335705781,0.2396694214876033,0.8800334064173717,1.0,1/17,0.40%,NCOA1
prerank,Elsevier_Pathway_Collection__Eosinophil Activation,-0.989160608290273,-1.3743946499321755,0.3008849557522124,0.8808657595240116,1.0,3/81,1.10%,AOC1;GNA14;VAV1
prerank,Reactome_2022__RHOQ GTPase Cycle R-HSA-9013406,0.9855176641772486,1.374229258261813,0.4206896551724138,0.8375966316547897,1.0,6/58,1.47%,DEPDC1B;WWP2;ARHGEF7;RHOQ;IQGAP3;CDC42EP1
prerank,GO_Biological_Process_2021__tRNA modification (GO:0006400),-0.988473983914802,-1.3737695440040851,0.366412213740458,0.8818213815783702,1.0,2/64,1.16%,TYW1;TRMT9B
prerank,GO_Biological_Process_2021__centromere complex assembly (GO:0034508),0.9994196920426885,1.373715930585595,0.03225806451612903,0.8386527778003052,1.0,2/37,0.07%,CENPA;CENPE
prerank,GO_Biological_Process_2021__neutrophil chemotaxis (GO:0030593),-0.9991794218601144,-1.373633001744861,0.02631578947368421,0.8814835193163161,1.0,1/64,0.09%,CCL23
prerank,GO_Biological_Process_2021__regulation of integrin activation (GO:0033623),-0.6423423804153072,-1.3731397674334926,0.23577235772357724,0.8821123420903285,1.0,1/15,0.42%,RAP1B
prerank,GO_Biological_Process_2021__response to reactive oxygen species (GO:0000302),0.9858641212024496,1.3730330598900042,0.4098360655737705,0.8403400682531056,1.0,5/56,1.43%,STK26;TXNRD2;AGAP3;APOE;MPV17
prerank,WikiPathway_2021_Human__The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,-0.9876709102660022,-1.3725940162243562,0.3951612903225806,0.8828041406893018,1.0,2/53,1.24%,RB1;MAOB
prerank,GO_Biological_Process_2021__positive regulation of leukocyte chemotaxis (GO:0002690),0.9894458099738425,1.3724441687262674,0.28346456692913385,0.8416000691293324,1.0,2/50,1.06%,PTK2;MOSPD2
prerank,Reactome_2022__Metabolism Of Non-Coding RNA R-HSA-194441,0.9952157700467729,1.372297939813181,0.12213740458015267,0.8413532176570813,1.0,1/52,0.48%,NUP210
prerank,Reactome_2022__Formation Of TC-NER Pre-Incision Complex R-HSA-6781823,0.9919388356240374,1.3719492686846737,0.183206106870229,0.8416879628757746,1.0,1/51,0.81%,TCEA1
prerank,GO_Biological_Process_2021__positive regulation of sprouting angiogenesis (GO:1903672),0.6765244206803612,1.371931867861913,0.2706766917293233,0.8409469253488463,1.0,2/15,1.36%,TJP1;FGF1
prerank,GO_Biological_Process_2021__fat cell differentiation (GO:0045444),-0.9901265552052188,-1.3719153404192095,0.2845528455284553,0.8840220925442167,1.0,1/54,0.99%,KLF4
prerank,GO_Biological_Process_2021__positive regulation of synaptic transmission (GO:0050806),-0.99340974757119,-1.3719091786409536,0.1941747572815534,0.8832355960206009,1.0,3/63,0.67%,GRIN2B;APP;PTK2B
prerank,Reactome_2022__Cyclin A:Cdk2-associated Events At S Phase Entry R-HSA-69656,-0.9948244590484253,-1.3718824396338556,0.07964601769911504,0.8825482665783867,1.0,2/83,0.53%,AKT3;RB1
prerank,GO_Biological_Process_2021__ribosome assembly (GO:0042255),0.9917882363428729,1.3710435639003296,0.2962962962962963,0.8434332752445963,1.0,1/47,0.82%,EIF2A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Primary Ovarian Insufficiency,0.990560023192838,1.3709934418834828,0.272108843537415,0.8428493811171066,1.0,2/55,0.95%,BRSK1;AMH
prerank,GO_Biological_Process_2021__regulation of response to DNA damage stimulus (GO:2001020),0.9957575369385643,1.3708349993430087,0.16279069767441862,0.8426454000053641,1.0,1/41,0.43%,NEK4
prerank,Elsevier_Pathway_Collection__mTOR Signaling,-0.9864574804049214,-1.3706933660239486,0.42063492063492064,0.8853824682991798,1.0,2/80,1.36%,DEPTOR;GRB10
prerank,TRRUST_Transcription_Factors_2019__GATA1 human,-0.988633905010084,-1.3703155012230297,0.44545454545454544,0.885948178704438,1.0,2/51,1.15%,SPI1;LTBP4
prerank,Reactome_2022__XBP1(S) Activates Chaperone Genes R-HSA-381038,0.9858947135474794,1.3701324584592272,0.5,0.8443769320752349,1.0,1/46,1.41%,ACD
prerank,Elsevier_Pathway_Collection__Apoptotic Keratinocytes Clearance Recession in Systemic Lupus Erythematosus,-0.9890907800294944,-1.3700008612716592,0.5,0.88606284526884,1.0,1/44,1.10%,VAV1
prerank,GO_Biological_Process_2021__fatty-acyl-CoA biosynthetic process (GO:0046949),0.9883032541484562,1.3699051660890578,0.4,0.8443645163863845,1.0,3/30,1.18%,ACACA;ACSF3;ACSL5
prerank,Reactome_2022__SMAD2/SMAD3:SMAD4 Heterotrimer Regulates Transcription R-HSA-2173796,0.9971440341503267,1.369847935604276,0.09352517985611511,0.843739177148924,1.0,1/35,0.29%,RBL1
prerank,Reactome_2022__Glyoxylate Metabolism And Glycine Degradation R-HSA-389661,-0.9892962286372737,-1.3697976030575763,0.4423076923076923,0.8858325830253769,1.0,1/30,1.08%,HAO1
prerank,GO_Biological_Process_2021__negative regulation of protein ubiquitination (GO:0031397),0.9877530436164785,1.3696751486706233,0.32894736842105265,0.8435493679454783,1.0,3/49,1.23%,HDAC8;PRR7;SH3RF2
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:0000288)",0.9912439667641025,1.3696570321048172,0.2,0.8428050280120188,1.0,1/56,0.88%,PARN
prerank,KEGG_2021_Human__Systemic lupus erythematosus,-0.989498391221832,-1.3696057334822578,0.21551724137931033,0.8856139594326032,1.0,2/101,1.06%,GRIN2B;C1R
prerank,GO_Biological_Process_2021__recombinational repair (GO:0000725),0.9970169020776621,1.3695315101932057,0.06474820143884892,0.8424778571893886,1.0,1/78,0.30%,MMS22L
prerank,"GO_Biological_Process_2021__regulation of synaptic transmission, glutamatergic (GO:0051966)",-0.9933780022942532,-1.3688721541995121,0.31932773109243695,0.8871462259996153,1.0,2/37,0.67%,ATAD1;PTK2B
prerank,KEGG_2021_Human__RIG-I-like receptor signaling pathway,0.995598235133374,1.3688377498610205,0.10526315789473684,0.8440578149768521,1.0,1/53,0.44%,TRAF3
prerank,GO_Biological_Process_2021__granulocyte chemotaxis (GO:0071621),-0.9991787652276355,-1.3685270609615015,0.017699115044247787,0.8874799172271688,1.0,1/67,0.09%,CCL23
prerank,GO_Biological_Process_2021__regulation of mitotic nuclear division (GO:0007088),0.9885223471168083,1.3684453902196014,0.3898305084745763,0.8448261053925128,1.0,3/51,1.16%,MKI67;LRP5;PKMYT1
prerank,KEGG_2021_Human__Arachidonic acid metabolism,-0.9962996529943938,-1.3683678825897279,0.11904761904761904,0.8871820089751128,1.0,3/54,0.38%,CYP2C8;PLAAT3;GGT5
prerank,Elsevier_Pathway_Collection__Mast-Cells De Novo Synthesized Mediators via IgE Independent Signaling,-0.9892017307910211,-1.3682998298489424,0.2905982905982906,0.8865861863744863,1.0,4/82,1.10%,MAP2K6;NTF3;GNA14;VAV1
prerank,GO_Biological_Process_2021__positive regulation of biosynthetic process (GO:0009891),0.987062768817505,1.3682227730983325,0.4855072463768116,0.8449232055408982,1.0,2/42,1.30%,PPARA;APOE
prerank,GO_Biological_Process_2021__G2/M transition of mitotic cell cycle (GO:0000086),0.9870588988781555,1.3678523406781244,0.1702127659574468,0.8455016154634346,1.0,7/130,1.31%,MELK;BRSK1;CEP164;HAUS8;HAUS2;PKMYT1;TUBA1A
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Activation by Citokines in Rheumatoid Arthritis,-0.9969468414544378,-1.367582474683626,0.11214953271028037,0.8877432024839287,1.0,1/48,0.31%,MAP2K6
prerank,Reactome_2022__RUNX2 Regulates Bone Development R-HSA-8941326,-0.9879176391860184,-1.3675312072880899,0.552,0.8871218673538227,1.0,2/28,1.22%,RB1;GLI3
prerank,Reactome_2022__Unattached Kinetochores Signal Amplification Via A MAD2 Inhibitory Signal R-HSA-141444,0.9891996334295505,1.367449331660176,0.18518518518518517,0.8461143180185219,1.0,4/90,1.09%,CENPA;CENPE;NDC80;ERCC6L
prerank,Reactome_2022__RAB Geranylgeranylation R-HSA-8873719,0.9922416458113608,1.366994715855765,0.19718309859154928,0.8468636970835931,1.0,1/62,0.78%,RAB40C
prerank,Reactome_2022__Homology Directed Repair R-HSA-5693538,0.9928933690440922,1.3668651900120623,0.09929078014184398,0.8464819237538262,1.0,4/111,0.72%,BRIP1;SLC19A1;HERC2;POLE4
prerank,GO_Biological_Process_2021__regulation of interleukin-6 production (GO:0032675),-0.9906133841102119,-1.3668291386130638,0.17592592592592593,0.8883396282371925,1.0,2/102,0.95%,APP;SCIMP
prerank,GO_Biological_Process_2021__ceramide biosynthetic process (GO:0046513),0.9845531661773663,1.366779075684363,0.5454545454545454,0.8459738803629053,1.0,1/38,1.54%,CERS4
prerank,GO_Biological_Process_2021__cholesterol metabolic process (GO:0008203),0.9864977081310367,1.3665628238222753,0.312,0.8459918472077436,1.0,2/73,1.35%,APOE;SOAT2
prerank,Reactome_2022__Fc Epsilon Receptor (FCERI) Signaling R-HSA-2454202,-0.9891795114885568,-1.3665251088003876,0.2,0.8885366855815251,1.0,4/128,1.10%,SLC7A8;PIK3CB;RASGRP2;VAV1
prerank,Elsevier_Pathway_Collection__Atopic Dermatitis,-0.9881582901609458,-1.366524852059789,0.375,0.8877602972566927,1.0,2/71,1.19%,ZAP70;IL12RB2
prerank,WikiPathway_2021_Human__Modulators of TCR signaling and T cell activation WP5072,-0.9885573551604907,-1.3665243691922124,0.32142857142857145,0.8869852710166405,1.0,5/61,1.16%,RASA2;RHOH;VAV1;ZAP70;MAP4K1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypothyroidism,-0.9899036784817022,-1.3663659491391476,0.3925925925925926,0.8866676393733867,1.0,2/53,1.02%,IYD;SLC16A2
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Cytokines,-0.9896319024423096,-1.3663250391291313,0.34513274336283184,0.8860393974333853,1.0,3/66,1.05%,MAP2K6;PROS1;GNA14
prerank,GO_Biological_Process_2021__nucleosome assembly (GO:0006334),0.993451812058211,1.3663069196957445,0.1889763779527559,0.8461224421350888,1.0,2/46,0.66%,HIRA;NAA60
prerank,GO_Biological_Process_2021__response to metal ion (GO:0010038),-0.9883388822932929,-1.3661336832952016,0.36283185840707965,0.8858563895402385,1.0,1/68,1.17%,AQP3
prerank,KEGG_2021_Human__Aminoacyl-tRNA biosynthesis,0.9847501986802644,1.366053198931075,0.5337837837837838,0.8462316905577089,1.0,2/44,1.53%,QRSL1;SARS2
prerank,GO_Biological_Process_2021__positive regulation of inflammatory response (GO:0050729),-0.9965496383537645,-1.365448876385323,0.041666666666666664,0.8871380651438695,1.0,1/81,0.35%,APP
prerank,Elsevier_Pathway_Collection__EGFR Signaling,0.9974461153945222,1.3654201053836672,0.046153846153846156,0.8477885662613874,1.0,1/52,0.26%,PTK2
prerank,Reactome_2022__ABC-family Proteins Mediated Transport R-HSA-382556,-0.995166412511133,-1.3649055246665398,0.10714285714285714,0.8880110896148284,1.0,2/99,0.49%,ABCA6;ABCD3
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway (GO:2001243),-0.9989483117666723,-1.3649003307241,0.008771929824561403,0.8872435936964861,1.0,1/63,0.11%,VNN1
prerank,GO_Biological_Process_2021__ribonucleoprotein complex assembly (GO:0022618),0.9901544663751625,1.3647517155097537,0.06569343065693431,0.8492969198463317,1.0,1/133,0.98%,SF3A2
prerank,Reactome_2022__Estrogen-dependent Gene Expression R-HSA-9018519,-0.996053185581819,-1.3645791597630048,0.03389830508474576,0.8873626078524129,1.0,2/108,0.40%,FOSB;NCOA1
prerank,WikiPathway_2021_Human__IL-3 signaling pathway WP286,-0.9891368606818194,-1.3645110611498017,0.36507936507936506,0.8868254841088363,1.0,2/48,1.10%,HCK;VAV1
prerank,Elsevier_Pathway_Collection__Macrophage M1 Lineage,-0.9897129377813362,-1.3643255146045192,0.4453125,0.8865985661700116,1.0,2/51,1.04%,MAP2K6;TICAM2
prerank,GO_Biological_Process_2021__cardiac ventricle morphogenesis (GO:0003208),0.986904426520484,1.3643227842064807,0.4527027027027027,0.8499255718864672,1.0,1/37,1.31%,CPE
prerank,GO_Biological_Process_2021__cell cycle G2/M phase transition (GO:0044839),0.9870584291662949,1.363675025509412,0.17857142857142858,0.8512259106631794,1.0,7/131,1.31%,MELK;BRSK1;CEP164;HAUS8;HAUS2;PKMYT1;TUBA1A
prerank,Reactome_2022__Chromosome Maintenance R-HSA-73886,0.9849091814198825,1.3636331373825603,0.2440944881889764,0.8505491835547954,1.0,6/106,1.53%,CENPA;SLC19A1;PIF1;ACD;WRAP53;LRIG1
prerank,GO_Biological_Process_2021__skeletal system development (GO:0001501),0.9890635985752794,1.3636153958919623,0.11267605633802817,0.8498177365854902,1.0,8/139,1.12%,HOXD3;DLX6;PAPSS1;ANKRD11;TBX3;PKDCC;CHRD;TEAD4
prerank,Reactome_2022__HDR Thru Homologous Recombination (HRR) R-HSA-5685942,0.9928683953741662,1.363572125727227,0.17857142857142858,0.849181994490296,1.0,3/66,0.72%,BRIP1;SLC19A1;POLE4
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902041),0.9957951917074601,1.3634583758212668,0.1,0.8488092860597608,1.0,1/41,0.42%,TNFRSF10A
prerank,KEGG_2021_Human__Mineral absorption,-0.9874970646086465,-1.3631084862845841,0.4563106796116505,0.8893590615502114,1.0,1/58,1.25%,VDR
prerank,KEGG_2021_Human__Th17 cell differentiation,-0.9887201323239119,-1.3630763871176905,0.23423423423423423,0.8886709119074551,1.0,2/98,1.13%,IL21R;ZAP70
prerank,MSigDB_Oncogenic_Signatures__YAP1 UP,0.9914151675152054,1.3630215233003269,0.3014705882352941,0.8494802674937292,1.0,2/36,0.86%,RAB40C;RHOQ
prerank,GO_Biological_Process_2021__regulation of cytokine production involved in inflammatory response (GO:1900015),0.9921391927274394,1.3629625872814282,0.2689075630252101,0.8489511398513311,1.0,1/42,0.79%,PPARA
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> ATF/CREB Signaling,-0.9888017136969556,-1.3627729596147533,0.46551724137931033,0.8887991871413343,1.0,3/32,1.13%,MAP2K6;VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Natural Killer T-Cell Roles in Diabetes Mellitus Type 1,-0.9886935375307083,-1.3624665636891558,0.3548387096774194,0.8890152964219328,1.0,1/59,1.13%,ZAP70
prerank,Elsevier_Pathway_Collection__Vitiligo,-0.9891634657230368,-1.3616700271146736,0.3333333333333333,0.8905030789171751,1.0,3/75,1.10%,PTK2B;C1R;VAV1
prerank,GO_Biological_Process_2021__inorganic anion transmembrane transport (GO:0098661),-0.9889267491640289,-1.3616674976910461,0.38181818181818183,0.8897430685897937,1.0,1/58,1.11%,SLC12A8
prerank,GO_Biological_Process_2021__positive regulation of cellular protein localization (GO:1903829),0.9991848973741478,1.3615837778728104,0.02097902097902098,0.8530504409355149,1.0,2/70,0.09%,PRKAA2;NDC80
prerank,Reactome_2022__ER To Golgi Anterograde Transport R-HSA-199977,0.9918578500475898,1.3614715148315029,0.1079136690647482,0.8526477234633838,1.0,1/130,0.81%,COG5
prerank,Elsevier_Pathway_Collection__Prolactin Production,0.9904002379957317,1.3614196268078838,0.27611940298507465,0.8520545892831899,1.0,1/49,0.96%,ERBB3
prerank,GO_Biological_Process_2021__regulation of ATP metabolic process (GO:1903578),0.9855907335903846,1.3613211069760578,0.42962962962962964,0.8516604645370526,1.0,2/56,1.44%,NUP210;SLC2A6
prerank,KEGG_2021_Human__PD-L1 expression and PD-1 checkpoint pathway in cancer,-0.9888925876939957,-1.3609930385863651,0.275,0.8908726758721506,1.0,6/87,1.13%,MAP2K6;AKT3;PIK3CB;CD274;TICAM2;ZAP70
prerank,KEGG_2021_Human__Aldosterone synthesis and secretion,-0.9889412309658483,-1.3607509513167206,0.27927927927927926,0.8906767359835617,1.0,1/90,1.11%,CREB5
prerank,Reactome_2022__L1CAM Interactions R-HSA-373760,0.9926647328262794,1.360725409724555,0.08264462809917356,0.8531196017174831,1.0,3/96,0.74%,ITGA2;CNTNAP1;DLG1
prerank,GO_Biological_Process_2021__tRNA aminoacylation for protein translation (GO:0006418),0.9846980214355547,1.3607115048184892,0.5070422535211268,0.8523959532257925,1.0,1/43,1.53%,SARS2
prerank,Reactome_2022__Peptide Ligand-Binding Receptors R-HSA-375276,-0.9965849379842253,-1.3603079438232832,0.036036036036036036,0.8911277475427256,1.0,2/143,0.35%,CCL23;APP
prerank,Elsevier_Pathway_Collection__Natural Killer Cell in Diabetes Mellitus Type 1,-0.9887913341533401,-1.3602541801452956,0.36065573770491804,0.8905267724762309,1.0,3/49,1.13%,CD274;VAV1;ZAP70
prerank,MSigDB_Oncogenic_Signatures__TBK1.DN.48HRS UP,0.986906090912048,1.3597086373621683,0.4076923076923077,0.8552715243792379,1.0,3/49,1.32%,PTK2;APOE;PIK3C2B
prerank,GO_Biological_Process_2021__ceramide metabolic process (GO:0006672),0.9845884352423075,1.359427576481381,0.47540983606557374,0.8554813502428614,1.0,2/52,1.54%,FUT6;CERS4
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Proliferation in Rheumatoid Arthritis,0.9849757387288145,1.359276544287195,0.4444444444444444,0.8552137913224886,1.0,3/56,1.51%,PTK2;BCAR1;FN1
prerank,GO_Biological_Process_2021__organic hydroxy compound biosynthetic process (GO:1901617),-0.9997594811840441,-1.3591221979251922,0.009523809523809525,0.8926036452636542,1.0,1/50,0.03%,CYP39A1
prerank,Elsevier_Pathway_Collection__Apoptosis Block by Death Receptor Signaling in Cancer,0.9885609878633304,1.359034992774762,0.34057971014492755,0.8553680335446322,1.0,3/50,1.15%,TNFRSF10A;TNFRSF25;TNFRSF10D
prerank,Reactome_2022__Gap-filling DNA Repair Synthesis And Ligation In TC-NER R-HSA-6782210,0.9848576930361482,1.3588525163735126,0.43846153846153846,0.8551873205069596,1.0,4/63,1.53%,SLC19A1;POLE4;TCEA1;LRIG1
prerank,KEGG_2021_Human__Glycosphingolipid biosynthesis,0.9857151140048841,1.3586740395590577,0.4672131147540984,0.854931099053316,1.0,2/43,1.43%,ST3GAL1;FUT6
prerank,Reactome_2022__Cargo Recognition For Clathrin-Mediated Endocytosis R-HSA-8856825,0.9883143061533395,1.3580892093708368,0.21641791044776118,0.8563112397912354,1.0,1/99,1.16%,GRK3
prerank,GO_Biological_Process_2021__lung development (GO:0030324),0.9864925442768419,1.3580190307718332,0.5068493150684932,0.8557619898695558,1.0,2/32,1.36%,CCDC40;FGF1
prerank,KEGG_2021_Human__Retinol metabolism,-0.9894815850864871,-1.3579101606144794,0.2777777777777778,0.8948263337116409,1.0,4/62,1.07%,CYP2C8;CYP3A7;CYP1A2;HSD17B6
prerank,Elsevier_Pathway_Collection__Insulin Signaling,0.9913621135801535,1.357858571904466,0.23255813953488372,0.8555471971953371,1.0,1/53,0.86%,RHOQ
prerank,GO_Biological_Process_2021__secondary alcohol metabolic process (GO:1902652),0.9865179062729181,1.3575283915878902,0.424,0.8559063788095436,1.0,2/46,1.35%,APOE;SOAT2
prerank,"GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479)",0.9866371633572991,1.3574767945053008,0.32592592592592595,0.8552972170836292,1.0,1/71,1.33%,ITGB5
prerank,GO_Biological_Process_2021__negative regulation of inflammatory response to antigenic stimulus (GO:0002862),-0.9905021468588442,-1.357446291423486,0.13761467889908258,0.8952795028639456,1.0,5/110,0.97%,GPR39;GGT5;HCK;CD163;HRH2
prerank,Elsevier_Pathway_Collection__Chronic Myeloid Leukemia,-0.9947826340428471,-1.3573579415046,0.09649122807017543,0.894709762188956,1.0,1/69,0.53%,RB1
prerank,Reactome_2022__E3 Ubiquitin Ligases Ubiquitinate Target Proteins R-HSA-8866654,0.9854991158992301,1.3572688021232762,0.4892086330935252,0.8552548482790324,1.0,1/52,1.45%,RNF144A
prerank,GO_Biological_Process_2021__regulation of tumor necrosis factor production (GO:0032680),-0.9900337107299317,-1.3572648943385006,0.17,0.8941482691501733,1.0,3/113,1.01%,APP;OAS1;CD2
prerank,GO_Biological_Process_2021__DNA synthesis involved in DNA repair (GO:0000731),-0.9903262276893636,-1.3572583311826276,0.36363636363636365,0.8934025472896012,1.0,1/42,0.97%,USP43
prerank,Reactome_2022__Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-5696399,0.9848057406322267,1.3570933705055415,0.4117647058823529,0.8550789675256776,1.0,3/81,1.53%,SLC19A1;POLE4;LRIG1
prerank,MSigDB_Hallmark_2020__IL-6/JAK/STAT3 Signaling,0.987555464335969,1.3570559088194163,0.24305555555555555,0.8544174436655391,1.0,1/85,1.24%,A2M
prerank,GO_Biological_Process_2021__peptidyl-threonine modification (GO:0018210),-0.9916710366758853,-1.356997401878913,0.2184873949579832,0.8932857686589198,1.0,2/67,0.84%,WNK3;GALNT3
prerank,GO_Biological_Process_2021__regulation of cellular catabolic process (GO:0031329),0.9849108823159158,1.3569892669149481,0.45185185185185184,0.8539041361570963,1.0,1/64,1.51%,BOK
prerank,Reactome_2022__Cell-cell Junction Organization R-HSA-421270,0.9878997921465178,1.3569070379717305,0.3170731707317073,0.8534703228777566,1.0,2/55,1.21%,CRB3;CDH15
prerank,GO_Biological_Process_2021__cellular response to interleukin-12 (GO:0071349),-0.9882577084701748,-1.3568612470712582,0.4594594594594595,0.8928538145220662,1.0,4/46,1.19%,GSTA2;RAP1B;PAK2;IL12RB2
prerank,TRRUST_Transcription_Factors_2019__JUN mouse,-0.9890690225812665,-1.356627255994588,0.21100917431192662,0.8926833771037731,1.0,3/110,1.10%,NR3C1;CCND2;SPI1
prerank,GO_Biological_Process_2021__negative regulation of G0 to G1 transition (GO:0070317),0.9882512715881935,1.3562513761615727,0.391304347826087,0.8550066040475122,1.0,1/37,1.18%,RRM2
prerank,GO_Biological_Process_2021__cellular response to retinoic acid (GO:0071300),-0.9933321547670606,-1.3562132800662303,0.22321428571428573,0.8929619631593044,1.0,1/40,0.67%,PTK2B
prerank,GO_Biological_Process_2021__negative regulation of protein metabolic process (GO:0051248),0.9859785416077531,1.356177967089846,0.44274809160305345,0.854535070249429,1.0,2/48,1.41%,APOE;FLNA
prerank,KEGG_2021_Human__Pyruvate metabolism,0.9888319013173998,1.355921146883234,0.3582089552238806,0.854725320715532,1.0,2/46,1.12%,ACACA;PKLR
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590),0.986632810226587,1.3558007897661657,0.31851851851851853,0.8544795384215805,1.0,1/76,1.33%,ITGB5
prerank,WikiPathway_2021_Human__Cardiac Progenitor Differentiation WP2406,0.999339492361096,1.3556996593727777,0.015037593984962405,0.854138974482275,1.0,1/38,0.07%,THY1
prerank,WikiPathway_2021_Human__ATM Signaling Network in Development and Disease  WP3878,0.9924510680651568,1.3556722162767987,0.2900763358778626,0.8534626435453065,1.0,2/44,0.76%,ATR;DCLRE1C
prerank,Elsevier_Pathway_Collection__ANGPT/TEK Maintains Endothelial Cell Quiescence in Cancer,-0.987979785306349,-1.3554930997339656,0.4793388429752066,0.8940680711564329,1.0,1/35,1.21%,TEK
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Melanoma,0.9864822719486953,1.354919456514923,0.3971631205673759,0.8554252091684094,1.0,2/46,1.36%,PTK2;FGF1
prerank,WikiPathway_2021_Human__Differentiation Pathway WP2848,0.9864366826575293,1.3548823886934507,0.5142857142857142,0.854796421008554,1.0,1/41,1.36%,FGF1
prerank,Reactome_2022__Recruitment Of NuMA To Mitotic Centrosomes R-HSA-380320,0.9869678739456827,1.3548030639083808,0.30935251798561153,0.8543280219601365,1.0,4/80,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__regulation of DNA recombination (GO:0000018),0.9982995050958775,1.354663095529103,0.04201680672268908,0.8540568246268104,1.0,1/37,0.17%,MSH2
prerank,GO_Biological_Process_2021__response to tumor necrosis factor (GO:0034612),-0.9962480062703218,-1.3546540321479275,0.027777777777777776,0.895407110594919,1.0,2/102,0.38%,CCL23;GGT5
prerank,GO_Biological_Process_2021__peptidyl-lysine modification (GO:0018205),0.9875341128760174,1.3543890638553548,0.1937984496124031,0.8543137969031084,1.0,5/104,1.26%,SENP1;NUP210;PLOD2;STX1A;P3H3
prerank,WikiPathway_2021_Human__Oncostatin M Signaling Pathway WP2374,-0.9933223421672565,-1.3541542688178185,0.24299065420560748,0.8959100607075935,1.0,1/63,0.67%,PTK2B
prerank,GO_Biological_Process_2021__histone deacetylation (GO:0016575),0.9867552186574471,1.354094142819683,0.45454545454545453,0.85458045030124,1.0,4/47,1.34%,MIER2;HDAC8;TBL1X;RCOR2
prerank,WikiPathway_2021_Human__Notch Signaling Pathway Netpath WP61,0.9957115909963519,1.3540924094663986,0.11278195488721804,0.8538269005793658,1.0,1/59,0.43%,NOTCH3
prerank,Elsevier_Pathway_Collection__Adipokines and Cytokines in Insulin Resistance in Skeletal Muscles,0.9921791022020248,1.3540040724147844,0.2589928057553957,0.8534086752696798,1.0,2/51,0.79%,ACACA;PPARA
prerank,GO_Biological_Process_2021__icosanoid metabolic process (GO:0006690),-0.9874434715458793,-1.3534712292814528,0.5161290322580645,0.8968449290908983,1.0,3/54,1.27%,CYP2C8;GGT5;CYP1B1
prerank,GO_Biological_Process_2021__response to insulin (GO:0032868),0.9888542170847998,1.3530738185959594,0.24812030075187969,0.8560112391574343,1.0,3/79,1.12%,SORT1;RHOQ;PKLR
prerank,Reactome_2022__Pyruvate Metabolism And Citric Acid (TCA) Cycle R-HSA-71406,-0.9976388184899667,-1.3530208052016828,0.025423728813559324,0.8971872483713731,1.0,1/53,0.24%,SUCLG2
prerank,WikiPathway_2021_Human__PPAR signaling pathway WP3942,0.9882434384816342,1.3529635590019127,0.3333333333333333,0.8556625373815935,1.0,2/62,1.18%,PPARA;ACSL5
prerank,KEGG_2021_Human__RNA degradation,0.9912340261244609,1.352263573923463,0.16312056737588654,0.8575014511649425,1.0,1/76,0.88%,PARN
prerank,Reactome_2022__ER-Phagosome Pathway R-HSA-1236974,-0.9929603636174388,-1.3522350125877218,0.1652892561983471,0.8984830714941641,1.0,1/87,0.71%,SEC61A2
prerank,Reactome_2022__Golgi Associated Vesicle Biogenesis R-HSA-432722,0.9954053221625372,1.352205923231887,0.06716417910447761,0.8569738807215286,1.0,1/55,0.46%,SORT1
prerank,"GO_Biological_Process_2021__Wnt signaling pathway, planar cell polarity pathway (GO:0060071)",0.998401888593195,1.3520512510650444,0.006993006993006993,0.8567125778675037,1.0,1/83,0.16%,CELSR3
prerank,GO_Biological_Process_2021__cellular response to hypoxia (GO:0071456),-0.9882830055061498,-1.3517280848631064,0.21621621621621623,0.8989924870740509,1.0,1/127,1.17%,AQP3
prerank,GO_Biological_Process_2021__positive regulation of cell-cell adhesion (GO:0022409),0.9955687429835576,1.3516192831804323,0.17123287671232876,0.8574752214769361,1.0,2/47,0.45%,THY1;TJP1
prerank,Reactome_2022__Negative Epigenetic Regulation Of rRNA Expression R-HSA-5250941,0.994128860946732,1.3513566852022783,0.136,0.8576397331193988,1.0,1/67,0.59%,TAF1B
prerank,WikiPathway_2021_Human__Myometrial relaxation and contraction pathways WP289,0.9887869751566295,1.3512022624012763,0.14388489208633093,0.8574689780637057,1.0,1/145,1.11%,GNB5
prerank,Reactome_2022__Potential Therapeutics For SARS R-HSA-9679191,-0.9878054698502292,-1.3509069720505964,0.32,0.9002737918996964,1.0,3/92,1.23%,NR3C1;VAV1;S1PR1
prerank,Reactome_2022__HDACs Deacetylate Histones R-HSA-3214815,0.9957213784758085,1.3504754297355628,0.09420289855072464,0.8591760840376691,1.0,2/48,0.43%,HDAC8;TBL1X
prerank,WikiPathway_2021_Human__Pathways affected in adenoid cystic carcinoma WP3651,0.9903256452591196,1.3504437931690558,0.25547445255474455,0.8585127287925286,1.0,2/62,0.97%,BCOR;MYCN
prerank,Reactome_2022__Regulation Of RAS By GAPs R-HSA-5658442,-0.9933981059340871,-1.3498119717070765,0.20833333333333334,0.9019623132961737,1.0,1/63,0.66%,RASA2
prerank,WikiPathway_2021_Human__T-cell receptor (TCR) signaling pathway WP69,-0.9885450606856636,-1.3497721236504883,0.2413793103448276,0.9012977572549762,1.0,5/86,1.16%,PTK2B;CD83;VAV1;ZAP70;MAP4K1
prerank,Reactome_2022__Nuclear Envelope (NE) Reassembly R-HSA-2995410,0.9868347465624403,1.3492392787802787,0.3916083916083916,0.8621369376496292,1.0,1/71,1.31%,TUBA1A
prerank,GO_Biological_Process_2021__regulation of protein localization (GO:0032880),0.9925908638065742,1.3491303816628948,0.12318840579710146,0.8616790998250936,1.0,1/60,0.74%,DLG1
prerank,GO_Biological_Process_2021__myeloid leukocyte differentiation (GO:0002573),-0.9869253418124927,-1.3487531292113952,0.43902439024390244,0.9028319760080346,1.0,2/69,1.31%,SPI1;PML
prerank,GO_Biological_Process_2021__regulation of inflammatory response to antigenic stimulus (GO:0002861),-0.9905017450389839,-1.3486262901717172,0.14678899082568808,0.9023433287269027,1.0,5/111,0.97%,GPR39;GGT5;HCK;CD163;HRH2
prerank,MSigDB_Hallmark_2020__Myc Targets V2,0.9949403857817117,1.3485343718082905,0.10071942446043165,0.8631730680885564,1.0,1/58,0.51%,SLC19A1
prerank,Elsevier_Pathway_Collection__VEGF Independent Angiogenesis in Cancer,0.9864780743972899,1.3485114947582215,0.4057971014492754,0.8625218617132654,1.0,2/52,1.36%,PTK2;FGF1
prerank,Elsevier_Pathway_Collection__VEGFA Dependent Angiogenesis in Cancer,0.9902756576964016,1.3481352443546186,0.3146853146853147,0.8630636493506474,1.0,1/60,0.97%,MYCN
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Metastases,0.9849882320479376,1.3481154005075204,0.23484848484848486,0.862383743850355,1.0,4/101,1.51%,PTK2;NOTCH3;TJP1;FN1
prerank,GO_Biological_Process_2021__regulation of interferon-gamma production (GO:0032649),-0.988196558046538,-1.3479681538505548,0.34579439252336447,0.9030866858891131,1.0,3/80,1.19%,CD2;CD274;IL12RB2
prerank,WikiPathway_2021_Human__IL-6 signaling pathway WP364,-0.9891806999711183,-1.347825519064852,0.4262295081967213,0.9025736175593763,1.0,3/43,1.10%,NCOA1;HCK;VAV1
prerank,GO_Biological_Process_2021__positive regulation of DNA repair (GO:0045739),0.985483628574587,1.3477947065394953,0.5072463768115942,0.8628017391310554,1.0,3/45,1.46%,SMCHD1;SPIRE2;WRAP53
prerank,GO_Biological_Process_2021__antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844),-0.9874293652036256,-1.3472789736806436,0.49038461538461536,0.9029439368015907,1.0,1/47,1.26%,HRG
prerank,GO_Biological_Process_2021__selective autophagy (GO:0061912),-0.9993727962575565,-1.3470945586153542,0.008403361344537815,0.9025532329681027,1.0,1/58,0.07%,KLHL3
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via FCGR3B,-0.9891363111947586,-1.3468747821868876,0.41346153846153844,0.9023237000195601,1.0,2/50,1.10%,HCK;VAV1
prerank,WikiPathway_2021_Human__Oxidative phosphorylation WP623,0.9942889427029455,1.3468048790671467,0.1796875,0.8655665655576145,1.0,1/52,0.57%,NDUFA10
prerank,Elsevier_Pathway_Collection__NTRK -> AP-1/CREB/ELK/SRF/MYC/SMAD3/TP53 Signaling,-0.99179576062917,-1.3466957956400407,0.3333333333333333,0.9019092295131723,1.0,3/50,0.83%,MAP2K6;PTK2B;NTF3
prerank,GO_Biological_Process_2021__embryonic digit morphogenesis (GO:0042733),0.748351971596213,1.3466707421589663,0.368,0.8653109020388099,1.0,2/18,0.95%,TBX3;MSX1
prerank,TRRUST_Transcription_Factors_2019__CTCF human,0.8180163324670389,1.3466383486433688,0.41044776119402987,0.8647109608392047,1.0,4/28,0.95%,SLC6A4;IRAK2;CELSR3;ASAP2
prerank,GO_Biological_Process_2021__inorganic cation import across plasma membrane (GO:0098659),-0.9889679405054337,-1.34640778074752,0.36507936507936506,0.9017269171505864,1.0,2/70,1.11%,SLC9A9;SLC12A8
prerank,GO_Biological_Process_2021__positive regulation of response to DNA damage stimulus (GO:2001022),0.9855181113729738,1.3461246915263916,0.4206896551724138,0.8658805485929786,1.0,4/55,1.46%,ATR;SMCHD1;MSX1;WRAP53
prerank,Reactome_2022__NoRC Negatively Regulates rRNA Expression R-HSA-427413,0.9941303525714651,1.3460086669472417,0.11570247933884298,0.8655458669857234,1.0,1/64,0.59%,TAF1B
prerank,GO_Biological_Process_2021__protein secretion (GO:0009306),-0.9873585782769769,-1.345505982646999,0.4224137931034483,0.9029680850770181,1.0,2/60,1.27%,TANGO6;OLFM2
prerank,GO_Biological_Process_2021__regulation of cellular ketone metabolic process (GO:0010565),0.9921263507390965,1.3454715896620886,0.16176470588235295,0.8668283996605336,1.0,1/61,0.79%,PPARA
prerank,GO_Biological_Process_2021__regulation of cytosolic calcium ion concentration (GO:0051480),0.9984268734318134,1.3453144840536082,0.013793103448275862,0.8666784502323498,1.0,1/132,0.16%,GPR35
prerank,GO_Biological_Process_2021__Fc-epsilon receptor signaling pathway (GO:0038095),-0.9891470412012788,-1.3452400609145359,0.2542372881355932,0.9027994091039703,1.0,3/109,1.10%,PAK2;PIK3CB;VAV1
prerank,Reactome_2022__Downstream TCR Signaling R-HSA-202424,-0.9927290686541869,-1.3452001526699717,0.13675213675213677,0.9021266381528629,1.0,1/89,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__inflammatory response (GO:0006954),-0.8748509302047742,-1.3450942205145069,0.056074766355140186,0.9015685633569699,1.0,6/211,1.17%,CCL23;VNN1;GGT5;TPST1;ADGRE5;CDO1
prerank,Reactome_2022__Cardiac Conduction R-HSA-5576891,-0.9892560201436137,-1.344987456106918,0.24299065420560748,0.9010078781386077,1.0,2/110,1.08%,KCNE1;KCNK6
prerank,Reactome_2022__tRNA Aminoacylation R-HSA-379724,0.9846994095173113,1.344829622752177,0.5217391304347826,0.8675782394148293,1.0,1/42,1.53%,SARS2
prerank,MSigDB_Oncogenic_Signatures__KRAS.50 UP.V1 UP,0.9876795946446308,1.3442893836035077,0.3700787401574803,0.8688688530239361,1.0,3/44,1.24%,ITGA2;ETV5;A2M
prerank,Reactome_2022__Gene Silencing By RNA R-HSA-211000,0.9952460730087319,1.3442760751647398,0.0546875,0.8681640443163275,1.0,2/95,0.48%,DROSHA;NUP210
prerank,Reactome_2022__AURKA Activation By TPX2 R-HSA-8854518,0.9869724336843969,1.3438609785551443,0.3197278911564626,0.8690305789500242,1.0,4/72,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__iron ion transport (GO:0006826),0.9890142960562841,1.3438286722189614,0.3383458646616541,0.8684222269614359,1.0,1/47,1.10%,MELTF
prerank,Reactome_2022__Retrograde Transport At Trans-Golgi-Network R-HSA-6811440,0.9919049657440396,1.3438121960378808,0.2540983606557377,0.8677656390266296,1.0,1/48,0.81%,COG5
prerank,GO_Biological_Process_2021__mitotic metaphase plate congression (GO:0007080),0.9991871681254272,1.3437763090906507,0.02112676056338028,0.8671627169042679,1.0,2/51,0.09%,CENPE;NDC80
prerank,GO_Biological_Process_2021__positive regulation of stress-activated protein kinase signaling cascade (GO:0070304),-0.7223932484455089,-1.3437525548435285,0.34146341463414637,0.9028467666771997,1.0,2/17,0.95%,RNF13;SCIMP
prerank,Reactome_2022__Regulation Of PLK1 Activity At G2/M Transition R-HSA-2565942,0.9869637246045324,1.3436388524296832,0.25,0.8669282281159226,1.0,4/87,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Evading of Growth Suppressors,0.9889050239045852,1.3436274299346886,0.36585365853658536,0.8662189147734106,1.0,3/57,1.12%,AXIN2;TRAF3;TEAD4
prerank,GO_Biological_Process_2021__negative regulation of cell-substrate adhesion (GO:0010812),0.9890671388129257,1.3435949574057708,0.4253731343283582,0.8655894162554535,1.0,2/37,1.10%,TBCD;MELTF
prerank,GO_Biological_Process_2021__Fc receptor signaling pathway (GO:0038093),-0.9891464515328309,-1.3435224315596646,0.24778761061946902,0.9025266749749317,1.0,3/110,1.10%,PAK2;PIK3CB;VAV1
prerank,Reactome_2022__Transcriptional Regulation By Small RNAs R-HSA-5578749,0.995209277751501,1.3433721262779756,0.10569105691056911,0.8655990029799104,1.0,1/66,0.48%,NUP210
prerank,Reactome_2022__MAPK6/MAPK4 Signaling R-HSA-5687128,0.9917444871797891,1.3431178718073151,0.15671641791044777,0.8657752909798806,1.0,2/85,0.83%,IGF2BP1;ARHGEF7
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hodgkin Lymphoma,0.995600380563855,1.342965362075726,0.1619718309859155,0.8655756668080917,1.0,1/49,0.44%,TRAF3
prerank,GO_Biological_Process_2021__monocarboxylic acid transport (GO:0015718),-0.9899457054907108,-1.3425092329450827,0.2920353982300885,0.9041065466298124,1.0,3/55,1.02%,NCOA1;SLCO1A2;SLC16A2
prerank,GO_Biological_Process_2021__regulation of cellular component movement (GO:0051270),0.9904877244941209,1.3424743099743477,0.26865671641791045,0.8665577203111688,1.0,3/50,0.96%,ZSWIM5;CDK6;ERBB3
prerank,GO_Biological_Process_2021__receptor internalization (GO:0031623),0.9883580513417735,1.3423847088920755,0.3893129770992366,0.8661132256150833,1.0,1/47,1.16%,GRK3
prerank,Elsevier_Pathway_Collection__T-Cell Acute Lymphoblastic Leukemia,-0.9888458440136899,-1.3422921833718982,0.21296296296296297,0.9038354154737548,1.0,5/102,1.13%,RB1;PTK2B;CCND2;VAV1;ZAP70
prerank,GO_Biological_Process_2021__cardiac muscle tissue development (GO:0048738),0.9904789682388861,1.3422618021338983,0.2781954887218045,0.8658551858824786,1.0,1/48,0.95%,MSX1
prerank,GO_Biological_Process_2021__regulation of cellular protein localization (GO:1903827),0.9996856645263258,1.3419257680214915,0.008333333333333333,0.8663755238066052,1.0,1/46,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__membrane protein proteolysis (GO:0033619),0.9874810099824554,1.3418765602341665,0.49230769230769234,0.8657762237725971,1.0,1/38,1.25%,CTSH
prerank,GO_Biological_Process_2021__cellular response to nutrient levels (GO:0031669),0.9854379438626022,1.3417607127707152,0.4251968503937008,0.8654541476460672,1.0,6/63,1.48%,PRKAA2;CLEC16A;FNIP1;PPARA;STK26;LAMP2
prerank,GO_Biological_Process_2021__nucleic acid-templated transcription (GO:0097659),0.9941845227396895,1.3414561849053697,0.12931034482758622,0.865944273843375,1.0,2/42,0.59%,HOXD3;TAF1B
prerank,Elsevier_Pathway_Collection__Proliferative Diabetic Retinopathy,0.9849324870531231,1.3413529379738773,0.49193548387096775,0.8655934101690391,1.0,2/60,1.51%,PTK2;FN1
prerank,GO_Biological_Process_2021__positive regulation of tumor necrosis factor production (GO:0032760),-0.9900535451823363,-1.3412463317856589,0.27102803738317754,0.9053232770503877,1.0,3/71,1.01%,APP;OAS1;CD2
prerank,GO_Biological_Process_2021__Rho protein signal transduction (GO:0007266),0.9853605485329078,1.3412000748954251,0.4520547945205479,0.8654311272392543,1.0,2/53,1.47%,PLEKHG5;CDC42EP1
prerank,MSigDB_Hallmark_2020__DNA Repair,0.9848773026930607,1.3411366549892096,0.22916666666666666,0.8649420534721632,1.0,3/147,1.51%,DAD1;POLE4;HPRT1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Mucinous Ovarian Carcinoma,0.9864328522416065,1.3411300568094167,0.46715328467153283,0.8642435038762679,1.0,1/42,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Podocyte Dysfunction in Glomerulonephritis,0.9921797238367829,1.3409270263092838,0.2537313432835821,0.8643284766073293,1.0,2/48,0.79%,TJP1;PPARA
prerank,Reactome_2022__Orc1 Removal From Chromatin R-HSA-68949,-0.9926639054502441,-1.3407729915435378,0.2184873949579832,0.9054643897748761,1.0,1/65,0.74%,ORC4
prerank,Reactome_2022__RHO GTPases Activate Formins R-HSA-5663220,0.9876843093886662,1.3404716640787826,0.18705035971223022,0.86528541193243,1.0,6/115,1.25%,CENPA;CENPE;NDC80;MRTFA;ERCC6L;FMNL2
prerank,GO_Biological_Process_2021__long-term memory (GO:0007616),-0.6840985363820896,-1.3401624490206805,0.3125,0.9059613245975956,1.0,1/17,0.07%,CPEB3
prerank,GO_Biological_Process_2021__regulation of proteasomal protein catabolic process (GO:0061136),0.9870073234256753,1.3399275461862608,0.35036496350364965,0.8666215388742872,1.0,1/52,1.30%,APOE
prerank,Reactome_2022__Transcriptional Regulation By RUNX3 R-HSA-8878159,0.9888401719353882,1.339904227602077,0.1925925925925926,0.8659465081256156,1.0,2/94,1.12%,ITGAL;TEAD4
prerank,GO_Biological_Process_2021__activation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0006919),0.9849981128773552,1.3397125058838368,0.4,0.8659330926233227,1.0,3/80,1.51%,SENP1;TNFRSF10A;BOK
prerank,GO_Biological_Process_2021__purine ribonucleotide biosynthetic process (GO:0009152),0.9976430386177364,1.3395033425280782,0.03968253968253968,0.8659679859020845,1.0,1/46,0.24%,PAPSS1
prerank,Reactome_2022__Resolution Of Sister Chromatid Cohesion R-HSA-2500257,0.989233093513475,1.3392135609640272,0.1702127659574468,0.8663051560201888,1.0,5/103,1.09%,CENPA;CENPE;NDC80;HDAC8;ERCC6L
prerank,MSigDB_Oncogenic_Signatures__CORDENONSI YAP CONSERVED SIGNATURE,0.9852505304697833,1.339124714433731,0.49295774647887325,0.8659186913642729,1.0,5/52,1.49%,ETV5;SHCBP1;ITGB5;FLNA;GLS
prerank,Reactome_2022__Base Excision Repair R-HSA-73884,0.9848586217384169,1.3389891544923942,0.4645669291338583,0.8656805819336915,1.0,4/62,1.53%,SLC19A1;POLE4;ACD;LRIG1
prerank,Reactome_2022__Immunoregulatory Interactions Between A Lymphoid And A non-Lymphoid Cell R-HSA-198933,0.9890034891820917,1.3388587427950192,0.15625,0.8654396668711606,1.0,1/112,1.10%,ITGAL
prerank,KEGG_2021_Human__Malaria,0.9890556802865502,1.3388233710342723,0.3533834586466165,0.8648401456489275,1.0,1/47,1.10%,ITGAL
prerank,GO_Biological_Process_2021__cellular response to mechanical stimulus (GO:0071260),0.995793105740428,1.3385186355426477,0.07936507936507936,0.8653017528695598,1.0,1/48,0.42%,TNFRSF10A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Polycystic Kidney Disease,0.984995564617424,1.338233316712423,0.373134328358209,0.8656441791219293,1.0,4/90,1.51%,HAVCR1;FNIP1;NEK8;FN1
prerank,WikiPathway_2021_Human__Pathogenic Escherichia coli infection WP2272,0.9868530879746616,1.3381001912186206,0.4411764705882353,0.8653817249632411,1.0,1/52,1.31%,TUBA1A
prerank,GO_Biological_Process_2021__protein homotetramerization (GO:0051289),0.9849424097419642,1.3380684237441263,0.48872180451127817,0.8647842711036318,1.0,3/49,1.51%,ACACA;GLS;HPRT1
prerank,TRRUST_Transcription_Factors_2019__PPARG mouse,0.986432989386116,1.3379484825540828,0.4318181818181818,0.8644495657614437,1.0,1/44,1.36%,FGF1
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation via IgE Signaling,-0.9891187265114302,-1.3376047052874913,0.325,0.9108251884719356,1.0,2/83,1.10%,MAP2K6;VAV1
prerank,Reactome_2022__Centrosome Maturation R-HSA-380287,0.986967287340227,1.3373710023354675,0.30935251798561153,0.8657674866423998,1.0,4/81,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__regulation of protein binding (GO:0043393),-0.9928473984627384,-1.3373186095548746,0.1559633027522936,0.9106481403064457,1.0,2/115,0.72%,APP;AMFR
prerank,GO_Biological_Process_2021__regulation of chemokine production (GO:0032642),-0.9965664461277293,-1.337141454257969,0.109375,0.9102674278414447,1.0,1/39,0.35%,APP
prerank,Elsevier_Pathway_Collection__Proteins Involved in High-Grade Serous Ovarian Carcinoma,0.995757940929564,1.336890403859267,0.09923664122137404,0.8666944250048447,1.0,2/56,0.43%,MSH2;NOTCH3
prerank,KEGG_2021_Human__B cell receptor signaling pathway,-0.9891636857516092,-1.336646032799427,0.29838709677419356,0.910611150962799,1.0,3/78,1.10%,AKT3;PIK3CB;VAV1
prerank,GO_Biological_Process_2021__regulation of mitotic cell cycle phase transition (GO:1901990),0.9116226208695877,1.3366118948143557,0.07586206896551724,0.8669575442231342,1.0,7/183,1.31%,CENPE;CEP164;HAUS8;HAUS2;ANLN;UBE2C;TUBA1A
prerank,GO_Biological_Process_2021__cellular response to glucose starvation (GO:0042149),0.9973412807896713,1.3365662185096223,0.08870967741935484,0.8664153554388069,1.0,2/43,0.27%,PRKAA2;BRSK1
prerank,GO_Biological_Process_2021__muscle organ development (GO:0007517),0.988815503598589,1.3363145575006936,0.3722627737226277,0.8665956233281522,1.0,1/53,1.12%,TEAD4
prerank,KEGG_2021_Human__Oxidative phosphorylation,0.9942609282746898,1.3361821430502956,0.08163265306122448,0.8663436579003718,1.0,1/112,0.57%,NDUFA10
prerank,Reactome_2022__Biosynthesis Of N-glycan Precursor (Dolichol LLO) And Transfer To Protein R-HSA-446193,0.996476974011705,1.335929376116217,0.10317460317460317,0.8664760846023434,1.0,1/75,0.35%,ST3GAL1
prerank,GO_Biological_Process_2021__skin development (GO:0043588),-0.9973277319291597,-1.3356363226485626,0.06306306306306306,0.9122357060897707,1.0,1/65,0.27%,SLC2A10
prerank,WikiPathway_2021_Human__Aryl Hydrocarbon Receptor Netpath WP2586,-0.9874484366902904,-1.3354176822995332,0.5247524752475248,0.9119247798963761,1.0,3/44,1.27%,RB1;CYP1A2;CYP1B1
prerank,WikiPathway_2021_Human__22q11.2 copy number variation syndrome WP4657,0.9880369926900936,1.3348455818782228,0.20930232558139536,0.8696426128090661,1.0,6/102,1.21%,CDC45;DROSHA;HIRA;TXNRD2;CHRD;CDH15
prerank,KEGG_2021_Human__Chagas disease,-0.9896163411004748,-1.3346868895303452,0.2636363636363636,0.9127639677645378,1.0,3/98,1.05%,AKT3;PIK3CB;GNA14
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometrial Cancer,0.9981469158964495,1.3346443642459194,0.0661764705882353,0.8696231680278962,1.0,2/49,0.19%,MSH2;CDK6
prerank,GO_Biological_Process_2021__positive regulation of blood vessel endothelial cell migration (GO:0043536),-0.9963717889660322,-1.3343638911911342,0.08411214953271028,0.9126877512497281,1.0,1/47,0.37%,AKT3
prerank,GO_Biological_Process_2021__positive regulation of cell growth (GO:0030307),-0.9904037177365839,-1.3342103216068328,0.25,0.9122722503876004,1.0,1/95,0.96%,SEMA4D
prerank,GO_Biological_Process_2021__protein glycosylation (GO:0006486),0.9857461982618079,1.333696324250356,0.2246376811594203,0.8722183532494395,1.0,4/124,1.43%,ST3GAL1;DAD1;PLOD2;FUT6
prerank,GO_Biological_Process_2021__L-amino acid transport (GO:0015807),-0.7372622391316508,-1.3333150913330036,0.3883495145631068,0.9134936507860154,1.0,2/24,0.41%,SLC7A8;SLC36A4
prerank,Elsevier_Pathway_Collection__AMPK Signaling,0.9919131570155335,1.3331896693518333,0.30303030303030304,0.8732183576847818,1.0,2/41,0.81%,ACACA;CAB39
prerank,TRRUST_Transcription_Factors_2019__RUNX2 mouse,0.9899876861928426,1.3329909688124357,0.3014705882352941,0.8732686664947731,1.0,2/45,1.01%,AXIN2;ASRGL1
prerank,MSigDB_Oncogenic_Signatures__RPS14 DN.V1 DN,0.9429630102895908,1.3326417871053682,0.16901408450704225,0.873836717019714,1.0,13/167,1.46%,CENPE;FOXRED2;MSH2;MKI67;DEPDC1;PBK;LRRC20;KIF23;ERCC6L;PKLR;CLCN4;PYCR1;CNN3
prerank,GO_Biological_Process_2021__glycolipid metabolic process (GO:0006664),-0.9902145301288253,-1.3323705378618744,0.3113207547169811,0.9146815943279707,1.0,2/51,0.99%,STS;GALC
prerank,Reactome_2022__GLI3 Is Processed To GLI3R By Proteasome R-HSA-5610785,-0.9878459341207084,-1.3323492376999726,0.4661016949152542,0.9139862436075301,1.0,1/56,1.22%,GLI3
prerank,GO_Biological_Process_2021__cytoplasmic microtubule organization (GO:0031122),0.9896784232816507,1.3322965089739074,0.3384615384615385,0.8743091777318807,1.0,4/53,1.05%,CLIP2;STMN3;DLG1;CAMSAP3
prerank,GO_Biological_Process_2021__positive regulation of receptor signaling pathway via JAK-STAT (GO:0046427),-0.7824266317965805,-1.3321568458795825,0.4140625,0.9136303305708307,1.0,3/25,1.27%,PTK2B;IL10RA;CYP1B1
prerank,WikiPathway_2021_Human__SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.995594813321211,1.3319959387519456,0.07971014492753623,0.8746610689948779,1.0,1/65,0.44%,TRAF3
prerank,GO_Biological_Process_2021__pre-replicative complex assembly (GO:0036388),-0.9926652375728798,-1.3316690918352407,0.23076923076923078,0.9138151269934836,1.0,1/62,0.74%,ORC4
prerank,GO_Biological_Process_2021__double-strand break repair via homologous recombination (GO:0000724),0.9970599293855466,1.3315645129523273,0.06870229007633588,0.875384030323792,1.0,2/95,0.30%,CDC45;MMS22L
prerank,Reactome_2022__Cellular Response To Starvation R-HSA-9711097,0.9930463106915469,1.3314322877307911,0.05755395683453238,0.8751491048486739,1.0,1/148,0.69%,FNIP1
prerank,GO_Biological_Process_2021__amide biosynthetic process (GO:0043604),0.984541080485953,1.3308275644325493,0.5354330708661418,0.8765622301892567,1.0,1/47,1.54%,CERS4
prerank,KEGG_2021_Human__PPAR signaling pathway,0.9882390674591697,1.3308048369608172,0.32575757575757575,0.8759214275147174,1.0,2/69,1.18%,PPARA;ACSL5
prerank,KEGG_2021_Human__Dilated cardiomyopathy,0.9866887339992297,1.3306761833948733,0.36054421768707484,0.8756426918153091,1.0,2/85,1.33%,ITGA2;ITGB5
prerank,GO_Biological_Process_2021__stress-activated MAPK cascade (GO:0051403),0.9990243942412882,1.3306231214788224,0.0,0.8751448550988685,1.0,1/62,0.10%,IRAK2
prerank,GO_Biological_Process_2021__regulation of interleukin-8 production (GO:0032677),-0.9900067577484504,-1.3304257835553455,0.336283185840708,0.9155873187474282,1.0,2/76,1.01%,KLF4;CD2
prerank,Elsevier_Pathway_Collection__T-Cell Dependent B-Cell Activation,-0.9890797606865089,-1.330372748297134,0.3821138211382114,0.9149491734677928,1.0,1/59,1.10%,VAV1
prerank,GO_Biological_Process_2021__cellular macromolecule biosynthetic process (GO:0034645),0.8943121749168386,1.3303270961374998,0.05333333333333334,0.8754626821745985,1.0,9/305,1.30%,HOXD3;CDC45;ING5;BRIP1;ATR;TAF1B;IGF2BP3;PIF1;APOE
prerank,GO_Biological_Process_2021__negative regulation of neuron projection development (GO:0010977),0.9868649758341391,1.3302742005964754,0.3448275862068966,0.8748718728833692,1.0,4/57,1.33%,THY1;GFI1;APOE;DPYSL3
prerank,Reactome_2022__Complement Cascade R-HSA-166658,-0.9895191984336343,-1.3302329266474613,0.39344262295081966,0.9144406916915746,1.0,2/55,1.06%,PROS1;C1R
prerank,GO_Biological_Process_2021__regulation of mRNA catabolic process (GO:0061013),0.9882602491163136,1.3298854565342142,0.1366906474820144,0.8753677447827823,1.0,5/120,1.19%,IGF2BP1;YTHDF3;PARN;IGF2BP3;PCBP4
prerank,Reactome_2022__Processing Of DNA Double-Strand Break Ends R-HSA-5693607,0.9947510034159017,1.3298619115472712,0.11678832116788321,0.8747154617904238,1.0,2/73,0.53%,BRIP1;HERC2
prerank,GO_Biological_Process_2021__NIK/NF-kappaB signaling (GO:0038061),0.9957833187435688,1.3298607601734356,0.06060606060606061,0.8740049024345238,1.0,1/72,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__cell-cell junction organization (GO:0045216),0.987931007760374,1.3298425429236513,0.22448979591836735,0.8733516919149248,1.0,3/77,1.21%,GJC1;TJP1;CDH15
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glomerulonephritis,0.9849364287487563,1.3298079076195848,0.32142857142857145,0.8727525703072507,1.0,3/114,1.51%,PPARA;COL4A5;FN1
prerank,Elsevier_Pathway_Collection__B-Cell Acute Lymphoblastic Leukemia,-0.9907846072170167,-1.3295205699731916,0.2713178294573643,0.9150965740111243,1.0,3/72,0.93%,RB1;HCK;CCND2
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Phosphorylation R-HSA-6804756,0.9927457119666643,1.3294286793621066,0.14965986394557823,0.8732761905450828,1.0,3/88,0.73%,PRKAA2;BRIP1;TAF4
prerank,GO_Biological_Process_2021__positive regulation of defense response (GO:0031349),-0.9965469350466015,-1.3293343530439168,0.05357142857142857,0.914755383437268,1.0,1/88,0.35%,APP
prerank,Reactome_2022__Signaling By FGFR2 R-HSA-5654738,0.9864140831188544,1.3292934988684437,0.38686131386861317,0.873026818952009,1.0,1/65,1.36%,FGF1
prerank,GO_Biological_Process_2021__response to ionizing radiation (GO:0010212),0.9973340547801137,1.3292408881685482,0.05343511450381679,0.8725134308173936,1.0,2/72,0.27%,MSH2;BRSK1
prerank,GO_Biological_Process_2021__sensory perception of light stimulus (GO:0050953),0.9896880336478165,1.3291653970347543,0.168141592920354,0.8720910254334171,1.0,1/75,1.03%,MYO7A
prerank,GO_Biological_Process_2021__positive regulation of cytosolic calcium ion concentration (GO:0007204),0.9984260272255275,1.329024703612276,0.0,0.8718339185175273,1.0,1/133,0.16%,GPR35
prerank,MSigDB_Oncogenic_Signatures__EIF4E UP,0.985070855461729,1.3289889978135971,0.3902439024390244,0.8713010423163852,1.0,2/81,1.49%,SNTB1;MAPK8IP1
prerank,GO_Biological_Process_2021__response to UV (GO:0009411),0.9950948451155539,1.3288907836279202,0.06666666666666667,0.8709147706747963,1.0,3/97,0.50%,MSH2;BRSK1;ATR
prerank,WikiPathway_2021_Human__Vitamin B12 metabolism WP1533,0.9870112479076835,1.3286554097055712,0.37410071942446044,0.8709752688888217,1.0,1/47,1.30%,APOE
prerank,GO_Biological_Process_2021__calcium ion transmembrane transport (GO:0070588),-0.999948511881947,-1.3281752579176418,0.0,0.9162872170631536,1.0,1/83,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__defense response to Gram-negative bacterium (GO:0050829),0.9952946284020383,1.3277339205398968,0.14285714285714285,0.8734502846723653,1.0,1/46,0.47%,DROSHA
prerank,GO_Biological_Process_2021__regulation of mitochondrial membrane potential (GO:0051881),0.9862030741789856,1.3275168116007292,0.5106382978723404,0.873530269813673,1.0,1/41,1.38%,PYCR1
prerank,GO_Biological_Process_2021__mitotic nuclear division (GO:0140014),0.9860459737346684,1.3273691687967324,0.37857142857142856,0.87334433135921,1.0,4/74,1.41%,NDC80;UBE2C;KIF3B;FLNA
prerank,Reactome_2022__Influenza Viral RNA Transcription And Replication R-HSA-168273,0.9951793078123038,1.3269493670959382,0.0364963503649635,0.8740851270903326,1.0,1/135,0.48%,NUP210
prerank,GO_Biological_Process_2021__regulation of macroautophagy (GO:0016241),0.9967883062766527,1.326831600938147,0.0234375,0.873766359300073,1.0,2/108,0.33%,PRKAA2;CLEC16A
prerank,KEGG_2021_Human__Olfactory transduction,0.9883599455734319,1.3268080009025005,0.39097744360902253,0.8731151358950264,1.0,1/46,1.16%,GRK3
prerank,Elsevier_Pathway_Collection__Osteoarthritis,-0.9879290633985367,-1.3267136840111253,0.37142857142857144,0.9184090031279295,1.0,3/79,1.22%,MAP2K6;ADAMTS5;GLI3
prerank,"GO_Biological_Process_2021__mitochondrial electron transport, NADH to ubiquinone (GO:0006120)",0.9942951762053058,1.3266003113289038,0.2047244094488189,0.8730810867905163,1.0,1/39,0.57%,NDUFA10
prerank,WikiPathway_2021_Human__Ferroptosis WP4313,0.9882100019055564,1.3263232850869089,0.4444444444444444,0.8733025741492347,1.0,1/39,1.18%,ACSL5
prerank,"Reactome_2022__Respiratory Electron Transport, ATP Synthesis By Chemiosmotic Coupling, Heat Production By Uncoupling Proteins R-HSA-163200",0.9942608229202914,1.3262015126840314,0.12056737588652482,0.8730746659913599,1.0,1/111,0.57%,NDUFA10
prerank,Reactome_2022__FCERI Mediated NF-kB Activation R-HSA-2871837,-0.9907278225880746,-1.326142004758512,0.26785714285714285,0.9189210170476377,1.0,1/76,0.93%,RASGRP2
prerank,GO_Biological_Process_2021__cellular response to oxidative stress (GO:0034599),0.98586525480668,1.3258044316746815,0.20833333333333334,0.873695303176414,1.0,6/121,1.43%,PRKAA2;ETV5;TXNRD2;AGAP3;PYCR1;MPV17
prerank,Elsevier_Pathway_Collection__CFTR Facilitates Oxidative Stress in Airway Epithelium in CF,0.9890439282230451,1.3257709879635196,0.32142857142857145,0.8731081839803432,1.0,1/57,1.10%,ITGAL
prerank,Reactome_2022__Constitutive Signaling By NOTCH1 HD+PEST Domain Mutants R-HSA-2894862,0.9957194459173412,1.3256822111438848,0.1037037037037037,0.8726999658052204,1.0,2/57,0.43%,HDAC8;TBL1X
prerank,GO_Biological_Process_2021__pattern recognition receptor signaling pathway (GO:0002221),0.9956415108694917,1.3254588098798927,0.07633587786259542,0.8728013059162483,1.0,2/60,0.44%,IRAK2;TRAF3
prerank,Reactome_2022__Dual Incision In TC-NER R-HSA-6782135,0.9920207894337909,1.3253961201579822,0.1746031746031746,0.8722929093927195,1.0,3/64,0.81%,SLC19A1;POLE4;TCEA1
prerank,Reactome_2022__Golgi-to-ER Retrograde Transport R-HSA-8856688,0.986603387172162,1.3251761518411815,0.2714285714285714,0.8723668679255822,1.0,4/110,1.35%,CENPE;RAB3GAP1;KIF23;KIF3B
prerank,GO_Biological_Process_2021__transcription-coupled nucleotide-excision repair (GO:0006283),0.9919256876005517,1.3249735163359502,0.168,0.8723673093979775,1.0,1/73,0.81%,TCEA1
prerank,GO_Biological_Process_2021__chromatin remodeling (GO:0006338),-0.9947718515261816,-1.3246851490859666,0.05172413793103448,0.9207915892060181,1.0,1/100,0.53%,RB1
prerank,GO_Biological_Process_2021__positive regulation of tumor necrosis factor superfamily cytokine production (GO:1903557),-0.990052131461653,-1.323838662211716,0.27102803738317754,0.9216706328896093,1.0,3/74,1.01%,APP;OAS1;CD2
prerank,GO_Biological_Process_2021__regulation of potassium ion transmembrane transporter activity (GO:1901016),0.7584940569554183,1.3238020125403835,0.3968253968253968,0.8754632574994005,1.0,3/24,0.81%,WWP2;DLG1;CAB39
prerank,WikiPathway_2021_Human__Regulatory circuits of the STAT3 signaling pathway WP4538,-0.9882393025610755,-1.3236560352123903,0.296,0.9212463192641832,1.0,4/77,1.19%,DEPTOR;IL21R;IL10RA;IL12RB2
prerank,GO_Biological_Process_2021__negative regulation of catabolic process (GO:0009895),0.9859828067404637,1.32345310129747,0.5106382978723404,0.8759314190618186,1.0,2/44,1.41%,PPARA;FLNA
prerank,KEGG_2021_Human__Choline metabolism in cancer,-0.9928202484007925,-1.3234334957376932,0.20353982300884957,0.9209331156733118,1.0,3/95,0.73%,SLC22A1;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__nucleotide-excision repair (GO:0006289),0.9919617217176557,1.3232596153617873,0.1079136690647482,0.8759656045068295,1.0,2/104,0.81%,BRIP1;TCEA1
prerank,Reactome_2022__Pre-NOTCH Expression And Processing R-HSA-1912422,0.9957090637336816,1.3230749672747628,0.0896551724137931,0.875856459349928,1.0,1/68,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__negative regulation of G2/M transition of mitotic cell cycle (GO:0010972),-0.9920092277493466,-1.3228790582693866,0.2972972972972973,0.9211306889199148,1.0,1/63,0.80%,GPR132
prerank,GO_Biological_Process_2021__positive regulation of interleukin-8 production (GO:0032757),-0.9899678531990834,-1.3227046513516094,0.37719298245614036,0.9207767503407361,1.0,1/57,1.01%,CD2
prerank,GO_Biological_Process_2021__positive regulation of cellular component biogenesis (GO:0044089),0.9866511174928894,1.3226801562455188,0.2727272727272727,0.8764419710650709,1.0,3/88,1.34%,FNIP1;CRB3;HAS3
prerank,KEGG_2021_Human__Epithelial cell signaling in Helicobacter pylori infection,0.9955157226118567,1.322562209342871,0.09090909090909091,0.8760891365795207,1.0,1/67,0.45%,TJP1
prerank,Elsevier_Pathway_Collection__Hepatic Stellate Cells in non-Alcoholic Fatty Liver Disease,0.9848806362522338,1.3221909213292808,0.4888888888888889,0.8766735235345194,1.0,1/53,1.51%,FN1
prerank,GO_Biological_Process_2021__myeloid cell differentiation (GO:0030099),-0.9890069768860742,-1.3220948140576718,0.4077669902912621,0.9211909837870695,1.0,1/52,1.10%,SPI1
prerank,KEGG_2021_Human__Pertussis,-0.9895070558066473,-1.3215507521830454,0.30973451327433627,0.9213465934637367,1.0,2/72,1.06%,TICAM2;C1R
prerank,GO_Biological_Process_2021__fat-soluble vitamin metabolic process (GO:0006775),-0.7205583823066888,-1.3212444672896135,0.3333333333333333,0.9211995345978247,1.0,2/22,1.25%,TTPA;VDR
prerank,Elsevier_Pathway_Collection__Cowden Syndrome,0.9851761228761293,1.3211410522471523,0.5655737704918032,0.8793354154877978,1.0,2/42,1.49%,PTK2;BCAR1
prerank,Reactome_2022__UCH Proteinases R-HSA-5689603,-0.9924616766488334,-1.321137780293712,0.23008849557522124,0.9206784353955709,1.0,1/85,0.76%,MBD5
prerank,GO_Biological_Process_2021__negative regulation of viral process (GO:0048525),-0.9869723445785465,-1.3209606826434395,0.41228070175438597,0.9202302317764052,1.0,3/67,1.31%,OAS1;OASL;PML
prerank,Reactome_2022__SUMOylation Of RNA Binding Proteins R-HSA-4570464,0.9898332826692646,1.3208943262053277,0.328,0.8793454600693712,1.0,2/46,1.02%,NUP210;CBX2
prerank,GO_Biological_Process_2021__embryonic skeletal system morphogenesis (GO:0048704),0.8171176082359749,1.3208505855437813,0.4108527131782946,0.8787790669482738,1.0,2/29,0.15%,HOXD3;MEGF8
prerank,Elsevier_Pathway_Collection__HPV Infection and Cancer,-0.9947863027777291,-1.3207502839116856,0.20952380952380953,0.9197930391442982,1.0,1/55,0.53%,RB1
prerank,GO_Biological_Process_2021__regulation of cell cycle G2/M phase transition (GO:1902749),0.9869662217377559,1.3204803138602266,0.2986111111111111,0.8792624343467064,1.0,4/83,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__excitatory postsynaptic potential (GO:0060079),-0.6467994045786443,-1.3202295596214522,0.2589928057553957,0.9199080458194202,1.0,1/15,0.01%,GRIN2B
prerank,TRRUST_Transcription_Factors_2019__SP3 mouse,0.9987533960831294,1.3201787745850686,0.022222222222222223,0.879390642395342,1.0,1/70,0.13%,ACACA
prerank,GO_Biological_Process_2021__protein sumoylation (GO:0016925),0.9880950306032624,1.3200419232982088,0.36666666666666664,0.8790041341251339,1.0,2/55,1.20%,NUP210;STX1A
prerank,Reactome_2022__Beta-catenin Independent WNT Signaling R-HSA-3858494,0.9888587240956188,1.319693610303493,0.14184397163120568,0.8793561291952525,1.0,2/137,1.11%,AXIN2;GNB5
prerank,Elsevier_Pathway_Collection__Steroids Induced Cataract,-0.9959874547371045,-1.31969358262525,0.0673076923076923,0.9199681041523847,1.0,2/58,0.41%,MAP2K6;NR3C1
prerank,GO_Biological_Process_2021__mitochondrial translation (GO:0032543),0.9921416269106601,1.3192629271808491,0.13138686131386862,0.8799644100406311,1.0,1/104,0.78%,QRSL1
prerank,GO_Biological_Process_2021__regulation of peptidyl-tyrosine phosphorylation (GO:0050730),-0.9876214871893162,-1.3190736637983493,0.32231404958677684,0.9202571969108564,1.0,6/86,1.26%,APP;PTK2B;PAK2;NTF3;SEMA4D;HRG
prerank,WikiPathway_2021_Human__Acute viral myocarditis WP4298,0.9890240979839005,1.319018578934169,0.1875,0.8799618210243899,1.0,1/84,1.10%,ITGAL
prerank,GO_Biological_Process_2021__cellular response to organonitrogen compound (GO:0071417),-0.99201168949078,-1.3188055746252834,0.21238938053097345,0.9199136570756161,1.0,5/98,0.82%,CPEB3;RAP1A;RAP1B;AOC1;KCNE1
prerank,GO_Biological_Process_2021__positive regulation of immune response (GO:0050778),-0.9874105151001176,-1.3185320263305855,0.4090909090909091,0.9195672574309107,1.0,1/68,1.26%,HRG
prerank,GO_Biological_Process_2021__non-canonical Wnt signaling pathway (GO:0035567),0.9983918039540248,1.318267669707891,0.023076923076923078,0.8815340667448089,1.0,1/122,0.16%,CELSR3
prerank,Reactome_2022__Transcriptional Activity Of SMAD2/SMAD3:SMAD4 Heterotrimer R-HSA-2173793,0.9971396965413735,1.3176493911564369,0.08955223880597014,0.8828144208756036,1.0,1/49,0.29%,RBL1
prerank,GO_Biological_Process_2021__glutathione metabolic process (GO:0006749),-0.864687472725653,-1.3168251206647876,0.46825396825396826,0.9213775474900584,1.0,3/39,0.38%,GSTA2;GSTA1;GGT5
prerank,GO_Biological_Process_2021__positive regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043280),0.9846305935458581,1.316816363912294,0.29411764705882354,0.8845295012786522,1.0,5/116,1.55%,SENP1;TNFRSF10A;PRR7;BOK;UACA
prerank,Elsevier_Pathway_Collection__Polycystic Ovary Syndrome,0.9905164795102179,1.3166620281567665,0.3383458646616541,0.8843126184977951,1.0,1/49,0.95%,AMH
prerank,"GO_Biological_Process_2021__positive regulation of gene expression, epigenetic (GO:0045815)",0.9895612903798308,1.316654995356611,0.21705426356589147,0.8836359541817572,1.0,3/53,1.05%,TAF1B;PHF2;PADI2
prerank,GO_Biological_Process_2021__protein modification process (GO:0036211),0.9870871529478228,1.316521216670824,0.36153846153846153,0.883354012905729,1.0,6/76,1.31%,ST3GAL1;WWP2;PHKA2;MANBA;PLOD2;CPE
prerank,Reactome_2022__Selenoamino Acid Metabolism R-HSA-2408522,0.9976725228906078,1.3165191244624888,0.022222222222222223,0.8826641646711293,1.0,2/111,0.24%,SCLY;PAPSS1
prerank,MSigDB_Hallmark_2020__Epithelial Mesenchymal Transition,0.9121673569979014,1.316225312597626,0.11920529801324503,0.8827524647321011,1.0,10/198,1.51%,THY1;ITGA2;SNTB1;PLOD2;MSX1;COL12A1;DPYSL3;ITGB5;FLNA;FN1
prerank,MSigDB_Hallmark_2020__G2-M Checkpoint,0.8870190428325639,1.316217955339931,0.10738255033557047,0.882067179314326,1.0,12/198,1.54%,CENPA;CENPE;NDC80;CDC45;MKI67;RBL1;HIRA;PBK;UBE2C;KIF23;SLC7A1;SLC38A1
prerank,WikiPathway_2021_Human__Exercise-induced Circadian Regulation WP410,0.9879738805158712,1.3157939944494483,0.4016393442622951,0.8826650438843491,1.0,1/46,1.20%,GSTM3
prerank,Reactome_2022__Regulation Of PTEN Gene Transcription R-HSA-8943724,0.9897755843944239,1.3156178733251196,0.24817518248175183,0.8825376293993282,1.0,1/59,1.02%,CBX2
prerank,Reactome_2022__TP53 Regulates Transcription Of DNA Repair Genes R-HSA-6796648,0.9919821751076229,1.3154559467429645,0.15942028985507245,0.8823356465869149,1.0,2/60,0.81%,MSH2;TCEA1
prerank,"GO_Biological_Process_2021__regulation of mRNA splicing, via spliceosome (GO:0048024)",0.9880989699020005,1.315168404600261,0.296875,0.8825045447716072,1.0,1/81,1.19%,PCBP4
prerank,KEGG_2021_Human__Synaptic vesicle cycle,0.9880896123534377,1.3151345698312982,0.2896551724137931,0.8819296484014407,1.0,2/67,1.20%,SLC6A4;STX1A
prerank,Reactome_2022__Transcription-Coupled Nucleotide Excision Repair (TC-NER) R-HSA-6781827,0.9848491498632864,1.3150605029308344,0.41044776119402987,0.8814690370062083,1.0,4/76,1.53%,SLC19A1;POLE4;TCEA1;LRIG1
prerank,Elsevier_Pathway_Collection__Thyroid Hormones Common Genomic Effects in Hyperthyroidism,-0.7966706376318006,-1.3148676338482848,0.424,0.9234099042190713,1.0,3/30,1.25%,NCOA1;SLC16A2;VDR
prerank,GO_Biological_Process_2021__NADH dehydrogenase complex assembly (GO:0010257),0.9942868222931796,1.314799369169613,0.17985611510791366,0.8808657604503118,1.0,1/58,0.57%,NDUFA10
prerank,GO_Biological_Process_2021__mitochondrial respiratory chain complex I assembly (GO:0032981),0.9942868222931796,1.314799369169613,0.17985611510791366,0.8808657604503118,1.0,1/58,0.57%,NDUFA10
prerank,WikiPathway_2021_Human__Metapathway biotransformation Phase I and II WP702,-0.9095792227184565,-1.3144115469888038,0.1792452830188679,0.923316984221377,1.0,13/165,1.27%,GSTA2;CYP39A1;CYP2C8;GLYAT;GSTA1;CYP3A7;CYP4V2;CYP20A1;SULT1B1;KCNAB3;CYP1A2;AKR7A3;CYP1B1
prerank,WikiPathway_2021_Human__Folate Metabolism WP176,0.9949404531286207,1.314404581488311,0.08270676691729323,0.8814548626198557,1.0,1/64,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__negative regulation of protein binding (GO:0032091),-0.9935971354976634,-1.3141512728629998,0.1619047619047619,0.9229383310119551,1.0,2/71,0.65%,CCL23;TTBK2
prerank,"GO_Biological_Process_2021__DNA-templated transcription, elongation (GO:0006354)",0.9919320448163452,1.314090099157391,0.14285714285714285,0.8816861184107089,1.0,1/67,0.81%,TCEA1
prerank,GO_Biological_Process_2021__glycoprotein biosynthetic process (GO:0009101),0.9857343097276179,1.3140418479723357,0.4435483870967742,0.8811383403304719,1.0,3/77,1.43%,FAM20B;DAD1;FUT6
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation in Asthma,-0.9891241034868951,-1.3139694361871053,0.344,0.9224514664129077,1.0,2/73,1.10%,MAP2K6;VAV1
prerank,Reactome_2022__Metal Ion SLC Transporters R-HSA-425410,-0.699447257906738,-1.313942034300535,0.3305084745762712,0.9217547142204193,1.0,1/25,0.10%,SLC41A2
prerank,GO_Biological_Process_2021__regulation of exit from mitosis (GO:0007096),0.9906437624797243,1.3136935659021,0.28368794326241137,0.8815803308585494,1.0,2/38,0.94%,ANLN;UBE2C
prerank,KEGG_2021_Human__Gap junction,0.9868859766485385,1.3135366377108002,0.32116788321167883,0.88139254527248,1.0,2/79,1.31%,TJP1;TUBA1A
prerank,GO_Biological_Process_2021__spliceosomal complex assembly (GO:0000245),0.990210668749889,1.3134919605859934,0.3262411347517731,0.8808255249556635,1.0,1/45,0.98%,SF3A2
prerank,Reactome_2022__PKMTs Methylate Histone Lysines R-HSA-3214841,0.9972186649362885,1.313477398810193,0.07246376811594203,0.8801882839406889,1.0,1/45,0.28%,ASH1L
prerank,Reactome_2022__CDK-mediated Phosphorylation And Removal Of Cdc6 R-HSA-69017,0.9905801592448763,1.3133305360751946,0.23880597014925373,0.8799161709298268,1.0,1/69,0.94%,UBE2C
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Melanoma Cell,0.9974520894439672,1.3133228178325325,0.08661417322834646,0.8792569670032371,1.0,1/39,0.26%,PTK2
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG.BREAST UP.V1 UP,0.9877211047701867,1.3133094681799098,0.2463768115942029,0.8786106131807614,1.0,5/116,1.24%,KCNC1;GFI1;ITGA2;TBX3;A2M
prerank,Reactome_2022__Unfolded Protein Response (UPR) R-HSA-381119,0.9859143928023442,1.3131580330692576,0.36363636363636365,0.878369898476798,1.0,2/89,1.41%,PARN;ACD
prerank,GO_Biological_Process_2021__regulation of interleukin-1 beta production (GO:0032651),-0.9965538679983387,-1.3128441204759596,0.0847457627118644,0.9225835123807148,1.0,1/76,0.35%,APP
prerank,Reactome_2022__Cellular Response To Heat Stress R-HSA-3371556,0.9951952591036146,1.312718815036233,0.06666666666666667,0.8790473905866867,1.0,1/97,0.48%,NUP210
prerank,MSigDB_Hallmark_2020__TGF-beta Signaling,0.9955205864500936,1.3126376535068727,0.14285714285714285,0.8785766935193484,1.0,1/54,0.45%,TJP1
prerank,Reactome_2022__Cell Junction Organization R-HSA-446728,0.9860398477678344,1.3125620726719218,0.352,0.8781361938190186,1.0,4/80,1.41%,CRB3;CDH15;FBLIM1;FLNA
prerank,GO_Biological_Process_2021__protein import into nucleus (GO:0006606),-0.9921213633970217,-1.3125252674874812,0.24347826086956523,0.9222575486970651,1.0,1/72,0.79%,KPNA3
prerank,Elsevier_Pathway_Collection__Tubular Cell Dysfunction in Progressive Diabetic Nephropathy,0.9848893799074128,1.3121380286931728,0.5474452554744526,0.8786945160065163,1.0,1/46,1.51%,FN1
prerank,TRRUST_Transcription_Factors_2019__NR3C1 mouse,0.6703351678709587,1.3121366800001006,0.3106060606060606,0.8780162995456255,1.0,1/16,0.19%,CDK6
prerank,GO_Biological_Process_2021__cellular response to peptide hormone stimulus (GO:0071375),0.985255405718584,1.311928075865421,0.3208955223880597,0.8779564917128871,1.0,3/98,1.48%,RHOQ;PKLR;SLC30A10
prerank,GO_Biological_Process_2021__positive regulation of neuron differentiation (GO:0045666),0.9996492600000496,1.3116709958259438,0.008,0.8780642153497531,1.0,1/33,0.04%,HOXD3
prerank,GO_Biological_Process_2021__canonical Wnt signaling pathway (GO:0060070),0.9959789805860904,1.311563223459392,0.109375,0.8777344197411402,1.0,1/66,0.40%,LRP5
prerank,Reactome_2022__p53-Dependent G1 DNA Damage Response R-HSA-69563,0.9881138627026919,1.3115517119911424,0.3533834586466165,0.8770854385934055,1.0,1/62,1.19%,PCBP4
prerank,Elsevier_Pathway_Collection__Peripheral Tissue Microangiopathy,0.984888023204901,1.311505486887321,0.5798319327731093,0.8765546885040381,1.0,1/46,1.51%,FN1
prerank,Reactome_2022__Viral Messenger RNA Synthesis R-HSA-168325,0.9952173202066171,1.3109282764732189,0.112,0.8777671899326063,1.0,1/47,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__Proteins Involved in Psoriatic Arthritis,0.9864296706039302,1.3108080922596959,0.4318181818181818,0.8774708286369317,1.0,1/48,1.36%,FGF1
prerank,WikiPathway_2021_Human__Wnt/beta-catenin signaling pathway in leukemia WP3658,0.8097999539004546,1.3104007127846962,0.45384615384615384,0.8779760850930899,1.0,2/25,0.40%,AXIN2;LRP5
prerank,WikiPathway_2021_Human__Genotoxicity pathway WP4286,0.9993770967722071,1.310208132510328,0.022058823529411766,0.877916676549893,1.0,1/52,0.07%,CENPE
prerank,GO_Biological_Process_2021__positive regulation of leukocyte activation (GO:0002696),0.6701930159343877,1.310066470899848,0.296,0.8776033674915465,1.0,1/18,0.06%,HAVCR1
prerank,GO_Biological_Process_2021__pyrimidine-containing compound catabolic process (GO:0072529),-0.6749350661015958,-1.3098620341774996,0.2892561983471074,0.9247320247399619,1.0,1/15,0.12%,DPYS
prerank,GO_Biological_Process_2021__regulation of protein ubiquitination (GO:0031396),0.9877191017623521,1.309858877351806,0.24475524475524477,0.8775822604038701,1.0,3/107,1.23%,HDAC8;PRR7;SH3RF2
prerank,GO_Biological_Process_2021__amino acid import (GO:0043090),-0.697797613695835,-1.3098558256062165,0.34782608695652173,0.9240018078673051,1.0,2/21,1.02%,SLC7A8;SLC16A2
prerank,Reactome_2022__MECP2 Regulates Neuronal Receptors And Channels R-HSA-9022699,-0.6518155971532191,-1.309628739246483,0.27906976744186046,0.9235198137437266,1.0,1/15,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__cellular response to chemical stress (GO:0062197),0.9863010963976241,1.3091458261316047,0.27702702702702703,0.8790332419107317,1.0,4/99,1.38%,PRKAA2;ETV5;TXNRD2;PYCR1
prerank,Reactome_2022__Regulation Of HSF1-mediated Heat Shock Response R-HSA-3371453,0.9952024664785326,1.3089248025565485,0.06923076923076923,0.8789906807705269,1.0,1/79,0.48%,NUP210
prerank,GO_Biological_Process_2021__calcium-mediated signaling (GO:0019722),0.9900362924823009,1.308654081899972,0.16783216783216784,0.8791199039311338,1.0,2/96,1.00%,PPP1R9A;MCTP1
prerank,Reactome_2022__Nucleotide Excision Repair R-HSA-5696398,0.9848299513126417,1.308634167306547,0.35074626865671643,0.8784985975420911,1.0,4/106,1.53%,SLC19A1;POLE4;TCEA1;LRIG1
prerank,GO_Biological_Process_2021__translesion synthesis (GO:0019985),-0.9903257032092017,-1.308535176053127,0.4,0.9240632154780429,1.0,1/42,0.97%,USP43
prerank,Elsevier_Pathway_Collection__Myoblast -> Neutrophil Surface Expression Markers,-0.9898161257013427,-1.3083995028767512,0.3652173913043478,0.9234805752464114,1.0,1/57,1.02%,CD274
prerank,Reactome_2022__HCMV Late Events R-HSA-9610379,0.9952051235156979,1.3083066280848226,0.09558823529411764,0.8788110797905342,1.0,1/77,0.48%,NUP210
prerank,Reactome_2022__ECM Proteoglycans R-HSA-3000178,0.9866350177812304,1.3079526076905603,0.416,0.879155025796845,1.0,3/52,1.34%,ITGA2;ITGB5;COL9A3
prerank,GO_Biological_Process_2021__negative regulation of protein modification by small protein conjugation or removal (GO:1903321),0.9877518511410269,1.3076986459915854,0.3591549295774648,0.8791879756197163,1.0,3/51,1.23%,HDAC8;PRR7;SH3RF2
prerank,Elsevier_Pathway_Collection__Dendritic Spine Morphogenesis and Stabilization,0.9917171814698865,1.3073340288802044,0.28225806451612906,0.8795137119418518,1.0,1/40,0.83%,ARHGEF7
prerank,GO_Biological_Process_2021__actin polymerization or depolymerization (GO:0008154),0.9859838885275449,1.3067001493735666,0.48905109489051096,0.8805922129252401,1.0,4/49,1.41%,SVIL;ABI2;SPIRE2;MICAL3
prerank,Reactome_2022__Signaling By B Cell Receptor (BCR) R-HSA-983705,-0.9890427585694411,-1.3063990910794243,0.24074074074074073,0.9249921114798908,1.0,1/107,1.10%,VAV1
prerank,Reactome_2022__Regulation Of APC/C Activators Between G1/S And Early Anaphase R-HSA-176408,0.9905741716671966,1.3047178514156594,0.2014388489208633,0.8853746065579934,1.0,1/77,0.94%,UBE2C
prerank,Reactome_2022__Complex I Biogenesis R-HSA-6799198,0.9942900542217704,1.3046479579844208,0.20610687022900764,0.8849167342277617,1.0,1/51,0.57%,NDUFA10
prerank,GO_Biological_Process_2021__peptidyl-threonine phosphorylation (GO:0018107),-0.9957119860366052,-1.3041365558518416,0.11666666666666667,0.926558586667666,1.0,1/60,0.43%,WNK3
prerank,KEGG_2021_Human__Basal transcription factors,0.9927215060136108,1.3037861131406658,0.20454545454545456,0.8866448089853776,1.0,2/41,0.73%,GTF2I;TAF4
prerank,GO_Biological_Process_2021__sulfur amino acid metabolic process (GO:0000096),-0.7377249198786415,-1.3036010258183555,0.36538461538461536,0.9264438953360574,1.0,2/24,1.17%,BHMT;CDO1
prerank,KEGG_2021_Human__Ferroptosis,0.9882094284565138,1.3035601413828015,0.44680851063829785,0.8866661316811254,1.0,1/40,1.18%,ACSL5
prerank,GO_Biological_Process_2021__mitotic spindle assembly (GO:0090307),0.9860243381595402,1.3031406657067368,0.5255474452554745,0.88718672513483,1.0,3/43,1.41%,KIF23;KIF3B;FLNA
prerank,GO_Biological_Process_2021__regulation of fat cell differentiation (GO:0045598),0.9959733511305314,1.3026410639217323,0.08163265306122448,0.8879141719912815,1.0,1/77,0.40%,LRP5
prerank,KEGG_2021_Human__Toxoplasmosis,-0.9866410999434889,-1.3026316582258133,0.33035714285714285,0.9267335634107691,1.0,4/109,1.35%,MAP2K6;AKT3;IL10RA;PIK3R6
prerank,Reactome_2022__HIV Transcription Initiation R-HSA-167161,0.9926748065969302,1.302599893204678,0.20930232558139536,0.8873783020884393,1.0,1/45,0.73%,TAF4
prerank,Reactome_2022__Regulation Of mRNA Stability By Proteins That Bind AU-rich Elements R-HSA-450531,0.9912259256444322,1.3024171687338602,0.1347517730496454,0.8871974332167412,1.0,1/86,0.88%,PARN
prerank,GO_Biological_Process_2021__regulation of cation transmembrane transport (GO:1904062),-0.7409570487996989,-1.3019947794528273,0.4049586776859504,0.9266794936469182,1.0,4/27,0.85%,KCNN2;WNK3;KCNE1;KCNAB3
prerank,GO_Biological_Process_2021__regulation of establishment of planar polarity (GO:0090175),0.9890017433226685,1.3019075413088876,0.2695035460992908,0.8879232174131084,1.0,2/86,1.10%,CELSR3;SAPCD2
prerank,GO_Biological_Process_2021__carbohydrate derivative catabolic process (GO:1901136),-0.6793509040989393,-1.3016593951862474,0.32432432432432434,0.9262253384231706,1.0,2/18,0.40%,DERA;FBXO27
prerank,GO_Biological_Process_2021__negative regulation of cell cycle process (GO:0010948),0.9882306427936426,1.301209592846199,0.3237410071942446,0.8890504317879775,1.0,1/61,1.18%,RRM2
prerank,GO_Biological_Process_2021__odontogenesis (GO:0042476),0.8788266774818502,1.3005542069248452,0.4961832061068702,0.8901587013350697,1.0,5/34,1.13%,AXIN2;BCOR;ANKRD11;MSX1;TUFT1
prerank,GO_Biological_Process_2021__transcription elongation from RNA polymerase II promoter (GO:0006368),0.9919329678969556,1.299924745522993,0.15827338129496402,0.8911648140061423,1.0,1/65,0.81%,TCEA1
prerank,GO_Biological_Process_2021__response to peptide hormone (GO:0043434),0.9954081204755318,1.2993190248873123,0.15267175572519084,0.8921091631579825,1.0,1/46,0.46%,SORT1
prerank,GO_Biological_Process_2021__innate immune response (GO:0045087),-0.8141979839671898,-1.2983697149715203,0.06930693069306931,0.9283155109941783,1.0,9/248,1.31%,VNN1;APP;OAS1;TRIM58;PTK2B;HCK;PGLYRP2;ZAP70;PML
prerank,Reactome_2022__RNA Polymerase I Transcription R-HSA-73864,0.9861200775848933,1.2980094455106879,0.3858267716535433,0.8951016524485178,1.0,2/69,1.39%,TAF1B;CAVIN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Female Infertility,0.9904745003363795,1.2975044333863666,0.2786885245901639,0.8957150675453597,1.0,1/54,0.95%,MSX1
prerank,Elsevier_Pathway_Collection__Basophil Activation,-0.9891228092462382,-1.2972997378110604,0.40186915887850466,0.9283140336106964,1.0,2/75,1.10%,MAP2K6;VAV1
prerank,WikiPathway_2021_Human__Thyroid stimulating hormone (TSH) signaling pathway WP2032,-0.9949115537466857,-1.297166303525838,0.175,0.9276818590333018,1.0,4/65,0.53%,MAP2K6;RAP1A;RAP1B;RB1
prerank,Reactome_2022__RNA Polymerase I Promoter Clearance R-HSA-73854,0.9941281540331187,1.2969900594798212,0.136,0.8964334589496861,1.0,1/68,0.59%,TAF1B
prerank,Reactome_2022__Formation Of RNA Pol II Elongation Complex R-HSA-112382,0.9919380440916887,1.2967352689431515,0.19402985074626866,0.8964128756752032,1.0,1/55,0.81%,TCEA1
prerank,GO_Biological_Process_2021__receptor clustering (GO:0043113),0.828120412694834,1.2957029192747946,0.46825396825396826,0.8984785850440514,1.0,4/28,1.41%,THY1;DLG1;ITGAL;FLNA
prerank,WikiPathway_2021_Human__Mitochondrial complex I assembly model OXPHOS system WP4324,0.994290527917618,1.2954916034480362,0.21212121212121213,0.898433647961289,1.0,1/50,0.57%,NDUFA10
prerank,Reactome_2022__Senescence-Associated Secretory Phenotype (SASP) R-HSA-2559582,0.9906306241806743,1.2954239254585895,0.22764227642276422,0.8979179352647816,1.0,2/69,0.94%,CDK6;UBE2C
prerank,KEGG_2021_Human__Chemical carcinogenesis,-0.8780482182111266,-1.2953911059687382,0.13043478260869565,0.9283848326499458,1.0,13/203,1.27%,GSTA2;CYP2C8;GSTA1;CYP3A7;AKT3;RB1;PIK3CB;KPNA3;CYP1A2;KLF4;CREB5;VDR;CYP1B1
prerank,WikiPathway_2021_Human__TGF-beta Receptor Signaling WP560,0.9852671443753054,1.295266716698621,0.48,0.8977023998623419,1.0,1/54,1.47%,ZFYVE9
prerank,Reactome_2022__G1/S DNA Damage Checkpoints R-HSA-69615,0.9881126151444931,1.2949345928503544,0.34328358208955223,0.8979459270615711,1.0,1/64,1.19%,PCBP4
prerank,GO_Biological_Process_2021__positive regulation of nucleocytoplasmic transport (GO:0046824),0.9859277769581299,1.2946773279027979,0.5263157894736842,0.8978531224780887,1.0,1/46,1.41%,FLNA
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen (GO:0002478),0.9865687928958908,1.294462401487024,0.3511450381679389,0.8977490768776183,1.0,3/99,1.35%,CENPE;KIF23;KIF3B
prerank,Reactome_2022__G Alpha (Q) Signaling Events R-HSA-416476,-0.8765732351893051,-1.2943735861779253,0.10619469026548672,0.9284201480852007,1.0,6/174,1.05%,CCL23;APP;GPR39;GPR132;RASGRP2;GNA14
prerank,GO_Biological_Process_2021__kidney development (GO:0001822),0.9874541588227576,1.2941999221270684,0.3472222222222222,0.8977788038012616,1.0,1/66,1.25%,CTSH
prerank,Elsevier_Pathway_Collection__Positive Acute Phase Proteins Synthesis,0.9849748597327148,1.2941004934798037,0.48360655737704916,0.8973028274664931,1.0,3/57,1.51%,PPARA;A2M;FN1
prerank,Elsevier_Pathway_Collection__CD4+T-Cell Response in Celiac Disease,-0.9881485351875999,-1.2940737341101085,0.3565217391304348,0.9279701183840017,1.0,2/86,1.19%,ZAP70;IL12RB2
prerank,WikiPathway_2021_Human__Neural Crest Differentiation WP2064,0.9905916776438524,1.2935788625984594,0.21323529411764705,0.8980595393180503,1.0,4/79,0.95%,AXIN2;HDAC8;NOTCH3;MSX1
prerank,Elsevier_Pathway_Collection__Catecholamines Secretion from Adrenal Gland,0.9865947772491089,1.2931100205221957,0.4580152671755725,0.8985626686035395,1.0,3/53,1.35%,RHOQ;STX1A;KIF3B
prerank,GO_Biological_Process_2021__regulation of Rho protein signal transduction (GO:0035023),0.9870861339564195,1.2930988158962722,0.38926174496644295,0.897919942797691,1.0,3/70,1.30%,GPR35;ARHGEF18;APOE
prerank,KEGG_2021_Human__Ribosome biogenesis in eukaryotes,0.9953283895154916,1.2929883891867266,0.1223021582733813,0.897538747846827,1.0,2/76,0.47%,REXO5;DROSHA
prerank,GO_Biological_Process_2021__second-messenger-mediated signaling (GO:0019932),0.987118883981363,1.2926989274237095,0.34306569343065696,0.8975883099216184,1.0,4/84,1.30%,PPP1R9A;GPR62;MCTP1;APOE
prerank,Reactome_2022__tRNA Processing In Nucleus R-HSA-6784531,0.9952140237023674,1.2921394177917676,0.1721311475409836,0.8982826000501389,1.0,1/56,0.48%,NUP210
prerank,GO_Biological_Process_2021__chromatin assembly (GO:0031497),0.9934019941754314,1.292111748248493,0.184,0.8976872126471892,1.0,1/56,0.66%,NAA60
prerank,GO_Biological_Process_2021__cytoskeleton-dependent cytokinesis (GO:0061640),0.9862052461829104,1.291779499087351,0.4014084507042254,0.8977789116794465,1.0,6/68,1.40%,CENPA;ANLN;KIF23;SPIRE2;SEPTIN6;SEPTIN9
prerank,MSigDB_Hallmark_2020__Hedgehog Signaling,0.8276538612424286,1.2917669332677093,0.47540983606557374,0.8971452793120173,1.0,2/35,0.19%,THY1;CDK6
prerank,GO_Biological_Process_2021__cellular response to UV (GO:0034644),0.9950107254840688,1.291670837762816,0.15384615384615385,0.8966620311808207,1.0,1/76,0.50%,ATR
prerank,KEGG_2021_Human__Osteoclast differentiation,-0.9013724262016,-1.2916115485432476,0.2523364485981308,0.9291159725051825,1.0,5/123,1.10%,FOSB;MAP2K6;AKT3;PIK3CB;SPI1
prerank,GO_Biological_Process_2021__epithelial to mesenchymal transition (GO:0001837),0.9910968209386135,1.2911940329706988,0.3380281690140845,0.8971290253268004,1.0,1/46,0.89%,TBX3
prerank,GO_Biological_Process_2021__mRNA stabilization (GO:0048255),0.8738487214697545,1.2908508892671773,0.4772727272727273,0.897299700080122,1.0,2/36,0.12%,IGF2BP1;AXIN2
prerank,Reactome_2022__SUMOylation Of Chromatin Organization Proteins R-HSA-4551638,0.9898281493253522,1.2907739032421661,0.36220472440944884,0.8968005317375704,1.0,2/56,1.02%,NUP210;CBX2
prerank,GO_Biological_Process_2021__regulation of translational initiation (GO:0006446),0.993628754683378,1.2902014855010524,0.11811023622047244,0.8974941024132115,1.0,1/61,0.64%,YTHDF3
prerank,Reactome_2022__Respiratory Electron Transport R-HSA-611105,0.994270710090174,1.2894781381773943,0.12949640287769784,0.89853499193367,1.0,1/90,0.57%,NDUFA10
prerank,GO_Biological_Process_2021__regulation of G0 to G1 transition (GO:0070316),0.9882493668389077,1.2893027620150252,0.42028985507246375,0.8982521689205433,1.0,1/40,1.18%,RRM2
prerank,GO_Biological_Process_2021__negative regulation of phosphorylation (GO:0042326),0.9921168391925739,1.289124103138928,0.1259259259259259,0.8980286707829737,1.0,1/83,0.79%,PPARA
prerank,GO_Biological_Process_2021__transforming growth factor beta receptor signaling pathway (GO:0007179),0.9853815790071224,1.2888033845772218,0.38028169014084506,0.8981362584712762,1.0,4/87,1.47%,PTK2;ARHGEF18;ITGB5;ZFYVE9
prerank,MSigDB_Oncogenic_Signatures__CAHOY NEURONAL,0.9880266804822573,1.288536697847946,0.3115942028985507,0.8980756306150681,1.0,1/76,1.20%,STX1A
prerank,GO_Biological_Process_2021__negative regulation of protein modification process (GO:0031400),0.9847329515189578,1.288032053932953,0.4326241134751773,0.8986084547681892,1.0,3/78,1.53%,PRKAA2;PPP1R16B;SNTA1
prerank,GO_Biological_Process_2021__visual perception (GO:0007601),0.9896885639167674,1.2872128489048313,0.23423423423423423,0.8997865584852889,1.0,1/74,1.03%,MYO7A
prerank,Reactome_2022__Recruitment And ATM-mediated Phosphorylation Of Repair And Signal Proteins At DNA Double Strand Breaks R-HSA-5693565,0.9947122323974389,1.28709760100266,0.12,0.8993531464978142,1.0,1/54,0.53%,HERC2
prerank,Reactome_2022__DNA Double Strand Break Response R-HSA-5693606,0.9947116163573854,1.2869626169158537,0.12,0.8989846044864188,1.0,1/55,0.53%,HERC2
prerank,KEGG_2021_Human__Hypertrophic cardiomyopathy,0.9867354846779034,1.2864319913295201,0.3825503355704698,0.8993533355549777,1.0,3/81,1.33%,PRKAA2;ITGA2;ITGB5
prerank,Reactome_2022__G2/M DNA Damage Checkpoint R-HSA-69473,0.9947522194181607,1.286298176748969,0.12030075187969924,0.8989713919915465,1.0,2/71,0.53%,BRIP1;HERC2
prerank,"GO_Biological_Process_2021__DNA-templated transcription, termination (GO:0006353)",0.9861621100833013,1.2861686549321425,0.4852941176470588,0.8985147724279547,1.0,3/70,1.39%,ZNF473;TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__regulation of posttranscriptional gene silencing (GO:0060147),0.99521385541382,1.286132395769909,0.12195121951219512,0.8972724286262611,1.0,1/55,0.48%,NUP210
prerank,GO_Biological_Process_2021__regulation of gene silencing by RNA (GO:0060966),0.99521385541382,1.286132395769909,0.12195121951219512,0.8972724286262611,1.0,1/55,0.48%,NUP210
prerank,Reactome_2022__Autodegradation Of Cdh1 By Cdh1:APC/C R-HSA-174084,0.990583682950949,1.2859174250818735,0.2426470588235294,0.8970516130659407,1.0,1/63,0.94%,UBE2C
prerank,Reactome_2022__RHOB GTPase Cycle R-HSA-9013026,0.986243946685621,1.285706579116808,0.40559440559440557,0.8968422343701513,1.0,5/67,1.39%,DEPDC1B;ARHGAP39;ANLN;IQGAP3;CAVIN1
prerank,WikiPathway_2021_Human__Aryl Hydrocarbon Receptor Pathway WP2873,-0.8636478061827532,-1.2854775952361635,0.5,0.9319040517619281,1.0,4/43,1.27%,GSTA2;NCOA1;CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__gland development (GO:0048732),0.991175258990468,1.285410980552633,0.1984732824427481,0.8967941907745173,1.0,3/64,0.89%,HOXD3;PHF2;TBX3
prerank,MSigDB_Hallmark_2020__mTORC1 Signaling,0.8773092892687867,1.2851711040687281,0.1564625850340136,0.8966518902473369,1.0,6/200,1.51%,ACACA;PLOD2;TCEA1;RRM2;FDXR;HPRT1
prerank,GO_Biological_Process_2021__mitotic spindle organization (GO:0007052),0.9198454020886618,1.2847592496697415,0.2013888888888889,0.8968951475898516,1.0,7/154,1.41%,CENPA;CENPE;NDC80;KIF23;ERCC6L;KIF3B;FLNA
prerank,GO_Biological_Process_2021__Wnt signaling pathway (GO:0016055),0.9869165132818329,1.2842415404889893,0.37681159420289856,0.8975369699069352,1.0,2/90,1.31%,LRP5;CPE
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Response against Melanocytes in Vitiligo,-0.9881484471416557,-1.284166733341946,0.35135135135135137,0.9318964113297635,1.0,2/86,1.19%,ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__regulation of cellular response to heat (GO:1900034),0.9950582214885473,1.2836569995408613,0.09090909090909091,0.8980532843391098,1.0,2/79,0.50%,NUP210;ATR
prerank,Elsevier_Pathway_Collection__Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma,-0.9933250821614736,-1.2835455950266823,0.2288135593220339,0.9315718378054239,1.0,1/58,0.67%,PTK2B
prerank,GO_Biological_Process_2021__regulation of epithelial cell proliferation (GO:0050678),0.9864973901445978,1.2834982277084939,0.3617021276595745,0.8976615193639639,1.0,3/89,1.36%,CDK6;ZNF304;FGF1
prerank,GO_Biological_Process_2021__cellular protein metabolic process (GO:0044267),0.8122318320300126,1.2834940031349562,0.06918238993710692,0.897016016323183,1.0,13/401,1.51%,ST3GAL1;WWP2;PHKA2;MANBA;PLOD2;CKAP4;IGF2BP3;MELTF;FDXR;CTSH;APOE;CPE;FN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to IGF1R/Akt Signaling Pathway,0.9974451514884103,1.282928044464689,0.11811023622047244,0.8974708138836163,1.0,1/54,0.26%,PTK2
prerank,GO_Biological_Process_2021__positive regulation of cell adhesion (GO:0045785),0.9891065644959818,1.282738348225819,0.29931972789115646,0.8971907354711401,1.0,1/77,1.09%,CHRD
prerank,GO_Biological_Process_2021__regulation of BMP signaling pathway (GO:0030510),0.9891152240372029,1.2821397983422376,0.2846153846153846,0.8978019623402905,1.0,1/67,1.09%,CHRD
prerank,GO_Biological_Process_2021__positive regulation of mitochondrion organization (GO:0010822),0.9849725632488597,1.2804976621762154,0.5454545454545454,0.9007054562527932,1.0,2/56,1.51%,ADCK1;BOK
prerank,Reactome_2022__Cdc20:Phospho-APC/C Mediated Degradation Of Cyclin A R-HSA-174184,0.9905794783854948,1.2801833840823742,0.23529411764705882,0.9007183391674539,1.0,1/69,0.94%,UBE2C
prerank,GO_Biological_Process_2021__regulation of hematopoietic progenitor cell differentiation (GO:1901532),-0.9889916667852104,-1.2797714995815272,0.3937007874015748,0.9329445963520613,1.0,1/72,1.10%,SPI1
prerank,GO_Biological_Process_2021__chromosome organization (GO:0051276),0.9896183336705167,1.2797198973640111,0.14728682170542637,0.9010064232277969,1.0,5/102,1.05%,NDC80;AXIN2;MSH2;HDAC8;PADI2
prerank,Elsevier_Pathway_Collection__APP and Glutamate Signaling Cause Neuronal Dysfunction in Alzheimer Disease,-0.761880470331447,-1.2793638875025524,0.4251968503937008,0.9324431650571464,1.0,2/26,0.80%,APP;DAB1
prerank,WikiPathway_2021_Human__Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.984928705533552,1.2789694043957478,0.5413533834586466,0.9018386301580061,1.0,2/64,1.51%,PTK2;FN1
prerank,Reactome_2022__Transcriptional Regulation By TP53 R-HSA-3700989,0.8250336533008715,1.2786860627222776,0.07051282051282051,0.9017764628033005,1.0,13/349,1.29%,PRKAA2;ARID3A;MSH2;ING5;RBL1;BRIP1;TNFRSF10A;PRELID3A;TAF4;TCEA1;TNFRSF10D;PCBP4;PPP1R13L
prerank,WikiPathway_2021_Human__Complement and Coagulation Cascades WP558,-0.9895178606478772,-1.278169565350411,0.4180327868852459,0.9322753617892333,1.0,2/58,1.06%,PROS1;C1R
prerank,GO_Biological_Process_2021__regulation of mRNA stability (GO:0043488),0.9186678378383808,1.278097316066715,0.19727891156462585,0.9022718688715555,1.0,6/142,1.19%,IGF2BP1;AXIN2;YTHDF3;PARN;IGF2BP3;PCBP4
prerank,GO_Biological_Process_2021__skeletal system morphogenesis (GO:0048705),0.8812870284292889,1.2779485376515476,0.5149253731343284,0.9018884022872744,1.0,4/38,0.57%,HOXD3;MEGF8;LRP5;ANKRD11
prerank,GO_Biological_Process_2021__negative regulation of apoptotic signaling pathway (GO:2001234),-0.9939020938113253,-1.2778642060974474,0.17094017094017094,0.9316821233845926,1.0,2/76,0.62%,RB1;BIRC6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Low-Grade Serous Ovarian Carcinoma,0.9957156629084941,1.2774922481820663,0.12781954887218044,0.9020758789661995,1.0,1/47,0.43%,NOTCH3
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Securin R-HSA-174154,0.9905823910635432,1.277453899478265,0.2446043165467626,0.9014985480783869,1.0,1/65,0.94%,UBE2C
prerank,WikiPathway_2021_Human__Electron Transport Chain (OXPHOS system in mitochondria) WP111,0.9942712951094743,1.2769965265878263,0.12408759124087591,0.9017736610541972,1.0,1/89,0.57%,NDUFA10
prerank,Reactome_2022__Positive Epigenetic Regulation Of rRNA Expression R-HSA-5250913,0.9941298812711923,1.2768366024558475,0.1111111111111111,0.9014080775001237,1.0,1/63,0.59%,TAF1B
prerank,GO_Biological_Process_2021__regulation of potassium ion transport (GO:0043266),-0.8077751962833373,-1.276356545344191,0.48717948717948717,0.9317112480667569,1.0,4/27,0.85%,KCNN2;PTK2B;KCNE1;KCNAB3
prerank,Reactome_2022__APC:Cdc20 Mediated Degradation Of Cell Cycle Proteins Before Cycle Checkpoint Satisfied R-HSA-179419,0.9905787939570656,1.2745151914403086,0.21804511278195488,0.9051418153232337,1.0,1/70,0.94%,UBE2C
prerank,WikiPathway_2021_Human__Circadian rhythm related genes WP3594,0.8923022636273743,1.2739532211394555,0.12213740458015267,0.905523006522311,1.0,4/177,1.31%,SLC6A4;PRKAA2;PPARA;DRD4
prerank,GO_Biological_Process_2021__negative regulation of cell cycle G2/M phase transition (GO:1902750),-0.992013650397083,-1.2737248020896441,0.34285714285714286,0.9321288316433629,1.0,1/55,0.80%,GPR132
prerank,GO_Biological_Process_2021__positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090100),-0.997321188191855,-1.273571841567842,0.04424778761061947,0.931450837373491,1.0,1/84,0.27%,SLC2A10
prerank,WikiPathway_2021_Human__Apoptosis WP254,0.9849967100499586,1.273327155348656,0.43703703703703706,0.9060237876506839,1.0,3/83,1.51%,TRAF3;TNFRSF25;BOK
prerank,GO_Biological_Process_2021__muscle contraction (GO:0006936),0.9848270406272844,1.271475941855954,0.35714285714285715,0.9083437284984898,1.0,6/114,1.53%,GJC1;SNTB1;TNNC2;MYOF;ITGB5;SNTA1
prerank,Reactome_2022__Signaling By EGFR R-HSA-177929,0.9847863452302454,1.2713029108091671,0.59375,0.9079447467793993,1.0,2/48,1.53%,ARHGEF7;LRIG1
prerank,GO_Biological_Process_2021__monosaccharide transmembrane transport (GO:0015749),-0.663614107051961,-1.2711951814476656,0.30158730158730157,0.9316889417410738,1.0,1/16,0.27%,SLC2A10
prerank,GO_Biological_Process_2021__antigen processing and presentation of peptide antigen via MHC class II (GO:0002495),0.9865706182649471,1.2711665264784284,0.4,0.9074863980620163,1.0,3/96,1.35%,CENPE;KIF23;KIF3B
prerank,Elsevier_Pathway_Collection__ERBB/VEGFR/Akt Signaling in Breast Cancer,0.9903964982829818,1.2708942250407445,0.328125,0.9072682942984879,1.0,1/54,0.96%,ERBB3
prerank,GO_Biological_Process_2021__mRNA metabolic process (GO:0016071),0.9902760942132226,1.2707292748887409,0.23404255319148937,0.9068464558383522,1.0,3/90,0.98%,ZNF473;DIS3L2;SF3A2
prerank,Reactome_2022__COPI-mediated Anterograde Transport R-HSA-6807878,0.9918867087670536,1.270659486673354,0.16393442622950818,0.9063083183626424,1.0,1/79,0.81%,COG5
prerank,Reactome_2022__COPI-dependent Golgi-to-ER Retrograde Traffic R-HSA-6811434,0.986583059130157,1.2706271564628402,0.41007194244604317,0.9056948826722927,1.0,3/76,1.35%,CENPE;KIF23;KIF3B
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to ERBB2/VEGFR/Akt Signaling Pathway,0.9904338396434733,1.2703992696058837,0.22535211267605634,0.9054135293919329,1.0,2/72,0.96%,PTK2;ERBB3
prerank,KEGG_2021_Human__Thermogenesis,0.8473272388223418,1.2697744359955372,0.1037037037037037,0.9057483959810206,1.0,4/211,1.27%,PRKAA2;NDUFA10;ACSL5;KLB
prerank,WikiPathway_2021_Human__DNA IR-damage and cellular response via ATR WP4016,0.9202247199289051,1.269376500295235,0.42142857142857143,0.9056137958377632,1.0,6/79,0.68%,CDC45;MSH2;BRIP1;ATR;HERC2;CEP164
prerank,Reactome_2022__Epigenetic Regulation Of Gene Expression R-HSA-212165,0.9941096601988727,1.2690105424127414,0.08064516129032258,0.9055308584696482,1.0,1/105,0.59%,TAF1B
prerank,Reactome_2022__RORA Activates Gene Expression R-HSA-1368082,0.6528854327462552,1.2684734042768002,0.3142857142857143,0.905751228803351,1.0,2/18,0.79%,TBL1X;PPARA
prerank,KEGG_2021_Human__Arrhythmogenic right ventricular cardiomyopathy,0.9866977323783122,1.2683080817299095,0.41007194244604317,0.9053355821141587,1.0,2/71,1.33%,ITGA2;ITGB5
prerank,GO_Biological_Process_2021__double-strand break repair (GO:0006302),0.8808760964278372,1.2682827518331385,0.16541353383458646,0.9047177881201832,1.0,4/161,0.76%,MMS22L;BRIP1;HERC2;DCLRE1C
prerank,Reactome_2022__Paracetamol ADME R-HSA-9753281,-0.6767471010045788,-1.267906753340026,0.34210526315789475,0.9323208906187133,1.0,1/25,0.38%,GGT5
prerank,GO_Biological_Process_2021__protein targeting to ER (GO:0045047),0.9967746402987707,1.267077276977441,0.04964539007092199,0.9059998649108604,1.0,1/103,0.32%,GET3
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Pancreatic Neoplasms,0.9903867676427903,1.2662135530648904,0.2734375,0.906624176731627,1.0,1/69,0.96%,ERBB3
prerank,WikiPathway_2021_Human__Selenium Micronutrient Network WP15,0.9893363142778075,1.26602960426125,0.21804511278195488,0.9062468552586607,1.0,1/84,1.06%,TXNRD2
prerank,GO_Biological_Process_2021__regulation of gene silencing by miRNA (GO:0060964),0.9952091878727057,1.2650731113496307,0.096,0.9071073099446612,1.0,1/66,0.48%,NUP210
prerank,TRRUST_Transcription_Factors_2019__BRCA1 human,-0.9873450214684913,-1.2648001421460653,0.56,0.9325678720510937,1.0,1/56,1.27%,CYP1B1
prerank,GO_Biological_Process_2021__positive regulation of proteolysis (GO:0045862),0.9870948473766981,1.2646337886451369,0.5,0.9070695746841482,1.0,3/54,1.30%,PACSIN3;CTSH;APOE
prerank,GO_Biological_Process_2021__aerobic electron transport chain (GO:0019646),0.9942799671696246,1.2634786901311874,0.14074074074074075,0.9079066918662794,1.0,1/70,0.57%,NDUFA10
prerank,WikiPathway_2021_Human__Lung fibrosis WP3624,0.9864726996086524,1.2623128198389488,0.4552238805970149,0.9089282174014838,1.0,2/60,1.36%,PARN;FGF1
prerank,KEGG_2021_Human__JAK-STAT signaling pathway,-0.8822224566669353,-1.2619871071652526,0.20175438596491227,0.9325730145738048,1.0,6/129,1.19%,AKT3;PIK3CB;CCND2;IL21R;IL10RA;IL12RB2
prerank,TRRUST_Transcription_Factors_2019__SMAD3 mouse,0.9848977430293303,1.26186855506478,0.553030303030303,0.9089322787426993,1.0,1/41,1.51%,FN1
prerank,GO_Biological_Process_2021__regulation of developmental growth (GO:0048638),-0.7652576626588853,-1.2612793171251633,0.41739130434782606,0.9320229112141798,1.0,2/30,0.76%,APP;MBD5
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886),0.9865717993495626,1.2611376356888737,0.40458015267175573,0.9091512122664329,1.0,3/94,1.35%,CENPE;KIF23;KIF3B
prerank,Reactome_2022__DNA Repair R-HSA-73894,0.8244575697555839,1.2609031380474232,0.0851063829787234,0.9088303371339039,1.0,10/295,1.53%,MSH2;BRIP1;SLC19A1;HERC2;POLE4;DCLRE1C;TCEA1;FANCL;ACD;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of double-strand break repair via nonhomologous end joining (GO:2001034),0.7273507898569262,1.26086389206965,0.3853211009174312,0.9082256046980507,1.0,2/16,1.46%,SMCHD1;WRAP53
prerank,GO_Biological_Process_2021__calcium ion transport (GO:0006816),0.98691420977286,1.2606521373538329,0.2894736842105263,0.9078361490852566,1.0,1/105,1.30%,CYP27B1
prerank,WikiPathway_2021_Human__Oxidation by Cytochrome P450 WP43,-0.914861404769156,-1.260586586244966,0.4634146341463415,0.9314802715344249,1.0,7/56,1.27%,CYP39A1;CYP2C8;CYP3A7;CYP4V2;CYP20A1;CYP1A2;CYP1B1
prerank,WikiPathway_2021_Human__MAPK Signaling Pathway WP382,-0.8329333808954998,-1.2605721211675334,0.09803921568627451,0.9307536878592811,1.0,10/228,1.26%,MAP2K6;RAP1A;AKT3;RAP1B;RASA2;PAK2;NTF3;RASGRP2;MAP4K1;DUSP4
prerank,KEGG_2021_Human__Ras signaling pathway,-0.8359151870118978,-1.2602151934642012,0.16981132075471697,0.9301304518527782,1.0,14/212,1.21%,GRIN2B;PLAAT3;RAP1A;AKT3;RAP1B;RASA2;EXOC2;PAK2;PIK3CB;NTF3;RASGRP2;RASSF5;ZAP70;TEK
prerank,GO_Biological_Process_2021__negative regulation of smoothened signaling pathway (GO:0045879),0.7755439273926192,1.2600543836308835,0.43902439024390244,0.9079534592499126,1.0,2/22,0.88%,MEGF8;HERC4
prerank,WikiPathway_2021_Human__Vitamin D-sensitive calcium signaling in depression WP4698,-0.7846351519699533,-1.2594864412701618,0.4411764705882353,0.9296070273571256,1.0,2/36,1.25%,GRIN2B;VDR
prerank,GO_Biological_Process_2021__protein maturation (GO:0051604),0.9869578640515035,1.2594227707795647,0.38636363636363635,0.9081000454905208,1.0,3/91,1.31%,NAA60;NAA10;CPE
prerank,GO_Biological_Process_2021__regulation of intrinsic apoptotic signaling pathway (GO:2001242),0.9849201722520528,1.2594119327807882,0.5289855072463768,0.9074707862095753,1.0,1/52,1.51%,BOK
prerank,GO_Biological_Process_2021__glycerophospholipid metabolic process (GO:0006650),0.9962851428504137,1.2590200184368596,0.078125,0.907347559825801,1.0,1/77,0.37%,PNPLA6
prerank,GO_Biological_Process_2021__spindle assembly (GO:0051225),0.9860422555383632,1.2588252333793022,0.37142857142857144,0.9069841301497075,1.0,4/79,1.41%,HAUS8;HAUS2;KIF3B;FLNA
prerank,WikiPathway_2021_Human__Parkin-Ubiquitin Proteasomal System pathway WP2359,0.9868388601667945,1.2584255532758215,0.43661971830985913,0.9068427364935188,1.0,1/66,1.31%,TUBA1A
prerank,Reactome_2022__Regulated Necrosis R-HSA-5218859,0.9957894512768578,1.2576933933346455,0.0962962962962963,0.9070402630990188,1.0,1/55,0.42%,TNFRSF10A
prerank,GO_Biological_Process_2021__cellular response to interferon-gamma (GO:0071346),-0.8781392201070742,-1.2571107278611215,0.24299065420560748,0.9293675404788724,1.0,6/115,1.31%,CCL23;OAS1;HCK;OASL;GBP4;PML
prerank,Reactome_2022__Sensory Processing Of Sound By Inner Hair Cells Of Cochlea R-HSA-9662360,0.9881312329938055,1.2567370131546547,0.3937007874015748,0.9075173609824687,1.0,3/61,1.20%,MYO7A;ESPN;STX1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in HIV Type 1 Infection,0.9849141759635336,1.2565556936253681,0.448,0.9070669415726618,1.0,2/79,1.51%,APOE;FN1
prerank,GO_Biological_Process_2021__nucleosome organization (GO:0034728),0.9933943376413679,1.2561986736634558,0.11811023622047244,0.9068034580259877,1.0,1/75,0.66%,NAA60
prerank,GO_Biological_Process_2021__metal ion transport (GO:0030001),0.9869392419281632,1.2557634542917697,0.40397350993377484,0.9065961958371943,1.0,1/80,1.30%,CYP27B1
prerank,WikiPathway_2021_Human__Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.9866995586158129,1.2555784072361522,0.4108527131782946,0.9060862392774282,1.0,2/68,1.33%,ITGA2;ITGB5
prerank,Reactome_2022__Signaling By FGFR In Disease R-HSA-1226099,0.9864777971614228,1.2555267021744552,0.4806201550387597,0.9055185666372279,1.0,2/55,1.36%,TRIM24;FGF1
prerank,GO_Biological_Process_2021__mitochondrial ATP synthesis coupled electron transport (GO:0042775),0.994279568666042,1.2547511476274584,0.1417910447761194,0.9056125446460741,1.0,1/71,0.57%,NDUFA10
prerank,GO_Biological_Process_2021__regulation of amyloid fibril formation (GO:1905906),-0.6373032799965279,-1.2529909903245837,0.2846715328467153,0.92957580721103,1.0,1/15,0.35%,APP
prerank,GO_Biological_Process_2021__epithelium development (GO:0060429),-0.8818240945680771,-1.2528905017446725,0.28431372549019607,0.9288831091886248,1.0,3/113,0.68%,GSTA2;GSTA1;SULT1B1
prerank,Reactome_2022__Protein Ubiquitination R-HSA-8852135,0.985582065596494,1.25192583006706,0.47368421052631576,0.9077910113127702,1.0,3/72,1.45%,UBE2H;UBE2C;RNF144A
prerank,GO_Biological_Process_2021__negative regulation of ion transport (GO:0043271),-0.7198516685740349,-1.251197321304129,0.371900826446281,0.9286217509544883,1.0,2/24,0.67%,WNK3;PTK2B
prerank,Reactome_2022__Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins R-HSA-176814,0.9905771827335919,1.2501074256372118,0.22794117647058823,0.9087578821150524,1.0,1/73,0.94%,UBE2C
prerank,GO_Biological_Process_2021__regulation of epidermal growth factor receptor signaling pathway (GO:0042058),0.9917001994497053,1.2496728692440773,0.21897810218978103,0.9084759662404532,1.0,1/65,0.83%,ARHGEF7
prerank,Reactome_2022__RNA Polymerase II Pre-transcription Events R-HSA-674695,0.9919745115855751,1.2488926175427513,0.1450381679389313,0.9085120403286295,1.0,2/76,0.81%,TAF4;TCEA1
prerank,KEGG_2021_Human__Hepatitis B,-0.8486421167272217,-1.2486153440085908,0.14423076923076922,0.9284559736674346,1.0,7/146,1.11%,MAP2K6;AKT3;RB1;PTK2B;PIK3CB;TICAM2;CREB5
prerank,Reactome_2022__RNA Polymerase II Transcription Termination R-HSA-73856,0.9975588469915023,1.248452696687372,0.06870229007633588,0.9082015959366129,1.0,1/66,0.25%,ZNF473
prerank,Elsevier_Pathway_Collection__Glycolysis,-0.6330283730825176,-1.2483966874058814,0.3047619047619048,0.9277821514943297,1.0,1/17,0.08%,ALDOB
prerank,GO_Biological_Process_2021__organelle assembly (GO:0070925),0.7752950874770437,1.2480987424719405,0.06289308176100629,0.907865154381791,1.0,12/408,1.41%,CENPA;CENPE;NUDCD3;YTHDF3;CEP164;HAUS8;HAUS2;EIF2A;ANLN;SEPTIN6;KIF3B;FLNA
prerank,GO_Biological_Process_2021__negative regulation of binding (GO:0051100),0.9924615498314899,1.2475471888809497,0.14925373134328357,0.9076295434313429,1.0,1/86,0.75%,ZNF304
prerank,GO_Biological_Process_2021__fatty acid transmembrane transport (GO:1902001),0.7371244928121482,1.246381949907151,0.41284403669724773,0.9078640516194845,1.0,2/19,0.13%,PRKAA2;ACACA
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.V1 DN,0.8897404267855015,1.2456552722891794,0.2116788321167883,0.9077210794290553,1.0,7/168,1.31%,KCNC1;QPRT;MYCN;CHRD;STX1A;TNNC2;CPE
prerank,WikiPathway_2021_Human__Lipid Metabolism Pathway WP3965,0.7289198621657624,1.2441038532987565,0.3893129770992366,0.9082451156782552,1.0,2/28,0.13%,PRKAA2;ACACA
prerank,WikiPathway_2021_Human__Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.9864694413862688,1.2424214140752081,0.5661764705882353,0.9087631570382025,1.0,1/46,1.35%,SOAT2
prerank,GO_Biological_Process_2021__positive regulation of cell differentiation (GO:0045597),0.8434151415690399,1.2415976272888842,0.11971830985915492,0.9086093309541002,1.0,7/228,1.54%,HOXD3;AXIN2;LRP5;PKDCC;CDH15;PPP1R13L;RIN2
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins R-HSA-176409,0.9905776805428751,1.2412147222299619,0.23308270676691728,0.9082426773260831,1.0,1/72,0.94%,UBE2C
prerank,GO_Biological_Process_2021__regulation of synaptic vesicle exocytosis (GO:2000300),-0.6808100446044469,-1.2398404843753013,0.35454545454545455,0.9292786326409406,1.0,2/17,0.42%,RAP1A;RAP1B
prerank,Elsevier_Pathway_Collection__beta-Cell Granules Exocytois,-0.748036717900366,-1.2396293189122984,0.4357142857142857,0.9285986682218434,1.0,2/22,0.66%,RAP1A;STXBP5
prerank,WikiPathway_2021_Human__Mammalian disorder of sexual development WP4842,0.6742283178103297,1.238963730334351,0.3798449612403101,0.9090566432836356,1.0,2/21,1.02%,AMH;CBX2
prerank,GO_Biological_Process_2021__regulation of Notch signaling pathway (GO:0008593),0.9908973159328901,1.2386720690608342,0.2,0.9085851278816643,1.0,3/81,0.92%,NOTCH3;WWP2;TSPEAR
prerank,MSigDB_Oncogenic_Signatures__STK33 SKM UP,-0.7794830525811908,-1.2386384560208608,0.10679611650485436,0.9281487786524358,1.0,7/239,1.12%,EVI5;FCAMR;GPR132;TNFAIP2;MFAP3L;CREB5;IL10RA
prerank,"Elsevier_Pathway_Collection__Integrins in Cancer Cell Motility, Invasion and Survival",0.9850051185957335,1.2372236887815586,0.48201438848920863,0.9087468115543833,1.0,4/73,1.51%,PTK2;ITGA2;BCAR1;FN1
prerank,GO_Biological_Process_2021__retinoid metabolic process (GO:0001523),-0.8946726105279446,-1.2358977045840551,0.3793103448275862,0.9280657381881562,1.0,6/83,1.27%,CYP2C8;CYP3A7;CYP4V2;CYP1A2;SDC3;CYP1B1
prerank,Reactome_2022__Transport Of Mature Transcript To Cytoplasm R-HSA-72202,0.9952029795675125,1.235872958111058,0.11764705882352941,0.9087456543026412,1.0,1/81,0.48%,NUP210
prerank,Elsevier_Pathway_Collection__CHRNA7 -> NOS1 Production,-0.655054791773562,-1.2348410869526671,0.31666666666666665,0.9276365551907612,1.0,2/17,0.35%,RAP1A;APP
prerank,Reactome_2022__Transport Of Mature mRNA Derived From An Intron-Containing Transcript R-HSA-159236,0.9952066895006966,1.2324253797117142,0.14925373134328357,0.9095570243756586,1.0,1/72,0.48%,NUP210
prerank,Reactome_2022__RUNX1 Regulates Transcription Of Genes Involved In Differentiation Of HSCs R-HSA-8939236,-0.9890395449679779,-1.232341500105808,0.3620689655172414,0.9275605664792476,1.0,2/85,1.10%,LDB2;SPI1
prerank,GO_Biological_Process_2021__negative regulation of cellular response to growth factor stimulus (GO:0090288),0.9891118533695644,1.2318899207360297,0.291970802919708,0.9091755194982301,1.0,1/71,1.09%,CHRD
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypoxia-Induced Pulmonary Hypertension,0.7452088160817711,1.2317362316502347,0.4365079365079365,0.9086060854793068,1.0,1/22,0.02%,SLC6A4
prerank,KEGG_2021_Human__Sphingolipid signaling pathway,-0.8688162290776177,-1.2316166206460837,0.24324324324324326,0.9270215380658123,1.0,4/117,1.23%,AKT3;SGPP1;PIK3CB;S1PR1
prerank,KEGG_2021_Human__Viral myocarditis,0.9890469195201362,1.2312493892594076,0.3560606060606061,0.9081943742415505,1.0,1/55,1.10%,ITGAL
prerank,WikiPathway_2021_Human__Synaptic Vesicle Pathway WP2267,0.9847155502367567,1.231128624008922,0.6178861788617886,0.9076211726264702,1.0,3/45,1.54%,SLC6A4;STX1A;SLC38A1
prerank,Reactome_2022__Drug ADME R-HSA-9748784,-0.8983168480937754,-1.2300705007480233,0.3898305084745763,0.9267049627659694,1.0,8/89,1.10%,GSTA2;CYP2C8;GLYAT;GSTA1;SLC22A1;GGT5;ACSM2B;VAV1
prerank,GO_Biological_Process_2021__plasma membrane invagination (GO:0099024),0.7495319297469456,1.229945855748255,0.45112781954887216,0.9073935481315466,1.0,2/30,1.08%,HAVCR1;SPIRE2
prerank,Elsevier_Pathway_Collection__ROS in Angiotensin Mediated Cardiovascular Remodeling and Hypertrophy,-0.829711645146437,-1.2297980102236692,0.4661016949152542,0.9260827501239047,1.0,3/51,1.10%,MAP2K6;PTK2B;VAV1
prerank,GO_Biological_Process_2021__metal ion homeostasis (GO:0055065),-0.7388266999801237,-1.2286195848596648,0.39823008849557523,0.925708809465439,1.0,2/39,1.11%,SLC7A8;SLC12A8
prerank,"KEGG_2021_Human__Glycine, serine and threonine metabolism",-0.8107904797673043,-1.228016889649496,0.4563106796116505,0.9251598550998733,1.0,3/39,1.24%,DMGDH;BHMT;MAOB
prerank,MSigDB_Hallmark_2020__Pancreas Beta Cells,-0.6754254861671625,-1.2277018589588544,0.376,0.9245272662759372,1.0,2/29,1.25%,AKT3;VDR
prerank,GO_Biological_Process_2021__embryonic limb morphogenesis (GO:0030326),0.7754476545134721,1.226530359007063,0.45,0.9080458858787717,1.0,2/34,0.89%,MEGF8;TBX3
prerank,GO_Biological_Process_2021__negative regulation of cell migration (GO:0030336),0.8951729938919615,1.226162605014417,0.2677165354330709,0.9075887395745692,1.0,6/137,1.33%,THY1;SRGAP2B;MCTP1;STK26;CHRD;DPYSL3
prerank,MSigDB_Hallmark_2020__Mitotic Spindle,0.8479993117602929,1.2260596902211303,0.12,0.9070018887509613,1.0,17/198,1.49%,CENPE;CLIP2;NDC80;TBCD;DLG1;ARHGEF7;RAB3GAP1;ANLN;KIF23;PIF1;MID1;SHROOM1;KIF3B;SEPTIN9;FLNA;CDC42EP1;BCAR1
prerank,GO_Biological_Process_2021__cellular response to oxygen-containing compound (GO:1901701),-0.7506460614589692,-1.2250039813655451,0.15,0.9245287449724305,1.0,8/297,1.04%,CPEB3;RAP1A;RAP1B;PTK2B;AOC1;KCNE1;CD274;TICAM2
prerank,GO_Biological_Process_2021__regulation of ventricular cardiac muscle cell membrane repolarization (GO:0060307),-0.6368933411034396,-1.2243763185407825,0.32142857142857145,0.9239689818593192,1.0,1/16,0.82%,KCNE1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetic Nephropathy,0.8354421402362303,1.2236067523750849,0.16556291390728478,0.9072441890632861,1.0,4/164,1.51%,PTK2;PPARA;APOE;FN1
prerank,GO_Biological_Process_2021__cellular response to osmotic stress (GO:0071470),-0.6290461020073421,-1.2231662451901142,0.30578512396694213,0.9236078186892434,1.0,2/22,1.06%,WNK3;RCSD1
prerank,TRRUST_Transcription_Factors_2019__EP300 mouse,0.9849366571482745,1.2223897997183308,0.5714285714285714,0.9070228098831444,1.0,2/54,1.51%,AXIN2;FN1
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Hepatocellular Carcinoma,0.9903794609071587,1.221755620546567,0.27611940298507465,0.9066196439013255,1.0,1/81,0.96%,ERBB3
prerank,"Reactome_2022__Gamma Carboxylation, Hypusine Formation And Arylsulfatase Activation R-HSA-163841",-0.8298207654667652,-1.221732737209311,0.5,0.9233379059533667,1.0,3/41,0.48%,STS;PROS1;TPST1
prerank,Elsevier_Pathway_Collection__NOTCH -> TCF3 Signaling,-0.6705725223832028,-1.221659907017285,0.4,0.922644396870303,1.0,1/21,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__Golgi to endosome transport (GO:0006895),-0.6443404581223767,-1.221545232258851,0.34234234234234234,0.9219648851515784,1.0,2/16,0.71%,MON2;VPS13C
prerank,Reactome_2022__Myogenesis R-HSA-525793,-0.7564677424814762,-1.2213047396483576,0.4666666666666667,0.9213251928573034,1.0,2/25,0.57%,MAP2K6;NEO1
prerank,Reactome_2022__G Beta:Gamma Signaling Thru PI3Kgamma R-HSA-392451,-0.6637432400212168,-1.2208699972216388,0.373134328358209,0.9207219994975009,1.0,2/23,1.35%,AKT3;PIK3R6
prerank,GO_Biological_Process_2021__epithelial cell differentiation (GO:0030855),-0.8912165190687729,-1.2203340790710717,0.3238095238095238,0.9201616752250243,1.0,4/94,1.08%,GSTA2;GSTA1;SULT1B1;BASP1
prerank,GO_Biological_Process_2021__cellular response to growth factor stimulus (GO:0071363),-0.8342603078803466,-1.2199725930541916,0.1792452830188679,0.9195473906837912,1.0,3/154,0.99%,RAP1A;NR3C1;KLF4
prerank,KEGG_2021_Human__MAPK signaling pathway,-0.7798106580161619,-1.2196689985419775,0.1,0.9189243760727106,1.0,11/276,1.26%,MAP2K6;RAP1A;AKT3;RAP1B;RASA2;PAK2;NTF3;RASGRP2;MAP4K1;TEK;DUSP4
prerank,KEGG_2021_Human__cAMP signaling pathway,-0.7947840963435227,-1.2194209580869368,0.1320754716981132,0.9182958707934623,1.0,8/189,1.22%,GRIN2B;RAP1A;AKT3;RAP1B;PIK3CB;VAV1;CREB5;GLI3
prerank,GO_Biological_Process_2021__negative regulation of cell aging (GO:0090344),0.70831421206713,1.219042023823285,0.3902439024390244,0.9068487106085997,1.0,3/16,1.48%,CDK6;RBL1;SLC30A10
prerank,Elsevier_Pathway_Collection__Leukocyte Adhesion to Endothelial Cell,-0.6833614918348418,-1.217676445371636,0.36585365853658536,0.9181476576560808,1.0,2/30,1.01%,GLG1;CD2
prerank,Reactome_2022__RHOF GTPase Cycle R-HSA-9035034,0.8624613105469197,1.2164773531863728,0.5354330708661418,0.9070852569263854,1.0,4/40,0.63%,BAIAP2L2;SENP1;DEPDC1B;ARHGAP39
prerank,GO_Biological_Process_2021__positive regulation of protein localization to nucleus (GO:1900182),0.9859061349929745,1.2164316866830451,0.5271317829457365,0.9064855831881719,1.0,1/67,1.41%,FLNA
prerank,GO_Biological_Process_2021__regulation of neurotransmitter receptor activity (GO:0099601),-0.8098779285917852,-1.216296381547708,0.44166666666666665,0.9178485846381538,1.0,4/48,1.05%,GRIN2B;APP;PTK2B;DLG2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Medulloblastoma,0.9903216180441101,1.216246734927621,0.302158273381295,0.9059178593644923,1.0,2/65,0.97%,AMH;MYCN
prerank,GO_Biological_Process_2021__negative regulation of osteoblast differentiation (GO:0045668),0.7849593305212634,1.215394149142382,0.484375,0.9056257060887064,1.0,3/30,1.09%,CDK6;LRP5;CHRD
prerank,GO_Biological_Process_2021__peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine (GO:0018231),-0.6390045677121527,-1.215066511138409,0.3305785123966942,0.9168313294876277,1.0,1/22,0.21%,ZDHHC21
prerank,GO_Biological_Process_2021__peptidyl-L-cysteine S-palmitoylation (GO:0018230),-0.6390045677121527,-1.215066511138409,0.3305785123966942,0.9168313294876277,1.0,1/22,0.21%,ZDHHC21
prerank,GO_Biological_Process_2021__ventricular cardiac muscle cell action potential (GO:0086005),-0.6368934838217071,-1.214898577203503,0.30935251798561153,0.9161522700399393,1.0,1/16,0.82%,KCNE1
prerank,GO_Biological_Process_2021__digestive tract development (GO:0048565),0.8198513680470738,1.2145806815464018,0.4896551724137931,0.90528472957665,1.0,3/34,1.04%,MEGF8;CCDC40;PKDCC
prerank,GO_Biological_Process_2021__estrogen metabolic process (GO:0008210),-0.7772759351438735,-1.21414903159462,0.46078431372549017,0.9156537102894807,1.0,4/30,1.27%,CYP2C8;CYP3A7;CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__positive regulation of potassium ion transmembrane transport (GO:1901381),-0.8574209142567816,-1.2137484692209115,0.5323741007194245,0.9150502258310664,1.0,3/44,0.82%,KCNN2;WNK3;KCNE1
prerank,Elsevier_Pathway_Collection__Ras-GAP Regulation Signaling,-0.8349660475072592,-1.213746367428378,0.5,0.9143580547071398,1.0,3/46,0.66%,RAP1A;APP;RASA2
prerank,GO_Biological_Process_2021__positive regulation of actin cytoskeleton reorganization (GO:2000251),-0.6567627179139137,-1.211664300573436,0.3492063492063492,0.9143416169779798,1.0,3/18,1.21%,HCK;NTF3;TEK
prerank,GO_Biological_Process_2021__regulation of cation channel activity (GO:2001257),-0.8353504576258903,-1.21145075651719,0.3697478991596639,0.9137404909385132,1.0,5/78,1.05%,GRIN2B;APP;PTK2B;KCNE1;DLG2
prerank,Elsevier_Pathway_Collection__OPRK -> Pain Perception,0.6206444315071543,1.2086880842274235,0.3277310924369748,0.9065570834199093,1.0,1/18,0.02%,SLC6A4
prerank,GO_Biological_Process_2021__gene expression (GO:0010467),0.7872880999268439,1.2075850259653502,0.1456953642384106,0.9063220081453718,1.0,6/349,0.97%,HOXD3;DROSHA;NUP210;TAF1B;UPF2;IGF2BP3
prerank,GO_Biological_Process_2021__microtubule cytoskeleton organization involved in mitosis (GO:1902850),0.9053447904221164,1.2073528096283161,0.3076923076923077,0.9057640854378591,1.0,5/125,1.35%,CENPA;CENPE;NDC80;ERCC6L;KIF3B
prerank,GO_Biological_Process_2021__RNA stabilization (GO:0043489),0.7892316125368243,1.2064361282727116,0.48872180451127817,0.9054058581133442,1.0,2/31,0.88%,AXIN2;PARN
prerank,MSigDB_Oncogenic_Signatures__ALK DN.V1 DN,-0.8855929378297781,-1.2059299698077783,0.29914529914529914,0.9146855595504939,1.0,7/110,1.33%,OAS1;PTK2B;FXYD6;VAV1;AQP3;DNAJA4;RTP4
prerank,GO_Biological_Process_2021__generation of neurons (GO:0048699),0.8738748148876583,1.2056999658604035,0.2589928057553957,0.9049938998664119,1.0,3/166,0.27%,VAX2;CDK6;BRSK1
prerank,GO_Biological_Process_2021__establishment or maintenance of epithelial cell apical/basal polarity (GO:0045197),0.7925637590802129,1.2042155586334498,0.49635036496350365,0.904778586967709,1.0,3/32,1.05%,LIN7A;DLG1;CAMSAP3
prerank,WikiPathway_2021_Human__Hepatitis B infection WP4666,-0.8266517932047454,-1.2034658248663341,0.19607843137254902,0.9148029060742981,1.0,6/137,1.11%,MAP2K6;AKT3;PTK2B;PIK3CB;TICAM2;CREB5
prerank,GO_Biological_Process_2021__regulation of lipid biosynthetic process (GO:0046890),0.7662511459553188,1.2017328142385542,0.4609375,0.9047517836968433,1.0,3/33,1.30%,PRKAA2;PPARA;APOE
prerank,WikiPathway_2021_Human__One-carbon metabolism WP241,-0.7602023503989381,-1.198980294675774,0.4728682170542636,0.9156086686975501,1.0,2/30,0.82%,AHCYL2;BHMT
prerank,WikiPathway_2021_Human__Sphingolipid Metabolism (general overview) WP4725,-0.6696911118872363,-1.198670878711911,0.3923076923076923,0.9150275123523772,1.0,1/22,0.51%,SGPP1
prerank,GO_Biological_Process_2021__regulation of transcription involved in G1/S transition of mitotic cell cycle (GO:0000083),0.7499107027266035,1.1972735322911419,0.43790849673202614,0.9054129598934784,1.0,3/31,1.18%,CDC45;GFI1;RRM2
prerank,MSigDB_Oncogenic_Signatures__KRAS.300 UP.V1 DN,-0.8577341590600611,-1.197171198417989,0.2689075630252101,0.9149056017187921,1.0,7/112,1.33%,DPYS;MAP2K6;OAS1;KCNE1;NTF3;PDE11A;RTP4
prerank,KEGG_2021_Human__Prolactin signaling pathway,-0.8241099912615233,-1.1959434077873383,0.38016528925619836,0.9146566448275947,1.0,3/67,0.93%,AKT3;PIK3CB;CCND2
prerank,WikiPathway_2021_Human__MET in type 1 papillary renal cell carcinoma WP4205,-0.815060366036503,-1.1955027011431092,0.4365079365079365,0.9141283672430995,1.0,5/57,0.73%,RAP1A;AKT3;RAP1B;PAK2;PIK3CB
prerank,MSigDB_Hallmark_2020__TNF-alpha Signaling via NF-kB,-0.7844947315905869,-1.1949870340612443,0.17094017094017094,0.9136358184684686,1.0,5/199,1.26%,FOSB;TNFAIP2;KLF4;CD83;DUSP4
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR1 R-HSA-5654687,-0.6620995620032909,-1.1942310236537945,0.38016528925619836,0.9132582576211083,1.0,1/25,0.20%,FLRT2
prerank,WikiPathway_2021_Human__Common Pathways Underlying Drug Addiction WP2636,-0.7758587532264469,-1.1936334546366967,0.45454545454545453,0.9128083251837611,1.0,2/36,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__cellular response to starvation (GO:0009267),0.8675109158134959,1.1927593564894567,0.2265625,0.9060088685264603,1.0,7/152,1.48%,PRKAA2;BRSK1;CLEC16A;FNIP1;PPARA;STK26;LAMP2
prerank,WikiPathway_2021_Human__Ras signaling WP4223,-0.8490217350264768,-1.1896894113623004,0.23076923076923078,0.9135758962417203,1.0,12/171,1.21%,GRIN2B;RAP1A;AKT3;RAP1B;RASA2;EXOC2;PAK2;PIK3CB;RASGRP2;RASSF5;ZAP70;TEK
prerank,Elsevier_Pathway_Collection__ANGPT/TEK Stimulates Endothelial Cell Migration in Cancer,0.6469046360098394,1.1890670429985875,0.3559322033898305,0.9065190577659812,1.0,1/19,0.26%,PTK2
prerank,Reactome_2022__Ion Channel Transport R-HSA-983712,-0.8345190364266969,-1.1890124922663114,0.2247191011235955,0.913116900238102,1.0,3/153,0.73%,ATP11C;WNK3;WWP1
prerank,GO_Biological_Process_2021__long-chain fatty acid transport (GO:0015909),0.7601782579363539,1.1887585595432915,0.46774193548387094,0.9060077381186399,1.0,3/31,1.30%,PRKAA2;ACACA;APOE
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway via death domain receptors (GO:0008625),0.7595854815357506,1.1883307611030562,0.463768115942029,0.9055099587871961,1.0,2/30,0.46%,TNFRSF10A;SORT1
prerank,GO_Biological_Process_2021__regulation of keratinocyte differentiation (GO:0045616),-0.7737191820623781,-1.1877388445412518,0.49122807017543857,0.912829451509174,1.0,3/30,1.25%,SGPP1;AQP3;VDR
prerank,Reactome_2022__Acyl Chain Remodelling Of PC R-HSA-1482788,-0.6705868306291489,-1.1861910542326097,0.4,0.9126878716464144,1.0,1/23,0.16%,PLAAT3
prerank,GO_Biological_Process_2021__negative regulation of inflammatory response (GO:0050728),-0.802680543300795,-1.185914924993528,0.1792452830188679,0.9121294676797587,1.0,8/178,1.21%,GPR39;GGT5;RB1;HCK;CD163;HRH2;KLF4;TEK
prerank,GO_Biological_Process_2021__positive regulation of cilium assembly (GO:0045724),-0.6570650312734312,-1.1853833517991923,0.375,0.9116634502297108,1.0,1/19,0.27%,CEP120
prerank,Reactome_2022__Synthesis Of DNA R-HSA-69239,0.8428076064416661,1.1852265118063838,0.25874125874125875,0.9058884896963385,1.0,6/115,1.53%,CDC45;GINS1;SLC19A1;POLE4;UBE2C;LRIG1
prerank,GO_Biological_Process_2021__regulation of smoothened signaling pathway (GO:0008589),0.8341909386834028,1.1848075438938808,0.5,0.9054222574809005,1.0,3/49,0.88%,MEGF8;TTC23;HERC4
prerank,Elsevier_Pathway_Collection__Ca2+ Flux Regulation,-0.8456310489642538,-1.184629634396474,0.3706896551724138,0.9112580661303333,1.0,3/93,0.97%,GRIN2B;PTK2B;HRH2
prerank,Reactome_2022__FOXO-mediated Transcription R-HSA-9614085,-0.8756207899642935,-1.1838100650337047,0.4594594594594595,0.910944702815248,1.0,5/61,0.99%,GLYAT;AKT3;ABCA6;NR3C1;KLF4
prerank,GO_Biological_Process_2021__peptide catabolic process (GO:0043171),-0.6268746050570025,-1.1828709876904238,0.3712121212121212,0.9106318061618381,1.0,1/25,0.38%,GGT5
prerank,GO_Biological_Process_2021__positive regulation of dendritic spine development (GO:0060999),-0.6840982790036895,-1.1819223130831997,0.40310077519379844,0.910287899060016,1.0,1/21,0.07%,CPEB3
prerank,Elsevier_Pathway_Collection__Mesangial Cell Dysfunction in Glomerulonephritis,-0.7932835503374385,-1.1815244827802316,0.4793388429752066,0.9097903852800797,1.0,2/41,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__phosphatidylcholine acyl-chain remodeling (GO:0036151),-0.670586416626031,-1.1810350290946692,0.40869565217391307,0.9093124683271444,1.0,1/26,0.16%,PLAAT3
prerank,Reactome_2022__Biological Oxidations R-HSA-211859,-0.7873483387231415,-1.1800231595940716,0.16666666666666666,0.9091022116857724,1.0,17/202,1.27%,GSTA2;CYP39A1;CYP2C8;GLYAT;GSTA1;CYP4V2;GGT5;NCOA1;TPST1;AADAC;ACSM2B;SULT1B1;AOC1;CYP1A2;AKR7A3;MAOB;CYP1B1
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP LATE.V1 DN,-0.8445370187962432,-1.1799130214342943,0.205607476635514,0.9084686009847925,1.0,6/155,0.99%,GJB5;TLE4;RBM43;BIRC6;RASGRP2;KLF4
prerank,Reactome_2022__DNA Replication R-HSA-69306,0.842791691275456,1.1794495152803433,0.22535211267605634,0.9064901541680761,1.0,6/141,1.53%,CDC45;GINS1;SLC19A1;POLE4;UBE2C;LRIG1
prerank,MSigDB_Oncogenic_Signatures__CSR LATE UP.V1 UP,0.8483774887703562,1.1785916777812606,0.23846153846153847,0.9061343391725036,1.0,8/154,1.52%,HAUS2;ANLN;HERC4;PBK;UBE2C;SHCBP1;RRM2;SMS
prerank,Reactome_2022__Activation Of Gene Expression By SREBF (SREBP) R-HSA-2426168,0.7798302107017321,1.1781419289438801,0.5,0.9056893722059375,1.0,4/42,1.16%,ACACA;TBL1X;PPARA;PKMYT1
prerank,MSigDB_Oncogenic_Signatures__PDGF UP.V1 UP,0.8543128479419754,1.1775343815345714,0.29457364341085274,0.90526547886418,1.0,4/135,1.02%,CDK6;ZNF304;ZNF394;CBX2
prerank,Elsevier_Pathway_Collection__High Fat Diet Activates cAMP Related Exocytosis in Synapse and Endocrine Cell,-0.7099426197990579,-1.1775342893308716,0.4108527131782946,0.9087516242584687,1.0,2/29,1.10%,RAP1A;VAV1
prerank,Reactome_2022__Anti-inflammatory Response Favoring Leishmania Infection R-HSA-9662851,-0.8516786739397526,-1.17730296529222,0.27884615384615385,0.9081787506665093,1.0,5/131,0.97%,GPR39;GGT5;HCK;CD163;HRH2
prerank,WikiPathway_2021_Human__Wnt Signaling Pathway WP363,0.8479728314724077,1.17717726180117,0.5118110236220472,0.9047782201250181,1.0,3/50,0.40%,AXIN2;CDK6;LRP5
prerank,GO_Biological_Process_2021__glycolytic process through glucose-6-phosphate (GO:0061620),-0.6330275480796791,-1.176930191773634,0.35344827586206895,0.9076630885119558,1.0,1/23,0.08%,ALDOB
prerank,GO_Biological_Process_2021__folic acid metabolic process (GO:0046655),0.6253665215964812,1.1766514606821812,0.36220472440944884,0.9043452882734528,1.0,1/19,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__defense response to virus (GO:0051607),-0.8262624080471426,-1.1765661721109415,0.28846153846153844,0.9070949964780789,1.0,4/124,1.33%,OAS1;OASL;SLFN11;RTP4
prerank,GO_Biological_Process_2021__endothelial cell proliferation (GO:0001935),0.6164560160745597,1.1756511874101487,0.33587786259541985,0.904061072564703,1.0,1/18,0.74%,DLG1
prerank,Reactome_2022__SARS-CoV-1 Infection R-HSA-9678108,-0.7963795304005225,-1.1751337566110907,0.5,0.9070749113278636,1.0,5/49,1.26%,PARP8;RB1;UVRAG;MOGAT1;TMPRSS2
prerank,MSigDB_Oncogenic_Signatures__BRCA1 DN.V1 DN,0.8974496151021734,1.1747386695875344,0.3828125,0.9037619252773882,1.0,5/106,1.33%,GPR35;PPP1R9A;TRAF3;RAB40C;DPYSL3
prerank,Elsevier_Pathway_Collection__Aryl Hydrocarbon Receptor Genomic and non-Genomic Signaling,-0.7433909735185944,-1.1738424446891305,0.43119266055045874,0.9069236327206424,1.0,4/38,1.27%,NCOA1;RB1;CYP1A2;CYP1B1
prerank,Reactome_2022__Glycosaminoglycan Metabolism R-HSA-1630316,0.8468017663974823,1.1718340932967366,0.32061068702290074,0.9040625692783993,1.0,4/115,1.34%,PAPSS1;ST3GAL1;SLC35D2;HAS3
prerank,Elsevier_Pathway_Collection__CCL2 Role in CGRP Expression and Release,-0.6842349647835888,-1.171812523042536,0.41739130434782606,0.9070410740739979,1.0,2/20,1.05%,SYT7;GNA14
prerank,WikiPathway_2021_Human__Sphingolipid Metabolism (integrated pathway) WP4726,-0.6696907678878776,-1.1715299209636196,0.4122137404580153,0.9064532782771363,1.0,1/23,0.51%,SGPP1
prerank,WikiPathway_2021_Human__PI3K/AKT/mTOR - VitD3 signaling WP4141,0.7478325262061408,1.1713432928903895,0.47368421052631576,0.9036261833068464,1.0,1/21,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__mitotic G1 DNA damage checkpoint signaling (GO:0031571),0.8742963558441171,1.1707551130364717,0.5,0.9032438736323036,1.0,4/64,1.19%,ARID3A;FBXO31;PRAP1;PCBP4
prerank,WikiPathway_2021_Human__DNA Repair Pathways Full Network WP4946,0.8447145836314697,1.1701476429422424,0.28776978417266186,0.9029053496077425,1.0,6/119,0.90%,MSH2;BRIP1;ATR;POLE4;DCLRE1C;FANCL
prerank,GO_Biological_Process_2021__regulation of dendritic spine development (GO:0060998),-0.684098161420806,-1.1699906822323556,0.3983050847457627,0.9064648997553473,1.0,1/21,0.07%,CPEB3
prerank,Reactome_2022__Transport Of Inorganic Cations/Anions And Amino Acids/Oligopeptides R-HSA-425393,-0.7879929906318482,-1.1690550415717926,0.26881720430107525,0.906245982478657,1.0,6/92,1.29%,SLC7A8;SLC36A4;AHCYL2;SLC9A9;SLC15A3;SLC4A5
prerank,GO_Biological_Process_2021__cellular response to lipid (GO:0071396),-0.7545431095246727,-1.168828618906926,0.15789473684210525,0.9056725207608056,1.0,5/198,1.16%,NR3C1;PTK2B;CD274;TICAM2;MAP4K1
prerank,GO_Biological_Process_2021__defense response to symbiont (GO:0140546),-0.8262675506443025,-1.1687870855697358,0.3153153153153153,0.9050190273884735,1.0,4/115,1.33%,OAS1;OASL;SLFN11;RTP4
prerank,GO_Biological_Process_2021__embryonic organ morphogenesis (GO:0048562),0.8171164889734073,1.1681348280054615,0.5111111111111111,0.9030505926910415,1.0,2/42,0.15%,HOXD3;MEGF8
prerank,GO_Biological_Process_2021__cortical cytoskeleton organization (GO:0030865),0.7606646835191391,1.1677714359645233,0.45588235294117646,0.9025931752307799,1.0,3/41,1.25%,DLG1;RHOQ;FMNL2
prerank,GO_Biological_Process_2021__cellular response to organic substance (GO:0071310),-0.8143805151841879,-1.1676261161200456,0.24742268041237114,0.9047830052790229,1.0,4/115,1.34%,NCOA1;KLF4;CYP1B1;PTPN18
prerank,Reactome_2022__Nucleotide Salvage R-HSA-8956321,0.6979279611146735,1.1666759911301332,0.40875912408759124,0.902372622570013,1.0,2/22,1.51%,PUDP;HPRT1
prerank,Reactome_2022__Metabolism Of Folate And Pterines R-HSA-196757,0.6253672658351221,1.1662154852722268,0.3359375,0.9019315024300092,1.0,1/16,0.51%,SLC19A1
prerank,TRRUST_Transcription_Factors_2019__CTNNB1 mouse,0.8440183124527874,1.165167870578014,0.5737704918032787,0.9017345194960056,1.0,3/45,0.97%,AXIN2;TBX3;MYCN
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP EARLY.V1 DN,-0.8101334762462296,-1.1649829636374676,0.21929824561403508,0.9053145138544106,1.0,6/154,1.17%,GJB5;APP;OAF;PBX1;KLF4;AQP3
prerank,WikiPathway_2021_Human__Signaling of Hepatocyte Growth Factor Receptor WP313,-0.7587030747794048,-1.1643814666965482,0.4608695652173913,0.9049079161469424,1.0,4/34,1.16%,RAP1A;RAP1B;PTK2B;MAP4K1
prerank,MSigDB_Oncogenic_Signatures__CSR EARLY UP.V1 UP,0.8245125757149996,1.1626853162756445,0.2214765100671141,0.9020676686865402,1.0,4/142,1.49%,VGLL4;ST3GAL1;SHB;BCAR1
prerank,GO_Biological_Process_2021__glucose catabolic process to pyruvate (GO:0061718),-0.6330277253182635,-1.162648495274851,0.3508771929824561,0.904350640908726,1.0,1/22,0.08%,ALDOB
prerank,GO_Biological_Process_2021__canonical glycolysis (GO:0061621),-0.6330277253182635,-1.162648495274851,0.3508771929824561,0.904350640908726,1.0,1/22,0.08%,ALDOB
prerank,MSigDB_Oncogenic_Signatures__RB P107 DN.V1 UP,0.834245412619494,1.1622608884814432,0.26119402985074625,0.9016529711959862,1.0,7/128,1.27%,CDC45;HAUS8;FANCL;PAQR4;SPIRE2;RRM2;TCFL5
prerank,WikiPathway_2021_Human__Melatonin metabolism and effects WP3298,-0.6833086698624782,-1.161471970103838,0.415929203539823,0.9042832053375482,1.0,2/33,1.27%,CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG Signaling,-0.7971398796332462,-1.1601249252630863,0.5241935483870968,0.9043025185680285,1.0,4/46,1.10%,MAP2K6;PTK2B;PAK2;VAV1
prerank,Elsevier_Pathway_Collection__Vitamine D Deficite and Dentin Formation,-0.7090645852262779,-1.1598412869504777,0.4224137931034483,0.9038084675414829,1.0,2/28,1.25%,PTK2B;VDR
prerank,Reactome_2022__DNA Double-Strand Break Repair R-HSA-5693532,0.8259700646224322,1.1597577142204611,0.25874125874125875,0.9020338359286202,1.0,5/141,0.76%,BRIP1;SLC19A1;HERC2;POLE4;DCLRE1C
prerank,Reactome_2022__Syndecan Interactions R-HSA-3000170,0.71466264546163,1.1590786133244715,0.43356643356643354,0.9016854988018179,1.0,2/20,1.33%,ITGA2;ITGB5
prerank,Reactome_2022__Canonical Retinoid Cycle In Rods (Twilight Vision) R-HSA-2453902,-0.6801026283456372,-1.1587609296329013,0.4244604316546763,0.903648871979189,1.0,2/19,1.07%,CYP4V2;HSD17B6
prerank,GO_Biological_Process_2021__regulation of DNA repair (GO:0006282),0.8247739482532453,1.1587182708363564,0.5112781954887218,0.9012137292185521,1.0,3/45,1.46%,AXIN2;SMCHD1;WRAP53
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Permeability Activation,0.7890500718373206,1.1584183669356476,0.5185185185185185,0.9007249000939852,1.0,3/37,1.49%,PTK2;TJP1;BCAR1
prerank,WikiPathway_2021_Human__Signal Transduction of S1P Receptor WP26,-0.7231644243350883,-1.1572487156776434,0.4628099173553719,0.9037303633597517,1.0,2/25,1.23%,AKT3;S1PR1
prerank,GO_Biological_Process_2021__protein localization to cell-cell junction (GO:0150105),0.6354792276829617,1.1569679889404634,0.35036496350364965,0.9007417489133304,1.0,2/15,1.15%,TJP1;ARHGEF18
prerank,Reactome_2022__Synthesis Of PIPs At Plasma Membrane R-HSA-1660499,-0.7909671826371754,-1.1560724494670702,0.425,0.9036358555807178,1.0,3/51,1.35%,SBF2;PIK3CB;PIK3R6
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-threonine phosphorylation (GO:0010800),-0.6796927847202715,-1.1559123783467558,0.42592592592592593,0.9030635632229507,1.0,2/24,0.43%,APP;WNK3
prerank,GO_Biological_Process_2021__negative regulation of microtubule depolymerization (GO:0007026),-0.6337410755050683,-1.1557854547582802,0.36885245901639346,0.9024489687634744,1.0,2/21,1.33%,TTBK2;HDGFL3
prerank,GO_Biological_Process_2021__regulation of double-strand break repair via nonhomologous end joining (GO:2001032),0.7273420942592734,1.1557167038846627,0.4793388429752066,0.9006197851144658,1.0,2/29,1.46%,SMCHD1;WRAP53
prerank,"Reactome_2022__BMAL1:CLOCK,NPAS2 Activates Circadian Gene Expression R-HSA-1368108",0.6528831268485745,1.1556936332708074,0.3945578231292517,0.9000339755610915,1.0,2/25,0.79%,TBL1X;PPARA
prerank,GO_Biological_Process_2021__interferon-gamma-mediated signaling pathway (GO:0060333),-0.823152500781913,-1.155519173104753,0.4537037037037037,0.9019122409552728,1.0,4/66,1.31%,OAS1;HCK;OASL;PML
prerank,TRRUST_Transcription_Factors_2019__AR human,0.8681951972528098,1.1548001917370647,0.4122137404580153,0.89975639705479,1.0,5/86,1.51%,CDK6;TJP1;ERBB3;MID1;FN1
prerank,MSigDB_Oncogenic_Signatures__PRC2 EDD UP.V1 UP,0.8028528842554001,1.1542093268669114,0.17901234567901234,0.899380967971302,1.0,9/174,1.56%,CDC45;LIN7A;LRRC20;KIF23;PACSIN3;TNFRSF10D;SLC35C2;SLC2A6;FOSL2
prerank,GO_Biological_Process_2021__regulation of cellular metabolic process (GO:0031323),0.817419708071835,1.1532805981627625,0.5294117647058824,0.8991142576947297,1.0,3/47,1.43%,ACACA;PPARA;MPV17
prerank,GO_Biological_Process_2021__negative regulation of cell motility (GO:2000146),0.8951883398227849,1.1527625639946533,0.4051724137931034,0.898739751737502,1.0,6/109,1.33%,THY1;SRGAP2B;MCTP1;STK26;CHRD;DPYSL3
prerank,Elsevier_Pathway_Collection__Mesangial Cell Dysfunction in Diabetic Nephropathy,-0.7932807951370366,-1.1525849936459782,0.45794392523364486,0.902686943596571,1.0,2/49,0.67%,MAP2K6;PTK2B
prerank,GO_Biological_Process_2021__positive regulation of ERK1 and ERK2 cascade (GO:0070374),-0.8238944511598335,-1.1522508170784502,0.2828282828282828,0.9022553527964298,1.0,6/159,1.21%,CCL23;RAP1A;APP;PTK2B;SCIMP;TEK
prerank,WikiPathway_2021_Human__Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.8672557573385951,1.1516935363409557,0.5102040816326531,0.8985718431918036,1.0,4/71,0.96%,MKI67;PTK2;LRP5;COL4A5
prerank,KEGG_2021_Human__Rap1 signaling pathway,-0.7608761736997929,-1.1514159003950637,0.2125984251968504,0.902067090598893,1.0,10/198,1.21%,GRIN2B;MAP2K6;RAP1A;AKT3;RAP1B;PIK3CB;RASGRP2;VAV1;RASSF5;TEK
prerank,GO_Biological_Process_2021__regulation of anoikis (GO:2000209),0.6673239982384866,1.1505855085076913,0.42105263157894735,0.8983840627502968,1.0,2/21,0.75%,PTK2;ZNF304
prerank,Reactome_2022__Metabolism Of Carbohydrates R-HSA-71387,0.757928901913805,1.1492234917905888,0.1875,0.8983621977433546,1.0,11/270,1.43%,PAPSS1;ST3GAL1;NUP210;RPIA;SLC35D2;PHKA2;MANBA;MAP4K5;PKLR;HAS3;FUT6
prerank,Reactome_2022__Protein Folding R-HSA-391251,0.8364457638691672,1.1485256483062398,0.40816326530612246,0.8980443648038665,1.0,5/87,1.46%,TBCD;KIF13A;GNB5;TUBA1A;WRAP53
prerank,GO_Biological_Process_2021__protein palmitoylation (GO:0018345),-0.6390034327924938,-1.147951503749541,0.3865546218487395,0.9032022477444823,1.0,1/30,0.21%,ZDHHC21
prerank,KEGG_2021_Human__Metabolism of xenobiotics by cytochrome P450,-0.8782027168428489,-1.1475273704774962,0.488,0.9027497481575909,1.0,5/69,1.27%,GSTA2;GSTA1;CYP1A2;AKR7A3;CYP1B1
prerank,GO_Biological_Process_2021__histone modification (GO:0016570),0.8524001739027176,1.147493704488303,0.3333333333333333,0.8979099474603219,1.0,4/110,1.34%,MIER2;TBL1X;PADI2;RCOR2
prerank,MSigDB_Oncogenic_Signatures__TBK1.DF UP,-0.7226323059223544,-1.1472881122428986,0.20689655172413793,0.9022243324785537,1.0,12/261,1.34%,DERA;SLC2A10;PROS1;FEZ1;TPST1;RB1;ZFYVE16;RNGTT;TNFAIP2;LIPG;CD83;EML1
prerank,KEGG_2021_Human__Amphetamine addiction,-0.8520753902235801,-1.1472473937198622,0.46923076923076923,0.9015985896254741,1.0,4/60,1.24%,GRIN2B;FOSB;CREB5;MAOB
prerank,Elsevier_Pathway_Collection__Vitamins Insufficiency Causes Homocysteine High Level Synthesis,0.6428339520663308,1.1471595500436171,0.366412213740458,0.897487616893743,1.0,1/15,0.51%,SLC19A1
prerank,GO_Biological_Process_2021__cell-matrix adhesion (GO:0007160),0.841177064093803,1.1464791668781327,0.3333333333333333,0.897198528133475,1.0,7/97,1.51%,HOXD3;THY1;ITGA2;ARHGEF7;ITGAL;ITGB5;FN1
prerank,GO_Biological_Process_2021__L-alpha-amino acid transmembrane transport (GO:1902475),-0.6305641966140745,-1.145466253340288,0.38738738738738737,0.9018155435704851,1.0,2/24,0.41%,SLC7A8;SLC36A4
prerank,TRRUST_Transcription_Factors_2019__MYC human,0.9029720523900914,1.1454327192531553,0.4552238805970149,0.8969998865122853,1.0,6/97,0.94%,IGF2BP1;AXIN2;CDK6;CDCA7;ST3GAL1;UBE2C
prerank,GO_Biological_Process_2021__protein localization to cell junction (GO:1902414),0.6354762351211739,1.1453207898153328,0.3951612903225806,0.8964714821314679,1.0,2/21,1.15%,TJP1;ARHGEF18
prerank,GO_Biological_Process_2021__DNA repair (GO:0006281),0.7489269732188322,1.1450540263904494,0.18493150684931506,0.8959937442667181,1.0,6/290,0.90%,MSH2;BRIP1;ATR;HERC2;DCLRE1C;FANCL
prerank,WikiPathway_2021_Human__One-carbon metabolism and related pathways WP3940,-0.8136268830130965,-1.1448138664212157,0.488,0.9015244153860382,1.0,3/49,1.17%,DMGDH;BHMT;CDO1
prerank,Reactome_2022__NCAM Signaling For Neurite Out-Growth R-HSA-375165,0.8002970587560748,1.1447939592479148,0.49624060150375937,0.8955241256915084,1.0,3/53,1.34%,PTK2;COL4A5;COL9A3
prerank,GO_Biological_Process_2021__regulation of signal transduction by p53 class mediator (GO:1901796),0.791062416676137,1.1445098640924851,0.24358974358974358,0.8950601151373804,1.0,6/154,1.29%,PRKAA2;ING5;BRIP1;ATR;TAF4;PPP1R13L
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Evading of Growth Suppressors,0.8252852680470437,1.143244785673312,0.5343511450381679,0.8950330968803137,1.0,3/47,1.12%,AXIN2;TRAF3;TEAD4
prerank,GO_Biological_Process_2021__positive regulation of glycolytic process (GO:0045821),0.6102818113679237,1.143174786743401,0.35537190082644626,0.8938983582382897,1.0,1/19,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__positive regulation of purine nucleotide metabolic process (GO:1900544),0.6102818113679237,1.143174786743401,0.35537190082644626,0.8938983582382897,1.0,1/19,0.03%,PRKAA2
prerank,Elsevier_Pathway_Collection__MC1R in anti-Inflammatory Signaling,-0.8164877665605598,-1.142768591288028,0.5126050420168067,0.9018480916520424,1.0,3/43,1.04%,MAP2K6;RAP1A;TICAM2
prerank,Reactome_2022__Interferon Gamma Signaling R-HSA-877300,-0.8155099203887062,-1.1412382779070436,0.375,0.9019941436572706,1.0,4/85,1.31%,OAS1;OASL;GBP4;PML
prerank,Reactome_2022__GPCR Downstream Signaling R-HSA-388396,-0.6854688339711917,-1.141019913467026,0.15555555555555556,0.9014257643019096,1.0,12/498,1.35%,CCL23;ARHGEF26;APP;AKT3;GPR39;GPR132;RASGRP2;PDE11A;HRH2;GNA14;VAV1;PIK3R6
prerank,GO_Biological_Process_2021__focal adhesion assembly (GO:0048041),0.6613303294912329,1.1396896788036397,0.40310077519379844,0.8949696756758583,1.0,2/20,0.83%,THY1;ARHGEF7
prerank,GO_Biological_Process_2021__regulation of mitotic metaphase/anaphase transition (GO:0030071),0.6900787028090409,1.139577769169702,0.45112781954887216,0.8944329364579483,1.0,2/26,0.94%,CENPE;UBE2C
prerank,Reactome_2022__Amino Acid Transport Across Plasma Membrane R-HSA-352230,-0.6305634328453571,-1.1388811476873577,0.39,0.9019714633688428,1.0,2/28,0.41%,SLC7A8;SLC36A4
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 UP.V1 DN,0.8021459734348121,1.1381856185396544,0.25,0.894505835377211,1.0,4/166,1.04%,SLC6A4;ATR;PPARA;ASGR2
prerank,GO_Biological_Process_2021__purine nucleotide metabolic process (GO:0006163),-0.6607493460439751,-1.137531898648573,0.4406779661016949,0.9019250977268363,1.0,1/22,0.48%,NT5C1B
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetic Neuropathy,-0.7964852746727555,-1.1361295744503288,0.4375,0.9020950387563138,1.0,3/61,1.25%,PDE5A;NTF3;VDR
prerank,Elsevier_Pathway_Collection__Lipogenesis/Lipolysis Activation in Cancer Cells and Cancer-Associated Adipocytes,0.7883697496590631,1.1353516171423106,0.5434782608695652,0.8952691416572576,1.0,2/32,0.26%,ACACA;PTK2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Enabling of Replicative Immortality,0.6427856710160342,1.1346725209535897,0.37606837606837606,0.8950236769208195,1.0,2/19,0.97%,ATR;MYCN
prerank,GO_Biological_Process_2021__anterior/posterior pattern specification (GO:0009952),0.8008342963944803,1.1345276463809637,0.4748201438848921,0.8945205531372695,1.0,2/49,0.40%,HOXD3;LRP5
prerank,WikiPathway_2021_Human__Pyrimidine metabolism and related diseases WP4225,-0.6361187477964612,-1.133786916303698,0.3739130434782609,0.9027303818061704,1.0,1/17,0.12%,DPYS
prerank,Reactome_2022__G2/M Checkpoints R-HSA-69481,0.7985962413880603,1.1335431904076259,0.26618705035971224,0.8943824931171315,1.0,4/139,1.16%,CDC45;BRIP1;HERC2;PKMYT1
prerank,GO_Biological_Process_2021__glycolytic process (GO:0006096),-0.6330274340372745,-1.1330845496221122,0.4132231404958678,0.9024980541074089,1.0,1/26,0.08%,ALDOB
prerank,Reactome_2022__Cytoprotection By HMOX1 R-HSA-9707564,0.7402826778269217,1.1324892157352702,0.4351145038167939,0.8942966374250887,1.0,3/57,0.79%,BRIP1;TBL1X;PPARA
prerank,Reactome_2022__SUMOylation Of DNA Damage Response And Repair Proteins R-HSA-3108214,0.83737641860506,1.1324609092318856,0.46825396825396826,0.8937182251129488,1.0,3/75,1.02%,NUP210;HERC2;CBX2
prerank,GO_Biological_Process_2021__cellular response to DNA damage stimulus (GO:0006974),0.7092478988027237,1.132215227463195,0.20945945945945946,0.8932568499931915,1.0,11/343,1.51%,MSH2;BRSK1;AATF;NEK4;ATR;FBXO31;HERC2;RBBP6;FANCL;PRAP1;BOK
prerank,GO_Biological_Process_2021__positive regulation of multicellular organismal process (GO:0051240),0.7260825744135041,1.1316402124519531,0.19463087248322147,0.8929716232341539,1.0,4/307,1.39%,AXIN2;APOE;CYP27B1;PRLR
prerank,GO_Biological_Process_2021__ubiquinone biosynthetic process (GO:0006744),0.6225993980615128,1.1308573237265487,0.3548387096774194,0.8927361855914333,1.0,2/15,1.22%,COQ8A;FDXR
prerank,KEGG_2021_Human__Platelet activation,-0.8216178144475174,-1.1304495508705519,0.3017241379310345,0.9032719919446395,1.0,6/121,1.35%,RAP1A;AKT3;RAP1B;PIK3CB;RASGRP2;PIK3R6
prerank,GO_Biological_Process_2021__steroid hormone biosynthetic process (GO:0120178),0.704672298936039,1.1300217413907219,0.47297297297297297,0.8925652555565033,1.0,2/27,1.22%,HSD17B11;FDXR
prerank,MSigDB_Hallmark_2020__Adipogenesis,0.7524914637180059,1.1298840692469612,0.22302158273381295,0.8920392028494182,1.0,4/198,1.39%,GPAT4;SLC19A1;APOE;CAVIN1
prerank,GO_Biological_Process_2021__3'-phosphoadenosine 5'-phosphosulfate metabolic process (GO:0050427),-0.6355127140413906,-1.129534962416209,0.39669421487603307,0.9031641213691717,1.0,2/21,0.68%,TPST1;SULT1B1
prerank,WikiPathway_2021_Human__Ovarian infertility WP34,-0.6921803262240706,-1.1294254026702164,0.43902439024390244,0.9025738869121984,1.0,2/27,1.25%,CCND2;VDR
prerank,GO_Biological_Process_2021__positive regulation of double-strand break repair (GO:2000781),0.7979047311573844,1.1293780787873642,0.5486725663716814,0.8916741283100625,1.0,3/38,1.46%,SMCHD1;SPIRE2;WRAP53
prerank,"GO_Biological_Process_2021__mRNA splicing, via spliceosome (GO:0000398)",0.7279866866879071,1.1290697146460826,0.21379310344827587,0.8911986268119421,1.0,3/270,0.98%,CDC5L;PRPF40A;SF3A2
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.N4.V1 DN,0.7949183932107847,1.1285841819297369,0.2537313432835821,0.8908789032079185,1.0,5/152,0.80%,BCOR;HSD17B11;BRIP1;STMN3;ZNF394
prerank,WikiPathway_2021_Human__Alzheimer's disease WP2059,-0.8230494119554858,-1.1283205297218273,0.41237113402061853,0.9025606799479846,1.0,2/80,0.35%,GRIN2B;APP
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Familial Hemiplegic Migraine Type 3,0.6553144039549832,1.1278595049144267,0.3951612903225806,0.8906334324514472,1.0,3/18,1.54%,STX1A;GLS;SLC38A1
prerank,Reactome_2022__Cytochrome P450 - Arranged By Substrate Type R-HSA-211897,-0.8241453515209991,-1.1271022917207905,0.509090909090909,0.9025990080375547,1.0,6/57,1.27%,CYP39A1;CYP2C8;CYP4V2;NCOA1;CYP1A2;CYP1B1
prerank,Elsevier_Pathway_Collection__Epithelial to Mesenchymal Transition in Cancer: Overview,0.8220946331362357,1.1268773547990432,0.3722627737226277,0.8905211024209673,1.0,6/85,1.51%,PTK2;NOTCH3;TJP1;CRB3;FGF1;FN1
prerank,Elsevier_Pathway_Collection__Drugs Targets in Autistic Disoreder (Hypothesis),0.6212755262425678,1.1248696575661177,0.368,0.8909054508324731,1.0,1/17,0.02%,SLC6A4
prerank,GO_Biological_Process_2021__negative regulation of TOR signaling (GO:0032007),0.726467206626181,1.124782711854257,0.4642857142857143,0.8903607474073026,1.0,2/38,0.69%,PRKAA2;FNIP1
prerank,GO_Biological_Process_2021__chemical homeostasis (GO:0048878),-0.811306353754538,-1.1243081383531492,0.45871559633027525,0.9036335562755354,1.0,5/63,1.29%,KLHL3;TLCD4;WNK3;TM6SF2;SLC4A5
prerank,GO_Biological_Process_2021__long-chain fatty acid metabolic process (GO:0001676),-0.8430946711529413,-1.1241852681443874,0.456,0.9030628309777219,1.0,4/81,1.27%,CYP2C8;GSTA1;CYP1A2;CYP1B1
prerank,GO_Biological_Process_2021__respiratory system development (GO:0060541),0.7738111041221576,1.1241110356983974,0.5408805031446541,0.8900892429786429,1.0,3/32,1.36%,SMCHD1;CCDC40;FGF1
prerank,GO_Biological_Process_2021__regulation of organelle organization (GO:0033043),0.8285412884078515,1.1237654300890063,0.41911764705882354,0.8897248635102171,1.0,5/79,1.05%,PTK2;CLEC16A;TJP1;STMN3;CAMSAP3
prerank,GO_Biological_Process_2021__ubiquinone metabolic process (GO:0006743),0.6225993859435666,1.123264386088631,0.35714285714285715,0.8893609548162982,1.0,2/15,1.22%,COQ8A;FDXR
prerank,GO_Biological_Process_2021__positive regulation of cation transmembrane transport (GO:1904064),-0.8124777926391902,-1.1231771995682558,0.5681818181818182,0.902976739579953,1.0,2/40,0.82%,KCNN2;KCNE1
prerank,KEGG_2021_Human__Progesterone-mediated oocyte maturation,-0.8151234078849132,-1.1230515657044806,0.3559322033898305,0.9024284506767624,1.0,3/90,0.73%,CPEB3;AKT3;PIK3CB
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Migraine Type 2,0.6553145330412941,1.1223696991830288,0.4,0.8892376306286405,1.0,3/18,1.54%,STX1A;GLS;SLC38A1
prerank,Reactome_2022__Cytosolic Sulfonation Of Small Molecules R-HSA-156584,-0.6355130525122122,-1.122203522762854,0.4016393442622951,0.9022916027065043,1.0,2/20,0.68%,TPST1;SULT1B1
prerank,GO_Biological_Process_2021__negative regulation of myeloid cell differentiation (GO:0045638),-0.6059790269015527,-1.1220116183099142,0.358974358974359,0.9017566542092119,1.0,2/22,0.86%,PTK2B;MEIS1
prerank,"Reactome_2022__Platelet Activation, Signaling And Aggregation R-HSA-76002",-0.7142413500423437,-1.121991530562839,0.21100917431192662,0.9011259805671448,1.0,12/245,1.35%,A1BG;RAP1A;APP;RAP1B;PROS1;NHLRC2;PIK3CB;RASGRP2;GNA14;VAV1;HRG;PIK3R6
prerank,WikiPathway_2021_Human__DNA damage response (only ATM dependent) WP710,-0.8171997920049201,-1.1219904800658815,0.37735849056603776,0.9004841529456582,1.0,3/109,0.93%,AKT3;PIK3CB;CCND2
prerank,Elsevier_Pathway_Collection__CD38 -> cADPR/Calcium Signaling,-0.6495645840850227,-1.1216767946370876,0.4214876033057851,0.9000389506544684,1.0,1/25,0.67%,PTK2B
prerank,Reactome_2022__Regulation Of Cholesterol Biosynthesis By SREBP (SREBF) R-HSA-1655829,0.7798241286717759,1.1214671134444156,0.5069444444444444,0.8891585398052447,1.0,4/55,1.16%,ACACA;TBL1X;PPARA;PKMYT1
prerank,MSigDB_Oncogenic_Signatures__KRAS.600.LUNG.BREAST UP.V1 UP,0.7837991346072939,1.1213729751608998,0.25735294117647056,0.8886244108326533,1.0,8/226,1.46%,KCNC1;GFI1;ITGA2;TBX3;STX1A;A2M;COL9A3;FAM120C
prerank,GO_Biological_Process_2021__purine nucleoside bisphosphate metabolic process (GO:0034032),-0.6797800003969084,-1.121267074014268,0.44274809160305345,0.8990091311358231,1.0,2/31,0.54%,GLYAT;ACSM2B
prerank,GO_Biological_Process_2021__ribonucleoside bisphosphate metabolic process (GO:0033875),-0.6797800003969084,-1.121267074014268,0.44274809160305345,0.8990091311358231,1.0,2/31,0.54%,GLYAT;ACSM2B
prerank,Reactome_2022__Phase II - Conjugation Of Compounds R-HSA-156580,-0.7989861996400252,-1.120885944534255,0.38524590163934425,0.8986109930368513,1.0,8/99,0.90%,GSTA2;GLYAT;GSTA1;GGT5;TPST1;ACSM2B;SULT1B1;CYP1A2
prerank,KEGG_2021_Human__Coronavirus disease,-0.7438015041931342,-1.1203834695172237,0.22448979591836735,0.8982314344820821,1.0,4/210,1.26%,OAS1;PIK3CB;C1R;TMPRSS2
prerank,GO_Biological_Process_2021__negative regulation of chemotaxis (GO:0050922),-0.6903791247591177,-1.120217189961479,0.4519230769230769,0.8976813988011171,1.0,2/32,1.26%,SEMA4D;HRG
prerank,GO_Biological_Process_2021__mitotic sister chromatid segregation (GO:0000070),0.845577563777798,1.12007559689208,0.3959731543624161,0.8887072143247352,1.0,5/101,1.03%,CENPE;NCAPG;NDC80;DIS3L2;KIF23
prerank,Elsevier_Pathway_Collection__Potassium Flux Regulation,-0.7443348541683015,-1.12004821472481,0.45528455284552843,0.8971381390510923,1.0,2/44,0.97%,RAP1A;HRH2
prerank,GO_Biological_Process_2021__negative regulation of DNA recombination (GO:0045910),0.8235908847391947,1.119699124114938,0.5078125,0.8883378010257187,1.0,3/52,1.41%,MSH2;SMCHD1;ACD
prerank,GO_Biological_Process_2021__negative regulation of protein depolymerization (GO:1901880),-0.6337392796704365,-1.1194134653405063,0.4051724137931034,0.8969162231852106,1.0,2/24,1.33%,TTBK2;HDGFL3
prerank,WikiPathway_2021_Human__Thermogenesis WP4321,0.8079329456502562,1.119164490944871,0.35658914728682173,0.8880201507493536,1.0,3/105,1.27%,PRKAA2;ACSL5;KLB
prerank,GO_Biological_Process_2021__regulation of telomere maintenance via telomerase (GO:0032210),0.8062166739700568,1.11900762284296,0.5116279069767442,0.8875345010389063,1.0,4/51,1.41%,ATR;PARN;PIF1;ACD
prerank,KEGG_2021_Human__Prostate cancer,-0.8028980578936519,-1.1184063199613818,0.3504273504273504,0.8968592860380712,1.0,5/96,1.26%,AKT3;RB1;PIK3CB;CREB5;TMPRSS2
prerank,GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process (GO:0000956),0.7983190639341151,1.1183954919912396,0.272108843537415,0.887242166582022,1.0,3/171,0.88%,DIS3L2;UPF2;PARN
prerank,"GO_Biological_Process_2021__DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977)",0.8410887938328231,1.117903189290365,0.5531914893617021,0.8869307071522767,1.0,3/55,1.19%,ARID3A;PRAP1;PCBP4
prerank,GO_Biological_Process_2021__hexose transmembrane transport (GO:0008645),-0.6636129056469287,-1.117852344340485,0.448,0.8965571030771526,1.0,1/22,0.27%,SLC2A10
prerank,MSigDB_Oncogenic_Signatures__DCA UP.V1 UP,-0.7660706196703263,-1.1169460930560167,0.23636363636363636,0.8964137997604592,1.0,6/139,1.35%,KLHL3;CD27;GARNL3;CREB5;PRRG4;COLQ
prerank,GO_Biological_Process_2021__transcription by RNA polymerase II (GO:0006366),0.7171877335933405,1.116828357620913,0.21935483870967742,0.8869241470171505,1.0,10/307,1.27%,TRIM24;ZNF473;NOTCH3;TBL1X;GTF2I;TAF4;PPARA;TCEA1;TEAD4;TCFL5
prerank,Reactome_2022__Signaling By ROBO Receptors R-HSA-376176,0.7789097846662838,1.1165669674414649,0.2653061224489796,0.8865061760763759,1.0,4/202,0.96%,ARHGAP39;UPF2;ARHGEF7;COL4A5
prerank,GO_Biological_Process_2021__amino acid transmembrane transport (GO:0003333),-0.6868963569078197,-1.1165586185321814,0.4444444444444444,0.8960436443627199,1.0,3/40,1.02%,SLC7A8;SLC36A4;SLC16A2
prerank,GO_Biological_Process_2021__positive regulation of telomerase activity (GO:0051973),0.7229916304159698,1.1165478582406398,0.49137931034482757,0.8859500672502284,1.0,3/34,1.46%,PARN;ACD;WRAP53
prerank,KEGG_2021_Human__ECM-receptor interaction,0.8458339753935218,1.1153946579753715,0.45528455284552843,0.8860024994759487,1.0,5/83,1.51%,ITGA2;COL4A5;ITGB5;COL9A3;FN1
prerank,WikiPathway_2021_Human__7q11.23 copy number variation syndrome WP4932,0.843754876641685,1.1152481893837471,0.3712121212121212,0.8854935905486108,1.0,6/99,1.20%,CLIP2;ACACA;GTF2I;EIF2A;PKLR;STX1A
prerank,GO_Biological_Process_2021__cellular response to cytokine stimulus (GO:0071345),-0.6861900196570184,-1.115099069560961,0.2222222222222222,0.8963815632228166,1.0,11/434,1.36%,CCL23;OAS1;PIK3CB;HCK;GBP4;VAV1;IL10RA;IL12RB2;S1PR1;PTPN18;GRB10
prerank,Elsevier_Pathway_Collection__FGFR -> AP-1/CREB/CREBBP/ELK/SRF/MYC Signaling,-0.7737744369171449,-1.1145508271592206,0.5309734513274337,0.8961312864507647,1.0,2/49,0.67%,MAP2K6;PTK2B
prerank,WikiPathway_2021_Human__Angiogenesis WP1539,0.6469036824415108,1.1145206264152798,0.42857142857142855,0.8852524351581587,1.0,1/24,0.26%,PTK2
prerank,GO_Biological_Process_2021__monocarboxylic acid metabolic process (GO:0032787),-0.810459430405401,-1.1143408617319577,0.3103448275862069,0.8956309380306308,1.0,8/139,0.90%,CYP2C8;GLYAT;CYP3A7;VNN1;GGT5;BTD;ECHDC3;CYP1A2
prerank,Elsevier_Pathway_Collection__TP53 Signaling in Hepatocellular Carcinoma,-0.5993384324324826,-1.113756633451666,0.3821138211382114,0.8953755840836083,1.0,2/18,0.93%,RB1;CCND2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Age-Related Macular Degeneration,-0.7778475770360755,-1.1135343473434487,0.30434782608695654,0.8949151733031452,1.0,2/138,0.35%,RAP1A;APP
prerank,GO_Biological_Process_2021__regulation of defense response to virus (GO:0050688),0.5998051632735225,1.112321850295487,0.3492063492063492,0.885877902396236,1.0,1/15,0.44%,TRAF3
prerank,GO_Biological_Process_2021__cilium assembly (GO:0060271),0.7372076937422383,1.111821095714066,0.2534246575342466,0.8855955829253749,1.0,9/302,1.41%,NUDCD3;CEP164;HAUS8;HAUS2;CCDC40;SEPTIN6;TUBA1A;KIF3B;FLNA
prerank,GO_Biological_Process_2021__endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888),-0.7274419088725224,-1.1114326092750701,0.28,0.8957762893431873,1.0,3/181,1.04%,PROS1;ATL2;TICAM2
prerank,GO_Biological_Process_2021__transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178),0.8242179091010053,1.1113726395732593,0.2876712328767123,0.8852942356047588,1.0,6/128,1.47%,MEGF8;PTK2;AMH;ARHGEF18;ITGB5;ZFYVE9
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771),0.6908090833642697,1.1106396048366463,0.4806201550387597,0.8850974191056509,1.0,1/21,0.17%,MSH2
prerank,GO_Biological_Process_2021__negative regulation of stress fiber assembly (GO:0051497),0.6354752119771012,1.1102761287750162,0.41353383458646614,0.8847411032805348,1.0,2/23,1.15%,TJP1;ARHGEF18
prerank,GO_Biological_Process_2021__regulation of osteoblast differentiation (GO:0045667),0.8316806409791142,1.110266861662475,0.4573643410852713,0.8841820525855915,1.0,4/80,1.09%,CDK6;PTK2;LRP5;CHRD
prerank,Elsevier_Pathway_Collection__JNK/MAPK Signaling,-0.7413469872068579,-1.1099468002338857,0.512,0.8960981069551269,1.0,2/36,1.16%,PAK2;MAP4K1
prerank,MSigDB_Oncogenic_Signatures__MYC UP.V1 UP,0.8535819763744414,1.1096938307931183,0.3142857142857143,0.883957312045101,1.0,6/147,1.45%,FOXRED2;SLC19A1;CGREF1;PRAP1;PRR7;LRRC61
prerank,GO_Biological_Process_2021__glutamate metabolic process (GO:0006536),-0.6504107328723842,-1.1096838422772293,0.415929203539823,0.895641129526537,1.0,1/22,0.61%,AADAT
prerank,Elsevier_Pathway_Collection__Proteins Involved in Dental Caries,-0.6311517616857057,-1.1096758652139094,0.39805825242718446,0.8950274528868597,1.0,1/24,0.09%,CCL23
prerank,"GO_Biological_Process_2021__RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377)",0.7279964264882696,1.1093047620790242,0.24161073825503357,0.8836434716110155,1.0,3/247,0.98%,CDC5L;PRPF40A;SF3A2
prerank,GO_Biological_Process_2021__negative regulation of biosynthetic process (GO:0009890),0.6069016763929006,1.1089798905089006,0.3770491803278688,0.8832165583094859,1.0,2/17,1.48%,PPARA;SLC30A10
prerank,WikiPathway_2021_Human__Nuclear Receptors Meta-Pathway WP2882,-0.681919001175124,-1.1089687469694893,0.22580645161290322,0.8948507283804792,1.0,10/301,1.27%,GSTA2;GSTA1;CYP3A7;SLC2A10;NCOA1;NR3C1;CYP1A2;PRRG4;VDR;CYP1B1
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Migraine Type 1,0.6553139628740392,1.108926163693471,0.40476190476190477,0.882679200557587,1.0,3/19,1.54%,STX1A;GLS;SLC38A1
prerank,"WikiPathway_2021_Human__Metabolic pathway of LDL, HDL and TG, including diseases WP4522",-0.5599383676153578,-1.1086462059029374,0.33076923076923076,0.8944311601418176,1.0,1/16,0.92%,LIPG
prerank,MSigDB_Oncogenic_Signatures__PRC1 BMI UP.V1 UP,0.80147213680682,1.1080085736352236,0.32142857142857145,0.8825789588535067,1.0,6/151,1.44%,KCNC1;STMN3;QPRT;PACSIN3;SOAT2;SERPINA7
prerank,GO_Biological_Process_2021__positive regulation of ATP metabolic process (GO:1903580),0.7055126644913379,1.1079032285126607,0.4883720930232558,0.8820884726334477,1.0,2/29,0.79%,PRKAA2;PPARA
prerank,MSigDB_Oncogenic_Signatures__AKT UP MTOR DN.V1 UP,0.7669381610882382,1.1078743806904063,0.25757575757575757,0.8815528535610738,1.0,4/159,1.31%,TRAF3;MYCN;PACSIN3;CPE
prerank,WikiPathway_2021_Human__FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,-0.5879031796564854,-1.107769826441155,0.3391304347826087,0.8944535851051684,1.0,1/18,0.84%,GALNT3
prerank,MSigDB_Oncogenic_Signatures__KRAS.DF.V1 UP,-0.7358819524744848,-1.1075406412897693,0.26881720430107525,0.8939815951555211,1.0,3/182,1.05%,SLC2A10;AKT3;HERC5
prerank,TRRUST_Transcription_Factors_2019__CREB1 human,0.84829321708669,1.1074528197620657,0.48031496062992124,0.8811911923219703,1.0,3/81,0.51%,NDC80;ACACA;SLC19A1
prerank,KEGG_2021_Human__Pentose phosphate pathway,-0.6947175006404176,-1.1072726532028327,0.46511627906976744,0.8935368901235485,1.0,2/27,0.25%,ALDOB;DERA
prerank,GO_Biological_Process_2021__regulation of cellular senescence (GO:2000772),0.7682356528576839,1.1062896340687907,0.5583333333333333,0.8812773420293352,1.0,4/31,1.48%,CDK6;RBL1;NEK4;SLC30A10
prerank,GO_Biological_Process_2021__mitotic cell cycle phase transition (GO:0044772),0.7540295435947328,1.1052874648105164,0.27972027972027974,0.881380207804329,1.0,9/206,1.31%,MELK;CDK6;BRSK1;CEP164;HAUS8;HAUS2;UBE2C;PKMYT1;TUBA1A
prerank,Elsevier_Pathway_Collection__G0/G1 Cell Cycle Phase Transition Activation in Cancer,0.7654657617040922,1.1051894647721254,0.4965034965034965,0.8808728158440747,1.0,3/49,0.28%,CDK6;PTK2;AATF
prerank,GO_Biological_Process_2021__regulation of G2/M transition of mitotic cell cycle (GO:0010389),0.7815800624588107,1.1046611730621358,0.30344827586206896,0.8805917181538406,1.0,4/145,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__response to interferon-gamma (GO:0034341),-0.7617202086016174,-1.1038936723517516,0.35964912280701755,0.8952508639427896,1.0,2/74,0.98%,CCL23;GBP4
prerank,Reactome_2022__Transmission Across Chemical Synapses R-HSA-112315,0.7500763578789292,1.1028221739616344,0.27692307692307694,0.8810786686694863,1.0,10/214,1.54%,SLC6A4;PRKAA2;LIN7A;DLG1;ARHGEF7;GPRIN1;PPFIA4;GNB5;STX1A;SLC38A1
prerank,GO_Biological_Process_2021__negative regulation of NIK/NF-kappaB signaling (GO:1901223),0.6454099956765034,1.102699901259965,0.416,0.8805868139194396,1.0,2/23,1.55%,TSPAN6;UACA
prerank,WikiPathway_2021_Human__LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.8112043567168313,1.1020607170510006,0.46564885496183206,0.8803591414104271,1.0,3/87,0.40%,AXIN2;CDK6;LRP5
prerank,Reactome_2022__RHOU GTPase Cycle R-HSA-9013420,0.748229099871679,1.101828909229884,0.5140845070422535,0.8799210402432314,1.0,3/39,0.83%,DEPDC1B;WWP2;ARHGEF7
prerank,Elsevier_Pathway_Collection__Proteins Involved in Male Infertility,0.7912898644403084,1.1012056376832005,0.2676056338028169,0.8797921871909917,1.0,4/153,1.06%,MSH2;SYCP3;ETV5;DMWD
prerank,"GO_Biological_Process_2021__DNA-templated transcription, initiation (GO:0006352)",0.7857693363711267,1.1011803858913156,0.2972972972972973,0.8792593361172202,1.0,7/163,1.39%,NOTCH3;TBL1X;TAF1B;TAF4;PPARA;TEAD4;CAVIN1
prerank,GO_Biological_Process_2021__negative regulation of blood vessel endothelial cell migration (GO:0043537),-0.6717067221807058,-1.1010494874205727,0.44642857142857145,0.8965370422413264,1.0,2/33,1.26%,KLF4;HRG
prerank,KEGG_2021_Human__T cell receptor signaling pathway,-0.8013299097398487,-1.1003252685084894,0.3888888888888889,0.8964162177841705,1.0,5/99,1.13%,AKT3;PAK2;PIK3CB;VAV1;ZAP70
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Acetylation R-HSA-6804758,-0.681371201086349,-1.0998384033361743,0.46564885496183206,0.8961008579933276,1.0,3/29,1.31%,MAP2K6;AKT3;PML
prerank,GO_Biological_Process_2021__endoplasmic reticulum organization (GO:0007029),-0.7501754530854658,-1.0996174430298322,0.4375,0.89561495358293,1.0,2/69,0.58%,APP;ATL2
prerank,GO_Biological_Process_2021__cellular component assembly (GO:0022607),0.7275862248798229,1.0979250374668421,0.24305555555555555,0.8806439166749751,1.0,12/251,1.41%,BAIAP2L2;LIN7A;YTHDF3;RHOQ;CCDC40;ESPN;DPYSL3;SHROOM1;HAS3;FBLIM1;FLNA;ACD
prerank,GO_Biological_Process_2021__extracellular matrix assembly (GO:0085029),-0.6431033917188572,-1.097568477929915,0.4274193548387097,0.8964701329786523,1.0,1/24,0.33%,NTN4
prerank,WikiPathway_2021_Human__Apoptosis Modulation and Signaling WP1772,0.7964599135960775,1.0974618335364505,0.4153846153846154,0.8804025938016116,1.0,5/87,1.51%,TNFRSF10A;TRAF3;TNFRSF25;TNFRSF10D;BOK
prerank,MSigDB_Hallmark_2020__KRAS Signaling Dn,-0.7533005655004468,-1.0973942414799565,0.31313131313131315,0.8959758161695376,1.0,4/162,1.28%,CYP39A1;CPEB3;NTF3;TENT5C
prerank,WikiPathway_2021_Human__Fatty Acid Biosynthesis WP357,0.6863744425276399,1.0969500653262836,0.4666666666666667,0.8801615744790319,1.0,2/22,1.18%,ACACA;ACSL5
prerank,Reactome_2022__Elastic Fibre Formation R-HSA-1566948,0.7739679132260772,1.0963954511505924,0.5547445255474452,0.879949483764958,1.0,2/39,1.33%,FBN3;ITGB5
prerank,GO_Biological_Process_2021__negative regulation of oxidative stress-induced cell death (GO:1903202),-0.6815942562428973,-1.09632225760242,0.4864864864864865,0.8961176269616978,1.0,1/27,0.11%,VNN1
prerank,KEGG_2021_Human__Sphingolipid metabolism,-0.7724718221828794,-1.0961899934034418,0.528,0.895591904259647,1.0,2/47,0.99%,SGPP1;GALC
prerank,KEGG_2021_Human__Cholinergic synapse,-0.7975366958759267,-1.0961271194477769,0.35537190082644626,0.8950052186338885,1.0,4/103,1.35%,AKT3;PIK3CB;CREB5;PIK3R6
prerank,GO_Biological_Process_2021__cell-substrate junction assembly (GO:0007044),0.6966384078885185,1.0960319019608953,0.47183098591549294,0.8796208449290389,1.0,3/33,1.51%,THY1;ARHGEF7;FN1
prerank,GO_Biological_Process_2021__regulation of vesicle-mediated transport (GO:0060627),-0.8208861730513186,-1.0951232318332356,0.44036697247706424,0.8951738292994246,1.0,4/91,0.88%,STXBP5;ZFYVE16;HCK;SYT7
prerank,Elsevier_Pathway_Collection__KRAS Signaling,-0.7319119752953294,-1.094995147015943,0.5283018867924528,0.894611716846336,1.0,2/35,1.13%,RASGRP2;RASSF5
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through Integrins and non-ITAM-Containing Receptors,-0.7501306079657193,-1.09493086921309,0.5175438596491229,0.8940386568468283,1.0,5/44,1.18%,RAP1A;PTK2B;CD2;VAV1;CLEC2B
prerank,GO_Biological_Process_2021__DNA replication (GO:0006260),0.834919305056112,1.094822341568779,0.381294964028777,0.8798119980801586,1.0,5/106,1.13%,CDC45;ING5;BRIP1;ATR;PIF1
prerank,Elsevier_Pathway_Collection__Androgens in Sebocyte Maturation,0.8058064827401904,1.0947850980177214,0.5217391304347826,0.8792886175151693,1.0,3/64,1.53%,AXIN2;PPARA;LRIG1
prerank,GO_Biological_Process_2021__glycosaminoglycan biosynthetic process (GO:0006024),0.799542321650992,1.094465529119515,0.43884892086330934,0.8789181803824018,1.0,3/94,1.34%,ST3GAL1;SLC35D2;HAS3
prerank,Reactome_2022__Signaling By WNT R-HSA-195721,0.7208018259225641,1.093980538809475,0.2714285714285714,0.8787051551860031,1.0,3/272,1.11%,AXIN2;LRP5;GNB5
prerank,KEGG_2021_Human__Tight junction,0.7531417395085174,1.093894185720367,0.2867132867132867,0.8781977099205333,1.0,6/159,1.31%,PRKAA2;TJP1;DLG1;CRB3;ARHGEF18;TUBA1A
prerank,GO_Biological_Process_2021__positive regulation of Wnt signaling pathway (GO:0030177),0.798170334038442,1.0938376839435715,0.31343283582089554,0.8776813996767792,1.0,3/149,0.43%,AXIN2;DEPDC1B;TBL1X
prerank,GO_Biological_Process_2021__regulation of DNA metabolic process (GO:0051052),0.7507801543644699,1.093758328660313,0.52,0.8771965911712564,1.0,3/45,1.43%,HDAC8;PIF1;MPV17
prerank,GO_Biological_Process_2021__synaptic vesicle cycle (GO:0099504),0.6689692960538182,1.0936642535258843,0.456,0.8767076445745439,1.0,2/25,1.20%,BRSK1;STX1A
prerank,KEGG_2021_Human__Non-small cell lung cancer,-0.750420870353632,-1.0934160590275777,0.47107438016528924,0.8944771124020744,1.0,4/71,1.13%,AKT3;RB1;PIK3CB;RASSF5
prerank,GO_Biological_Process_2021__cell-cell junction assembly (GO:0007043),0.8109368030480546,1.0926949579673384,0.4566929133858268,0.876764539719469,1.0,4/61,0.47%,GJC1;TBCD;TJP1;CNTNAP1
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Activation,-0.7359563198321619,-1.092153268781255,0.4434782608695652,0.8946602598022515,1.0,3/58,1.19%,PTK2B;ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__Golgi organization (GO:0007030),-0.763380466621994,-1.0917162186733453,0.3181818181818182,0.8943458058840744,1.0,4/124,1.11%,ATL2;ZNF501;TICAM2;SYNE1
prerank,GO_Biological_Process_2021__post-Golgi vesicle-mediated transport (GO:0006892),-0.7990001302596825,-1.0916034105274317,0.4108527131782946,0.8938066728856244,1.0,5/88,1.32%,APP;MON2;EXOC2;VPS13C;VPS35L
prerank,KEGG_2021_Human__Central carbon metabolism in cancer,-0.7883746933194963,-1.0915523682352828,0.39823008849557523,0.8932186184402428,1.0,2/68,0.73%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway (GO:2001236),-0.7523519025705935,-1.0911597068866397,0.4666666666666667,0.8928766152930412,1.0,4/62,1.31%,BIRC6;PAK2;DEPTOR;PML
prerank,GO_Biological_Process_2021__steroid metabolic process (GO:0008202),-0.8083810595610759,-1.0909514266664144,0.45217391304347826,0.8924154661312229,1.0,8/95,1.27%,CYP39A1;CYP2C8;CYP3A7;CYP4V2;STS;CYP1A2;VDR;CYP1B1
prerank,GO_Biological_Process_2021__negative regulation of actin filament bundle assembly (GO:0032232),0.6354737054362855,1.0907394713588925,0.4461538461538462,0.8773662544304852,1.0,2/26,1.15%,TJP1;ARHGEF18
prerank,Elsevier_Pathway_Collection__Proteins Involved in Prostate Cancer,-0.7422529331890307,-1.0902887034028368,0.35,0.8923164740089551,1.0,6/130,1.26%,NR3C1;RB1;PTK2B;PIK3CB;VDR;TMPRSS2
prerank,KEGG_2021_Human__Salmonella infection,-0.7035458820309777,-1.0897044241129028,0.2413793103448276,0.8920894247971306,1.0,7/242,0.96%,ARHGEF26;MAP2K6;AKT3;EXOC2;PIK3CB;KPNA3;RHOH
prerank,Reactome_2022__Glycosphingolipid Metabolism R-HSA-1660662,-0.7355483650134449,-1.0896856864338527,0.49523809523809526,0.8914929298740657,1.0,2/43,0.99%,STS;GALC
prerank,GO_Biological_Process_2021__protein targeting to lysosome (GO:0006622),-0.6375259901535811,-1.0893704403718718,0.41911764705882354,0.891115466422557,1.0,1/20,0.74%,ZFYVE16
prerank,GO_Biological_Process_2021__positive regulation of DNA biosynthetic process (GO:2000573),0.7940688864330344,1.0888846694362366,0.48412698412698413,0.8780571876480229,1.0,4/61,1.46%,ATR;PARN;ACD;WRAP53
prerank,Reactome_2022__Activation Of Pre-Replicative Complex R-HSA-68962,0.6966098197447443,1.0885699658806736,0.5036496350364964,0.8777250887857799,1.0,2/31,0.72%,CDC45;POLE4
prerank,TRRUST_Transcription_Factors_2019__TFAP2A human,-0.7879074539265984,-1.088221637227476,0.48739495798319327,0.8913200178482726,1.0,4/66,0.84%,APP;DCBLD2;NR3C1;GALNT3
prerank,Reactome_2022__Chromatin Modifying Enzymes R-HSA-3247509,0.7412394457299253,1.087927680679512,0.3263888888888889,0.8776180465815824,1.0,6/220,1.05%,ING5;ASH1L;HDAC8;TBL1X;PHF2;PADI2
prerank,GO_Biological_Process_2021__positive regulation of cell cycle process (GO:0090068),0.8200350743989047,1.0878658469972948,0.43410852713178294,0.8771212115031397,1.0,5/84,1.03%,NDC80;CEP295;LRP5;SVIL;KIF23
prerank,Elsevier_Pathway_Collection__Follicular Lymphoma,-0.7718105278179536,-1.0877643982279666,0.40458015267175573,0.8910361671124524,1.0,5/94,1.19%,PTK2B;CCND2;SCIMP;IL21R;IL12RB2
prerank,MSigDB_Oncogenic_Signatures__ERB2 UP.V1 DN,0.7820191322410313,1.087555828757849,0.31690140845070425,0.8767785064588461,1.0,10/177,1.53%,CENPE;NCAPG;MSH2;RALGAPA1;ATR;DEPDC1;HIRA;CEBPZ;COL9A3;LRIG1
prerank,Reactome_2022__Heme Signaling R-HSA-9707616,0.7402874354988305,1.0875015195523061,0.4961832061068702,0.8762639294392477,1.0,3/43,0.79%,BRIP1;TBL1X;PPARA
prerank,GO_Biological_Process_2021__limb development (GO:0060173),0.66586137450337,1.0869584392699807,0.4782608695652174,0.8760707864980989,1.0,1/28,0.15%,MEGF8
prerank,GO_Biological_Process_2021__mitotic DNA damage checkpoint signaling (GO:0044773),0.7859942377221956,1.0867579589293321,0.48175182481751827,0.8756232931771356,1.0,2/58,0.52%,BRSK1;FBXO31
prerank,"GO_Biological_Process_2021__DNA damage response, signal transduction by p53 class mediator (GO:0030330)",0.8410794810618318,1.0864172869674456,0.49264705882352944,0.8753200625225501,1.0,3/73,1.19%,ARID3A;PRAP1;PCBP4
prerank,MSigDB_Oncogenic_Signatures__BRCA1 DN.V1 UP,-0.7700442157350276,-1.0864012294865106,0.35,0.8914379294380133,1.0,4/93,1.10%,LDB2;SLCO1A2;RHOH;VAV1
prerank,KEGG_2021_Human__Oxytocin signaling pathway,0.7747691115843794,1.086365233823828,0.28776978417266186,0.8748382742194273,1.0,1/142,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__neuron differentiation (GO:0030182),0.7898330078911593,1.0863167719458877,0.34532374100719426,0.8743359068980099,1.0,3/136,1.03%,VAX2;BRSK1;MYO7A
prerank,GO_Biological_Process_2021__regulation of axon extension involved in axon guidance (GO:0048841),0.681558164960918,1.0853381473261505,0.46099290780141844,0.8744149765373015,1.0,2/24,1.40%,MEGF8;SEMA3G
prerank,KEGG_2021_Human__cGMP-PKG signaling pathway,-0.7434318286683553,-1.0843879687889355,0.3047619047619048,0.8922424488248721,1.0,4/154,1.35%,PDE5A;AKT3;CREB5;PIK3R6
prerank,MSigDB_Oncogenic_Signatures__RAF UP.V1 DN,0.7710410517973763,1.0830875135318088,0.3076923076923077,0.8753164550748966,1.0,4/176,1.53%,GTF2I;CPE;COL9A3;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of binding (GO:0051099),-0.7659826112848546,-1.0823697514235857,0.3944954128440367,0.8931647452430641,1.0,2/89,0.72%,APP;AMFR
prerank,KEGG_2021_Human__p53 signaling pathway,0.823473372079685,1.0823678907515333,0.49264705882352944,0.8752750432526939,1.0,4/72,1.18%,CDK6;TNFRSF10A;ATR;RRM2
prerank,KEGG_2021_Human__Fc gamma R-mediated phagocytosis,-0.7902262676608327,-1.0821779943696141,0.4166666666666667,0.8927500201330456,1.0,4/94,1.10%,AKT3;PIK3CB;HCK;VAV1
prerank,GO_Biological_Process_2021__autophagosome maturation (GO:0097352),-0.6399673930887122,-1.0819686194418288,0.44166666666666665,0.8923011162735762,1.0,1/34,0.70%,UVRAG
prerank,GO_Biological_Process_2021__negative regulation of DNA replication (GO:0008156),-0.5186863915409493,-1.0819283552457755,0.3153846153846154,0.8917139356665343,1.0,2/15,1.30%,GMNC;SLFN11
prerank,KEGG_2021_Human__Cysteine and methionine metabolism,-0.8205932050709497,-1.0817382007713114,0.5641025641025641,0.8912576789303688,1.0,3/49,1.17%,AHCYL2;BHMT;CDO1
prerank,Reactome_2022__Termination Of O-glycan Biosynthesis R-HSA-977068,-0.6123579204809774,-1.0812807353589888,0.4198473282442748,0.8910129867543636,1.0,1/20,0.02%,MUC6
prerank,GO_Biological_Process_2021__cellular response to insulin stimulus (GO:0032869),0.8070602532780483,1.0810992627771971,0.36428571428571427,0.8755599313353779,1.0,3/121,1.49%,RHOQ;PKLR;BCAR1
prerank,WikiPathway_2021_Human__Pathways Regulating Hippo Signaling WP4540,0.824486340956508,1.080902456029501,0.4,0.8751618795662538,1.0,3/92,1.21%,PRKAA2;TEAD4;CDH15
prerank,GO_Biological_Process_2021__phosphatidylinositol metabolic process (GO:0046488),-0.8027230404310861,-1.0803784010457296,0.35964912280701755,0.8911411333963807,1.0,3/107,1.35%,PLAAT3;PIK3CB;PIK3R6
prerank,Reactome_2022__NCAM1 Interactions R-HSA-419037,0.6991628428237355,1.0797552933974133,0.5109489051094891,0.8753925687076187,1.0,2/33,1.34%,COL4A5;COL9A3
prerank,GO_Biological_Process_2021__positive regulation of cell population proliferation (GO:0008284),0.6705265328917446,1.079679655094461,0.2608695652173913,0.8749014010174303,1.0,13/437,1.51%,CDK6;PTK2;LRP5;TJP1;ZNF304;TBX3;ERBB3;CHRD;SAPCD2;CTSH;FGF1;PRLR;FN1
prerank,Elsevier_Pathway_Collection__Hedgehog Signaling Activation in Cancer,-0.6000738597005152,-1.0796376392250318,0.35833333333333334,0.890485654290097,1.0,2/17,1.22%,CCND2;GLI3
prerank,Elsevier_Pathway_Collection__Hedgehog Signaling Activation by Blocking of Tumor Suppressors,-0.6000738597005152,-1.0796376392250318,0.35833333333333334,0.890485654290097,1.0,2/17,1.22%,CCND2;GLI3
prerank,GO_Biological_Process_2021__negative regulation of mRNA catabolic process (GO:1902373),0.6869613918052094,1.0794766970212315,0.4888888888888889,0.8745232227444711,1.0,1/27,0.12%,AXIN2
prerank,GO_Biological_Process_2021__protein acylation (GO:0043543),0.6878726077392067,1.0789231528707524,0.4666666666666667,0.8743233414797098,1.0,3/37,1.23%,ING5;NAA10;ZDHHC9
prerank,GO_Biological_Process_2021__regulation of cell migration (GO:0030334),0.6826541932781685,1.0789078495111475,0.2978723404255319,0.8737916486287499,1.0,18/387,1.49%,THY1;PTK2;SRGAP2B;TJP1;YTHDF3;ZNF304;MCTP1;STK26;CAMSAP3;CHRD;SH3RF2;CTSH;ULK4;DPYSL3;FGF1;SEMA3G;FLNA;BCAR1
prerank,GO_Biological_Process_2021__positive regulation of carbohydrate metabolic process (GO:0045913),0.6102815979216009,1.0788853274544234,0.4016393442622951,0.8732699585558262,1.0,1/22,0.03%,PRKAA2
prerank,MSigDB_Oncogenic_Signatures__EGFR UP.V1 DN,0.7412009473518902,1.0785988626147849,0.32653061224489793,0.8729637818824185,1.0,10/164,1.34%,TRIM24;BRIP1;GTF2I;DEPDC1;HIRA;FANCL;PRR7;CTSH;CPE;COL9A3
prerank,Reactome_2022__Integrin Cell Surface Interactions R-HSA-216083,0.8417640650749312,1.0785435219493253,0.5422535211267606,0.8724619156093413,1.0,5/64,1.51%,ITGA2;ITGAL;ITGB5;COL9A3;FN1
prerank,MSigDB_Oncogenic_Signatures__SNF5 DN.V1 DN,-0.7420815496166459,-1.078538540361055,0.3238095238095238,0.8907262858454876,1.0,2/141,1.30%,VNN1;DNAJA4
prerank,GO_Biological_Process_2021__lipid modification (GO:0030258),-0.7510403128734666,-1.0783635515787462,0.5,0.8902552863514286,1.0,3/41,0.51%,CYP2C8;CYP3A7;SGPP1
prerank,GO_Biological_Process_2021__folic acid-containing compound metabolic process (GO:0006760),0.6253662331592252,1.0783134236666845,0.42063492063492064,0.8720912967205001,1.0,1/20,0.51%,SLC19A1
prerank,WikiPathway_2021_Human__MTHFR deficiency WP4288,-0.6039399176710541,-1.0782021681421157,0.39344262295081966,0.889764782989211,1.0,1/23,0.82%,BHMT
prerank,KEGG_2021_Human__Axon guidance,-0.7459102667254088,-1.0776123145428038,0.3047619047619048,0.8896660628873306,1.0,6/176,1.36%,NTN4;NEO1;PAK2;PIK3CB;SEMA4D;ABLIM3
prerank,GO_Biological_Process_2021__camera-type eye development (GO:0043010),0.6283113121836853,1.0776085047663437,0.4306569343065693,0.8719752398197539,1.0,1/23,0.83%,RAB3GAP1
prerank,GO_Biological_Process_2021__positive regulation of nitric-oxide synthase activity (GO:0051000),-0.6111773098193053,-1.0774037009175716,0.3853211009174312,0.8891881218651795,1.0,1/16,0.73%,PIK3CB
prerank,WikiPathway_2021_Human__Pancreatic adenocarcinoma pathway WP4263,-0.7698514855568782,-1.0773791871703824,0.4,0.8886103114989272,1.0,4/88,0.73%,AKT3;RB1;PAK2;PIK3CB
prerank,MSigDB_Oncogenic_Signatures__SRC UP.V1 DN,0.807492918838219,1.077299012567749,0.3472222222222222,0.8716100343603062,1.0,8/145,1.44%,IRAK2;GINS1;CDCA7;ZNF436;CPPED1;FANCL;PIK3C2B;SLC2A6
prerank,WikiPathway_2021_Human__Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.6982771078807132,1.0769839638129202,0.291044776119403,0.8713128004181464,1.0,11/283,1.51%,PRKAA2;ACACA;PTK2;ITGA2;CAB39;ITGAL;PIK3C2B;ITGB5;FGF1;PRLR;FN1
prerank,WikiPathway_2021_Human__Non-small cell lung cancer WP4255,-0.7504212863681512,-1.076922188550329,0.456,0.8883862954360666,1.0,4/70,1.13%,AKT3;RB1;PIK3CB;RASSF5
prerank,Reactome_2022__Chaperonin-mediated Protein Folding R-HSA-390466,0.7907245980006945,1.0765780341867113,0.46,0.871062470275514,1.0,4/81,1.46%,KIF13A;GNB5;TUBA1A;WRAP53
prerank,GO_Biological_Process_2021__regulation of nucleic acid-templated transcription (GO:1903506),-0.648907970393921,-1.0742703322666112,0.2636363636363636,0.8898317921093074,1.0,9/398,1.31%,ZNF66;ZNF90;ZNF708;ZNF85;NR3C1;RB1;RHOH;SPI1;PML
prerank,Elsevier_Pathway_Collection__EGFR Transactivation in Cancer and Non-Cancer Cells,-0.7727251500281045,-1.0736923117035326,0.512396694214876,0.8896387792788896,1.0,3/60,0.93%,PTK2B;PIK3CB;CCND2
prerank,GO_Biological_Process_2021__negative regulation of multicellular organismal process (GO:0051241),-0.6977275219642717,-1.0736723883767452,0.2980769230769231,0.8890536360983241,1.0,5/199,1.31%,MAP2K6;ADAMTS5;RB1;SPI1;PARP3
prerank,"GO_Biological_Process_2021__transcription, DNA-templated (GO:0006351)",0.7493143655507162,1.0732593709219889,0.3103448275862069,0.8729682225906997,1.0,6/210,1.27%,HOXD3;TRIM24;TAF1B;TAF4;TCEA1;TCFL5
prerank,GO_Biological_Process_2021__DNA-dependent DNA replication maintenance of fidelity (GO:0045005),0.795146825040925,1.0730013093001864,0.5869565217391305,0.8726242206659625,1.0,2/42,0.50%,MMS22L;ATR
prerank,Elsevier_Pathway_Collection__Amyloid beta and APP Intracellular Transport in Alzheimer Disease,-0.6373022338644363,-1.0726476127228017,0.43103448275862066,0.8892850217483333,1.0,1/20,0.35%,APP
prerank,WikiPathway_2021_Human__Oxidative Damage WP3941,0.7537898282552096,1.072415689475309,0.5367647058823529,0.8724943276138791,1.0,2/40,0.44%,MAP3K9;TRAF3
prerank,GO_Biological_Process_2021__regulation of microtubule depolymerization (GO:0031114),-0.6337386370337356,-1.0716392067628415,0.4322033898305085,0.8894159840060467,1.0,2/25,1.33%,TTBK2;HDGFL3
prerank,GO_Biological_Process_2021__positive regulation of plasma membrane bounded cell projection assembly (GO:0120034),0.7936686543390837,1.0713843351876209,0.4318181818181818,0.8726547525851971,1.0,6/79,1.47%,ABI2;RHOQ;ANLN;DPYSL3;DOCK11;CDC42EP1
prerank,GO_Biological_Process_2021__regulation of inflammatory response (GO:0050727),-0.7211665392880734,-1.0703115457210346,0.34545454545454546,0.8899269321380334,1.0,5/190,1.21%,APP;RB1;HCK;KLF4;TEK
prerank,WikiPathway_2021_Human__AMP-activated protein kinase (AMPK) signaling WP1403,0.7911468043993504,1.070250475908609,0.5227272727272727,0.8729147351682016,1.0,3/63,0.81%,PRKAA2;ACACA;CAB39
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG UP.V1 UP,0.8378463960965801,1.0702451872020546,0.4222222222222222,0.8723838130828558,1.0,6/114,1.53%,SLC6A4;ITGA2;ZNF749;TBX3;ASGR2;LRIG1
prerank,Reactome_2022__Apoptotic Cleavage Of Cellular Proteins R-HSA-111465,0.7367050699981013,1.0698110101369351,0.5474452554744526,0.8721385329165657,1.0,3/36,1.00%,PTK2;TJP1;STK26
prerank,GO_Biological_Process_2021__positive regulation of protein binding (GO:0032092),-0.7659939413792383,-1.0695870013649136,0.5391304347826087,0.8899116058080582,1.0,2/57,0.72%,APP;AMFR
prerank,MSigDB_Oncogenic_Signatures__CSR EARLY UP.V1 DN,-0.7543823382977479,-1.0690490355853481,0.36607142857142855,0.8896936299620589,1.0,3/134,1.21%,PDE5A;GLG1;NYNRIN
prerank,WikiPathway_2021_Human__Glycerolipids and Glycerophospholipids WP4722,0.5824411168442108,1.0685159946544571,0.36363636363636365,0.8725025569501472,1.0,1/22,0.32%,GPAT4
prerank,Reactome_2022__Translocation Of SLC2A4 (GLUT4) To Plasma Membrane R-HSA-1445148,0.7525571184315815,1.0682138918021686,0.5323741007194245,0.8721788208368563,1.0,3/51,1.35%,PRKAA2;RHOQ;KIF3B
prerank,GO_Biological_Process_2021__carboxylic acid metabolic process (GO:0019752),-0.7145102693979379,-1.068176726901777,0.4838709677419355,0.8897954376053304,1.0,3/38,1.08%,GLYAT;CYP1A2;HAO1
prerank,MSigDB_Oncogenic_Signatures__TBK1.DF DN,0.7036055071017534,1.067667571357128,0.32413793103448274,0.8720266254304897,1.0,10/263,1.52%,MSH2;CDK6;CLEC16A;ITGA2;ZNF557;ANKRD11;COL4A5;IGF2BP3;ZNF395;AMMECR1
prerank,"Reactome_2022__Transport Of Vitamins, Nucleosides, And Related Molecules R-HSA-425397",-0.7280228121728682,-1.067470923714986,0.5038167938931297,0.8896947109826354,1.0,3/41,1.02%,SLC35A3;SLCO1A2;SLC16A2
prerank,KEGG_2021_Human__Parkinson disease,0.7254573797941495,1.0671384146745437,0.3310810810810811,0.8718884836657531,1.0,2/222,1.31%,NDUFA10;TUBA1A
prerank,GO_Biological_Process_2021__osteoclast differentiation (GO:0030316),-0.5327245720955193,-1.0666424885254202,0.3252032520325203,0.8897166159747074,1.0,12/21,25.73%,FARP2;SNX10;OSCAR;DCSTAMP;TYROBP;GLO1;CSF1R;MAPK14;ANXA2;GPR183;CSF1;TNFRSF11A
prerank,MSigDB_Oncogenic_Signatures__KRAS.BREAST UP.V1 UP,0.7633520612334401,1.0663654114731453,0.35555555555555557,0.8719191379021786,1.0,6/109,1.34%,GFI1;MYCN;SPON2;STX1A;A2M;COL9A3
prerank,GO_Biological_Process_2021__vitamin transport (GO:0051180),-0.574691228166574,-1.0663461747366143,0.40310077519379844,0.8893427826558724,1.0,2/30,0.32%,SLC2A10;TTPA
prerank,Elsevier_Pathway_Collection__TERT Activation in Cancer,-0.6583601298741618,-1.0663120656667846,0.46825396825396826,0.8887617735899195,1.0,2/28,0.99%,RB1;KLF4
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Precursor -> Natural Killer Cell Surface Expression Markers,-0.7943614101691187,-1.066242289478267,0.45038167938931295,0.8882128184471534,1.0,3/73,1.02%,SEMA4D;CD2;CD274
prerank,GO_Biological_Process_2021__regulation of response to external stimulus (GO:0032101),-0.727402833390242,-1.0661097450997081,0.3879310344827586,0.8877384690020469,1.0,4/123,1.26%,HCK;ADGRA2;HERC5;HRG
prerank,GO_Biological_Process_2021__microvillus assembly (GO:0030033),-0.5690254988451158,-1.0654218790355894,0.33884297520661155,0.8877814876868713,1.0,2/15,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__reverse cholesterol transport (GO:0043691),-0.5599379034621736,-1.0652488922455026,0.3435114503816794,0.887302389256155,1.0,1/17,0.92%,LIPG
prerank,MSigDB_Oncogenic_Signatures__RB P130 DN.V1 DN,-0.7630520876453738,-1.0643454820479044,0.36633663366336633,0.8873541486870707,1.0,4/119,1.25%,EVI5;ATAD1;RB1;VDR
prerank,Elsevier_Pathway_Collection__B-Cell Chronic Lymphocytic Leukemia,-0.8119244618833483,-1.0643419642960237,0.4336283185840708,0.8867598056537908,1.0,3/90,1.13%,PTK2B;CCND2;ZAP70
prerank,TRRUST_Transcription_Factors_2019__HNF4A human,-0.711044667709006,-1.0641520217160265,0.48412698412698413,0.886302174199317,1.0,2/42,0.38%,CYP2C8;GPR39
prerank,Reactome_2022__Neddylation R-HSA-8951664,-0.6899691053655734,-1.0636761915512107,0.330188679245283,0.8860687003148063,1.0,2/227,0.40%,KLHL3;FBXO27
prerank,WikiPathway_2021_Human__Toll-like Receptor Signaling related to MyD88 WP3858,0.5985242963548062,1.0635525366222178,0.45081967213114754,0.8734156938520361,1.0,1/30,0.44%,TRAF3
prerank,Reactome_2022__G-protein Beta:Gamma Signaling R-HSA-397795,-0.6637389896969488,-1.0631319664101186,0.4883720930232558,0.8859260280498695,1.0,2/30,1.35%,AKT3;PIK3R6
prerank,Elsevier_Pathway_Collection__Macrophage Survival through CCR5 and CXCR4 Mediated Signaling,0.609560250663869,1.0629791430750344,0.3879310344827586,0.8733231028386781,1.0,2/17,1.49%,PTK2;BCAR1
prerank,Reactome_2022__Neurotransmitter Receptors And Postsynaptic Signal Transmission R-HSA-112314,0.7697511725699148,1.0624452190921538,0.3533834586466165,0.8731683688014323,1.0,6/156,1.11%,PRKAA2;LIN7A;DLG1;ARHGEF7;GPRIN1;GNB5
prerank,MSigDB_Oncogenic_Signatures__YAP1 DN,0.7156876692551124,1.0623722364577566,0.5114503816793893,0.8727096470991698,1.0,3/35,1.42%,ITGA2;RFX1;DOCK11
prerank,GO_Biological_Process_2021__lamellipodium organization (GO:0097581),-0.676997204906761,-1.0619638834068432,0.5087719298245614,0.8862667765863134,1.0,3/29,1.36%,CARMIL1;S1PR1;ABLIM3
prerank,Reactome_2022__RHOC GTPase Cycle R-HSA-9013106,0.8182578667140752,1.0613696440277978,0.4930555555555556,0.8728479492687717,1.0,6/73,1.39%,DEPDC1B;ARHGAP39;ANLN;IQGAP3;FMNL2;CAVIN1
prerank,Elsevier_Pathway_Collection__Interstitial Fibroblasts in Pyelonephritis,-0.6732064802679542,-1.0611513251011562,0.46296296296296297,0.8863613803497016,1.0,1/40,0.31%,MAP2K6
prerank,MSigDB_Hallmark_2020__Xenobiotic Metabolism,-0.7021142786513008,-1.060963904016443,0.3584905660377358,0.8859224739680498,1.0,9/197,1.26%,SLC22A1;VNN1;TTPA;PROS1;TPST1;CYP1A2;CDO1;ITIH1;HRG
prerank,WikiPathway_2021_Human__Biomarkers for pyrimidine metabolism disorders WP4584,-0.636119253529446,-1.0605572617706387,0.41346153846153844,0.8856308060929463,1.0,1/15,0.12%,DPYS
prerank,GO_Biological_Process_2021__diterpenoid metabolic process (GO:0016101),-0.7368718099384866,-1.0605569266756918,0.48333333333333334,0.8850407789070083,1.0,2/57,1.16%,CYP4V2;SDC3
prerank,Elsevier_Pathway_Collection__Ca2+ Toxicity in Neurons,-0.6373009622253645,-1.0596541901961098,0.4528301886792453,0.885175377978644,1.0,1/25,0.35%,APP
prerank,KEGG_2021_Human__Lipid and atherosclerosis,-0.7013304376223374,-1.0595203994161697,0.3431372549019608,0.8847018386236941,1.0,8/196,1.10%,CYP2C8;MAP2K6;RAP1A;AKT3;RAP1B;PIK3CB;TICAM2;VAV1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Gout,-0.6710886433991907,-1.0594976866006112,0.5042016806722689,0.884133295303586,1.0,1/32,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of hydrolase activity (GO:0051336),0.8162812395768657,1.0591513010681946,0.5307692307692308,0.8739320271051972,1.0,3/70,0.83%,PTK2;STMN3;RAB3GAP1
prerank,Reactome_2022__Protein Localization R-HSA-9609507,-0.7441203880423269,-1.0587396905941857,0.3090909090909091,0.8841810915811171,1.0,7/159,1.08%,GLYAT;APP;ABCD3;ATAD1;CHCHD3;TOMM70;HAO1
prerank,KEGG_2021_Human__Pyrimidine metabolism,-0.8319387076640847,-1.0585899226861666,0.5865384615384616,0.8837119647680395,1.0,4/53,1.18%,DPYS;NT5C1B;ENTPD8;ENTPD3
prerank,WikiPathway_2021_Human__Neural Crest Cell Migration in Cancer WP4565,-0.7556412459997074,-1.0578888278823786,0.5370370370370371,0.8837038340820899,1.0,4/42,1.35%,AKT3;PAK2;PIK3CB;PIK3R6
prerank,GO_Biological_Process_2021__endoderm formation (GO:0001706),0.7521640745376599,1.057718453149911,0.5409836065573771,0.8744397482628433,1.0,3/35,1.51%,COL12A1;ITGB5;FN1
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V1 UP,0.7530789030370538,1.057675899070754,0.31690140845070425,0.873946886212603,1.0,7/178,1.53%,NDC80;ITGA2;PTPRH;MYOF;CPE;CNN3;LRIG1
prerank,KEGG_2021_Human__TNF signaling pathway,-0.7699764559366196,-1.0567678963265859,0.35135135135135137,0.883995880654948,1.0,4/111,1.11%,MAP2K6;AKT3;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway (GO:0097191),0.7872903935184834,1.056666654723039,0.5142857142857142,0.874171405239096,1.0,4/71,1.51%,TNFRSF10A;SORT1;ERBB3;BOK
prerank,Elsevier_Pathway_Collection__HTR1 -> Membrane Transport,0.6192202705025865,1.0562568038721705,0.4263565891472868,0.8739180854385098,1.0,1/20,0.02%,SLC6A4
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP LATE.V1 UP,0.7762327153717627,1.056174629857986,0.34459459459459457,0.873456262631268,1.0,7/163,1.51%,CDCA7;PHTF2;YTHDF3;EIF2A;ASB3;RRM2;BOK
prerank,Reactome_2022__Aberrant Regulation Of Mitotic G1/S Transition In Cancer Due To RB1 Defects R-HSA-9659787,-0.5993388270579736,-1.0560719009180786,0.39473684210526316,0.8839651451159214,1.0,2/17,0.93%,RB1;CCND2
prerank,Reactome_2022__Insertion Of Tail-Anchored Proteins Into Endoplasmic Reticulum Membrane R-HSA-9609523,0.610253706189319,1.0560304450395865,0.42063492063492064,0.873052328453661,1.0,2/22,1.20%,GET3;STX1A
prerank,KEGG_2021_Human__Epstein-Barr virus infection,-0.7048716905783956,-1.0556031168968893,0.35964912280701755,0.8837719587308253,1.0,8/183,1.18%,MAP2K6;AKT3;OAS1;RB1;PIK3CB;ENTPD8;CCND2;ENTPD3
prerank,GO_Biological_Process_2021__DNA metabolic process (GO:0006259),0.6954668115461319,1.0555160088840647,0.3541666666666667,0.8729009841484289,1.0,7/271,1.41%,CDC45;AXIN2;MSH2;ATR;POLE4;FANCL;ACD
prerank,GO_Biological_Process_2021__regulation of heterotypic cell-cell adhesion (GO:0034114),0.6540448756070206,1.0553516038639161,0.48905109489051096,0.8725116153513781,1.0,1/24,0.07%,THY1
prerank,GO_Biological_Process_2021__adenylate cyclase-modulating G protein-coupled receptor signaling pathway (GO:0007188),-0.717605853369354,-1.0553421280010162,0.3333333333333333,0.883377447894217,1.0,3/139,1.23%,GNA14;ADGRE5;S1PR1
prerank,Reactome_2022__HCMV Early Events R-HSA-9609690,0.7957916475300815,1.0552783205299168,0.4782608695652174,0.8720219970690889,1.0,2/83,0.48%,TBL1X;NUP210
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731),-0.7952834005810709,-1.0549192686673887,0.39814814814814814,0.883179309989807,1.0,4/119,0.96%,PTK2B;PAK2;NTF3;SEMA4D
prerank,MSigDB_Oncogenic_Signatures__RELA DN.V1 UP,-0.7244422219007037,-1.0549170335742044,0.34,0.8825955827525368,1.0,5/131,1.25%,GLYAT;FOSB;PDE5A;AGPAT4;VDR
prerank,GO_Biological_Process_2021__regulation of cell-substrate adhesion (GO:0010810),0.784173668966783,1.0547069243277805,0.5648854961832062,0.8719173013433901,1.0,3/42,0.32%,THY1;PTK2;TBCD
prerank,GO_Biological_Process_2021__regulation of p38MAPK cascade (GO:1900744),0.6970962365608686,1.0546245934894847,0.5144927536231884,0.8714812162081427,1.0,2/37,1.29%,DLG1;ULK4
prerank,Reactome_2022__Downregulation Of ERBB2 Signaling R-HSA-8863795,-0.6258000954488169,-1.0545646247412737,0.453781512605042,0.8822976326496115,1.0,2/29,1.34%,AKT3;PTPN18
prerank,Reactome_2022__Signaling By TGF-beta Receptor Complex R-HSA-170834,0.8094855081851364,1.054463935836355,0.4195804195804196,0.871073075412304,1.0,4/89,1.47%,RBL1;ARHGEF18;ITGB5;ZFYVE9
prerank,"KEGG_2021_Human__Valine, leucine and isoleucine degradation",0.742963363218746,1.0542473240623198,0.5474452554744526,0.8707156641433312,1.0,3/48,0.63%,OXCT1;AUH;ACSF3
prerank,Elsevier_Pathway_Collection__Cell Cycle Overiew,0.7773695191736709,1.0539555900149258,0.38926174496644295,0.8704066086970524,1.0,5/105,0.50%,CENPA;CENPE;CDC45;CDK6;ATR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Frontotemporal Dementia,-0.6373016041047588,-1.0538222889124822,0.45081967213114754,0.8823100247773827,1.0,1/22,0.35%,APP
prerank,MSigDB_Oncogenic_Signatures__RELA DN.V1 DN,0.7963573124956892,1.0535518946613636,0.42748091603053434,0.8702210888935528,1.0,3/106,1.12%,HOXD3;TXNRD2;PKLR
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Fatty Acids and Glucose,-0.680674634058927,-1.053446824981897,0.5,0.882032189544749,1.0,1/48,0.08%,ALDOB
prerank,GO_Biological_Process_2021__circulatory system development (GO:0072359),0.7907946647235937,1.0530053290285486,0.38848920863309355,0.8701018959380212,1.0,3/116,1.51%,BCOR;ERBB3;FN1
prerank,WikiPathway_2021_Human__Phosphoinositides metabolism WP4971,-0.7596945990456526,-1.05275135263844,0.5169491525423728,0.882000121897499,1.0,2/49,0.73%,SBF2;PIK3CB
prerank,GO_Biological_Process_2021__cellular protein-containing complex assembly (GO:0034622),0.7518758851460412,1.0527399316803518,0.3870967741935484,0.8697800969418029,1.0,6/161,1.39%,CENPA;CENPE;TBCD;ANLN;CCDC40;PRLR
prerank,KEGG_2021_Human__Regulation of actin cytoskeleton,0.7384334710151707,1.0524561091348161,0.3382352941176471,0.8694586840271639,1.0,10/205,1.51%,PTK2;ITGA2;ABI2;ARHGEF7;IQGAP3;ITGAL;ITGB5;FGF1;BCAR1;FN1
prerank,GO_Biological_Process_2021__protein insertion into membrane (GO:0051205),-0.6881977174729569,-1.0520298687927505,0.4838709677419355,0.8820684218028162,1.0,2/31,1.33%,APP;RTP4
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Overiew,0.65530987366149,1.0518122698439298,0.44881889763779526,0.8688897811961598,1.0,3/25,1.54%,STX1A;GLS;SLC38A1
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Caused by Mutations in SLC1A3 Gene,0.65530987366149,1.0518122698439298,0.44881889763779526,0.8688897811961598,1.0,3/25,1.54%,STX1A;GLS;SLC38A1
prerank,GO_Biological_Process_2021__positive regulation of protein catabolic process (GO:0045732),0.7688287428281916,1.0513632151524281,0.4251968503937008,0.8687012909635625,1.0,4/84,1.30%,VGLL4;WWP2;PACSIN3;APOE
prerank,GO_Biological_Process_2021__regulation of glycolytic process (GO:0006110),0.7846467546010594,1.050575224438126,0.5354330708661418,0.8687969342813077,1.0,4/68,1.44%,PRKAA2;NUP210;PPARA;SLC2A6
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Caused by Mutations in PRRT2 Gene,0.655310585020098,1.0502582275218248,0.4523809523809524,0.8685088492181251,1.0,3/24,1.54%,STX1A;GLS;SLC38A1
prerank,GO_Biological_Process_2021__cytosolic transport (GO:0016482),-0.7365070381897474,-1.0500638569324656,0.36283185840707965,0.8831921389455019,1.0,3/115,0.71%,EVI5;MON2;VPS13C
prerank,GO_Biological_Process_2021__positive regulation of extracellular matrix organization (GO:1903055),-0.5702509527438686,-1.0499833718955875,0.37962962962962965,0.8826806701632562,1.0,1/18,0.53%,RB1
prerank,Reactome_2022__HCMV Infection R-HSA-9609646,0.7957854604001919,1.0498465132122161,0.4338235294117647,0.8683163875807228,1.0,2/107,0.48%,TBL1X;NUP210
prerank,GO_Biological_Process_2021__activation of protein kinase B activity (GO:0032148),-0.5984694368176896,-1.049810799818934,0.40707964601769914,0.8822227189522883,1.0,1/29,0.83%,NTF3
prerank,Elsevier_Pathway_Collection__Endometrial Cancer,0.793624128455593,1.049542060308618,0.4274193548387097,0.8680107962243316,1.0,4/105,0.96%,MSH2;CDK6;LRP5;ERBB3
prerank,MSigDB_Oncogenic_Signatures__SRC UP.V1 UP,-0.765266245913872,-1.0494165412893106,0.39805825242718446,0.8819293594198104,1.0,3/130,1.22%,ETV7;AADAC;COL4A4
prerank,GO_Biological_Process_2021__high-density lipoprotein particle remodeling (GO:0034375),-0.5599376315161114,-1.0492938074391067,0.3492063492063492,0.8814502815800748,1.0,1/17,0.92%,LIPG
prerank,GO_Biological_Process_2021__regulation of sodium ion transmembrane transport (GO:1902305),0.6214708669697646,1.0490181003351855,0.43902439024390244,0.8678981661255997,1.0,2/24,1.53%,DLG1;SNTA1
prerank,Reactome_2022__G Alpha (I) Signaling Events R-HSA-418594,-0.683150233639053,-1.0487416672772218,0.3883495145631068,0.881338243629133,1.0,3/245,1.05%,CCL23;APP;GNA14
prerank,GO_Biological_Process_2021__phospholipid catabolic process (GO:0009395),0.5726556359286851,1.0480716852288927,0.39568345323741005,0.8681570464201774,1.0,1/22,0.37%,PNPLA6
prerank,GO_Biological_Process_2021__lamellipodium assembly (GO:0030032),-0.6769988072913535,-1.0477986879055603,0.5092592592592593,0.881492658728186,1.0,3/26,1.36%,CARMIL1;S1PR1;ABLIM3
prerank,GO_Biological_Process_2021__neurotransmitter transport (GO:0006836),0.8145845563226188,1.047781075084636,0.5833333333333334,0.8678475704795972,1.0,7/63,1.54%,SLC6A4;BRSK1;LIN7A;PPFIA4;STX1A;GLS;SLC38A1
prerank,WikiPathway_2021_Human__Chemokine signaling pathway WP3929,-0.7489507863927573,-1.0476621612875179,0.38392857142857145,0.8810120366883284,1.0,8/157,1.10%,RAP1A;AKT3;RAP1B;PTK2B;PIK3CB;HCK;RASGRP2;VAV1
prerank,Elsevier_Pathway_Collection__Sonic Hedgehog Signaling in Neuroblastoma,-0.6000727819239339,-1.0475104108676578,0.3951612903225806,0.8806068446427119,1.0,2/19,1.22%,CCND2;GLI3
prerank,KEGG_2021_Human__MicroRNAs in cancer,0.7583481367026036,1.0471536131100505,0.36363636363636365,0.8678053544697901,1.0,7/159,1.49%,IGF2BP1;CDK6;NOTCH3;ERBB3;KIF23;SLC7A1;GLS
prerank,Reactome_2022__DDX58/IFIH1-mediated Induction Of Interferon-Alpha/Beta R-HSA-168928,-0.7100592951021438,-1.0471464569054263,0.4462809917355372,0.8803516860384207,1.0,3/66,1.05%,APP;TOMM70;HERC5
prerank,WikiPathway_2021_Human__Hippo-Merlin Signaling Dysregulation WP4541,0.7793088928849222,1.04693349664947,0.38636363636363635,0.8674512478053782,1.0,7/112,1.33%,PTK2;VGLL4;ITGA2;ITGAL;TEAD4;CDH15;ITGB5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Azoospermia,0.6614453309413789,1.046877696461292,0.5,0.8669710533146106,1.0,2/28,0.47%,SYCP3;DROSHA
prerank,Elsevier_Pathway_Collection__Hypoxia Inhibits mTOR Signaling,0.6424434948021218,1.0465087684999326,0.48905109489051096,0.8667104321078022,1.0,1/25,0.81%,CAB39
prerank,MSigDB_Oncogenic_Signatures__IL15 UP.V1 UP,-0.7138473736150186,-1.0464002901425167,0.330188679245283,0.8804786747550156,1.0,4/162,1.26%,SLCO1A2;HABP2;VDR;DUSP4
prerank,Reactome_2022__Translesion Synthesis By Y Family DNA Polymerases Bypasses Lesions On DNA Template R-HSA-110313,0.721921870425714,1.046137877521564,0.5289855072463768,0.8665065310429942,1.0,2/39,0.72%,SLC19A1;POLE4
prerank,Elsevier_Pathway_Collection__Graves Ophthalmopathy,0.73395611101097,1.0459815790467712,0.5658914728682171,0.866088640711217,1.0,3/41,1.10%,THY1;PPARA;ITGAL
prerank,Reactome_2022__SLC-mediated Transmembrane Transport R-HSA-425407,-0.6731116432468607,-1.0459225060214306,0.32222222222222224,0.8803400616397326,1.0,12/227,1.29%,SLC22A1;SLC41A2;SLC35A3;SLC7A8;SLC2A10;SLC36A4;SLCO1A2;AHCYL2;SLC9A9;SLC16A2;SLC15A3;SLC4A5
prerank,Reactome_2022__Translation R-HSA-72766,-0.6530457227683014,-1.045556081930016,0.34951456310679613,0.8800883404243461,1.0,1/277,0.71%,SEC61A2
prerank,GO_Biological_Process_2021__cation transport (GO:0006812),-0.7572074858953641,-1.0451408179223647,0.37,0.8798949361136423,1.0,9/157,1.24%,KCNN2;SLC22A1;SLC7A8;SLC36A4;CATSPER3;KCNAB3;KCNK6;SLC17A4;KCNS3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteoarthritis,-0.7436251385806181,-1.045134021193915,0.44554455445544555,0.8793237263598809,1.0,2/80,1.25%,ADAMTS5;VDR
prerank,KEGG_2021_Human__Pathogenic Escherichia coli infection,0.7225163366181496,1.0446530464908483,0.36428571428571427,0.8665930222895825,1.0,3/188,1.31%,TNFRSF10A;TJP1;TUBA1A
prerank,TRRUST_Transcription_Factors_2019__STAT3 human,-0.7243138477178992,-1.0445681592282274,0.3302752293577982,0.8792634444972579,1.0,7/134,1.25%,STS;OAS1;PROS1;FGL1;CCND2;S1PR1;VDR
prerank,GO_Biological_Process_2021__fatty acid oxidation (GO:0019395),-0.723713050863882,-1.04388639029556,0.5087719298245614,0.8792886756347921,1.0,3/57,1.08%,CYP4V2;ABCD3;HAO1
prerank,GO_Biological_Process_2021__telomere organization (GO:0032200),0.7382254891111107,1.0437871934580618,0.5263157894736842,0.8668130037333657,1.0,2/47,1.41%,ATR;ACD
prerank,Elsevier_Pathway_Collection__Hereditary Breast and Ovarian Cancer Syndrome,0.6784486407358366,1.0435001390932381,0.5109489051094891,0.8665645044499865,1.0,2/32,0.38%,MSH2;BRIP1
prerank,GO_Biological_Process_2021__lipid transport (GO:0006869),-0.7564338489389493,-1.043246258731528,0.3813559322033898,0.8792945948273678,1.0,5/107,0.56%,TTPA;NCOA1;ABCA6;ABCD3;SLCO1A2
prerank,GO_Biological_Process_2021__regulation of nitric-oxide synthase activity (GO:0050999),-0.7710289201270241,-1.0432120683107322,0.5528455284552846,0.8787417764086,1.0,2/35,0.73%,ZDHHC21;PIK3CB
prerank,Elsevier_Pathway_Collection__Smooth Muscle Cell Dysfunction in Pulmonary Hypertension,0.7787448208775567,1.043048559971999,0.47761194029850745,0.8664445339405432,1.0,3/86,0.43%,SLC6A4;MRTFA;NOTCH3
prerank,Reactome_2022__Termination Of Translesion DNA Synthesis R-HSA-5656169,0.7219242868401674,1.0428484629381716,0.5488721804511278,0.8661335924696973,1.0,2/32,0.72%,SLC19A1;POLE4
prerank,Reactome_2022__HIV Life Cycle R-HSA-162587,0.7694334046863929,1.0428261454694316,0.36879432624113473,0.8656432545313332,1.0,4/144,1.53%,NUP210;TAF4;TCEA1;LRIG1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cataract,-0.7690270366712241,-1.0428003058472965,0.4519230769230769,0.8784894894910948,1.0,4/82,1.22%,FOSB;APP;NR3C1;COL4A4
prerank,GO_Biological_Process_2021__regulation of long-term synaptic potentiation (GO:1900271),-0.6372997785948622,-1.0427132220003101,0.4608695652173913,0.8779818932164013,1.0,1/28,0.35%,APP
prerank,Reactome_2022__RAC2 GTPase Cycle R-HSA-9013404,0.8310787001677578,1.0424536826657032,0.5303030303030303,0.865438704416015,1.0,4/87,1.47%,DEPDC1B;ARHGAP39;ABI2;CDC42EP1
prerank,Reactome_2022__Response To Elevated Platelet Cytosolic Ca2+ R-HSA-76005,-0.7411995595278799,-1.0417355998623166,0.36283185840707965,0.8782770808397327,1.0,5/127,1.26%,A1BG;APP;PROS1;NHLRC2;HRG
prerank,GO_Biological_Process_2021__positive regulation of cysteine-type endopeptidase activity (GO:2001056),-0.7842957932662862,-1.0417151789153734,0.5084745762711864,0.8777208672363237,1.0,1/59,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__regulation of chemotaxis (GO:0050920),0.6991509823630135,1.0415095773904826,0.5036496350364964,0.8656473659437277,1.0,1/32,0.02%,ZSWIM5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Autistic Disorder and Aggression,0.6212753217214088,1.041223111990755,0.4365079365079365,0.8653241722536955,1.0,1/19,0.02%,SLC6A4
prerank,KEGG_2021_Human__Adipocytokine signaling pathway,0.7468718467850761,1.0411810356696514,0.48484848484848486,0.8648287456724475,1.0,3/64,1.18%,PRKAA2;PPARA;ACSL5
prerank,GO_Biological_Process_2021__glucose transmembrane transport (GO:1904659),0.5801613456895218,1.041153985938874,0.39416058394160586,0.8643428657139807,1.0,2/19,1.44%,SORT1;SLC2A6
prerank,Reactome_2022__Death Receptor Signaling R-HSA-73887,0.7392990402288154,1.040219396367898,0.4,0.8645270511924672,1.0,6/139,1.15%,AATF;TNFRSF10A;ARHGEF7;PLEKHG5;ARHGEF18;TNFRSF10D
prerank,GO_Biological_Process_2021__protein modification by small protein removal (GO:0070646),0.684299811957098,1.0399031891856467,0.35947712418300654,0.8642634626954775,1.0,2/250,0.44%,SENP1;TRAF3
prerank,Reactome_2022__Organelle Biogenesis And Maintenance R-HSA-1852241,0.6783470447419087,1.0392326587668521,0.35333333333333333,0.8643669651448538,1.0,9/271,1.35%,PRKAA2;SMOX;TBL1X;CEP164;HAUS8;HAUS2;PPARA;TUBA1A;KIF3B
prerank,GO_Biological_Process_2021__Rac protein signal transduction (GO:0016601),0.5577001950322443,1.039069805296807,0.3722627737226277,0.8639674373629107,1.0,1/19,0.77%,ABI2
prerank,WikiPathway_2021_Human__Retinoblastoma gene in cancer WP2446,0.7908995436009141,1.0389739363736978,0.47586206896551725,0.8635415739000238,1.0,4/86,1.18%,CDC45;CDK6;ANLN;RRM2
prerank,GO_Biological_Process_2021__protein localization to chromosome (GO:0034502),0.7205456289719364,1.0389452435922153,0.5488721804511278,0.8630603984903693,1.0,4/34,1.41%,CENPA;MSH2;ATR;ACD
prerank,GO_Biological_Process_2021__cytoskeleton organization (GO:0007010),0.7867825092340167,1.038756010229365,0.42857142857142855,0.8626980427562312,1.0,10/117,1.41%,THY1;CNTNAP1;SIPA1L3;ABI2;PRPF40A;PACSIN3;FMNL2;APOE;SYNE3;MICAL3
prerank,GO_Biological_Process_2021__substrate adhesion-dependent cell spreading (GO:0034446),-0.7521532140504709,-1.038655812986017,0.5206611570247934,0.8798155375383558,1.0,2/48,1.21%,NTN4;TEK
prerank,GO_Biological_Process_2021__regulation of programmed cell death (GO:0043067),0.7247871256541721,1.038585701883402,0.34074074074074073,0.8623517220877035,1.0,6/169,1.49%,TRIM24;TNFRSF10A;TNFRSF25;STK26;TNFRSF10D;BCAR1
prerank,Reactome_2022__Peroxisomal Protein Import R-HSA-9033241,-0.7770297936564322,-1.0385428945155937,0.5,0.879308397736152,1.0,2/61,1.08%,GLYAT;HAO1
prerank,Elsevier_Pathway_Collection__Insulin Synthesis in beta-Cell,-0.6390752558606632,-1.0383768305652872,0.46153846153846156,0.8788786316517775,1.0,1/32,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in non-Alcoholic Fatty Liver Disease,0.7488399197732406,1.038336936479772,0.3931034482758621,0.8620147224803422,1.0,4/177,1.56%,ACACA;PPARA;APOE;FOSL2
prerank,GO_Biological_Process_2021__regulation of neuronal synaptic plasticity (GO:0048168),0.6811924709789823,1.0380038191224195,0.5227272727272727,0.8618184369170075,1.0,3/27,1.30%,RAB3GAP1;MCTP1;APOE
prerank,KEGG_2021_Human__Pancreatic cancer,-0.71822324467331,-1.0376706189052942,0.47413793103448276,0.8789450202361915,1.0,3/76,0.73%,AKT3;RB1;PIK3CB
prerank,GO_Biological_Process_2021__glycoprotein catabolic process (GO:0006516),-0.5085102336216496,-1.0372118522123543,0.3203125,0.8787869429524641,1.0,1/17,0.40%,FBXO27
prerank,TRRUST_Transcription_Factors_2019__E2F1 human,0.7734767131651392,1.0370404699024913,0.3925925925925926,0.8620586720203876,1.0,4/131,1.18%,CDCA7;DROSHA;MYCN;RRM2
prerank,Reactome_2022__ESR-mediated Signaling R-HSA-8939211,-0.7049184679084176,-1.0369126391608647,0.3445378151260504,0.8785716440132904,1.0,4/173,0.40%,FOSB;ZDHHC21;AKT3;NCOA1
prerank,GO_Biological_Process_2021__potassium ion transmembrane transport (GO:0071805),-0.7828151641933682,-1.0368264596155607,0.4017094017094017,0.8780751442261562,1.0,8/118,1.24%,KCNN2;KCNT2;KCNE1;KCNAB3;SLC9A9;KCNK6;SLC12A8;KCNS3
prerank,KEGG_2021_Human__Human papillomavirus infection,0.6501378644432108,1.0367771786988282,0.31333333333333335,0.8617602561373301,1.0,14/302,1.51%,AXIN2;CDK6;PTK2;RBL1;ITGA2;NOTCH3;TRAF3;ATR;DLG1;COL4A5;CRB3;ITGB5;COL9A3;FN1
prerank,WikiPathway_2021_Human__Toll-like Receptor Signaling Pathway WP75,-0.7726673264253314,-1.036765748184668,0.48672566371681414,0.8775656302889819,1.0,4/88,1.04%,MAP2K6;AKT3;PIK3CB;TICAM2
prerank,GO_Biological_Process_2021__regulation of glucose import (GO:0046324),0.6577049040020975,1.0366731495440493,0.47244094488188976,0.8613554684451444,1.0,1/34,0.86%,RHOQ
prerank,KEGG_2021_Human__Hippo signaling pathway,0.7368883111520417,1.0362498475948874,0.38571428571428573,0.8611578064853411,1.0,5/159,1.36%,AXIN2;DLG1;AMH;TEAD4;FGF1
prerank,GO_Biological_Process_2021__axon guidance (GO:0007411),-0.6955492634231797,-1.0360933428664885,0.373015873015873,0.877597171177703,1.0,8/191,1.36%,NTN4;FEZ1;PIK3CB;DAB1;SEMA4D;RHOH;DSCAML1;GRB10
prerank,GO_Biological_Process_2021__cell projection assembly (GO:0030031),0.5515308357345151,1.0359664042570036,0.3875968992248062,0.8608493377678178,1.0,1/22,0.86%,RHOQ
prerank,KEGG_2021_Human__Chemokine signaling pathway,-0.7366396403881602,-1.0358362446854268,0.3739130434782609,0.8772522736278661,1.0,10/181,1.35%,CCL23;RAP1A;AKT3;RAP1B;PTK2B;PIK3CB;HCK;RASGRP2;VAV1;PIK3R6
prerank,GO_Biological_Process_2021__regulation of protein tyrosine kinase activity (GO:0061097),0.6705280313076563,1.0356875607813318,0.5111111111111111,0.8605478882209421,1.0,2/38,0.96%,THY1;ERBB3
prerank,GO_Biological_Process_2021__epidermis development (GO:0008544),-0.7708702438679459,-1.035210064493499,0.5350877192982456,0.8772321862862619,1.0,2/55,0.27%,GJB5;STS
prerank,Reactome_2022__Detoxification Of Reactive Oxygen Species R-HSA-3299685,-0.6316437077717336,-1.03487839278621,0.48717948717948717,0.8769778601715195,1.0,1/32,0.04%,GLYAT
prerank,Reactome_2022__Platelet Degranulation R-HSA-114608,-0.741201553961806,-1.0345756690338506,0.3652173913043478,0.8766803053017402,1.0,5/123,1.26%,A1BG;APP;PROS1;NHLRC2;HRG
prerank,WikiPathway_2021_Human__Fluoropyrimidine Activity WP1601,-0.6361170955691628,-1.0331172274636242,0.49557522123893805,0.8773733965664648,1.0,1/33,0.12%,DPYS
prerank,Reactome_2022__Translation Of Structural Proteins R-HSA-9683701,-0.6418581486334185,-1.0331078948213246,0.4700854700854701,0.8768149694267657,1.0,2/29,0.92%,PARP8;MOGAT1
prerank,GO_Biological_Process_2021__neuropeptide signaling pathway (GO:0007218),0.722564557352309,1.0329003586759886,0.49166666666666664,0.8622653217980836,1.0,2/43,1.31%,SORT1;CPE
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332),0.7489782417621635,1.032654957936376,0.5923076923076923,0.8619656141884278,1.0,2/35,1.51%,MSH2;BOK
prerank,MSigDB_Oncogenic_Signatures__HOXA9 DN.V1 DN,0.732193114636834,1.0325641144929014,0.38095238095238093,0.861539968675769,1.0,9/169,1.54%,CDC45;GINS1;FANCL;SPON2;ITGB5;COL9A3;RNF144A;ZNF395;SLC38A1
prerank,Elsevier_Pathway_Collection__G2/M Phase Transition,0.673611740479959,1.0324877960348366,0.5169491525423728,0.8610948912832443,1.0,2/29,1.16%,CENPA;PKMYT1
prerank,Reactome_2022__Smooth Muscle Contraction R-HSA-445355,-0.6433694498341964,-1.0324267568165804,0.4962962962962963,0.8769256439050583,1.0,1/38,0.33%,PDE5A
prerank,GO_Biological_Process_2021__regulation of cellular macromolecule biosynthetic process (GO:2000112),-0.6145634083451061,-1.03238819513586,0.35714285714285715,0.8763899431297488,1.0,11/435,1.31%,ZNF66;ZNF90;ZNF708;ZNF85;APP;NR3C1;RB1;RABL3;RHOH;SPI1;PML
prerank,MSigDB_Oncogenic_Signatures__PKCA DN.V1 DN,0.7490019039859657,1.0323797837459285,0.391304347826087,0.8606923797813745,1.0,4/135,1.38%,PRPF40A;CKAP4;TXNRD2;PYCR1
prerank,MSigDB_Hallmark_2020__Protein Secretion,-0.7549503887909383,-1.0322423691853264,0.44339622641509435,0.8759770381616419,1.0,2/95,0.99%,MON2;GALC
prerank,GO_Biological_Process_2021__negative regulation of blood coagulation (GO:0030195),0.6726615747916886,1.0322148729963927,0.5037037037037037,0.8603323597542665,1.0,2/39,1.30%,A2M;APOE
prerank,KEGG_2021_Human__Thyroid hormone signaling pathway,-0.7714435292412154,-1.0321430325452141,0.44339622641509435,0.8755022915186623,1.0,4/117,1.02%,AKT3;NCOA1;PIK3CB;SLC16A2
prerank,GO_Biological_Process_2021__ERBB2 signaling pathway (GO:0038128),0.633318457414314,1.0320911876076277,0.5076923076923077,0.859932971628046,1.0,1/31,0.96%,ERBB3
prerank,GO_Biological_Process_2021__regulation of pri-miRNA transcription by RNA polymerase II (GO:1902893),-0.7015007031513083,-1.0317826044431804,0.5042735042735043,0.8752422468599694,1.0,3/44,1.10%,NR3C1;KLF4;SPI1
prerank,TRRUST_Transcription_Factors_2019__MYOD1 mouse,-0.7029774662108735,-1.0316232416313198,0.518796992481203,0.8747983699379616,1.0,2/40,1.17%,RB1;CDO1
prerank,GO_Biological_Process_2021__regulation of cell death (GO:0010941),0.7755157624585485,1.0315631364705553,0.4899328859060403,0.8598654176082519,1.0,2/99,1.11%,AXIN2;PRR7
prerank,Reactome_2022__DNA Replication Pre-Initiation R-HSA-69002,0.7584312796689842,1.031530477534509,0.3873239436619718,0.859382867773493,1.0,3/116,0.94%,CDC45;POLE4;UBE2C
prerank,GO_Biological_Process_2021__cation transmembrane transport (GO:0098655),-0.7372587111115116,-1.0313500598570922,0.55,0.8745012162840903,1.0,2/41,0.41%,SLC7A8;SLC36A4
prerank,KEGG_2021_Human__Dopaminergic synapse,-0.7405520015191256,-1.0312840679542972,0.39316239316239315,0.8739907595631614,1.0,4/119,1.24%,GRIN2B;AKT3;CREB5;MAOB
prerank,Reactome_2022__Metabolic Disorders Of Biological Oxidation Enzymes R-HSA-5579029,0.6787105079215578,1.0312657903713784,0.5314685314685315,0.8590972627930163,1.0,2/30,1.30%,FDXR;CYP27B1
prerank,Reactome_2022__Formation Of Senescence-Associated Heterochromatin Foci (SAHF) R-HSA-2559584,-0.49448999608723565,-1.0310027702267357,0.29133858267716534,0.8736755798597703,1.0,1/15,0.53%,RB1
prerank,KEGG_2021_Human__Glucagon signaling pathway,0.7316030147799732,1.0306468572105258,0.4198473282442748,0.8591229337541048,1.0,4/97,0.79%,PRKAA2;ACACA;PHKA2;PPARA
prerank,Reactome_2022__VEGFR2 Mediated Vascular Permeability R-HSA-5218920,-0.6281767304530382,-1.0305504082731787,0.4453125,0.8735066779811945,1.0,2/26,1.10%,AKT3;VAV1
prerank,Reactome_2022__Diseases Of Glycosylation R-HSA-3781865,-0.7064142708267374,-1.0303367679217599,0.3805309734513274,0.8731490147445758,1.0,5/135,1.16%,MUC6;ADAMTS5;GALNT3;ADAMTSL2;SDC3
prerank,GO_Biological_Process_2021__regulation of cellular response to stress (GO:0080135),0.7587810920243314,1.0301187985783955,0.3953488372093023,0.8590427830822837,1.0,3/117,0.50%,NEK4;NUP210;ATR
prerank,TRRUST_Transcription_Factors_2019__TRP53 mouse,-0.70787675132553,-1.0300242624079943,0.42201834862385323,0.8728997256599753,1.0,4/145,1.31%,NR3C1;KLF4;DUSP4;PML
prerank,GO_Biological_Process_2021__regulation of intracellular signal transduction (GO:1902531),0.6352993888752076,1.0298126662749245,0.36,0.8588393732924924,1.0,19/428,1.36%,PRKAA2;PPP1R16B;ING5;BRIP1;DEPDC1B;TRAF3;ATR;ARHGAP39;TAF4;DLG1;NEK8;ARHGEF7;RHOQ;PLEKHG5;ARHGEF18;A2M;PPP1R13L;ULK4;FGF1
prerank,GO_Biological_Process_2021__regulation of TOR signaling (GO:0032006),0.7264574115146876,1.029687553699765,0.4925373134328358,0.8584248612983411,1.0,2/68,0.69%,PRKAA2;FNIP1
prerank,Elsevier_Pathway_Collection__MAVS in Antiviral Innate Immune Response in Myocarditis,0.598526474397763,1.0295054427393444,0.41025641025641024,0.8580856354453694,1.0,1/20,0.44%,TRAF3
prerank,KEGG_2021_Human__Base excision repair,0.6469109274339395,1.0292845878611039,0.5,0.8577358082276351,1.0,1/33,0.72%,POLE4
prerank,GO_Biological_Process_2021__positive regulation of metabolic process (GO:0009893),0.7719518526537587,1.0289924028324215,0.3805970149253731,0.8574567098234894,1.0,2/103,1.39%,ACACA;PRLR
prerank,Reactome_2022__Uptake And Actions Of Bacterial Toxins R-HSA-5339562,-0.6138060565525294,-1.0289497497318554,0.4608695652173913,0.8733248116406982,1.0,1/29,0.31%,MAP2K6
prerank,Reactome_2022__TNFR2 Non-Canonical NF-kB Pathway R-HSA-5668541,0.7422992787162475,1.0289419085407632,0.37583892617449666,0.8570000306315952,1.0,3/97,1.20%,TRAF3;TNFRSF25;EDA2R
prerank,WikiPathway_2021_Human__RAC1/PAK1/p38/MMP2 Pathway WP3303,0.8090270707236459,1.0289295647184946,0.5461538461538461,0.8565175388202084,1.0,3/67,1.51%,MSH2;PTK2;FN1
prerank,Reactome_2022__Asparagine N-linked Glycosylation R-HSA-446203,0.6794578368359763,1.0288841823709427,0.35766423357664234,0.8560597366502392,1.0,4/275,1.04%,ST3GAL1;DAD1;COG5;ASGR2
prerank,GO_Biological_Process_2021__water-soluble vitamin metabolic process (GO:0006767),-0.7231104414375097,-1.0287873999310149,0.48333333333333334,0.8729329190214586,1.0,3/72,1.19%,VNN1;BTD;MTHFD2L
prerank,Reactome_2022__Phase I - Functionalization Of Compounds R-HSA-211945,-0.7803202584427512,-1.0287771562587258,0.4528301886792453,0.8723799575094128,1.0,9/96,1.27%,CYP39A1;CYP2C8;CYP4V2;NCOA1;AADAC;AOC1;CYP1A2;MAOB;CYP1B1
prerank,GO_Biological_Process_2021__regulation of ERK1 and ERK2 cascade (GO:0070372),-0.6929084966986304,-1.0281964932551848,0.3838383838383838,0.8722851837420001,1.0,7/222,1.26%,CCL23;RAP1A;APP;PTK2B;SCIMP;TEK;DUSP4
prerank,Reactome_2022__RAC3 GTPase Cycle R-HSA-9013423,0.7968061126670705,1.027891152718139,0.5037037037037037,0.8564005468747123,1.0,4/91,1.47%,DEPDC1B;ARHGAP39;ABI2;CDC42EP1
prerank,GO_Biological_Process_2021__central nervous system development (GO:0007417),-0.6845822238637501,-1.0273240257189886,0.3148148148148148,0.8724540890210399,1.0,8/230,1.34%,GRIN2B;BTD;WWP1;MEIS1;ADGRA2;PBX1;DSCAML1;EML1
prerank,MSigDB_Oncogenic_Signatures__RB DN.V1 UP,-0.7184432022028305,-1.0272751543507326,0.3577981651376147,0.8719589266005312,1.0,2/126,0.86%,GANC;FXYD6
prerank,GO_Biological_Process_2021__adherens junction organization (GO:0034332),0.7294596858337552,1.0272256736975232,0.5259259259259259,0.8565306015331664,1.0,3/45,1.21%,TBCD;TJP1;CDH15
prerank,KEGG_2021_Human__Insulin secretion,-0.7639196050839482,-1.0269730216317092,0.45045045045045046,0.8717249308681357,1.0,2/78,1.11%,KCNN2;CREB5
prerank,KEGG_2021_Human__Prion disease,-0.6672285413280914,-1.0268514599491658,0.3854166666666667,0.8712764918005129,1.0,3/246,1.11%,GRIN2B;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__protein catabolic process (GO:0030163),0.7446143569572151,1.0259135763215923,0.5347222222222222,0.8571861076863831,1.0,4/57,1.48%,TRIM24;MANBA;APOE;LAMP2
prerank,Elsevier_Pathway_Collection__Podocyte Dysfunction in Diabetic Nephropathy,-0.6167130112962756,-1.0256042693565794,0.49586776859504134,0.8718077527272757,1.0,2/38,1.22%,MAP2K6;COL4A4
prerank,KEGG_2021_Human__Drug metabolism,-0.7838556024414877,-1.025196863547663,0.4491525423728814,0.8715984253177232,1.0,6/101,1.24%,GSTA2;CYP2C8;GSTA1;DPYS;CYP1A2;MAOB
prerank,GO_Biological_Process_2021__regulation of cAMP-mediated signaling (GO:0043949),0.5868942819580875,1.0248989110983346,0.4393939393939394,0.8575847747722384,1.0,1/25,0.27%,GPR62
prerank,Elsevier_Pathway_Collection__G0/G1 Phase Transition,0.6878497900313414,1.0248157772469315,0.5208333333333334,0.8571736139195603,1.0,2/38,0.26%,CDK6;PTK2
prerank,"WikiPathway_2021_Human__4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",-0.5396742106455448,-1.0245126460417076,0.3533834586466165,0.8716572784113676,1.0,1/18,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of substrate adhesion-dependent cell spreading (GO:1900024),0.7396594709791406,1.023548848228826,0.562962962962963,0.8577467266714149,1.0,4/50,1.41%,PTK2;ARHGEF7;MELTF;FLNA
prerank,Reactome_2022__SARS-CoV-2 Activates/Modulates Innate And Adaptive Immune Responses R-HSA-9705671,0.7734798766758294,1.0233474884087814,0.42424242424242425,0.8574342693509087,1.0,3/105,0.48%,IRAK2;TRAF3;NUP210
prerank,GO_Biological_Process_2021__nucleobase-containing compound biosynthetic process (GO:0034654),-0.5299039665132822,-1.0232939568000474,0.33980582524271846,0.8722381613121543,1.0,1/20,1.18%,GMPR
prerank,Reactome_2022__MyD88 Cascade Initiated On Plasma Membrane R-HSA-975871,-0.7141875726120833,-1.0226948454925489,0.42727272727272725,0.8722430200262115,1.0,4/95,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,GO_Biological_Process_2021__negative regulation of angiogenesis (GO:0016525),-0.7498574863899564,-1.0225896600564328,0.5,0.8717959542488841,1.0,5/83,1.31%,PIK3CB;KLF4;TEK;HRG;PML
prerank,GO_Biological_Process_2021__lymphocyte differentiation (GO:0030098),-0.7187803668962265,-1.0220485077410697,0.4435483870967742,0.8718064309394606,1.0,4/63,1.13%,RABL3;PBX1;RHOH;ZAP70
prerank,GO_Biological_Process_2021__Notch signaling pathway (GO:0007219),0.7684929322358734,1.0220305567845598,0.5271317829457365,0.8581179416386581,1.0,2/59,0.43%,HOXD3;NOTCH3
prerank,GO_Biological_Process_2021__phosphate-containing compound metabolic process (GO:0006796),-0.6790762884093595,-1.0217634947402838,0.3274336283185841,0.8715284591566222,1.0,6/197,1.26%,ALDOB;PLAAT3;PAK2;PIK3CB;SLC17A4;DUSP4
prerank,Reactome_2022__Cilium Assembly R-HSA-5617833,0.7140222285671454,1.0215017922485923,0.36666666666666664,0.8580522471153591,1.0,6/182,1.35%,SMOX;CEP164;HAUS8;HAUS2;TUBA1A;KIF3B
prerank,Reactome_2022__TRAF6 Mediated Induction Of NFkB And MAP Kinases Upon TLR7/8 Or 9 Activation R-HSA-975138,-0.7141860211528097,-1.0214439535919797,0.43243243243243246,0.8712401620798892,1.0,4/98,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,GO_Biological_Process_2021__regulation of response to cytokine stimulus (GO:0060759),0.6348458106127993,1.0211504789488317,0.48120300751879697,0.8578492127398988,1.0,1/21,0.10%,IRAK2
prerank,Reactome_2022__Regulation Of Actin Dynamics For Phagocytic Cup Formation R-HSA-2029482,0.7538771477404658,1.020811770246251,0.5476190476190477,0.8576616712070301,1.0,2/57,0.77%,PTK2;ABI2
prerank,KEGG_2021_Human__Toll-like receptor signaling pathway,-0.7726678135616666,-1.0206772316852013,0.4954954954954955,0.871381668504617,1.0,4/87,1.04%,MAP2K6;AKT3;PIK3CB;TICAM2
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630),0.748968203604093,1.020624556420297,0.5354330708661418,0.8573196578599254,1.0,2/50,1.51%,MSH2;BOK
prerank,Elsevier_Pathway_Collection__Breast Cancer,0.7985483372008728,1.0200829532043045,0.48091603053435117,0.8572872337231613,1.0,4/108,0.42%,MSH2;BRIP1;LRP5;TNFRSF10A
prerank,GO_Biological_Process_2021__intracellular lipid transport (GO:0032365),0.5845469996555477,1.0200038946255272,0.4188034188034188,0.8568631319407369,1.0,2/21,0.13%,PRKAA2;ACACA
prerank,Reactome_2022__Post NMDA Receptor Activation Events R-HSA-438064,0.7113639436099622,1.0195108627262655,0.5447154471544715,0.8568114320682007,1.0,4/59,0.91%,PRKAA2;DLG1;ARHGEF7;GPRIN1
prerank,Reactome_2022__HS-GAG Biosynthesis R-HSA-2022928,0.6182568133434567,1.0193422357882869,0.48739495798319327,0.8564706892208251,1.0,1/28,0.55%,SLC35D2
prerank,"Elsevier_Pathway_Collection__Hypothyroidism, Secondary (Central)",-0.5468729721495952,-1.0188382535138554,0.3700787401574803,0.872565265019888,1.0,1/20,1.02%,SLC16A2
prerank,MSigDB_Oncogenic_Signatures__CAHOY ASTROCYTIC,-0.762622853842897,-1.01863361900222,0.46534653465346537,0.872191612659939,1.0,5/93,0.95%,VNN1;TTPA;APP;RASA2;AGPAT4
prerank,GO_Biological_Process_2021__cellular protein localization (GO:0034613),0.6603308106277854,1.0184476956203627,0.4041095890410959,0.8567516590136723,1.0,11/308,1.41%,AXIN2;CNTNAP1;HERC2;KIF13A;MYO7A;SEPTIN6;STX1A;CPE;SEPTIN9;FLNA;ACD
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 UP.V1 UP,0.716338266796954,1.0181886661223956,0.40816326530612246,0.8564916751323538,1.0,8/165,1.22%,THY1;MKI67;KSR1;SMOX;SLC19A1;CGREF1;DMWD;FDXR
prerank,Reactome_2022__CD28 Co-Stimulation R-HSA-389356,-0.6281732177932513,-1.0180405078255206,0.4700854700854701,0.8721671909834171,1.0,2/33,1.10%,AKT3;VAV1
prerank,GO_Biological_Process_2021__DNA-dependent DNA replication (GO:0006261),0.7714900479199545,1.0179768338888215,0.42276422764227645,0.8561690593502361,1.0,3/127,0.72%,CDC45;GINS1;POLE4
prerank,Reactome_2022__Glucagon-like Peptide-1 (GLP1) Regulates Insulin Secretion R-HSA-381676,-0.6763965692723743,-1.0179534706894775,0.5040650406504065,0.8717064585731826,1.0,2/39,1.24%,RAP1A;KCNS3
prerank,GO_Biological_Process_2021__protein localization to membrane (GO:0072657),0.716698397089031,1.0177812906861303,0.432258064516129,0.8558468122718693,1.0,9/187,1.41%,THY1;LIN7A;DLG1;RAB40C;ITGAL;CRB3;CPE;SYNE3;FLNA
prerank,Reactome_2022__Signaling By NOTCH R-HSA-157118,0.6824027211580127,1.017533708462257,0.43703703703703706,0.855613800506983,1.0,4/191,0.59%,HDAC8;NOTCH3;TBL1X;WWP2
prerank,Reactome_2022__Thromboxane Signaling Thru TP Receptor R-HSA-428930,0.5056791038624949,1.0174797546052021,0.375,0.8551665953398487,1.0,1/22,1.11%,GNB5
prerank,Reactome_2022__Apoptotic Execution Phase R-HSA-75153,0.7366998257852421,1.0171864573123433,0.5886524822695035,0.8549190823030063,1.0,3/48,1.00%,PTK2;TJP1;STK26
prerank,Reactome_2022__Early SARS-CoV-2 Infection Events R-HSA-9772572,-0.670841839644097,-1.016805690739098,0.5315315315315315,0.8722992480795716,1.0,4/35,1.26%,RB1;UVRAG;SDC3;TMPRSS2
prerank,GO_Biological_Process_2021__endomembrane system organization (GO:0010256),-0.6664029211399212,-1.01623261942682,0.4864864864864865,0.8722588611568349,1.0,4/191,1.11%,ATL2;ZNF501;TICAM2;SYNE1
prerank,Reactome_2022__Class A/1 (Rhodopsin-like Receptors) R-HSA-373076,-0.6430786462528376,-1.0160553477500178,0.36936936936936937,0.8718812627193393,1.0,6/240,1.23%,CCL23;APP;GPR39;GPR132;HRH2;S1PR1
prerank,GO_Biological_Process_2021__acylglycerol metabolic process (GO:0006639),-0.6601738072827392,-1.0153588646519234,0.5178571428571429,0.8719738857960193,1.0,1/35,0.16%,PLAAT3
prerank,KEGG_2021_Human__Propanoate metabolism,0.6746172571730545,1.0151809340876052,0.5114503816793893,0.8561215884237655,1.0,2/34,0.25%,ACACA;ACSS3
prerank,Elsevier_Pathway_Collection__Metastatic Colorectal Cancer,0.7835084895825898,1.0150309391939125,0.43478260869565216,0.8557548728529293,1.0,4/109,1.51%,AXIN2;MSH2;PTK2;FN1
prerank,Elsevier_Pathway_Collection__TP53 Signaling in Pancreatic Neoplasms,-0.599337288960583,-1.014873717238214,0.4369747899159664,0.8719258219906868,1.0,2/21,0.93%,RB1;CCND2
prerank,GO_Biological_Process_2021__positive regulation of cytoskeleton organization (GO:0051495),-0.7103413733394595,-1.014188424945059,0.43333333333333335,0.8720156504627166,1.0,5/79,1.21%,CARMIL1;PTK2B;HCK;NTF3;TEK
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell migration (GO:0010596),-0.6338528724769286,-1.013818172745216,0.5045871559633027,0.871808683305541,1.0,2/37,1.30%,HRG;DNAJA4
prerank,KEGG_2021_Human__Insulin signaling pathway,0.7221506609863382,1.0137193253384407,0.4460431654676259,0.856415202910417,1.0,5/127,1.12%,PRKAA2;ACACA;PHKA2;RHOQ;PKLR
prerank,TRRUST_Transcription_Factors_2019__SP3 human,-0.7036120443756929,-1.0136859140480001,0.43636363636363634,0.8713901912713509,1.0,5/105,1.24%,MUC6;CYP3A7;CD83;ADGRE5;MAOB
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell apoptotic process (GO:2000353),0.5287299225120319,1.013434470883951,0.3602941176470588,0.8561589023486729,1.0,6/16,16.25%,FASLG;CD160;GPER1;ECSCR;ANO6;CD40LG
prerank,Reactome_2022__Late Phase Of HIV Life Cycle R-HSA-162599,0.7493144322206148,1.0129569877507596,0.4027777777777778,0.8561382094547126,1.0,3/131,0.81%,NUP210;TAF4;TCEA1
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell/Pericyte Differentiation and Proliferation,-0.5775747714925977,-1.0125012942499505,0.408,0.872046353849149,1.0,1/20,0.99%,KLF4
prerank,Reactome_2022__TNFs Bind Their Physiological Receptors R-HSA-5669034,0.6367597089387649,1.0123083820530652,0.4888888888888889,0.8562167913377973,1.0,2/28,1.20%,TNFRSF25;EDA2R
prerank,Reactome_2022__Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168181,-0.7141849996925875,-1.012222405663829,0.4444444444444444,0.8717710118323204,1.0,4/100,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,Elsevier_Pathway_Collection__ERK5/MAPK7 Signaling,0.676751146696449,1.011939600982893,0.518796992481203,0.8560861121611546,1.0,1/35,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Priming,-0.5892116642918162,-1.011787050436444,0.4,0.8716281306923805,1.0,1/18,0.66%,STXBP5
prerank,KEGG_2021_Human__Glycerolipid metabolism,-0.6739351237849031,-1.011784300168925,0.5038759689922481,0.8710840432200381,1.0,3/54,0.95%,MOGAT1;LIPG;AGPAT4
prerank,GO_Biological_Process_2021__regulation of peptide hormone secretion (GO:0090276),-0.7744002338656559,-1.0116815221855895,0.5779816513761468,0.8706198058305801,1.0,3/64,1.24%,RAP1A;SYT7;KCNS3
prerank,GO_Biological_Process_2021__androgen metabolic process (GO:0008209),0.6092684033709032,1.0116050650396637,0.4444444444444444,0.8558801499108887,1.0,1/20,0.35%,HSD17B11
prerank,GO_Biological_Process_2021__regulation of proteolysis involved in cellular protein catabolic process (GO:1903050),-0.6151315377857611,-1.01141403736391,0.4811320754716981,0.8703513146138019,1.0,1/25,0.67%,PTK2B
prerank,Elsevier_Pathway_Collection__FibronectinR -> NF-kB Signaling,0.5388026982674561,1.0112346988388823,0.3508771929824561,0.8557131927631942,1.0,3/17,1.51%,PTK2;BCAR1;FN1
prerank,Elsevier_Pathway_Collection__CC Chemokine Receptor Signaling,-0.7587256466220679,-1.011213563307654,0.48333333333333334,0.870014628386995,1.0,6/85,1.10%,CCL23;RAP1A;PTK2B;RASGRP2;GNA14;VAV1
prerank,GO_Biological_Process_2021__axonogenesis (GO:0007409),-0.6571488991672082,-1.011191126751226,0.3584905660377358,0.8694939736176247,1.0,9/225,1.36%,NTN4;APP;FEZ1;PIK3CB;DAB1;SLITRK3;SEMA4D;DSCAML1;GRB10
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Mediated Cell Death,0.7039677634983255,1.0109677352695432,0.5190839694656488,0.8554452462143681,1.0,2/47,1.10%,TNFRSF10A;ITGAL
prerank,GO_Biological_Process_2021__protein localization to organelle (GO:0033365),0.7182962771059929,1.010929144423999,0.40425531914893614,0.8549968757713743,1.0,4/138,1.48%,MSX1;TUB;STX1A;LAMP2
prerank,Reactome_2022__Toll Like Receptor 9 (TLR9) Cascade R-HSA-168138,-0.7141834405271082,-1.0109039107446407,0.4380952380952381,0.8692161543183785,1.0,4/103,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via Adherence on Endothelial Cells,0.7694318739003594,1.010597350446292,0.5985401459854015,0.8548221016377047,1.0,3/57,1.49%,PTK2;ITGAL;BCAR1
prerank,TRRUST_Transcription_Factors_2019__GATA4 human,0.5245313544069476,1.0105018447135397,0.3565217391304348,0.8544476606709336,1.0,1/17,0.95%,AMH
prerank,Elsevier_Pathway_Collection__Proteins Involved in Myocarditis,-0.6720404924130662,-1.0104202952481913,0.39215686274509803,0.8690860073574701,1.0,3/182,1.07%,CD2;CD274;IL21R
prerank,Reactome_2022__G-protein Activation R-HSA-202040,0.505680075274825,1.0102674747684433,0.3644067796610169,0.8541681496792912,1.0,1/20,1.11%,GNB5
prerank,GO_Biological_Process_2021__positive regulation of cell projection organization (GO:0031346),-0.720586515837384,-1.0095765379138626,0.4426229508196721,0.8693188518386671,1.0,3/111,0.67%,CARMIL1;RAP1A;PTK2B
prerank,MSigDB_Hallmark_2020__Estrogen Response Early,-0.6656686736321497,-1.0093862086590852,0.391304347826087,0.8689707146652283,1.0,5/199,1.17%,PLAAT3;AMFR;DEPTOR;KLF4;AQP3
prerank,Reactome_2022__Integrin Signaling R-HSA-354192,-0.5653518324123794,-1.0092799197008555,0.4344262295081967,0.868565239090304,1.0,3/27,0.93%,RAP1A;RAP1B;RASGRP2
prerank,Elsevier_Pathway_Collection__Norepinephrine Release Regulation,-0.6121059029484451,-1.008753130976955,0.46923076923076923,0.8685250453213181,1.0,1/34,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__Inhibition of THBS1 Activates Angiogenesis in Cancer,0.6912273382800835,1.0086108912514167,0.5652173913043478,0.8550696137009253,1.0,2/39,1.51%,TNFRSF10A;FN1
prerank,Reactome_2022__Metabolism Of Fat-Soluble Vitamins R-HSA-6806667,-0.7277952736250329,-1.0085676691865104,0.5652173913043478,0.8681754250942157,1.0,2/45,1.16%,TTPA;SDC3
prerank,WikiPathway_2021_Human__Leptin signaling pathway WP2034,0.7896108105719988,1.0085444070305585,0.5419847328244275,0.8546398864102132,1.0,3/76,0.26%,PRKAA2;ACACA;PTK2
prerank,MSigDB_Oncogenic_Signatures__CSR LATE UP.V1 DN,-0.7026485731288116,-1.008028543210451,0.42342342342342343,0.8681748384847674,1.0,9/147,1.26%,MAMDC2;PDE5A;NTN4;ABCA6;OAF;EPSTI1;NYNRIN;GLI3;DUSP4
prerank,WikiPathway_2021_Human__Fragile X Syndrome  WP4549,-0.748698451382983,-1.0068028714363737,0.42574257425742573,0.8687714832272705,1.0,5/116,0.73%,GRIN2B;APP;ABCD3;DEPTOR;PIK3CB
prerank,Reactome_2022__Netrin-1 Signaling R-HSA-373752,-0.7285646667728937,-1.0060137101815512,0.6116504854368932,0.86902183841264,1.0,4/47,1.36%,NTN4;NEO1;DSCAML1;ABLIM3
prerank,Reactome_2022__Activation Of NMDA Receptors And Postsynaptic Events R-HSA-442755,0.7498297923066024,1.0059737410706369,0.53125,0.8564963904686611,1.0,5/71,0.91%,PRKAA2;LIN7A;DLG1;ARHGEF7;GPRIN1
prerank,MSigDB_Hallmark_2020__Myogenesis,0.6991142672033286,1.0059233944370414,0.437125748502994,0.8560513417254438,1.0,7/183,1.46%,SVIL;ERBB3;PPFIA4;TEAD4;TNNC2;ITGB5;CNN3
prerank,Reactome_2022__MHC Class II Antigen Presentation R-HSA-2132295,0.7472077949950365,1.0054216666365312,0.46825396825396826,0.856030873019485,1.0,4/100,1.35%,CENPE;KIF23;CTSH;KIF3B
prerank,GO_Biological_Process_2021__ciliary basal body-plasma membrane docking (GO:0097711),0.7710001446556797,1.0052757619200594,0.5068493150684932,0.8556743534103245,1.0,4/95,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,WikiPathway_2021_Human__Gastrin signaling pathway WP4659,0.7707846544686683,1.0048245531748539,0.44029850746268656,0.8556006354875089,1.0,3/109,1.49%,PTK2;TJP1;BCAR1
prerank,GO_Biological_Process_2021__anterograde trans-synaptic signaling (GO:0098916),-0.6894194727897699,-1.0044932224024536,0.39316239316239315,0.8699285483120168,1.0,4/184,1.32%,GRIN2B;HRH2;DLG2;OMP
prerank,Reactome_2022__DNA Damage Bypass R-HSA-73893,0.7219187189294924,1.0044896186885752,0.5460992907801419,0.8554243676637904,1.0,2/48,0.72%,SLC19A1;POLE4
prerank,MSigDB_Oncogenic_Signatures__STK33 UP,-0.6411302019756463,-1.0039444599904168,0.36893203883495146,0.8698902755794894,1.0,4/254,1.18%,FCAMR;CREB5;IL10RA;CLEC2B
prerank,GO_Biological_Process_2021__positive regulation of transferase activity (GO:0051347),0.7118237905726424,1.0035172659622698,0.39436619718309857,0.8558145987825378,1.0,5/143,1.46%,PARN;ERBB3;DRD4;ACD;WRAP53
prerank,GO_Biological_Process_2021__regulation of cytoskeleton organization (GO:0051493),0.7543810509991927,1.0034314687613906,0.47101449275362317,0.8554184235768583,1.0,7/109,1.05%,PRKAA2;PTK2;TJP1;STMN3;RHOQ;IQGAP3;CAMSAP3
prerank,GO_Biological_Process_2021__positive regulation of establishment of protein localization (GO:1904951),0.588672353539999,1.0033260643782365,0.4318181818181818,0.8550312323285695,1.0,2/19,1.46%,CEP295;WRAP53
prerank,GO_Biological_Process_2021__negative regulation of cell-cell adhesion (GO:0022408),0.7323954236156274,1.0032260412595584,0.5748031496062992,0.8546444763711722,1.0,2/40,0.79%,PTK2;PPARA
prerank,Reactome_2022__Signaling By FGFR1 R-HSA-5654736,-0.6620963865010736,-1.002885922337697,0.48,0.8702701238605702,1.0,1/44,0.20%,FLRT2
prerank,WikiPathway_2021_Human__Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.7085011611049252,1.0027400577821575,0.564625850340136,0.8545929073242828,1.0,2/45,1.36%,MAP3K9;SYNE3
prerank,Reactome_2022__MyD88 Dependent Cascade Initiated On Endosome R-HSA-975155,-0.7141855054724964,-1.0026555418940686,0.4537037037037037,0.8699705527392697,1.0,4/99,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,Reactome_2022__Interferon Signaling R-HSA-913531,-0.6680937307465415,-1.0025863584528243,0.3838383838383838,0.8694991085919488,1.0,6/181,1.31%,OAS1;KPNA3;OASL;GBP4;HERC5;PML
prerank,MSigDB_Hallmark_2020__IL-2/STAT5 Signaling,-0.6522707433677495,-1.0024091098895416,0.3953488372093023,0.8691351790042974,1.0,6/197,1.12%,CDCP1;CCND2;RHOH;GBP4;CD83;IL10RA
prerank,Elsevier_Pathway_Collection__Neutrophil Degranulation via FPR1/IL8,0.7694273799185628,1.0023272082189596,0.5766423357664233,0.8545371342207844,1.0,3/64,1.49%,PTK2;ITGAL;BCAR1
prerank,Elsevier_Pathway_Collection__Hematopoietic Cell Lineage: B-cell (mouse),0.6788642344959073,1.002143216108735,0.552,0.8542450172926235,1.0,3/42,0.69%,GFI1;ITGA2;FNIP1
prerank,Reactome_2022__Costimulation By CD28 Family R-HSA-388841,-0.7032958462030724,-1.0020546546884452,0.4608695652173913,0.8689385152265052,1.0,3/64,1.10%,AKT3;CD274;VAV1
prerank,GO_Biological_Process_2021__regulation of peptidyl-threonine phosphorylation (GO:0010799),-0.6796899541738387,-1.0020533729441332,0.5272727272727272,0.8684060594804283,1.0,2/37,0.43%,APP;WNK3
prerank,Reactome_2022__Factors Involved In Megakaryocyte Development And Platelet Production R-HSA-983231,0.7409991059129185,1.001904316528195,0.44366197183098594,0.8539532280334792,1.0,4/116,1.42%,CENPE;KIF23;KIF3B;DOCK11
prerank,Reactome_2022__MyD88:MAL(TIRAP) Cascade Initiated On Plasma Membrane R-HSA-166058,-0.7141792909041376,-1.0017539291790085,0.4482758620689655,0.8681944665614028,1.0,4/111,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,GO_Biological_Process_2021__positive regulation of phosphatidylinositol 3-kinase activity (GO:0043552),-0.5760267404847796,-1.0016426619675654,0.44274809160305345,0.8677723952379847,1.0,2/27,1.21%,PTK2B;TEK
prerank,KEGG_2021_Human__Alcoholism,-0.6897961357788294,-1.0016029448173975,0.40310077519379844,0.8672806397016103,1.0,4/145,1.24%,GRIN2B;FOSB;CREB5;MAOB
prerank,GO_Biological_Process_2021__positive regulation of cell migration (GO:0030335),0.6533893303317155,1.0013565908512605,0.4342105263157895,0.8539617292810562,1.0,10/262,1.51%,PTK2;TJP1;ZNF304;ARHGEF7;SH3RF2;CTSH;FGF1;SEMA3G;BCAR1;FN1
prerank,MSigDB_Oncogenic_Signatures__IL2 UP.V1 DN,-0.7141607272371303,-1.0011120280275057,0.4329896907216495,0.8672338344761752,1.0,9/156,1.35%,MAP2K6;ZNF571;SULT1B1;DEPTOR;TNFAIP2;PBX1;CLEC2B;TEK;COLQ
prerank,GO_Biological_Process_2021__telomere maintenance (GO:0000723),0.738221918037512,1.0007965608951583,0.5929203539823009,0.8539255706333406,1.0,2/53,1.41%,ATR;ACD
prerank,GO_Biological_Process_2021__neural crest cell differentiation (GO:0014033),-0.474449725152752,-1.000741174173571,0.3025210084033613,0.8670312714819333,1.0,8/17,20.96%,SOX8;CYP26C1;CDH2;FAM172A;LRP6;PEF1;TCOF1;SNAI2
prerank,Elsevier_Pathway_Collection__Plasmin Role in Glomerulonephritis,-0.668504987006937,-1.0003747987050924,0.53125,0.8668133850670806,1.0,1/49,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of translation (GO:0006417),0.6897679619346937,1.0002899933340663,0.4316546762589928,0.8539425779171628,1.0,4/174,0.97%,IGF2BP1;YTHDF3;EIF2A;IGF2BP3
prerank,GO_Biological_Process_2021__regulation of calcium ion-dependent exocytosis (GO:0017158),0.6525892908765184,1.0002837005136278,0.5038759689922481,0.8534668379639115,1.0,2/30,1.20%,RAB3GAP1;STX1A
prerank,Reactome_2022__RHO GTPase Cycle R-HSA-9012999,0.6146772911938925,0.9997139529364429,0.44594594594594594,0.8535286582391792,1.0,21/430,1.55%,BAIAP2L2;SENP1;DEPDC1B;RALGAPA1;WWP2;ARHGAP39;ABI2;ARHGEF7;RBBP6;RHOQ;ANLN;CKAP4;PLEKHG5;IQGAP3;MOSPD2;ARHGEF18;FMNL2;CAVIN1;DOCK11;CDC42EP1;UACA
prerank,TRRUST_Transcription_Factors_2019__SOX2 mouse,0.5856686035754816,0.9995188710431075,0.43902439024390244,0.8532085476576239,1.0,1/18,0.97%,MYCN
prerank,GO_Biological_Process_2021__positive regulation of cellular biosynthetic process (GO:0031328),-0.6585589865555515,-0.9991996745374255,0.4017857142857143,0.8675191358891782,1.0,2/176,0.99%,CPEB3;KLF4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pulmonary Hypertension,0.7035190488421196,0.9991487517781652,0.48322147651006714,0.8530435743763717,1.0,3/157,1.30%,KCNC1;SLC6A4;APOE
prerank,GO_Biological_Process_2021__regulation of sprouting angiogenesis (GO:1903670),0.6179760022740688,0.9990467109029129,0.48507462686567165,0.8526584004669834,1.0,3/32,1.36%,PPP1R16B;TJP1;FGF1
prerank,Reactome_2022__Intrinsic Pathway For Apoptosis R-HSA-109606,-0.6815419914463123,-0.9984279021100725,0.4806201550387597,0.8677522511007661,1.0,1/55,0.37%,AKT3
prerank,GO_Biological_Process_2021__regulation of blood vessel endothelial cell migration (GO:0043535),-0.7188638874017766,-0.996983401048981,0.5865384615384616,0.8687518864068889,1.0,2/54,1.26%,AKT3;HRG
prerank,Reactome_2022__SUMOylation Of Intracellular Receptors R-HSA-4090294,-0.6086959510735075,-0.996882697012212,0.5,0.8683211844937234,1.0,2/29,1.25%,NR3C1;VDR
prerank,GO_Biological_Process_2021__positive regulation of transcription of Notch receptor target (GO:0007221),0.5666011464314055,0.9966317141000989,0.4032258064516129,0.854266602784768,1.0,1/17,0.43%,NOTCH3
prerank,Elsevier_Pathway_Collection__Neurotrophic Factor Deprivation in Retinal Ganglion Cell Death,-0.6441702470260164,-0.9965888342523279,0.5294117647058824,0.8680591898207108,1.0,2/34,0.83%,MAP2K6;NTF3
prerank,GO_Biological_Process_2021__regulation of erythrocyte differentiation (GO:0045646),0.6372973229994927,0.9965346734937464,0.512396694214876,0.8538727095187603,1.0,1/37,0.19%,CDK6
prerank,TRRUST_Transcription_Factors_2019__SP1 human,-0.6038824799234607,-0.9964013242366199,0.46938775510204084,0.8677406276355991,1.0,13/441,1.27%,MUC6;CYP3A7;APP;GPR39;CD163;CCND2;PGLYRP2;CD83;ADGRE5;LTBP4;MAOB;VDR;CYP1B1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Obesity,-0.6878944853782976,-0.9963412236517616,0.4793388429752066,0.8672777378041354,1.0,4/93,1.25%,APP;NR3C1;RB1;VDR
prerank,Reactome_2022__Downstream Signal Transduction R-HSA-186763,-0.6408802905492584,-0.9953657287763628,0.5,0.8676470270312743,1.0,1/28,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of mitotic spindle organization (GO:0060236),0.6705547792454154,0.9951159820653136,0.5185185185185185,0.8547189626967225,1.0,1/35,0.33%,CCSAP
prerank,Elsevier_Pathway_Collection__Synaptic Exocytosis in Dementia,-0.5892098582182964,-0.9945829501177771,0.44166666666666665,0.8678790686018475,1.0,1/23,0.66%,STXBP5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glioblastoma,0.6786630134347348,0.9943820615533755,0.45454545454545453,0.8549172779179856,1.0,4/161,1.36%,CDK6;RFX1;MYCN;FGF1
prerank,WikiPathway_2021_Human__Hedgehog Signaling Pathway WP4249,-0.6453989413133375,-0.994075206016096,0.5555555555555556,0.8679122055259985,1.0,2/41,1.22%,CCND2;GLI3
prerank,Elsevier_Pathway_Collection__CHRNA7 -> CREB Signaling,0.5063262753284389,0.9938583320852996,0.3228346456692913,0.8548934878032495,1.0,1/15,0.26%,PTK2
prerank,GO_Biological_Process_2021__DNA replication initiation (GO:0006270),0.6966074747784675,0.9938224593183331,0.5793650793650794,0.8544557702620293,1.0,2/38,0.72%,CDC45;POLE4
prerank,MSigDB_Oncogenic_Signatures__KRAS.KIDNEY UP.V1 DN,-0.7228189109401196,-0.9934648235076937,0.4636363636363636,0.8679272565518991,1.0,4/105,1.26%,OAS1;AADAC;ADAMTSL2;HRG
prerank,MSigDB_Oncogenic_Signatures__PRC2 EZH2 UP.V1 UP,0.7168493617767893,0.9931987744641485,0.48299319727891155,0.8545610242278148,1.0,8/166,1.56%,CDC45;DEPDC1;LIN7A;LRRC20;SOAT2;SLC2A6;LRRC61;FOSL2
prerank,Elsevier_Pathway_Collection__CagA Phosphorylation Independent Signaling,0.70055186475824,0.9927379611116236,0.5846153846153846,0.8545184848584482,1.0,3/38,1.49%,PTK2;TJP1;BCAR1
prerank,GO_Biological_Process_2021__BMP signaling pathway (GO:0030509),0.7344752310276075,0.9926667424428708,0.5555555555555556,0.8540964646093219,1.0,3/62,1.09%,MEGF8;AMH;CHRD
prerank,Elsevier_Pathway_Collection__Adipose Tissue Inflammation Provokes Insulin Resistance,-0.5241641859717341,-0.992658153017756,0.328,0.8681226344655938,1.0,5/15,3.70%,TNF;PNPLA2;CXCL5;TRADD;TNFRSF1A
prerank,GO_Biological_Process_2021__regulation of reactive oxygen species metabolic process (GO:2000377),0.7338251401057075,0.9922347174690669,0.5655172413793104,0.8539678303474564,1.0,2/55,1.43%,AATF;MPV17
prerank,KEGG_2021_Human__Cholesterol metabolism,0.7248411948799455,0.9921658142618239,0.5447761194029851,0.8535465840689236,1.0,3/50,1.35%,SORT1;APOE;SOAT2
prerank,KEGG_2021_Human__Glioma,-0.7182251294170009,-0.9918538650065294,0.5047619047619047,0.8684490889511903,1.0,3/71,0.73%,AKT3;RB1;PIK3CB
prerank,GO_Biological_Process_2021__negative regulation of translation (GO:0017148),0.7675662034839177,0.9916420745657937,0.47580645161290325,0.8535299614910837,1.0,3/86,0.97%,IGF2BP1;YTHDF3;IGF2BP3
prerank,GO_Biological_Process_2021__actin filament organization (GO:0007015),0.7109564956838306,0.9914541016634714,0.46710526315789475,0.853204096602235,1.0,11/145,1.49%,BAIAP2L2;PPP1R9A;SVIL;DLG1;ABI2;MYO7A;SPIRE2;DPYSL3;SHROOM1;FLNA;BCAR1
prerank,GO_Biological_Process_2021__positive regulation of focal adhesion assembly (GO:0051894),0.5444161979311942,0.9914192955099544,0.3813559322033898,0.8527650497361485,1.0,1/18,0.07%,THY1
prerank,"GO_Biological_Process_2021__protein localization to chromosome, centromeric region (GO:0071459)",0.5939673471842855,0.9909395798440012,0.4418604651162791,0.8527699023613202,1.0,1/17,0.05%,CENPA
prerank,Reactome_2022__O-linked Glycosylation Of Mucins R-HSA-913709,-0.6972023874078349,-0.9908404868341092,0.5303030303030303,0.8689526988864473,1.0,2/51,0.84%,MUC6;GALNT3
prerank,Reactome_2022__Muscle Contraction R-HSA-397014,-0.670579221049091,-0.9906835523186601,0.39215686274509803,0.8685787598693964,1.0,3/171,1.08%,PDE5A;KCNE1;KCNK6
prerank,GO_Biological_Process_2021__mitotic chromosome condensation (GO:0007076),0.5707101617254715,0.9904125421481152,0.4714285714285714,0.8527936525115972,1.0,1/27,0.08%,NCAPG
prerank,Reactome_2022__Anchoring Of Basal Body To Plasma Membrane R-HSA-5620912,0.770999100916629,0.990210724811105,0.5238095238095238,0.852494105734486,1.0,4/97,1.31%,CEP164;HAUS8;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__positive regulation of cholesterol transport (GO:0032376),-0.5599314403076813,-0.9899250141426497,0.4645669291338583,0.8687989681725206,1.0,1/31,0.92%,LIPG
prerank,GO_Biological_Process_2021__positive regulation of canonical Wnt signaling pathway (GO:0090263),0.7305030153032185,0.9898299831494871,0.46715328467153283,0.8524088861006552,1.0,2/126,0.43%,AXIN2;TBL1X
prerank,GO_Biological_Process_2021__cellular calcium ion homeostasis (GO:0006874),-0.7369185934033097,-0.9896470071528133,0.4434782608695652,0.8685411608316238,1.0,2/119,1.31%,CCL23;PML
prerank,WikiPathway_2021_Human__Wnt signaling pathway and pluripotency WP399,0.7415477790926335,0.9894874495329969,0.49612403100775193,0.8522419838493852,1.0,2/97,0.40%,AXIN2;LRP5
prerank,GO_Biological_Process_2021__peripheral nervous system development (GO:0007422),0.6203369298682233,0.989309979574108,0.5084745762711864,0.8519558120020019,1.0,2/23,1.20%,ERBB3;GSTM3
prerank,GO_Biological_Process_2021__negative regulation of cellular amide metabolic process (GO:0034249),0.7473948715238844,0.9892715083122035,0.5,0.8515191501318662,1.0,3/83,1.30%,IGF2BP1;IGF2BP3;APOE
prerank,"GO_Biological_Process_2021__regulation of gene expression, epigenetic (GO:0040029)",0.7487655693422703,0.9888182061682378,0.5298507462686567,0.8514786170643565,1.0,2/82,0.70%,TAF1B;PHF2
prerank,"GO_Biological_Process_2021__chemical synaptic transmission, postsynaptic (GO:0099565)",-0.5316542912670323,-0.9884287514926325,0.37404580152671757,0.8691795425017323,1.0,1/20,0.01%,GRIN2B
prerank,WikiPathway_2021_Human__Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.7468175878193232,0.9884178188950562,0.5615384615384615,0.8513586244437925,1.0,2/68,0.13%,PRKAA2;ACACA
prerank,Elsevier_Pathway_Collection__Metabolic Effects of Oncogenes and Tumor Suppressor in Cancer Cells,0.7351903757139422,0.9884134093620005,0.5578231292517006,0.8508958295236425,1.0,4/66,1.49%,ACACA;PKLR;PYCR1;GLS
prerank,GO_Biological_Process_2021__transcription initiation from RNA polymerase II promoter (GO:0006367),0.7391425607472564,0.9878532632551061,0.475177304964539,0.8509037746462913,1.0,5/136,1.12%,NOTCH3;TBL1X;TAF4;PPARA;TEAD4
prerank,MSigDB_Oncogenic_Signatures__VEGF A UP.V1 DN,0.7103977257954209,0.9873147585410098,0.4315068493150685,0.850897089686141,1.0,10/185,1.18%,CENPA;CENPE;NDC80;CDC45;ITGA2;HIRA;CEBPZ;PRPF40A;KIF23;RRM2
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Neuroblastoma,-0.6858464413431243,-0.9871958470685368,0.5565217391304348,0.8698941126160968,1.0,2/46,0.83%,MAP2K6;NTF3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hepatocellular Carcinoma,0.7314616258230422,0.9871786153800081,0.4230769230769231,0.8505689195915037,1.0,6/120,1.31%,PTK2;FBXO31;PPARA;ERBB3;FMNL2;CPE
prerank,WikiPathway_2021_Human__p53 transcriptional gene network WP4963,0.7729949419013824,0.9868753862731516,0.5522388059701493,0.8504122005247304,1.0,2/64,1.15%,MSH2;TNFRSF10D
prerank,Elsevier_Pathway_Collection__TERT/WNT Activation in Cancer,0.5881425342024369,0.9865605988480307,0.46564885496183206,0.8502243738844815,1.0,1/23,0.40%,LRP5
prerank,GO_Biological_Process_2021__potassium ion transport (GO:0006813),-0.7298266682934561,-0.9863420662950905,0.48031496062992124,0.8702309278643824,1.0,6/103,1.24%,KCNN2;KCNE1;KCNAB3;SLC9A9;KCNK6;KCNS3
prerank,GO_Biological_Process_2021__triglyceride biosynthetic process (GO:0019432),0.5765252021003247,0.9857149248983423,0.44525547445255476,0.8504827668406812,1.0,1/18,0.32%,GPAT4
prerank,GO_Biological_Process_2021__regulation of axonogenesis (GO:0050770),0.7164109129109827,0.9855500855021732,0.5797101449275363,0.8501242991507452,1.0,2/50,0.27%,THY1;BRSK1
prerank,Reactome_2022__Stimuli-sensing Channels R-HSA-2672351,-0.760023370342769,-0.9855463177323732,0.5145631067961165,0.8704930279371269,1.0,2/87,0.73%,WNK3;WWP1
prerank,TRRUST_Transcription_Factors_2019__FOS human,-0.7481785133595532,-0.9849774530875963,0.5929203539823009,0.8705345849169464,1.0,3/53,1.10%,NTF3;CYP1A2;SPI1
prerank,GO_Biological_Process_2021__negative regulation of leukocyte cell-cell adhesion (GO:1903038),-0.5014842735997942,-0.9849044538234839,0.3333333333333333,0.8700898406278939,1.0,1/18,0.55%,FGL1
prerank,GO_Biological_Process_2021__cell junction organization (GO:0034330),0.7217869804597754,0.984635219874133,0.5664335664335665,0.8505719153112407,1.0,4/70,1.41%,TJP1;PPFIA4;FBLIM1;FLNA
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Response in Ulcerative Colitis,-0.6240557066817387,-0.9842809272674469,0.5238095238095238,0.8702083211755901,1.0,2/45,1.13%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of apoptotic process (GO:0043065),0.6367068704404054,0.9842237074645955,0.4625,0.8504697236115193,1.0,8/300,1.51%,MELK;ING5;TNFRSF10A;ARHGEF7;PLEKHG5;PRR7;ARHGEF18;BOK
prerank,WikiPathway_2021_Human__Nuclear Receptors in Lipid Metabolism and Toxicity WP299,-0.5907154522204882,-0.9839560634506388,0.4666666666666667,0.8699841380597622,1.0,3/32,1.25%,ABCD3;CYP1A2;VDR
prerank,MSigDB_Oncogenic_Signatures__PIGF UP.V1 DN,0.6886730308276576,0.9834079503555584,0.4583333333333333,0.8508002020085145,1.0,7/165,1.48%,THY1;SNX29;UBE2H;PTPRH;PPFIA4;PKLR;SLC30A10
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometriosis,-0.6304678287871669,-0.9833260224249372,0.42718446601941745,0.8701280851397323,1.0,7/238,1.25%,STS;NCOA1;NTF3;MEIS1;CD163;VAV1;VDR
prerank,Elsevier_Pathway_Collection__FSH Action in Polycystic Ovary Syndrome,-0.541355029355828,-0.9833107597389216,0.38016528925619836,0.8696208338422317,1.0,1/20,0.34%,RAP1A
prerank,Reactome_2022__Sphingolipid De Novo Biosynthesis R-HSA-1660661,-0.6696848787033064,-0.983272706973287,0.56,0.8691141944280814,1.0,1/43,0.51%,SGPP1
prerank,GO_Biological_Process_2021__regulation of response to biotic stimulus (GO:0002831),0.5998018969700527,0.9830568124103678,0.46774193548387094,0.8506813694791349,1.0,1/29,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__Androgen Receptor Genomic Signaling,0.5610023226189101,0.9829748651843582,0.4083333333333333,0.8503071554751065,1.0,2/18,1.41%,AMH;FLNA
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Rheumatoid Arthritis,-0.6544765764688382,-0.9828757073963902,0.5169491525423728,0.8689447605074035,1.0,2/57,0.67%,MAP2K6;PTK2B
prerank,WikiPathway_2021_Human__Melanoma WP4685,-0.7182271047661054,-0.9826896412202702,0.5137614678899083,0.8686379158358747,1.0,3/64,0.73%,AKT3;RB1;PIK3CB
prerank,Elsevier_Pathway_Collection__Hematopoietic Cell Lineage: B-cell,0.6330342418584629,0.9822054829580211,0.5079365079365079,0.8506662471507379,1.0,2/36,0.12%,THY1;GFI1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetes Mellitus Type 2,0.7436865205484628,0.9819514112848312,0.48175182481751827,0.8504543051554586,1.0,3/105,1.30%,PRKAA2;PPARA;APOE
prerank,Elsevier_Pathway_Collection__Proteins Involved in Epilepsy,0.6609391981271433,0.9815532727134244,0.4393939393939394,0.8503773998698578,1.0,6/242,1.46%,KCNC1;SLC6A4;IRAK2;RALGAPA1;APOE;CNN3
prerank,TRRUST_Transcription_Factors_2019__SRF mouse,-0.5410684952900301,-0.9812570018266555,0.38405797101449274,0.8696379949902061,1.0,8/16,27.90%,KCNMB1;TAGLN;ACTG2;HMGXB4;MYLK;MMP14;CKM;ACTA2
prerank,KEGG_2021_Human__Ether lipid metabolism,-0.6705838395604622,-0.9807613056707515,0.5431034482758621,0.8695983649592164,1.0,1/44,0.16%,PLAAT3
prerank,MSigDB_Oncogenic_Signatures__KRAS.PROSTATE UP.V1 DN,0.7278050310028574,0.9802355191724605,0.49166666666666664,0.8512167524841356,1.0,4/116,0.93%,PPP1R9A;ACSS3;CGREF1;PTPRH
prerank,GO_Biological_Process_2021__RNA phosphodiester bond hydrolysis (GO:0090501),-0.611471950176026,-0.9801070613447683,0.509090909090909,0.8697648325418422,1.0,2/28,1.21%,LACTB2;NYNRIN
prerank,WikiPathway_2021_Human__B Cell Receptor Signaling Pathway WP23,-0.7158305396495517,-0.979930487557052,0.4789915966386555,0.8694429788589362,1.0,4/97,1.34%,MAP2K6;VAV1;MAP4K1;PTPN18
prerank,Elsevier_Pathway_Collection__Cell Cycle Dysregulation in Melanoma,-0.6379742560987798,-0.9798828273320275,0.5289256198347108,0.8689766878440901,1.0,2/39,0.53%,AKT3;RB1
prerank,MSigDB_Oncogenic_Signatures__NFE2L2.V2,-0.5971323829517373,-0.9794767539835115,0.4803921568627451,0.8688232838427475,1.0,9/375,1.26%,GSTA2;NT5DC1;GAS2;FGL1;RABL3;TMEM18;SMG6;HAO1;HRG
prerank,GO_Biological_Process_2021__acyl-CoA metabolic process (GO:0006637),-0.5965915236817534,-0.979030595688565,0.5,0.86871828061906,1.0,3/37,0.54%,GLYAT;SUCLG2;ACSM2B
prerank,Reactome_2022__RAC1 GTPase Cycle R-HSA-9013149,0.6797237408020301,0.9789889731709909,0.49645390070921985,0.8519557490857621,1.0,8/175,1.47%,DEPDC1B;ARHGAP39;ABI2;ARHGEF7;IQGAP3;ARHGEF18;DOCK11;CDC42EP1
prerank,KEGG_2021_Human__Cushing syndrome,-0.6814318522028159,-0.978862042930233,0.46226415094339623,0.8683673917823691,1.0,6/146,1.11%,RAP1A;RAP1B;RB1;PBX1;PDE11A;CREB5
prerank,Reactome_2022__Signaling By ALK R-HSA-201556,-0.6487649487583257,-0.9784879437282545,0.5491803278688525,0.8682298366783598,1.0,2/26,1.02%,PIK3CB;CD274
prerank,TRRUST_Transcription_Factors_2019__USF2 human,0.6995697257743807,0.9784556134748889,0.5310344827586206,0.851950619099087,1.0,2/46,1.12%,SLC19A1;PKLR
prerank,Reactome_2022__Cellular Hexose Transport R-HSA-189200,0.5703270250485093,0.978414204106667,0.4330708661417323,0.8515336839052036,1.0,2/20,1.44%,MFSD4B;SLC2A6
prerank,GO_Biological_Process_2021__visual system development (GO:0150063),-0.6153151758548479,-0.9782260538157608,0.5193798449612403,0.8679683212832973,1.0,2/34,0.90%,MEIS1;PBX1
prerank,Reactome_2022__Gap Junction Trafficking And Regulation R-HSA-157858,-0.5267388063495146,-0.9781880251016173,0.40476190476190477,0.8674843338799931,1.0,1/23,0.16%,GJB5
prerank,WikiPathway_2021_Human__Synaptic signaling pathways associated with autism spectrum disorder WP4539,-0.6881508269323857,-0.9781400601225372,0.5462184873949579,0.8669933350077982,1.0,3/50,0.73%,GRIN2B;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__substantia nigra development (GO:0021762),-0.7206427183477898,-0.9780726987499971,0.6030534351145038,0.8665332665605359,1.0,3/41,1.24%,ZNF148;BASP1;MAOB
prerank,GO_Biological_Process_2021__negative regulation of axon extension involved in axon guidance (GO:0048843),-0.5671379301459604,-0.977672406110259,0.44660194174757284,0.8664325975205074,1.0,1/20,0.96%,SEMA4D
prerank,Reactome_2022__Defective B3GALTL Causes PpS R-HSA-5083635,-0.6491737955388817,-0.9772848949791109,0.5483870967741935,0.8663118438651368,1.0,2/35,1.14%,ADAMTS5;ADAMTSL2
prerank,GO_Biological_Process_2021__phosphatidylinositol 3-kinase signaling (GO:0014065),0.5892137761259908,0.9768249984915245,0.47244094488188976,0.8526022233471213,1.0,2/32,1.32%,ERBB3;PIK3C2B
prerank,GO_Biological_Process_2021__phosphatidylinositol biosynthetic process (GO:0006661),-0.6975213080024282,-0.9764396568490397,0.4144144144144144,0.8667187702092558,1.0,2/123,1.35%,PIK3CB;PIK3R6
prerank,GO_Biological_Process_2021__regulation of myeloid cell differentiation (GO:0045637),-0.6724508279614095,-0.9763827157792215,0.5210084033613446,0.866265008026622,1.0,3/68,1.10%,PTK2B;MEIS1;SPI1
prerank,WikiPathway_2021_Human__Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,-0.5927149080180655,-0.9756981577307446,0.4830508474576271,0.8664395372862354,1.0,2/29,1.26%,OAS1;TMPRSS2
prerank,Reactome_2022__RND1 GTPase Cycle R-HSA-9696273,0.736095052181367,0.9756439951938813,0.6170212765957447,0.8532230951018658,1.0,2/41,0.99%,DEPDC1B;PLEKHG5
prerank,Elsevier_Pathway_Collection__Pancreatic Ductal Carcinoma,0.7435907778918585,0.9754058682371747,0.4689655172413793,0.8530106842377846,1.0,3/116,0.96%,CDK6;LRP5;ERBB3
prerank,KEGG_2021_Human__Proteoglycans in cancer,0.6668550700533957,0.975359741987001,0.43312101910828027,0.8525816902772491,1.0,7/194,1.51%,PTK2;ITGA2;DROSHA;ERBB3;ITGB5;FLNA;FN1
prerank,Reactome_2022__Aberrant Regulation Of Mitotic Exit In Cancer Due To RB1 Defects R-HSA-9687136,-0.5244447319362477,-0.9753055421900918,0.3697478991596639,0.8663266259332159,1.0,1/20,0.53%,RB1
prerank,GO_Biological_Process_2021__sensory perception of mechanical stimulus (GO:0050954),0.7462422126727786,0.9752123064456103,0.5333333333333333,0.852239841400523,1.0,3/77,1.03%,TBL1X;TSPEAR;MYO7A
prerank,KEGG_2021_Human__Kaposi sarcoma-associated herpesvirus infection,-0.6624573957055653,-0.9749974259411958,0.41904761904761906,0.8660829085537959,1.0,7/171,1.35%,MAP2K6;AKT3;RB1;PIK3CB;HCK;CLEC2B;PIK3R6
prerank,Elsevier_Pathway_Collection__CHRM1/2/3 -> Vascular Motility,-0.49988766036655924,-0.9749866475338882,0.37606837606837606,0.8655752394534021,1.0,13/20,27.95%,MAPK3;CHRM3;CALD1;RAF1;CHRM2;RASGRP1;MYLK;MAP2K2;GNAQ;ITPR1;PLCB1;ACTA2;NOS3
prerank,GO_Biological_Process_2021__cellular protein catabolic process (GO:0044257),-0.6368506810485992,-0.9747843134799732,0.5074626865671642,0.8652442303946322,1.0,1/57,0.26%,CTSO
prerank,Reactome_2022__Transcriptional Regulation By RUNX2 R-HSA-8878166,-0.7387220191622705,-0.9745007292679574,0.5277777777777778,0.8650744848939989,1.0,5/112,1.22%,AKT3;NR3C1;RB1;WWP1;GLI3
prerank,Reactome_2022__O-glycosylation Of TSR Domain-Containing Proteins R-HSA-5173214,-0.6491732785433952,-0.9742415432755737,0.5491803278688525,0.8648119931332121,1.0,2/36,1.14%,ADAMTS5;ADAMTSL2
prerank,Reactome_2022__Cell Surface Interactions At Vascular Wall R-HSA-202733,-0.6854264317372571,-0.9740099376709509,0.45544554455445546,0.8645297280280595,1.0,8/122,1.21%,SLC7A8;PROS1;GLG1;PIK3CB;FCAMR;CD2;SDC3;TEK
prerank,WikiPathway_2021_Human__Pre-implantation embryo WP3527,-0.6547942287282041,-0.9740031389901943,0.5403225806451613,0.8640194674441739,1.0,4/40,1.17%,FOSB;PBX1;KLF4;AQP3
prerank,GO_Biological_Process_2021__phosphatidylinositol phosphate biosynthetic process (GO:0046854),-0.613845828019138,-0.9733182703981401,0.5241935483870968,0.8642520723410035,1.0,1/41,0.73%,PIK3CB
prerank,WikiPathway_2021_Human__Energy Metabolism WP1541,0.7091245633267065,0.9731485185152005,0.5615384615384615,0.853804255439153,1.0,2/45,0.79%,PRKAA2;PPARA
prerank,Reactome_2022__Signaling By FGFR3 R-HSA-5654741,-0.5950129394221061,-0.9727696072491638,0.48760330578512395,0.8643490694629233,1.0,1/35,0.84%,GALNT3
prerank,Reactome_2022__Signaling By Receptor Tyrosine Kinases R-HSA-9006934,-0.5689268494036316,-0.9727032729501767,0.5268817204301075,0.8639049435231152,1.0,17/473,1.36%,GRIN2B;FOSB;FLRT2;RAP1A;AKT3;RAP1B;PTK2B;PIK3CB;WWP1;NTF3;GALNT3;CD274;VAV1;COL4A4;DUSP4;PTPN18;GRB10
prerank,GO_Biological_Process_2021__sphingolipid metabolic process (GO:0006665),-0.7237565830125301,-0.9719512678947146,0.46774193548387094,0.8641647383186433,1.0,3/113,0.99%,STS;SGPP1;GALC
prerank,Elsevier_Pathway_Collection__Hepatocellular Carcinoma,0.7435929270379065,0.9717362795779805,0.45255474452554745,0.8546103874990274,1.0,3/111,0.96%,CDK6;LRP5;ERBB3
prerank,GO_Biological_Process_2021__positive regulation of programmed cell death (GO:0043068),0.6367193423730291,0.9711606772939412,0.4838709677419355,0.8547089224883493,1.0,8/279,1.51%,MELK;ING5;TNFRSF10A;ARHGEF7;PLEKHG5;PRR7;ARHGEF18;BOK
prerank,Elsevier_Pathway_Collection__Proteins Involved in Neuroblastoma,0.6745934156481697,0.9710442821671295,0.496551724137931,0.8543687206245115,1.0,6/199,1.15%,PTK2;HDAC8;TNFRSF10A;MSX1;MYCN;TNFRSF10D
prerank,GO_Biological_Process_2021__glucose metabolic process (GO:0006006),-0.6829994036230421,-0.9702993663197517,0.5526315789473685,0.8653048260985923,1.0,2/54,0.39%,ALDOB;OAS1
prerank,Reactome_2022__Digestion And Absorption R-HSA-8963743,-0.466819883574357,-0.9701636775537069,0.31746031746031744,0.8649259286426573,1.0,7/16,19.80%,CHIT1;NPC1L1;GUCY2C;GUCA2A;TREH;MGAM;SLC2A2
prerank,GO_Biological_Process_2021__integrin-mediated signaling pathway (GO:0007229),0.7494064622040487,0.9700933122835315,0.5428571428571428,0.8548315774223095,1.0,7/75,1.51%,THY1;PTK2;ITGA2;ZNF304;ITGB5;BCAR1;FN1
prerank,GO_Biological_Process_2021__tight junction assembly (GO:0120192),0.7318171982573798,0.9691017409826004,0.5703703703703704,0.8552959895414415,1.0,3/52,1.14%,TBCD;DLG1;CRB3
prerank,GO_Biological_Process_2021__neuron apoptotic process (GO:0051402),-0.545419753105541,-0.9688149987661554,0.42342342342342343,0.8658393324948801,1.0,1/20,0.35%,APP
prerank,GO_Biological_Process_2021__heart development (GO:0007507),0.7175508221828918,0.9687050667072367,0.5362318840579711,0.8552438553604607,1.0,5/146,1.51%,MEGF8;PTK2;BCOR;ERBB3;FN1
prerank,Elsevier_Pathway_Collection__rRNA Transcription and Processing,0.49514869747852475,0.968515802117664,0.38333333333333336,0.854932868339603,1.0,1/18,0.59%,TAF1B
prerank,KEGG_2021_Human__Circadian entrainment,-0.7065570276471215,-0.9679832605147979,0.5161290322580645,0.8662322247792513,1.0,1/86,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__positive regulation of MAPK cascade (GO:0043410),-0.6521252122882755,-0.9676510296672903,0.46875,0.8660581065260683,1.0,8/249,1.35%,CCL23;RAP1A;APP;PTK2B;SCIMP;PELI2;TEK;PIK3R6
prerank,GO_Biological_Process_2021__positive regulation of monooxygenase activity (GO:0032770),-0.5494131432711179,-0.9669235998577734,0.43636363636363634,0.8663306786622851,1.0,2/26,1.25%,PIK3CB;VDR
prerank,GO_Biological_Process_2021__acylglycerol biosynthetic process (GO:0046463),0.5765244058438898,0.9668009308391794,0.48175182481751827,0.8561008989720271,1.0,1/22,0.32%,GPAT4
prerank,WikiPathway_2021_Human__Kynurenine Pathway and links to Cellular Senescence WP5044,-0.502190816822635,-0.966546258364068,0.3879310344827586,0.8661616933200141,1.0,1/22,0.61%,AADAT
prerank,GO_Biological_Process_2021__regulation of macromolecule metabolic process (GO:0060255),0.6744247324761989,0.9662153072070824,0.4117647058823529,0.8562269913891494,1.0,7/169,1.30%,IGF2BP1;MEGF8;CDK6;SORT1;IGF2BP3;PCBP4;APOE
prerank,GO_Biological_Process_2021__negative regulation of type I interferon-mediated signaling pathway (GO:0060339),-0.5076421462827754,-0.9658356464007954,0.35294117647058826,0.8663267535447174,1.0,1/16,0.39%,OAS1
prerank,Reactome_2022__MAPK Family Signaling Cascades R-HSA-5683057,0.596424802131566,0.9656113606866313,0.4206896551724138,0.8563919260564631,1.0,11/299,1.51%,IGF2BP1;KSR1;PTK2;DLG1;ARHGEF7;GPRIN1;ERBB3;ZDHHC9;KLB;FGF1;FN1
prerank,MSigDB_Oncogenic_Signatures__KRAS.KIDNEY UP.V1 UP,-0.6841840016976276,-0.9655752901686069,0.5126050420168067,0.8661056809983613,1.0,3/124,1.03%,CPEB3;CCND2;PELI2
prerank,Reactome_2022__GRB2:SOS Provides Linkage To MAPK Signaling For Integrins R-HSA-354194,-0.5615860709461321,-0.9652790741196886,0.39655172413793105,0.8659520569827227,1.0,2/15,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__mesenchymal cell development (GO:0014031),-0.47138174300066227,-0.9651862974029385,0.35,0.865544939799011,1.0,9/18,20.96%,HEY2;SOX8;CYP26C1;FOXC1;CDH2;FAM172A;PEF1;TCOF1;SNAI2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Myocardial Ischemia,0.6444394203135104,0.9648700574252723,0.4774193548387097,0.8567022605693363,1.0,5/236,1.36%,PTK2;PPARA;STX1A;APOE;FGF1
prerank,Reactome_2022__Sphingolipid Metabolism R-HSA-428157,-0.7088096447846304,-0.964828887679251,0.5081967213114754,0.8654191666698593,1.0,3/86,0.99%,STS;SGPP1;GALC
prerank,Elsevier_Pathway_Collection__TGF-beta Signaling,-0.6644325431225822,-0.9645656754798949,0.5514018691588785,0.8652289552393153,1.0,1/62,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of cell-substrate junction organization (GO:0150117),0.6356140152225918,0.9643308781198104,0.5365853658536586,0.8568011832792272,1.0,2/23,1.13%,THY1;IQSEC1
prerank,MSigDB_Oncogenic_Signatures__RB DN.V1 DN,-0.7386227534350083,-0.9642245867897565,0.5233644859813084,0.8650538627785157,1.0,2/110,1.08%,RB1;BASP1
prerank,KEGG_2021_Human__Chronic myeloid leukemia,-0.718223720986979,-0.9641613477108091,0.5185185185185185,0.8646432651817509,1.0,3/76,0.73%,AKT3;RB1;PIK3CB
prerank,GO_Biological_Process_2021__amino acid transport (GO:0006865),-0.6305603762050813,-0.9639065819114423,0.5531914893617021,0.8644216068280033,1.0,2/43,0.41%,SLC7A8;SLC36A4
prerank,GO_Biological_Process_2021__regulation of cell cycle (GO:0051726),-0.5931511706574316,-0.9638830073834019,0.4945054945054945,0.8639399912621831,1.0,4/281,1.31%,MAP2K6;RB1;GMNC;PML
prerank,Reactome_2022__C-type Lectin Receptors (CLRs) R-HSA-5621481,-0.6950953821976859,-0.9635315204347499,0.45045045045045046,0.8638700893428981,1.0,2/130,1.14%,MUC6;CLEC10A
prerank,GO_Biological_Process_2021__alpha-amino acid metabolic process (GO:1901605),-0.6149503103533801,-0.9631870658575343,0.5158730158730159,0.863735909969142,1.0,2/46,0.89%,AADAT;IYD
prerank,WikiPathway_2021_Human__Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839,0.6646726361924209,0.9631757697115956,0.5652173913043478,0.8574448156611145,1.0,2/31,1.36%,LRP5;FGF1
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell proliferation (GO:0050680),0.7439252636315641,0.9630973825998481,0.5763888888888888,0.8570560267273497,1.0,2/69,1.30%,CDK6;APOE
prerank,GO_Biological_Process_2021__sensory perception of sound (GO:0007605),0.7462412069645465,0.9626322292047721,0.5373134328358209,0.8569847829168958,1.0,3/79,1.03%,TBL1X;TSPEAR;MYO7A
prerank,GO_Biological_Process_2021__regulation of interferon-beta production (GO:0032648),-0.648786955365187,-0.9620256363504273,0.55,0.864405907804665,1.0,2/48,0.78%,OAS1;TOMM70
prerank,GO_Biological_Process_2021__cardiac muscle cell action potential involved in contraction (GO:0086002),0.6238393180309906,0.962019213579468,0.5203252032520326,0.857136506868544,1.0,2/29,1.53%,GJC1;SNTA1
prerank,Elsevier_Pathway_Collection__Endometrioid Endometrial Cancer,0.7390428044077589,0.9616654095660166,0.5416666666666666,0.8570223772728867,1.0,3/91,0.96%,MSH2;LRP5;ERBB3
prerank,WikiPathway_2021_Human__Focal Adhesion WP306,-0.6670344402737098,-0.9616041540723332,0.4953271028037383,0.864377888007162,1.0,10/191,1.22%,TESK2;RAP1A;AKT3;RAP1B;PAK2;PIK3CB;HCK;CCND2;VAV1;COL4A4
prerank,Reactome_2022__Assembly And Cell Surface Presentation Of NMDA Receptors R-HSA-9609736,0.6151434703854446,0.9615882067893257,0.5259259259259259,0.8566244393546425,1.0,3/25,0.91%,LIN7A;DLG1;GPRIN1
prerank,GO_Biological_Process_2021__peptide metabolic process (GO:0006518),-0.7241256662551373,-0.9614222001581952,0.5391304347826087,0.8640682048390422,1.0,2/78,0.05%,GSTA2;GSTA1
prerank,GO_Biological_Process_2021__proteolysis involved in cellular protein catabolic process (GO:0051603),-0.6368485268463655,-0.9613905690697652,0.48717948717948717,0.8635909520747288,1.0,1/71,0.26%,CTSO
prerank,KEGG_2021_Human__PI3K-Akt signaling pathway,0.6164232636656889,0.9613250562042969,0.5379310344827586,0.8564433361380147,1.0,12/313,1.51%,PRKAA2;CDK6;PTK2;ITGA2;ERBB3;COL4A5;GNB5;ITGB5;COL9A3;FGF1;PRLR;FN1
prerank,Reactome_2022__Insulin Processing R-HSA-264876,0.5492973204633067,0.9609100515137724,0.42857142857142855,0.856372613246723,1.0,2/25,1.31%,STX1A;CPE
prerank,GO_Biological_Process_2021__regulation of Ras protein signal transduction (GO:0046578),-0.6829586823756217,-0.9605631269543032,0.5462962962962963,0.8639805716255717,1.0,2/84,1.10%,RABL3;VAV1
prerank,MSigDB_Oncogenic_Signatures__WNT UP.V1 UP,0.7003863945243368,0.9604327909355778,0.4861111111111111,0.8564202502534983,1.0,6/154,1.49%,HOXD3;VAX2;CLEC16A;CKAP4;PKLR;MAPK8IP1
prerank,GO_Biological_Process_2021__protein-containing complex disassembly (GO:0032984),-0.639960064736231,-0.9602680813020154,0.5546218487394958,0.8638270636950702,1.0,1/54,0.70%,UVRAG
prerank,TRRUST_Transcription_Factors_2019__STAT3 mouse,-0.6771501351967705,-0.9602671314469813,0.5210084033613446,0.8633261332288127,1.0,4/67,1.23%,CCND2;KLF4;SPI1;S1PR1
prerank,GO_Biological_Process_2021__dicarboxylic acid metabolic process (GO:0043648),-0.7012956782479727,-0.9597078782077241,0.5299145299145299,0.8633702910770189,1.0,3/57,1.19%,AADAT;SDHAF3;MTHFD2L
prerank,GO_Biological_Process_2021__bicellular tight junction assembly (GO:0070830),0.7318186350632877,0.9596400279046832,0.6015037593984962,0.8567205830855616,1.0,3/49,1.14%,TBCD;DLG1;CRB3
prerank,GO_Biological_Process_2021__fatty acid derivative biosynthetic process (GO:1901570),0.6850642234139304,0.9596367388541455,0.5845070422535211,0.8562627595205439,1.0,2/37,0.25%,ACACA;ACSS3
prerank,"GO_Biological_Process_2021__retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890)",0.7322458947042233,0.9593809398341017,0.5862068965517241,0.8560823361300519,1.0,3/82,1.35%,CENPE;KIF23;KIF3B
prerank,GO_Biological_Process_2021__regulation of focal adhesion assembly (GO:0051893),0.7301995501775341,0.9591752052746401,0.5905511811023622,0.8558023910534344,1.0,3/53,1.05%,THY1;PTK2;CAMSAP3
prerank,GO_Biological_Process_2021__apical junction assembly (GO:0043297),0.731815166077953,0.9588160403921039,0.5970149253731343,0.8557118999241253,1.0,3/56,1.14%,TBCD;DLG1;CRB3
prerank,KEGG_2021_Human__Neuroactive ligand-receptor interaction,-0.6278590486279328,-0.9585234098725931,0.5051546391752577,0.8640940167699024,1.0,4/237,1.23%,GRIN2B;NR3C1;HRH2;S1PR1
prerank,Reactome_2022__Extracellular Matrix Organization R-HSA-1474244,0.6265368178909824,0.9584542028799374,0.5328947368421053,0.8555930462034169,1.0,10/277,1.51%,FBN3;ITGA2;PLOD2;COL4A5;ITGAL;COL12A1;P3H3;ITGB5;COL9A3;FN1
prerank,Reactome_2022__Interleukin-1 Family Signaling R-HSA-446652,-0.7090548275828337,-0.9583017119472007,0.5094339622641509,0.8638423618019873,1.0,4/141,1.34%,MAP2K6;APP;PELI2;PTPN18
prerank,Elsevier_Pathway_Collection__TGFB Family in Epithelial to Mesenchymal Transition in Cancer,0.74280132983476,0.9575958358123301,0.54421768707483,0.8560391421361118,1.0,4/80,1.51%,MRTFA;TJP1;CRB3;FN1
prerank,GO_Biological_Process_2021__protein-containing complex subunit organization (GO:0043933),-0.6955898725195133,-0.9571156166700097,0.4953271028037383,0.8645625119682964,1.0,3/110,1.31%,PTK2B;KPNA3;PML
prerank,GO_Biological_Process_2021__MyD88-independent toll-like receptor signaling pathway (GO:0002756),0.5985237881923767,0.9568383710606805,0.515625,0.8563223088508047,1.0,1/31,0.44%,TRAF3
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V2 DN,0.6762873342199329,0.9567719100855567,0.549618320610687,0.8559455649734997,1.0,5/126,1.30%,CENPA;NDC80;SNTB1;TNNC2;CYP27B1
prerank,GO_Biological_Process_2021__positive regulation of macrophage activation (GO:0043032),-0.47026065806301787,-0.9567136304632533,0.32,0.8644411563294887,1.0,11/15,34.49%,WNT5A;HSPD1;TNIP2;LBP;KARS1;IL33;MMP8;TLR6;CCL3;TTBK1;TLR4
prerank,GO_Biological_Process_2021__heart morphogenesis (GO:0003007),0.7308762759775504,0.9563973289694465,0.6148148148148148,0.8558511821920323,1.0,3/48,0.89%,MEGF8;PTK2;TBX3
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.V1 UP,0.6840530747835586,0.9561635979817034,0.4857142857142857,0.8555947087316029,1.0,4/145,1.34%,CPPED1;UBE2C;RRM2;RCOR2
prerank,GO_Biological_Process_2021__negative regulation of cellular protein metabolic process (GO:0032269),0.7473926266112789,0.9558774068858059,0.5396825396825397,0.8554296931529126,1.0,3/87,1.30%,IGF2BP1;IGF2BP3;APOE
prerank,WikiPathway_2021_Human__NOTCH1 regulation of endothelial cell calcification WP3413,0.5063529301236198,0.9552140257118928,0.36764705882352944,0.8556172437453637,1.0,9/16,26.47%,DLL1;LPAR1;SAT1;SOX6;GJA5;ITGA1;ALPL;CALU;PLAT
prerank,GO_Biological_Process_2021__regulation of cell-matrix adhesion (GO:0001952),0.6855462807468911,0.954782332347165,0.5782312925170068,0.855563720420696,1.0,4/62,1.05%,THY1;CDK6;PTK2;CAMSAP3
prerank,GO_Biological_Process_2021__protein ubiquitination (GO:0016567),-0.5596700720457424,-0.9545204057678145,0.4845360824742268,0.8663172133363695,1.0,13/495,1.28%,KLHL3;RNF217;TRIM44;FBXO27;TRIM58;RNF13;BIRC6;AMFR;WWP1;UBE3D;PELI2;HERC5;HERC6
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG UP.V1 DN,-0.6885974791985067,-0.9541800717421675,0.4732142857142857,0.8661704277346693,1.0,5/108,1.33%,GLYAT;MAP2K6;IL10RA;NYNRIN;RTP4
prerank,Elsevier_Pathway_Collection__ESR1/ERBB Positive Luminal Breast Cancer,0.7394164521398118,0.9541540997193423,0.5564516129032258,0.8556923305596754,1.0,3/92,0.96%,MSH2;BRIP1;ERBB3
prerank,MSigDB_Oncogenic_Signatures__ATM DN.V1 UP,0.7130194971682674,0.9540078938389278,0.5033557046979866,0.8553941630706535,1.0,4/119,1.34%,DLX6;ACACA;TNNC2;COL9A3
prerank,WikiPathway_2021_Human__Nuclear receptors WP170,-0.6086921357721293,-0.9536531581647505,0.5263157894736842,0.8662078488272852,1.0,2/36,1.25%,NR3C1;VDR
prerank,GO_Biological_Process_2021__TRIF-dependent toll-like receptor signaling pathway (GO:0035666),0.5985241009704818,0.953579643742954,0.512,0.8553812623656843,1.0,1/30,0.44%,TRAF3
prerank,Reactome_2022__Diseases Of Signal Transduction By Growth Factor Receptors And Second Messengers R-HSA-5663202,0.5844390962458741,0.9531317316099894,0.5405405405405406,0.8553501968221279,1.0,11/409,1.51%,TRIM24;KSR1;PAPSS1;HDAC8;LRP5;TBL1X;ERBB3;KLB;FGF1;ZFYVE9;FN1
prerank,GO_Biological_Process_2021__ubiquitin-dependent ERAD pathway (GO:0030433),-0.6957449025316664,-0.9529912540414095,0.5126050420168067,0.8664217990658831,1.0,3/71,0.72%,FBXO27;DNAJB14;AMFR
prerank,GO_Biological_Process_2021__protein-containing complex assembly (GO:0065003),-0.6047177874633374,-0.9529637435640741,0.49,0.8659541302195891,1.0,6/265,1.31%,TLE4;DNAJB14;PTK2B;KPNA3;BIN2;PML
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Sustaining of Proliferative Signaling,0.6665906060367309,0.9529463881339142,0.4928571428571429,0.8550486495848562,1.0,6/170,1.36%,CDK6;PTK2;NOTCH3;ATR;ERBB3;FGF1
prerank,Reactome_2022__Antiviral Mechanism By IFN-stimulated Genes R-HSA-1169410,-0.6785246099167568,-0.9527902400691249,0.5081967213114754,0.8656413250121608,1.0,4/82,1.05%,OAS1;KPNA3;OASL;HERC5
prerank,GO_Biological_Process_2021__regulation of double-strand break repair (GO:2000779),0.698947812124071,0.9524876333076983,0.5789473684210527,0.8550299000607635,1.0,2/40,1.46%,SPIRE2;WRAP53
prerank,Elsevier_Pathway_Collection__Ovarian Cancer,0.7316951195434713,0.9520523631406543,0.5267175572519084,0.8549627715484001,1.0,3/128,0.96%,LRP5;NOTCH3;ERBB3
prerank,WikiPathway_2021_Human__Overview of nanoparticle effects WP3287,0.5885697272292941,0.9515689809398011,0.4576271186440678,0.8550065696091503,1.0,2/19,1.51%,PTK2;FN1
prerank,GO_Biological_Process_2021__B cell differentiation (GO:0030183),0.679172532723725,0.9515524176178609,0.6065573770491803,0.8545789327138932,1.0,2/42,0.69%,MSH2;FNIP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Insulin Resistance,-0.699185029992366,-0.9513743423813964,0.5348837209302325,0.8666288434740481,1.0,2/77,0.41%,ALDOB;NR3C1
prerank,KEGG_2021_Human__Glutathione metabolism,-0.6963795674814806,-0.9512632622328976,0.5476190476190477,0.8662352680170249,1.0,3/52,0.38%,GSTA2;GSTA1;GGT5
prerank,MSigDB_Oncogenic_Signatures__KRAS.600.LUNG.BREAST UP.V1 DN,-0.6358530538965869,-0.9512607652682848,0.46875,0.8657369992977071,1.0,11/226,1.33%,GLYAT;DPYS;MAP2K6;TRIM58;EPB41L4A;NTF3;PBX1;IL12RB2;NYNRIN;PARP3;RTP4
prerank,GO_Biological_Process_2021__axon development (GO:0061564),-0.6857258080899152,-0.9511680461205098,0.5263157894736842,0.8653639449636583,1.0,3/75,1.15%,APP;SLITRK3;DSCAML1
prerank,Reactome_2022__Class B/2 (Secretin Family Receptors) R-HSA-373080,0.7251682277282769,0.9510258776821512,0.5371900826446281,0.8545866465181357,1.0,2/83,1.11%,SMOX;GNB5
prerank,Reactome_2022__TCF Dependent Signaling In Response To WNT R-HSA-201681,0.6695444838672532,0.9509080530727277,0.5481481481481482,0.8542361548467686,1.0,2/179,0.40%,AXIN2;LRP5
prerank,Elsevier_Pathway_Collection__Male Sex Determination,0.5743290557856087,0.9508451254183682,0.48507462686567165,0.8538498316529386,1.0,2/26,1.02%,AMH;CBX2
prerank,TRRUST_Transcription_Factors_2019__NR5A1 mouse,0.5192878021046151,0.9501797140234005,0.3793103448275862,0.8541996555246497,1.0,1/18,0.95%,AMH
prerank,Elsevier_Pathway_Collection__Ions Reabsorption Dysregulation in Nephrolithiasis,0.5016030040583386,0.9495613915074915,0.375,0.8544466424445012,1.0,1/18,1.30%,CYP27B1
prerank,GO_Biological_Process_2021__positive regulation of lipid kinase activity (GO:0090218),-0.5760256283583534,-0.9494637908177598,0.49166666666666664,0.8667157156459812,1.0,2/29,1.21%,PTK2B;TEK
prerank,TRRUST_Transcription_Factors_2019__PPARG human,-0.6951327846759021,-0.9493493279298736,0.5528455284552846,0.8663693789183317,1.0,2/63,1.09%,KLF4;CD83
prerank,Elsevier_Pathway_Collection__Antiviral Signaling through Pattern Recognition Receptors,0.5985257357515461,0.9493273961115415,0.5271317829457365,0.8541893385603263,1.0,1/23,0.44%,TRAF3
prerank,WikiPathway_2021_Human__IL-18 signaling pathway WP4754,-0.5954830528727498,-0.9491624485971728,0.48695652173913045,0.8660600366701598,1.0,5/257,1.09%,GRIN2B;ADAMTS5;TNFAIP2;TICAM2;CD83
prerank,WikiPathway_2021_Human__Monoamine GPCRs WP58,-0.5499675793699301,-0.9490251131504608,0.4358974358974359,0.8657144770908858,1.0,1/22,0.97%,HRH2
prerank,GO_Biological_Process_2021__stem cell development (GO:0048864),-0.4959956228019435,-0.9486447652756236,0.36607142857142855,0.8656690490217643,1.0,8/16,20.96%,SOX8;CYP26C1;CDH2;FAM172A;PEF1;TCOF1;WNT7A;SNAI2
prerank,GO_Biological_Process_2021__chemokine-mediated signaling pathway (GO:0070098),-0.649107300011607,-0.9484351021847476,0.5585585585585585,0.8654288369390304,1.0,2/52,0.67%,CCL23;PTK2B
prerank,Reactome_2022__Leishmania Infection R-HSA-9658195,-0.6384427008475974,-0.9483549353109048,0.5050505050505051,0.8650014792217591,1.0,6/208,1.10%,GPR39;GGT5;HCK;CD163;HRH2;VAV1
prerank,GO_Biological_Process_2021__regulation of stress-activated MAPK cascade (GO:0032872),0.682513193630281,0.9481342218703108,0.5925925925925926,0.8550281416478213,1.0,3/48,1.49%,MID1;ULK4;MAPK8IP1
prerank,GO_Biological_Process_2021__epidermal growth factor receptor signaling pathway (GO:0007173),0.673124649743339,0.9479049648889147,0.5833333333333334,0.8548450230292295,1.0,3/46,1.49%,PTK2;SLC30A10;BCAR1
prerank,Reactome_2022__Regulation Of RUNX1 Expression And Activity R-HSA-8934593,-0.5172203862385772,-0.9477612194425139,0.3951612903225806,0.8651803436040623,1.0,2/17,1.31%,CCND2;PML
prerank,GO_Biological_Process_2021__enzyme linked receptor protein signaling pathway (GO:0007167),-0.6540151381673268,-0.9476901567739704,0.49137931034482757,0.8647463261499965,1.0,6/135,1.21%,PTK2B;PIK3CB;HCK;NTF3;ZAP70;TEK
prerank,GO_Biological_Process_2021__triglyceride metabolic process (GO:0006641),-0.6105585362871591,-0.947527090068751,0.5630252100840336,0.8644391599204954,1.0,3/45,0.92%,PLAAT3;MOGAT1;LIPG
prerank,Reactome_2022__Regulation Of TP53 Activity R-HSA-5633007,0.6613869164789138,0.9473246632838956,0.49324324324324326,0.8550310000394656,1.0,5/154,1.29%,PRKAA2;ING5;BRIP1;TAF4;PPP1R13L
prerank,GO_Biological_Process_2021__regulation of phosphatidylinositol 3-kinase activity (GO:0043551),-0.5760232136604992,-0.9457094966169719,0.5042016806722689,0.865992549470549,1.0,2/34,1.21%,PTK2B;TEK
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation,-0.7174565286121584,-0.9457076767096958,0.5897435897435898,0.8654957092241516,1.0,3/64,1.13%,CD2;VAV1;ZAP70
prerank,WikiPathway_2021_Human__SARS-CoV-2 mitochondrial interactions WP5038,-0.5785337612994135,-0.9456476907800011,0.4830508474576271,0.8650722091087243,1.0,2/30,1.26%,TOMM70;TMPRSS2
prerank,Elsevier_Pathway_Collection__CDC73 Mutations Cause Hyperparathyroidism,0.5303201194766956,0.9455232360869831,0.39669421487603307,0.8563469489545964,1.0,1/16,0.19%,CDK6
prerank,WikiPathway_2021_Human__Prion disease pathway WP3995,0.627094516860025,0.9448022211415824,0.5271317829457365,0.856632076462414,1.0,1/33,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in Sterile Inflammation,0.6954287051675488,0.9446825173138359,0.5874125874125874,0.856302371869814,1.0,2/56,1.24%,TRAF3;A2M
prerank,Elsevier_Pathway_Collection__Alzheimer's Disease,-0.6372910908415843,-0.944575622663083,0.5520833333333334,0.8656770927442897,1.0,1/65,0.35%,APP
prerank,Reactome_2022__Signaling By ERBB2 R-HSA-1227986,-0.6257884969313813,-0.9441887452596295,0.5726495726495726,0.8655616821669875,1.0,2/49,1.34%,AKT3;PTPN18
prerank,Reactome_2022__Receptor-type Tyrosine-Protein Phosphatases R-HSA-388844,-0.5067552396835924,-0.9441480995240716,0.38461538461538464,0.8651267639687994,1.0,1/19,0.86%,SLITRK3
prerank,GO_Biological_Process_2021__platelet degranulation (GO:0002576),-0.6750082466406652,-0.9441468477853285,0.4954954954954955,0.8646366804466173,1.0,5/124,1.26%,A1BG;APP;PROS1;NHLRC2;HRG
prerank,GO_Biological_Process_2021__cellular response to transforming growth factor beta stimulus (GO:0071560),0.7242486194044135,0.9439189325604133,0.5289855072463768,0.8566252351023321,1.0,4/112,1.47%,PTK2;ARHGEF18;ITGB5;ZFYVE9
prerank,Reactome_2022__Glucose Metabolism R-HSA-70326,0.6729496898077194,0.9432038393749667,0.503448275862069,0.8568797709923786,1.0,3/83,1.12%,NUP210;MAP4K5;PKLR
prerank,GO_Biological_Process_2021__ERAD pathway (GO:0036503),-0.695740507469963,-0.9431857928765723,0.5333333333333333,0.865155773669498,1.0,3/85,0.72%,FBXO27;DNAJB14;AMFR
prerank,GO_Biological_Process_2021__supramolecular fiber organization (GO:0097435),0.610052611577814,0.9430131525573616,0.5870967741935483,0.856590428194614,1.0,12/337,1.49%,CLIP2;PPP1R9A;STMN3;DLG1;PLOD2;COL4A5;MYO7A;CAMSAP3;COL12A1;SHROOM1;COL9A3;BCAR1
prerank,GO_Biological_Process_2021__modulation of chemical synaptic transmission (GO:0050804),-0.6895009841181118,-0.9426170353448309,0.5175438596491229,0.8653165040587532,1.0,2/94,0.83%,APP;NTF3
prerank,WikiPathway_2021_Human__Tumor suppressor activity of SMARCB1 WP4204,-0.5695181046387313,-0.9416932143962962,0.4918032786885246,0.8658877677151476,1.0,2/29,1.22%,RB1;GLI3
prerank,MSigDB_Hallmark_2020__Inflammatory Response,-0.6424708682652097,-0.9414757777888568,0.5050505050505051,0.8656108537631164,1.0,5/194,1.33%,DCBLD2;GPR132;SEMA4D;IL10RA;RTP4
prerank,Reactome_2022__Meiotic Synapsis R-HSA-1221632,0.7037787722659727,0.9412237747838588,0.6101694915254238,0.8579293659617214,1.0,2/47,1.41%,SYCP3;ACD
prerank,GO_Biological_Process_2021__defense response to bacterium (GO:0042742),-0.6955560200752205,-0.9411761828624237,0.5,0.8654404376469007,1.0,3/123,1.03%,OAS1;GBP4;PGLYRP2
prerank,GO_Biological_Process_2021__positive regulation of mitotic cell cycle phase transition (GO:1901992),-0.6564948475438952,-0.940731588365874,0.5309734513274337,0.8654342215973032,1.0,2/57,0.93%,RB1;CCND2
prerank,Reactome_2022__ADORA2B Mediated Anti-Inflammatory Cytokine Production R-HSA-9660821,-0.7011946800320302,-0.9404932816392374,0.5267857142857143,0.8652086594079595,1.0,2/99,0.97%,GPR39;HRH2
prerank,TRRUST_Transcription_Factors_2019__NFKB1 human,-0.6103233747539192,-0.940076344579789,0.5254237288135594,0.8651857187143741,1.0,6/282,1.09%,MUC6;CYP3A7;BHMT;CCND2;PGLYRP2;CD83
prerank,GO_Biological_Process_2021__positive regulation of phosphorylation (GO:0042327),0.629834166197942,0.9397176655903776,0.5878378378378378,0.8589893863179439,1.0,7/238,1.36%,PRKAA2;AXIN2;PTK2;FNIP1;ERBB3;DRD4;FGF1
prerank,GO_Biological_Process_2021__sodium ion transmembrane transport (GO:0035725),0.7009615903968719,0.9394568057827686,0.5514705882352942,0.8588031523786678,1.0,1/76,0.02%,SLC6A4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetes Mellitus Type 1,-0.6679626350733713,-0.9394507554869406,0.5409836065573771,0.8654661782567851,1.0,2/79,1.25%,CD274;VDR
prerank,GO_Biological_Process_2021__negative regulation of phosphatase activity (GO:0010923),-0.5388086293130996,-0.9393637659194567,0.4728682170542636,0.8650556929689871,1.0,1/26,0.96%,SEMA4D
prerank,GO_Biological_Process_2021__regulation of transforming growth factor beta receptor signaling pathway (GO:0017015),-0.6939878164080671,-0.9391007936146595,0.52,0.8648933887392316,1.0,3/94,1.15%,SLC2A10;ADAMTSL2;LTBP4
prerank,Reactome_2022__Diseases Associated With O-glycosylation Of Proteins R-HSA-3906995,-0.6782485084975434,-0.9390231721099637,0.5675675675675675,0.8644812917335334,1.0,4/62,1.14%,MUC6;ADAMTS5;GALNT3;ADAMTSL2
prerank,GO_Biological_Process_2021__negative regulation of developmental process (GO:0051093),0.7477559387704233,0.939012335148107,0.6204379562043796,0.8587347818518227,1.0,3/73,0.50%,THY1;CDK6;ADCK1
prerank,GO_Biological_Process_2021__O-glycan processing (GO:0016266),-0.6972008998843597,-0.9388920210528462,0.6129032258064516,0.8641249147827753,1.0,2/55,0.84%,MUC6;GALNT3
prerank,Reactome_2022__Negative Regulation Of MAPK Pathway R-HSA-5675221,0.6659962232333035,0.9388841181541768,0.6016260162601627,0.8583953916100969,1.0,1/40,0.22%,KSR1
prerank,WikiPathway_2021_Human__G Protein Signaling Pathways WP35,-0.702010515164302,-0.9382208712494847,0.536,0.8644147841098677,1.0,2/87,1.05%,AKAP7;GNA14
prerank,Reactome_2022__Nonhomologous End-Joining (NHEJ) R-HSA-5693571,0.6562309677827467,0.938179647031758,0.5517241379310345,0.858654039802838,1.0,2/45,0.76%,HERC2;DCLRE1C
prerank,Elsevier_Pathway_Collection__FibronectinR -> AP-1/ELK/SRF/SREBF Signaling,-0.6269967386467497,-0.9381274243250328,0.5537190082644629,0.8640324542617499,1.0,4/47,1.10%,MAP2K6;RAP1A;PTK2B;VAV1
prerank,KEGG_2021_Human__Human cytomegalovirus infection,-0.6338353205564938,-0.938107919389661,0.48484848484848486,0.863564223535057,1.0,7/201,1.12%,MAP2K6;AKT3;RB1;PTK2B;PIK3CB;CREB5;IL10RA
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell migration (GO:0010595),-0.681590501426933,-0.9378236175439124,0.4881889763779528,0.863345792443249,1.0,4/86,1.21%,AKT3;PTK2B;PIK3CB;TEK
prerank,GO_Biological_Process_2021__insulin receptor signaling pathway (GO:0008286),0.740392963409445,0.9376189405614741,0.6190476190476191,0.858812855168062,1.0,2/68,1.49%,RHOQ;BCAR1
prerank,MSigDB_Oncogenic_Signatures__BCAT BILD ET AL DN,0.7324304207026838,0.9375612113574421,0.6428571428571429,0.8584142523692788,1.0,3/44,1.15%,IRAK2;ASH1L;ARHGEF18
prerank,MSigDB_Hallmark_2020__Bile Acid Metabolism,-0.6835231151342724,-0.9372522820210324,0.5607476635514018,0.8634390186163513,1.0,7/112,1.08%,CYP39A1;ABCA6;ABCD3;SLCO1A2;SULT1B1;HSD17B6;HAO1
prerank,GO_Biological_Process_2021__RNA export from nucleus (GO:0006405),0.7305124931238026,0.9371070236991487,0.5633802816901409,0.8583979825083312,1.0,2/102,0.73%,NUP210;UPF2
prerank,Reactome_2022__Glycolysis R-HSA-70171,0.672958137818185,0.937071523359082,0.5606060606060606,0.857988086042452,1.0,3/65,1.12%,NUP210;MAP4K5;PKLR
prerank,GO_Biological_Process_2021__regulation of lamellipodium assembly (GO:0010591),0.6291110057147593,0.937042568139026,0.5524475524475524,0.8575746446708227,1.0,1/33,0.77%,ABI2
prerank,Reactome_2022__O-linked Glycosylation R-HSA-5173105,-0.6759283102170969,-0.936933580412926,0.5403225806451613,0.8632999110818794,1.0,4/97,1.14%,MUC6;ADAMTS5;GALNT3;ADAMTSL2
prerank,GO_Biological_Process_2021__positive regulation of cell motility (GO:2000147),0.6241203396981978,0.9368016034098819,0.5517241379310345,0.857370167943754,1.0,9/213,1.49%,PTK2;TJP1;ZNF304;SH3RF2;CTSH;FGF1;CAVIN1;SEMA3G;BCAR1
prerank,GO_Biological_Process_2021__regulation of proteolysis (GO:0030162),0.6222422592265799,0.9365239690212996,0.5777777777777777,0.8571837699230497,1.0,1/48,0.44%,TRAF3
prerank,WikiPathway_2021_Human__ID signaling pathway WP53,0.516063212960277,0.9360987976094808,0.4,0.8572217522477251,1.0,1/15,0.29%,RBL1
prerank,GO_Biological_Process_2021__regulation of endocytosis (GO:0030100),0.6823761754088061,0.9360949047049432,0.6027397260273972,0.8567798317106947,1.0,3/60,1.30%,MCTP1;PACSIN3;APOE
prerank,GO_Biological_Process_2021__skeletal muscle organ development (GO:0060538),0.597638687480133,0.9358695258122298,0.5259259259259259,0.8565405234711652,1.0,1/27,0.65%,SVIL
prerank,GO_Biological_Process_2021__mRNA export from nucleus (GO:0006406),0.7305114756600336,0.9356906574700494,0.5683453237410072,0.8562994841956345,1.0,2/105,0.73%,NUP210;UPF2
prerank,Elsevier_Pathway_Collection__Airway Smooth Muscle Cell High Rate Proliferation,-0.6495539132281617,-0.9353466770920108,0.5982142857142857,0.8645248289238358,1.0,1/54,0.67%,PTK2B
prerank,Elsevier_Pathway_Collection__Thyroid Hormones Common non-Genomic Effects in Hyperthyroidism,0.6256432258458542,0.9351848544448337,0.5725190839694656,0.8563457677630107,1.0,1/36,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Ulcerative Colitis,-0.6321798534090458,-0.9348537946373193,0.504424778761062,0.864650710074531,1.0,1/130,0.41%,NR3C1
prerank,"Reactome_2022__Nucleotide-binding Domain, Leucine Rich Repeat Containing NLR Signaling Pathways R-HSA-168643",-0.6225541476305826,-0.9348338709125561,0.5230769230769231,0.8641765471318809,1.0,2/52,0.35%,MAP2K6;APP
prerank,GO_Biological_Process_2021__cellular response to chemokine (GO:1990869),-0.6491060821334265,-0.9347018156405221,0.5377358490566038,0.8638295206412587,1.0,2/56,0.67%,CCL23;PTK2B
prerank,GO_Biological_Process_2021__cellular transition metal ion homeostasis (GO:0046916),-0.6633719392025473,-0.9346833054261128,0.5047619047619047,0.863361130995738,1.0,1/92,0.35%,APP
prerank,GO_Biological_Process_2021__regulation of signal transduction (GO:0009966),0.6399824224828877,0.9343326370713108,0.5563380281690141,0.8567382878725585,1.0,4/187,1.16%,IRAK2;TSPEAR;ERBB3;GRK3
prerank,KEGG_2021_Human__Glycolysis / Gluconeogenesis,-0.6330238916691706,-0.9337346198933034,0.5833333333333334,0.8638763030091989,1.0,1/61,0.08%,ALDOB
prerank,GO_Biological_Process_2021__positive regulation of cellular component organization (GO:0051130),0.7284204161198984,0.9336626632401193,0.5704225352112676,0.8569563578474226,1.0,4/111,1.34%,FNIP1;CRB3;APOE;HAS3
prerank,TRRUST_Transcription_Factors_2019__PAX5 human,-0.5337479304736767,-0.9335084158179087,0.40869565217391307,0.8636588041611071,1.0,1/20,0.53%,RB1
prerank,GO_Biological_Process_2021__mRNA transport (GO:0051028),0.7305121036335617,0.9332359412723553,0.5714285714285714,0.8569626927931849,1.0,2/103,0.73%,NUP210;UPF2
prerank,MSigDB_Hallmark_2020__p53 Pathway,-0.6263655448396712,-0.9332142237620098,0.5208333333333334,0.8635487995437612,1.0,6/196,1.25%,APP;RB1;WWP1;CCND2;KLF4;VDR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Thrombophilia,-0.6421908886513058,-0.933160413775526,0.559322033898305,0.8631244984029873,1.0,2/40,1.26%,PROS1;HRG
prerank,WikiPathway_2021_Human__Airway smooth muscle cell contraction WP4962,-0.4247451286684109,-0.9328750670284759,0.2882882882882883,0.8629792087890368,1.0,8/15,31.99%,CD38;PPP1CB;MYLK;CALM2;GNAQ;PLCB1;RYR1;ADRB2
prerank,Reactome_2022__FOXO-mediated Transcription Of Cell Cycle Genes R-HSA-9617828,-0.5089135659226738,-0.9326922554046928,0.39805825242718446,0.8626770492435937,1.0,1/16,0.99%,KLF4
prerank,WikiPathway_2021_Human__Inflammatory Response Pathway WP453,-0.5404832041439978,-0.932456044873091,0.46923076923076923,0.8624655917193919,1.0,1/28,1.13%,ZAP70
prerank,GO_Biological_Process_2021__negative regulation of ERBB signaling pathway (GO:1901185),0.6580750393344906,0.9321139671047518,0.5952380952380952,0.8577099011780821,1.0,1/39,0.83%,ARHGEF7
prerank,GO_Biological_Process_2021__ameboidal-type cell migration (GO:0001667),0.6815417847185459,0.9320875739220627,0.5985401459854015,0.8572873379503552,1.0,2/51,1.40%,MEGF8;SEMA3G
prerank,Reactome_2022__KEAP1-NFE2L2 Pathway R-HSA-9755511,-0.6896778029458296,-0.9315693134311719,0.5135135135135135,0.863050539487404,1.0,2/96,0.37%,GSTA1;AKT3
prerank,GO_Biological_Process_2021__positive regulation of lamellipodium organization (GO:1902745),0.6304401348677,0.9314883249300617,0.5620437956204379,0.8574829589257359,1.0,2/31,0.83%,ABI2;ARHGEF7
prerank,Reactome_2022__Activated TAK1 Mediates P38 MAPK Activation R-HSA-450302,0.5424126864487467,0.9314721911483712,0.44274809160305345,0.857058980306767,1.0,1/19,0.10%,IRAK2
prerank,GO_Biological_Process_2021__protein targeting to membrane (GO:0006612),-0.667990625438164,-0.9313721677125929,0.6,0.8627821028607147,1.0,4/84,1.33%,ZDHHC21;ABCD3;ATAD1;RTP4
prerank,MSigDB_Hallmark_2020__Myc Targets V1,0.6391297183189171,0.9310784775300264,0.5170068027210885,0.8569883540712196,1.0,2/200,1.51%,CDC45;HPRT1
prerank,GO_Biological_Process_2021__organelle organization (GO:0006996),0.5849579028576557,0.9309119375172253,0.5620915032679739,0.8567404515746746,1.0,16/406,1.41%,THY1;ATAD3B;SORT1;CNTNAP1;ADCK1;YTHDF3;SIPA1L3;ABI2;PRPF40A;ARHGEF7;RAB3GAP1;PACSIN3;FMNL2;APOE;SYNE3;MICAL3
prerank,TRRUST_Transcription_Factors_2019__SP1 mouse,0.6031067217096382,0.9307626595498184,0.59375,0.8564455376873764,1.0,3/241,1.30%,ACACA;CDK6;APOE
prerank,GO_Biological_Process_2021__positive regulation of dendrite extension (GO:1903861),-0.46458100199823926,-0.9305261936116102,0.34782608695652173,0.8631596826266833,1.0,9/15,27.53%,SYT3;SMURF1;SYT4;SYT1;CPNE9;NEDD4L;ITSN2;CPNE5;SYT2
prerank,WikiPathway_2021_Human__Integrated Cancer Pathway WP1971,0.6808560263588519,0.930058763166489,0.6013986013986014,0.8566981746677605,1.0,2/44,0.50%,MSH2;ATR
prerank,GO_Biological_Process_2021__response to retinoic acid (GO:0032526),-0.7093195715931997,-0.930031271188908,0.6031746031746031,0.8632544969368976,1.0,2/57,1.17%,PTK2B;AQP3
prerank,GO_Biological_Process_2021__regulation of cell cycle process (GO:0010564),0.7015594414372945,0.9299227134487307,0.5337837837837838,0.8563819461141334,1.0,5/102,1.16%,MKI67;CEP85;KIF13A;PRPF40A;PKMYT1
prerank,GO_Biological_Process_2021__regulation of cellular component biogenesis (GO:0044087),-0.6060149614823926,-0.9296271583055277,0.5658914728682171,0.8631950710215268,1.0,3/37,1.26%,RAP1A;RAP1B;HRG
prerank,GO_Biological_Process_2021__RNA processing (GO:0006396),0.6549705564239034,0.9295394863835647,0.5384615384615384,0.8563590488528579,1.0,2/171,0.98%,DROSHA;SF3A2
prerank,Reactome_2022__Signaling By NOTCH3 R-HSA-9012852,0.7170471714615323,0.9293308987618044,0.6287878787878788,0.8561062178080628,1.0,2/47,0.59%,NOTCH3;WWP2
prerank,GO_Biological_Process_2021__Fc-gamma receptor signaling pathway (GO:0038094),-0.6863195592301092,-0.9287964326643963,0.5652173913043478,0.863676063208124,1.0,3/71,1.10%,PIK3CB;HCK;VAV1
prerank,Reactome_2022__Signaling By TGFB Family Members R-HSA-9006936,0.6916851857343663,0.928208030720507,0.5524475524475524,0.8568024688574409,1.0,5/117,1.47%,RBL1;AMH;ARHGEF18;ITGB5;ZFYVE9
prerank,Reactome_2022__Cellular Senescence R-HSA-2559583,0.6670974917177384,0.9279654900743867,0.5474452554744526,0.856618389542128,1.0,5/148,1.41%,CDK6;HIRA;UBE2C;CBX2;ACD
prerank,GO_Biological_Process_2021__regulation of sodium ion transport (GO:0002028),0.5738321951474255,0.9278621892591801,0.5294117647058824,0.8562519973949152,1.0,2/33,1.53%,DLG1;SNTA1
prerank,GO_Biological_Process_2021__regulation of ion transmembrane transporter activity (GO:0032412),-0.6415076545883559,-0.9273234670798023,0.5689655172413793,0.8648860566061393,1.0,2/36,0.86%,WNK3;FXYD6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Inflammatory Bowel Diseases,-0.6335828370939103,-0.9269092170791735,0.5575221238938053,0.8648518578522942,1.0,2/58,1.25%,VNN1;VDR
prerank,Reactome_2022__ADP Signaling Thru P2Y Purinoceptor 1 R-HSA-418592,0.5056786249958859,0.9267740295080243,0.4396551724137931,0.8568804065309699,1.0,1/23,1.11%,GNB5
prerank,GO_Biological_Process_2021__response to organic cyclic compound (GO:0014070),-0.6382263332814365,-0.926768823470095,0.5504587155963303,0.8645290470171509,1.0,3/53,1.27%,GGT5;AQP3;CYP1B1
prerank,WikiPathway_2021_Human__MicroRNAs in cardiomyocyte hypertrophy WP1544,-0.6504138265420928,-0.9267118100898446,0.5855855855855856,0.8641049165212958,1.0,2/82,0.73%,MAP2K6;PIK3CB
prerank,"KEGG_2021_Human__Growth hormone synthesis, secretion and action",-0.6862375862691461,-0.9264993742571026,0.5089285714285714,0.8638301505101451,1.0,4/109,1.11%,MAP2K6;AKT3;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__cellular senescence (GO:0090398),-0.5367952792040472,-0.9264295773893297,0.46564885496183206,0.8634234180280699,1.0,2/26,1.31%,SPI1;PML
prerank,GO_Biological_Process_2021__positive regulation of lipid catabolic process (GO:0050996),-0.5071509600942157,-0.926017839734672,0.3968253968253968,0.8634208200661402,1.0,1/22,0.48%,AADAC
prerank,GO_Biological_Process_2021__Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096),-0.6863200054083844,-0.9258670181971383,0.5689655172413793,0.8631115044958871,1.0,3/70,1.10%,PIK3CB;HCK;VAV1
prerank,GO_Biological_Process_2021__positive regulation of macromolecule biosynthetic process (GO:0010557),-0.6585813168071887,-0.9257340844703956,0.5096153846153846,0.8627813110988585,1.0,2/125,0.99%,CPEB3;KLF4
prerank,Reactome_2022__Regulation Of Gene Expression In Beta Cells R-HSA-210745,0.5190722421085325,0.9255632730832609,0.41935483870967744,0.8576630359236621,1.0,2/16,1.55%,PKLR;FOXA3
prerank,KEGG_2021_Human__Neurotrophin signaling pathway,-0.6758630387168542,-0.9249873294789556,0.5,0.8632245027752036,1.0,5/114,0.83%,RAP1A;AKT3;RAP1B;PIK3CB;NTF3
prerank,GO_Biological_Process_2021__double-strand break repair via nonhomologous end joining (GO:0006303),0.6666062922489177,0.9249537090272277,0.5845070422535211,0.857855089695591,1.0,2/60,0.76%,HERC2;DCLRE1C
prerank,GO_Biological_Process_2021__negative regulation of cell cycle G1/S phase transition (GO:1902807),0.5797104504672269,0.9249475168563464,0.5474452554744526,0.857418315059201,1.0,3/34,0.74%,CDK6;RBL1;DLG1
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP EARLY.V1 UP,0.6766105880421429,0.9247987979342468,0.5266666666666666,0.8571053033320836,1.0,4/147,1.53%,KCNC1;CELSR3;ZNF286A;LRIG1
prerank,KEGG_2021_Human__Complement and coagulation cascades,-0.7231985189884734,-0.9246371929863978,0.5431034482758621,0.8630995380872392,1.0,2/85,1.06%,PROS1;C1R
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-serine phosphorylation (GO:0033138),-0.6545987868201519,-0.9243909793084072,0.5700934579439252,0.8629323380206573,1.0,2/71,0.83%,APP;NTF3
prerank,GO_Biological_Process_2021__Fc receptor mediated stimulatory signaling pathway (GO:0002431),-0.6863186630192124,-0.9242336338074999,0.5652173913043478,0.8626265071242051,1.0,3/73,1.10%,PIK3CB;HCK;VAV1
prerank,GO_Biological_Process_2021__fatty acid biosynthetic process (GO:0006633),-0.6850719114236605,-0.9242272053672457,0.5772357723577236,0.8621517068240774,1.0,5/69,0.92%,CYP2C8;ABCD3;ACSM2B;CYP1A2;LIPG
prerank,TRRUST_Transcription_Factors_2019__NR5A1 human,0.5192888201360533,0.9241261553020754,0.4017094017094017,0.8573756008305929,1.0,1/15,0.95%,AMH
prerank,Reactome_2022__Collagen Formation R-HSA-1474290,0.7205449630229296,0.9240200533277022,0.582089552238806,0.8570472910540292,1.0,5/88,1.34%,PLOD2;COL4A5;COL12A1;P3H3;COL9A3
prerank,WikiPathway_2021_Human__PI3K-Akt signaling pathway WP4172,0.5955038808447918,0.9238245692138849,0.5845070422535211,0.8568346240300564,1.0,11/300,1.51%,PRKAA2;CDK6;PTK2;ITGA2;COL4A5;GNB5;ITGB5;COL9A3;FGF1;PRLR;FN1
prerank,GO_Biological_Process_2021__negative regulation of innate immune response (GO:0045824),0.5956092268235877,0.9237446967142577,0.5481481481481482,0.856479584277143,1.0,2/37,1.24%,YTHDF3;A2M
prerank,GO_Biological_Process_2021__regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032434),-0.658659178928334,-0.9235717453868703,0.5357142857142857,0.8624741563239954,1.0,2/99,0.28%,RNF180;RNF217
prerank,GO_Biological_Process_2021__establishment or maintenance of apical/basal cell polarity (GO:0035088),0.5815239721267431,0.9235668599112679,0.484375,0.8561795743392031,1.0,1/19,0.74%,DLG1
prerank,Elsevier_Pathway_Collection__Apoptosis and Immediate Early Gene Activation in Epileptiform Disorders,-0.6386689091286776,-0.9233008019153272,0.5683453237410072,0.8623123726645341,1.0,1/47,0.34%,RAP1A
prerank,KEGG_2021_Human__Relaxin signaling pathway,-0.6583433085234741,-0.9232211370167845,0.5739130434782609,0.8619512221690846,1.0,4/120,1.22%,AKT3;PIK3CB;CREB5;COL4A4
prerank,Elsevier_Pathway_Collection__CD157/ITGB2 Signaling in Myeloid Cell,-0.5332430112345881,-0.9231418911271172,0.4461538461538462,0.8615599703504107,1.0,3/26,1.10%,PTK2B;HCK;VAV1
prerank,MSigDB_Oncogenic_Signatures__PKCA DN.V1 UP,-0.6473359767799949,-0.9229602072045721,0.5398230088495575,0.8612770223837946,1.0,3/144,0.20%,GSTA2;CYP2C8;SLC7A8
prerank,Elsevier_Pathway_Collection__CXC Chemokine Receptor Signaling,-0.6706768868585797,-0.9226821612153265,0.52,0.8611303226967223,1.0,4/74,1.10%,RAP1A;PTK2B;RASGRP2;VAV1
prerank,GO_Biological_Process_2021__regulation of phagocytosis (GO:0050764),-0.6670688334775862,-0.9224959569946938,0.5746268656716418,0.8608221595163835,1.0,2/55,0.88%,HCK;SYT7
prerank,KEGG_2021_Human__Primary immunodeficiency,0.6015109570596576,0.9224121428790567,0.5546875,0.856970650444698,1.0,1/33,0.76%,DCLRE1C
prerank,Reactome_2022__SUMOylation Of Transcription Factors R-HSA-3232118,-0.4904236154514821,-0.9223972254403654,0.3893129770992366,0.8604464452580366,1.0,11/17,32.49%,TFAP2A;SUMO1;HIC1;MTA1;TFAP2C;MDM2;TP53;UBE2I;PIAS4;SUMO2;PIAS2
prerank,WikiPathway_2021_Human__Nonalcoholic fatty liver disease WP4396,0.6733422984811142,0.9223540677415054,0.5503355704697986,0.8565965851410503,1.0,4/144,1.12%,PRKAA2;NDUFA10;PPARA;PKLR
prerank,Reactome_2022__Generation Of Second Messenger Molecules R-HSA-202433,0.5970905835893459,0.9217651835310628,0.5298507462686567,0.8567823523534989,1.0,1/29,0.83%,ARHGEF7
prerank,TRRUST_Transcription_Factors_2019__SOX9 human,0.5399039969210138,0.9214679290901545,0.4473684210526316,0.8566152871849475,1.0,1/20,0.95%,AMH
prerank,Elsevier_Pathway_Collection__ADRA1 -> Vasoconstriction,-0.4513136833357923,-0.9213698013942333,0.3418803418803419,0.86106088790797,1.0,12/19,27.90%,MAPK3;CALD1;RAF1;RASGRP1;MYLK;MAP2K2;GNAQ;ADRA1B;ADRA1A;ITPR1;PLCB1;ACTA2
prerank,GO_Biological_Process_2021__positive regulation of DNA-binding transcription factor activity (GO:0051091),0.6339915038532413,0.921155551027182,0.5608108108108109,0.8565029177635178,1.0,2/234,1.20%,IRAK2;EDA2R
prerank,Reactome_2022__Platelet Homeostasis R-HSA-418346,-0.7040335281433745,-0.921109544525996,0.6033057851239669,0.8608959239115808,1.0,2/79,0.96%,PDE5A;PDE11A
prerank,GO_Biological_Process_2021__regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122),0.6310511038684631,0.9208017262396276,0.6137931034482759,0.8564179117673416,1.0,5/217,1.41%,TRAF3;PLEKHG5;TSPAN6;EDA2R;FLNA
prerank,GO_Biological_Process_2021__negative regulation of blood vessel morphogenesis (GO:2000181),-0.6835731180562629,-0.9207806622211331,0.5961538461538461,0.8607662006234523,1.0,4/74,1.31%,KLF4;TEK;HRG;PML
prerank,MSigDB_Oncogenic_Signatures__ATF2 S UP.V1 UP,0.6475470106887563,0.9205995930772735,0.567741935483871,0.8561948765700006,1.0,6/162,1.03%,ANKRD11;PPM1H;SLC13A3;DBNDD1;MYO7A;KIF23
prerank,GO_Biological_Process_2021__cell chemotaxis (GO:0060326),0.647081716948428,0.920470195764067,0.5797101449275363,0.8559079078594964,1.0,2/63,1.49%,PLEKHG5;BCAR1
prerank,Reactome_2022__S Phase R-HSA-69242,0.6421504022311934,0.9204519302325773,0.6158940397350994,0.8554910313557433,1.0,6/157,1.53%,CDC45;GINS1;SLC19A1;POLE4;UBE2C;LRIG1
prerank,GO_Biological_Process_2021__neural crest cell development (GO:0014032),-0.5671263983117711,-0.9203780296138606,0.5096153846153846,0.8607230503003576,1.0,1/44,0.96%,SEMA4D
prerank,KEGG_2021_Human__Lysosome,0.6607409895907872,0.9203058071395964,0.5785123966942148,0.8552202550885827,1.0,5/126,1.48%,SORT1;MANBA;ARSG;CTSH;LAMP2
prerank,GO_Biological_Process_2021__phospholipid metabolic process (GO:0006644),-0.6858025736963671,-0.9201568808541308,0.5546875,0.8604581559700354,1.0,3/68,0.95%,PLAAT3;LIPG;AGPAT4
prerank,GO_Biological_Process_2021__mRNA-containing ribonucleoprotein complex export from nucleus (GO:0071427),0.730513851815814,0.9198980865545466,0.6,0.8552001861669566,1.0,2/98,0.73%,NUP210;UPF2
prerank,Elsevier_Pathway_Collection__T-lymphoid precursor cell -> CD8+ Naive T-cell Surface Expression Markers,-0.6552144097260436,-0.9198196539016842,0.5614035087719298,0.8603475556860901,1.0,4/56,1.19%,CD27;HRH2;CD2;IL12RB2
prerank,GO_Biological_Process_2021__mesoderm development (GO:0007498),0.5007323783676774,0.9195480410080159,0.4074074074074074,0.8551316295671155,1.0,1/18,0.89%,TBX3
prerank,Reactome_2022__Transcriptional Regulation By MECP2 R-HSA-8986944,0.6695971580509005,0.9193485329892446,0.6260162601626016,0.8548498160193452,1.0,3/51,0.91%,SLC6A4;TBL1X;GPRIN1
prerank,"Reactome_2022__Cell Death Signaling Via NRAGE, NRIF And NADE R-HSA-204998",0.6577453289469833,0.9191819950567323,0.5763888888888888,0.8545721670221414,1.0,4/74,1.15%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,Reactome_2022__Meiosis R-HSA-1500620,0.7037637067488516,0.9191233127937619,0.6147540983606558,0.8541998710145189,1.0,2/71,1.41%,SYCP3;ACD
prerank,MSigDB_Oncogenic_Signatures__KRAS.DF.V1 DN,0.6472227758632954,0.9190720122031871,0.5369127516778524,0.8538047184836963,1.0,7/164,1.45%,TAF4;COG5;COL4A5;SF3A2;TUFT1;TCFL5;LRRC61
prerank,KEGG_2021_Human__Wnt signaling pathway,0.6349067200579899,0.9190506894648172,0.5289855072463768,0.8534002920608673,1.0,3/154,0.43%,AXIN2;LRP5;TBL1X
prerank,GO_Biological_Process_2021__regulation of RNA metabolic process (GO:0051252),0.6778924707149379,0.9189676574523263,0.5877862595419847,0.8530562441181713,1.0,3/61,1.19%,IGF2BP1;IGF2BP3;PCBP4
prerank,Reactome_2022__HIV Infection R-HSA-162906,0.6349347538566347,0.9189358654881697,0.5633802816901409,0.8526487442181626,1.0,4/222,1.53%,NUP210;TAF4;TCEA1;LRIG1
prerank,MSigDB_Oncogenic_Signatures__STK33 NOMO UP,0.6004032232031794,0.9184218719965861,0.5763888888888888,0.8527769408372271,1.0,4/261,1.54%,ST3GAL1;AUH;A2M;RIN2
prerank,Reactome_2022__Synthesis Of PA R-HSA-1483166,0.5824390094927575,0.91812824960755,0.5481481481481482,0.852601770747881,1.0,1/34,0.32%,GPAT4
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway (GO:0097193),-0.6635623477820801,-0.9178712027438783,0.5486725663716814,0.8620281107512562,1.0,2/100,1.31%,CYP1B1;PML
prerank,KEGG_2021_Human__Non-alcoholic fatty liver disease,0.6733423144979812,0.9176857195762731,0.5755395683453237,0.8526256160859382,1.0,4/144,1.12%,PRKAA2;NDUFA10;PPARA;PKLR
prerank,WikiPathway_2021_Human__EGFR Tyrosine Kinase Inhibitor Resistance WP4806,-0.6916966947909416,-0.9175282577979983,0.5784313725490197,0.8619167673520418,1.0,2/83,0.73%,AKT3;PIK3CB
prerank,Reactome_2022__P75 NTR Receptor-Mediated Signaling R-HSA-193704,0.6577356080414867,0.9174422815873688,0.6204379562043796,0.8524333357433206,1.0,4/95,1.15%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,GO_Biological_Process_2021__positive regulation of protein polymerization (GO:0032273),-0.6845508920948965,-0.917021074945356,0.6068376068376068,0.862064121786582,1.0,4/66,0.84%,CARMIL1;PTK2B;HCK;TPPP2
prerank,WikiPathway_2021_Human__MECP2 and Associated Rett Syndrome WP3584,0.6760480698199415,0.9169994301266432,0.6187050359712231,0.8524803843953086,1.0,2/64,0.91%,DLX6;GPRIN1
prerank,GO_Biological_Process_2021__regulation of cyclin-dependent protein kinase activity (GO:1904029),-0.6609261261414489,-0.9169832552122732,0.546875,0.861631586169061,1.0,2/52,1.05%,CCND2;HERC5
prerank,GO_Biological_Process_2021__regulation of telomerase activity (GO:0051972),0.6431437977991337,0.9168806045012319,0.5950413223140496,0.8521515193949513,1.0,4/46,1.46%,PARN;PIF1;ACD;WRAP53
prerank,KEGG_2021_Human__NOD-like receptor signaling pathway,-0.6210338504916575,-0.9167302472777482,0.5533980582524272,0.8614438554739554,1.0,2/155,0.98%,OAS1;GBP4
prerank,TRRUST_Transcription_Factors_2019__GATA4 mouse,0.5245314952619681,0.9166052507983031,0.4188034188034188,0.8519790379113646,1.0,1/16,0.95%,AMH
prerank,KEGG_2021_Human__Cellular senescence,-0.6167541800321398,-0.9163165012756279,0.5714285714285714,0.8614423843440907,1.0,6/149,1.13%,MAP2K6;AKT3;RB1;PIK3CB;CCND2;RASSF5
prerank,GO_Biological_Process_2021__regulation of neuron projection development (GO:0010975),0.6533155806451704,0.9162171620411763,0.5488721804511278,0.8519395951814651,1.0,7/158,1.33%,GFI1;BRSK1;ABI2;FRMD7;ULK4;APOE;DPYSL3
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell membrane repolarization (GO:0099623),0.5230240104512612,0.9149608474079606,0.4424778761061947,0.8529125241209242,1.0,2/20,1.53%,FLNA;SNTA1
prerank,GO_Biological_Process_2021__positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123),0.6578783365254623,0.9149040114925738,0.5821917808219178,0.8525552526828664,1.0,4/164,1.41%,PLEKHG5;TSPAN6;EDA2R;FLNA
prerank,GO_Biological_Process_2021__cellular response to arsenic-containing substance (GO:0071243),0.4936208774340955,0.9146045667925627,0.375,0.8524367499598926,1.0,12/15,37.53%,PPIF;GSTO2;DAXX;HSF1;VCP;MAPK13;ZFAND1;CPEB2;GSTO1;ZC3H12A;DHX36;DDX3X
prerank,GO_Biological_Process_2021__positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436),-0.6586624686468352,-0.9145062199148649,0.575,0.8630517147390516,1.0,2/77,0.28%,RNF180;RNF217
prerank,GO_Biological_Process_2021__ubiquitin-dependent protein catabolic process (GO:0006511),-0.5484241287872698,-0.9144286113091894,0.5980392156862745,0.8626753415355082,1.0,8/345,1.31%,KLHL3;RNF217;RNF13;BIRC6;AMFR;WWP1;UBE3D;PML
prerank,GO_Biological_Process_2021__glial cell development (GO:0021782),0.5179324923036824,0.9140062350829629,0.42857142857142855,0.8525720265573252,1.0,1/25,0.19%,CDK6
prerank,GO_Biological_Process_2021__regulation of protein kinase B signaling (GO:0051896),0.6380302262171798,0.9139895198601967,0.5878378378378378,0.8521578491821016,1.0,5/192,1.36%,PTK2;PPARA;ERBB3;KLB;FGF1
prerank,MSigDB_Oncogenic_Signatures__LTE2 UP.V1 DN,-0.6160078347922026,-0.9138510902862266,0.5757575757575758,0.8628496563994535,1.0,7/179,1.36%,OAS1;DNAJB14;OASL;KLF4;HERC5;HERC6;GRB10
prerank,Reactome_2022__Class I MHC Mediated Antigen Processing And Presentation R-HSA-983169,-0.5607012677035553,-0.9136589034632846,0.5,0.8625991172710611,1.0,9/367,1.28%,KLHL3;HERC3;RNF217;FBXO27;SEC61A2;WWP1;UBE3D;HERC5;HERC6
prerank,MSigDB_Oncogenic_Signatures__JNK DN.V1 DN,0.6730641622619948,0.9133172473458292,0.5611510791366906,0.8524332693778968,1.0,5/154,1.00%,THY1;CDC45;SHB;UBE2C;PAQR4
prerank,Reactome_2022__Platelet Aggregation (Plug Formation) R-HSA-76009,-0.5653483611643355,-0.9132558905652449,0.5333333333333333,0.8625552696001333,1.0,3/36,0.93%,RAP1A;RAP1B;RASGRP2
prerank,Reactome_2022__Collagen Biosynthesis And Modifying Enzymes R-HSA-1650814,0.7205571019179087,0.9131202060269324,0.6349206349206349,0.8521615682108462,1.0,5/66,1.34%,PLOD2;COL4A5;COL12A1;P3H3;COL9A3
prerank,Reactome_2022__NOTCH1 Intracellular Domain Regulates Transcription R-HSA-2122947,0.6530919045119032,0.9130391924286554,0.5851851851851851,0.8517961705359275,1.0,2/47,0.43%,HDAC8;TBL1X
prerank,GO_Biological_Process_2021__regulation of cell junction assembly (GO:1901888),-0.5378430379482629,-0.9128006487506364,0.49193548387096775,0.8625717384600943,1.0,2/27,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__protein import (GO:0017038),-0.6385566659989865,-0.9127190258181903,0.5213675213675214,0.8621966587079728,1.0,2/86,0.51%,ABCD3;ATAD1
prerank,KEGG_2021_Human__AGE-RAGE signaling pathway in diabetic complications,-0.6423307963366282,-0.9126777683829876,0.5567010309278351,0.8617687334915745,1.0,3/99,1.22%,AKT3;PIK3CB;COL4A4
prerank,GO_Biological_Process_2021__monocarboxylic acid biosynthetic process (GO:0072330),-0.6466108346559595,-0.9126530280038386,0.5853658536585366,0.8613204485366956,1.0,4/62,0.92%,CYP39A1;ABCD3;ACSM2B;LIPG
prerank,GO_Biological_Process_2021__regulation of protein secretion (GO:0050708),-0.6370782880613293,-0.9126244890446964,0.5833333333333334,0.8608819055743256,1.0,4/114,1.24%,RAP1A;STXBP5;SYT7;KCNS3
prerank,WikiPathway_2021_Human__Methionine De Novo and Salvage Pathway WP3580,0.5289139762723628,0.912500235432513,0.44366197183098594,0.8519505971389204,1.0,2/22,1.52%,CHDH;SMS
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.N4.V1 UP,0.6412803936691212,0.9124800137142098,0.5422535211267606,0.8515396946742226,1.0,4/179,1.38%,ASPHD1;ACACA;FGF1;PYCR1
prerank,GO_Biological_Process_2021__embryonic skeletal system development (GO:0048706),0.6214675839431439,0.9124750373047045,0.5652173913043478,0.851115802721497,1.0,2/32,0.15%,HOXD3;MEGF8
prerank,GO_Biological_Process_2021__apoptotic process (GO:0006915),0.6225988502674611,0.9117971334814844,0.6058394160583942,0.8514253654243603,1.0,5/217,1.51%,MELK;TNFRSF10A;TNFRSF25;ERBB3;BOK
prerank,WikiPathway_2021_Human__Ciliary landscape WP4352,0.6120688000380854,0.9117828670898801,0.5625,0.8510172619619639,1.0,5/208,1.02%,MSH2;UBE2H;NEK8;CCDC40;IQGAP3
prerank,"GO_Biological_Process_2021__synaptic transmission, cholinergic (GO:0007271)",0.5391457084411203,0.9117255062671148,0.48484848484848486,0.8506497212791779,1.0,1/18,1.30%,APOE
prerank,MSigDB_Oncogenic_Signatures__LEF1 UP.V1 UP,-0.6160068312650302,-0.9114767934027191,0.5625,0.8617453205634311,1.0,6/177,1.24%,NR3C1;EPB41L4A;CCND2;PELI2;ZAP70;MAOB
prerank,Elsevier_Pathway_Collection__Melanocyte Role in Skin Aging,0.43946278106512743,0.9113269600907685,0.3064516129032258,0.8506265339416446,1.0,9/16,32.91%,CASP9;CREBBP;MC1R;HIF1A;TYRP1;CREB1;POMC;BCL2;GNAS
prerank,WikiPathway_2021_Human__Glycolysis and Gluconeogenesis WP534,-0.6330256367174506,-0.9111943845898854,0.5726495726495726,0.8615588606300085,1.0,1/43,0.08%,ALDOB
prerank,GO_Biological_Process_2021__glucose 6-phosphate metabolic process (GO:0051156),-0.5136760871261246,-0.9110264244341947,0.4049586776859504,0.8612779286400237,1.0,1/20,0.25%,DERA
prerank,GO_Biological_Process_2021__regulation of peptidyl-serine phosphorylation (GO:0033135),-0.6545912461960168,-0.9108868979756195,0.5495495495495496,0.8609857636691298,1.0,2/91,0.83%,APP;NTF3
prerank,Reactome_2022__Neuronal System R-HSA-112316,0.5814124853519677,0.9108096601997021,0.644927536231884,0.8507619045988906,1.0,12/337,1.54%,KCNC1;SLC6A4;PRKAA2;LIN7A;DLG1;ARHGEF7;GPRIN1;PPFIA4;GNB5;STX1A;HOMER3;SLC38A1
prerank,GO_Biological_Process_2021__protein complex oligomerization (GO:0051259),0.6896172113594681,0.9107139250960204,0.5634920634920635,0.8504504107680524,1.0,2/86,1.51%,KCNC1;BOK
prerank,Reactome_2022__Signaling By ALK Fusions And Activated Point Mutants R-HSA-9725370,-0.6531379996449082,-0.9105178028836752,0.6017699115044248,0.8609522613442765,1.0,1/53,0.62%,BIRC6
prerank,GO_Biological_Process_2021__positive regulation of protein phosphorylation (GO:0001934),-0.5713871027156087,-0.9103993042899609,0.66,0.8606075684030827,1.0,10/348,1.21%,RAP1A;APP;WNK3;PTK2B;PAK2;NTF3;CCND2;SEMA4D;PELI2;TEK
prerank,GO_Biological_Process_2021__regulation of primary metabolic process (GO:0080090),0.6665109202049176,0.9102224841626455,0.5692307692307692,0.8505895501255367,1.0,4/127,1.30%,ACACA;TBL1X;PPARA;APOE
prerank,WikiPathway_2021_Human__Netrin-UNC5B signaling pathway WP4747,-0.6192601536372422,-0.9099728898338807,0.5904761904761905,0.8606480407378312,1.0,3/49,0.67%,NTN4;NEO1;PTK2B
prerank,Reactome_2022__Interleukin-1 Signaling R-HSA-9020702,-0.6793843281775848,-0.9099176303738511,0.5454545454545454,0.8602348023957502,1.0,3/110,1.03%,MAP2K6;APP;PELI2
prerank,MSigDB_Oncogenic_Signatures__JAK2 DN.V1 DN,-0.6370190972142369,-0.9096986364999249,0.5327102803738317,0.8600130484471725,1.0,4/114,1.29%,TLE4;HIBADH;ZNF44;SLC4A5
prerank,GO_Biological_Process_2021__protein insertion into ER membrane (GO:0045048),0.6102465888587097,0.9096302815177828,0.5692307692307692,0.8508353515347249,1.0,2/36,1.20%,GET3;STX1A
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Diabetes,0.5004205896744357,0.9095526780217088,0.3971631205673759,0.8504899782304193,1.0,1/19,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Retinitis Pigmentosa,0.70613418652724,0.909503428527999,0.5947712418300654,0.85010875171272,1.0,3/101,1.03%,SORT1;TUB;MYO7A
prerank,GO_Biological_Process_2021__protein tetramerization (GO:0051262),0.683428092651047,0.9093481135872563,0.5664335664335665,0.8498554962490461,1.0,4/67,1.51%,KCNC1;ACACA;GLS;HPRT1
prerank,MSigDB_Oncogenic_Signatures__PDGF ERK DN.V1 UP,0.6911907840098561,0.909153866294381,0.5797101449275363,0.8496424651692884,1.0,5/123,1.21%,CDK6;OXCT1;RPIA;TAF1B;MID1
prerank,WikiPathway_2021_Human__Hippo-Yap signaling pathway WP4537,0.5345862989485488,0.908999583062526,0.4846153846153846,0.8493649661660284,1.0,1/23,1.12%,TEAD4
prerank,Reactome_2022__Nuclear Receptor Transcription Pathway R-HSA-383280,-0.6086841101778152,-0.9089339635968651,0.5714285714285714,0.8604885482984191,1.0,2/51,1.25%,NR3C1;VDR
prerank,WikiPathway_2021_Human__Corticotropin-releasing hormone signaling pathway WP2355,0.7051808327026072,0.9086380439199739,0.6,0.8492607765869251,1.0,6/86,1.56%,PRKAA2;ACACA;PTK2;GNB5;GRK3;FOSL2
prerank,Reactome_2022__NRAGE Signals Death Thru JNK R-HSA-193648,0.6577532350530529,0.9085457277232352,0.5671641791044776,0.8489571397500082,1.0,4/57,1.15%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,GO_Biological_Process_2021__intracellular cholesterol transport (GO:0032367),-0.4683042153703526,-0.9082780660863935,0.36363636363636365,0.8607060296917315,1.0,5/15,13.34%,STAR;SERAC1;OSBPL2;NPC2;LRP6
prerank,GO_Biological_Process_2021__regulation of protein modification process (GO:0031399),0.7050011584876219,0.9077765175761809,0.6299212598425197,0.849404125260083,1.0,4/50,1.51%,PPP1R16B;PTK2;FNIP1;FN1
prerank,GO_Biological_Process_2021__positive regulation of cell cycle (GO:0045787),-0.6482758421402433,-0.9077526448668383,0.5739130434782609,0.8608750194944244,1.0,2/65,0.93%,APP;CCND2
prerank,GO_Biological_Process_2021__negative regulation of androgen receptor signaling pathway (GO:0060766),-0.49782791117271996,-0.9077488244754455,0.4094488188976378,0.8604145505103297,1.0,10/15,32.49%,NODAL;NCOR2;SFRP1;HDAC1;FOXH1;SMARCA4;ZBTB7A;PHB;DAB2;PIAS2
prerank,Reactome_2022__Ras Activation Upon Ca2+ Influx Thru NMDA Receptor R-HSA-442982,0.5127052200145814,0.907595105234745,0.4318181818181818,0.8491614753824622,1.0,2/19,0.91%,DLG1;GPRIN1
prerank,Elsevier_Pathway_Collection__Eat me Signal: Apoptotic Cell Initiates Phagocytosis,0.584714313446129,0.9072844391304562,0.5144927536231884,0.849072777053738,1.0,1/25,0.06%,HAVCR1
prerank,GO_Biological_Process_2021__cellular response to BMP stimulus (GO:0071773),0.6726705228942145,0.9072520493093155,0.6330935251798561,0.8486920767521204,1.0,2/65,0.95%,MEGF8;AMH
prerank,GO_Biological_Process_2021__cellular response to lipopolysaccharide (GO:0071222),-0.6429466402450528,-0.9068903934702266,0.5567010309278351,0.8608658467058836,1.0,3/109,1.04%,HCK;CD274;TICAM2
prerank,MSigDB_Oncogenic_Signatures__STK33 DN,-0.5880632083753866,-0.9064653542103945,0.5625,0.8609243564656852,1.0,9/236,1.16%,KCNN2;ARHGEF26;TRIM58;GAS2;NHLRC2;NEO1;VPS13C;PIK3CB;MAP4K1
prerank,GO_Biological_Process_2021__regulation of epidermal growth factor-activated receptor activity (GO:0007176),-0.5067195908927158,-0.9064127291283216,0.4460431654676259,0.8605173459600287,1.0,1/26,0.35%,APP
prerank,MSigDB_Oncogenic_Signatures__E2F1 UP.V1 DN,0.6247572566472606,0.9058432307832267,0.6013986013986014,0.8498131867975294,1.0,3/179,1.53%,UBE2H;ERBB3;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of supramolecular fiber organization (GO:1902905),-0.6782526333223402,-0.9055744607357911,0.5811965811965812,0.8610113943789373,1.0,5/88,0.81%,CARMIL1;APP;RB1;PTK2B;HCK
prerank,GO_Biological_Process_2021__regulated exocytosis (GO:0045055),-0.6518522326240912,-0.9054740274546648,0.5728155339805825,0.8606757801237486,1.0,6/175,1.26%,A1BG;APP;PROS1;NHLRC2;SYT7;HRG
prerank,GO_Biological_Process_2021__organic substance transport (GO:0071702),-0.6267581921314549,-0.9053879965080486,0.576271186440678,0.8603130590640918,1.0,5/133,1.26%,SLC22A1;ABCA6;ABCD3;SLCO1A2;HRG
prerank,WikiPathway_2021_Human__Nanoparticle-mediated activation of receptor signaling WP2643,0.5885639051575563,0.9053312340473954,0.5546875,0.8499800937510319,1.0,2/28,1.51%,PTK2;FN1
prerank,GO_Biological_Process_2021__cellular metal ion homeostasis (GO:0006875),-0.6789834108194833,-0.905111039827513,0.5614035087719298,0.8601314768612796,1.0,1/91,0.09%,CCL23
prerank,WikiPathway_2021_Human__PKC-gamma calcium signaling pathway in ataxia WP4760,-0.5118035722383133,-0.9050271060720402,0.4188034188034188,0.8597648687628052,1.0,1/19,1.05%,GNA14
prerank,GO_Biological_Process_2021__membrane lipid biosynthetic process (GO:0046467),-0.6696809829129208,-0.9047423672586812,0.6198347107438017,0.8596614845054358,1.0,1/57,0.51%,SGPP1
prerank,TRRUST_Transcription_Factors_2019__USF1 human,0.6995614329872314,0.904609690845016,0.6180555555555556,0.8503835657585511,1.0,2/63,1.12%,SLC19A1;PKLR
prerank,GO_Biological_Process_2021__cellular response to reactive oxygen species (GO:0034614),0.66510304207318,0.904463251706877,0.5669291338582677,0.8501146527978212,1.0,2/61,1.43%,AGAP3;MPV17
prerank,Elsevier_Pathway_Collection__HRAS Signaling,-0.6020660054667507,-0.904373088768769,0.5648148148148148,0.8596518650947206,1.0,1/44,0.66%,RASA2
prerank,GO_Biological_Process_2021__mitochondrion organization (GO:0007005),-0.6407339777273279,-0.9038862708518391,0.5288461538461539,0.8597084628254749,1.0,5/172,0.78%,AKT3;VPS13D;CHCHD3;VPS13C;TOMM70
prerank,GO_Biological_Process_2021__neurotrophin signaling pathway (GO:0038179),-0.5465362734717165,-0.9036228362594833,0.4672131147540984,0.8595778951568551,1.0,2/20,0.83%,RAP1A;NTF3
prerank,GO_Biological_Process_2021__transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169),-0.5324803586362059,-0.9035735673121533,0.6530612244897959,0.8591829267540314,1.0,12/382,1.36%,GRIN2B;FLRT2;PTK2B;PAK2;PIK3CB;HCK;NTF3;GALNT3;VAV1;ZAP70;TEK;GRB10
prerank,Reactome_2022__RHOBTB1 GTPase Cycle R-HSA-9013422,-0.5233444008099953,-0.9034404346427973,0.4462809917355372,0.8589183041496188,1.0,1/23,0.33%,PDE5A
prerank,GO_Biological_Process_2021__regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0000079),-0.6609124275780274,-0.9034303919233553,0.5263157894736842,0.8584648863953053,1.0,2/80,1.05%,CCND2;HERC5
prerank,GO_Biological_Process_2021__regulation of platelet activation (GO:0010543),0.5023839699343032,0.9032310144166094,0.4117647058823529,0.8510114582835463,1.0,1/21,1.30%,APOE
prerank,Elsevier_Pathway_Collection__Oncogene Induced Cellular Senescence,0.6785531059708702,0.9030342710393181,0.6335877862595419,0.8507916670225099,1.0,2/46,0.50%,CDK6;ATR
prerank,GO_Biological_Process_2021__synaptic vesicle exocytosis (GO:0016079),-0.5448262937619475,-0.9030037734064121,0.5079365079365079,0.8584787105532378,1.0,1/37,0.88%,SYT7
prerank,GO_Biological_Process_2021__leukocyte cell-cell adhesion (GO:0007159),-0.49517053602669847,-0.90226800338573,0.45614035087719296,0.8588634464260936,1.0,1/27,0.96%,SEMA4D
prerank,TRRUST_Transcription_Factors_2019__SOX9 mouse,-0.545591305666282,-0.902252779598184,0.46788990825688076,0.8584267102826227,1.0,1/24,0.11%,VNN1
prerank,WikiPathway_2021_Human__Autophagy WP4923,-0.530855446994005,-0.9021502086983562,0.46153846153846156,0.8580790974237198,1.0,2/30,0.73%,UVRAG;DEPTOR
prerank,GO_Biological_Process_2021__regulation of cell motility (GO:2000145),0.6788374689786636,0.9021108798643312,0.581081081081081,0.8513980598149303,1.0,6/123,1.41%,CDK6;ERBB3;CAMSAP3;FGF1;CAVIN1;FLNA
prerank,TRRUST_Transcription_Factors_2019__NR4A1 human,-0.4980426751833502,-0.9017943388216874,0.423728813559322,0.8580999149453107,1.0,7/15,19.79%,TNF;STAR;RNF7;E2F1;TIMP2;HSD3B2;MDM2
prerank,Elsevier_Pathway_Collection__Eat me Signal: Apoptotic Cell Induces Phagocytosis,0.5956342536396119,0.9017835379340182,0.5616438356164384,0.851289754162141,1.0,2/29,1.49%,PTK2;BCAR1
prerank,KEGG_2021_Human__Oocyte meiosis,-0.6425931505304787,-0.9015108241382627,0.5405405405405406,0.8580253391517488,1.0,1/116,0.07%,CPEB3
prerank,Reactome_2022__Amine Ligand-Binding Receptors R-HSA-375280,-0.54996629058596,-0.9014526363053011,0.48695652173913045,0.8576240326251274,1.0,1/25,0.97%,HRH2
prerank,GO_Biological_Process_2021__microtubule polymerization or depolymerization (GO:0031109),-0.5695770027826569,-0.9014400505639565,0.5169491525423728,0.8571800587122889,1.0,2/26,1.33%,TPPP2;HDGFL3
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Pulmonary Hypertension,-0.6742539867237821,-0.9013665131776606,0.5811965811965812,0.8567977719939585,1.0,3/66,1.21%,PDE5A;VAV1;TEK
prerank,GO_Biological_Process_2021__regulation of ubiquitin-dependent protein catabolic process (GO:2000058),-0.5631269010886691,-0.9010082576843863,0.5396825396825397,0.8567353827907084,1.0,2/41,1.31%,PTK2B;PML
prerank,GO_Biological_Process_2021__mRNA destabilization (GO:0061157),0.6086387957708967,0.9006306628936951,0.5528455284552846,0.8521332089400786,1.0,2/37,0.64%,DIS3L2;YTHDF3
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Neurotoxicity,0.500421066726348,0.9005416248655791,0.40714285714285714,0.8518113849668076,1.0,1/16,0.40%,LRP5
prerank,Reactome_2022__Plasma Lipoprotein Remodeling R-HSA-8963899,-0.5599307249290622,-0.9004519373917773,0.5441176470588235,0.8568972616573395,1.0,1/33,0.92%,LIPG
prerank,Reactome_2022__GPCR Ligand Binding R-HSA-500792,-0.5554149322196521,-0.9001908782596602,0.6666666666666666,0.8567579287657188,1.0,7/338,1.23%,CCL23;APP;GPR39;GPR132;HRH2;ADGRE5;S1PR1
prerank,GO_Biological_Process_2021__protein homooligomerization (GO:0051260),0.6765131641354885,0.8996651249239831,0.5507246376811594,0.8523274082176749,1.0,3/113,1.51%,ACACA;GLS;HPRT1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Melanoma,0.6119165255522588,0.8995620079133765,0.589041095890411,0.8520208906032348,1.0,7/228,1.51%,CDK6;PTK2;TBX3;ERBB3;IGF2BP3;MELTF;FN1
prerank,GO_Biological_Process_2021__G1/S transition of mitotic cell cycle (GO:0000082),0.6820898315171335,0.8994268142536321,0.5734265734265734,0.8517712108631473,1.0,4/82,1.18%,CDC45;GFI1;CDK6;RRM2
prerank,KEGG_2021_Human__Yersinia infection,-0.6218502682764065,-0.8993003552239689,0.59,0.8573788565984153,1.0,6/133,1.13%,MAP2K6;AKT3;PTK2B;PIK3CB;VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__S/G2 Phase Transition,0.5620485070974572,0.8992749905440771,0.5136986301369864,0.8515180119154002,1.0,1/26,0.09%,CDC45
prerank,MSigDB_Oncogenic_Signatures__AKT UP MTOR DN.V1 DN,-0.6024358486968961,-0.8992295039200937,0.6198347107438017,0.8570133124353423,1.0,4/170,1.06%,TYW1;KCNAB3;GNA14;C1R
prerank,"Reactome_2022__Unblocking Of NMDA Receptors, Glutamate Binding And Activation R-HSA-438066",0.5127051399022136,0.8991456060866293,0.43609022556390975,0.8512594164168216,1.0,2/19,0.91%,DLG1;GPRIN1
prerank,MSigDB_Oncogenic_Signatures__STK33 NOMO DN,-0.5908845584680561,-0.8991385120235411,0.6261682242990654,0.8566526784515006,1.0,7/235,1.19%,BIVM;TRIM58;NHLRC2;NEO1;VPS13C;MAP4K1;MTHFD2L
prerank,Elsevier_Pathway_Collection__Age-Related Cataract,-0.4699171101632031,-0.8987322856372851,0.3697478991596639,0.8566402560757477,1.0,10/19,23.82%,ATP1A1;CAPN2;SLC8A1;CASR;GSR;SOD1;CRYAB;ATP2B1;CAST;GPX1
prerank,GO_Biological_Process_2021__regulation of neuroinflammatory response (GO:0150077),-0.42475041906573846,-0.898632659281515,0.2966101694915254,0.8563050375368885,1.0,9/18,24.48%,TNF;PTGS2;IL18;IGF1;MMP9;MMP3;IL33;MMP8;CD200R1
prerank,GO_Biological_Process_2021__organonitrogen compound biosynthetic process (GO:1901566),-0.622864732620461,-0.8985179210451503,0.6050420168067226,0.8560017634286639,1.0,5/152,1.17%,GSTA2;GSTA1;SGPP1;TYW1;CDO1
prerank,Elsevier_Pathway_Collection__Oxidation of Fatty Acid in non-Alcoholic Fatty Liver Disease,-0.5199016093424645,-0.8981490008486054,0.46875,0.8559288228359725,1.0,1/27,0.31%,MAP2K6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Colorectal Neoplasms,0.6749383376331313,0.8981078328232972,0.6439393939393939,0.8519720070476134,1.0,1/91,0.17%,MSH2
prerank,Elsevier_Pathway_Collection__Club-Cell Role in Asthma,-0.5788100932706737,-0.8980355254863087,0.5916666666666667,0.8555990267031076,1.0,1/38,1.04%,TICAM2
prerank,GO_Biological_Process_2021__sensory organ development (GO:0007423),0.6180094883685864,0.8977937869642314,0.5748031496062992,0.8518996335808154,1.0,3/46,1.03%,SIPA1L3;SMCHD1;MYO7A
prerank,Elsevier_Pathway_Collection__Dendritic Cells Function in Psoriasis,-0.5017327464837928,-0.8977713940747853,0.5217391304347826,0.8554858314315872,1.0,1/39,0.31%,MAP2K6
prerank,TRRUST_Transcription_Factors_2019__NR1H4 human,-0.4536451291007135,-0.8977400210130196,0.36036036036036034,0.8550778230356915,1.0,8/18,22.74%,ABCC4;ABCB4;KRT13;EDN1;CYP7A1;NR1I2;HSD3B2;STK11
prerank,MSigDB_Hallmark_2020__Apical Surface,-0.6099654004517842,-0.8975497406228902,0.5446428571428571,0.8548232625660761,1.0,3/43,0.39%,AKAP7;APP;DCBLD2
prerank,Reactome_2022__Signaling By Hedgehog R-HSA-5358351,0.6464950486241,0.897348108120349,0.5804195804195804,0.8519739548641901,1.0,1/132,0.30%,SMOX
prerank,GO_Biological_Process_2021__positive regulation of epidermal cell differentiation (GO:0045606),0.501602607617217,0.8973477334627863,0.43884892086330934,0.851552185579604,1.0,1/19,1.30%,CYP27B1
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V2 DN,0.6497559810562525,0.8972760512114338,0.627906976744186,0.8512021947383354,1.0,4/118,1.21%,MEGF8;BCOR;TBX3;MID1
prerank,Reactome_2022__Regulation Of Expression Of SLITs And ROBOs R-HSA-9010553,0.6339613140310764,0.8970638487602727,0.5906040268456376,0.8510177255340207,1.0,2/162,0.96%,UPF2;COL4A5
prerank,KEGG_2021_Human__Fluid shear stress and atherosclerosis,-0.6437320862016895,-0.8966168362673735,0.5950413223140496,0.8554730738811765,1.0,5/130,0.73%,GSTA2;GSTA1;MAP2K6;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__regulation of neural precursor cell proliferation (GO:2000177),0.532738128022525,0.8965001372319408,0.4715447154471545,0.8512142800935374,1.0,1/20,1.01%,SHCBP1
prerank,GO_Biological_Process_2021__endocytic recycling (GO:0032456),0.659824455024718,0.8964339667499724,0.5912408759124088,0.8508668501018075,1.0,1/51,0.51%,ANKRD50
prerank,Reactome_2022__Semaphorin Interactions R-HSA-373755,0.6582098018826721,0.8964017209208536,0.6097560975609756,0.8504897758417657,1.0,2/63,1.33%,ARHGEF7;DPYSL3
prerank,MSigDB_Oncogenic_Signatures__KRAS.600 UP.V1 UP,0.6057897115472416,0.8963763403960827,0.6038961038961039,0.8500943409370779,1.0,9/233,1.30%,KCNC1;GFI1;ITGA2;ETV5;TBX3;STX1A;A2M;FMNL2;CYP27B1
prerank,Reactome_2022__SUMOylation Of Transcription Cofactors R-HSA-3899300,0.6341651597550324,0.8963310365801656,0.6363636363636364,0.8497161474743855,1.0,2/42,1.02%,MRTFA;CBX2
prerank,GO_Biological_Process_2021__carbohydrate catabolic process (GO:0016052),-0.5759598686826026,-0.8963154963007983,0.5555555555555556,0.8553534426814503,1.0,2/37,0.25%,ALDOB;DERA
prerank,KEGG_2021_Human__Apelin signaling pathway,0.680109759683889,0.8961030575878743,0.5671641791044776,0.8495030137528982,1.0,3/126,1.11%,PRKAA2;NOTCH3;GNB5
prerank,GO_Biological_Process_2021__negative regulation of apoptotic process (GO:0043066),0.5430731820230703,0.8959098074492249,0.689873417721519,0.8492732554549333,1.0,17/456,1.48%,PRKAA2;MSH2;PTK2;AATF;TJP1;FNIP1;ZNF304;TBX3;ERBB3;PRAP1;TNFRSF10D;SH3RF2;CTSH;APOE;PRLR;FLNA;SLC30A10
prerank,TRRUST_Transcription_Factors_2019__CREM human,-0.533493522722581,-0.8955325718877432,0.4732824427480916,0.8557416744426308,1.0,2/22,1.26%,ZAP70;DUSP4
prerank,GO_Biological_Process_2021__cell projection organization (GO:0030030),0.5515274099420078,0.8953335215233049,0.5234375,0.8494793395688582,1.0,1/30,0.86%,RHOQ
prerank,GO_Biological_Process_2021__organic anion transport (GO:0015711),-0.6655518604119431,-0.8953105649619907,0.5833333333333334,0.8555411923152695,1.0,5/91,1.29%,SLC35A3;SLC2A10;SLCO1A2;SLC16A2;SLC4A5
prerank,GO_Biological_Process_2021__embryonic digestive tract development (GO:0048566),0.5702636051835062,0.8951654094776805,0.5037593984962406,0.8492199203587635,1.0,1/19,1.04%,PKDCC
prerank,WikiPathway_2021_Human__Breast cancer pathway WP4262,0.648192319341645,0.8951515817039741,0.6216216216216216,0.8488188069792145,1.0,6/145,1.36%,AXIN2;CDK6;LRP5;NOTCH3;ATR;FGF1
prerank,Reactome_2022__Long-term Potentiation R-HSA-9620244,0.512703966792374,0.8949326560200194,0.44525547445255476,0.8486253072093626,1.0,2/22,0.91%,DLG1;GPRIN1
prerank,WikiPathway_2021_Human__Regulation of Actin Cytoskeleton WP51,0.6552716281359633,0.894916437933946,0.6453900709219859,0.8482304783353596,1.0,7/139,1.51%,PTK2;ABI2;ARHGEF7;PIK3C2B;FGF1;BCAR1;FN1
prerank,GO_Biological_Process_2021__regulation of viral genome replication (GO:0045069),-0.6496503688831324,-0.8947614448948962,0.603448275862069,0.8556169638466465,1.0,2/63,0.87%,OAS1;OASL
prerank,KEGG_2021_Human__Butanoate metabolism,0.5232732775216151,0.894733147401193,0.47794117647058826,0.84800948279466,1.0,1/27,0.23%,OXCT1
prerank,Elsevier_Pathway_Collection__HPV E5 Regulates EDNRA and EGFR Signaling Pathway in Keratinocytes,-0.6435246779336826,-0.8945788101020216,0.5867768595041323,0.8553674134455367,1.0,2/51,0.67%,MAP2K6;PTK2B
prerank,TRRUST_Transcription_Factors_2019__TWIST2 human,0.5504529277728065,0.8939701374608338,0.5039370078740157,0.8483926685816771,1.0,2/25,1.51%,ERBB3;FN1
prerank,WikiPathway_2021_Human__Regulation of toll-like receptor signaling pathway WP1449,-0.6485144350691554,-0.8939110851621633,0.6037735849056604,0.855703252138065,1.0,5/124,1.04%,MAP2K6;AKT3;PIK3CB;PELI2;TICAM2
prerank,KEGG_2021_Human__Human immunodeficiency virus 1 infection,-0.6301058121083031,-0.8936703986252164,0.5092592592592593,0.8555659538515608,1.0,5/189,0.73%,MAP2K6;AKT3;PTK2B;PAK2;PIK3CB
prerank,GO_Biological_Process_2021__mRNA processing (GO:0006397),0.5803938117943838,0.8936573644986002,0.6168831168831169,0.8483227273359567,1.0,3/292,0.98%,CDC5L;PRPF40A;SF3A2
prerank,GO_Biological_Process_2021__modification-dependent protein catabolic process (GO:0019941),-0.6045300264690702,-0.8932173729094777,0.5773195876288659,0.855699778387632,1.0,5/197,0.72%,KLHL3;RNF217;RNF13;BIRC6;AMFR
prerank,GO_Biological_Process_2021__pyruvate metabolic process (GO:0006090),-0.6330249824638309,-0.8926025075904087,0.6071428571428571,0.8559655209042155,1.0,1/51,0.08%,ALDOB
prerank,KEGG_2021_Human__Measles,-0.6273347630685239,-0.8910420870037234,0.5909090909090909,0.8572242612167612,1.0,4/122,0.93%,AKT3;OAS1;PIK3CB;CCND2
prerank,GO_Biological_Process_2021__semaphorin-plexin signaling pathway (GO:0071526),0.5806142728823882,0.8908812062692113,0.5704225352112676,0.8508488421421999,1.0,2/35,1.41%,SEMA3G;FLNA
prerank,Reactome_2022__SUMOylation Of Ubiquitinylation Proteins R-HSA-3232142,0.6607359481927652,0.8907000212384483,0.6491228070175439,0.8505879077627332,1.0,1/39,0.48%,NUP210
prerank,MSigDB_Oncogenic_Signatures__MEL18 DN.V1 UP,-0.6263783437407167,-0.8905879052849401,0.6037735849056604,0.8573256940237968,1.0,6/134,1.36%,CDCP1;VNN1;CD83;LTBP4;TEK;ABLIM3
prerank,TRRUST_Transcription_Factors_2019__FOXA2 mouse,-0.5537577040977689,-0.8905557690870876,0.512,0.8569152616911635,1.0,1/30,0.24%,TLE4
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG.BREAST UP.V1 DN,-0.6748897922431436,-0.8905264541740243,0.5714285714285714,0.8565030291901391,1.0,8/112,1.33%,GLYAT;MAP2K6;EPB41L4A;NTF3;PBX1;NYNRIN;PARP3;RTP4
prerank,Reactome_2022__Negative Regulation Of NMDA Receptor-Mediated Neuronal Transmission R-HSA-9617324,0.5127044367139737,0.8905192763422926,0.47058823529411764,0.8503774608676313,1.0,2/21,0.91%,DLG1;GPRIN1
prerank,Elsevier_Pathway_Collection__Ovulation Block,-0.5413531771786496,-0.8904606975998159,0.5078125,0.8561314148261878,1.0,1/30,0.34%,RAP1A
prerank,MSigDB_Oncogenic_Signatures__KRAS.600 UP.V1 DN,-0.5785431768162486,-0.8903836636211818,0.6,0.8557802733953079,1.0,9/222,1.33%,DPYS;MAP2K6;OAS1;KCNE1;NTF3;PDE11A;PRRG4;NYNRIN;RTP4
prerank,GO_Biological_Process_2021__protein localization to cell periphery (GO:1990778),0.6560287716416909,0.8901744825068246,0.5960264900662252,0.8503159818365034,1.0,5/133,1.41%,LIN7A;DLG1;RAB40C;CRB3;FLNA
prerank,Reactome_2022__Transcriptional Activation Of Mitochondrial Biogenesis R-HSA-2151201,0.6528736649405591,0.8898184629660784,0.6106870229007634,0.8503028868778292,1.0,2/52,0.79%,TBL1X;PPARA
prerank,Reactome_2022__SARS-CoV-2-host Interactions R-HSA-9705683,0.6208538783956471,0.8892647362389215,0.5925925925925926,0.8504625708547603,1.0,5/178,1.14%,IRAK2;TRAF3;TJP1;NUP210;CRB3
prerank,GO_Biological_Process_2021__protein phosphorylation (GO:0006468),0.548889968838701,0.8891275269769902,0.7430555555555556,0.850195036581632,1.0,16/484,1.16%,PRKAA2;MELK;COQ8A;CDK6;FAM20B;PTK2;MAP3K9;BRSK1;NEK4;ATR;MAP4K5;ABI2;CAB39;STK26;PKDCC;GRK3
prerank,WikiPathway_2021_Human__16p11.2 proximal deletion syndrome WP4949,0.6849174303719197,0.8891268089067859,0.6716417910447762,0.8497811491708132,1.0,4/70,0.85%,SEZ6L2;ASPHD1;HIRA;QPRT
prerank,KEGG_2021_Human__Transcriptional misregulation in cancer,-0.6264558002333719,-0.8890126782698909,0.580952380952381,0.8569726890188233,1.0,7/170,1.31%,ETV7;MEIS1;PBX1;CCND2;SPI1;TMPRSS2;PML
prerank,GO_Biological_Process_2021__negative regulation of nucleic acid-templated transcription (GO:1903507),0.5481295298530856,0.8889894837967396,0.762589928057554,0.8495123544914154,1.0,11/437,1.34%,GFI1;NKX6-2;VGLL4;BCOR;DEPDC1;ZGPAT;WWP2;ZNF256;TBX3;SCML2;RCOR2
prerank,WikiPathway_2021_Human__Joubert Syndrome WP4656,0.6862291936194321,0.8883112955261324,0.6,0.8497759405485056,1.0,3/75,1.41%,CEP164;NEK8;FLNA
prerank,GO_Biological_Process_2021__regulation of lipid metabolic process (GO:0019216),0.6337870150463333,0.8878823914485705,0.6323529411764706,0.8498113299301284,1.0,3/92,0.79%,ACACA;TBL1X;PPARA
prerank,MSigDB_Oncogenic_Signatures__IL21 UP.V1 UP,-0.5834175324262103,-0.8875428573802092,0.6607142857142857,0.8582641470188564,1.0,5/153,1.25%,FOSB;ABCA6;SLCO1A2;SLC12A8;VDR
prerank,GO_Biological_Process_2021__negative regulation of ERK1 and ERK2 cascade (GO:0070373),0.6319658120940425,0.8873898944846,0.6330935251798561,0.8499726384724786,1.0,1/47,0.74%,DLG1
prerank,GO_Biological_Process_2021__negative regulation of microtubule polymerization or depolymerization (GO:0031111),0.550064448517439,0.8867856572168702,0.5390625,0.8501985871289357,1.0,2/32,1.05%,TBCD;CAMSAP3
prerank,Elsevier_Pathway_Collection__Negative Acute Phase Proteins Synthesis,0.627628466200193,0.8867176483732938,0.6044776119402985,0.8498469737610262,1.0,1/46,0.79%,PPARA
prerank,KEGG_2021_Human__Endometrial cancer,-0.6177997519625631,-0.8866532415899591,0.6065573770491803,0.8588369286448361,1.0,2/58,0.73%,AKT3;PIK3CB
prerank,Elsevier_Pathway_Collection__Acute Myeloid Leukemia,-0.665619001452905,-0.8862835633381447,0.5867768595041323,0.858810174086119,1.0,3/81,1.31%,MEIS1;SPI1;PML
prerank,KEGG_2021_Human__Signaling pathways regulating pluripotency of stem cells,-0.6143896269817024,-0.8860251753990547,0.5982905982905983,0.8586477015419642,1.0,4/128,0.99%,AKT3;PIK3CB;MEIS1;KLF4
prerank,Reactome_2022__Norepinephrine Neurotransmitter Release Cycle R-HSA-181430,0.5159542791344458,0.8859134594396598,0.41379310344827586,0.8503631431563661,1.0,2/17,1.20%,PPFIA4;STX1A
prerank,GO_Biological_Process_2021__cellular response to metal ion (GO:0071248),-0.6515591490173425,-0.8855969731573389,0.6076923076923076,0.8586811273688139,1.0,4/120,1.05%,AOC1;SYT7;RASGRP2;DLG2
prerank,GO_Biological_Process_2021__purine ribonucleotide metabolic process (GO:0009150),-0.6236114724674637,-0.8855608733017556,0.6048387096774194,0.8582565784858913,1.0,4/72,0.68%,GLYAT;TPST1;ACSM2B;SULT1B1
prerank,GO_Biological_Process_2021__regulation of apoptotic signaling pathway (GO:2001233),-0.621492935773441,-0.8850924452816527,0.5945945945945946,0.8583723827079625,1.0,2/37,0.73%,RB1;DEPTOR
prerank,KEGG_2021_Human__Endocytosis,0.5732817655315716,0.8849563166071747,0.7315436241610739,0.8509749395838473,1.0,5/246,1.47%,ASAP2;IQSEC1;GRK3;AGAP3;ZFYVE9
prerank,Reactome_2022__Reproduction R-HSA-1474165,-0.6350232499133405,-0.8849287290503345,0.6046511627906976,0.8581038887826448,1.0,3/87,1.11%,ADAM20;CATSPER3;SYNE1
prerank,Reactome_2022__NOTCH3 Intracellular Domain Regulates Transcription R-HSA-9013508,0.5665997264644576,0.8848041044040564,0.504,0.8507232403767658,1.0,1/23,0.43%,NOTCH3
prerank,GO_Biological_Process_2021__positive regulation of cytokine-mediated signaling pathway (GO:0001961),-0.5773304482883754,-0.8848010064137201,0.5645161290322581,0.8578023839622019,1.0,2/35,1.04%,TRIM44;TICAM2
prerank,GO_Biological_Process_2021__regulation of Rac protein signal transduction (GO:0035020),0.5014864221537529,0.8847712955353032,0.3805309734513274,0.8503406596197811,1.0,1/16,0.66%,STMN3
prerank,GO_Biological_Process_2021__protein O-linked glycosylation (GO:0006493),-0.631547805056594,-0.8845758363921529,0.5677966101694916,0.8576232043161125,1.0,3/96,0.84%,MUC6;CRPPA;GALNT3
prerank,Reactome_2022__Synaptic Adhesion-Like Molecules R-HSA-8849932,0.5127047987613123,0.8845570974848929,0.43846153846153846,0.8501578140568127,1.0,2/20,0.91%,DLG1;GPRIN1
prerank,Reactome_2022__SUMOylation R-HSA-2990846,0.6449140709351525,0.8842932313824208,0.5985401459854015,0.8500341880843928,1.0,6/171,1.02%,SENP1;MRTFA;NUP210;HERC2;PPARA;CBX2
prerank,GO_Biological_Process_2021__inositol lipid-mediated signaling (GO:0048017),-0.6138431511005291,-0.8837396829277601,0.625,0.858138190511346,1.0,1/50,0.73%,PIK3CB
prerank,Reactome_2022__Negative Regulators Of DDX58/IFIH1 Signaling R-HSA-936440,0.5998005205164133,0.8835669807104496,0.626984126984127,0.8503625014749325,1.0,1/34,0.44%,TRAF3
prerank,GO_Biological_Process_2021__neuron projection morphogenesis (GO:0048812),-0.6031641452353137,-0.8834284067991266,0.6415094339622641,0.8580631756540548,1.0,4/133,1.15%,APP;NTF3;SLITRK3;DSCAML1
prerank,GO_Biological_Process_2021__negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512),-0.625450229346823,-0.8832380642246789,0.6018518518518519,0.8578376288308466,1.0,2/66,1.14%,SLC2A10;ADAMTSL2
prerank,MSigDB_Hallmark_2020__Apical Junction,0.6013450080740064,0.8829226955124179,0.6352201257861635,0.8505338184834196,1.0,8/194,1.21%,THY1;PTK2;ITGA2;TJP1;DLG1;AMH;CRB3;CDH15
prerank,MSigDB_Oncogenic_Signatures__PRC2 SUZ12 UP.V1 DN,-0.5954565100274678,-0.8826703817494058,0.6557377049180327,0.8580794090786352,1.0,7/151,1.27%,GGT5;DCBLD2;TRIM58;IPCEF1;GIMAP4;SLC15A3;CYP1B1
prerank,GO_Biological_Process_2021__regulation of dendrite extension (GO:1903859),-0.4395810557481423,-0.8823383937589859,0.3602941176470588,0.8580598562589676,1.0,9/16,27.53%,SYT3;SMURF1;SYT4;SYT1;CPNE9;NEDD4L;ITSN2;CPNE5;SYT2
prerank,GO_Biological_Process_2021__positive regulation of proteasomal protein catabolic process (GO:1901800),-0.6586617429397168,-0.8821415359233686,0.5398230088495575,0.8578390876516818,1.0,2/83,0.28%,RNF180;RNF217
prerank,GO_Biological_Process_2021__RNA metabolic process (GO:0016070),0.6672157874623119,0.882064946765,0.6097560975609756,0.8510402804390922,1.0,2/127,0.88%,DROSHA;PARN
prerank,GO_Biological_Process_2021__negative regulation of cytokine production (GO:0001818),-0.5915178277945156,-0.8819317589060874,0.6306306306306306,0.8576296008914184,1.0,4/176,1.05%,SLC2A10;KLF4;CD274;HERC5
prerank,KEGG_2021_Human__Human T-cell leukemia virus 1 infection,-0.5727048964434274,-0.8817280776139951,0.6346153846153846,0.8574203329162831,1.0,6/211,1.11%,AKT3;RB1;PIK3CB;CCND2;SPI1;CREB5
prerank,GO_Biological_Process_2021__regulation of postsynaptic membrane potential (GO:0060078),-0.5316540781936661,-0.8812480073590927,0.49606299212598426,0.8575490958525966,1.0,1/26,0.01%,GRIN2B
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pancreatic Cancer,0.6556472274582257,0.881216698664737,0.5797101449275363,0.8515462509227071,1.0,4/87,1.51%,PTK2;NOTCH3;ERBB3;FN1
prerank,GO_Biological_Process_2021__regulation of actin filament polymerization (GO:0030833),-0.6270381454041501,-0.8810664121007172,0.5932203389830508,0.8572959527439421,1.0,3/71,0.81%,CARMIL1;PTK2B;HCK
prerank,WikiPathway_2021_Human__3q29 copy number variation syndrome WP4906,0.6305711453481442,0.8810156179776812,0.625,0.8513228599135771,1.0,2/58,1.10%,DLG1;MELTF
prerank,MSigDB_Oncogenic_Signatures__AKT UP.V1 UP,0.6316547158200504,0.8809495358787788,0.6312056737588653,0.8509874643543387,1.0,2/144,1.08%,UBE2C;PACSIN3
prerank,GO_Biological_Process_2021__glycoprotein metabolic process (GO:0009100),-0.6676724587849233,-0.8807664705341025,0.6071428571428571,0.8571952615406213,1.0,2/51,0.56%,FBXO27;GANC
prerank,Elsevier_Pathway_Collection__Medulloblastoma,0.6567063372842878,0.8806879039488505,0.624113475177305,0.8508491453004514,1.0,5/96,0.97%,AXIN2;CDK6;LRP5;NOTCH3;MYCN
prerank,GO_Biological_Process_2021__positive regulation of protein modification process (GO:0031401),0.6372444090818726,0.8806590973051373,0.6524822695035462,0.8504757078986603,1.0,7/205,1.36%,PPP1R16B;AXIN2;CEP295;PTK2;FNIP1;RAB3GAP1;FGF1
prerank,Elsevier_Pathway_Collection__Multiple Myeloma,-0.6225718957856956,-0.8805557835056851,0.5871559633027523,0.8569976784686844,1.0,5/120,0.93%,RB1;PTK2B;DEPTOR;HCK;CCND2
prerank,GO_Biological_Process_2021__negative regulation of G1/S transition of mitotic cell cycle (GO:2000134),0.5797098766316482,0.8802416817821085,0.5909090909090909,0.8504755468814901,1.0,3/36,0.74%,CDK6;RBL1;DLG1
prerank,Reactome_2022__Assembly Of Collagen Fibrils And Other Multimeric Structures R-HSA-2022090,0.6991496377677034,0.8801792501400713,0.6567164179104478,0.8501595715979369,1.0,2/55,1.34%,COL4A5;COL9A3
prerank,GO_Biological_Process_2021__muscle cell differentiation (GO:0042692),-0.523410389157192,-0.8795976356441998,0.5042735042735043,0.8576243446840033,1.0,2/31,1.23%,SYNE1;NRAP
prerank,GO_Biological_Process_2021__branched-chain amino acid metabolic process (GO:0009081),-0.5022259016051923,-0.8792575331177003,0.452991452991453,0.8571038900214509,1.0,1/20,0.38%,HIBADH
prerank,GO_Biological_Process_2021__branched-chain amino acid catabolic process (GO:0009083),-0.5022259016051923,-0.8792575331177003,0.452991452991453,0.8571038900214509,1.0,1/20,0.38%,HIBADH
prerank,Elsevier_Pathway_Collection__MEN1 Mutation in Hyperparathyroidism,0.5303195746292455,0.8789447618890598,0.5079365079365079,0.8511138896988065,1.0,1/21,0.19%,CDK6
prerank,Reactome_2022__Neutrophil Degranulation R-HSA-6798695,-0.5228432103369148,-0.8789397668955485,0.81,0.8570343589268672,1.0,10/451,1.32%,GLYAT;A1BG;VNN1;DERA;RAP1A;RAP1B;AOC1;BIN2;ADGRE5;VPS35L
prerank,GO_Biological_Process_2021__nucleotide-binding oligomerization domain containing signaling pathway (GO:0070423),0.5424120491474338,0.8789180991925921,0.5076923076923077,0.8507373775953697,1.0,1/27,0.10%,IRAK2
prerank,GO_Biological_Process_2021__Golgi to plasma membrane transport (GO:0006893),-0.5901065155697948,-0.878844842318787,0.6147540983606558,0.8566856596126021,1.0,2/47,1.32%,EXOC2;VPS35L
prerank,GO_Biological_Process_2021__regulation of catecholamine secretion (GO:0050433),-0.5448313822339942,-0.8784892105460619,0.5193798449612403,0.8566120228169292,1.0,1/25,0.88%,SYT7
prerank,Reactome_2022__Oncogenic MAPK Signaling R-HSA-6802957,0.6359173382959845,0.8784647555720417,0.5954198473282443,0.8507939280272556,1.0,4/76,1.51%,TRIM24;KSR1;PAPSS1;FN1
prerank,GO_Biological_Process_2021__cell cycle G1/S phase transition (GO:0044843),-0.6190581003002875,-0.8781553774928198,0.6218487394957983,0.856531873104745,1.0,2/61,0.80%,RB1;GPR132
prerank,Reactome_2022__Metabolism Of Vitamins And Cofactors R-HSA-196854,-0.5941451331462368,-0.8779609532909461,0.6363636363636364,0.8563332592437133,1.0,6/176,1.19%,VNN1;PARP8;PDSS2;TTPA;SDC3;MTHFD2L
prerank,GO_Biological_Process_2021__negative regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043154),-0.6212893135619243,-0.8778718094957045,0.6185567010309279,0.8559922295600146,1.0,2/54,0.99%,PAK2;KLF4
prerank,WikiPathway_2021_Human__Development of ureteric collection system WP5053,0.5856556833209136,0.8778231901543322,0.5955882352941176,0.8510794968470186,1.0,1/44,0.97%,MYCN
prerank,WikiPathway_2021_Human__VEGFA-VEGFR2 Signaling Pathway WP3888,0.5437126770410525,0.8777057690864347,0.7643312101910829,0.8507786461668004,1.0,12/424,1.51%,PRKAA2;ACACA;PTK2;SHB;EIF2A;TNFRSF25;PBK;SLC7A1;TEAD4;ITGB5;BCAR1;FN1
prerank,GO_Biological_Process_2021__endothelial cell development (GO:0001885),-0.5167201354255545,-0.8776975419547607,0.48717948717948717,0.8557590126578789,1.0,2/25,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__negative regulation of DNA-binding transcription factor activity (GO:0043433),0.6214698727519773,0.8771843528514072,0.6338028169014085,0.8509522670730701,1.0,5/135,1.41%,IRAK2;GFI1;TRAF3;WWP2;FLNA
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell apoptotic process (GO:1904036),0.6135137712862787,0.8766808454249749,0.6031746031746031,0.8510836320895957,1.0,1/34,0.79%,PPARA
prerank,MSigDB_Oncogenic_Signatures__ATF2 S UP.V1 DN,-0.5979838655554319,-0.8760970929355072,0.6213592233009708,0.8570910601714271,1.0,5/165,1.27%,KLHL3;AADAC;SLC12A8;SDC3;CYP1B1
prerank,MSigDB_Hallmark_2020__KRAS Signaling Up,-0.6113003161341546,-0.8760070703204913,0.6448598130841121,0.8567282601366929,1.0,8/195,1.16%,EVI5;DCBLD2;GALNT3;ADGRA2;CCND2;KLF4;IL10RA;MAP4K1
prerank,MSigDB_Oncogenic_Signatures__STK33 SKM DN,-0.5585212949974502,-0.8758038898347854,0.6699029126213593,0.8565388171952588,1.0,7/226,1.36%,KCNN2;ARHGEF26;ADAMTS5;GAS2;PIK3CB;IL12RB2;GRB10
prerank,GO_Biological_Process_2021__protein localization to plasma membrane (GO:0072659),0.6537823482377161,0.8757924098721782,0.6418918918918919,0.8515349544675602,1.0,5/129,1.41%,DLG1;RAB40C;ASB3;CRB3;FLNA
prerank,MSigDB_Hallmark_2020__PI3K/AKT/mTOR  Signaling,0.6777146035397961,0.8754902771756261,0.6222222222222222,0.851459329011014,1.0,3/101,0.81%,PRKAA2;ACACA;CAB39
prerank,MSigDB_Oncogenic_Signatures__BCAT.100 UP.V1 UP,0.6201687351530102,0.8753879398402838,0.616,0.8511626742788706,1.0,3/45,0.91%,ETV5;TBX3;DBNDD1
prerank,KEGG_2021_Human__Morphine addiction,0.6427304397210363,0.8750915848906953,0.608,0.8510763422979539,1.0,2/79,1.16%,GNB5;GRK3
prerank,Elsevier_Pathway_Collection__Glioma Invasion Signaling,-0.5897302371267246,-0.8745950817876064,0.5794392523364486,0.8575204213880374,1.0,2/75,1.21%,MAP2K6;TEK
prerank,GO_Biological_Process_2021__response to cytokine (GO:0034097),-0.5957397158790736,-0.8745662874797535,0.6551724137931034,0.8571032777384922,1.0,5/143,1.34%,APP;GGT5;CD274;PML;PTPN18
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Sustaining of Proliferative Signaling,0.6468348708166914,0.8740886342591375,0.6090225563909775,0.8518462679733206,1.0,5/112,0.96%,CDK6;NOTCH3;TRAF3;ATR;ERBB3
prerank,GO_Biological_Process_2021__intracellular protein transport (GO:0006886),0.5679499355069575,0.8740153791901981,0.7533333333333333,0.851529783880218,1.0,7/316,1.48%,HERC2;KIF13A;CAMSAP3;STX1A;HOMER3;ACD;LAMP2
prerank,MSigDB_Oncogenic_Signatures__KRAS.BREAST UP.V1 DN,-0.6110821159142691,-0.8740057663121186,0.6190476190476191,0.8573074587550605,1.0,4/115,0.90%,DPYS;ADAMTS5;NTF3;PBX1
prerank,GO_Biological_Process_2021__dopamine metabolic process (GO:0042417),0.49786522065993377,0.8739906920208155,0.4083333333333333,0.8511370052878274,1.0,1/16,1.31%,DRD4
prerank,KEGG_2021_Human__Cell cycle,0.6464167941994288,0.8735178463188972,0.6242038216560509,0.8512331416751335,1.0,5/123,1.16%,CDC45;CDK6;RBL1;ATR;PKMYT1
prerank,WikiPathway_2021_Human__Cell cycle WP179,0.6464186834842539,0.8734142236904847,0.6447368421052632,0.8509538482722482,1.0,5/119,1.16%,CDC45;CDK6;RBL1;ATR;PKMYT1
prerank,Reactome_2022__p130Cas Linkage To MAPK Signaling For Integrins R-HSA-372708,-0.4917659501571275,-0.8733987781415018,0.4122137404580153,0.8575573162662106,1.0,2/15,0.42%,RAP1A;RAP1B
prerank,WikiPathway_2021_Human__EGF/EGFR signaling pathway WP437,-0.6174916647921945,-0.872918216640106,0.580952380952381,0.8577173723098792,1.0,6/161,1.36%,FOSB;RAP1A;PTK2B;VAV1;MAP4K1;GRB10
prerank,Reactome_2022__Heparan Sulfate/Heparin (HS-GAG) Metabolism R-HSA-1638091,0.6182497249226974,0.8725201310345119,0.6153846153846154,0.8514797722354431,1.0,1/51,0.55%,SLC35D2
prerank,GO_Biological_Process_2021__regulation of wound healing (GO:0061041),0.6607603295294316,0.8725091177607867,0.6507936507936508,0.8510859508826484,1.0,1/46,0.26%,PTK2
prerank,GO_Biological_Process_2021__protein polyubiquitination (GO:0000209),-0.5471624869949272,-0.8724052378970198,0.723404255319149,0.8578990917817654,1.0,9/307,1.28%,KLHL3;RNF217;FBXO27;AMFR;WWP1;UBE3D;PELI2;HERC5;HERC6
prerank,MSigDB_Oncogenic_Signatures__ATF2 UP.V1 DN,-0.6001856540464877,-0.8722384720549421,0.6796116504854369,0.8576573672841734,1.0,6/166,1.27%,AADAC;BHMT;PELI2;SLC12A8;SDC3;CYP1B1
prerank,Reactome_2022__Signal Amplification R-HSA-392518,0.5056750720133658,0.8718816995780988,0.5,0.8513474933684522,1.0,1/30,1.11%,GNB5
prerank,GO_Biological_Process_2021__negative regulation of cell adhesion (GO:0007162),0.6107510215083618,0.8718699943215774,0.6071428571428571,0.8509541128022275,1.0,3/72,0.96%,PTK2;TBCD;ERBB3
prerank,GO_Biological_Process_2021__negative regulation of NF-kappaB transcription factor activity (GO:0032088),0.6436980314529988,0.871476379627178,0.624,0.8509609950146086,1.0,3/76,0.44%,IRAK2;GFI1;TRAF3
prerank,Reactome_2022__Antigen Processing: Ubiquitination And Proteasome Degradation R-HSA-983168,-0.5549376563795956,-0.8714122378293107,0.6976744186046512,0.858172563692383,1.0,8/296,1.28%,KLHL3;HERC3;RNF217;FBXO27;WWP1;UBE3D;HERC5;HERC6
prerank,GO_Biological_Process_2021__cell morphogenesis involved in neuron differentiation (GO:0048667),-0.6070840122304177,-0.8712341142054453,0.6153846153846154,0.857917870454709,1.0,4/72,1.15%,APP;RB1;SLITRK3;DSCAML1
prerank,KEGG_2021_Human__Basal cell carcinoma,0.6729904766203338,0.8711794900407447,0.6691176470588235,0.8508879317274471,1.0,1/61,0.12%,AXIN2
prerank,GO_Biological_Process_2021__positive regulation of protein metabolic process (GO:0051247),-0.6215420249179929,-0.8710929620246695,0.6721311475409836,0.8576416558733182,1.0,3/110,0.99%,APP;WWP1;KLF4
prerank,GO_Biological_Process_2021__aminoglycan biosynthetic process (GO:0006023),0.6182512183256754,0.8708828511478824,0.6115702479338843,0.8508294657504448,1.0,1/47,0.55%,SLC35D2
prerank,Reactome_2022__NR1H3 And NR1H2 Regulate Gene Expression Linked To Cholesterol Transport And Efflux R-HSA-9029569,0.5996547995262657,0.8705789421201444,0.6190476190476191,0.8507474599709604,1.0,2/36,1.30%,TBL1X;APOE
prerank,GO_Biological_Process_2021__skeletal muscle contraction (GO:0003009),-0.5023968702950347,-0.8704849771633529,0.4609375,0.8578011742557059,1.0,1/17,1.06%,RCSD1
prerank,GO_Biological_Process_2021__protein transport (GO:0015031),-0.5389993512460239,-0.8701115745827249,0.7526881720430108,0.8577994954040584,1.0,7/348,1.27%,TANGO6;EVI5;RABL3;SNX13;TICAM2;IL10RA;OLFM2
prerank,GO_Biological_Process_2021__negative regulation of ossification (GO:0030279),0.5228422383710735,0.8699745642341007,0.4765625,0.851055583027455,1.0,1/22,0.31%,BCOR
prerank,GO_Biological_Process_2021__ERBB signaling pathway (GO:0038127),0.6595559096982473,0.8699429187075581,0.6564885496183206,0.8506816028474278,1.0,4/65,1.49%,PTK2;ERBB3;SLC30A10;BCAR1
prerank,Reactome_2022__Integration Of Energy Metabolism R-HSA-163685,0.6718072957752196,0.8698888188618283,0.675,0.850329729323488,1.0,5/99,1.20%,PRKAA2;ACACA;GNB5;PKLR;STX1A
prerank,GO_Biological_Process_2021__positive regulation of gene expression (GO:0010628),0.5508784414558892,0.8698709526067783,0.7083333333333334,0.8499455830934945,1.0,9/444,1.51%,HOXD3;TAF1B;YTHDF3;PHF2;AMH;MYCN;CTSH;FGF1;FN1
prerank,GO_Biological_Process_2021__response to molecule of bacterial origin (GO:0002237),-0.6349462162483923,-0.8695834693998681,0.6460176991150443,0.8579674686235121,1.0,1/70,0.38%,GGT5
prerank,Elsevier_Pathway_Collection__Ras-GRF Regulation Signaling,-0.5768648625893175,-0.8694054824308726,0.5877192982456141,0.8577613606892286,1.0,3/44,1.10%,RAP1A;RASGRP2;VAV1
prerank,GO_Biological_Process_2021__postreplication repair (GO:0006301),0.607966514522123,0.8693748981855813,0.6028368794326241,0.8500525101303785,1.0,1/45,0.17%,MSH2
prerank,KEGG_2021_Human__Melanoma,-0.6303696986374252,-0.869135525257466,0.6481481481481481,0.8576597574434597,1.0,3/66,0.73%,AKT3;RB1;PIK3CB
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Response in Celiac Disease,-0.6212926680196933,-0.8689875677844866,0.5737704918032787,0.8573410930307311,1.0,2/62,1.13%,VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Osteoporosis,0.5004204556434299,0.8689431065803841,0.4326241134751773,0.8501213280758577,1.0,1/19,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__NTRK -> FOXO/MYCN Signaling,-0.4990429911223089,-0.8689132496006855,0.42063492063492064,0.8569880269716552,1.0,1/16,0.83%,NTF3
prerank,Reactome_2022__Signaling By BRAF And RAF1 Fusions R-HSA-6802952,0.6359263472348183,0.8688267887310811,0.608,0.8498409434678859,1.0,4/61,1.51%,TRIM24;KSR1;PAPSS1;FN1
prerank,KEGG_2021_Human__Protein digestion and absorption,-0.6065200348610822,-0.8687749823214325,0.6697247706422018,0.8567329472684747,1.0,4/88,1.22%,SLC7A8;SLC36A4;COL26A1;COL4A4
prerank,GO_Biological_Process_2021__sterol metabolic process (GO:0016125),-0.6178061027836571,-0.8686152040127959,0.64,0.8564889706290529,1.0,3/66,1.27%,CYP39A1;CYP4V2;CYP1B1
prerank,GO_Biological_Process_2021__fatty acid catabolic process (GO:0009062),-0.6111364904138624,-0.8680814204335545,0.6181818181818182,0.8566201703808245,1.0,2/69,1.08%,ABCD3;HAO1
prerank,Reactome_2022__Hedgehog On State R-HSA-5632684,0.646505359155623,0.8677185808745805,0.6095890410958904,0.8506167785551265,1.0,1/83,0.30%,SMOX
prerank,KEGG_2021_Human__Shigellosis,0.575262150725731,0.8674734512434168,0.7039473684210527,0.8505099236322179,1.0,4/232,1.49%,PTK2;SEPTIN6;SEPTIN9;BCAR1
prerank,KEGG_2021_Human__Cell adhesion molecules,-0.6105400406684214,-0.8671875073994096,0.6396396396396397,0.8572386071576282,1.0,5/141,1.16%,NEO1;GLG1;CD2;CD274;SDC3
prerank,MSigDB_Hallmark_2020__Complement,-0.5766723234921005,-0.8669610114701504,0.6274509803921569,0.8570640258841951,1.0,3/198,1.20%,CTSO;C1R;ITIH1
prerank,Reactome_2022__Sensory Perception R-HSA-9709957,-0.5796104140252839,-0.8665104615954993,0.7075471698113207,0.8571687636115793,1.0,5/194,1.16%,KCNN2;CYP4V2;LDB2;HSD17B6;SDC3
prerank,Reactome_2022__Disorders Of Transmembrane Transporters R-HSA-5619115,-0.5880011306608449,-0.8664042298242904,0.7422680412371134,0.8568408396851223,1.0,3/168,0.98%,SLC35A3;SLC2A10;SLC9A9
prerank,GO_Biological_Process_2021__negative regulation of gene expression (GO:0010629),0.5577481652329903,0.8663359206887821,0.7124183006535948,0.8512973466870272,1.0,8/314,1.30%,IGF2BP1;PRKAA2;RBL1;DIS3L2;WWP2;IGF2BP3;MYCN;APOE
prerank,GO_Biological_Process_2021__positive regulation of muscle cell differentiation (GO:0051149),0.5273456305480604,0.866315750543836,0.49612403100775193,0.8509194360662719,1.0,1/24,1.21%,CDH15
prerank,KEGG_2021_Human__Lysine degradation,0.6680225273203284,0.8663021182597112,0.6484375,0.8505256425582723,1.0,2/61,0.77%,ASH1L;PLOD2
prerank,GO_Biological_Process_2021__neutrophil mediated immunity (GO:0002446),-0.5054929508103883,-0.8662819828331713,0.912621359223301,0.8565348675644017,1.0,10/472,1.32%,A1BG;VNN1;DERA;RAP1A;RAP1B;AOC1;BIN2;TICAM2;ADGRE5;VPS35L
prerank,GO_Biological_Process_2021__membrane organization (GO:0061024),0.5878767432072918,0.8662716616395948,0.6944444444444444,0.8501448502656801,1.0,3/232,1.38%,BAIAP2L2;MYOF;LPCAT2
prerank,Reactome_2022__Antigen processing-Cross Presentation R-HSA-1236975,-0.6165516958999877,-0.8661566703916754,0.6050420168067226,0.8562486530517593,1.0,1/102,0.71%,SEC61A2
prerank,GO_Biological_Process_2021__negative regulation of response to external stimulus (GO:0032102),-0.58569045054906,-0.8658298741166444,0.6086956521739131,0.8561916335826789,1.0,3/105,1.21%,RB1;KLF4;TEK
prerank,Elsevier_Pathway_Collection__FOXL2 Mutation in Ovarian Dysgenesis,0.5245315565593996,0.8655552522011835,0.4881889763779528,0.8505793685684625,1.0,1/17,0.95%,AMH
prerank,GO_Biological_Process_2021__response to interleukin-1 (GO:0070555),-0.6422461463504929,-0.8655515067404744,0.625,0.8560548130145365,1.0,2/81,0.35%,CCL23;APP
prerank,KEGG_2021_Human__Ubiquitin mediated proteolysis,0.6318624626296767,0.8654650892823752,0.6756756756756757,0.8502673932530548,1.0,7/137,1.21%,HERC2;WWP2;UBE2H;HERC4;FANCL;UBE2C;MID1
prerank,GO_Biological_Process_2021__regulation of cell differentiation (GO:0045595),0.593789930379353,0.8650992690836488,0.625,0.8502529240558616,1.0,4/144,1.29%,CDK6;PTK2;TCFL5;PPP1R13L
prerank,GO_Biological_Process_2021__positive regulation of NF-kappaB transcription factor activity (GO:0051092),0.6340353115545757,0.8649058999310121,0.6433566433566433,0.8500350213357671,1.0,2/150,1.20%,IRAK2;EDA2R
prerank,GO_Biological_Process_2021__negative regulation of axon extension (GO:0030517),-0.567132752689967,-0.8647548430997493,0.5929203539823009,0.8566041401389359,1.0,1/31,0.96%,SEMA4D
prerank,MSigDB_Oncogenic_Signatures__CTIP DN.V1 DN,0.6582552051332785,0.8644808851958835,0.6319444444444444,0.8501106542643084,1.0,2/102,0.10%,KCNC1;FOXRED2
prerank,Elsevier_Pathway_Collection__Prolactinoma Overiew,0.6572894571163214,0.8642863941306921,0.6453900709219859,0.849903817783065,1.0,2/54,0.96%,CDK6;ERBB3
prerank,GO_Biological_Process_2021__synaptic vesicle recycling (GO:0036465),-0.5448280084007024,-0.864132990108797,0.5573770491803278,0.8568876997624612,1.0,1/33,0.88%,SYT7
prerank,Reactome_2022__Molecules Associated With Elastic Fibres R-HSA-2129379,-0.5057347360036684,-0.8640758306317439,0.4782608695652174,0.8565222972963114,1.0,1/28,1.15%,LTBP4
prerank,GO_Biological_Process_2021__positive regulation of ATPase activity (GO:0032781),-0.5198311040476123,-0.8639976083720164,0.5446428571428571,0.8561701907092433,1.0,1/41,0.08%,ALDOB
prerank,GO_Biological_Process_2021__positive regulation of ion transport (GO:0043270),0.5911130058193563,0.8639658192503443,0.6377952755905512,0.8498104424125602,1.0,2/45,1.31%,DLG1;DRD4
prerank,Reactome_2022__Signaling By FGFR R-HSA-190236,-0.6217285128428258,-0.8634462911656098,0.6194690265486725,0.8564341624539814,1.0,2/79,0.84%,FLRT2;GALNT3
prerank,WikiPathway_2021_Human__Tryptophan catabolism leading to NAD+ production WP4210,-0.5021929246339637,-0.8633568319260789,0.4418604651162791,0.8561018248396457,1.0,1/16,0.61%,AADAT
prerank,GO_Biological_Process_2021__neutrophil degranulation (GO:0043312),-0.5054965506020235,-0.8630641245111311,0.9038461538461539,0.8559461807332951,1.0,10/465,1.32%,A1BG;VNN1;DERA;RAP1A;RAP1B;AOC1;BIN2;TICAM2;ADGRE5;VPS35L
prerank,Reactome_2022__Thrombin Signaling Thru Proteinase Activated Receptors (PARs) R-HSA-456926,0.5056747077585103,0.8630637491181644,0.5130434782608696,0.8503928305736218,1.0,1/30,1.11%,GNB5
prerank,WikiPathway_2021_Human__Senescence and Autophagy in Cancer WP615,-0.6482789333224378,-0.8629717598958487,0.65,0.8556316254999184,1.0,2/101,0.70%,RB1;UVRAG
prerank,"GO_Biological_Process_2021__nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (GO:0035872)",0.5424123164277128,0.8629594193170005,0.5116279069767442,0.8500909578481285,1.0,1/24,0.10%,IRAK2
prerank,GO_Biological_Process_2021__response to organophosphorus (GO:0046683),0.4549841580636984,0.8627465412197362,0.3900709219858156,0.8499078610552888,1.0,5/15,17.16%,TRIM16;ABCC9;DUOX2;TRPC3;STAT1
prerank,GO_Biological_Process_2021__activation of GTPase activity (GO:0090630),-0.6401980422326112,-0.8627055925948056,0.6721311475409836,0.8555064571974857,1.0,4/94,1.06%,ARHGEF26;EVI5;NTF3;GARNL3
prerank,MSigDB_Oncogenic_Signatures__CAHOY ASTROGLIAL,0.626678290756902,0.8624750206196596,0.6491228070175439,0.8497662099679348,1.0,2/87,1.28%,MYOF;CLCN4
prerank,Reactome_2022__Vasopressin Regulates Renal Water Homeostasis Via Aquaporins R-HSA-432040,0.5355809683664271,0.8621147864509643,0.5603448275862069,0.8497484519442505,1.0,1/38,1.11%,GNB5
prerank,Reactome_2022__Activation Of ATR In Response To Replication Stress R-HSA-176187,0.5734866580649637,0.8620002821028837,0.568,0.8494868947887104,1.0,1/35,0.09%,CDC45
prerank,GO_Biological_Process_2021__regulation of DNA replication (GO:0006275),0.6213550186960807,0.8618395565851109,0.6136363636363636,0.8492614229700239,1.0,2/52,0.86%,ATR;RBBP6
prerank,WikiPathway_2021_Human__Thyroid hormones production and their peripheral downstream signaling effects WP4746,-0.607827195534528,-0.8609995301480737,0.6153846153846154,0.857095043436801,1.0,3/88,1.02%,AKT3;IYD;SLC16A2
prerank,TRRUST_Transcription_Factors_2019__HDAC2 human,0.5324044048543543,0.8609693389333497,0.5111111111111111,0.8498367731216204,1.0,1/26,0.97%,MYCN
prerank,GO_Biological_Process_2021__sphingolipid biosynthetic process (GO:0030148),-0.6696769992900173,-0.8609380807629621,0.6694214876033058,0.8567481893952242,1.0,1/71,0.51%,SGPP1
prerank,KEGG_2021_Human__VEGF signaling pathway,-0.6402734769371474,-0.8608168894672169,0.6370967741935484,0.8564424464066046,1.0,2/56,0.73%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__interleukin-1-mediated signaling pathway (GO:0070498),0.6448568984342449,0.8608100900914772,0.6615384615384615,0.8495862857958127,1.0,1/91,0.10%,IRAK2
prerank,KEGG_2021_Human__Purine metabolism,-0.6073427061045111,-0.860626911876591,0.6330275229357798,0.8562249229889259,1.0,6/122,1.18%,PDE5A;NT5C1B;ENTPD8;PDE11A;ENTPD3;GMPR
prerank,GO_Biological_Process_2021__regulation of cellular amide metabolic process (GO:0034248),-0.5195208532549951,-0.8602166350105961,0.5289256198347108,0.8562969319078582,1.0,1/31,0.35%,APP
prerank,Reactome_2022__Transcription Of HIV Genome R-HSA-167172,0.6631324349821007,0.8601031418498485,0.6285714285714286,0.8499981063973201,1.0,2/66,0.81%,TAF4;TCEA1
prerank,Reactome_2022__tRNA Processing R-HSA-72306,-0.5952180048356991,-0.8599202254077636,0.5798319327731093,0.856233924024528,1.0,2/104,1.16%,TYW1;TRMT9B
prerank,GO_Biological_Process_2021__phosphatidic acid biosynthetic process (GO:0006654),0.5824371378403058,0.8596175655251066,0.6153846153846154,0.8500661392132499,1.0,1/44,0.32%,GPAT4
prerank,MSigDB_Oncogenic_Signatures__IL15 UP.V1 DN,-0.5946515850875147,-0.8594882926236678,0.7027027027027027,0.8563379687405684,1.0,5/141,1.18%,MAP2K6;ZNF571;DEPTOR;TNFAIP2;CLEC2B
prerank,Reactome_2022__Axon Guidance R-HSA-422475,0.5232380302540912,0.8592464863138726,0.7948717948717948,0.8500286337947897,1.0,11/498,1.34%,PTK2;ITGA2;CNTNAP1;ARHGAP39;UPF2;DLG1;ARHGEF7;GPRIN1;COL4A5;DPYSL3;COL9A3
prerank,GO_Biological_Process_2021__positive regulation of potassium ion transport (GO:0043268),-0.614445970540614,-0.8589779537515184,0.6165413533834586,0.8564633061963864,1.0,2/38,0.82%,KCNN2;KCNE1
prerank,GO_Biological_Process_2021__phosphate ion transport (GO:0006817),-0.4391165546257804,-0.8584826208294465,0.3783783783783784,0.8566377074276477,1.0,6/17,12.00%,SLC20A2;SLC37A4;SLC25A10;SLC37A3;SLC34A3;SLC34A2
prerank,GO_Biological_Process_2021__blood vessel morphogenesis (GO:0048514),0.6532865189595137,0.8582712350083602,0.6642857142857143,0.8507666590558421,1.0,1/55,0.40%,LRP5
prerank,Reactome_2022__CDC42 GTPase Cycle R-HSA-9013148,0.6046403132017658,0.8582236385568668,0.6666666666666666,0.8504234507488192,1.0,7/146,1.47%,DEPDC1B;ARHGAP39;ARHGEF7;IQGAP3;FMNL2;DOCK11;CDC42EP1
prerank,GO_Biological_Process_2021__myelination (GO:0042552),-0.61659703166893,-0.8579655239343441,0.6377952755905512,0.8568140700440197,1.0,2/46,0.94%,SBF2;MARVELD1
prerank,GO_Biological_Process_2021__regulation of telomere maintenance (GO:0032204),0.5801652154913285,0.8577009268037179,0.5851851851851851,0.8506357546477321,1.0,2/26,1.13%,HDAC8;PIF1
prerank,GO_Biological_Process_2021__regulation of immune response (GO:0050776),-0.5497769139159416,-0.8576674885737386,0.7155172413793104,0.8566719074678519,1.0,3/168,1.18%,FGL1;HERC5;CLEC2B
prerank,GO_Biological_Process_2021__protein dephosphorylation (GO:0006470),0.6381446167705255,0.8576055384080142,0.6493506493506493,0.8503428919927192,1.0,2/134,0.93%,PPM1H;PTPRH
prerank,GO_Biological_Process_2021__actin cytoskeleton reorganization (GO:0031532),0.6380982173613927,0.8569045279526062,0.6304347826086957,0.8506638275269004,1.0,2/62,1.49%,FLNA;BCAR1
prerank,GO_Biological_Process_2021__chemical synaptic transmission (GO:0007268),0.5568494592322888,0.8568291835321578,0.7692307692307693,0.8503355736193208,1.0,6/238,1.31%,BRSK1;LIN7A;DLG1;STX1A;APOE;DRD4
prerank,GO_Biological_Process_2021__regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043281),0.6542448771640941,0.8566722614037093,0.6912751677852349,0.8501002826899537,1.0,2/86,1.55%,FNIP1;UACA
prerank,Reactome_2022__Neurotransmitter Release Cycle R-HSA-112310,0.6430970680714144,0.8566488216486741,0.64,0.8497209527102916,1.0,3/45,1.20%,LIN7A;PPFIA4;STX1A
prerank,Elsevier_Pathway_Collection__Mantle Cell Lymphoma,0.6337419639581676,0.8564185378219352,0.6538461538461539,0.849552036366612,1.0,4/103,0.50%,CDK6;LRP5;TRAF3;ATR
prerank,KEGG_2021_Human__Apoptosis,-0.6124610600816738,-0.8563838850566904,0.6764705882352942,0.8576574212493429,1.0,5/137,1.31%,CTSO;AKT3;BIRC6;PIK3CB;PARP3
prerank,Reactome_2022__Amyloid Fiber Formation R-HSA-977225,-0.6372920179645831,-0.8563519568189732,0.6538461538461539,0.857275923663614,1.0,1/66,0.35%,APP
prerank,GO_Biological_Process_2021__neutrophil activation involved in immune response (GO:0002283),-0.5054944839718549,-0.8562622763839843,0.93,0.8569417439973569,1.0,10/469,1.32%,A1BG;VNN1;DERA;RAP1A;RAP1B;AOC1;BIN2;TICAM2;ADGRE5;VPS35L
prerank,MSigDB_Hallmark_2020__Androgen Response,-0.6036053364584711,-0.8557407883248455,0.6574074074074074,0.8571516249040035,1.0,3/100,1.26%,HERC3;PTK2B;TMPRSS2
prerank,Elsevier_Pathway_Collection__SCF/SKP2 Complex,0.530319012852103,0.8554955598112808,0.5407407407407407,0.8501323705274758,1.0,1/25,0.19%,CDK6
prerank,GO_Biological_Process_2021__negative regulation of cell population proliferation (GO:0008285),0.5464747095047006,0.8546890725267916,0.7972027972027972,0.8505414264839264,1.0,9/353,1.30%,AXIN2;ING5;CDK6;VGLL4;DIS3L2;TBX3;CGREF1;P3H3;CYP27B1
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Amino Acids,-0.531238093407507,-0.8546160085916699,0.5520833333333334,0.8579516299893087,1.0,1/45,0.20%,SLC7A8
prerank,GO_Biological_Process_2021__MAPK cascade (GO:0000165),0.5522418964263455,0.8544990231939236,0.7410071942446043,0.8503439208062614,1.0,8/286,1.36%,KSR1;PTK2;DLG1;ERBB3;ZDHHC9;CTSH;KLB;FGF1
prerank,MSigDB_Oncogenic_Signatures__CRX DN.V1 DN,0.628440095279506,0.8538227413392084,0.656934306569343,0.8506938597447903,1.0,4/121,1.38%,KSR1;PLOD2;TNNC2;PYCR1
prerank,GO_Biological_Process_2021__response to hydrogen peroxide (GO:0042542),0.5940805599382111,0.8536465576690874,0.6111111111111112,0.8504431880092767,1.0,1/49,1.00%,STK26
prerank,MSigDB_Hallmark_2020__heme Metabolism,-0.5489647002279959,-0.8533002005694598,0.6814159292035398,0.8590618243973899,1.0,5/193,1.28%,NR3C1;TRIM58;AGPAT4;AQP3;TENT5C
prerank,WikiPathway_2021_Human__ErbB signaling pathway WP673,-0.5952848512350774,-0.8532208477982791,0.6605504587155964,0.85873806382319,1.0,3/89,0.73%,AKT3;PAK2;PIK3CB
prerank,WikiPathway_2021_Human__IL-1 signaling pathway WP195,-0.571127086554551,-0.8531342619914106,0.6120689655172413,0.8583976052874055,1.0,2/53,1.03%,MAP2K6;PELI2
prerank,GO_Biological_Process_2021__regulation of establishment of protein localization (GO:0070201),0.5045010653277064,0.8528406698848571,0.425531914893617,0.8509223394834924,1.0,1/15,0.23%,CEP295
prerank,MSigDB_Oncogenic_Signatures__VEGF A UP.V1 UP,0.600963165493972,0.8528322810421574,0.696551724137931,0.8505280749783177,1.0,5/173,1.21%,THY1;CLIP2;TUB;PPFIA4;TNNC2
prerank,GO_Biological_Process_2021__phosphatidic acid metabolic process (GO:0046473),0.5824369102348872,0.8528144441631085,0.6220472440944882,0.8501501404087155,1.0,1/45,0.32%,GPAT4
prerank,Elsevier_Pathway_Collection__Melanoma,0.6329246246189227,0.8527135682669281,0.6458333333333334,0.8498363749197302,1.0,4/140,1.36%,CDK6;PTK2;TBX3;FGF1
prerank,Reactome_2022__Cell-Cell Communication R-HSA-1500931,0.6358140818049404,0.8526154605005579,0.640625,0.8495459363167962,1.0,5/113,1.41%,PTK2;CRB3;CDH15;FBLIM1;FLNA
prerank,Reactome_2022__RHOA GTPase Cycle R-HSA-8980692,0.6244300420697976,0.8520167274607315,0.6766917293233082,0.8498490582203418,1.0,8/146,1.39%,DEPDC1B;ARHGAP39;ARHGEF7;ANLN;PLEKHG5;IQGAP3;ARHGEF18;CAVIN1
prerank,WikiPathway_2021_Human__mRNA Processing WP411,0.6466850758865192,0.8519321669439845,0.6312056737588653,0.8495199405137911,1.0,2/126,0.98%,PRPF40A;SF3A2
prerank,WikiPathway_2021_Human__Insulin Signaling WP481,0.5921715432006796,0.8516125550625063,0.6938775510204082,0.8494512258886525,1.0,4/158,0.86%,PRKAA2;MAP3K9;MAP4K5;RHOQ
prerank,GO_Biological_Process_2021__cellular component disassembly (GO:0022411),-0.6173933515065961,-0.8512370015884652,0.6140350877192983,0.8601716174468341,1.0,1/57,0.46%,ADAMTS5
prerank,KEGG_2021_Human__Huntington disease,0.5606227096345165,0.8510483105882262,0.7432432432432432,0.8497203659641598,1.0,4/274,1.31%,NDUFA10;TAF4;STX1A;TUBA1A
prerank,Elsevier_Pathway_Collection__Dendritic Cell Dysfunction in Crohn's disease,0.5985214898719016,0.8508342974335501,0.6231884057971014,0.8495437914577486,1.0,1/42,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__Necrosis,-0.5556107934644876,-0.8506234566602815,0.5655737704918032,0.8604578978681596,1.0,1/36,1.04%,TICAM2
prerank,TRRUST_Transcription_Factors_2019__ELK1 human,0.4606209280478926,0.8506103614890793,0.4117647058823529,0.8493762158136741,1.0,8/18,25.30%,EIF2AK1;SRF;EZH2;ERBB2;PDGFB;FOSL1;TNFRSF10B;ZFP36
prerank,WikiPathway_2021_Human__NRF2 pathway WP2884,-0.595003829671578,-0.8502539608439776,0.6260869565217392,0.8604549242814115,1.0,3/135,0.27%,GSTA2;GSTA1;SLC2A10
prerank,"WikiPathway_2021_Human__GPCRs, Other WP117",0.64405744689526,0.8496570714186734,0.6439393939393939,0.8499540770826983,1.0,3/63,1.31%,CELSR3;GPR62;DRD4
prerank,GO_Biological_Process_2021__negative regulation of response to stimulus (GO:0048585),0.665777968705588,0.8494663244009586,0.680327868852459,0.8497529267958215,1.0,6/61,1.48%,THY1;CDK6;RBL1;ERBB3;MCTP1;SLC30A10
prerank,GO_Biological_Process_2021__nervous system development (GO:0007399),0.5223513698437637,0.8493039553938005,0.8333333333333334,0.8495801943629151,1.0,8/393,1.51%,IGF2BP1;DLX6;VAX2;STMN3;TBX3;ERBB3;IGF2BP3;FN1
prerank,GO_Biological_Process_2021__sister chromatid segregation (GO:0000819),0.5643466377152603,0.8491543333127038,0.5864661654135338,0.849328260163879,1.0,1/34,0.09%,NDC80
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V2 UP,-0.6112790567669038,-0.8490730739902584,0.6495726495726496,0.8614734469082533,1.0,5/123,1.09%,CYP2C8;DPYS;PTK2B;HAO1;CD83
prerank,Reactome_2022__Toll-like Receptor Cascades R-HSA-168898,-0.5805215973553991,-0.8488212300319122,0.7019230769230769,0.8613426094892401,1.0,4/159,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,GO_Biological_Process_2021__positive regulation of macromolecule metabolic process (GO:0010604),-0.5161569510934383,-0.8486240666167807,0.865546218487395,0.8611440134943621,1.0,8/352,1.30%,SLC2A10;APP;ATAD1;PIK3CB;NTF3;KLF4;VDR;DNAJA4
prerank,GO_Biological_Process_2021__endothelial cell migration (GO:0043542),-0.6043847869884778,-0.8485646265142881,0.6521739130434783,0.8607950615879961,1.0,2/39,1.27%,ADGRA2;CYP1B1
prerank,Reactome_2022__SARS-CoV-2 Infection R-HSA-9694516,0.5534889626480761,0.848510630614426,0.7593984962406015,0.8496353636287293,1.0,9/264,1.23%,HAVCR1;IRAK2;ST3GAL1;TRAF3;TJP1;DAD1;NUP210;CRB3;ZDHHC9
prerank,WikiPathway_2021_Human__Osteoblast differentiation WP4787,0.6036562185757981,0.848420652183266,0.6802721088435374,0.8493536842645861,1.0,4/107,1.36%,LRP5;NOTCH3;PIK3C2B;FGF1
prerank,GO_Biological_Process_2021__regulation of organelle assembly (GO:1902115),-0.6338197281828213,-0.8482341729230943,0.648,0.8607325824719343,1.0,2/69,0.81%,EVI5;HCK
prerank,GO_Biological_Process_2021__metanephros development (GO:0001656),-0.5049840488751951,-0.8481853160403612,0.48360655737704916,0.8603502921565942,1.0,1/23,1.08%,BASP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glioma,0.5719824934428417,0.8480695652423959,0.7153284671532847,0.8493082606192365,1.0,8/256,1.51%,PTK2;NOTCH3;RFX1;UBE2C;MYCN;ACSL5;CYP27B1;FN1
prerank,Reactome_2022__Branched-chain Amino Acid Catabolism R-HSA-70895,-0.5022256634131916,-0.8479959320234389,0.48739495798319327,0.860152590406617,1.0,1/21,0.38%,HIBADH
prerank,"GO_Biological_Process_2021__G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (GO:0007187)",-0.5499610977450146,-0.8478852318465834,0.5934959349593496,0.859847157711186,1.0,1/36,0.97%,HRH2
prerank,WikiPathway_2021_Human__Glioblastoma signaling pathways WP2261,-0.642514510553196,-0.8477262673889302,0.6548672566371682,0.8595779887090274,1.0,5/81,0.93%,MAP2K6;AKT3;RB1;PIK3CB;CCND2
prerank,Elsevier_Pathway_Collection__Glioma Stem Cell Program Activation,0.6293442203108326,0.8476434167409762,0.6762589928057554,0.8493456148383496,1.0,2/69,0.40%,AXIN2;LRP5
prerank,WikiPathway_2021_Human__Eicosanoid metabolism via lipooxygenases (LOX) WP4721,-0.5143326249935021,-0.8470178726652415,0.5229357798165137,0.8599940683942887,1.0,1/29,0.38%,GGT5
prerank,Reactome_2022__SLC Transporter Disorders R-HSA-5619102,-0.5880316173292889,-0.8469646678709575,0.660377358490566,0.8596194409742762,1.0,3/93,0.98%,SLC35A3;SLC2A10;SLC9A9
prerank,GO_Biological_Process_2021__positive regulation of nucleic acid-templated transcription (GO:1903508),0.5255481114959946,0.8468374179846896,0.832258064516129,0.8498509663496235,1.0,8/484,1.34%,ING5;LRP5;NEK4;TBL1X;PPARA;MYCN;APOE;HAS3
prerank,GO_Biological_Process_2021__muscle cell development (GO:0055001),0.5026837438270292,0.8467552829289797,0.5230769230769231,0.8495310177188797,1.0,1/29,1.26%,MYOF
prerank,GO_Biological_Process_2021__extracellular matrix disassembly (GO:0022617),-0.6173932943267898,-0.8465703284037661,0.6173913043478261,0.8596000076127687,1.0,1/57,0.46%,ADAMTS5
prerank,WikiPathway_2021_Human__NAD+ metabolism WP3644,-0.46027393278118234,-0.8459948199887694,0.4,0.8598339100289047,1.0,11/16,35.62%,SIRT7;SIRT2;CD38;NADK;SIRT5;NMNAT2;SIRT3;NMNAT3;SIRT4;NMNAT1;NT5E
prerank,MSigDB_Hallmark_2020__Allograft Rejection,-0.5462377076128835,-0.8459535437902244,0.7222222222222222,0.8594535932771386,1.0,5/192,1.16%,CCND2;CD2;SPI1;ZAP70;MAP4K1
prerank,GO_Biological_Process_2021__regulation of collagen biosynthetic process (GO:0032965),-0.4122717133786668,-0.845880571851714,0.3524590163934426,0.8590968532218201,1.0,9/18,34.31%,LARP6;F2;CREB3L1;EMILIN1;F2R;SUCO;TGFB1;CIITA;BMP4
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 KE .V1 UP,0.5963766847179398,0.845817710814176,0.7074829931972789,0.8500639414383117,1.0,6/175,1.56%,THY1;CDK6;CGREF1;PTPRH;DMWD;FOSL2
prerank,GO_Biological_Process_2021__negative regulation of cytokine-mediated signaling pathway (GO:0001960),0.622080643020179,0.8457878113011698,0.6747967479674797,0.8497072918869987,1.0,2/50,1.05%,YTHDF3;PADI2
prerank,GO_Biological_Process_2021__maturation of LSU-rRNA (GO:0000470),-0.5407310546430922,-0.8453240178279836,0.5350877192982456,0.859254775387652,1.0,14/26,23.17%,RPL35;PES1;RPL7A;NOP2;URB1;RPL7;BOP1;NSA2;NHP2;RSL1D1;SNU13;EIF6;ZNHIT6;MAK16
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 KE .V1 DN,-0.5970554750567759,-0.8453233504605973,0.7333333333333333,0.8588268596628575,1.0,4/162,1.34%,GRIN2B;CD27;HRG;EML1
prerank,GO_Biological_Process_2021__brain development (GO:0007420),-0.6127426126276824,-0.8451600013874824,0.675,0.858593095815813,1.0,5/133,1.34%,GRIN2B;MEIS1;PBX1;DSCAML1;EML1
prerank,TRRUST_Transcription_Factors_2019__MYC mouse,0.5811693573877624,0.845102412859082,0.6056338028169014,0.8500534770797875,1.0,1/44,0.28%,CDCA7
prerank,Elsevier_Pathway_Collection__Dendritic Cell Activation in Systemic Lupus Erythematosis,0.5985189165405124,0.8448426917901338,0.6541353383458647,0.849930637055429,1.0,1/50,0.44%,TRAF3
prerank,WikiPathway_2021_Human__TGF-beta Signaling Pathway WP366,-0.5925677677684483,-0.844792384658324,0.6956521739130435,0.8585847640944426,1.0,8/131,1.31%,FOSB;MAP2K6;APP;PAK2;WWP1;ZFYVE16;MAP4K1;PML
prerank,KEGG_2021_Human__C-type lectin receptor signaling pathway,-0.6364745275984651,-0.8445435881823896,0.6504854368932039,0.8584228762621026,1.0,2/98,0.73%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__histone H3 acetylation (GO:0043966),0.5617072734698577,0.8442027609210327,0.6190476190476191,0.8502149865725093,1.0,2/41,0.66%,ING5;NAA60
prerank,KEGG_2021_Human__Serotonergic synapse,-0.6406619016174617,-0.8438587607770373,0.6829268292682927,0.8587573573684432,1.0,4/96,1.24%,KCNN2;CYP2C8;APP;MAOB
prerank,Reactome_2022__Metabolism Of Amino Acids And Derivatives R-HSA-71291,-0.5025247025098957,-0.8436456397938147,0.9021739130434783,0.8585787323843955,1.0,8/350,1.17%,DMGDH;HIBADH;SLC36A4;AADAT;BHMT;IYD;HAO1;CDO1
prerank,Elsevier_Pathway_Collection__T-Cell Maturation (Hypothesis),0.6436305435277441,0.8430912080484394,0.6544117647058824,0.8509796218660464,1.0,1/62,0.19%,CDK6
prerank,GO_Biological_Process_2021__positive regulation of neuron projection development (GO:0010976),-0.6272105385666181,-0.8426888834301037,0.6692307692307692,0.8592782889264827,1.0,2/82,0.67%,RAP1A;PTK2B
prerank,GO_Biological_Process_2021__positive regulation of substrate adhesion-dependent cell spreading (GO:1900026),0.566297983620899,0.8426432530259927,0.5867768595041323,0.8510528621643204,1.0,2/35,1.41%,ARHGEF7;FLNA
prerank,TRRUST_Transcription_Factors_2019__RBPJ mouse,-0.44805074233652853,-0.8426314310301143,0.3851851851851852,0.8589232292507416,1.0,5/16,11.06%,NODAL;PRDM1;HESX1;TYROBP;CDH2
prerank,Reactome_2022__Signaling By Nuclear Receptors R-HSA-9006931,-0.5581499743536464,-0.8425638590910063,0.7837837837837838,0.8585559313893691,1.0,4/241,0.40%,FOSB;ZDHHC21;AKT3;NCOA1
prerank,Reactome_2022__Oxidative Stress Induced Senescence R-HSA-2559580,0.6387074820469538,0.8423029323194335,0.6492537313432836,0.8510016281024554,1.0,2/81,1.02%,CDK6;CBX2
prerank,KEGG_2021_Human__Alzheimer disease,-0.513342906005826,-0.8416752712837684,0.8823529411764706,0.8591768562697157,1.0,4/333,0.73%,GRIN2B;APP;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__anaphase-promoting complex-dependent catabolic process (GO:0031145),0.6467503906591374,0.8414599841166605,0.6879432624113475,0.8515529225543965,1.0,2/82,0.94%,FBXO31;UBE2C
prerank,GO_Biological_Process_2021__negative regulation of canonical Wnt signaling pathway (GO:0090090),-0.582613384314208,-0.8413630199038276,0.6990291262135923,0.8591494013773548,1.0,3/158,1.22%,TLE4;AMFR;GLI3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Huntington Disease,-0.642193907200381,-0.8413057635588896,0.6666666666666666,0.8588097759816696,1.0,1/94,0.01%,GRIN2B
prerank,GO_Biological_Process_2021__adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189),-0.6215895329193736,-0.8411902633018986,0.6446280991735537,0.8585333143279201,1.0,2/95,1.23%,ADGRE5;S1PR1
prerank,Elsevier_Pathway_Collection__Adherens Junction Assembly (Nectin),-0.5005485687855468,-0.8411721712017487,0.5081967213114754,0.8581294402663886,1.0,1/27,0.34%,RAP1A
prerank,Elsevier_Pathway_Collection__TLR4 Signaling in Leukocytes,-0.616289847837221,-0.8406482210379198,0.6435643564356436,0.8582573788566056,1.0,2/54,1.04%,MAP2K6;TICAM2
prerank,GO_Biological_Process_2021__protein autoubiquitination (GO:0051865),-0.6342164158274934,-0.8405763863397644,0.6886792452830188,0.8579021367804087,1.0,3/65,0.76%,RNF13;AMFR;UBE3D
prerank,Reactome_2022__Estrogen-dependent Nuclear Events Downstream Of ESR-membrane Signaling R-HSA-9634638,0.5071466723555507,0.8403450808050502,0.5121951219512195,0.8523592947295183,1.0,1/23,0.26%,PTK2
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-tyrosine phosphorylation (GO:0050732),-0.5343046339122679,-0.8401020587640676,0.5952380952380952,0.8580217008112958,1.0,2/31,0.96%,NTF3;SEMA4D
prerank,Elsevier_Pathway_Collection__Cell Cycle Dysregulation in Mantle Cell Lymphoma,0.5447935148036689,0.8400788561690142,0.5409836065573771,0.8522217897954609,1.0,2/25,0.50%,CDK6;ATR
prerank,GO_Biological_Process_2021__neural crest cell migration (GO:0001755),0.5697842746974915,0.8400663013657713,0.6338028169014085,0.8518430526811118,1.0,2/35,1.51%,SEMA3G;FN1
prerank,Reactome_2022__ISG15 Antiviral Mechanism R-HSA-1169408,-0.6032152956240029,-0.8400309050898525,0.6692913385826772,0.8576731932106496,1.0,2/74,1.05%,KPNA3;HERC5
prerank,KEGG_2021_Human__Mucin type O-glycan biosynthesis,0.5472769671263129,0.8393158506071685,0.5669291338582677,0.8522093857533213,1.0,1/34,0.35%,ST3GAL1
prerank,Reactome_2022__TGF-beta Receptor Signaling Activates SMADs R-HSA-2173789,0.6263938635375879,0.8390901101952385,0.6503496503496503,0.8520599081919976,1.0,2/44,1.47%,ITGB5;ZFYVE9
prerank,MSigDB_Hallmark_2020__Estrogen Response Late,-0.5467536331227751,-0.8387587898714884,0.7281553398058253,0.8585674177203633,1.0,3/194,0.99%,PLAAT3;AMFR;KLF4
prerank,WikiPathway_2021_Human__Disruption of postsynaptic signaling by CNV WP4875,0.5112395323731529,0.8386551934522588,0.5808823529411765,0.8521446076534049,1.0,3/33,1.20%,TJP1;DLG1;STX1A
prerank,TRRUST_Transcription_Factors_2019__TWIST1 human,0.5504471017041213,0.83856943176272,0.6046511627906976,0.8518434163139953,1.0,2/34,1.51%,ERBB3;FN1
prerank,Reactome_2022__G Alpha (12/13) Signaling Events R-HSA-416482,0.6344303366995209,0.8385189587537748,0.7258064516129032,0.8514988780073435,1.0,4/76,1.15%,ARHGEF7;PLEKHG5;GNB5;ARHGEF18
prerank,KEGG_2021_Human__Natural killer cell mediated cytotoxicity,-0.630401858970937,-0.8384937008115618,0.6633663366336634,0.8584068162973434,1.0,4/104,1.13%,PTK2B;PIK3CB;VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Proteins Involved in Astrocytoma,-0.632225248216906,-0.8383095840995582,0.639344262295082,0.858196309547159,1.0,3/89,1.21%,APP;GLG1;TEK
prerank,Reactome_2022__Intracellular Signaling By Second Messengers R-HSA-9006925,0.535890197436195,0.8380704175179248,0.8679245283018868,0.8515680211262345,1.0,5/291,1.36%,WWP2;ERBB3;CBX2;KLB;FGF1
prerank,Reactome_2022__TCR Signaling R-HSA-202403,-0.6111422000329855,-0.8378597430580487,0.6915887850467289,0.8583070941165822,1.0,2/111,1.13%,PIK3CB;ZAP70
prerank,KEGG_2021_Human__Type II diabetes mellitus,-0.5600760937395872,-0.8377427857102941,0.603448275862069,0.8580468294990806,1.0,1/42,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__mitotic recombination (GO:0006312),-0.4134995533324709,-0.8376170400841781,0.3821138211382114,0.8577618262927401,1.0,5/15,16.78%,ERCC1;RAD54B;TEP1;MSH3;TPRKB
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP LATE.V1 DN,0.6018196139972385,0.8373200249126931,0.706766917293233,0.8519805414434911,1.0,8/163,1.21%,ARID3A;SLC19A1;NDUFA10;TTC23;RBBP6;PPFIA4;STX1A;TNNC2
prerank,Elsevier_Pathway_Collection__Neuroblastoma,-0.598544257144099,-0.8373062800961752,0.7008547008547008,0.8577206837592813,1.0,5/123,1.22%,MAP2K6;RAP1A;NTF3;CCND2;GLI3
prerank,GO_Biological_Process_2021__regulation of cytokinesis (GO:0032465),0.6476743507021128,0.8373009931681722,0.6986301369863014,0.8516137615532057,1.0,4/72,1.03%,SVIL;KIF13A;PRPF40A;KIF23
prerank,Reactome_2022__Signaling By NOTCH1 R-HSA-1980143,0.65308646779457,0.8372456082865176,0.703125,0.8512717028653901,1.0,2/73,0.43%,HDAC8;TBL1X
prerank,WikiPathway_2021_Human__Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.5653126071574028,0.8370559725668738,0.5755395683453237,0.8510953486985904,1.0,2/31,1.39%,ERBB3;PRLR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Multiple Myeloma,0.5948592303350567,0.8369288642684727,0.6444444444444445,0.8508286681093039,1.0,1/55,0.19%,CDK6
prerank,GO_Biological_Process_2021__cytoplasmic pattern recognition receptor signaling pathway (GO:0002753),0.5424118747302216,0.8366601300660054,0.556390977443609,0.850701380681227,1.0,1/27,0.10%,IRAK2
prerank,GO_Biological_Process_2021__protein lipidation (GO:0006497),-0.6389991237236645,-0.8364277701040176,0.6697247706422018,0.8582643026994602,1.0,1/58,0.21%,ZDHHC21
prerank,MSigDB_Hallmark_2020__Glycolysis,0.5523082554822625,0.8358055780109431,0.7794117647058824,0.8512174779137271,1.0,5/194,1.07%,CENPA;DEPDC1;PHKA2;PLOD2;PPFIA4
prerank,Elsevier_Pathway_Collection__Clear Cell Endometrial Cancer and Papillary Serous Endometrial Cancer,0.650154229101922,0.8356485037297692,0.6528925619834711,0.8510084540097163,1.0,2/65,0.96%,CDK6;ERBB3
prerank,Reactome_2022__G Alpha (S) Signaling Events R-HSA-418555,-0.6305816454001193,-0.8356225146294269,0.6752136752136753,0.8586659583542429,1.0,3/121,0.97%,GPR39;PDE11A;HRH2
prerank,GO_Biological_Process_2021__regulation of NIK/NF-kappaB signaling (GO:1901222),-0.6064219477928219,-0.8356048802390249,0.6517857142857143,0.858268955231301,1.0,4/77,1.10%,APP;TRIM44;CD27;SPI1
prerank,Elsevier_Pathway_Collection__beta-Cell Mass Regulation,-0.5715275516466424,-0.8355239813259268,0.5905511811023622,0.8579284424636503,1.0,1/40,0.93%,CCND2
prerank,KEGG_2021_Human__Pathways of neurodegeneration,0.5247443072106293,0.8353042231832145,0.8654970760233918,0.8509750554947173,1.0,5/429,1.31%,AXIN2;LRP5;NDUFA10;STX1A;TUBA1A
prerank,GO_Biological_Process_2021__macromolecule catabolic process (GO:0009057),0.5458675899731223,0.8352434952694596,0.5486111111111112,0.8506465375603665,1.0,1/27,0.15%,TRIM24
prerank,GO_Biological_Process_2021__regulation of actin cytoskeleton reorganization (GO:2000249),-0.5898406599181932,-0.8351172056978563,0.5982905982905983,0.8579143171531962,1.0,4/36,1.21%,PTK2B;HCK;NTF3;TEK
prerank,Elsevier_Pathway_Collection__Neutrophil and Macrophage Function in Systemic Lupus Erythematosus,0.5440776841963613,0.8350011676274641,0.5714285714285714,0.8505005352130667,1.0,2/28,1.49%,PTK2;BCAR1
prerank,GO_Biological_Process_2021__regulation of neuron differentiation (GO:0045664),0.6481374462839181,0.8343100228162331,0.6766917293233082,0.8508993273732035,1.0,1/66,0.04%,HOXD3
prerank,GO_Biological_Process_2021__proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161),-0.5101489242789101,-0.8342324508447451,0.8888888888888888,0.8586018100500562,1.0,7/315,1.31%,FBXO27;RB1;DNAJB14;AMFR;WWP1;UBE3D;PML
prerank,GO_Biological_Process_2021__intracellular steroid hormone receptor signaling pathway (GO:0030518),-0.5599949920101401,-0.8341611543268874,0.59375,0.8582969055240132,1.0,1/41,0.41%,NR3C1
prerank,Reactome_2022__Signaling By RAF1 Mutants R-HSA-9656223,-0.5587975771132508,-0.8341151988709087,0.609375,0.8579238672481375,1.0,2/37,0.42%,RAP1A;RAP1B
prerank,KEGG_2021_Human__Autophagy,-0.5574766601997998,-0.8340644541951022,0.6846846846846847,0.8575594853225516,1.0,4/132,0.73%,AKT3;UVRAG;DEPTOR;PIK3CB
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Synovial Fibroblast,-0.5002351924195827,-0.8340169131277174,0.5384615384615384,0.8571975319706423,1.0,1/35,0.31%,MAP2K6
prerank,MSigDB_Hallmark_2020__Spermatogenesis,0.6135183334494326,0.8340137543423896,0.7071428571428572,0.8508296300048899,1.0,3/103,1.20%,GFI1;MLLT10;GSTM3
prerank,Reactome_2022__PIP3 Activates AKT Signaling R-HSA-1257604,0.5359096206241195,0.8339442497537698,0.864516129032258,0.8505295065913352,1.0,5/255,1.36%,WWP2;ERBB3;CBX2;KLB;FGF1
prerank,KEGG_2021_Human__Pathways in cancer,0.5109416695401308,0.8336458107499541,0.8848920863309353,0.8504496483498013,1.0,15/493,1.51%,AXIN2;MSH2;CDK6;PTK2;ITGA2;LRP5;NOTCH3;TRAF3;COL4A5;PLEKHG5;TXNRD2;GNB5;GSTM3;FGF1;FN1
prerank,GO_Biological_Process_2021__negative regulation of intracellular signal transduction (GO:1902532),0.5781348658050698,0.8332482119852498,0.7769784172661871,0.8505118397414694,1.0,6/192,1.55%,PRKAA2;VGLL4;FNIP1;PPARA;TSPAN6;UACA
prerank,GO_Biological_Process_2021__purine-containing compound biosynthetic process (GO:0072522),-0.5299011450472381,-0.8331313681062531,0.5408163265306123,0.857829855678647,1.0,1/25,1.18%,GMPR
prerank,Reactome_2022__Hedgehog Off State R-HSA-5610787,0.6465038061923908,0.8329757567610859,0.6962962962962963,0.8504597525380793,1.0,1/95,0.30%,SMOX
prerank,GO_Biological_Process_2021__regulation of type I interferon-mediated signaling pathway (GO:0060338),-0.5076392824453535,-0.8328019956185486,0.528,0.8577868517447078,1.0,1/30,0.39%,OAS1
prerank,Reactome_2022__Diseases Of Carbohydrate Metabolism R-HSA-5663084,-0.5517851389593835,-0.8327920741167074,0.5409836065573771,0.8573756706604263,1.0,1/30,0.08%,ALDOB
prerank,Elsevier_Pathway_Collection__Proteins Involved in Atherosclerosis,-0.5392977976456279,-0.8325955014271621,0.7798165137614679,0.8571881962187041,1.0,2/186,0.92%,CCL23;LIPG
prerank,Reactome_2022__NOD1/2 Signaling Pathway R-HSA-168638,0.5424115010784553,0.8324336954958564,0.5887096774193549,0.8506377822937692,1.0,1/32,0.10%,IRAK2
prerank,GO_Biological_Process_2021__small GTPase mediated signal transduction (GO:0007264),0.6339784456830893,0.8324049491852744,0.6887417218543046,0.8502952034944957,1.0,4/104,1.54%,KSR1;ZNF304;ARHGEF18;RIN2
prerank,GO_Biological_Process_2021__inorganic cation transmembrane transport (GO:0098662),-0.552503908989188,-0.8319722913022902,0.7906976744186046,0.8574142301640565,1.0,6/235,1.24%,KCNN2;KCNE1;KCNAB3;SLC9A9;KCNK6;KCNS3
prerank,WikiPathway_2021_Human__Mitochondrial complex III assembly WP4921,-0.4338288569926403,-0.8319400898727802,0.4,0.8570410144457831,1.0,5/15,10.69%,UQCR11;UQCRFS1;UQCRB;UQCR10;LYRM7
prerank,WikiPathway_2021_Human__Rett syndrome causing genes WP4312,0.6325982369563773,0.8318703834316251,0.7076923076923077,0.8504541350687205,1.0,3/47,0.59%,HDAC8;TBL1X;TAF1B
prerank,KEGG_2021_Human__Phosphatidylinositol signaling system,-0.6138275754142762,-0.8318489001403995,0.6822429906542056,0.8567259720667781,1.0,1/92,0.73%,PIK3CB
prerank,KEGG_2021_Human__Necroptosis,0.6001247705482429,0.8316745765154292,0.6510067114093959,0.8502656977598974,1.0,1/130,0.42%,TNFRSF10A
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP LATE.V1 UP,0.5865691422710908,0.831616625625855,0.7194244604316546,0.8499323893101315,1.0,5/167,1.35%,PLOD2;PKDCC;ZDHHC9;CTSH;SOAT2
prerank,TRRUST_Transcription_Factors_2019__STAT1 mouse,0.5356828958075002,0.8314372418505552,0.5701754385964912,0.8497409088259839,1.0,1/30,0.12%,GFI1
prerank,TRRUST_Transcription_Factors_2019__RB1 human,0.5160606297556138,0.8314129684391558,0.5343511450381679,0.8493908906449732,1.0,1/31,0.29%,RBL1
prerank,Reactome_2022__Mitochondrial Biogenesis R-HSA-1592230,0.6388396374035656,0.8313099840243054,0.6484375,0.8490998182185779,1.0,3/89,0.79%,PRKAA2;TBL1X;PPARA
prerank,TRRUST_Transcription_Factors_2019__HDAC1 human,-0.5992671587622714,-0.8305745249029937,0.6666666666666666,0.8576473344973027,1.0,3/70,0.99%,GRIN2B;CCND2;KLF4
prerank,Reactome_2022__Toll Like Receptor 4 (TLR4) Cascade R-HSA-166016,-0.5805323401878988,-0.8303742209307745,0.7247706422018348,0.8574436838681564,1.0,4/138,1.26%,MAP2K6;APP;PELI2;DUSP4
prerank,KEGG_2021_Human__Inositol phosphate metabolism,-0.6138345050013717,-0.8302553594561444,0.7155172413793104,0.8571536449301271,1.0,1/73,0.73%,PIK3CB
prerank,Elsevier_Pathway_Collection__FOXO1 Signaling,0.5842602542351509,0.8302184805277028,0.6640625,0.8498672766548557,1.0,1/43,0.26%,PTK2
prerank,KEGG_2021_Human__Vitamin digestion and absorption,-0.49546743999401244,-0.8296184872400159,0.4507042253521127,0.8574017015579863,1.0,1/22,0.45%,BTD
prerank,Reactome_2022__Binding And Uptake Of Ligands By Scavenger Receptors R-HSA-2173782,-0.5598662685030914,-0.8295928877438656,0.624,0.857008986320211,1.0,1/40,0.93%,CD163
prerank,KEGG_2021_Human__Amyotrophic lateral sclerosis,-0.5153489187462799,-0.8295843456159637,0.9072164948453608,0.8566001846404393,1.0,2/330,0.31%,GRIN2B;MAP2K6
prerank,WikiPathway_2021_Human__Male infertility WP4673,-0.6069059558743787,-0.8295701017985491,0.6635514018691588,0.8562082412642364,1.0,2/116,1.10%,BHMT;EPSTI1
prerank,GO_Biological_Process_2021__positive regulation of cell-matrix adhesion (GO:0001954),0.570947755931639,0.8294112411794262,0.6287878787878788,0.8503635620971882,1.0,3/43,1.54%,THY1;CDK6;RIN2
prerank,GO_Biological_Process_2021__glycosaminoglycan metabolic process (GO:0030203),0.6182494716822078,0.8290500724418688,0.6722689075630253,0.8503324660981397,1.0,1/53,0.55%,SLC35D2
prerank,Reactome_2022__Metabolism Of Steroids R-HSA-8957322,0.6180031226996229,0.8287781846602607,0.7569444444444444,0.8501809131784518,1.0,8/143,1.35%,ACACA;HSD17B11;TBL1X;PPARA;PKMYT1;FDXR;CYP27B1;SOAT2
prerank,"Reactome_2022__Transport Of Bile Salts And Organic Acids, Metal Ions And Amine Compounds R-HSA-425366",-0.6293110203030206,-0.828737299223473,0.6517857142857143,0.8566948383269233,1.0,2/78,0.10%,SLC22A1;SLC41A2
prerank,KEGG_2021_Human__Leukocyte transendothelial migration,-0.6074575255769054,-0.8286128769202005,0.6752136752136753,0.8564039532740116,1.0,7/106,1.13%,RAP1A;RAP1B;PTK2B;PIK3CB;RHOH;VAV1;RASSF5
prerank,GO_Biological_Process_2021__carboxylic acid transport (GO:0046942),-0.5976505524069766,-0.8283863495635417,0.6601941747572816,0.8562653898123118,1.0,4/53,1.24%,SLC7A8;SLC36A4;SLC16A2;SLC17A4
prerank,GO_Biological_Process_2021__antigen receptor-mediated signaling pathway (GO:0050851),-0.562106900392918,-0.8282691376897033,0.6869565217391305,0.8559811563950372,1.0,3/177,1.13%,PAK2;PIK3CB;ZAP70
prerank,GO_Biological_Process_2021__macroautophagy (GO:0016236),-0.5869209251545255,-0.8281899385803229,0.6949152542372882,0.8556438315140582,1.0,3/119,0.78%,KLHL3;UVRAG;TOMM70
prerank,Elsevier_Pathway_Collection__Diffuse Large-B-Cell Lymphoma ABC Subtype,0.611530377463628,0.827815348016218,0.6691176470588235,0.8508415433746582,1.0,1/48,0.50%,ATR
prerank,GO_Biological_Process_2021__negative regulation of cytokine production involved in immune response (GO:0002719),-0.43169522890423784,-0.8277145668896724,0.41025641025641024,0.8557233070792538,1.0,7/17,26.57%,TNF;JAK3;APOA2;IRAK3;HLA-F;XCL1;APOA1
prerank,GO_Biological_Process_2021__cellular response to interleukin-1 (GO:0071347),-0.5956019906193976,-0.8276877673868668,0.7130434782608696,0.8553351692603905,1.0,2/148,1.03%,CCL23;PELI2
prerank,WikiPathway_2021_Human__Endoderm differentiation WP2853,-0.5994078455354606,-0.8274952017918953,0.6796116504854369,0.8551134255050055,1.0,6/130,1.28%,PARP8;APP;NR3C1;PBX1;DUSP4;ZFHX4
prerank,TRRUST_Transcription_Factors_2019__CEBPA human,0.5922800471949935,0.8274616129141197,0.648,0.850827469632652,1.0,3/47,1.51%,HSD17B11;HOMER3;FN1
prerank,GO_Biological_Process_2021__regulation of cell growth (GO:0001558),-0.5298774483007481,-0.8273680460991976,0.8285714285714286,0.8548386326038485,1.0,6/210,1.31%,DCBLD2;RB1;RASGRP2;LTBP4;HRG;PML
prerank,Reactome_2022__NR1H2 And NR1H3-mediated Signaling R-HSA-9024446,0.5996497430249949,0.8273595535581033,0.6766917293233082,0.8505194805909597,1.0,2/45,1.30%,TBL1X;APOE
prerank,KEGG_2021_Human__Herpes simplex virus 1 infection,0.5160722489354108,0.8272755189881423,0.8827586206896552,0.8502083341998647,1.0,35/461,0.88%,ZNF878;ZNF251;ZNF563;ZNF250;ZNF189;ZNF473;ZNF530;ZNF234;ZNF200;ZNF419;ZNF436;ZNF2;TRAF3;ZNF778;ZNF37A;ZNF283;ZNF432;ZSCAN32;ZNF286A;ZNF557;ZNF805;ZNF599;ZNF175;ZNF275;ZNF772;ZNF79;ZNF587;ZNF749;ZNF304;ZNF211;ZNF791;ZNF383;ZNF101;ZNF780B;ZNF256
prerank,GO_Biological_Process_2021__positive regulation of organelle assembly (GO:1902117),-0.525914391564855,-0.8269450123396954,0.6126126126126126,0.8548896773492412,1.0,1/46,0.27%,CEP120
prerank,WikiPathway_2021_Human__Signal transduction through IL1R WP4496,0.5424119042930164,0.8263005818734073,0.574468085106383,0.8508883641407231,1.0,1/30,0.10%,IRAK2
prerank,GO_Biological_Process_2021__positive regulation of cell junction assembly (GO:1901890),0.6353733099358294,0.8262980354325469,0.6950354609929078,0.8505052374637969,1.0,2/53,1.14%,THY1;CRB3
prerank,KEGG_2021_Human__FoxO signaling pathway,-0.5832619606154319,-0.8262184256997385,0.72,0.8552108278253313,1.0,4/123,1.23%,AKT3;PIK3CB;CCND2;S1PR1
prerank,WikiPathway_2021_Human__DNA Replication WP466,0.5734858211012399,0.8261928374569402,0.6397058823529411,0.8502013825772813,1.0,1/42,0.09%,CDC45
prerank,WikiPathway_2021_Human__Overview of leukocyte-intrinsic Hippo pathway functions WP4542,-0.5228626031625654,-0.8260078650843642,0.5454545454545454,0.8550488966621985,1.0,2/35,1.13%,RAP1A;RASSF5
prerank,GO_Biological_Process_2021__protein stabilization (GO:0050821),0.5808388360602823,0.8258835758077063,0.7194244604316546,0.8501464764124441,1.0,4/176,1.48%,TBL1X;MSX1;FLNA;LAMP2
prerank,Elsevier_Pathway_Collection__Pancreatic Neuroendocrine Tumors,0.6572824508745907,0.8258611905630189,0.6793893129770993,0.8497967741327388,1.0,2/70,0.96%,CDK6;ERBB3
prerank,KEGG_2021_Human__Glutamatergic synapse,0.6201719409445643,0.8256154086591286,0.6818181818181818,0.8497078313049803,1.0,5/101,1.54%,GNB5;GRK3;HOMER3;GLS;SLC38A1
prerank,Reactome_2022__EPH-Ephrin Signaling R-HSA-2682334,0.6208946945142595,0.8255869555055602,0.7114093959731543,0.8493552172413185,1.0,3/87,0.91%,PTK2;ARHGEF7;GPRIN1
prerank,MSigDB_Oncogenic_Signatures__NOTCH DN.V1 DN,0.5997249511306467,0.8255102869032467,0.7181208053691275,0.8490542782664456,1.0,5/147,1.25%,NOTCH3;TBX3;MYCN;PPFIA4;FMNL2
prerank,GO_Biological_Process_2021__positive regulation of histone acetylation (GO:0035066),-0.4216485408717941,-0.8249795213886765,0.4083333333333333,0.8557520095415891,1.0,8/23,16.53%,MAPK3;ARRB1;KAT7;RPS6KA4;WBP2;TADA2A;SMARCB1;PAXIP1
prerank,Reactome_2022__Paradoxical Activation Of RAF Signaling By Kinase Inactive BRAF R-HSA-6802955,-0.5587971938018889,-0.8247863653468559,0.6220472440944882,0.8554959648688595,1.0,2/39,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__positive regulation of organelle organization (GO:0010638),-0.49418163153713496,-0.8246220588241523,0.5083333333333333,0.8552646795841131,1.0,1/31,0.70%,UVRAG
prerank,"Elsevier_Pathway_Collection__Proteins Involved in Adhesion, Migration and Invasion of Endometriotic Cell",-0.40155963169974274,-0.8245516936763305,0.36752136752136755,0.854911116092191,1.0,9/17,22.87%,TNF;CDH1;MMP9;ITGB1;MMP3;TIMP1;CXCL8;SNAI2;CDH3
prerank,TRRUST_Transcription_Factors_2019__CDX2 human,-0.5025314426220702,-0.8244369037431731,0.5225225225225225,0.8546293184241419,1.0,2/27,1.25%,KLF4;VDR
prerank,Elsevier_Pathway_Collection__CUL4/CRL (SCF4) Complex,0.5275773795137234,0.8242142569780639,0.5271317829457365,0.8500882903351288,1.0,1/23,0.17%,MSH2
prerank,GO_Biological_Process_2021__regulation of macrophage chemotaxis (GO:0010758),0.5273043502255449,0.8235815527072666,0.5217391304347826,0.8503311856587067,1.0,1/20,0.26%,PTK2
prerank,GO_Biological_Process_2021__B cell proliferation (GO:0042100),-0.4123490764542239,-0.823539354489888,0.4032258064516129,0.8552248729943626,1.0,6/16,20.59%,CTPS1;HSPD1;MS4A1;RASGRP1;GAPT;CD180
prerank,Elsevier_Pathway_Collection__STAT3 and NFkB Activate Inflammation-Induced Tumorigenesis,0.5998880412086379,0.823453352664576,0.6879432624113475,0.8500661150437929,1.0,1/65,0.17%,MSH2
prerank,GO_Biological_Process_2021__receptor-mediated endocytosis (GO:0006898),0.6112319136480115,0.8230114747389959,0.7291666666666666,0.8501755139382754,1.0,2/140,1.30%,GRK3;APOE
prerank,MSigDB_Oncogenic_Signatures__LEF1 UP.V1 DN,0.5629228027442271,0.8224367955303103,0.75,0.8504026696386808,1.0,9/168,1.46%,MANBA;PLOD2;ACSL5;GSTM3;CTSH;CPE;DPYSL3;RNF144A;CNN3
prerank,Elsevier_Pathway_Collection__HPV E6 and E7 Induced Disruption of TNFR/NF-kB Signaling in Keratinocytes,0.5985178419167146,0.8222676346899713,0.6834532374100719,0.8501925575188175,1.0,1/53,0.44%,TRAF3
prerank,Elsevier_Pathway_Collection__TLR3 Role in Retinal Pigment Epithelial Cell,0.4458933682116649,0.8220613251162594,0.4090909090909091,0.8500628403866928,1.0,5/15,16.33%,CYCS;TLR3;CASP9;JAK2;IKBKE
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Obstructive Pulmonary Disease,0.5921752867416457,0.8217574942011111,0.7279411764705882,0.849989529421918,1.0,2/156,0.96%,SLC6A4;ERBB3
prerank,MSigDB_Oncogenic_Signatures__BCAT GDS748 UP,0.5698895161337469,0.8216391245537812,0.624113475177305,0.8497168018764744,1.0,1/41,1.01%,ASRGL1
prerank,GO_Biological_Process_2021__establishment of endothelial barrier (GO:0061028),0.5206605853655962,0.8214848689391256,0.53125,0.8495465720151464,1.0,2/29,0.45%,PPP1R16B;TJP1
prerank,GO_Biological_Process_2021__negative regulation of biomineral tissue development (GO:0070168),0.5228424446647538,0.8210211590844576,0.5323741007194245,0.8496609707279137,1.0,1/21,0.31%,BCOR
prerank,GO_Biological_Process_2021__positive regulation of cellular catabolic process (GO:0031331),0.6119800961599378,0.8209789913333975,0.7132352941176471,0.8493138395742202,1.0,5/135,1.30%,PRKAA2;VGLL4;PPARA;PACSIN3;APOE
prerank,KEGG_2021_Human__mRNA surveillance pathway,-0.6196391568609565,-0.8207987476295154,0.6730769230769231,0.857982955703179,1.0,2/92,1.00%,RNGTT;SMG6
prerank,Reactome_2022__TP53 Regulates Metabolic Genes R-HSA-5628897,0.6104223019510647,0.8206859422685436,0.6567164179104478,0.8492035866200179,1.0,1/81,0.03%,PRKAA2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteoporosis,-0.5893335473933425,-0.8204987544367179,0.7352941176470589,0.8579283143531885,1.0,2/86,1.25%,NR3C1;VDR
prerank,GO_Biological_Process_2021__chromosome condensation (GO:0030261),0.5707085959835055,0.8204236114004422,0.6527777777777778,0.8490985359743233,1.0,1/41,0.08%,NCAPG
prerank,Elsevier_Pathway_Collection__Dystrophin Glycoprotein Complex Signaling in Muscular Dystrophies,0.5273032386915895,0.8203153690133462,0.5488721804511278,0.848825240363137,1.0,1/26,0.26%,PTK2
prerank,GO_Biological_Process_2021__negative regulation of macroautophagy (GO:0016242),0.5078983626621066,0.8200675698598978,0.5284552845528455,0.8487170539738838,1.0,1/26,0.33%,CLEC16A
prerank,KEGG_2021_Human__Tuberculosis,0.5939839406563062,0.8200109385033058,0.75177304964539,0.8483983042328306,1.0,4/156,1.48%,IRAK2;KSR1;CYP27B1;LAMP2
prerank,KEGG_2021_Human__Influenza A,-0.5477070536604809,-0.8196693303822316,0.7307692307692307,0.8584664274131703,1.0,5/148,1.31%,AKT3;OAS1;PIK3CB;TMPRSS2;PML
prerank,Elsevier_Pathway_Collection__TNFR -> NF-kB Signaling,-0.5002365514085494,-0.8195246744244589,0.512,0.85823652755578,1.0,1/29,0.31%,MAP2K6
prerank,Reactome_2022__Selective Autophagy R-HSA-9663891,0.6344026826253044,0.8193847974288704,0.6884057971014492,0.8486690847670119,1.0,1/59,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__regulation of cell cycle phase transition (GO:1901987),0.6058691727830442,0.8191254913852282,0.6814814814814815,0.8485526266011386,1.0,1/91,0.94%,UBE2C
prerank,Reactome_2022__Oncogene Induced Senescence R-HSA-2559585,0.5303179481030128,0.8187107008384773,0.5944055944055944,0.8486313809001359,1.0,1/33,0.19%,CDK6
prerank,TRRUST_Transcription_Factors_2019__WT1 human,0.5813459139393987,0.8186541408324968,0.6592592592592592,0.8483047599637082,1.0,2/54,0.97%,AMH;MYCN
prerank,KEGG_2021_Human__ErbB signaling pathway,-0.595286734739617,-0.8185722312171254,0.719626168224299,0.8587780443328717,1.0,3/83,0.73%,AKT3;PAK2;PIK3CB
prerank,MSigDB_Oncogenic_Signatures__KRAS.AMP.LUNG UP.V1 DN,0.6056009608087864,0.8183250293476949,0.673469387755102,0.8482920203633522,1.0,3/110,0.93%,PPM1H;CGREF1;PTPRH
prerank,GO_Biological_Process_2021__regulation of protein localization to plasma membrane (GO:1903076),0.644247780704442,0.8182762454770801,0.6737588652482269,0.847962453908842,1.0,2/77,0.86%,DLG1;RHOQ
prerank,KEGG_2021_Human__Phagosome,0.6116559677827694,0.8178662109183515,0.7293233082706767,0.848014233933935,1.0,4/143,1.48%,ITGA2;TUBA1A;ITGB5;LAMP2
prerank,GO_Biological_Process_2021__regulation of canonical Wnt signaling pathway (GO:0060828),-0.5361181135591772,-0.8174791710655699,0.7669902912621359,0.859599710101729,1.0,4/243,1.22%,TLE4;AMFR;ADGRA2;GLI3
prerank,WikiPathway_2021_Human__Kisspeptin/kisspeptin receptor system in the ovary WP4871,-0.5129344737335995,-0.8169127404075981,0.6153846153846154,0.8597924321593412,1.0,1/36,0.73%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of protein metabolic process (GO:0051246),-0.5836303641841398,-0.816820125700954,0.6515151515151515,0.8594465196841017,1.0,3/45,1.15%,APP;KLF4;LTBP4
prerank,GO_Biological_Process_2021__regulation of calcium ion transport (GO:0051924),0.5604644268572745,0.8166034406620368,0.6796875,0.8489682358397888,1.0,2/55,1.23%,PACSIN3;HOMER3
prerank,GO_Biological_Process_2021__negative regulation of protein phosphorylation (GO:0001933),-0.5647481621963398,-0.8163023570590621,0.7117117117117117,0.8596025738788005,1.0,5/146,0.96%,RB1;PAK2;DEPTOR;NTF3;SEMA4D
prerank,Reactome_2022__Voltage Gated Potassium Channels R-HSA-1296072,0.5677972442957469,0.816296888920354,0.6299212598425197,0.8489433787683336,1.0,1/32,0.02%,KCNC1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Metabolic Reprogramming,0.615935517822144,0.8161728914643513,0.6666666666666666,0.8487206615291619,1.0,2/85,1.49%,ACACA;GLS
prerank,GO_Biological_Process_2021__negative regulation of supramolecular fiber organization (GO:1902904),0.6133938909213755,0.8157821427546921,0.7338129496402878,0.8487669399185792,1.0,3/71,1.30%,TBCD;CAMSAP3;APOE
prerank,GO_Biological_Process_2021__negative regulation of cell differentiation (GO:0045596),0.5653518488086878,0.8156990263066102,0.7730496453900709,0.8484532505844103,1.0,5/182,1.09%,CDK6;LRP5;PPARA;TBX3;CHRD
prerank,GO_Biological_Process_2021__clathrin coat assembly (GO:0048268),-0.40063194143440717,-0.8155934172862201,0.4180327868852459,0.8599553819605182,1.0,7/15,27.22%,NSG1;EPS15;HIP1;CLTB;HIP1R;FCHO2;CALY
prerank,GO_Biological_Process_2021__RNA modification (GO:0009451),0.5998615043923454,0.815423323929463,0.7063492063492064,0.8483442147593632,1.0,1/57,0.88%,PARN
prerank,Elsevier_Pathway_Collection__Leukotriene Effect on Vascular Endothelial Cell Response,-0.5023274322566624,-0.8153670432864102,0.5737704918032787,0.8598148141044399,1.0,1/34,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__actomyosin structure organization (GO:0031032),0.6192540674072154,0.8153031795278285,0.696,0.8480951476668329,1.0,2/72,1.33%,TJP1;ITGB5
prerank,GO_Biological_Process_2021__regulation of T cell activation (GO:0050863),-0.5446566162442716,-0.8152694486830749,0.5943396226415094,0.8595080859802571,1.0,2/47,1.01%,FGL1;CD2
prerank,GO_Biological_Process_2021__regulation of autophagy (GO:0010506),0.560290184068665,0.8151629676610184,0.7985611510791367,0.8478749902759292,1.0,2/224,1.51%,PRKAA2;BOK
prerank,Reactome_2022__CREB1 Phosphorylation Thru NMDA Receptor-Mediated Activation Of RAS Signaling R-HSA-442742,0.5127020911190048,0.8149031906805955,0.53125,0.8477309342096292,1.0,2/27,0.91%,DLG1;GPRIN1
prerank,GO_Biological_Process_2021__negative chemotaxis (GO:0050919),-0.5671327203027462,-0.8146566989931436,0.6330275229357798,0.8597752974891752,1.0,1/31,0.96%,SEMA4D
prerank,Reactome_2022__SARS-CoV Infections R-HSA-9679506,-0.49038520017510795,-0.8143757477514149,0.9907407407407407,0.8596633824867376,1.0,11/345,1.26%,PARP8;AKT3;NR3C1;RB1;UVRAG;TOMM70;MOGAT1;VAV1;SDC3;S1PR1;TMPRSS2
prerank,Reactome_2022__Interleukin-17 Signaling R-HSA-448424,-0.5483315055010067,-0.8137486450767687,0.652542372881356,0.8599444393597806,1.0,2/66,1.26%,MAP2K6;DUSP4
prerank,GO_Biological_Process_2021__regulation of autophagosome assembly (GO:2000785),-0.5121942916645704,-0.8136371679222059,0.5652173913043478,0.8596625255372289,1.0,1/34,0.44%,FEZ1
prerank,GO_Biological_Process_2021__cellular amide metabolic process (GO:0043603),-0.5841946278433366,-0.8135915037906817,0.711864406779661,0.8593080483565435,1.0,6/114,1.19%,GLYAT;VNN1;PLAAT3;BTD;ACSM2B;MTHFD2L
prerank,MSigDB_Oncogenic_Signatures__RB P130 DN.V1 UP,0.6197227153410781,0.8135842982460587,0.6923076923076923,0.8488110729234705,1.0,4/114,1.53%,STMN3;UBE2C;CRB3;SNTA1
prerank,GO_Biological_Process_2021__regulation of biomineral tissue development (GO:0070167),0.49540910279563044,0.8134348064794115,0.5231788079470199,0.8486026879646792,1.0,1/24,1.30%,CYP27B1
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V1 UP,-0.588801589221205,-0.8133644748481853,0.6857142857142857,0.8591298390187481,1.0,4/136,1.33%,CYP39A1;CD27;NYNRIN;RTP4
prerank,KEGG_2021_Human__Longevity regulating pathway,-0.6053528746388982,-0.8132474924647396,0.6416666666666667,0.8588325488335735,1.0,3/97,1.11%,AKT3;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__aorta morphogenesis (GO:0035909),-0.46951278820308273,-0.8131026795065983,0.4424778761061947,0.8585779676435821,1.0,9/16,29.58%,HEY2;DLL4;ADAMTS9;MYLK;ENG;TBX1;LRP1;ACVRL1;BMPR1A
prerank,WikiPathway_2021_Human__Epithelial to mesenchymal transition in colorectal cancer WP4239,0.6006293899306351,0.8127926264729952,0.7638888888888888,0.8488981671539731,1.0,7/154,1.51%,LRP5;NOTCH3;TJP1;COL4A5;CRB3;FMNL2;FN1
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP LATE.V1 UP,0.5685834057653508,0.8127360041174924,0.7266187050359713,0.8485585921872054,1.0,7/169,1.47%,MYO7A;TUFT1;ZDHHC9;CTSH;KLB;SOAT2;CDC42EP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Arterial Hypertension,0.541967744583374,0.8126782196001954,0.7972027972027972,0.8482428811185909,1.0,6/223,1.51%,SLC6A4;PTK2;ATR;PPARA;APOE;FN1
prerank,GO_Biological_Process_2021__development of primary male sexual characteristics (GO:0046546),0.5513445793760351,0.812594622452586,0.6176470588235294,0.8479493199086116,1.0,2/35,1.34%,MSH2;COL9A3
prerank,KEGG_2021_Human__Hepatocellular carcinoma,-0.5578156321629831,-0.8124769630616527,0.7565217391304347,0.8589092195827526,1.0,5/160,0.73%,GSTA2;GSTA1;AKT3;RB1;PIK3CB
prerank,Reactome_2022__Phospholipid Metabolism R-HSA-1483257,-0.5545338260561546,-0.8124307430419386,0.8363636363636363,0.8585498924693696,1.0,5/199,1.35%,PLAAT3;SBF2;PIK3CB;AGPAT4;PIK3R6
prerank,GO_Biological_Process_2021__protein localization to nucleus (GO:0034504),0.6188236245102082,0.8121310755673772,0.7557251908396947,0.8480780904523719,1.0,1/103,0.95%,MSX1
prerank,KEGG_2021_Human__AMPK signaling pathway,0.5814242144458606,0.8113757449425124,0.7251908396946565,0.8485361867820199,1.0,3/114,0.81%,PRKAA2;ACACA;CAB39
prerank,GO_Biological_Process_2021__mRNA methylation (GO:0080009),-0.43137614814306124,-0.811308870471186,0.46923076923076923,0.85940131824707,1.0,5/15,13.20%,PCIF1;METTL3;CMTR1;TRMT10C;ZC3H13
prerank,GO_Biological_Process_2021__regulation of protein catabolic process (GO:0042176),0.6055502666550359,0.8109635614923171,0.6992481203007519,0.848609141169937,1.0,2/97,1.41%,WWP2;FLNA
prerank,GO_Biological_Process_2021__regulation of protein phosphorylation (GO:0001932),-0.5175827987354187,-0.8109360329979094,0.8640776699029126,0.859380852430116,1.0,7/254,1.31%,APP;CCND2;SEMA4D;PELI2;TEK;HRG;PML
prerank,Elsevier_Pathway_Collection__Receptors and Adaptor Proteins Activated in Cancer,-0.5778850262431066,-0.8109014744678417,0.7924528301886793,0.8590117370511334,1.0,5/119,1.36%,PROS1;NTF3;VAV1;ZAP70;GRB10
prerank,GO_Biological_Process_2021__regulation of adaptive immune response (GO:0002819),-0.4148944171965005,-0.8107084443809699,0.37606837606837606,0.8588142030228785,1.0,8/18,25.54%,IL4I1;EIF2AK4;PYCARD;FADD;TRIM27;TNFSF4;IL6ST;ALOX15
prerank,Reactome_2022__Nicotinate Metabolism R-HSA-196807,-0.5577402694387622,-0.8106867158682128,0.5922330097087378,0.8584296006431282,1.0,1/29,0.12%,PARP8
prerank,MSigDB_Hallmark_2020__Apoptosis,-0.56817222081179,-0.8106238110095724,0.7641509433962265,0.8581178160627413,1.0,4/158,1.01%,APP;FEZ1;CCND2;CD2
prerank,WikiPathway_2021_Human__Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.5800787377753998,0.8102352444752301,0.65625,0.848967516769782,1.0,3/45,1.33%,MAP4K5;TEAD4;ITGB5
prerank,MSigDB_Oncogenic_Signatures__RAF UP.V1 UP,0.5665173661092885,0.8102023387566494,0.7553956834532374,0.8486222481052356,1.0,7/181,1.45%,NDC80;HSD17B11;LRP5;ETV5;FGF1;SLC2A6;RNF144A
prerank,Reactome_2022__MET Promotes Cell Motility R-HSA-8875878,0.5040027940893023,0.8100519995303095,0.5546875,0.8484148678654567,1.0,2/28,0.38%,PTK2;ITGA2
prerank,GO_Biological_Process_2021__I-kappaB kinase/NF-kappaB signaling (GO:0007249),0.6471217085493924,0.8098099678606316,0.7352941176470589,0.8482495984506494,1.0,1/60,0.10%,IRAK2
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection assembly (GO:0120031),-0.5072040506555684,-0.8095330924146776,0.9148936170212766,0.8588221833063168,1.0,7/270,1.36%,CARMIL1;RAP1A;RAP1B;TTBK2;EXOC2;S1PR1;ABLIM3
prerank,Elsevier_Pathway_Collection__Crohn's Disease,0.5985184164579086,0.8094197650362571,0.664179104477612,0.8482454056960567,1.0,1/52,0.44%,TRAF3
prerank,WikiPathway_2021_Human__ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,-0.5772110835084869,-0.809242716328775,0.7666666666666667,0.8587839553588811,1.0,2/80,0.99%,CCND2;KLF4
prerank,WikiPathway_2021_Human__Endochondral Ossification WP474,-0.612978768757239,-0.8091533222185312,0.6754385964912281,0.8580587888589574,1.0,2/60,1.22%,ADAMTS5;GLI3
prerank,WikiPathway_2021_Human__Endochondral Ossification with Skeletal Dysplasias WP4808,-0.612978768757239,-0.8091533222185312,0.6754385964912281,0.8580587888589574,1.0,2/60,1.22%,ADAMTS5;GLI3
prerank,GO_Biological_Process_2021__negative regulation of cell-substrate junction organization (GO:0150118),0.43371284015498823,0.8090326360447048,0.4318181818181818,0.8479171289239378,1.0,12/16,39.19%,APOD;ARHGAP6;RCC2;PTEN;DLC1;DMTN;SRC;PHLDB2;ITGB1BP1;CLASP2;THBS1;DUSP22
prerank,GO_Biological_Process_2021__negative regulation of focal adhesion assembly (GO:0051895),0.43371284015498823,0.8090326360447048,0.4318181818181818,0.8479171289239378,1.0,12/16,39.19%,APOD;ARHGAP6;RCC2;PTEN;DLC1;DMTN;SRC;PHLDB2;ITGB1BP1;CLASP2;THBS1;DUSP22
prerank,Reactome_2022__HATs Acetylate Histones R-HSA-3214847,-0.6300346532958929,-0.8089783096388434,0.7297297297297297,0.857830238954496,1.0,2/92,0.60%,NCOA1;KAT14
prerank,GO_Biological_Process_2021__myotube differentiation (GO:0014902),0.499243990838348,0.8088843027250373,0.4961832061068702,0.8477138653949197,1.0,1/19,0.46%,SORT1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Polycystic Ovary Syndrome,0.6077335882017099,0.8086234016458227,0.6938775510204082,0.8476145321910371,1.0,3/92,0.95%,FBN3;NEK4;AMH
prerank,GO_Biological_Process_2021__regulation of secretion by cell (GO:1903530),-0.5304319012653465,-0.808154236112608,0.635593220338983,0.8582661644155529,1.0,1/51,0.66%,STXBP5
prerank,GO_Biological_Process_2021__regulation of protein serine/threonine kinase activity (GO:0071900),0.5922893752114118,0.8081236411706186,0.7014925373134329,0.8477812405993675,1.0,5/105,1.16%,THY1;KSR1;LRP5;CAB39;PKMYT1
prerank,GO_Biological_Process_2021__regulation of oxidative phosphorylation (GO:0002082),0.4328131668995361,0.8080721853873671,0.41304347826086957,0.8474579265919308,1.0,5/15,9.37%,PPIF;MLXIPL;PDE12;SLC25A33;VCP
prerank,GO_Biological_Process_2021__response to lipopolysaccharide (GO:0032496),-0.5625561045466048,-0.8080385651414593,0.7115384615384616,0.8579976154842097,1.0,3/146,1.04%,GGT5;CD274;TICAM2
prerank,GO_Biological_Process_2021__male gonad development (GO:0008584),0.5513445330634296,0.8079063593489743,0.6159420289855072,0.8472602368633617,1.0,2/35,1.34%,MSH2;COL9A3
prerank,GO_Biological_Process_2021__negative regulation of defense response (GO:0031348),-0.585703880125874,-0.8070974088351399,0.7368421052631579,0.858663614351066,1.0,3/78,1.21%,RB1;KLF4;TEK
prerank,WikiPathway_2021_Human__Complement system WP2806,-0.6070348574387793,-0.8070953643261287,0.7165354330708661,0.8582568575465415,1.0,2/95,1.06%,PROS1;C1R
prerank,MSigDB_Oncogenic_Signatures__KRAS.50 UP.V1 DN,0.5072615028099026,0.8069911988900663,0.5877862595419847,0.8478695525587848,1.0,1/32,0.90%,CGREF1
prerank,Elsevier_Pathway_Collection__Bone Remodeling in Hyperthyroidism,-0.5874868172794485,-0.8067478444301313,0.7105263157894737,0.8582310602103383,1.0,2/56,1.25%,ADAMTS5;VDR
prerank,Reactome_2022__MAP Kinase Activation R-HSA-450294,-0.5483336462957782,-0.8066772967642135,0.6666666666666666,0.8578969678058386,1.0,2/62,1.26%,MAP2K6;DUSP4
prerank,MSigDB_Oncogenic_Signatures__NOTCH DN.V1 UP,-0.5543258513983037,-0.8065450414573339,0.7641509433962265,0.857625226430821,1.0,3/149,1.21%,CPEB3;DHX32;NYNRIN
prerank,KEGG_2021_Human__mTOR signaling pathway,0.5663021956138571,0.8065288636065283,0.7222222222222222,0.8479156353098678,1.0,4/147,0.81%,PRKAA2;LRP5;FNIP1;CAB39
prerank,WikiPathway_2021_Human__p38 MAPK Signaling Pathway WP400,0.5033904016739859,0.8056259810043956,0.5925925925925926,0.8483922767462935,1.0,1/34,0.27%,MAP3K9
prerank,GO_Biological_Process_2021__response to calcium ion (GO:0051592),-0.559835265681089,-0.8053789063331742,0.6724137931034483,0.8585078466720621,1.0,3/102,1.17%,SYT7;RASGRP2;AQP3
prerank,Reactome_2022__SUMO E3 Ligases SUMOylate Target Proteins R-HSA-3108232,0.5989260550288296,0.8053337475479682,0.7333333333333333,0.8483396621366436,1.0,5/165,1.02%,MRTFA;NUP210;HERC2;PPARA;CBX2
prerank,KEGG_2021_Human__Viral carcinogenesis,0.5421236589570946,0.805126285576738,0.8148148148148148,0.8481570269977992,1.0,5/184,0.74%,CDK6;RBL1;HDAC8;TRAF3;DLG1
prerank,GO_Biological_Process_2021__regulation of type I interferon production (GO:0032479),0.5997872019698915,0.805054307065179,0.6739130434782609,0.8478662109083867,1.0,1/87,0.44%,TRAF3
prerank,GO_Biological_Process_2021__positive regulation of signal transduction (GO:0009967),-0.5224615643982369,-0.8049087050646188,0.847457627118644,0.8586319221950348,1.0,7/239,1.36%,TRIM44;PTK2B;MBD5;NTF3;SCIMP;TEK;GRB10
prerank,GO_Biological_Process_2021__vascular endothelial growth factor receptor signaling pathway (GO:0048010),-0.5654584124311879,-0.804783564973524,0.6864406779661016,0.8583861965292757,1.0,4/67,1.10%,PTK2B;PAK2;PIK3CB;VAV1
prerank,Reactome_2022__Collagen Chain Trimerization R-HSA-8948216,0.6011428773098291,0.8046413395828123,0.6666666666666666,0.847967173912316,1.0,3/43,1.34%,COL4A5;COL12A1;COL9A3
prerank,Reactome_2022__Metabolism Of Nucleotides R-HSA-15869,-0.5908568657024611,-0.804564562942602,0.7798165137614679,0.8581906366053789,1.0,4/92,1.18%,DPYS;ENTPD8;ENTPD3;GMPR
prerank,MSigDB_Oncogenic_Signatures__RAPA EARLY UP.V1 UP,-0.5438672946700258,-0.8044145378167065,0.7938144329896907,0.8579872756363941,1.0,5/149,1.08%,HERC3;PDE5A;NCOA1;TNFAIP2;BASP1
prerank,GO_Biological_Process_2021__cholesterol transport (GO:0030301),0.5852481064070996,0.8042850358286712,0.6692913385826772,0.8479498100582059,1.0,2/51,1.35%,APOE;SOAT2
prerank,Reactome_2022__Deubiquitination R-HSA-5688426,0.5369065565285982,0.8039799028503575,0.8175675675675675,0.8478941757015478,1.0,2/243,0.44%,AXIN2;TRAF3
prerank,KEGG_2021_Human__beta-Alanine metabolism,-0.5276058894427571,-0.803830632330468,0.5909090909090909,0.8582251040527578,1.0,1/29,0.12%,DPYS
prerank,GO_Biological_Process_2021__dephosphorylation (GO:0016311),0.5925601292031495,0.8037383380307025,0.7054794520547946,0.8477736992983665,1.0,3/146,0.93%,PLPPR1;PPM1H;PTPRH
prerank,"WikiPathway_2021_Human__GPCRs, Class B Secretin-like WP334",0.5088673764404262,0.8035489314389355,0.5169491525423728,0.8476050974747411,1.0,1/22,1.17%,ADGRG2
prerank,GO_Biological_Process_2021__positive regulation of autophagy (GO:0010508),0.6327826950696597,0.8033603891556176,0.6866666666666666,0.8474449554018529,1.0,1/84,0.03%,PRKAA2
prerank,GO_Biological_Process_2021__peptide biosynthetic process (GO:0043043),-0.5446798144770612,-0.8031889776582831,0.8285714285714286,0.8585704124584763,1.0,1/157,0.38%,GGT5
prerank,Reactome_2022__Signaling By BMP R-HSA-201451,-0.5125874929248151,-0.802964460427579,0.5701754385964912,0.858416999603057,1.0,1/27,0.74%,ZFYVE16
prerank,GO_Biological_Process_2021__positive regulation of cell-substrate adhesion (GO:0010811),0.5899145285070698,0.8027260228558387,0.6538461538461539,0.8476472002124268,1.0,4/68,1.51%,CDK6;ARHGEF7;FLNA;FN1
prerank,Reactome_2022__Degradation Of Extracellular Matrix R-HSA-1474228,-0.5698771429793397,-0.8016303822254658,0.7090909090909091,0.859503155953114,1.0,2/101,0.91%,ADAMTS5;COL26A1
prerank,Reactome_2022__DNA Damage/Telomere Stress Induced Senescence R-HSA-2559586,0.5941721373371054,0.8012811900146962,0.7024793388429752,0.8487727588088261,1.0,2/48,1.41%,HIRA;ACD
prerank,GO_Biological_Process_2021__phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200),0.629128417655548,0.8010565952159796,0.7674418604651163,0.8486206172486986,1.0,1/63,0.16%,GPR35
prerank,Reactome_2022__Mitotic G1 Phase And G1/S Transition R-HSA-453279,0.5665214698041494,0.8008444679739828,0.7647058823529411,0.8484503542137529,1.0,5/145,1.18%,CDC45;CDK6;RBL1;POLE4;RRM2
prerank,Reactome_2022__MAP2K And MAPK Activation R-HSA-5674135,-0.5587976730297234,-0.8001992914560869,0.6532258064516129,0.8605803227329782,1.0,2/36,0.42%,RAP1A;RAP1B
prerank,GO_Biological_Process_2021__positive regulation of protein kinase B signaling (GO:0051897),0.5746450708813554,0.799964626689173,0.7432432432432432,0.8489802438453414,1.0,4/149,1.36%,PTK2;ERBB3;KLB;FGF1
prerank,Elsevier_Pathway_Collection__EphrinB -> MAPK/JUN/FOS Signaling,-0.4961126198931668,-0.7997960517926445,0.5785123966942148,0.8606192851891961,1.0,2/33,1.16%,RAP1A;MAP4K1
prerank,GO_Biological_Process_2021__positive regulation of GTPase activity (GO:0043547),-0.554857379968876,-0.7994710061097595,0.8378378378378378,0.860572648200637,1.0,9/196,1.06%,CCL23;ARHGEF26;EVI5;RAP1A;SNX13;NTF3;RASGRP2;SEMA4D;GARNL3
prerank,Reactome_2022__TAK1-dependent IKK And NF-kappa-B Activation R-HSA-445989,0.5445744632991191,0.7993689538190887,0.6412213740458015,0.8491498731643536,1.0,1/44,0.10%,IRAK2
prerank,Elsevier_Pathway_Collection__Angiogenesis in Endometriosis,-0.5757957525630195,-0.7993383474953747,0.7008547008547008,0.8603172208953225,1.0,3/57,1.21%,MAP2K6;VAV1;TEK
prerank,Elsevier_Pathway_Collection__FLT3/KIT/MLL Signaling in Leukemia,0.5200757332597616,0.799096677515186,0.5833333333333334,0.8490591538163673,1.0,1/29,0.89%,MLLT10
prerank,Reactome_2022__Aquaporin-mediated Transport R-HSA-445717,0.535577232326119,0.7990254850916704,0.6260162601626016,0.848761438072283,1.0,1/45,1.11%,GNB5
prerank,WikiPathway_2021_Human__Proximal tubule transport WP4917,-0.5403480360768339,-0.7989219142705954,0.6020408163265306,0.8603999872301162,1.0,1/50,0.20%,SLC7A8
prerank,KEGG_2021_Human__Focal adhesion,-0.5389895852561782,-0.7983101883259327,0.8380952380952381,0.8606277288913227,1.0,8/193,1.22%,RAP1A;AKT3;RAP1B;PAK2;PIK3CB;CCND2;VAV1;COL4A4
prerank,GO_Biological_Process_2021__anion transport (GO:0006820),0.5492294984045767,0.7982850060979496,0.6788321167883211,0.8491693878309378,1.0,2/41,0.90%,SLC19A1;SLC13A3
prerank,Reactome_2022__RHOH GTPase Cycle R-HSA-9013407,0.5103060386620538,0.7981576074145904,0.6086956521739131,0.848926503960191,1.0,2/34,1.55%,RALGAPA1;UACA
prerank,GO_Biological_Process_2021__anterograde axonal transport (GO:0008089),-0.5333694908069105,-0.7977140910797414,0.6048387096774194,0.8608771037620351,1.0,1/37,1.05%,DLG2
prerank,GO_Biological_Process_2021__protein modification by small protein conjugation (GO:0032446),0.49807073537955315,0.7971754837933958,0.9530201342281879,0.8496450604967701,1.0,8/383,1.45%,TRIM24;NUP210;HERC2;WWP2;UBE2H;UBE2C;STX1A;RNF144A
prerank,TRRUST_Transcription_Factors_2019__VDR human,0.5709819968321225,0.7970692105009666,0.6666666666666666,0.8493757215461798,1.0,2/37,0.95%,ASAP2;AMH
prerank,Elsevier_Pathway_Collection__CRH Secretion Regulation,-0.42989457030646366,-0.796922303610284,0.41935483870967744,0.8612830725109477,1.0,13/22,27.32%,MAPK3;GRIN1;KCNJ10;RAF1;RASGRP1;MAP2K2;GNAQ;HTR4;ADRA1B;ITPR1;PLCB1;GRIK1;OPRD1
prerank,GO_Biological_Process_2021__extracellular matrix organization (GO:0030198),0.5227063613584833,0.7968445128434984,0.9387755102040817,0.8492537339577835,1.0,10/275,1.51%,ITGA2;PLOD2;COL4A5;ITGAL;COL12A1;A2M;ITGB5;HAS3;COL9A3;FN1
prerank,WikiPathway_2021_Human__Integrated breast cancer pathway WP1984,0.574429575216463,0.7967080849587054,0.7323943661971831,0.8490228022679495,1.0,4/151,1.56%,MSH2;RALGAPA1;ATR;FOSL2
prerank,GO_Biological_Process_2021__protein targeting (GO:0006605),-0.5774547489105742,-0.7964318577726552,0.7281553398058253,0.8614108678822251,1.0,3/121,1.33%,ZDHHC21;TOMM70;RTP4
prerank,Elsevier_Pathway_Collection__Fatty Acid Synthase (FASN) Signaling,0.45419739192710384,0.7964228112781341,0.464,0.8489473180630421,1.0,8/16,19.98%,GSK3B;MAPK1;CEBPA;STAT5A;FASN;SREBF1;PPARG;SP1
prerank,GO_Biological_Process_2021__peptidyl-tyrosine modification (GO:0018212),-0.5770699279400447,-0.7962877222497131,0.6974789915966386,0.8611676659148075,1.0,5/56,1.21%,TPST1;PTK2B;HCK;ZAP70;TEK
prerank,GO_Biological_Process_2021__proteolysis (GO:0006508),-0.49409733670897926,-0.7962418981804383,0.963302752293578,0.8608156613729212,1.0,4/255,1.26%,CTSO;GGT5;HABP2;TMPRSS2
prerank,Reactome_2022__Signaling By ERBB4 R-HSA-1236394,0.590547377545416,0.796047605668816,0.7,0.8489329806099088,1.0,2/55,1.30%,ERBB3;APOE
prerank,GO_Biological_Process_2021__import into cell (GO:0098657),-0.5097032966618492,-0.7960263135586106,0.6186440677966102,0.8606482608983099,1.0,3/39,1.12%,SLC7A8;SLC16A2;IL10RA
prerank,GO_Biological_Process_2021__positive regulation of secretion by cell (GO:1903532),-0.589194390559349,-0.7957914154521238,0.6695652173913044,0.860481017165716,1.0,1/69,0.66%,STXBP5
prerank,MSigDB_Oncogenic_Signatures__RPS14 DN.V1 UP,-0.5236347606365581,-0.795751947196417,0.824,0.8601258689154442,1.0,7/178,1.27%,CDCP1;VNN1;HCK;TNFAIP2;CLEC2B;NYNRIN;CYP1B1
prerank,GO_Biological_Process_2021__positive regulation of mitotic nuclear division (GO:0045840),0.5079853360946548,0.7955443521550709,0.5736434108527132,0.8490077622322528,1.0,1/30,0.40%,LRP5
prerank,Elsevier_Pathway_Collection__Insulin Resistance in Hepatocytes,0.5915979080295465,0.7954203465567924,0.6595744680851063,0.8487525978073585,1.0,1/47,0.79%,PPARA
prerank,GO_Biological_Process_2021__lipid biosynthetic process (GO:0008610),0.5808164403267994,0.7951938710785683,0.656,0.8486031711505415,1.0,7/75,1.39%,PRKAA2;ACACA;GPAT4;ACSF3;ACSL5;FDXR;PRLR
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell proliferation (GO:0050679),0.6181534662970067,0.7949472248935463,0.7520661157024794,0.8484818897990164,1.0,3/117,1.36%,PPP1R16B;ZNF304;FGF1
prerank,WikiPathway_2021_Human__Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.575523946198606,0.7947406534853267,0.725925925925926,0.8483294158324804,1.0,4/130,0.86%,PRKAA2;MAP3K9;MAP4K5;RHOQ
prerank,Elsevier_Pathway_Collection__High-Grade Serous Ovarian Carcinoma,0.639361987936327,0.794414436459985,0.7815126050420168,0.8482594013109751,1.0,2/81,0.96%,NOTCH3;ERBB3
prerank,Reactome_2022__Post-translational Modification: Synthesis Of GPI-anchored Proteins R-HSA-163125,-0.560256625567848,-0.7943890325420486,0.7235772357723578,0.8612194349260321,1.0,2/77,0.11%,CNTN3;VNN1
prerank,GO_Biological_Process_2021__negative regulation of programmed cell death (GO:0043069),0.5009968423070733,0.794236123437253,0.9357142857142857,0.84808740612108,1.0,11/363,1.41%,PRKAA2;PTK2;AATF;TJP1;TBX3;PRAP1;TNFRSF10D;SH3RF2;CTSH;PRLR;FLNA
prerank,TRRUST_Transcription_Factors_2019__ESR1 human,0.6074449620511285,0.7940044612085729,0.746268656716418,0.8479550428104021,1.0,1/71,0.95%,AMH
prerank,GO_Biological_Process_2021__cellular macromolecule catabolic process (GO:0044265),-0.5085037458398052,-0.7937754224521475,0.6097560975609756,0.8614338623441848,1.0,1/48,0.40%,FBXO27
prerank,GO_Biological_Process_2021__positive regulation of actin filament polymerization (GO:0030838),-0.538917667164237,-0.7937674205260449,0.6638655462184874,0.8610451608595292,1.0,3/47,0.81%,CARMIL1;PTK2B;HCK
prerank,GO_Biological_Process_2021__T cell receptor signaling pathway (GO:0050852),-0.5621193404220262,-0.7937374185640944,0.6896551724137931,0.8606686778263228,1.0,3/150,1.13%,PAK2;PIK3CB;ZAP70
prerank,GO_Biological_Process_2021__regulation of release of sequestered calcium ion into cytosol (GO:0051279),0.5851306913213223,0.7937238825159415,0.696969696969697,0.8478819926969005,1.0,1/49,0.07%,THY1
prerank,Elsevier_Pathway_Collection__Metabolic Reprogramming in Cancer: Overview,-0.5382865437138222,-0.7937143304142329,0.6296296296296297,0.8602984712248898,1.0,1/61,0.08%,ALDOB
prerank,MSigDB_Oncogenic_Signatures__MEL18 DN.V1 DN,-0.5441181221688137,-0.793529242981186,0.7321428571428571,0.8601062743933864,1.0,5/125,1.24%,PDE5A;OAS1;GAS2;AQP3;MAOB
prerank,GO_Biological_Process_2021__cellular response to tumor necrosis factor (GO:0071356),-0.5317505341493813,-0.7934753745170088,0.8363636363636363,0.8597642992224559,1.0,3/185,0.85%,CCL23;PTK2B;CD27
prerank,GO_Biological_Process_2021__positive regulation of immunoglobulin mediated immune response (GO:0002891),-0.3938178903024748,-0.7932033242583973,0.43795620437956206,0.8596810020009834,1.0,8/15,25.82%,NECTIN2;CD226;SHLD3;TFRC;PAXIP1;TNFSF4;XCL1;MAD2L2
prerank,GO_Biological_Process_2021__positive regulation of kinase activity (GO:0033674),0.5909370217217698,0.7926647972479037,0.7571428571428571,0.848624276365566,1.0,4/111,1.31%,CENPE;PTK2;ERBB3;DRD4
prerank,TRRUST_Transcription_Factors_2019__DNMT1 human,0.5355226593140067,0.7925497294683573,0.5905511811023622,0.848355485288107,1.0,1/30,0.17%,MSH2
prerank,Reactome_2022__PI Metabolism R-HSA-1483255,-0.5799717672264887,-0.7924917091695247,0.7454545454545455,0.8600216092845718,1.0,3/81,1.35%,SBF2;PIK3CB;PIK3R6
prerank,GO_Biological_Process_2021__positive regulation of DNA metabolic process (GO:0051054),0.5757002109161335,0.7924709248458153,0.6853146853146853,0.8480820000253529,1.0,2/62,1.46%,SMCHD1;WRAP53
prerank,"GO_Biological_Process_2021__phagocytosis, engulfment (GO:0006911)",0.5008040882523414,0.7923570095524664,0.5702479338842975,0.8478169591301644,1.0,1/36,0.06%,HAVCR1
prerank,GO_Biological_Process_2021__negative regulation of cell cycle (GO:0045786),-0.5785985591221249,-0.79218274297895,0.7857142857142857,0.859942210550093,1.0,2/75,1.12%,RB1;GMNC
prerank,MSigDB_Hallmark_2020__Wnt-beta Catenin Signaling,0.6089427971217095,0.7921722561882304,0.6956521739130435,0.847627626418644,1.0,1/42,0.12%,AXIN2
prerank,Reactome_2022__Regulation Of Insulin Secretion R-HSA-422356,-0.6108342612560399,-0.7921489548620575,0.7235772357723578,0.8595950402272702,1.0,3/72,1.24%,RAP1A;GNA14;KCNS3
prerank,Reactome_2022__Programmed Cell Death R-HSA-5357801,0.5538624376485046,0.7918038652476659,0.8368794326241135,0.8476647965189316,1.0,5/199,1.55%,PTK2;TNFRSF10A;TJP1;STK26;UACA
prerank,Elsevier_Pathway_Collection__Apoptosis,0.5926054553744776,0.791794211551725,0.7391304347826086,0.8473051923415279,1.0,4/76,1.51%,TNFRSF10A;TNFRSF25;TNFRSF10D;BOK
prerank,GO_Biological_Process_2021__gonad development (GO:0008406),-0.5228309865651372,-0.7917435262036057,0.6272727272727273,0.8596202462844074,1.0,2/41,1.08%,ADAM20;BASP1
prerank,GO_Biological_Process_2021__tumor necrosis factor-mediated signaling pathway (GO:0033209),0.5773923745874849,0.7917205944781366,0.7535211267605634,0.8470114476056806,1.0,3/113,1.20%,TRAF3;TNFRSF25;EDA2R
prerank,Reactome_2022__Collagen Degradation R-HSA-1442490,0.6131686128389578,0.7913505413863692,0.6976744186046512,0.8470373694100299,1.0,2/38,1.34%,COL12A1;COL9A3
prerank,MSigDB_Hallmark_2020__Unfolded Protein Response,-0.598378227311569,-0.7909826911393802,0.7475728155339806,0.8600369853293336,1.0,2/113,1.30%,EXOC2;DNAJA4
prerank,GO_Biological_Process_2021__negative regulation of macromolecule metabolic process (GO:0010605),-0.5252935740469461,-0.7906747501704604,0.819047619047619,0.8599518269798391,1.0,7/187,1.25%,SLC2A10;APP;RB1;ZNF148;KLF4;SPI1;VDR
prerank,Elsevier_Pathway_Collection__Celiac Disease,-0.5404720920304291,-0.7902038632217576,0.6875,0.8600928138117515,1.0,1/48,1.13%,ZAP70
prerank,GO_Biological_Process_2021__positive regulation of protein kinase activity (GO:0045860),0.5840922152023191,0.7900293819462721,0.7551020408163265,0.8480129078673554,1.0,4/149,0.96%,CENPE;PTK2;CAB39;ERBB3
prerank,Elsevier_Pathway_Collection__Apoptosis Evasion in Cancer: Overview,0.5691494787524884,0.7898650931177659,0.676056338028169,0.8478010680868959,1.0,5/103,1.51%,AATF;TNFRSF10A;TNFRSF25;TNFRSF10D;BOK
prerank,GO_Biological_Process_2021__negative regulation of neuron apoptotic process (GO:0043524),0.6145570055015468,0.7897823244235612,0.7194244604316546,0.8475027083764047,1.0,4/64,1.48%,MSH2;ERBB3;APOE;SLC30A10
prerank,GO_Biological_Process_2021__regulation of phosphorylation (GO:0042325),0.6011155114797573,0.7897574761498128,0.7480916030534351,0.8471669963375655,1.0,5/121,1.51%,PTK2;NUP210;FNIP1;SLC2A6;FN1
prerank,Reactome_2022__RNA Polymerase III Chain Elongation R-HSA-73780,0.44017210298243986,0.7895034857870556,0.4496124031007752,0.8470702087245818,1.0,8/17,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;POLR2H;POLR3F;CRCP
prerank,Elsevier_Pathway_Collection__Sebocyte Proliferation in Acne Vulgaris,-0.5181216040738319,-0.7893295812297858,0.6423357664233577,0.8606030668501787,1.0,1/40,0.34%,RAP1A
prerank,MSigDB_Hallmark_2020__UV Response Dn,-0.560387232187543,-0.7893079813403436,0.8598130841121495,0.8602172774436472,1.0,4/144,1.11%,AKT3;NR3C1;RASA2;SYNE1
prerank,Reactome_2022__Cooperation Of PDCL (PhLP1) And TRiC/CCT In G-protein Beta Folding R-HSA-6814122,0.5056727539117448,0.7893044782604232,0.608,0.8468918152150693,1.0,1/34,1.11%,GNB5
prerank,WikiPathway_2021_Human__Pathways in clear cell renal cell carcinoma WP4018,0.5866815820887208,0.7893021438556223,0.7571428571428571,0.8465323031794224,1.0,4/83,1.12%,ACACA;KSR1;PLOD2;PKLR
prerank,GO_Biological_Process_2021__positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068),-0.5514129391797941,-0.7892357773657378,0.7456140350877193,0.859875033289066,1.0,4/73,1.21%,PIK3CB;NTF3;SEMA4D;TEK
prerank,Elsevier_Pathway_Collection__CDH2 Activation Promotes Cancer Cell Migration and Survival,0.6095397140006177,0.7890009493843859,0.6825396825396826,0.8464342810608645,1.0,2/49,1.49%,PTK2;BCAR1
prerank,GO_Biological_Process_2021__regulation of bone mineralization (GO:0030500),0.603201016682348,0.7887248815569572,0.7272727272727273,0.8462661811011952,1.0,3/54,1.30%,BCOR;PKDCC;CYP27B1
prerank,WikiPathway_2021_Human__Metabolic reprogramming in colon cancer WP4290,-0.5261148366807095,-0.7886031075584944,0.6461538461538462,0.8601806143086108,1.0,2/42,0.24%,ALDOB;SUCLG2
prerank,WikiPathway_2021_Human__Ciliopathies WP4803,0.5592840745753562,0.7885935870932469,0.8064516129032258,0.8460346175502439,1.0,5/171,1.01%,DNAAF5;CEP164;NEK8;CCDC40;TUB
prerank,GO_Biological_Process_2021__positive regulation of collagen biosynthetic process (GO:0032967),-0.3719368564769274,-0.7884558264483272,0.376,0.859966184750816,1.0,7/15,34.31%,LARP6;F2;CREB3L1;F2R;SUCO;TGFB1;BMP4
prerank,GO_Biological_Process_2021__B cell activation (GO:0042113),-0.5691539952535157,-0.7883986883868985,0.717948717948718,0.859630413708352,1.0,2/66,1.13%,RABL3;ZAP70
prerank,MSigDB_Oncogenic_Signatures__E2F3 UP.V1 UP,-0.5257431908182363,-0.7882065845452929,0.8235294117647058,0.8594458288998279,1.0,3/167,1.24%,CDK19;CD83;KCNS3
prerank,GO_Biological_Process_2021__negative regulation of signal transduction (GO:0009968),0.5343640213623697,0.788178037328935,0.896774193548387,0.8460803997788608,1.0,6/252,0.96%,MEGF8;VGLL4;NOTCH3;WWP2;HERC4;ERBB3
prerank,WikiPathway_2021_Human__Mesodermal commitment pathway WP2857,0.5819842509356452,0.7880038288921374,0.7941176470588235,0.8458735584822175,1.0,7/133,1.51%,AXIN2;ACACA;TBX3;AMH;CHRD;PHF6;HPRT1
prerank,MSigDB_Oncogenic_Signatures__AKT UP.V1 DN,-0.5475638422048233,-0.7874329135022043,0.7909090909090909,0.8598235076385443,1.0,3/169,1.06%,TYW1;GNA14;C1R
prerank,GO_Biological_Process_2021__apoptotic DNA fragmentation (GO:0006309),-0.38651983653923905,-0.787382248832058,0.42592592592592593,0.8595019719849839,1.0,8/15,28.93%,DNASE1L3;EXOG;HMGB1;H1-0;DNASE2;KPNA1;DFFB;CASP3
prerank,WikiPathway_2021_Human__Calcium Regulation in the Cardiac Cell WP536,0.5994997432016742,0.7870591106589897,0.8296296296296296,0.8464568996702784,1.0,2/139,1.11%,GJC1;GNB5
prerank,GO_Biological_Process_2021__defense response to Gram-positive bacterium (GO:0050830),-0.5714701568310222,-0.7869582406098476,0.6846846846846847,0.8595583767132848,1.0,2/49,1.03%,GBP4;PGLYRP2
prerank,KEGG_2021_Human__Hepatitis C,-0.5554450622463447,-0.7867069924220165,0.8260869565217391,0.8594171940385423,1.0,4/139,0.73%,AKT3;OAS1;RB1;PIK3CB
prerank,Reactome_2022__Signaling By High-Kinase Activity BRAF Mutants R-HSA-6802948,-0.5587984379768846,-0.7864695503448631,0.6587301587301587,0.8592800516283765,1.0,2/32,0.42%,RAP1A;RAP1B
prerank,KEGG_2021_Human__Nicotinate and nicotinamide metabolism,-0.5096092517446715,-0.7864021483252716,0.6218487394957983,0.858935913201355,1.0,1/33,0.48%,NT5C1B
prerank,GO_Biological_Process_2021__positive regulation of hormone secretion (GO:0046887),0.4566555794158614,0.7860409717584967,0.49166666666666664,0.8471569691219797,1.0,5/15,12.08%,NMB;C1QTNF3;VAMP7;SNX4;FGA
prerank,Reactome_2022__Diseases Of Metabolism R-HSA-5668914,-0.5186453078690072,-0.7858933740298912,0.900990099009901,0.8590471615033377,1.0,7/228,1.27%,MUC6;ALDOB;ADAMTS5;GALNT3;ADAMTSL2;SDC3;CYP1B1
prerank,GO_Biological_Process_2021__negative regulation of protein localization to membrane (GO:1905476),0.5064098957383818,0.7857007157065031,0.578125,0.8471338374133365,1.0,1/24,0.86%,RHOQ
prerank,GO_Biological_Process_2021__regulation of chromosome organization (GO:0033044),0.49802910747659035,0.7855629786831358,0.5454545454545454,0.8469106313987246,1.0,2/21,1.13%,HDAC8;PIF1
prerank,Elsevier_Pathway_Collection__OPRD/OPRM -> Ion Channels,0.44492115781626423,0.78533995802989,0.43846153846153846,0.8467640426251238,1.0,5/16,10.24%,KCNJ3;CACNA1E;KCNJ5;GNAI1;TRPV1
prerank,MSigDB_Oncogenic_Signatures__KRAS.AMP.LUNG UP.V1 UP,0.5914655364485171,0.7852107387610939,0.7602739726027398,0.846546062328366,1.0,1/106,0.02%,KCNC1
prerank,GO_Biological_Process_2021__receptor metabolic process (GO:0043112),-0.570850067236093,-0.78499671081667,0.7029702970297029,0.8596404966774601,1.0,1/58,0.70%,UVRAG
prerank,GO_Biological_Process_2021__positive regulation of mRNA catabolic process (GO:0061014),-0.5624299096922044,-0.7845675894960383,0.6614173228346457,0.8596810711373845,1.0,1/43,0.07%,CPEB3
prerank,Reactome_2022__PI3K/AKT Signaling In Cancer R-HSA-2219528,-0.5547805812957779,-0.7845567865843276,0.7289719626168224,0.8593022755547371,1.0,3/98,1.10%,AKT3;PIK3CB;VAV1
prerank,GO_Biological_Process_2021__negative regulation of cysteine-type endopeptidase activity (GO:2000117),0.5693370878466508,0.784478827939388,0.7066666666666667,0.8468904122305819,1.0,1/51,0.69%,FNIP1
prerank,Reactome_2022__Cyclin D Associated Events In G1 R-HSA-69231,0.5533368134400405,0.7841037081042651,0.6785714285714286,0.8468836840435506,1.0,2/47,0.29%,CDK6;RBL1
prerank,Reactome_2022__RHOG GTPase Cycle R-HSA-9013408,0.5758730558838088,0.7838284503003218,0.75,0.846792549877305,1.0,3/73,1.47%,DEPDC1B;ARHGAP39;CDC42EP1
prerank,GO_Biological_Process_2021__histone acetylation (GO:0016573),0.5616989046660643,0.7833517942809792,0.7557251908396947,0.8468962066658278,1.0,2/70,0.66%,ING5;NAA60
prerank,GO_Biological_Process_2021__post-translational protein modification (GO:0043687),0.49783175765134857,0.7830077808329703,0.9671052631578947,0.8468797531375069,1.0,6/330,1.51%,FBXO31;ASB3;CKAP4;MELTF;APOE;FN1
prerank,KEGG_2021_Human__Small cell lung cancer,0.5986538168685815,0.7829016237408155,0.7238805970149254,0.8466152666506626,1.0,6/92,1.51%,CDK6;PTK2;ITGA2;TRAF3;COL4A5;FN1
prerank,GO_Biological_Process_2021__regulation of MAPK cascade (GO:0043408),-0.5616468746380392,-0.7828893390369503,0.7768595041322314,0.8606257299590027,1.0,4/154,1.21%,PAK2;LBH;PELI2;TEK
prerank,GO_Biological_Process_2021__regulation of Wnt signaling pathway (GO:0030111),0.5773052549137181,0.7825192254981141,0.7538461538461538,0.8466362193224223,1.0,2/105,0.42%,VGLL4;DEPDC1B
prerank,MSigDB_Oncogenic_Signatures__TGFB UP.V1 UP,0.5603285061775094,0.7824963186416847,0.8278145695364238,0.8462943102990182,1.0,6/173,1.36%,TMC7;SMOX;BCOR;TBX3;PPP1R13L;FGF1
prerank,Reactome_2022__Insulin Receptor Signaling Cascade R-HSA-74751,-0.5362124611057668,-0.7824598213808225,0.616822429906542,0.8606618973604949,1.0,2/45,1.36%,PIK3CB;GRB10
prerank,MSigDB_Oncogenic_Signatures__TBK1.DN.48HRS DN,0.5323702213175902,0.782184823453012,0.6865671641791045,0.8462554735668059,1.0,1/49,1.20%,STX1A
prerank,WikiPathway_2021_Human__ESC Pluripotency Pathways WP3931,-0.5621337064540212,-0.7820355940800535,0.7777777777777778,0.8607214037437387,1.0,2/108,0.37%,MAP2K6;AKT3
prerank,MSigDB_Oncogenic_Signatures__MEK UP.V1 UP,0.550143216660929,0.7820040415990946,0.8264462809917356,0.8460726272924908,1.0,7/181,1.48%,MAP3K9;LRP5;ETV5;DBNDD1;PACSIN3;SLC2A6;LGALSL
prerank,Reactome_2022__Ub-specific Processing Proteases R-HSA-5689880,0.558003857928608,0.7819971375933014,0.8231292517006803,0.8457168358249202,1.0,1/167,0.12%,AXIN2
prerank,MSigDB_Oncogenic_Signatures__HOXA9 DN.V1 UP,0.5567714623705483,0.7818894211861998,0.8435374149659864,0.8454454355881601,1.0,7/169,1.37%,PHTF2;SLC35D2;FNDC3B;ZNF394;FDXR;MYOF;FRY
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP LATE.V1 DN,-0.5507877809228522,-0.7818152465301679,0.76,0.8605686548003048,1.0,6/167,0.99%,DPYS;TLE4;TTPA;HCK;RASGRP2;KLF4
prerank,KEGG_2021_Human__Hematopoietic cell lineage,0.5937183397048922,0.7817600537741435,0.7720588235294118,0.8452082106968326,1.0,1/89,0.38%,ITGA2
prerank,Reactome_2022__Cellular Response To Chemical Stress R-HSA-9711123,-0.5491031246647877,-0.7814356639894243,0.7830188679245284,0.8605989608504456,1.0,4/176,0.40%,GLYAT;GSTA1;AKT3;NCOA1
prerank,"Reactome_2022__Plasma Lipoprotein Assembly, Remodeling, And Clearance R-HSA-174824",0.5852377189132774,0.7812891285480723,0.7196969696969697,0.8453347204916117,1.0,2/69,1.35%,APOE;SOAT2
prerank,GO_Biological_Process_2021__phosphorylation (GO:0016310),0.49923698191147936,0.7809174627753674,0.9517241379310345,0.8453173864271207,1.0,11/390,1.16%,PRKAA2;MELK;COQ8A;CDK6;FAM20B;MAP3K9;BRSK1;NEK4;MAP4K5;STK26;GRK3
prerank,KEGG_2021_Human__Calcium signaling pathway,0.547947301240346,0.7808879518761007,0.8251748251748252,0.8449755874945825,1.0,4/211,1.36%,PHKA2;ERBB3;TNNC2;FGF1
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection morphogenesis (GO:0120039),0.5350978918332733,0.7805004490463819,0.6870229007633588,0.8450100573449547,1.0,1/49,0.47%,CNTNAP1
prerank,GO_Biological_Process_2021__collagen fibril organization (GO:0030199),0.6087644724576895,0.7803288164624091,0.7686567164179104,0.8448251361125017,1.0,4/88,1.34%,PLOD2;COL4A5;COL12A1;COL9A3
prerank,GO_Biological_Process_2021__negative regulation of mitotic metaphase/anaphase transition (GO:0045841),-0.3983499432359462,-0.7797846792956256,0.4158415841584158,0.862093827009396,1.0,8/22,18.38%,FBXO5;APC;BUB1;CDC20;BUB1B;TPR;ZW10;MAD2L1
prerank,GO_Biological_Process_2021__regulation of actin cytoskeleton organization (GO:0032956),-0.5488598683175093,-0.7795943675870527,0.7739130434782608,0.8619017757459337,1.0,3/88,1.26%,PTK2B;RHOH;HRG
prerank,Elsevier_Pathway_Collection__Th0-Cell Aberrant Activation in Systemic Lupus Erythematosus,0.5975558900917048,0.7794891560230334,0.7741935483870968,0.8453159127445578,1.0,2/76,0.93%,TNFRSF10A;TNFRSF25
prerank,GO_Biological_Process_2021__vascular transport (GO:0010232),-0.5553945032751619,-0.7793507740728599,0.7254901960784313,0.8617837431683806,1.0,4/81,1.02%,SLC22A1;SLC7A8;SLC2A10;SLC16A2
prerank,GO_Biological_Process_2021__regulation of neuron apoptotic process (GO:0043523),0.6145427749722913,0.7791281077622303,0.7253521126760564,0.8453389130811286,1.0,4/88,1.48%,MSH2;ERBB3;APOE;SLC30A10
prerank,WikiPathway_2021_Human__TGF-beta receptor signaling in skeletal dysplasias WP4816,-0.5303081049550016,-0.7789772547311006,0.704,0.8618250896175182,1.0,1/58,1.14%,ADAMTSL2
prerank,Elsevier_Pathway_Collection__Proplatelet Maturation,0.6161628144912078,0.7788955803484461,0.7375886524822695,0.8451701967393945,1.0,1/79,0.41%,MRTFA
prerank,Reactome_2022__G1/S Transition R-HSA-69206,0.5614539870836339,0.7788812777860874,0.7697368421052632,0.8448293303411301,1.0,4/127,1.18%,CDC45;RBL1;POLE4;RRM2
prerank,WikiPathway_2021_Human__Small cell lung cancer WP4658,0.5986519941280963,0.7784661999788347,0.7384615384615385,0.8448235361548693,1.0,6/95,1.51%,CDK6;PTK2;ITGA2;TRAF3;COL4A5;FN1
prerank,MSigDB_Oncogenic_Signatures__TGFB UP.V1 DN,0.5322355180271291,0.778398690979428,0.8449612403100775,0.8445185004414036,1.0,4/164,1.50%,ANKMY1;FNDC3B;TUFT1;ZNF395
prerank,GO_Biological_Process_2021__eye development (GO:0001654),0.5351368044851796,0.7782713985403126,0.7121212121212122,0.8442828745474671,1.0,2/50,0.83%,SIPA1L3;RAB3GAP1
prerank,GO_Biological_Process_2021__phosphatidylinositol-mediated signaling (GO:0048015),0.5891937316582214,0.7776158683946152,0.75,0.8445618447221918,1.0,2/68,1.32%,ERBB3;PIK3C2B
prerank,Reactome_2022__FCGR3A-mediated Phagocytosis R-HSA-9664422,0.562106073705835,0.7763850062024908,0.7407407407407407,0.8453258348206001,1.0,2/55,0.77%,PTK2;ABI2
prerank,GO_Biological_Process_2021__positive regulation of natural killer cell mediated immunity (GO:0002717),-0.4411403877666702,-0.7763382808856625,0.46564885496183206,0.8642213569526663,1.0,8/21,16.54%,NECTIN2;RAET1G;PVR;CD226;KLRD1;NCR3;SH2D1B;RASGRP1
prerank,Elsevier_Pathway_Collection__TNFR -> AP-1/ATF/TP53 Signaling,-0.5002345630009583,-0.776089090884304,0.6141732283464567,0.8640966011483857,1.0,1/39,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of cellular component organization (GO:0051128),-0.5385026086603686,-0.7760391669779078,0.8240740740740741,0.8637605375492878,1.0,8/134,1.26%,SLC2A10;RAP1A;RAP1B;ZFYVE16;RASGRP2;SEMA4D;LTBP4;HRG
prerank,KEGG_2021_Human__Hedgehog signaling pathway,0.5690776178067207,0.7758054320860656,0.6785714285714286,0.8455414885004218,1.0,2/52,1.16%,MEGF8;GRK3
prerank,GO_Biological_Process_2021__negative regulation of protein kinase activity (GO:0006469),0.5937591722531929,0.7757746732180466,0.7575757575757576,0.8452111070690652,1.0,4/89,0.91%,THY1;CEP85;LRP5;DBNDD1
prerank,Reactome_2022__RHOBTB GTPase Cycle R-HSA-9706574,-0.5233422569288375,-0.7749702932600826,0.6239316239316239,0.8645628365985899,1.0,1/35,0.33%,PDE5A
prerank,WikiPathway_2021_Human__Wnt signaling WP428,0.5730856183081797,0.774945646428979,0.8125,0.8456545042530399,1.0,1/107,0.40%,LRP5
prerank,MSigDB_Oncogenic_Signatures__MYC UP.V1 DN,-0.5596881239330807,-0.7748085605738848,0.7844827586206896,0.8643373262550089,1.0,7/135,1.21%,GJB5;RAP1A;FBXO27;PTK2B;TNFAIP2;ZNF334;NYNRIN
prerank,MSigDB_Oncogenic_Signatures__PRC2 EDD UP.V1 DN,-0.5389016661250556,-0.7747768478106142,0.8113207547169812,0.8639822441713496,1.0,6/154,1.19%,CTSO;EVI5;GALNT3;CCND2;SLC12A8;MTHFD2L
prerank,MSigDB_Oncogenic_Signatures__EGFR UP.V1 UP,0.5408009725382138,0.7745396272257049,0.8581560283687943,0.8456724422736418,1.0,6/180,1.30%,ITGA2;FNDC3B;ETV5;RHOQ;A2M;CYP27B1
prerank,Elsevier_Pathway_Collection__Mucinous Ovarian Carcinoma,-0.5404714248596573,-0.7743824902674717,0.725925925925926,0.8639624328091999,1.0,1/60,0.40%,NCOA1
prerank,WikiPathway_2021_Human__Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,-0.5322495296357876,-0.7741857411305533,0.6967213114754098,0.8637878222407106,1.0,3/53,0.71%,APP;PTK2B;PAK2
prerank,GO_Biological_Process_2021__negative regulation of cell projection organization (GO:0031345),0.5630436177834433,0.7733260651280247,0.7226277372262774,0.8464183151930827,1.0,3/48,1.33%,GFI1;APOE;DPYSL3
prerank,GO_Biological_Process_2021__peptidyl-serine modification (GO:0018209),-0.5228794236974921,-0.7731958530246315,0.9565217391304348,0.8644103160449788,1.0,5/165,1.16%,AKT3;TTBK2;PAK2;GALNT3;MAP4K1
prerank,WikiPathway_2021_Human__T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.602651387133367,0.7729559714620309,0.7734375,0.846418285399913,1.0,1/60,0.74%,DLG1
prerank,KEGG_2021_Human__Peroxisome,-0.5666614448098093,-0.7728835354102433,0.7117117117117117,0.864345866903796,1.0,2/82,1.08%,ABCD3;HAO1
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN MEL18 DN.V1 UP,0.5625132882911661,0.7726715662722041,0.8214285714285714,0.846290090787413,1.0,4/131,1.20%,SLC19A1;TUFT1;SCML2;STX1A
prerank,MSigDB_Oncogenic_Signatures__JAK2 DN.V1 UP,-0.5452779208453857,-0.772555355979283,0.8666666666666667,0.8643008022917383,1.0,3/130,1.28%,NEK11;CYP1B1;ZFHX4
prerank,MSigDB_Hallmark_2020__Hypoxia,-0.5223029000184604,-0.7725122959055118,0.8421052631578947,0.8639525047593379,1.0,3/194,1.16%,ALDOB;NR3C1;SDC3
prerank,Elsevier_Pathway_Collection__CD8+ Naive T-cell -> CD4+ Naive T-cell Surface Expression Markers,-0.5270069682896803,-0.7724594910939708,0.6466165413533834,0.8636219023649754,1.0,1/35,0.85%,CD27
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell proliferation (GO:0001938),-0.5523690894706615,-0.7724113712166384,0.7355371900826446,0.8632896716956086,1.0,2/76,1.21%,AKT3;TEK
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP EARLY.V1 DN,-0.5301440548414162,-0.7723150008424916,0.85,0.8629982538474376,1.0,4/154,1.05%,TLE4;KLF4;SLC16A2;GNA14
prerank,GO_Biological_Process_2021__extracellular structure organization (GO:0043062),0.520036088345508,0.7723144217714681,0.8918918918918919,0.846291716507091,1.0,6/200,1.51%,ITGA2;COL4A5;ITGAL;ITGB5;COL9A3;FN1
prerank,Reactome_2022__Peptide Hormone Metabolism R-HSA-2980736,-0.5661988420944929,-0.7721020448210968,0.7906976744186046,0.8628208631040689,1.0,2/76,0.99%,EXOC2;KLF4
prerank,Elsevier_Pathway_Collection__MERTK Signaling,0.5783124143379377,0.7720274414661472,0.7096774193548387,0.8462293124883763,1.0,3/45,1.49%,PTK2;TUB;BCAR1
prerank,Reactome_2022__MAPK1/MAPK3 Signaling R-HSA-5684996,0.4984979772920687,0.7718740652297397,0.9624060150375939,0.8460293581335376,1.0,9/261,1.51%,KSR1;PTK2;DLG1;GPRIN1;ERBB3;ZDHHC9;KLB;FGF1;FN1
prerank,KEGG_2021_Human__Cytokine-cytokine receptor interaction,0.5299469454400443,0.7718232275232447,0.8543046357615894,0.845708020937552,1.0,6/239,1.39%,TNFRSF10A;TNFRSF25;AMH;TNFRSF10D;EDA2R;PRLR
prerank,GO_Biological_Process_2021__regulation of osteoblast proliferation (GO:0033688),-0.4447323875546784,-0.7715252435917381,0.4609375,0.8630098175383641,1.0,9/16,28.60%,SOX8;TMEM119;MN1;PLXNB1;SFRP1;LTF;ATRAID;BMP2;TNN
prerank,GO_Biological_Process_2021__regulation of MAP kinase activity (GO:0043405),0.5995157728007711,0.7715235598048567,0.7534246575342466,0.8456315534708636,1.0,3/89,1.36%,KSR1;APOE;FGF1
prerank,TRRUST_Transcription_Factors_2019__SIRT1 human,-0.5134613041114563,-0.7714836231933165,0.6460176991150443,0.8626553539019376,1.0,1/45,0.46%,ADAMTS5
prerank,MSigDB_Oncogenic_Signatures__LTE2 UP.V1 UP,-0.5279652988343073,-0.7712592874012502,0.8205128205128205,0.8625014677900406,1.0,7/171,1.27%,SLC2A10;PROS1;SGPP1;GNA14;AQP3;DUSP4;CYP1B1
prerank,GO_Biological_Process_2021__regulation of protein polymerization (GO:0032271),-0.5149245606571548,-0.7706702429336747,0.6583333333333333,0.8626826110312612,1.0,1/35,0.84%,TPPP2
prerank,Elsevier_Pathway_Collection__Prostate Cancer,-0.5231217227475964,-0.7702483904897441,0.8407079646017699,0.862796257359163,1.0,4/113,1.26%,RB1;PTK2B;VDR;TMPRSS2
prerank,GO_Biological_Process_2021__positive regulation of cell morphogenesis involved in differentiation (GO:0010770),0.5662895965585029,0.7701985107491277,0.7007874015748031,0.8465842709277137,1.0,2/49,1.41%,ARHGEF7;FLNA
prerank,Reactome_2022__EPHB-mediated Forward Signaling R-HSA-3928662,0.5271610633214602,0.7694021100456521,0.6428571428571429,0.847029829438073,1.0,2/32,0.91%,PTK2;GPRIN1
prerank,Elsevier_Pathway_Collection__Diffuse Large-B-Cell Lymphoma,-0.5549897596675577,-0.7693761285796689,0.7884615384615384,0.8633693738630182,1.0,2/87,1.12%,CD274;IL10RA
prerank,Reactome_2022__Rab Regulation Of Trafficking R-HSA-9007101,-0.57532241636179,-0.7693157491353324,0.8349514563106796,0.8630463045470886,1.0,2/120,0.70%,AKT3;SBF2
prerank,Elsevier_Pathway_Collection__Low-Grade Serous Ovarian Carcinoma,0.6393669500005277,0.7688501052880082,0.7565217391304347,0.8472371094233367,1.0,2/69,0.96%,NOTCH3;ERBB3
prerank,GO_Biological_Process_2021__negative regulation of neuron death (GO:1901215),0.6145419936907417,0.7688264688855705,0.7619047619047619,0.8468935960264633,1.0,4/89,1.48%,MSH2;ERBB3;APOE;SLC30A10
prerank,GO_Biological_Process_2021__regulation of AMPA receptor activity (GO:2000311),0.43880583748362056,0.7687203461696209,0.45,0.8466349237157723,1.0,7/21,20.10%,NLGN2;CNIH3;GSG1L;SHISA9;NLGN3;SHANK1;CNIH2
prerank,GO_Biological_Process_2021__transport across blood-brain barrier (GO:0150104),-0.5553936882898279,-0.768656362750169,0.7425742574257426,0.863278742496486,1.0,4/83,1.02%,SLC22A1;SLC7A8;SLC2A10;SLC16A2
prerank,Elsevier_Pathway_Collection__Platelet Activation via Adhesion Molecules,-0.5722413873088269,-0.7686070523343989,0.7345132743362832,0.8629444859215528,1.0,4/65,1.10%,MAP2K6;RAP1A;PTK2B;VAV1
prerank,Reactome_2022__Apoptosis R-HSA-109581,0.5538795519172404,0.7682775272515862,0.8928571428571429,0.8467400503617514,1.0,5/171,1.55%,PTK2;TNFRSF10A;TJP1;STK26;UACA
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V2 UP,-0.5628443514077989,-0.7681420047317978,0.8083333333333333,0.8630366420833476,1.0,5/121,1.05%,VPS13C;SLITRK3;LIPG;AGPAT4;GNA14
prerank,GO_Biological_Process_2021__external encapsulating structure organization (GO:0045229),0.5200354363451638,0.7677797540399524,0.9041095890410958,0.846840306744117,1.0,6/201,1.51%,ITGA2;COL4A5;ITGAL;ITGB5;COL9A3;FN1
prerank,Reactome_2022__RAF/MAP Kinase Cascade R-HSA-5673001,0.4985014851482934,0.76764517510521,0.9770992366412213,0.8465787959545426,1.0,9/255,1.51%,KSR1;PTK2;DLG1;GPRIN1;ERBB3;ZDHHC9;KLB;FGF1;FN1
prerank,GO_Biological_Process_2021__protein deubiquitination (GO:0016579),0.5175163734175671,0.7668366348321548,0.922077922077922,0.8469322669795208,1.0,1/241,0.44%,TRAF3
prerank,GO_Biological_Process_2021__DNA modification (GO:0006304),0.5014777755707298,0.7666052542124362,0.5666666666666667,0.846780783657184,1.0,1/25,1.41%,ACD
prerank,WikiPathway_2021_Human__Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.5538489831678353,0.7665158443520778,0.6861313868613139,0.8465100788913882,1.0,1/43,0.13%,ACACA
prerank,Elsevier_Pathway_Collection__Glutamate Mediated Excitotoxicity in Glaucoma,-0.37305968958150215,-0.7663935610052338,0.4094488188976378,0.8645292498159811,1.0,12/20,30.56%,TNF;AIFM1;MCU;TNFRSF1A;GRB2;SLC1A2;SLC1A3;GNAQ;ITPR1;AKT1;CASP3;SOS1
prerank,GO_Biological_Process_2021__organonitrogen compound catabolic process (GO:1901565),-0.5267130048885157,-0.7659797253590654,0.7304347826086957,0.8645496501893273,1.0,1/61,0.06%,GGACT
prerank,MSigDB_Oncogenic_Signatures__IL2 UP.V1 UP,0.5613440557864735,0.7658024306948193,0.85,0.8468472278247553,1.0,5/160,1.56%,KIF13A;PRR7;RNF144A;LGALSL;FOSL2
prerank,Reactome_2022__Transport To Golgi And Subsequent Modification R-HSA-948021,0.5439281602429946,0.7655455627781521,0.8661971830985915,0.8467325400460457,1.0,1/159,0.81%,COG5
prerank,MSigDB_Oncogenic_Signatures__CRX NRL DN.V1 DN,-0.5397894262302423,-0.7652178363448415,0.8440366972477065,0.8650108967007025,1.0,2/104,0.66%,NTN4;RASA2
prerank,Reactome_2022__Transcriptional Regulation Of White Adipocyte Differentiation R-HSA-381340,-0.5701026414000018,-0.7651437360743959,0.7307692307692307,0.8646900240994341,1.0,3/82,0.99%,NCOA1;CDK19;KLF4
prerank,GO_Biological_Process_2021__regulation of insulin secretion (GO:0050796),-0.5748641488595362,-0.7650496443039833,0.7545454545454545,0.8643905077520238,1.0,3/94,1.24%,RAP1A;SYT7;KCNS3
prerank,MSigDB_Hallmark_2020__Fatty Acid Metabolism,0.5481916993064097,0.7649329083482804,0.8992805755395683,0.8469834905046586,1.0,5/154,1.52%,HSD17B11;AUH;PPARA;ACSL5;SMS
prerank,KEGG_2021_Human__TGF-beta signaling pathway,0.6099125352358592,0.7648719814893861,0.8041958041958042,0.8466782038720383,1.0,4/92,1.47%,RBL1;AMH;CHRD;ZFYVE9
prerank,WikiPathway_2021_Human__Glycerophospholipid Biosynthetic Pathway WP2533,0.5262445800085394,0.7647209137715207,0.6377952755905512,0.8464763916611698,1.0,1/30,0.32%,GPAT4
prerank,Reactome_2022__Signaling By Non-Receptor Tyrosine Kinases R-HSA-9006927,0.5580366605223418,0.7646440938133349,0.732824427480916,0.8461906203148716,1.0,2/51,1.49%,ERBB3;BCAR1
prerank,GO_Biological_Process_2021__regulation of blood coagulation (GO:0030193),0.5023803439657735,0.7646387635122422,0.592,0.8458400350065937,1.0,1/27,1.30%,APOE
prerank,GO_Biological_Process_2021__cellular amino acid catabolic process (GO:0009063),-0.5633187255146115,-0.7645520815843283,0.7235772357723578,0.8645123866191378,1.0,2/90,0.61%,HIBADH;AADAT
prerank,GO_Biological_Process_2021__phospholipid dephosphorylation (GO:0046839),0.5392742632641002,0.7644447534053248,0.64,0.8456911638294016,1.0,1/37,0.15%,PLPPR1
prerank,GO_Biological_Process_2021__regulation of cell adhesion mediated by integrin (GO:0033628),0.49531623519216644,0.7643163360524973,0.6258503401360545,0.8454361998722254,1.0,1/33,0.26%,PTK2
prerank,Elsevier_Pathway_Collection__Cetuximab Resistance in Colorectal Cancer,0.6008427503015169,0.7640689347369997,0.7794117647058824,0.8453018836472687,1.0,1/64,0.96%,ERBB3
prerank,Reactome_2022__Negative Regulation Of PI3K/AKT Network R-HSA-199418,-0.5547776952653652,-0.7639318325588411,0.7818181818181819,0.8647700020207039,1.0,3/105,1.10%,AKT3;PIK3CB;VAV1
prerank,MSigDB_Hallmark_2020__Pperoxisome,0.5708888725009316,0.763496976587447,0.7938931297709924,0.8454892330184189,1.0,3/100,1.18%,MSH2;HSD17B11;ACSL5
prerank,Elsevier_Pathway_Collection__G1/S Phase Transition,0.5303178470046855,0.7627035880127994,0.6853146853146853,0.84585851091224,1.0,1/33,0.19%,CDK6
prerank,GO_Biological_Process_2021__peptidyl-serine phosphorylation (GO:0018105),-0.5278153752785256,-0.7626052508802744,0.8974358974358975,0.865780897669345,1.0,4/153,1.16%,AKT3;TTBK2;PAK2;MAP4K1
prerank,Elsevier_Pathway_Collection__Glutamine in Cancer Metabolism,0.5039039042492983,0.7624848708923412,0.6090225563909775,0.8457146904958285,1.0,2/26,1.49%,PYCR1;GLS
prerank,MSigDB_Oncogenic_Signatures__DCA UP.V1 DN,0.5741205419098889,0.7622667317436366,0.8523489932885906,0.8455045448687576,1.0,3/148,1.00%,ZNF286A;CMC1;MCTP1
prerank,GO_Biological_Process_2021__steroid biosynthetic process (GO:0006694),-0.5362478935715499,-0.7617579261134271,0.7416666666666667,0.8662269560145524,1.0,1/60,0.03%,CYP39A1
prerank,GO_Biological_Process_2021__positive regulation of cellular amide metabolic process (GO:0034250),-0.5624271368544611,-0.761478323943644,0.8070175438596491,0.8661719969165889,1.0,1/81,0.07%,CPEB3
prerank,TRRUST_Transcription_Factors_2019__ATF1 human,-0.41455375881330353,-0.7603947900765826,0.408,0.8668676701761564,1.0,7/19,20.24%,MAP1LC3B;CFTR;FTH1;NTS;PLAUR;USP7;CGA
prerank,Reactome_2022__Late SARS-CoV-2 Infection Events R-HSA-9772573,0.5659137142688154,0.760349686175607,0.7196969696969697,0.8468933366769105,1.0,3/57,1.23%,ST3GAL1;DAD1;ZDHHC9
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Aging,-0.41787080946746125,-0.760234755909565,0.472,0.8666177517267085,1.0,7/19,17.07%,TNF;ELN;ATG7;IGF1;COL1A1;GLB1;SPRED1
prerank,MSigDB_Oncogenic_Signatures__PRC2 SUZ12 UP.V1 UP,-0.49759627995427524,-0.7595593970571223,0.9142857142857143,0.866906158947687,1.0,4/148,1.14%,LDB2;SLITRK3;IL10RA;CLEC10A
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Tethering,-0.49803330003963914,-0.7594149125352551,0.6194690265486725,0.8666678922789923,1.0,1/32,0.67%,EXOC2
prerank,GO_Biological_Process_2021__phospholipid transport (GO:0015914),0.5556006874528253,0.7592940716323456,0.7398373983739838,0.8475380385773059,1.0,2/58,1.30%,PRELID3A;APOE
prerank,GO_Biological_Process_2021__epithelial cell migration (GO:0010631),0.5593148951008982,0.7592491193305848,0.7286821705426356,0.847235753384989,1.0,2/40,0.99%,ANLN;PLEKHG5
prerank,Elsevier_Pathway_Collection__ERK/MAPK Canonical Signaling,0.5618043392905594,0.7591944303312719,0.7107438016528925,0.8469242434243164,1.0,2/47,0.26%,KSR1;PTK2
prerank,Elsevier_Pathway_Collection__Huntingtin Gene Mutation in Striatal Neuron,0.5172316240709327,0.7591009510281888,0.6285714285714286,0.8466603547047581,1.0,2/33,0.80%,TAF4;PRPF40A
prerank,GO_Biological_Process_2021__platelet aggregation (GO:0070527),0.5107346075853082,0.7590094246310278,0.632,0.8463982635148866,1.0,2/36,1.51%,FLNA;FN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Spontaneous Abortion,-0.5875961674839079,-0.7589588646689467,0.75,0.8667520282066384,1.0,1/80,0.96%,SEMA4D
prerank,Elsevier_Pathway_Collection__Preconditioning Ischemia,0.5507177821398048,0.7589446629977992,0.6991869918699187,0.8461048417153866,1.0,1/35,0.13%,ACACA
prerank,GO_Biological_Process_2021__cilium organization (GO:0044782),0.5133373842265536,0.7588885934926929,0.9328859060402684,0.8458022031127524,1.0,5/218,1.41%,NUDCD3;CEP164;SEPTIN6;KIF3B;FLNA
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell migration (GO:0010633),0.5160238030979555,0.7587161709383222,0.6220472440944882,0.8456196005017946,1.0,1/34,1.30%,APOE
prerank,KEGG_2021_Human__Diabetic cardiomyopathy,-0.496705492746845,-0.758480409485647,0.9439252336448598,0.8668398994925454,1.0,2/181,0.73%,AKT3;PIK3CB
prerank,TRRUST_Transcription_Factors_2019__TP53 human,0.5572678911976852,0.7583431108025421,0.852112676056338,0.8456262046073547,1.0,3/159,1.22%,MKI67;TNFRSF10A;FDXR
prerank,TRRUST_Transcription_Factors_2019__HDAC3 human,0.5032407444131515,0.7580859635412838,0.5905511811023622,0.8455131180079515,1.0,1/22,0.45%,GTF2I
prerank,GO_Biological_Process_2021__regulation of actin filament-based process (GO:0032970),0.5667143434052638,0.7580461222012417,0.7591240875912408,0.8451923370994817,1.0,2/71,1.02%,RHOQ;IQGAP3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hearing Loss,0.512810519812366,0.7571097786891458,0.9328358208955224,0.8456900420614885,1.0,6/177,1.34%,KCNC1;COL4A5;MYO7A;ESPN;APOE;COL9A3
prerank,GO_Biological_Process_2021__regulation of cellular protein metabolic process (GO:0032268),-0.5241355499930265,-0.7569546934857954,0.6722689075630253,0.8680210010541272,1.0,2/47,0.99%,APP;KLF4
prerank,GO_Biological_Process_2021__positive regulation of translation (GO:0045727),-0.56242610009102,-0.7569213573123571,0.8333333333333334,0.8676570066208723,1.0,1/92,0.07%,CPEB3
prerank,WikiPathway_2021_Human__Head and Neck Squamous Cell Carcinoma WP4674,0.5557288053586946,0.7568280508672173,0.7552447552447552,0.8456415563581031,1.0,3/73,0.44%,PRKAA2;CDK6;TRAF3
prerank,Reactome_2022__Non-integrin membrane-ECM Interactions R-HSA-3000171,-0.4932004724940602,-0.7563684788385436,0.672,0.8678014424212404,1.0,2/41,1.16%,NTN4;SDC3
prerank,MSigDB_Oncogenic_Signatures__KRAS.PROSTATE UP.V1 UP,0.5727320897504747,0.7561406788880514,0.7986577181208053,0.8458965446781876,1.0,4/109,0.86%,MEGF8;ITGA2;RAB40C;ETV5
prerank,Elsevier_Pathway_Collection__PGF2-alpha Effect on Treatment,-0.3985882462388582,-0.755571989765223,0.415929203539823,0.868231070968008,1.0,10/17,26.01%,MAPK3;MMP9;PTGFR;RAF1;RASGRP1;MMP3;MAP2K2;GNAQ;ITPR1;PLCB1
prerank,MSigDB_Oncogenic_Signatures__PDGF UP.V1 DN,-0.5507846928493932,-0.755079337060432,0.8303571428571429,0.8683846254119887,1.0,2/105,0.38%,HERC3;GPR39
prerank,"KEGG_2021_Human__Parathyroid hormone synthesis, secretion and action",0.5647972399389423,0.7550300425831398,0.8,0.8465834967349615,1.0,2/98,1.30%,LRP5;CYP27B1
prerank,GO_Biological_Process_2021__fatty acid metabolic process (GO:0006631),-0.5378967154344271,-0.754928853942344,0.808695652173913,0.8681484513086503,1.0,5/120,0.92%,GGT5;ABCD3;ACSM2B;ECHDC3;LIPG
prerank,GO_Biological_Process_2021__cardiac muscle cell development (GO:0055013),-0.43436189032868217,-0.754900811121484,0.48360655737704916,0.867792815230268,1.0,6/18,13.68%,HEY2;SLC8A1;CXADR;PDLIM5;TCAP;ALPK3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Alzheimer's Disease,-0.5512717262457172,-0.7543480241830652,0.8018867924528302,0.8680185115813867,1.0,2/122,0.35%,GRIN2B;APP
prerank,Reactome_2022__Nonsense Mediated Decay (NMD) Enhanced By Exon Junction Complex (EJC) R-HSA-975957,0.5713200353794539,0.7542949740983589,0.8378378378378378,0.8469384213531618,1.0,1/110,0.73%,UPF2
prerank,WikiPathway_2021_Human__Vitamin D Receptor Pathway WP2877,-0.515774374491293,-0.7542266019586086,0.9339622641509434,0.8677372703761215,1.0,5/156,1.25%,STS;ADAMTS5;KLF4;ADGRE5;VDR
prerank,GO_Biological_Process_2021__positive regulation of cell death (GO:0010942),-0.5282927142517784,-0.754144909832832,0.7706422018348624,0.8674695606361441,1.0,2/64,1.30%,GRIN2B;SLFN11
prerank,Elsevier_Pathway_Collection__Proteins Involved in Amyotrophic Lateral Sclerosis,-0.5133968240190143,-0.7540906907012233,0.9099099099099099,0.8671489977714494,1.0,4/172,1.24%,APP;RB1;NTF3;MAOB
prerank,"Reactome_2022__Cobalamin (Cbl, Vitamin B12) Transport And Metabolism R-HSA-196741",-0.41072544283656254,-0.7540471395938615,0.45925925925925926,0.8667983968190187,1.0,10/17,33.59%,AMN;TCN2;MMACHC;MTR;CUBN;MMUT;LRP2;PRSS3;MMADHC;TCN1
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP EARLY.V1 DN,-0.5328100778887898,-0.7540283047138734,0.832,0.8664310595251322,1.0,5/145,1.20%,STS;BTD;GNA14;VAV1;ZNF518B
prerank,GO_Biological_Process_2021__activation of protein kinase activity (GO:0032147),-0.5556300036014726,-0.7539398946028057,0.7948717948717948,0.866170094727233,1.0,3/110,0.83%,PTK2B;PAK2;NTF3
prerank,Reactome_2022__PI3K Cascade R-HSA-109704,0.5375854118345867,0.7539351604638135,0.6861313868613139,0.8468832184125785,1.0,2/37,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__regulation of ion transmembrane transport (GO:0034765),-0.5010763831840191,-0.7534102423523222,0.6102941176470589,0.8663390265763947,1.0,1/31,0.43%,WNK3
prerank,WikiPathway_2021_Human__Adipogenesis WP236,-0.5356994220058039,-0.7533293037798187,0.8389830508474576,0.8660140103116961,1.0,3/122,0.53%,NCOA1;NR3C1;RB1
prerank,GO_Biological_Process_2021__regulation of protein transport (GO:0051223),0.5025658267130333,0.7533241310952714,0.6153846153846154,0.8470807659767509,1.0,1/26,0.59%,WWP2
prerank,GO_Biological_Process_2021__carbohydrate homeostasis (GO:0033500),-0.5398375259843615,-0.7533233623086562,0.71900826446281,0.865632551724517,1.0,2/60,0.76%,OAS1;MBD5
prerank,KEGG_2021_Human__Arginine and proline metabolism,0.5707849110115114,0.7529865861524324,0.708029197080292,0.8470490840296016,1.0,3/49,1.52%,SMOX;PYCR1;SMS
prerank,WikiPathway_2021_Human__Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.5329381726881532,0.7528961861733353,0.8582089552238806,0.8467837518455776,1.0,5/143,0.74%,IGF2BP1;PRKAA2;KSR1;SORT1;DLG1
prerank,GO_Biological_Process_2021__proteasomal protein catabolic process (GO:0010498),0.511384858734558,0.7525950083847534,0.9507042253521126,0.8467083245441209,1.0,3/200,1.24%,TBL1X;WWP2;AGAP3
prerank,Elsevier_Pathway_Collection__MITF as a Regulator of Melanoma Cell Development,-0.5220228047289458,-0.7524604039262269,0.7,0.8661436328938596,1.0,1/53,0.37%,AKT3
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN MEL18 DN.V1 DN,-0.5308801501067818,-0.7519357663773734,0.8584905660377359,0.866287712464179,1.0,5/123,1.24%,EVI5;PDE5A;GAS2;AQP3;MAOB
prerank,Reactome_2022__Nuclear Events Mediated By NFE2L2 R-HSA-9759194,-0.5580461245697471,-0.751758299976877,0.7586206896551724,0.8660671705195798,1.0,1/76,0.05%,GSTA1
prerank,Reactome_2022__Citric Acid (TCA) Cycle And Respiratory Electron Transport R-HSA-1428517,-0.5177404892342334,-0.7507708766719708,0.8879310344827587,0.8667378298877026,1.0,1/161,0.24%,SUCLG2
prerank,GO_Biological_Process_2021__positive regulation of Ras protein signal transduction (GO:0046579),-0.5682663079502187,-0.7506561695314462,0.7565217391304347,0.8664908676023825,1.0,2/60,1.10%,PIK3CB;VAV1
prerank,KEGG_2021_Human__Rheumatoid arthritis,0.5451563913732864,0.7503032181260793,0.7959183673469388,0.8485838783611133,1.0,1/83,1.10%,ITGAL
prerank,Reactome_2022__Protein-protein Interactions At Synapses R-HSA-6794362,0.5821333293987441,0.7494179643255202,0.7862595419847328,0.8489839427192077,1.0,6/85,1.23%,LIN7A;DLG1;GPRIN1;PPFIA4;STX1A;HOMER3
prerank,Elsevier_Pathway_Collection__Endometrioid Ovarian Carcinoma,-0.5404679179442704,-0.7493200998215165,0.762962962962963,0.867500226940052,1.0,1/76,0.40%,NCOA1
prerank,MSigDB_Oncogenic_Signatures__CAMP UP.V1 UP,-0.4977339043904457,-0.7492766735634292,0.9829059829059829,0.8671626555258762,1.0,2/179,0.73%,NT5DC1;WWP1
prerank,MSigDB_Hallmark_2020__Coagulation,-0.5298888395468191,-0.7490822367501582,0.8376068376068376,0.8669855552692052,1.0,5/137,1.26%,CTSO;PROS1;C1R;ITIH1;HRG
prerank,GO_Biological_Process_2021__beta-catenin-TCF complex assembly (GO:1904837),0.5230953640857062,0.7490771094359675,0.6371681415929203,0.848948409563345,1.0,1/29,0.12%,AXIN2
prerank,WikiPathway_2021_Human__Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.5376516044830539,0.7483907268328664,0.7730496453900709,0.8492321788749426,1.0,2/72,0.17%,AXIN2;MSH2
prerank,GO_Biological_Process_2021__regulation of stress fiber assembly (GO:0051492),-0.5316920493398798,-0.7483426130043517,0.7699115044247787,0.8672813759757726,1.0,2/73,0.71%,CARMIL1;PAK2
prerank,WikiPathway_2021_Human__Fibrin Complement Receptor 3 Signaling Pathway WP4136,-0.4987552663839386,-0.7481590960411301,0.6470588235294118,0.8670761403057077,1.0,2/40,1.13%,TICAM2;RASSF5
prerank,TRRUST_Transcription_Factors_2019__RELA human,-0.496154722754035,-0.7478734063926472,0.9827586206896551,0.8669651793915168,1.0,5/281,1.09%,MUC6;CYP3A7;BHMT;CCND2;CD83
prerank,TRRUST_Transcription_Factors_2019__JUN human,0.5420669487231857,0.747854682928652,0.8835616438356164,0.8493874318559061,1.0,4/136,1.10%,TNFRSF10A;SLC19A1;PPARA;MELTF
prerank,KEGG_2021_Human__NF-kappa B signaling pathway,0.5523665804746214,0.747780093937784,0.8102189781021898,0.8491109550518828,1.0,2/102,1.20%,TRAF3;EDA2R
prerank,MSigDB_Oncogenic_Signatures__KRAS.300 UP.V1 UP,-0.5326047253532865,-0.7477593974221581,0.8349514563106796,0.8666831455624637,1.0,4/121,1.30%,DCBLD2;ZNF528;MAP4K1;DNAJA4
prerank,TRRUST_Transcription_Factors_2019__E2F1 mouse,-0.5337414692368664,-0.7468452913967155,0.7207207207207207,0.8672982037527732,1.0,1/46,0.53%,RB1
prerank,MSigDB_Oncogenic_Signatures__CRX NRL DN.V1 UP,0.5655463076189913,0.7462481125283373,0.8153846153846154,0.8501539883399224,1.0,6/122,1.53%,ST3GAL1;PPARA;PAQR4;MYO7A;DRD4;SNTA1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Noise-Induced Hearing Loss,0.5328422203134163,0.7459028968980828,0.678082191780822,0.8500821094231054,1.0,2/39,1.30%,SLC6A4;APOE
prerank,"GO_Biological_Process_2021__positive regulation of DNA-templated transcription, elongation (GO:0032786)",-0.3779066484074613,-0.7458261495058217,0.4247787610619469,0.8678770080982453,1.0,10/23,22.58%,THOC5;EAPP;CDK13;KAT7;SUPT16H;HMGN1;SCAF8;CDK12;CCNK;ELL
prerank,GO_Biological_Process_2021__positive regulation of angiogenesis (GO:0045766),0.5638964171979113,0.7451066621288597,0.8175182481751825,0.8504335494498064,1.0,4/114,1.36%,TJP1;ZNF304;CTSH;FGF1
prerank,GO_Biological_Process_2021__regulation of interleukin-1 production (GO:0032652),-0.3654391714509283,-0.7447976933394418,0.43609022556390975,0.8685341954376762,1.0,5/16,18.15%,ANXA1;SAA1;HMGB1;NLRP12;F2R
prerank,GO_Biological_Process_2021__nitrogen compound transport (GO:0071705),-0.5308139239594234,-0.7447717147699273,0.8252427184466019,0.8681693485775488,1.0,4/135,1.26%,SLC22A1;SLC7A8;SLC15A3;HRG
prerank,Elsevier_Pathway_Collection__VEGFA in Neovascular Glaucoma,0.5048115766444846,0.7446736723887013,0.6666666666666666,0.8504708987924428,1.0,1/39,0.26%,PTK2
prerank,Reactome_2022__Fatty Acid Metabolism R-HSA-8978868,0.533763383479464,0.7443308790544346,0.8873239436619719,0.8504192655110049,1.0,4/167,1.18%,PRKAA2;ACACA;ACSF3;ACSL5
prerank,GO_Biological_Process_2021__zymogen activation (GO:0031638),-0.5164091882915872,-0.7443134760331555,0.6904761904761905,0.8681933300662941,1.0,1/42,1.06%,C1R
prerank,Elsevier_Pathway_Collection__CD16/CD14 Proinflammatory Monocyte Activation,-0.5461282098710425,-0.7442752372401057,0.7747747747747747,0.8678608499823285,1.0,2/66,1.13%,TICAM2;ZAP70
prerank,"Reactome_2022__PI5P, PP2A And IER3 Regulate PI3K/AKT Signaling R-HSA-6811558",0.5462991986340935,0.7436033215921984,0.8156028368794326,0.8507451749255052,1.0,3/98,1.36%,ERBB3;KLB;FGF1
prerank,Elsevier_Pathway_Collection__Single-Strand Base Excision,0.39311114225496957,0.7430208560389185,0.4772727272727273,0.8505560852691071,1.0,6/15,30.01%,UNG;PCNA;XRCC1;LIG3;POLE;PNKP
prerank,Elsevier_Pathway_Collection__Single Strand Base Excision DNA Repair Impairment in Cancer,0.39311114225496957,0.7430208560389185,0.4772727272727273,0.8505560852691071,1.0,6/15,30.01%,UNG;PCNA;XRCC1;LIG3;POLE;PNKP
prerank,Reactome_2022__Signaling By MET R-HSA-6806834,0.5441978258638867,0.7427870545082192,0.746268656716418,0.8504515298928838,1.0,3/63,1.53%,PTK2;ITGA2;LRIG1
prerank,MSigDB_Oncogenic_Signatures__IL21 UP.V1 DN,0.5455181910184946,0.7425823343250797,0.8409090909090909,0.8502754218550758,1.0,4/141,1.54%,ASPHD1;ITGA2;ZNF286A;RIN2
prerank,Elsevier_Pathway_Collection__Bone Loss in Osteoporosis,-0.4995691808347257,-0.7423397390788246,0.7168141592920354,0.8693944588342997,1.0,1/43,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection organization (GO:0120036),-0.5092414387146897,-0.7423385347248657,0.8958333333333334,0.8690092596943642,1.0,5/122,1.33%,CARMIL1;APP;RB1;ATXN10;HDGFL3
prerank,Reactome_2022__Extra-nuclear Estrogen Signaling R-HSA-9009391,-0.5394106568836134,-0.7422182269855165,0.752,0.8687274447422635,1.0,2/69,0.37%,ZDHHC21;AKT3
prerank,Reactome_2022__Regulation Of IGF Transport And Uptake By IGFBPs R-HSA-381426,0.5428719376054685,0.7421458559146149,0.841726618705036,0.8503407497655656,1.0,4/117,1.51%,CKAP4;MELTF;APOE;FN1
prerank,MSigDB_Oncogenic_Signatures__SNF5 DN.V1 UP,-0.5272956865509351,-0.7416081566171285,0.8793103448275862,0.8690320280619009,1.0,7/149,1.17%,RNF13;OASL;SEMA4D;GALC;C1R;SPI1;CDO1
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP EARLY.V1 UP,-0.4885307444273874,-0.7412380805574339,0.9814814814814815,0.8689919212273167,1.0,5/152,1.26%,CYP2C8;ANKRD13C;ATL2;SDC3;TMPRSS2
prerank,Reactome_2022__RAB GEFs Exchange GTP For GDP On RABs R-HSA-8876198,-0.5753318891226468,-0.7411224467527645,0.7920792079207921,0.8687179719619532,1.0,2/89,0.70%,AKT3;SBF2
prerank,GO_Biological_Process_2021__protein monoubiquitination (GO:0006513),-0.4937225438243994,-0.7411129778609101,0.6694915254237288,0.868347014717576,1.0,1/39,0.76%,UBE3D
prerank,Reactome_2022__Aberrant Regulation Of Mitotic Cell Cycle Due To RB1 Defects R-HSA-9687139,0.5245113478449835,0.7409308871542387,0.6589147286821705,0.8510642463519871,1.0,2/36,0.94%,CDK6;UBE2C
prerank,WikiPathway_2021_Human__Integrin-mediated Cell Adhesion WP185,-0.5034936730378471,-0.7407980719033225,0.8135593220338984,0.8683222187104892,1.0,5/98,0.71%,MAP2K6;RAP1A;AKT3;RAP1B;PAK2
prerank,GO_Biological_Process_2021__chromatin organization (GO:0006325),0.5189617051593843,0.7407580541499706,0.8857142857142857,0.8508647720788495,1.0,2/135,1.05%,HDAC8;PADI2
prerank,Reactome_2022__Signaling By PDGF R-HSA-186797,0.5453031315549874,0.7406547780175066,0.7272727272727273,0.8506048238080525,1.0,3/51,1.49%,COL4A5;COL9A3;BCAR1
prerank,GO_Biological_Process_2021__neuron projection development (GO:0031175),0.5307309536523747,0.7404191634395323,0.9117647058823529,0.8504476636096227,1.0,6/163,1.37%,PPP1R9A;CNTNAP1;STMN3;GPRIN1;APOE;FRY
prerank,GO_Biological_Process_2021__regulation of endothelial cell proliferation (GO:0001936),0.5178518301211271,0.740213176814595,0.8041958041958042,0.8502921856059752,1.0,2/89,1.30%,PPP1R16B;APOE
prerank,GO_Biological_Process_2021__regulation of protein-containing complex assembly (GO:0043254),-0.5235126814173816,-0.7401854193292406,0.8738738738738738,0.8685347496949527,1.0,3/109,1.26%,RB1;HCK;HRG
prerank,Reactome_2022__Signaling By Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-2404192,0.5375807819017855,0.7398330248611418,0.7152777777777778,0.8503014419683166,1.0,2/45,1.36%,KLB;FGF1
prerank,Reactome_2022__IGF1R Signaling Cascade R-HSA-2428924,0.5375813338682003,0.7397648034830216,0.7183098591549296,0.850023522223371,1.0,2/44,1.36%,KLB;FGF1
prerank,Elsevier_Pathway_Collection__T-Cell Independent B-Cell Activation,-0.5505283242802863,-0.7397120617919037,0.728,0.8686238235582728,1.0,2/54,1.10%,TICAM2;VAV1
prerank,GO_Biological_Process_2021__positive regulation of protein localization to plasma membrane (GO:1903078),-0.5077473517316677,-0.739543568174636,0.7169811320754716,0.8683879791101825,1.0,1/51,0.43%,WNK3
prerank,Elsevier_Pathway_Collection__TNFR -> CREB/ELK-SRF Signaling,-0.5002342198633771,-0.7393155879979476,0.6615384615384615,0.8682680391490479,1.0,1/40,0.31%,MAP2K6
prerank,WikiPathway_2021_Human__Genes related to primary cilium development (based on CRISPR) WP4536,0.5537845479495965,0.7391544908428709,0.7832167832167832,0.8502578668776011,1.0,3/97,1.35%,CEP295;TTC23;KIF3B
prerank,Reactome_2022__Regulation Of RUNX2 Expression And Activity R-HSA-8939902,-0.557039811324776,-0.7389788354390021,0.7758620689655172,0.8681985666645664,1.0,2/69,0.73%,NR3C1;WWP1
prerank,MSigDB_Oncogenic_Signatures__PDGF ERK DN.V1 DN,0.5143594911122961,0.7388981649645809,0.9274193548387096,0.850129087481849,1.0,2/138,0.97%,SMOX;MYCN
prerank,MSigDB_Oncogenic_Signatures__PIGF UP.V1 UP,0.5186908593737861,0.7388218525399071,0.8863636363636364,0.8498608808915052,1.0,4/182,0.73%,ITGA2;ATR;CEBPZ;UPF2
prerank,Reactome_2022__Diseases Of Mitotic Cell Cycle R-HSA-9675126,0.5245105692313755,0.7386025558825142,0.6796875,0.8497013742256972,1.0,2/38,0.94%,CDK6;UBE2C
prerank,GO_Biological_Process_2021__phosphatidylcholine metabolic process (GO:0046470),0.5729237223208724,0.7384568892234163,0.8253968253968254,0.8494815830849907,1.0,2/71,1.38%,GPAT4;LPCAT2
prerank,Reactome_2022__Neurexins And Neuroligins R-HSA-6794361,0.5437896922811345,0.7381474187886032,0.7520661157024794,0.849429205236681,1.0,4/56,1.23%,LIN7A;GPRIN1;STX1A;HOMER3
prerank,WikiPathway_2021_Human__Nephrotic syndrome WP4758,0.5109365055299595,0.7379743234100954,0.7058823529411765,0.8492514958050349,1.0,2/42,0.96%,ANLN;COL4A5
prerank,GO_Biological_Process_2021__synapse organization (GO:0050808),-0.5059562969022315,-0.7376991465237805,0.8728813559322034,0.8690911994604601,1.0,2/121,0.86%,APP;SLITRK3
prerank,GO_Biological_Process_2021__maintenance of blood-brain barrier (GO:0035633),0.4984657646966092,0.7376893754399269,0.6267605633802817,0.8491512912619849,1.0,1/30,0.45%,TJP1
prerank,Reactome_2022__Signaling By Insulin Receptor R-HSA-74752,-0.5362004089008122,-0.7376588809055615,0.6929824561403509,0.8687381575829695,1.0,2/66,1.36%,PIK3CB;GRB10
prerank,Reactome_2022__IRS-related Events Triggered By IGF1R R-HSA-2428928,0.5375819424380155,0.7372044967315529,0.7194244604316546,0.8492785140959936,1.0,2/43,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__positive regulation of apoptotic signaling pathway (GO:2001235),0.5151912434894838,0.7369742882108954,0.7533333333333333,0.849124272298276,1.0,2/57,1.51%,ING5;BOK
prerank,Elsevier_Pathway_Collection__Platelet Activation via GPCR Signaling,0.4969267952784503,0.7369739846123682,0.7185185185185186,0.8487785376597182,1.0,1/49,0.38%,ITGA2
prerank,GO_Biological_Process_2021__regulation of cell adhesion (GO:0030155),0.5318339721039796,0.736865042276792,0.8251748251748252,0.8485396674451844,1.0,3/128,1.09%,PTK2;ERBB3;CHRD
prerank,"Elsevier_Pathway_Collection__Hyperparathyroidism, Secondary Effect",-0.4995711048333522,-0.7367886631676511,0.6578947368421053,0.8692329935656824,1.0,1/32,0.31%,MAP2K6
prerank,GO_Biological_Process_2021__neuron development (GO:0048666),0.5380633206046352,0.7364373962335855,0.9044585987261147,0.8485619364929392,1.0,6/134,1.37%,PPP1R9A;TBCD;STMN3;GPRIN1;APOE;FRY
prerank,MSigDB_Oncogenic_Signatures__JNK DN.V1 UP,-0.5052708785120277,-0.7360117362308702,0.9252336448598131,0.8696119521474284,1.0,6/160,1.23%,SLC16A2;CD83;SYNE1;IL10RA;TEK;S1PR1
prerank,WikiPathway_2021_Human__Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.5345418706791983,0.7357834913087002,0.8394160583941606,0.8488126142912339,1.0,2/142,1.53%,SLC6A4;SNTA1
prerank,GO_Biological_Process_2021__regulation of ion transport (GO:0043269),0.5455837680905017,0.7354904217041309,0.7815126050420168,0.8487205872768836,1.0,1/71,0.59%,WWP2
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - interferon induction WP4880,-0.4960958278104583,-0.7353644948492685,0.6379310344827587,0.869841685650007,1.0,1/33,0.39%,OAS1
prerank,MSigDB_Hallmark_2020__Reactive Oxygen Species Pathway,-0.4914152140463101,-0.7349251011449179,0.7166666666666667,0.8699037876702808,1.0,1/48,0.91%,IPCEF1
prerank,WikiPathway_2021_Human__RANKL/RANK signaling pathway WP2018,0.5516588721550645,0.7348937488488957,0.7593984962406015,0.8488692136397621,1.0,2/55,0.44%,PTK2;TRAF3
prerank,Reactome_2022__Regulation Of Beta-Cell Development R-HSA-186712,0.5190619285318959,0.7348483958865119,0.6666666666666666,0.8485521729625041,1.0,2/32,1.55%,PKLR;FOXA3
prerank,MSigDB_Oncogenic_Signatures__MEK UP.V1 DN,0.5491312504868836,0.734835788510632,0.9078014184397163,0.8482168987098777,1.0,5/165,1.53%,RALGAPA1;HIRA;QPRT;COL9A3;LRIG1
prerank,Elsevier_Pathway_Collection__Penile Detumescense Augmentation Mechanisms,-0.33744209447437185,-0.7342697245363411,0.4519230769230769,0.8701722406247342,1.0,8/16,26.01%,AGTR1;PTGFR;EDN1;MYLK;GNAQ;ADRA1B;ITPR1;PLCB1
prerank,Reactome_2022__Transcriptional Regulation By RUNX1 R-HSA-8878171,0.49441055308734333,0.7338311551522572,0.9844961240310077,0.8487968305181738,1.0,3/187,1.02%,CDK6;TJP1;CBX2
prerank,Elsevier_Pathway_Collection__Monoblast -> Promonocyte Surface Expression Markers,-0.4148402595068307,-0.7335871470811135,0.48360655737704916,0.8704664793720055,1.0,7/18,18.79%,TNF;ITGAM;ITGB1;CD36;ADORA1;CSF1R;ENG
prerank,GO_Biological_Process_2021__positive regulation by host of viral transcription (GO:0043923),-0.3594315786848229,-0.7329240731877911,0.456,0.8707214442795589,1.0,11/16,36.45%,RRP1B;EP300;TFAP4;CHD1;SMARCB1;TAF11;SMARCA4;SNW1;ZNF639;LEF1;CTDP1
prerank,GO_Biological_Process_2021__establishment of protein localization to organelle (GO:0072594),-0.5362884024794753,-0.7325643458099831,0.75,0.8706679133104811,1.0,1/73,1.12%,IL10RA
prerank,Reactome_2022__Constitutive Signaling By Aberrant PI3K In Cancer R-HSA-2219530,0.5463140590330748,0.7325412620506867,0.7878787878787878,0.8495903056363856,1.0,3/71,1.36%,ERBB3;KLB;FGF1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Migraine,-0.5042408346216654,-0.7324679825944951,0.6585365853658537,0.8703823986258602,1.0,1/35,0.01%,GRIN2B
prerank,Reactome_2022__APC/C-mediated Degradation Of Cell Cycle Proteins R-HSA-174143,-0.5244272270076524,-0.7323397328324052,0.8240740740740741,0.8701175441381422,1.0,1/84,0.53%,RB1
prerank,MSigDB_Oncogenic_Signatures__EIF4E DN,0.5687170261869313,0.7321315909471792,0.8571428571428571,0.8496320839576079,1.0,5/92,1.07%,SORT1;FNDC3B;SVIL;UPF2;TSPAN6
prerank,KEGG_2021_Human__Th1 and Th2 cell differentiation,-0.5268654478205291,-0.7319219595425288,0.8303571428571429,0.8701366784269967,1.0,2/84,1.19%,ZAP70;IL12RB2
prerank,GO_Biological_Process_2021__regulation of centrosome duplication (GO:0010824),0.5044990192969464,0.7318761897432057,0.626984126984127,0.8494907564620261,1.0,1/29,0.23%,CEP295
prerank,WikiPathway_2021_Human__Ectoderm Differentiation WP2858,0.5242014603733417,0.7318753216767407,0.851063829787234,0.8491465543726979,1.0,4/130,1.20%,VAX2;BCOR;TBL1X;EDA2R
prerank,GO_Biological_Process_2021__regulation of viral life cycle (GO:1903900),-0.38260336396287425,-0.7317884698329995,0.49193548387096775,0.8698703099364643,1.0,8/23,16.75%,TRIM14;NECTIN2;TRIM68;TRIM31;AXL;TRIM27;KPNA6;TRIM21
prerank,GO_Biological_Process_2021__negative regulation of Wnt signaling pathway (GO:0030178),-0.5065040417017836,-0.7315915493734761,0.96,0.8696931184716223,1.0,4/181,1.36%,TLE4;AMFR;GLI3;GRB10
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN.V1 DN,-0.5122154000521205,-0.7315309606466924,0.9272727272727272,0.8693660554268982,1.0,4/119,1.24%,SUCLG2;PDE5A;GAS2;MAOB
prerank,GO_Biological_Process_2021__cellular response to molecule of bacterial origin (GO:0071219),-0.5212883862863384,-0.731356926896492,0.8272727272727273,0.8691392527061751,1.0,2/103,1.04%,CD274;TICAM2
prerank,GO_Biological_Process_2021__negative regulation of kinase activity (GO:0033673),0.5274457877893229,0.7312992682612063,0.7368421052631579,0.8493314187983448,1.0,3/61,0.91%,THY1;CEP85;DBNDD1
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V1 DN,0.5034911822437609,0.7309732869394552,0.9415584415584416,0.8492964067149883,1.0,4/176,1.49%,RHOQ;ITGAL;FDXR;GLS
prerank,Reactome_2022__Toll Like Receptor 3 (TLR3) Cascade R-HSA-168164,-0.5237955431283989,-0.7309486866631072,0.8623853211009175,0.8691828303925592,1.0,3/102,1.26%,MAP2K6;APP;DUSP4
prerank,Reactome_2022__Negative Regulation Of FLT3 R-HSA-9706369,0.4098281072092992,0.730641596324632,0.4566929133858268,0.849223024735936,1.0,8/15,24.31%,SLA2;SH2B3;PTPRJ;UBB;SEPSECS;UBA52;ABL2;FLT3
prerank,GO_Biological_Process_2021__positive regulation of MAP kinase activity (GO:0043406),0.5306480020711073,0.7304073608633933,0.7414965986394558,0.8491036428864308,1.0,1/65,1.36%,FGF1
prerank,KEGG_2021_Human__Glycerophospholipid metabolism,0.5711086295665945,0.7303416941724279,0.8492063492063492,0.8488186113670169,1.0,3/92,1.38%,GPAT4;PNPLA6;LPCAT2
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, nonsense-mediated decay (GO:0000184)",0.5713191154591674,0.7303163649658329,0.8513513513513513,0.8485031289316343,1.0,1/113,0.73%,UPF2
prerank,Reactome_2022__PTEN Regulation R-HSA-6807070,0.5280781367757329,0.7302437010540528,0.8951048951048951,0.8482155034785148,1.0,2/135,1.02%,WWP2;CBX2
prerank,GO_Biological_Process_2021__cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742),-0.499852940937091,-0.7302051434790152,0.9626168224299065,0.8694760865355504,1.0,2/156,1.15%,SLITRK3;DSCAML1
prerank,Reactome_2022__PPARA Activates Gene Expression R-HSA-1989781,0.558460306376887,0.7300511549042124,0.8486842105263158,0.8480522694021903,1.0,3/114,1.16%,TBL1X;PPARA;PKMYT1
prerank,GO_Biological_Process_2021__positive regulation of vasculature development (GO:1904018),0.5582098160446637,0.7293175657110691,0.8013698630136986,0.848344233170418,1.0,3/100,1.36%,ZNF304;CTSH;FGF1
prerank,Elsevier_Pathway_Collection__Effector T-cell Inactivation in Cancer Immune Escape,-0.5275755752254313,-0.7291560291255136,0.732824427480916,0.8700834067953487,1.0,3/57,1.13%,PTK2B;CD274;ZAP70
prerank,Reactome_2022__Visual Phototransduction R-HSA-2187338,-0.5209285241468576,-0.7290951619951744,0.8032786885245902,0.869775369029293,1.0,3/83,1.16%,CYP4V2;HSD17B6;SDC3
prerank,KEGG_2021_Human__Nitrogen metabolism,0.3693129977893449,0.7287050672720268,0.4264705882352941,0.848576229261338,1.0,5/15,13.55%,CA14;CA2;CA3;CPS1;CA9
prerank,GO_Biological_Process_2021__homotypic cell-cell adhesion (GO:0034109),0.5107294363754866,0.7284277172551283,0.6916666666666667,0.8484834719593092,1.0,2/44,1.51%,FLNA;FN1
prerank,Reactome_2022__Post-translational Protein Phosphorylation R-HSA-8957275,0.5428816558454436,0.7284207189635225,0.8068965517241379,0.8481413415270675,1.0,4/101,1.51%,CKAP4;MELTF;APOE;FN1
prerank,TRRUST_Transcription_Factors_2019__HIF1A human,-0.5118677591827584,-0.7283772059473168,0.8504672897196262,0.8701030814959889,1.0,1/80,0.41%,NR3C1
prerank,KEGG_2021_Human__Breast cancer,0.5400574465288382,0.7282366327657044,0.8496732026143791,0.8479585797092631,1.0,5/137,1.36%,AXIN2;CDK6;LRP5;NOTCH3;FGF1
prerank,Reactome_2022__Regulation Of Lipid Metabolism By PPARalpha R-HSA-400206,0.5584594041396084,0.7281600757138358,0.8533333333333334,0.8476903343145165,1.0,3/116,1.16%,TBL1X;PPARA;PKMYT1
prerank,Elsevier_Pathway_Collection__Renin-Angiotensin-Aldosterone System in Myocardial ischemia,-0.35617029842883685,-0.7276559374856698,0.5210084033613446,0.8704508196259919,1.0,7/15,30.54%,AGTR1;CTSG;HSD3B2;MAS1;NPR1;CYP21A2;ACE2
prerank,GO_Biological_Process_2021__regulation of glucose transmembrane transport (GO:0010827),-0.3935465634713119,-0.7276289555966255,0.44525547445255476,0.870096881820903,1.0,9/17,26.62%,PLA2G1B;SLC2A1;NR4A3;INPP5K;APPL1;C3;OCLN;BRAF;FFAR4
prerank,MSigDB_Oncogenic_Signatures__ALK DN.V1 UP,0.5521405691449093,0.7275450478910688,0.8881118881118881,0.8478762713940323,1.0,1/122,0.05%,DLX6
prerank,Elsevier_Pathway_Collection__Myeloblast -> Neutrophil Surface Expression Markers,0.5432519478782474,0.7275319119330085,0.7862595419847328,0.8475441036876513,1.0,2/64,1.10%,ITGA2;ITGAL
prerank,MSigDB_Oncogenic_Signatures__E2F3 UP.V1 DN,-0.5412582768713063,-0.7272911571386813,0.839622641509434,0.8700661123564751,1.0,4/118,1.21%,GJB5;RAP1A;FBXO27;NYNRIN
prerank,MSigDB_Oncogenic_Signatures__CAMP UP.V1 DN,-0.5111219602153795,-0.727260997922325,0.9203539823008849,0.8697181831536841,1.0,6/189,1.21%,FOSB;AKT3;SEL1L3;CCND2;CD83;NYNRIN
prerank,MSigDB_Oncogenic_Signatures__PRC2 EZH2 UP.V1 DN,0.5054676338552668,0.7270011787885693,0.9568345323741008,0.8476948226114132,1.0,8/172,1.52%,TMC7;ITGA2;SLC35D2;COL4A5;MCTP1;TUB;PPFIA4;AMMECR1
prerank,Elsevier_Pathway_Collection__Desmosome Assembly,0.3754012310062841,0.7268162262966923,0.40476190476190477,0.8475538278601213,1.0,6/17,14.97%,DSC3;PLEC;EVPL;PNN;JUP;PKP2
prerank,Elsevier_Pathway_Collection__Myocardial Infarction,-0.5190454371816423,-0.7265008340279991,0.7924528301886793,0.8700691695246531,1.0,1/74,1.04%,TICAM2
prerank,TRRUST_Transcription_Factors_2019__NR3C1 human,0.5227726329982831,0.7264662671744931,0.7076923076923077,0.8475167177604562,1.0,1/35,0.19%,CDK6
prerank,WikiPathway_2021_Human__Amino Acid metabolism WP3925,0.5575351494649268,0.7261192493255716,0.8450704225352113,0.8474887901000772,1.0,4/83,1.52%,AUH;PYCR1;GLS;SMS
prerank,MSigDB_Oncogenic_Signatures__NRL DN.V1 UP,0.5236597188055602,0.7259537811315642,0.8740740740740741,0.8472733317993115,1.0,3/119,1.53%,ST3GAL1;PPARA;SNTA1
prerank,GO_Biological_Process_2021__protein polymerization (GO:0051258),0.5331115853777412,0.7258067517995433,0.7777777777777778,0.847070240232787,1.0,2/59,1.08%,UBE2C;SPIRE2
prerank,Reactome_2022__Macroautophagy R-HSA-1632852,-0.5291810536766405,-0.7253978579849815,0.84,0.8707551854435162,1.0,2/111,0.78%,UVRAG;TOMM70
prerank,Reactome_2022__Sensory Processing Of Sound R-HSA-9659379,0.5619150327784834,0.7253326064012882,0.7969924812030075,0.8471400356851226,1.0,3/67,1.20%,MYO7A;ESPN;STX1A
prerank,Reactome_2022__Potassium Channels R-HSA-1296071,-0.5763675326555343,-0.7250692672639029,0.7984496124031008,0.8706818238813511,1.0,4/85,1.24%,KCNN2;KCNAB3;KCNK6;KCNS3
prerank,Reactome_2022__Synthesis Of PIPs At Golgi Membrane R-HSA-1660514,-0.34395926519862186,-0.7244249129808524,0.4260869565217391,0.8709398878068436,1.0,7/16,25.54%,OCRL;PI4K2B;FIG4;PI4KA;PIK3C2G;INPP5E;PIK3C3
prerank,TRRUST_Transcription_Factors_2019__EGR1 human,0.5565866583669529,0.7243811369683576,0.7985074626865671,0.8475768147812358,1.0,2/84,1.51%,BCAR1;FN1
prerank,GO_Biological_Process_2021__DNA unwinding involved in DNA replication (GO:0006268),-0.35116764646916043,-0.724194333533726,0.4878048780487805,0.8707929058344434,1.0,6/16,18.21%,RPA1;MCM4;MCM7;RECQL;RECQL5;SSBP1
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V1 DN,0.5396622728241753,0.7240703935435071,0.9,0.8475139043963335,1.0,3/142,0.89%,LIN7A;ETV5;TBX3
prerank,Reactome_2022__Signaling By VEGF R-HSA-194138,0.5407770077782075,0.7238972779986766,0.8571428571428571,0.8473201726864298,1.0,5/100,1.49%,PTK2;SHB;ABI2;ARHGEF7;BCAR1
prerank,Elsevier_Pathway_Collection__Hodgkin Lymphoma,-0.5274987468527762,-0.723766886976424,0.8367346938775511,0.8708299813940753,1.0,3/105,1.10%,SCIMP;IL21R;SPI1
prerank,GO_Biological_Process_2021__muscle tissue morphogenesis (GO:0060415),-0.36845811440665716,-0.7234566602581634,0.4603174603174603,0.8707493608644651,1.0,10/15,34.31%,HEY2;ANKRD1;MYLK2;TCAP;MYLK;TBX1;TTN;BMP2;NOTCH1;BMP4
prerank,KEGG_2021_Human__Vibrio cholerae infection,0.515313894688139,0.72292348540673,0.7054263565891473,0.847776129411663,1.0,1/46,0.45%,TJP1
prerank,GO_Biological_Process_2021__ceramide catabolic process (GO:0046514),0.3872726016825795,0.7227271702143445,0.46564885496183206,0.8475778862410351,1.0,6/15,19.41%,HEXB;ACER2;NEU4;HEXA;ACER3;ASAH2
prerank,Reactome_2022__MyD88-independent TLR4 Cascade R-HSA-166166,-0.5237940366819935,-0.7226205007221558,0.8785046728971962,0.8711613137688834,1.0,3/105,1.26%,MAP2K6;APP;DUSP4
prerank,Reactome_2022__Formation Of beta-catenin:TCF Transactivating Complex R-HSA-201722,0.5230934377802468,0.7225433726547558,0.7368421052631579,0.8473737221094589,1.0,1/49,0.12%,AXIN2
prerank,Reactome_2022__IRS-mediated Signaling R-HSA-112399,0.5375837337558367,0.722502985703686,0.7372262773722628,0.8470724844450562,1.0,2/40,1.36%,KLB;FGF1
prerank,GO_Biological_Process_2021__neutrophil activation (GO:0042119),-0.3618601333485758,-0.7222817120662001,0.47115384615384615,0.8711191943092809,1.0,5/15,19.25%,DNASE1L3;TYROBP;PREX1;KMT2E;CXCL8
prerank,GO_Biological_Process_2021__regulation of plasma membrane bounded cell projection assembly (GO:0120032),0.5418963596956049,0.7218400002753597,0.782258064516129,0.8472772216508392,1.0,1/64,0.10%,PPP1R16B
prerank,MSigDB_Oncogenic_Signatures__E2F1 UP.V1 UP,0.5050178060442916,0.7215258542141323,0.9477611940298507,0.8472373789410105,1.0,4/169,1.51%,TRAF3;ARHGAP39;SLC7A1;BOK
prerank,GO_Biological_Process_2021__anion transmembrane transport (GO:0098656),-0.4991657339923394,-0.7214461650594057,0.8148148148148148,0.8714792181859309,1.0,3/64,0.41%,SLC35A3;SLC7A8;SLC36A4
prerank,KEGG_2021_Human__Neutrophil extracellular trap formation,0.5310249077083463,0.7212844118047098,0.8809523809523809,0.8470943777131194,1.0,3/155,1.28%,HDAC8;ITGAL;CLCN4
prerank,MSigDB_Oncogenic_Signatures__ATM DN.V1 DN,-0.524975115275704,-0.720134324281208,0.8660714285714286,0.8722683916131289,1.0,4/119,1.26%,KCNE1;CYP1A2;TEK;TMPRSS2
prerank,GO_Biological_Process_2021__carboxylic acid transmembrane transport (GO:1905039),0.5176857967279318,0.7197864296881183,0.6788321167883211,0.8480557933131005,1.0,3/37,1.54%,SLC19A1;SLC13A3;SLC38A1
prerank,GO_Biological_Process_2021__regulation of JNK cascade (GO:0046328),0.529168488482907,0.7195223748852146,0.8296296296296296,0.8479535192875385,1.0,5/104,1.49%,TRAF3;EDA2R;SH3RF2;ULK4;MAPK8IP1
prerank,GO_Biological_Process_2021__protein K48-linked ubiquitination (GO:0070936),-0.5376567451114647,-0.7193100923203871,0.7807017543859649,0.8727138269312428,1.0,2/57,0.72%,KLHL3;AMFR
prerank,GO_Biological_Process_2021__negative regulation of RNA metabolic process (GO:0051253),-0.3843194404706836,-0.7185600187974535,0.4628099173553719,0.8730873611522911,1.0,6/19,13.20%,TNF;PTBP3;NCOR2;PTBP1;SHQ1;PTBP2
prerank,"WikiPathway_2021_Human__GPCRs, Class A Rhodopsin-like WP455",-0.49601830541853675,-0.718419471843285,0.9811320754716981,0.8728355453407923,1.0,2/155,0.97%,GPR39;HRH2
prerank,GO_Biological_Process_2021__positive regulation of intracellular protein transport (GO:0090316),0.5220994310806144,0.7181628293997122,0.9428571428571428,0.8487561923778036,1.0,1/148,1.41%,FLNA
prerank,Reactome_2022__Transcriptional Regulation Of Granulopoiesis R-HSA-9616222,0.5115635877895305,0.7179200613458706,0.76,0.8486112981000196,1.0,1/49,0.12%,GFI1
prerank,GO_Biological_Process_2021__regulation of angiogenesis (GO:0045765),0.5004012723645016,0.7171635255097024,0.9931506849315068,0.8489102614661023,1.0,5/195,1.36%,PPP1R16B;GTF2I;ZNF304;CTSH;FGF1
prerank,Reactome_2022__Degradation Of Beta-Catenin By Destruction Complex R-HSA-195253,0.5230904259937192,0.7167723730283254,0.8345864661654135,0.8489168086981675,1.0,1/82,0.12%,AXIN2
prerank,GO_Biological_Process_2021__regulation of endopeptidase activity (GO:0052548),-0.4942843643603963,-0.7166095565962001,0.7692307692307693,0.8741320958226387,1.0,1/62,1.26%,HRG
prerank,Reactome_2022__APC/C:Cdh1 Mediated Degradation Of Cdc20 And APC/C:Cdh1 Targets In Late Mitosis/Early G1 R-HSA-174178,-0.5244308682075454,-0.7165167739300796,0.7850467289719626,0.873854407078928,1.0,1/71,0.53%,RB1
prerank,GO_Biological_Process_2021__positive regulation of stress-activated MAPK cascade (GO:0032874),-0.5407155029659666,-0.7164981447057982,0.8272727272727273,0.8734945842441787,1.0,5/97,1.10%,APP;PTK2B;CD27;SCIMP;SPI1
prerank,GO_Biological_Process_2021__striated muscle contraction (GO:0006941),-0.5023806838489222,-0.7163714817592799,0.6984126984126984,0.8732137519545645,1.0,1/48,1.06%,RCSD1
prerank,GO_Biological_Process_2021__positive regulation of developmental process (GO:0051094),0.5134991574421386,0.7158201388005538,0.9241379310344827,0.8493576592331704,1.0,3/159,1.30%,ARHGEF7;PPP1R13L;APOE
prerank,GO_Biological_Process_2021__establishment of protein localization to membrane (GO:0090150),0.5585964348805939,0.715809575281695,0.8125,0.8490312361930846,1.0,3/67,1.36%,RAB3GAP1;ZDHHC9;SYNE3
prerank,Reactome_2022__NS1 Mediated Effects On Host Pathways R-HSA-168276,0.5149709644727152,0.7157665964522089,0.7203389830508474,0.8487353145375508,1.0,1/42,0.48%,NUP210
prerank,WikiPathway_2021_Human__Endometrial cancer WP4155,-0.5233825015481074,-0.7156490784725793,0.7610619469026548,0.8734635607837545,1.0,2/63,0.73%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__cellular divalent inorganic cation homeostasis (GO:0072503),-0.5277484080299402,-0.7155689550577446,0.8288288288288288,0.8731647029332359,1.0,1/97,0.09%,CCL23
prerank,GO_Biological_Process_2021__regulation of glycogen biosynthetic process (GO:0005979),-0.372683275278965,-0.7154861208040832,0.44166666666666665,0.8728606211366736,1.0,12/23,26.50%,SELENOS;GSK3A;IGF1;PPP1R3C;PPP1R3B;GCK;PPP1R3F;INPP5K;EPM2AIP1;PASK;ENPP1;AKT1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Resisting to Cell Death,0.5116627109920183,0.7154555421316576,0.7058823529411765,0.8486693708289758,1.0,1/47,0.42%,TNFRSF10A
prerank,KEGG_2021_Human__Gastric cancer,-0.5084315308832933,-0.7153304097668867,0.9326923076923077,0.872624385780825,1.0,3/138,0.73%,AKT3;RB1;PIK3CB
prerank,GO_Biological_Process_2021__regulation of cytokine-mediated signaling pathway (GO:0001959),0.5446461571162875,0.7150752559867399,0.8181818181818182,0.8486216099487861,1.0,1/72,0.10%,IRAK2
prerank,Elsevier_Pathway_Collection__Insulin Influence on Lipogenesis,-0.3511572762696548,-0.7149009653690357,0.44776119402985076,0.8726421408396225,1.0,9/15,36.67%,GPAT3;CD36;SLC2A1;SLC27A1;AKT1;ACSL1;INSR;SLC2A4;APOC2
prerank,GO_Biological_Process_2021__negative regulation of protein serine/threonine kinase activity (GO:0071901),-0.5368409971695077,-0.714820581737263,0.7678571428571429,0.8723624032165928,1.0,2/75,0.73%,RB1;PIK3CB
prerank,GO_Biological_Process_2021__regulation of protein localization to cell periphery (GO:1904375),-0.3918839697911479,-0.7146068888347447,0.45081967213114754,0.8721887120462964,1.0,7/19,27.26%,STX8;MISP;ABCA2;ZDHHC7;MMP14;APPL1;ZDHHC2
prerank,GO_Biological_Process_2021__toll-like receptor signaling pathway (GO:0002224),-0.5089404035571107,-0.7143414859174497,0.8608695652173913,0.872046169110265,1.0,3/89,1.04%,OAS1;SCIMP;TICAM2
prerank,Elsevier_Pathway_Collection__UrokinaseR -> ELK/SRF Signaling,-0.3632626744491886,-0.7140670818620026,0.3983739837398374,0.8718964583808182,1.0,10/23,19.32%,MAPK3;ELK4;RAF1;FYN;GRB2;PLAUR;SHC1;RASGRP1;TYK2;MAP2K2
prerank,GO_Biological_Process_2021__cell surface receptor signaling pathway involved in heart development (GO:0061311),-0.32801400451285206,-0.7140600314637982,0.4956521739130435,0.8715282521258692,1.0,9/17,34.31%,HEY2;DLL4;SNAI2;BMP2;BMPR1A;NOTCH1;SNAI1;TGFB1;BMP4
prerank,GO_Biological_Process_2021__posttranscriptional regulation of gene expression (GO:0010608),-0.5195183713689702,-0.7139670018757421,0.7241379310344828,0.8712477750251086,1.0,1/44,0.35%,APP
prerank,GO_Biological_Process_2021__cellular response to hormone stimulus (GO:0032870),-0.5338347720392369,-0.7138316661554399,0.7716535433070866,0.870982101720811,1.0,2/69,0.41%,NCOA1;NR3C1
prerank,GO_Biological_Process_2021__glutamine family amino acid metabolic process (GO:0009064),0.5078345925062255,0.713502014974749,0.7153284671532847,0.8496552326918172,1.0,2/37,1.49%,PYCR1;GLS
prerank,GO_Biological_Process_2021__regulation of mitotic cell cycle (GO:0007346),0.4987613364506045,0.7133315108097608,0.9795918367346939,0.8494561518093094,1.0,3/171,1.16%,MKI67;UBE2C;PKMYT1
prerank,GO_Biological_Process_2021__positive regulation of fat cell differentiation (GO:0045600),0.5359541577200251,0.7132357826625235,0.7265625,0.8491938487958117,1.0,1/47,0.40%,LRP5
prerank,GO_Biological_Process_2021__regulation of ossification (GO:0030278),0.4954031911029458,0.7131440070203053,0.6992481203007519,0.8489317542902739,1.0,1/34,1.30%,CYP27B1
prerank,KEGG_2021_Human__Colorectal cancer,0.5393872114394911,0.7129010074491079,0.8455882352941176,0.848784465338873,1.0,2/86,0.17%,AXIN2;MSH2
prerank,WikiPathway_2021_Human__Structural Pathway of Interleukin 1 (IL-1) WP2637,0.5424100053150207,0.7128945866258015,0.736,0.8484534076186545,1.0,1/48,0.10%,IRAK2
prerank,Reactome_2022__Host Interactions Of HIV Factors R-HSA-162909,0.5244979459093854,0.712891796170373,0.9078014184397163,0.8481180927611073,1.0,1/128,0.48%,NUP210
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN.V1 UP,0.5237573771437971,0.7126871818524138,0.9523809523809523,0.8479472050101298,1.0,6/134,1.53%,LRP5;SLC19A1;STX1A;SEMA3G;SLC2A6;LRIG1
prerank,GO_Biological_Process_2021__negative regulation of MAP kinase activity (GO:0043407),0.5210511231534396,0.7126219625998246,0.7251908396946565,0.8476755865641369,1.0,2/44,1.49%,APOE;MAPK8IP1
prerank,GO_Biological_Process_2021__positive regulation of cell adhesion mediated by integrin (GO:0033630),-0.3633587401776713,-0.7124319546733542,0.4909090909090909,0.871915720518545,1.0,8/18,26.65%,ADAM9;CXCL13;CCL21;P2RY12;RET;CD3E;SFRP2;RAC3
prerank,MSigDB_Hallmark_2020__Angiogenesis,0.509513791355477,0.7120309351899522,0.6928571428571428,0.8478405957388796,1.0,2/36,0.95%,PTK2;MSX1
prerank,GO_Biological_Process_2021__negative regulation of cell growth (GO:0030308),-0.4885049467152916,-0.7117494048543249,0.97,0.8721537787953157,1.0,4/123,1.31%,DCBLD2;RB1;HRG;PML
prerank,KEGG_2021_Human__Protein processing in endoplasmic reticulum,0.49663900547339135,0.7114475868591403,0.9703703703703703,0.8479874228304528,1.0,2/165,0.91%,DAD1;CKAP4
prerank,Reactome_2022__Cargo Trafficking To Periciliary Membrane R-HSA-5620920,0.5234876852402994,0.7112770920547203,0.7299270072992701,0.8478078356072849,1.0,1/49,0.30%,SMOX
prerank,GO_Biological_Process_2021__chloride transport (GO:0006821),-0.504961069310111,-0.710919543246303,0.7903225806451613,0.8725679741981646,1.0,1/68,1.11%,SLC12A8
prerank,MSigDB_Oncogenic_Signatures__CAHOY OLIGODENDROCUTIC,-0.5272617054027362,-0.7106053725551383,0.8305084745762712,0.8724784562645636,1.0,1/82,0.59%,KIAA1958
prerank,Elsevier_Pathway_Collection__Plasmin Effects in Inflammation,-0.503292097611851,-0.710543073155737,0.7739130434782608,0.8721674150321205,1.0,2/65,1.06%,MAP2K6;C1R
prerank,GO_Biological_Process_2021__negative regulation of growth (GO:0045926),0.5300793398664883,0.7104821393415691,0.8698630136986302,0.8481589784945549,1.0,4/123,1.30%,ING5;VGLL4;MSX1;CYP27B1
prerank,WikiPathway_2021_Human__G1 to S cell cycle control WP45,-0.5196866868262668,-0.7103577466974196,0.8301886792452831,0.8719619464739731,1.0,3/63,0.93%,RB1;ORC4;CCND2
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Multiple Myeloma,-0.5017279980358139,-0.7091051132801586,0.8125,0.8727330361794285,1.0,1/66,0.31%,MAP2K6
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP EARLY.V1 UP,-0.5040342458207844,-0.7089360928033226,0.9393939393939394,0.8725184309994894,1.0,3/139,1.35%,RB1;AQP3;COLQ
prerank,GO_Biological_Process_2021__sulfur compound biosynthetic process (GO:0044272),-0.549397064344622,-0.7087468063872502,0.8608695652173913,0.8723420886853468,1.0,4/107,1.17%,GSTA2;GSTA1;GGT5;CDO1
prerank,Reactome_2022__VEGFA-VEGFR2 Pathway R-HSA-4420097,0.5407822088509635,0.70849824733379,0.8857142857142857,0.8494999821080942,1.0,5/91,1.49%,PTK2;SHB;ABI2;ARHGEF7;BCAR1
prerank,WikiPathway_2021_Human__Ebola Virus Pathway on Host WP4217,0.5315001172078507,0.7082609244248137,0.8947368421052632,0.8493590587235808,1.0,3/125,1.41%,HAVCR1;ITGA2;FLNA
prerank,"GO_Biological_Process_2021__synaptic transmission, glutamatergic (GO:0035249)",-0.3603361047100073,-0.7081838923006157,0.45,0.8724631480826799,1.0,7/15,27.21%,NAPA;CDH8;UNC13C;GRIK3;SLC17A8;UNC13B;GRIK1
prerank,Elsevier_Pathway_Collection__Cardiovascular Effects in Hyperthyroidism,0.5063226599460832,0.7080429627798324,0.7196969696969697,0.8491987299545045,1.0,1/38,0.26%,PTK2
prerank,KEGG_2021_Human__Viral protein interaction with cytokine and cytokine receptor,-0.5055547447029111,-0.7077944301283714,0.875,0.8724156131359688,1.0,2/90,1.12%,CCL23;IL10RA
prerank,GO_Biological_Process_2021__response to lipid (GO:0033993),0.5553250960859031,0.7075528364164021,0.8602941176470589,0.8492816420923531,1.0,3/105,1.30%,PPARA;CTSH;CYP27B1
prerank,Elsevier_Pathway_Collection__Peripheral T-Cell Tolerance,-0.5275749991239752,-0.7072313349453694,0.7804878048780488,0.8725292936045199,1.0,3/58,1.13%,PTK2B;CD274;ZAP70
prerank,Elsevier_Pathway_Collection__Smooth Muscle Cell Dysfunction in Arterial Hypertension,0.5157755457058515,0.7067613090739165,0.7318840579710145,0.8495970059304382,1.0,1/49,0.41%,MRTFA
prerank,Elsevier_Pathway_Collection__NURD in Chromatin Remodeling,-0.3882914330683873,-0.7065867988696669,0.42016806722689076,0.8726881312099967,1.0,10/19,27.61%,SUMO1;MTA1;RBBP7;TRIM28;CHD3;SHC1;HDAC1;RBBP4;HAT1;MECP2
prerank,MSigDB_Oncogenic_Signatures__ATF2 UP.V1 UP,-0.4959116107085019,-0.7062101795141832,0.9705882352941176,0.8726315140150933,1.0,5/152,1.36%,NEO1;SULT1B1;KCNAB3;GNA14;ABLIM3
prerank,Elsevier_Pathway_Collection__Antigen-Presenting Cell Role in Asthma,-0.5505273650494515,-0.7057738191760887,0.782608695652174,0.8726219695897152,1.0,2/56,1.10%,TICAM2;VAV1
prerank,GO_Biological_Process_2021__Ras protein signal transduction (GO:0007265),-0.5003967888981333,-0.705696430835488,0.9292929292929293,0.8723050977614785,1.0,5/138,0.96%,RAP1A;RAP1B;RB1;RASGRP2;RHOH
prerank,GO_Biological_Process_2021__cardiac ventricle development (GO:0003231),-0.37784165400549985,-0.7054165602866587,0.4782608695652174,0.872171012130159,1.0,11/19,33.63%,SCN5A;HEY2;DLL4;SALL1;PDE2A;ENG;HES1;MDM4;NOTCH1;GATA4;MATR3
prerank,Elsevier_Pathway_Collection__Astrocytoma,0.5303165027247911,0.7053084803906178,0.7352941176470589,0.8504999318402606,1.0,1/41,0.19%,CDK6
prerank,GO_Biological_Process_2021__plasma membrane organization (GO:0007009),-0.5164353788953147,-0.7048094360596102,0.7289719626168224,0.8723278572974844,1.0,2/61,1.03%,SYT7;BIN2
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway (GO:2001237),0.5116556164113315,0.7046946039387746,0.8541666666666666,0.8507366212497512,1.0,1/77,0.42%,TNFRSF10A
prerank,Reactome_2022__Regulation Of PTEN Stability And Activity R-HSA-8948751,-0.5076876815040213,-0.7042071061133117,0.8189655172413793,0.8725260960339106,1.0,1/65,0.37%,AKT3
prerank,GO_Biological_Process_2021__glycerophospholipid biosynthetic process (GO:0046474),0.4890959874375467,0.7041906920345168,0.9927536231884058,0.8507858319537641,1.0,3/172,1.38%,GPAT4;PIK3C2B;LPCAT2
prerank,GO_Biological_Process_2021__microtubule bundle formation (GO:0001578),-0.49464760248199663,-0.7037851542204419,0.7033898305084746,0.8725112026278654,1.0,1/41,0.84%,TPPP2
prerank,Reactome_2022__Glycerophospholipid Biosynthesis R-HSA-1483206,-0.5295274771220161,-0.7037674590245351,0.897196261682243,0.8721625816402904,1.0,2/119,0.95%,PLAAT3;AGPAT4
prerank,Reactome_2022__Opioid Signaling R-HSA-111885,0.5056492444981759,0.7037604197554915,0.813953488372093,0.8508260173577961,1.0,1/81,1.11%,GNB5
prerank,GO_Biological_Process_2021__vesicle organization (GO:0016050),0.5155480054088502,0.703532651471588,0.7737226277372263,0.8506685469341491,1.0,1/46,0.46%,SORT1
prerank,Reactome_2022__Signaling To RAS R-HSA-167044,-0.4081873846881602,-0.7033748031755618,0.5338345864661654,0.8721568720446425,1.0,10/19,25.02%,MAPKAPK3;RALGDS;RALA;GRB2;RALB;SHC1;SHC2;MAPK14;MAPK12;NGF
prerank,GO_Biological_Process_2021__regulation of membrane depolarization (GO:0003254),-0.38756980405519914,-0.7033314477910162,0.47058823529411764,0.8718123040352325,1.0,5/15,9.70%,SCN5A;PTPN3;SCN1B;ABCD1;SCN2B
prerank,GO_Biological_Process_2021__embryonic organ development (GO:0048568),0.5176844733988795,0.7032828567070424,0.7910447761194029,0.8505590906853759,1.0,2/60,1.12%,PKDCC;TEAD4
prerank,KEGG_2021_Human__IL-17 signaling pathway,-0.5421170828189192,-0.7030988305164119,0.8782608695652174,0.8716319839148226,1.0,1/81,0.09%,FOSB
prerank,GO_Biological_Process_2021__positive regulation of macroautophagy (GO:0016239),0.5638369017909675,0.7029775128282866,0.8048780487804879,0.8504975918347617,1.0,2/49,0.83%,PRKAA2;RAB3GAP1
prerank,"GO_Biological_Process_2021__mRNA cis splicing, via spliceosome (GO:0045292)",0.39688397123109215,0.7026730139015659,0.48507462686567165,0.8504122153223609,1.0,9/16,29.84%,NCBP2;SRSF12;RBM22;SNRNP200;PRPF39;SRSF1;PSIP1;SFSWAP;WBP11
prerank,GO_Biological_Process_2021__positive regulation of protein serine/threonine kinase activity (GO:0071902),0.5375137817969098,0.7023295451491534,0.881578947368421,0.8503672654946273,1.0,2/100,1.36%,CAB39;FGF1
prerank,GO_Biological_Process_2021__protein autophosphorylation (GO:0046777),0.5112309619579951,0.7021369718128707,0.9402985074626866,0.8501475290405777,1.0,5/154,1.00%,MELK;PTK2;MAP3K9;ATR;STK26
prerank,GO_Biological_Process_2021__mitotic spindle checkpoint signaling (GO:0071174),-0.3609903780729989,-0.7020943997016255,0.4948453608247423,0.8713636529728342,1.0,7/21,18.38%,APC;BUB1;CDC20;BUB1B;TPR;ZW10;MAD2L1
prerank,GO_Biological_Process_2021__spindle assembly checkpoint signaling (GO:0071173),-0.3609903780729989,-0.7020943997016255,0.4948453608247423,0.8713636529728342,1.0,7/21,18.38%,APC;BUB1;CDC20;BUB1B;TPR;ZW10;MAD2L1
prerank,GO_Biological_Process_2021__mitotic spindle assembly checkpoint signaling (GO:0007094),-0.3609903780729989,-0.7020943997016255,0.4948453608247423,0.8713636529728342,1.0,7/21,18.38%,APC;BUB1;CDC20;BUB1B;TPR;ZW10;MAD2L1
prerank,GO_Biological_Process_2021__positive regulation of protein localization to cell periphery (GO:1904377),-0.5077471867334084,-0.702041167999372,0.7669902912621359,0.8710327451438238,1.0,1/51,0.43%,WNK3
prerank,Reactome_2022__Influenza Infection R-HSA-168255,0.5149426632590024,0.7019968861331954,0.9465648854961832,0.8499100421321483,1.0,1/155,0.48%,NUP210
prerank,GO_Biological_Process_2021__rRNA catabolic process (GO:0016075),0.4060140022101878,0.7001380062538736,0.4732824427480916,0.8510030315227862,1.0,8/18,21.82%,DEDD2;EXOSC9;EXOSC6;EXOSC10;DIS3;SLFN14;EXOSC3;XRN1
prerank,Elsevier_Pathway_Collection__Vitamin C Related Norepinephrine Synthesis,-0.36088155661001864,-0.6999341852971238,0.456,0.8724909973211725,1.0,7/16,24.65%,ADRB1;ADRA2B;AGTR1;SLC23A2;ADRA2A;ADRA1B;SLC23A1
prerank,MSigDB_Hallmark_2020__UV Response Up,-0.49539972339600014,-0.6998486764080746,0.9827586206896551,0.87217786277478,1.0,3/156,1.17%,FOSB;AQP3;CDO1
prerank,GO_Biological_Process_2021__regulation of small GTPase mediated signal transduction (GO:0051056),0.5031910576651835,0.699796603827403,0.9716312056737588,0.8509504578554242,1.0,7/140,1.24%,DEPDC1B;ARHGAP39;ARHGEF7;RHOQ;PLEKHG5;ARHGEF18;A2M
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.503390282666843,0.6997229523533306,0.7154471544715447,0.8506786226995079,1.0,1/36,0.27%,MAP3K9
prerank,Elsevier_Pathway_Collection__PI3K/RAC1 Signaling,0.4980526692428893,0.699340102638057,0.696551724137931,0.8506292003559464,1.0,2/36,1.32%,PTK2;PIK3C2B
prerank,Elsevier_Pathway_Collection__beta-Cell Destruction in Diabetes Mellitus Type 1,0.4981905860412321,0.6985361797683379,0.7692307692307693,0.8509182021033054,1.0,1/54,1.10%,ITGAL
prerank,GO_Biological_Process_2021__sodium ion transport (GO:0006814),0.5264071585171334,0.6978946070338946,0.8646616541353384,0.8511190610907613,1.0,1/80,0.02%,SLC6A4
prerank,GO_Biological_Process_2021__regulation of cell division (GO:0051302),0.5499861665591582,0.6976156051392942,0.8601398601398601,0.850999516926222,1.0,3/75,1.36%,KIF13A;PRPF40A;FGF1
prerank,GO_Biological_Process_2021__establishment of melanosome localization (GO:0032401),-0.3604398899406001,-0.6975594617006815,0.4666666666666667,0.8737116329447817,1.0,8/19,20.81%,BBS5;BLOC1S3;RAB17;MKKS;MLPH;RAB11B;SHROOM2;BLOC1S5
prerank,Reactome_2022__Sensory Processing Of Sound By Outer Hair Cells Of Cochlea R-HSA-9662361,-0.5150593452975228,-0.6974996017410942,0.75,0.873391063805469,1.0,1/46,0.02%,KCNN2
prerank,Elsevier_Pathway_Collection__VEGF Signaling,-0.5036195600198999,-0.6972438915683267,0.7807017543859649,0.8732323002079617,1.0,2/58,1.10%,MAP2K6;VAV1
prerank,WikiPathway_2021_Human__MAP3K1 role in promoting and blocking gonadal determination WP4872,0.3742970740004589,0.6971154769371465,0.48872180451127817,0.8510557602470826,1.0,7/15,26.85%,GSK3B;MAPK11;MAPK1;RHOA;CTNNB1;AXIN1;WNT4
prerank,GO_Biological_Process_2021__regulation of phosphatidylinositol 3-kinase signaling (GO:0014066),0.5249055297874478,0.6971122141235514,0.8805970149253731,0.8507220128901231,1.0,4/101,1.51%,PPP1R16B;PTK2;ERBB3;FN1
prerank,Reactome_2022__Interleukin-4 And Interleukin-13 Signaling R-HSA-6785807,-0.5161215400676046,-0.6969786171961276,0.9196428571428571,0.8730862296606562,1.0,1/99,1.23%,S1PR1
prerank,"GO_Biological_Process_2021__DNA catabolic process, endonucleolytic (GO:0000737)",-0.3852155226227046,-0.696679341819636,0.4642857142857143,0.8729277298873706,1.0,11/22,28.93%,SETMAR;DNASE1L3;EXOG;HMGB1;H1-0;MUS81;DNASE2;KPNA1;DNASE1L1;DFFB;CASP3
prerank,GO_Biological_Process_2021__regulation of anatomical structure morphogenesis (GO:0022603),0.5019079276590238,0.6964138600292248,0.9424460431654677,0.8509375114572875,1.0,3/122,1.25%,BRSK1;ABI2;FMNL2
prerank,GO_Biological_Process_2021__positive regulation of amyloid-beta formation (GO:1902004),-0.3246648547343703,-0.6961398160748619,0.5161290322580645,0.8729862612220594,1.0,5/18,17.26%,TNF;GSK3A;EPHA4;EFNA1;ABCA2
prerank,MSigDB_Oncogenic_Signatures__SIRNA EIF4GI DN,-0.4921598598599435,-0.6961287265416031,0.9291338582677166,0.8726218837928217,1.0,3/83,1.26%,MBD5;S1PR1;DUSP4
prerank,Reactome_2022__Metabolism Of Water-Soluble Vitamins And Cofactors R-HSA-196849,0.5037762751758683,0.6957166415393043,0.9096774193548387,0.8511171488363215,1.0,3/114,0.85%,ACACA;SLC19A1;QPRT
prerank,Reactome_2022__Retinoid Metabolism And Transport R-HSA-975634,-0.49760618210957663,-0.6950516957677458,0.725,0.873108548261794,1.0,1/41,1.16%,SDC3
prerank,Reactome_2022__Fcgamma Receptor (FCGR) Dependent Phagocytosis R-HSA-2029480,-0.5383206550215994,-0.6944635866620473,0.8137254901960784,0.8732295878544286,1.0,3/82,1.10%,PIK3CB;HCK;VAV1
prerank,GO_Biological_Process_2021__SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146),-0.49965337753329536,-0.6938496268305001,0.9,0.8733129454949787,1.0,1/87,0.40%,FBXO27
prerank,GO_Biological_Process_2021__regulation of acute inflammatory response (GO:0002673),-0.35325389962613174,-0.6937695143126446,0.46616541353383456,0.873009863570076,1.0,4/18,10.80%,GSTP1;DNASE1L3;NLRP3;OSM
prerank,MSigDB_Oncogenic_Signatures__ERB2 UP.V1 UP,0.4969545016889767,0.6934188908662161,0.9777777777777777,0.8525543063242778,1.0,5/173,1.08%,HSD17B11;LRP5;NOTCH3;ETV5;PACSIN3
prerank,GO_Biological_Process_2021__protein processing (GO:0016485),-0.49516353571656807,-0.6927584016594464,0.9243697478991597,0.8734472655729535,1.0,2/100,1.26%,C1R;TMPRSS2
prerank,Reactome_2022__Switching Of Origins To A Post-Replicative State R-HSA-69052,-0.510673794875436,-0.692722015851073,0.8288288288288288,0.873099702132985,1.0,1/86,0.74%,ORC4
prerank,GO_Biological_Process_2021__regulation of leukocyte activation (GO:0002694),0.3670280102895556,0.692000216620844,0.46875,0.8532517891061921,1.0,7/15,35.30%,GPER1;CD74;MFHAS1;PLA2G10;CD200;LCK;LILRB4
prerank,GO_Biological_Process_2021__positive regulation of hydrolase activity (GO:0051345),-0.5217825330022005,-0.6917793538134968,0.9067796610169492,0.8734437998328103,1.0,6/142,0.96%,CCL23;EVI5;RAP1A;SNX13;RASGRP2;SEMA4D
prerank,GO_Biological_Process_2021__positive regulation of ubiquitin-dependent protein catabolic process (GO:2000060),-0.49839285033510955,-0.6913033753984636,0.8666666666666667,0.8734626049998763,1.0,2/76,0.28%,RNF180;RNF217
prerank,WikiPathway_2021_Human__Androgen receptor signaling pathway WP138,0.5467902088943803,0.6912501195277552,0.8455284552845529,0.8534570475718972,1.0,3/87,1.41%,PTK2;ETV5;FLNA
prerank,GO_Biological_Process_2021__positive regulation of cold-induced thermogenesis (GO:0120162),0.524111726903127,0.6910648082661144,0.8759124087591241,0.8532612354153841,1.0,1/89,1.39%,PRLR
prerank,GO_Biological_Process_2021__regulation of GTPase activity (GO:0043087),0.49115270570952974,0.6909949219072711,0.9769230769230769,0.8529780044158265,1.0,7/181,1.42%,THY1;PTK2;STMN3;ARHGEF7;RAB3GAP1;GNB5;DOCK11
prerank,GO_Biological_Process_2021__negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736),-0.38115938901220187,-0.689818762723556,0.5089285714285714,0.8742043079503047,1.0,5/20,4.69%,HHEX;HEXIM1;NR2F2;APC;TFAP4
prerank,GO_Biological_Process_2021__positive regulation of alpha-beta T cell proliferation (GO:0046641),0.3812808542665635,0.6896219094350633,0.5043478260869565,0.8537231926937809,1.0,7/16,16.99%,IL12B;EBI3;IL23A;CD81;RASAL3;CD55;PTPN22
prerank,Reactome_2022__Mitotic Prophase R-HSA-68875,0.501522961815389,0.6891469428844883,0.904,0.8537737025432278,1.0,1/101,0.48%,NUP210
prerank,GO_Biological_Process_2021__negative regulation of protein localization to nucleus (GO:1900181),0.3806999356996852,0.689144033385067,0.45112781954887216,0.8534416797224912,1.0,11/19,37.23%,GSK3B;CABP1;APOD;MFHAS1;FLCN;POLR1A;ILRUN;CHP1;LILRB4;LATS1;MDFIC
prerank,Elsevier_Pathway_Collection__PTGER1/4 -> Vascular Motility,-0.35455509125651374,-0.6889391641047864,0.47619047619047616,0.8744993304683317,1.0,9/18,27.95%,MAPK3;CALD1;RAF1;MYLK;MAP2K2;GNAQ;ITPR1;ACTA2;NOS3
prerank,GO_Biological_Process_2021__positive regulation of T cell proliferation (GO:0042102),0.507736710742442,0.6889252235462336,0.8082191780821918,0.8532536656276407,1.0,1/61,1.08%,SLC7A1
prerank,GO_Biological_Process_2021__lipid homeostasis (GO:0055088),0.5317870859656703,0.6887704610040017,0.8091603053435115,0.8530258011927607,1.0,3/62,1.30%,PRKAA2;ADCK1;APOE
prerank,GO_Biological_Process_2021__positive regulation of JNK cascade (GO:0046330),-0.4952148396278326,-0.6886660450423027,0.8571428571428571,0.8743428870946427,1.0,3/72,0.85%,APP;PTK2B;CD27
prerank,KEGG_2021_Human__Staphylococcus aureus infection,0.5102421993352386,0.6881191697735632,0.8148148148148148,0.8531905256439681,1.0,1/68,1.10%,ITGAL
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte proliferation (GO:0050671),0.5077337134873784,0.6874931351991579,0.8345323741007195,0.8533299578823533,1.0,1/68,1.08%,SLC7A1
prerank,GO_Biological_Process_2021__negative regulation of natural killer cell mediated cytotoxicity (GO:0045953),-0.37154860550428426,-0.6871235461708279,0.496,0.8751028912792151,1.0,5/15,26.20%,HLA-A;KLRD1;MICA;HLA-F;SERPINB9
prerank,GO_Biological_Process_2021__negative regulation of protein kinase B signaling (GO:0051898),0.4953021948692976,0.6871034469479542,0.7293233082706767,0.853271009387893,1.0,1/38,0.79%,PPARA
prerank,WikiPathway_2021_Human__15q13.3 copy number variation syndrome WP4942,0.39438422191155,0.6866000515939382,0.47692307692307695,0.8533245157990214,1.0,8/18,23.07%,SERPINH1;FAN1;CREBBP;GOLGA8R;GPR75;GOLGA8O;MTMR10;FANCD2
prerank,GO_Biological_Process_2021__calcium ion homeostasis (GO:0055074),-0.5140097811658446,-0.6861633009989992,0.865546218487395,0.8753864706833135,1.0,1/82,0.09%,CCL23
prerank,GO_Biological_Process_2021__fibroblast growth factor receptor signaling pathway (GO:0008543),-0.49116651684119794,-0.6861198077451561,0.8301886792452831,0.8750588548315469,1.0,2/68,0.84%,FLRT2;GALNT3
prerank,GO_Biological_Process_2021__protein-DNA complex assembly (GO:0065004),0.5018716383689368,0.6856660202578317,0.9548872180451128,0.8536515010012558,1.0,1/129,0.66%,NAA60
prerank,MSigDB_Oncogenic_Signatures__PRC1 BMI UP.V1 DN,0.4996450019619024,0.6856079684615507,0.9928571428571429,0.8533648975059963,1.0,3/154,1.52%,CDK6;MCTP1;AMMECR1
prerank,Elsevier_Pathway_Collection__AGER -> CREB/SP1 Signaling,-0.3532321977146505,-0.6853909649739217,0.5,0.8752247034108214,1.0,9/17,25.89%,MAP3K1;MAPK3;CDC42;HMGB1;RAF1;MAP2K2;S100P;AGER;TTR
prerank,GO_Biological_Process_2021__regulation of transcription by RNA polymerase III (GO:0006359),0.42425581838348314,0.6851931972214771,0.5433070866141733,0.8533444379847718,1.0,12/21,34.96%,CEBPA;ICE1;ZNF76;POLR3G;ZNF345;ZNF143;MTOR;MAF1;POLR3F;RPTOR;CHD8;DHX36
prerank,GO_Biological_Process_2021__negative regulation of endopeptidase activity (GO:0010951),-0.4942888736514062,-0.6850419850087163,0.7899159663865546,0.8751003188291713,1.0,1/55,1.26%,HRG
prerank,WikiPathway_2021_Human__Prolactin Signaling Pathway WP2037,-0.49194794108519657,-0.6849775995260554,0.8650793650793651,0.8747785735199621,1.0,3/75,1.13%,PIK3CB;VAV1;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of catabolic process (GO:0009896),0.5066213463608772,0.6848034152891626,0.8264462809917356,0.853295935884308,1.0,1/65,0.59%,WWP2
prerank,TRRUST_Transcription_Factors_2019__YY1 human,-0.5033052786769893,-0.6847281868557242,0.8974358974358975,0.874611803773419,1.0,1/84,0.41%,NR3C1
prerank,GO_Biological_Process_2021__negative regulation of peptidase activity (GO:0010466),-0.4942898246837017,-0.6844281064180235,0.7981651376146789,0.8744433966974203,1.0,1/53,1.26%,HRG
prerank,GO_Biological_Process_2021__cardiac muscle contraction (GO:0060048),-0.41806595584659073,-0.6837542366842034,0.5602836879432624,0.8745789511540923,1.0,14/31,24.43%,SCN4B;SCN5A;ATP1B1;MYLK2;PIK3CA;KCNQ1;SLC8A1;SCN1B;SCN2B;TCAP;GRK2;MYL3;TTN;KCNE5
prerank,GO_Biological_Process_2021__preassembly of GPI anchor in ER membrane (GO:0016254),-0.32795875260990276,-0.683603749725041,0.4878048780487805,0.8743076924484247,1.0,6/16,22.12%,DPM2;PIGB;PIGA;PIGN;PIGV;PIGP
prerank,Elsevier_Pathway_Collection__Osteoclasts Function in Osteopetrosis,0.4037477633758438,0.6833295241315831,0.5,0.8540180420782381,1.0,14/19,39.20%,CA2;FERMT3;SLC4A2;IKBKB;CLCN7;ACP5;NFKBIA;IKBKG;TNFSF11;TCIRG1;NFATC1;OSTM1;VTN;MAP3K7
prerank,Elsevier_Pathway_Collection__NFKB Canonical Signaling Activation in Cancer,0.5132768551429439,0.6831755595247265,0.8098591549295775,0.853793717624234,1.0,1/70,0.44%,TRAF3
prerank,GO_Biological_Process_2021__regulation of protein kinase activity (GO:0045859),-0.492818261812108,-0.6824210379032245,0.9528301886792453,0.8747680579809003,1.0,6/108,0.73%,RAP1A;RB1;PTK2B;UVRAG;PAK2;DEPTOR
prerank,Reactome_2022__Assembly Of Pre-Replicative Complex R-HSA-68867,-0.5106693150460547,-0.6814444530607702,0.9298245614035088,0.8750576862833402,1.0,1/99,0.74%,ORC4
prerank,TRRUST_Transcription_Factors_2019__STAT1 human,-0.5007129824879751,-0.6811840780144127,0.8617886178861789,0.8748468754113395,1.0,2/77,1.31%,APP;PML
prerank,GO_Biological_Process_2021__phosphatidylethanolamine biosynthetic process (GO:0006646),0.34610481958537687,0.6796981093651744,0.4888888888888889,0.8558514565449977,1.0,4/15,8.21%,CHKB;PCYT2;PHOSPHO1;CHKA
prerank,GO_Biological_Process_2021__positive regulation of cytokine production involved in inflammatory response (GO:1900017),-0.3508817158632174,-0.6796053935440177,0.48872180451127817,0.8754606873366919,1.0,9/16,34.49%,TNF;NOD2;CLEC7A;TICAM1;CD6;APPL1;TLR6;IL17RA;TLR4
prerank,Elsevier_Pathway_Collection__Li-Fraumeni Syndrome,0.44590778981207435,0.6795961680997267,0.5939849624060151,0.855597104742624,1.0,9/19,20.03%,CYCS;CEBPA;CASP9;CDK2;BCL2L1;CCND1;BBC3;CDKN1A;CCNE1
prerank,Elsevier_Pathway_Collection__Cholesteatoma,0.534922632987952,0.6787795079997196,0.8444444444444444,0.8558543923069574,1.0,1/69,0.96%,ERBB3
prerank,MSigDB_Oncogenic_Signatures__CRX DN.V1 UP,-0.5015179182139646,-0.6784995986426035,0.9339622641509434,0.8757762453583176,1.0,1/113,0.04%,ARHGAP10
prerank,GO_Biological_Process_2021__cellular response to estradiol stimulus (GO:0071392),-0.36049392962113025,-0.6783503602663454,0.49137931034482757,0.875526425036736,1.0,6/18,15.98%,EGFR;CCDC62;FAM210B;LCOR;CRHBP;SFRP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Parkinson's Disease,0.49859533451126836,0.6779265385279206,0.8888888888888888,0.8560613871132646,1.0,1/88,1.30%,APOE
prerank,KEGG_2021_Human__Notch signaling pathway,-0.5087353366427714,-0.6779179444288919,0.8425925925925926,0.8754184759283926,1.0,1/56,0.24%,TLE4
prerank,GO_Biological_Process_2021__regulation of kinase activity (GO:0043549),-0.4953503390430708,-0.6777996249471322,0.9130434782608695,0.8751336136562365,1.0,3/92,1.21%,LDB2;RB1;TEK
prerank,GO_Biological_Process_2021__positive regulation of T cell activation (GO:0050870),0.4954661445272963,0.6776052630221086,0.875,0.8559368521106878,1.0,2/70,1.08%,THY1;SLC7A1
prerank,WikiPathway_2021_Human__Pyrimidine metabolism WP4022,-0.5086769109933101,-0.6774442816981673,0.9035087719298246,0.8749852253537734,1.0,2/81,1.18%,DPYS;ENTPD3
prerank,Elsevier_Pathway_Collection__Neonatal Diabetes Mellitus,-0.3345731971138879,-0.6766766549708133,0.46825396825396826,0.8751128557042293,1.0,6/15,19.80%,GATA6;GLIS3;ERN1;GCK;NEUROD1;SLC2A2
prerank,Reactome_2022__Cell Recruitment (Pro-Inflammatory Response) R-HSA-9664424,-0.36724351537723454,-0.6764376399339337,0.46774193548387094,0.8748832805605966,1.0,10/24,25.34%,IL18;PYCARD;NLRP3;GSDMD;ENTPD1;PSTPIP1;P2RX7;CTSG;TXNIP;C3
prerank,"Elsevier_Pathway_Collection__Glioblastoma, Secondary",0.5303152587012365,0.6764234033440817,0.7913669064748201,0.8563850919556193,1.0,1/50,0.19%,CDK6
prerank,GO_Biological_Process_2021__regulation of heart contraction (GO:0008016),0.5245612929304909,0.676064848978579,0.900709219858156,0.8562899602079117,1.0,1/85,0.84%,ASB3
prerank,WikiPathway_2021_Human__Prader-Willi and Angelman Syndrome WP3998,0.5106982096967837,0.6756832414692764,0.8181818181818182,0.8562007863630431,1.0,3/51,0.95%,CDK6;HERC2;MSX1
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell migration (GO:0010634),0.5211961611431738,0.6752842159401247,0.9098360655737705,0.8561219749040289,1.0,5/94,1.54%,IQSEC1;CTSH;FGF1;BCAR1;RIN2
prerank,KEGG_2021_Human__Thyroid hormone synthesis,-0.5073083411262971,-0.67475546988893,0.8632478632478633,0.8755886812203285,1.0,2/68,1.11%,IYD;CREB5
prerank,Reactome_2022__trans-Golgi Network Vesicle Budding R-HSA-199992,-0.5005906217739399,-0.6747535444857676,0.8067226890756303,0.875223090956771,1.0,1/71,0.35%,APP
prerank,Elsevier_Pathway_Collection__Vascularization in Hepatocellular Carcinoma,-0.33963276062613634,-0.6742380516823593,0.49514563106796117,0.8751809111184352,1.0,6/17,17.47%,EP300;IGF1;E2F1;SMAD2;TGFA;ANG
prerank,GO_Biological_Process_2021__mitochondrial respiratory chain complex assembly (GO:0033108),0.5078886039475533,0.6739890136570478,0.9029850746268657,0.8565812078432614,1.0,1/90,0.57%,NDUFA10
prerank,GO_Biological_Process_2021__cellular response to calcium ion (GO:0071277),0.5081983337116444,0.6738982319775715,0.8244274809160306,0.856303950470468,1.0,1/65,0.03%,PRKAA2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Asthma,-0.3777108488688502,-0.6737524135214544,0.5175438596491229,0.8750858204965192,1.0,12/19,37.89%,CCL26;IGF1;MMP9;EDN1;MYLK;CXCL8;IL33;NGF;CXCL10;BDNF;ADAM33;CCL24
prerank,"Elsevier_Pathway_Collection__Glioblastoma, Primary",0.5303155627093906,0.6735399037197485,0.7835820895522388,0.8562016903918539,1.0,1/48,0.19%,CDK6
prerank,KEGG_2021_Human__Bacterial invasion of epithelial cells,-0.49570765817785495,-0.6731552681558757,0.9026548672566371,0.8750666667703191,1.0,3/75,0.73%,ARHGAP10;ARHGEF26;PIK3CB
prerank,TRRUST_Transcription_Factors_2019__POU5F1 mouse,0.3989589859805993,0.6722289230035429,0.5153846153846153,0.8566809142502724,1.0,6/17,19.73%,PAX2;STK40;LEFTY1;POU5F1;CDKN1A;KIF2A
prerank,Reactome_2022__Signaling By ERBB2 ECD Mutants R-HSA-9665348,-0.3375778703347402,-0.6716524999726634,0.5583333333333333,0.8756029983048943,1.0,5/15,15.15%,PIK3CA;EGFR;PIK3R1;GRB2;SHC1
prerank,MSigDB_Oncogenic_Signatures__RB P107 DN.V1 DN,0.5063470214632355,0.6711789749953341,0.9473684210526315,0.8570423573800378,1.0,1/113,0.46%,DAD1
prerank,Reactome_2022__Autophagy R-HSA-9612973,0.5173838839126891,0.6711077202362111,0.9,0.8567330751475208,1.0,2/125,1.48%,PRKAA2;LAMP2
prerank,"GO_Biological_Process_2021__positive regulation of DNA-templated transcription, initiation (GO:2000144)",0.39162447908038056,0.66987004797116,0.5149253731343284,0.8571631439269515,1.0,12/21,35.79%,JUN;MED12;SRF;MED13;FOSL1;MED30;SUB1;MED14;TWIST1;MED16;DHX36;BCLAF1
prerank,Elsevier_Pathway_Collection__Double Strand DNA Homologous Repair,0.3911915876004349,0.6698076377432718,0.5225225225225225,0.8568643154403284,1.0,10/19,32.43%,BRCA2;BARD1;XRCC2;MDC1;BRCA1;UIMC1;RBBP8;ABRAXAS1;BRCC3;RAD52
prerank,GO_Biological_Process_2021__regulation of defense response (GO:0031347),0.49262552286099937,0.6691876230159115,0.9097744360902256,0.8569335229779307,1.0,2/81,1.30%,TRAF3;APOE
prerank,GO_Biological_Process_2021__fatty acid beta-oxidation (GO:0006635),0.49772393277599836,0.6691474251023591,0.7952755905511811,0.8566232954277275,1.0,1/51,0.52%,AUH
prerank,"WikiPathway_2021_Human__Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.5015735780859608,0.669101598491577,0.8620689655172413,0.8563133072506341,1.0,1/67,1.30%,CYP27B1
prerank,GO_Biological_Process_2021__ephrin receptor signaling pathway (GO:0048013),0.5305001182518756,0.6690920746958976,0.8661971830985915,0.8559903851912571,1.0,2/80,0.83%,PTK2;ARHGEF7
prerank,WikiPathway_2021_Human__TNF-alpha signaling pathway WP231,0.5093244023476805,0.6688972504356585,0.8985507246376812,0.8557672029095256,1.0,1/90,0.22%,KSR1
prerank,GO_Biological_Process_2021__cellular glucuronidation (GO:0052695),0.3506876697110053,0.6685061641744472,0.4740740740740741,0.8556787459683066,1.0,7/16,20.60%,UGT1A5;UGT2B11;UGT1A4;UGT2A3;UGT2B15;UGT2B4;UGT2B17
prerank,WikiPathway_2021_Human__BMP Signaling Pathway in Eyelid Development WP3927,-0.3714265904776061,-0.6677363082965667,0.5384615384615384,0.8775542987417841,1.0,7/19,17.51%,MAP3K1;MAPK3;FOXC1;EGFR;SFRP1;TGFA;FGF10
prerank,WikiPathway_2021_Human__DNA damage response WP707,-0.5010266282372127,-0.6674219301035769,0.8611111111111112,0.8773632340509846,1.0,3/67,1.31%,RB1;CCND2;PML
prerank,GO_Biological_Process_2021__glucose homeostasis (GO:0042593),0.5006932132492766,0.6672857046628687,0.849624060150376,0.8560201771866854,1.0,2/75,1.55%,PRKAA2;FOXA3
prerank,Reactome_2022__Regulation Of Pyruvate Dehydrogenase (PDH) Complex R-HSA-204174,0.33721420426173176,0.6672487413878561,0.5681818181818182,0.8557212479350165,1.0,5/15,16.31%,PDP2;PDK2;PPARD;PDPK1;PDK3
prerank,Reactome_2022__Circadian Clock R-HSA-400253,-0.5024774073379769,-0.6664784933919912,0.8545454545454545,0.8774734923096099,1.0,2/65,0.41%,NCOA1;NR3C1
prerank,Elsevier_Pathway_Collection__Invadopodia Formation in Cancer Cells,0.49902430073082227,0.666192225948835,0.90625,0.8560317221576268,1.0,2/75,1.13%,ARHGEF7;IQSEC1
prerank,MSigDB_Oncogenic_Signatures__NRL DN.V1 DN,0.49102714831394956,0.6655427217389468,0.9477124183006536,0.8560630429724725,1.0,2/112,1.13%,GTF2I;TUFT1
prerank,GO_Biological_Process_2021__regulation of epithelial cell differentiation (GO:0030856),0.3731125895244243,0.6652835930267171,0.5447154471544715,0.8558695422542232,1.0,5/17,15.32%,APOLD1;CAV1;DLL1;PRKX;CD24
prerank,GO_Biological_Process_2021__vacuolar acidification (GO:0007035),0.33556306905202565,0.6646973039554875,0.5,0.8558396165166156,1.0,9/20,25.21%,DMXL1;GRN;ATP6V0A1;ATP6V0D2;ATP6V1H;ATP6V0A2;ATP6AP2;CLN5;ATP6V0E2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Otitis Media,-0.42890381237708086,-0.6646473147285596,0.5825242718446602,0.8781329220895989,1.0,11/29,22.63%,TNF;PTGS2;TNFRSF1A;PDE4B;CA4;EGFR;MMP9;ALB;TIMP1;CXCL8;TICAM1
prerank,GO_Biological_Process_2021__heart contraction (GO:0060047),-0.41205017431281804,-0.6646354246165387,0.5864661654135338,0.8777729213527863,1.0,16/34,24.43%,SCN4B;SCN5A;ATP1B1;MYLK2;PIK3CA;KCNQ1;SLC8A1;SCN1B;SCN2B;TCAP;SOD1;GRK2;MYL3;TTN;GPX1;KCNE5
prerank,GO_Biological_Process_2021__melanosome localization (GO:0032400),-0.3448905687896365,-0.6638267386999117,0.4806201550387597,0.8778177889023979,1.0,8/21,20.81%,BBS5;BLOC1S3;RAB17;MKKS;MLPH;RAB11B;SHROOM2;BLOC1S5
prerank,Elsevier_Pathway_Collection__Oxygen Shortage in Myocardial Ischemia,0.4005997940373935,0.6632623026691891,0.5284552845528455,0.8562881351177682,1.0,5/16,7.88%,CACNA1C;CYCS;SLC9A6;CACNB2;MYBPC3
prerank,Reactome_2022__Processing Of SMDT1 R-HSA-8949664,-0.38140897580036337,-0.6629130559272582,0.52,0.8779347079866687,1.0,7/15,23.43%,MCU;PMPCA;PARL;YME1L1;SPG7;MICU1;AFG3L2
prerank,GO_Biological_Process_2021__positive regulation of protein localization to membrane (GO:1905477),-0.5077360474144208,-0.6628770513640659,0.9134615384615384,0.8775840259595775,1.0,1/100,0.43%,WNK3
prerank,Elsevier_Pathway_Collection__Hypoxia-Induced Cell Death Evasion in Cancer,0.3859980405929721,0.6621329350517364,0.48031496062992124,0.856590504974039,1.0,8/23,14.95%,BNIP3L;TWIST2;BIRC3;CYCS;CASP9;PDPK1;BCL2L1;HIF1A
prerank,MSigDB_Oncogenic_Signatures__SIRNA EIF4GI UP,0.5176392417750015,0.6620208635474805,0.8897058823529411,0.8563169374588323,1.0,3/84,1.43%,PAPSS1;CTSH;MPV17
prerank,GO_Biological_Process_2021__cobalamin metabolic process (GO:0009235),-0.36579351007131283,-0.6617408321753189,0.518796992481203,0.8778467597296248,1.0,9/17,33.59%,AMN;TCN2;MMACHC;MTR;CUBN;MMUT;PRSS3;MMADHC;TCN1
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell apoptotic process (GO:1904037),0.37439987372500694,0.6603375597005858,0.49264705882352944,0.856871111595353,1.0,6/22,16.25%,FASLG;CD160;GPER1;ECSCR;ANO6;CD40LG
prerank,GO_Biological_Process_2021__positive regulation of cellular protein metabolic process (GO:0032270),0.5017825685243771,0.6602514346606746,0.950354609929078,0.8565758009130513,1.0,2/101,0.64%,VGLL4;YTHDF3
prerank,GO_Biological_Process_2021__positive regulation of cellular metabolic process (GO:0031325),0.5002363155190465,0.6594017143075099,0.8848920863309353,0.8567436625072246,1.0,3/100,1.30%,ACACA;PPARA;APOE
prerank,Reactome_2022__Synthesis Of Glycosylphosphatidylinositol (GPI) R-HSA-162710,-0.3198632899416331,-0.6593878192413569,0.5454545454545454,0.8787063407207341,1.0,6/17,22.12%,DPM2;PIGB;PIGA;PIGN;PIGV;PIGP
prerank,GO_Biological_Process_2021__negative regulation of cellular component organization (GO:0051129),-0.4915850679120196,-0.6589710231602539,0.8878504672897196,0.8785383310203921,1.0,2/75,1.30%,CARMIL1;DNAJA4
prerank,GO_Biological_Process_2021__sensory perception of pain (GO:0019233),-0.34495848614907965,-0.6586665050370082,0.46825396825396826,0.8782915028868369,1.0,8/16,30.00%,CHRNB2;SCN9A;PROK2;P2RX7;CHRNA4;NIPSNAP1;CCR2;KCNA2
prerank,GO_Biological_Process_2021__regulation of platelet aggregation (GO:0090330),0.35215404809926054,0.6585852643492168,0.5,0.8568284463536022,1.0,5/17,14.24%,SH2B3;ADAMTS18;PDPN;PRKCQ;C1QTNF1
prerank,Reactome_2022__Constitutive Signaling By Ligand-Responsive EGFR Cancer Variants R-HSA-1236382,-0.3389900364073024,-0.6579638257919616,0.5726495726495726,0.8782465768137937,1.0,6/18,15.15%,PIK3CA;EGFR;RPS27A;PIK3R1;GRB2;SHC1
prerank,GO_Biological_Process_2021__regulation of G1/S transition of mitotic cell cycle (GO:2000045),0.5070188484050158,0.6575135641398123,0.8666666666666667,0.8570149933790963,1.0,3/70,0.74%,CDK6;RBL1;DLG1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glaucoma,-0.492373273063311,-0.6572485504444262,0.8925619834710744,0.8782507765562791,1.0,2/75,1.27%,APP;CYP1B1
prerank,Reactome_2022__Triglyceride Catabolism R-HSA-163560,0.3958922952085534,0.6562089927541356,0.5284552845528455,0.8573424481468518,1.0,9/18,32.01%,CAV1;PNPLA4;PLIN1;FABP4;PPP1CA;MGLL;ABHD5;GPD2;FABP1
prerank,GO_Biological_Process_2021__cellular response to fibroblast growth factor stimulus (GO:0044344),-0.491160617862273,-0.6561734077543074,0.8990825688073395,0.8784775323540135,1.0,2/85,0.84%,FLRT2;GALNT3
prerank,Elsevier_Pathway_Collection__Persistent Double Strand DNA Homologous Repair in Cancer,0.37766646780099866,0.655465318737953,0.5089285714285714,0.8574138230808227,1.0,10/20,32.43%,BRCA2;BARD1;XRCC2;MDC1;BRCA1;UIMC1;RBBP8;ABRAXAS1;BRCC3;RAD52
prerank,KEGG_2021_Human__Insulin resistance,-0.49207366957349935,-0.6550212096952737,0.9454545454545454,0.8786042527991016,1.0,3/104,1.11%,AKT3;PIK3CB;CREB5
prerank,GO_Biological_Process_2021__positive regulation of protein-containing complex assembly (GO:0031334),0.5051874498696245,0.6548258339251443,0.9558823529411765,0.8573718080057836,1.0,2/116,0.69%,ATR;FNIP1
prerank,GO_Biological_Process_2021__regulation of T cell proliferation (GO:0042129),0.5077327250695244,0.6547484557447217,0.8695652173913043,0.8570872640470051,1.0,1/71,1.08%,SLC7A1
prerank,GO_Biological_Process_2021__protein localization to endoplasmic reticulum (GO:0070972),-0.33740498569327704,-0.6546807864976121,0.5454545454545454,0.8784296986499741,1.0,11/16,36.24%,PPP1R15A;BCAP31;GBF1;VAPA;SEC16A;HSPA5;DDRGK1;SEC16B;ANK2;UBAC2;RYR2
prerank,GO_Biological_Process_2021__mesenchyme morphogenesis (GO:0072132),-0.31699713497784904,-0.654586552310556,0.5630252100840336,0.8781240192788782,1.0,8/16,30.93%,SMAD2;ENG;MDM4;BMP2;NOS3;ACVRL1;BMPR1A;NOTCH1
prerank,TRRUST_Transcription_Factors_2019__BCL6 mouse,-0.3360532383536233,-0.6540952071097675,0.4596774193548387,0.8780355354928963,1.0,8/15,35.15%,PRDM1;BATF;CSF1R;TBX21;RORC;IFNG;MYC;CDKN2B
prerank,GO_Biological_Process_2021__cell morphogenesis involved in differentiation (GO:0000904),0.5030233007533536,0.6539663817310418,0.9343065693430657,0.857158654688435,1.0,4/72,1.51%,TBCD;SIPA1L3;ABI2;FN1
prerank,Reactome_2022__Activation Of HOX Genes During Differentiation R-HSA-5619507,0.49898858285541436,0.653601821228731,0.8790322580645161,0.8569963233046637,1.0,1/78,0.04%,HOXD3
prerank,GO_Biological_Process_2021__cholesterol homeostasis (GO:0042632),0.49230590952318865,0.6527957990143968,0.8581560283687943,0.8570328750334352,1.0,3/70,1.35%,LRP5;APOE;SOAT2
prerank,GO_Biological_Process_2021__negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090101),0.49149881813970264,0.6521666496603445,0.950354609929078,0.8569881853158695,1.0,2/101,1.09%,PPARA;CHRD
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell differentiation (GO:0030858),0.34318889615133213,0.6510125827987259,0.5073529411764706,0.8572088225219527,1.0,16/16,65.70%,VEZF1;FGF2;SFN;TMEM100;SFRP4;SULT2B1;BAD;SOX9;AHI1;KDF1;MESP1;BTG1;RFX3;FOXJ1;ATOH8;BMP4
prerank,GO_Biological_Process_2021__negative regulation of MAPK cascade (GO:0043409),0.4968636508893857,0.6503421771306678,0.9384615384615385,0.8571481592785822,1.0,2/88,1.30%,DLG1;APOE
prerank,WikiPathway_2021_Human__miRNA regulation of DNA damage response WP1530,-0.5010250441269765,-0.6501558818223986,0.8796296296296297,0.8795630299671332,1.0,3/70,1.31%,RB1;CCND2;PML
prerank,WikiPathway_2021_Human__Apoptosis Modulation by HSP70 WP384,-0.32937408470531215,-0.6490157681914852,0.5080645161290323,0.8797502232742322,1.0,6/19,16.51%,AIFM1;MAP3K1;TNFRSF1A;FADD;BID;FAS
prerank,GO_Biological_Process_2021__negative regulation of mitotic cell cycle phase transition (GO:1901991),0.49538777029968006,0.6487491686946671,0.9280575539568345,0.8575177708135671,1.0,3/89,0.74%,CDK6;RBL1;DLG1
prerank,GO_Biological_Process_2021__regulation of potassium ion transmembrane transport (GO:1901379),0.49502379869138646,0.6483437833361375,0.8207547169811321,0.8573629141644253,1.0,4/51,1.41%,WWP2;DLG1;CAB39;FLNA
prerank,Reactome_2022__FGFR2 Alternative Splicing R-HSA-6803529,0.41995058249890166,0.6481722599833531,0.5950413223140496,0.8571126422357717,1.0,11/26,22.84%,NCBP2;HNRNPH1;GTF2F2;POLR2A;POLR2F;ESRP2;POLR2C;POLR2L;TIA1;HNRNPM;POLR2H
prerank,Elsevier_Pathway_Collection__AHR Signaling in Th17 Cells Function,0.3898278448665056,0.6477252780210706,0.5307692307692308,0.8569913373652777,1.0,5/18,14.41%,STAT5A;IKZF3;JAK2;SMAD3;RORA
prerank,Elsevier_Pathway_Collection__Inherited Channelopathies,-0.3356786400696939,-0.647569183158313,0.5609756097560976,0.8800508410122316,1.0,5/22,8.87%,CACNA1H;CLCN2;KCNAB1;CHRNB2;SCN1B
prerank,GO_Biological_Process_2021__sterol homeostasis (GO:0055092),0.4923053454094859,0.6466233625082325,0.8661971830985915,0.8571709704341317,1.0,3/71,1.35%,LRP5;APOE;SOAT2
prerank,GO_Biological_Process_2021__neuromuscular synaptic transmission (GO:0007274),-0.34389621468131065,-0.6462863856487365,0.5603448275862069,0.8802638780667708,1.0,7/16,24.30%,CHRNA3;CHRNB2;RIMBP2;STAC3;FCHSD1;TSPOAP1;DTNA
prerank,Elsevier_Pathway_Collection__Microglia Activation in Parkinson's Disease,-0.31043072113827735,-0.6458938986494495,0.5238095238095238,0.8801031106789123,1.0,4/16,13.71%,TNF;PTGS2;SNCA;IRAK1
prerank,GO_Biological_Process_2021__negative regulation of cyclin-dependent protein kinase activity (GO:1904030),-0.3558613835403402,-0.6454657203427996,0.5233644859813084,0.8799372403141497,1.0,5/22,4.69%,HHEX;HEXIM1;NR2F2;APC;TFAP4
prerank,Reactome_2022__InlB-mediated Entry Of Listeria Monocytogenes Into Host Cell R-HSA-8875360,-0.31695362420676454,-0.6443155092624815,0.5172413793103449,0.8801500606633421,1.0,6/15,23.67%,RNMT;EPS15;RPS27A;GRB2;SH3GL2;UBC
prerank,Reactome_2022__FOXO-mediated Transcription Of Cell Death Genes R-HSA-9614657,-0.3270250207084292,-0.644312893046524,0.559322033898305,0.8797890055615012,1.0,8/16,25.16%,EP300;BCL2L11;CITED2;PINK1;NFYA;STK11;NFYB;DDIT3
prerank,Reactome_2022__TRP Channels R-HSA-3295583,0.419323864844606,0.6434120204668816,0.5874125874125874,0.8581904889355673,1.0,10/23,16.94%,TRPM2;TRPC5;MCOLN1;TRPC1;TRPV1;TRPM4;TRPM6;MCOLN2;TRPC3;MCOLN3
prerank,WikiPathway_2021_Human__Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,-0.32269671187566445,-0.6427421926013408,0.5663716814159292,0.8801062946415927,1.0,4/17,11.28%,ACADL;HADHA;CPT1A;ACADS
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypogonadotropic Hypogonadism,-0.37058987558773493,-0.6423039010934383,0.49572649572649574,0.8799215305692213,1.0,12/20,40.48%,POLR3B;GNRHR;WDR11;PROK2;LEP;HS6ST1;GNRH1;INSR;NR5A1;SEMA3A;SOX2;KISS1
prerank,GO_Biological_Process_2021__regulation of endothelial cell migration (GO:0010594),0.5020582718895678,0.6419320630100233,0.9133858267716536,0.8584504637195388,1.0,5/89,1.54%,PTK2;APOE;FGF1;BCAR1;RIN2
prerank,TRRUST_Transcription_Factors_2019__KLF6 human,-0.3254209402140507,-0.6411986105782027,0.5581395348837209,0.8800591174617093,1.0,6/16,23.97%,CDH1;LAMA1;MMP9;ATF3;LTC4S;TXNIP
prerank,GO_Biological_Process_2021__positive regulation of neuron apoptotic process (GO:0043525),-0.36868449002654563,-0.6406676968185843,0.5357142857142857,0.8799667924987951,1.0,5/23,9.03%,TNF;TFAP2A;SRPK2;TYROBP;ITGAM
prerank,WikiPathway_2021_Human__Hypertrophy Model WP516,-0.3455211247718801,-0.6402571846282116,0.5233644859813084,0.8797840540035349,1.0,10/17,30.23%,ANKRD1;IL18;ATF3;JUND;NR4A3;IFRD1;ZEB1;IFNG;VEGFA;EIF4E
prerank,GO_Biological_Process_2021__positive regulation of collagen metabolic process (GO:0010714),-0.3072169289343465,-0.6396821711328976,0.49166666666666664,0.8797110522038419,1.0,5/16,23.31%,LARP6;F2;CREB3L1;F2R;SUCO
prerank,GO_Biological_Process_2021__hemopoiesis (GO:0030097),0.5063367304696389,0.6391679319468059,0.9507042253521126,0.8592115586847432,1.0,1/90,0.05%,MELK
prerank,GO_Biological_Process_2021__regulation of catabolic process (GO:0009894),-0.31726067120342105,-0.63850332810333,0.5483870967741935,0.8799336982525415,1.0,7/18,21.03%,ITGB1;NEDD4L;ZDHHC7;FAF1;CENATAC;MDM2;TMEM9
prerank,GO_Biological_Process_2021__Arp2/3 complex-mediated actin nucleation (GO:0034314),0.36079407044218276,0.6380152732430608,0.5373134328358209,0.8592889815345706,1.0,11/15,40.35%,IQGAP2;ARPC5;WHAMM;ARPC1B;ACTR2;WASHC1;ARPC1A;ARPC4;ACTR3;ARPC5L;JMY
prerank,KEGG_2021_Human__Amoebiasis,0.5107752676765074,0.6372253162681535,0.9193548387096774,0.8592768409397232,1.0,3/94,1.51%,PTK2;COL4A5;FN1
prerank,GO_Biological_Process_2021__pigment granule transport (GO:0051904),-0.3343468094313637,-0.6370164250564295,0.5037037037037037,0.8798815671116993,1.0,7/18,20.81%,BBS5;BLOC1S3;RAB17;MKKS;MLPH;RAB11B;BLOC1S5
prerank,GO_Biological_Process_2021__melanosome transport (GO:0032402),-0.3343468094313637,-0.6370164250564295,0.5037037037037037,0.8798815671116993,1.0,7/18,20.81%,BBS5;BLOC1S3;RAB17;MKKS;MLPH;RAB11B;BLOC1S5
prerank,WikiPathway_2021_Human__Major receptors targeted by epinephrine and norepinephrine WP4589,-0.3315594018932011,-0.6358696698353311,0.5514705882352942,0.8800569804797007,1.0,5/15,20.98%,ADCY8;ADRB1;ADCY3;ADCY5;ADRA2A
prerank,GO_Biological_Process_2021__peptidyl-tyrosine phosphorylation (GO:0018108),0.5113485415909084,0.6356837696291162,0.8790322580645161,0.8595129180984263,1.0,4/67,1.39%,PTK2;ABI2;PKDCC;PRLR
prerank,Reactome_2022__Synthesis Of PIPs At Early Endosome Membrane R-HSA-1660516,-0.30229920547045996,-0.635423650183017,0.616,0.8799111087462516,1.0,5/16,18.18%,MTMR2;MTMR4;PI4K2B;INPP4A;FIG4
prerank,GO_Biological_Process_2021__modulation by host of viral genome replication (GO:0044827),-0.3279631481040963,-0.6354012382338982,0.5537190082644629,0.8795606047236254,1.0,8/15,30.05%,EIF2AK4;FBXL2;PPIB;VAPA;ZBED1;CCNK;FMR1;PHB
prerank,Reactome_2022__GAB1 Signalosome R-HSA-180292,-0.3495130245852125,-0.6349695056379685,0.6033057851239669,0.8793942424268535,1.0,6/16,17.20%,PIK3CA;EGFR;BTC;PIK3R1;GRB2;TGFA
prerank,Reactome_2022__NOTCH4 Intracellular Domain Regulates Transcription R-HSA-9013695,-0.33583561639545445,-0.6340064462645758,0.532258064516129,0.8794846135304881,1.0,9/19,30.93%,HES5;HEY2;EP300;NOTCH4;MAMLD1;MAML2;ACTA2;SNW1;NOTCH1
prerank,GO_Biological_Process_2021__negative regulation of leukocyte mediated cytotoxicity (GO:0001911),-0.32209473702335556,-0.6334017141274864,0.532258064516129,0.8793548127950968,1.0,4/15,23.32%,KLRD1;MICA;HLA-F;CX3CR1
prerank,GO_Biological_Process_2021__regulation of T cell cytokine production (GO:0002724),0.36058931988661796,0.6330551841460113,0.5294117647058824,0.8601815730917393,1.0,7/19,18.17%,TNFRSF1B;TRAF2;TRPM4;SMAD7;CD55;B2M;FZD5
prerank,GO_Biological_Process_2021__transepithelial transport (GO:0070633),-0.3141454635051947,-0.6316374887602944,0.5398230088495575,0.8798886060479252,1.0,9/16,28.34%,SLC1A1;CXADR;SLC23A2;SLC1A2;SLC1A3;SLC23A1;RHCG;BEST1;ABCG2
prerank,GO_Biological_Process_2021__regulation of synapse organization (GO:0050807),-0.3520508692915532,-0.6315668043718835,0.49557522123893805,0.8795578765821479,1.0,7/24,12.28%,TNF;WNT5A;RAB17;EPHA4;CHRNB2;ABHD17B;PDLIM5
prerank,WikiPathway_2021_Human__Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,-0.3582360523775545,-0.6307649459863023,0.5116279069767442,0.8795770648518797,1.0,4/17,9.40%,VCAM1;TNC;TCF7L2;VHL
prerank,GO_Biological_Process_2021__positive regulation of natural killer cell mediated cytotoxicity (GO:0045954),-0.3496594275876326,-0.6305811078275402,0.5,0.8792969096701306,1.0,5/18,8.98%,NECTIN2;PVR;CD226;KLRD1;NCR3
prerank,Elsevier_Pathway_Collection__Single-Strand Nucleotide Excision,0.36102576593070507,0.6297577229276253,0.5258620689655172,0.8610645744479487,1.0,5/18,10.62%,ERCC6;DDB1;GTF2H5;PCNA;ERCC3
prerank,GO_Biological_Process_2021__cellular response to sterol (GO:0036315),0.33316818199637654,0.6291762514268546,0.5826771653543307,0.8609090765060441,1.0,8/15,30.42%,SMO;RORA;PTCH1;INSIG1;MLC1;GRAMD1A;GPLD1;GRAMD1C
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to ESR1 Signaling Pathway,0.511424589600534,0.6276815474986625,0.9008264462809917,0.8610995081562521,1.0,1/64,0.26%,PTK2
prerank,GO_Biological_Process_2021__macrophage differentiation (GO:0030225),-0.31461155188883216,-0.6269052958158098,0.5967741935483871,0.8806617484014592,1.0,10/15,40.04%,CDC42;MMP9;CSF1R;CSF1;IFNG;VEGFA;BMP4;HLA-DRB1;CD4;SIRT1
prerank,TRRUST_Transcription_Factors_2019__FOXA2 human,-0.32780911168042004,-0.626904603806499,0.5877862595419847,0.880301853939505,1.0,3/15,7.00%,CDH1;CFTR;TCF7L2
prerank,GO_Biological_Process_2021__organic acid transport (GO:0015849),0.4896445657418086,0.6259406684400346,0.9527027027027027,0.861387738013592,1.0,4/92,1.54%,SLC19A1;SLC13A3;SLC7A1;SLC38A1
prerank,GO_Biological_Process_2021__regulation of steroid biosynthetic process (GO:0050810),-0.32921171199507837,-0.6258440038584961,0.5609756097560976,0.8804053837393968,1.0,7/15,30.39%,STAR;AKR1C3;CYP7A1;CGA;BMP5;BMP2;DGKQ
prerank,Elsevier_Pathway_Collection__Aldosterone Synthesis Acute Regulation,-0.34076081594911334,-0.6255536391978165,0.49572649572649574,0.8801668053270123,1.0,12/24,27.95%,MAPKAPK3;MAPK3;STAR;AGTR1;RASGRP1;HSD3B2;MAP2K2;GNAQ;ATF1;ITPR1;BRAF;CYP21A2
prerank,GO_Biological_Process_2021__wound healing (GO:0042060),0.5109242606126031,0.6249537547197989,0.8992248062015504,0.8613892313497984,1.0,3/67,1.36%,ERBB3;MYOF;FGF1
prerank,GO_Biological_Process_2021__presynapse assembly (GO:0099054),0.32615884629758385,0.6248684220270527,0.5241935483870968,0.8610985574040577,1.0,6/17,21.17%,NLGN2;FZD1;NLGN3;PCLO;CEL;PTEN
prerank,GO_Biological_Process_2021__mRNA 3'-end processing (GO:0031124),0.5079473179549999,0.623080974721063,0.8923076923076924,0.861423865949445,1.0,1/78,0.25%,ZNF473
prerank,Elsevier_Pathway_Collection__NTSR1 Expression Targets,-0.3304395569666577,-0.6225647526688524,0.5166666666666667,0.8812976846082922,1.0,12/26,20.28%,MAPK3;EGFR;ELK4;RAF1;NTS;GRB2;SHC1;JUND;RASGRP1;CXCL8;MAP2K2;GNAQ
prerank,WikiPathway_2021_Human__IL1 and megakaryocytes in obesity WP2865,-0.37331683804804006,-0.6218037586633358,0.5303030303030303,0.8813489019120649,1.0,10/24,18.58%,IL18;PIK3CA;NLRP3;MMP9;F2;FCER1A;IRAK1;TIMP2;F2R;TIMP1
prerank,Reactome_2022__Glucagon Signaling In Metabolic Regulation R-HSA-163359,0.3543994535855645,0.621474674227393,0.49586776859504134,0.8616425047544276,1.0,18/30,35.27%,GNG12;PRKAR2B;GNB1;GNG11;GNB2;GNG3;GNG2;GNB4;GCG;ADCY2;ADCY4;GNG10;ADCY7;GNG8;GNAS;PRKAR1A;PRKAR1B;ADCY1
prerank,WikiPathway_2021_Human__Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,-0.3181742343083929,-0.6213202952785384,0.5887096774193549,0.8812240990031415,1.0,9/16,30.61%,UNC13D;GCC2;MLPH;TBC1D10A;SYTL3;RAB27B;RPH3AL;MADD;MYRIP
prerank,KEGG_2021_Human__Collecting duct acid secretion,0.3601663136478466,0.6210301996218694,0.5223880597014925,0.8614570104658127,1.0,10/23,25.21%,CA2;ATP6V1G1;ATP6V0A1;ATP4A;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V0A2;ATP6V1E1;ATP6V0E2
prerank,GO_Biological_Process_2021__cellular response to pH (GO:0071467),0.36723626524209313,0.6201315455949024,0.5564516129032258,0.8614570376829012,1.0,8/16,34.13%,MCOLN1;TRPV1;SLC9A1;HVCN1;PKD1L3;GPLD1;INSRR;CHP1
prerank,Reactome_2022__Platelet Calcium Homeostasis R-HSA-418360,-0.34755707989545737,-0.6200344085529086,0.5344827586206896,0.8815115713838919,1.0,11/25,28.35%,SLC8A1;ATP2A3;P2RX2;ATP2B3;SLC8A3;P2RX7;ATP2B1;ORAI1;ORAI2;ITPR1;TRPC6
prerank,Reactome_2022__Signal Transduction By L1 R-HSA-445144,-0.33055289915938774,-0.6195951717339689,0.5254237288135594,0.8813678413016905,1.0,5/20,10.56%,MAPK3;ITGAV;EGFR;ITGA2B;ITGB1
prerank,Elsevier_Pathway_Collection__Luteinizing Hormone in Oocyte Meiotic Resumption,-0.32860527553058033,-0.6193014579050373,0.5365853658536586,0.8811432392973267,1.0,8/18,24.70%,MAPK3;EGFR;BTC;RAF1;RASGRP1;MAP2K2;MAPK14;ITPR1
prerank,GO_Biological_Process_2021__regulation of cartilage development (GO:0061035),0.3688494418785858,0.6191106018284508,0.5575221238938053,0.8615260177597602,1.0,5/18,11.15%,WNT11;TAPT1;SOX6;BMP1;ZBTB16
prerank,GO_Biological_Process_2021__negative regulation of actin filament polymerization (GO:0030837),-0.4005638923410934,-0.6173544446705549,0.5793650793650794,0.8818162264860402,1.0,15/25,32.40%,PFN4;KANK3;VIL1;ARFGEF1;TWF1;TMSB15B;TWF2;HIP1R;SCIN;TMSB15A;TMSB4Y;SSH1;MYADM;PFN1;PRKCD
prerank,GO_Biological_Process_2021__electron transport chain (GO:0022900),-0.3412308404438542,-0.615751498215188,0.6141732283464567,0.8822906625603597,1.0,3/15,6.01%,SDHA;DHRS2;UQCRFS1
prerank,GO_Biological_Process_2021__regulation of lipid storage (GO:0010883),-0.3835875914016703,-0.6157319887837971,0.5675675675675675,0.8819437634645991,1.0,5/21,10.41%,TNF;FTO;ITGAV;MEST;CRP
prerank,GO_Biological_Process_2021__positive regulation of morphogenesis of an epithelium (GO:1905332),0.35738391450318796,0.6151515590455101,0.5615384615384615,0.862621667636764,1.0,8/22,16.51%,SMO;NOG;FGF2;PAX2;AGT;EGF;ITGAX;GJA1
prerank,GO_Biological_Process_2021__negative regulation of cellular component movement (GO:0051271),-0.32282479444009204,-0.6140755276684677,0.6048387096774194,0.8824212025312194,1.0,3/15,7.75%,CD9;PKHD1;FRMD5
prerank,GO_Biological_Process_2021__mitochondrial RNA metabolic process (GO:0000959),0.33059624173048896,0.6139639115822241,0.6015037593984962,0.8627317825744977,1.0,7/15,29.42%,MTERF2;SLC25A33;MTERF1;TFAM;TWNK;POLRMT;FOXO3
prerank,Elsevier_Pathway_Collection__SNS Related Adrenal Cortex Response,-0.37047987863609644,-0.6136405079285128,0.5309734513274337,0.8822894909183377,1.0,11/25,26.01%,ADRB1;SLC8A1;ADRA2B;AGTR1;GNAQ;ADRA2A;ADRA1B;ADRA1A;ITPR1;NGF;PLCB1
prerank,Elsevier_Pathway_Collection__CFL1 in Cancer Cell Motility,0.3707595156601867,0.613630265258784,0.5537190082644629,0.8625433573334095,1.0,7/18,31.66%,LIMK2;SLC9A1;ABL2;LIMK1;EZR;WASL;SRC
prerank,Elsevier_Pathway_Collection__G-cell: Gastrin Secretion,-0.3053123867595777,-0.6125949704139736,0.5873015873015873,0.8824690197988879,1.0,8/16,31.08%,PCSK2;GRPR;GNAO1;GNA12;GNAQ;ITPR1;CPB2;SSTR2
prerank,GO_Biological_Process_2021__acetylcholine receptor signaling pathway (GO:0095500),-0.3475079665689753,-0.6116209046156348,0.5407407407407407,0.8826363749414436,1.0,8/17,26.92%,CHRNA3;CHRNB2;CHRM3;CHRM2;GRK2;GNAQ;PLCB1;LYPD1
prerank,GO_Biological_Process_2021__protein deacylation (GO:0035601),-0.3421189973018905,-0.6108699882267722,0.5461538461538461,0.8826782113211543,1.0,14/23,34.09%,SIRT7;SIRT2;ABHD17B;HDAC5;HDAC10;HDAC1;PPT1;HDAC3;HDAC4;SIRT5;SIRT3;ABHD10;LYPLA1;HDAC6
prerank,GO_Biological_Process_2021__ventricular cardiac muscle tissue development (GO:0003229),0.3953418374574416,0.6107753515767372,0.6081081081081081,0.8632042077813523,1.0,6/19,14.97%,HOPX;ID2;MYBPC3;SMAD7;FKBP1A;PKP2
prerank,Elsevier_Pathway_Collection__ER Stress in Macular Degeneration,0.39615131298799083,0.6105004293551786,0.5851851851851851,0.8629626956537348,1.0,11/25,23.61%,EIF2AK3;CYCS;JUN;TRAF2;CASP9;BBC3;CASP12;XBP1;EIF2S1;MAP2K7;ATF4
prerank,Elsevier_Pathway_Collection__DNMT and MBD Families Activation in DNA Methylation in Cancer,-0.2812688978279375,-0.6100642434259859,0.5943396226415094,0.8827989900599219,1.0,9/17,31.25%,CDH1;DNMT3B;MGMT;MBD1;DNMT3A;AKT1;MECP2;MBD3;UHRF1
prerank,TRRUST_Transcription_Factors_2019__GLI2 human,0.3414950551137236,0.6091807441887637,0.5555555555555556,0.8631513449541504,1.0,3/16,5.80%,JUN;FOXL1;WNT2B
prerank,GO_Biological_Process_2021__regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902229),-0.3198306872040042,-0.6090731162115242,0.6065573770491803,0.8830174930613944,1.0,9/16,36.48%,TMEM161A;NACC2;SNAI2;SFRP2;TRIM32;CDKN2D;SNAI1;CCAR2;RPS3
prerank,GO_Biological_Process_2021__positive regulation of JUN kinase activity (GO:0043507),-0.354807528026922,-0.6084324998768339,0.5555555555555556,0.8829836426991993,1.0,11/22,28.63%,TNF;DUSP19;MAP3K5;EDN1;ARHGEF5;DAB2IP;TAOK3;DKK1;TNFRSF11A;MAP3K4;TLR6
prerank,GO_Biological_Process_2021__negative regulation of neuron differentiation (GO:0045665),0.3497006392364167,0.6082510844960263,0.5642857142857143,0.8631894159791363,1.0,8/19,21.64%,GSK3B;DLL1;DLX1;DTX1;B2M;REST;BMP7;CALR
prerank,GO_Biological_Process_2021__cellular response to drug (GO:0035690),-0.3429836715499541,-0.6082114286950294,0.5206611570247934,0.8827320416211014,1.0,8/24,14.82%,PDE4B;KCNQ1;HTR1B;DPEP1;CERS1;SLAMF8;CRHBP;TFRC
prerank,TRRUST_Transcription_Factors_2019__FLI1 human,-0.3503730863223691,-0.6079641590566425,0.5615384615384615,0.8825029276535876,1.0,7/22,12.25%,ERG;GP6;PHLDA1;EP300;MPL;ITGA2B;FOXM1
prerank,GO_Biological_Process_2021__positive regulation of amyloid precursor protein catabolic process (GO:1902993),-0.2914038947655104,-0.6077595792571564,0.5564516129032258,0.8822345910879358,1.0,13/22,40.25%,TNF;GSK3A;EPHA4;EFNA1;ABCA2;AGER;CASP3;IFNG;EFNA3;SLC2A13;ABCG1;RELA;CHRNA7
prerank,GO_Biological_Process_2021__beta-catenin destruction complex disassembly (GO:1904886),0.3395276507058776,0.6070744074813977,0.5289855072463768,0.8632919064469627,1.0,10/19,31.98%,GSK3B;CAV1;FZD1;PPP1CA;FZD5;CTNNB1;AXIN1;DVL3;WNT1;AMER1
prerank,GO_Biological_Process_2021__phagosome acidification (GO:0090383),0.3593514033220503,0.6069087991387326,0.5648854961832062,0.8630464307227678,1.0,11/25,25.21%,RAB39A;ATP6V1G1;ATP6V0A1;RAB20;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;ATP6V0A2;ATP6V1E1;ATP6V0E2
prerank,GO_Biological_Process_2021__myeloid cell activation involved in immune response (GO:0002275),-0.3529964523668173,-0.6053606809389267,0.5862068965517241,0.8831499515825509,1.0,7/19,16.66%,DNASE1L3;TYROBP;PYCARD;SLAMF1;IFI35;LBP;KARS1
prerank,TRRUST_Transcription_Factors_2019__ING4 human,-0.30795687497172686,-0.6041790322034942,0.6106194690265486,0.8834294144504627,1.0,7/15,28.93%,PTGS2;CXCL8;TP53;ANGPT1;NGF;ARL6IP5;CASP3
prerank,GO_Biological_Process_2021__histone mRNA catabolic process (GO:0071044),0.3109102031391682,0.6041236681186503,0.5481481481481482,0.8637585470974983,1.0,4/15,21.82%,TUT7;EXOSC10;LSM1;XRN1
prerank,Elsevier_Pathway_Collection__EphrinR -> STAT Signaling,-0.3010317090758071,-0.6029564385673666,0.5826771653543307,0.8837274757382103,1.0,5/15,18.20%,EPHA4;EFNA5;FYN;EFNA1;EFNB3
prerank,"GO_Biological_Process_2021__maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000466)",0.355525776554731,0.6022577998885011,0.5476190476190477,0.8641840141981242,1.0,8/22,16.62%,EXOSC9;UTP20;EXOSC10;NOP9;KRI1;RPS21;EXOSC3;ERI2
prerank,GO_Biological_Process_2021__regulation of stem cell proliferation (GO:0072091),0.31053579133044495,0.6021540583999889,0.6136363636363636,0.8639184594908923,1.0,5/15,21.42%,KDM1A;HNRNPU;TERT;GJA1;FBLN1
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-threonine phosphorylation (GO:0010801),-0.32096187099565665,-0.601559164690593,0.6062992125984252,0.8841296442952097,1.0,9/16,34.86%,SIRT2;DDIT4;SPRED1;CALM2;EIF4G1;INPP5K;DGKQ;CALM3;SPRY2
prerank,Elsevier_Pathway_Collection__Cyclosporine Induced Nephrotoxicity,-0.3117497053824305,-0.6014418423186602,0.5178571428571429,0.88382528384542,1.0,10/22,26.50%,PTGS2;AGTR1;PPIB;EDN1;MAPK14;GNAQ;SLC12A1;PLCB1;BRAF;AKT1
prerank,WikiPathway_2021_Human__Purinergic signaling WP4900,-0.3664019167901019,-0.6009745880946475,0.5855855855855856,0.8837194418676246,1.0,13/31,25.03%,GNAT1;P2RY6;GNAZ;P2RY12;ADORA2A;PANX1;ADORA1;GNAO1;P2RX2;P2RY10;P2RX7;GNAT2;P2RY14
prerank,GO_Biological_Process_2021__positive regulation of transcription by RNA polymerase I (GO:0045943),0.35244019143834754,0.6007080996066924,0.5245901639344263,0.8641362705998435,1.0,10/23,23.61%,EIF2AK3;IPPK;ERBB2;MARS1;WDR75;PWP1;MTOR;BNC1;DHX33;ATF4
prerank,GO_Biological_Process_2021__intracellular pH reduction (GO:0051452),0.3660527824696974,0.6003495025405329,0.6111111111111112,0.8639781048091426,1.0,12/32,17.87%,RAB39A;DMXL1;ATP6V1G1;ATP6V0A1;RAB20;ATP6V0C;ATP6V1E2;GPR89A;ATP6V0D2;ATP6V1H;CLCN3;ATP6V0A2
prerank,GO_Biological_Process_2021__positive regulation of activated T cell proliferation (GO:0042104),-0.34495288900473814,-0.6002919929368028,0.578125,0.8837025302739226,1.0,7/19,14.59%,IL18;PYCARD;IGF1;TNFSF9;FADD;HMGB1;IL12RB1
prerank,TRRUST_Transcription_Factors_2019__SMARCA4 mouse,-0.3050432353362823,-0.6001407583065125,0.6209677419354839,0.8834174974038427,1.0,3/15,5.91%,CDH1;SALL4;EPB42
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804),0.31484703180886153,0.5999829129308327,0.5447154471544715,0.8637800626355959,1.0,5/15,19.33%,CARD16;RFFL;GPS2;PYDC1;CARD8
prerank,GO_Biological_Process_2021__T cell proliferation (GO:0042098),0.32383504425885756,0.5982023644212479,0.6176470588235294,0.8641061981818231,1.0,5/15,17.61%,BTN3A1;TNFSF18;CRTAM;PPP3CB;PIK3CG
prerank,GO_Biological_Process_2021__response to purine-containing compound (GO:0014074),0.3257607488194474,0.5975964084857647,0.5887096774193549,0.8640595542126551,1.0,5/16,17.16%,ABCC9;TRPM2;DUOX2;TRPC3;STAT1
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, preincision complex stabilization (GO:0006293)",-0.33620487957378786,-0.5973380142242529,0.5327868852459017,0.8843856671692821,1.0,6/21,12.12%,RPA1;CUL4A;CHD1L;RBX1;ERCC1;RPA3
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision, 3'-to lesion (GO:0006295)",-0.33620487957378786,-0.5973380142242529,0.5327868852459017,0.8843856671692821,1.0,6/21,12.12%,RPA1;CUL4A;CHD1L;RBX1;ERCC1;RPA3
prerank,GO_Biological_Process_2021__protein localization to microtubule organizing center (GO:1905508),-0.2944103170127041,-0.5971605979610155,0.6030534351145038,0.8841348196353558,1.0,4/16,17.85%,SNX10;CEP83;DCTN2;C2CD3
prerank,GO_Biological_Process_2021__negative regulation of immune system process (GO:0002683),0.3680148938630643,0.5964116593947513,0.59375,0.8642241113501083,1.0,6/18,18.32%,FCRLB;AMBP;GPER1;IL17D;HMOX1;ADTRP
prerank,Reactome_2022__RNA Polymerase I Promoter Opening R-HSA-73728,-0.356892424426892,-0.5962901411050957,0.5813953488372093,0.8842678245820655,1.0,6/22,13.33%,MAPK3;H2BC13;H2AZ2;H2BC15;H2AC6;H2BC5
prerank,GO_Biological_Process_2021__regulation of insulin-like growth factor receptor signaling pathway (GO:0043567),0.3469072171122367,0.5962503574589106,0.6302521008403361,0.863960666401334,1.0,9/17,33.91%,NKX3-1;IGFBP5;PHIP;GHRHR;IGFBP6;IGFBP2;MYORG;WNT1;IGFBP1
prerank,Elsevier_Pathway_Collection__HIF1 Signaling,-0.3302838121164898,-0.595520733357841,0.5677966101694916,0.8843598161459277,1.0,8/24,17.47%,HIPK2;EP300;OS9;RWDD3;EGLN2;VHL;SLC2A1;ANG
prerank,Reactome_2022__DARPP-32 Events R-HSA-180024,0.31362927090002785,0.5950428858033265,0.5211267605633803,0.8641222856013799,1.0,6/23,16.10%,PPP3CC;PDE4C;PRKAR2B;PPP1CA;PPP2CB;PPP3CB
prerank,GO_Biological_Process_2021__regulation of transcription elongation from RNA polymerase II promoter (GO:0034243),-0.3557609287474945,-0.5933776101973474,0.5700934579439252,0.8852473796617863,1.0,13/25,28.22%,HEXIM1;EAPP;CDK13;SUPT16H;NELFE;RNF168;WDR43;CDK12;RECQL5;NELFCD;ELL;EAF1;LEO1
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Systemic Scleroderma,-0.28947072551197517,-0.5923989510699954,0.5982905982905983,0.8854444920971557,1.0,8/15,36.92%,TNF;CD22;TNFSF4;CXCL8;NOS3;TGFB1;CD19;ACE
prerank,TRRUST_Transcription_Factors_2019__FOXO1 human,0.3376329458197339,0.5922623584887609,0.5675675675675675,0.864942221284659,1.0,6/20,18.37%,RAG1;CXCR4;FABP4;TNFSF10;PDGFB;ADIPOR1
prerank,Elsevier_Pathway_Collection__Melatonin Effects on Circadian Cycle,-0.3066830556216451,-0.5915944571731342,0.56,0.8855376014643943,1.0,9/21,20.28%,MAP3K1;MAPK3;ADRB1;DDC;RAF1;NFE2L2;TPH2;MAP2K2;GNAQ
prerank,GO_Biological_Process_2021__positive regulation of cardiac muscle tissue growth (GO:0055023),-0.2891398042657154,-0.5910643304084245,0.6829268292682927,0.8854655726869539,1.0,6/17,20.95%,PIM1;IGF1;ZFPM2;EDN1;ERBB4;AKAP6
prerank,GO_Biological_Process_2021__maturation of 5.8S rRNA (GO:0000460),-0.33129853030790474,-0.589964556898022,0.6120689655172413,0.8857389045559974,1.0,8/17,28.20%,PES1;URB1;NSA2;EIF6;MAK16;C1D;MPHOSPH6;MTREX
prerank,GO_Biological_Process_2021__positive regulation of myeloid leukocyte cytokine production involved in immune response (GO:0061081),-0.33919106899195745,-0.5892760929530796,0.6101694915254238,0.8857722722968427,1.0,7/16,22.98%,WNT5A;BCL10;GPRC5B;KIT;CAMK4;TICAM1;NR4A3
prerank,Elsevier_Pathway_Collection__SIRT7 Signaling in Aging,-0.3148134762422048,-0.5890257678421057,0.5581395348837209,0.8855523680845032,1.0,9/15,37.43%,SIRT7;SMARCA5;ELK4;XRCC6;TP53;POLR1E;UBTF;FOXO1;PPARGC1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Mantle Cell Lymphoma,0.3030129610804573,0.5890057019924025,0.5652173913043478,0.8659367739904144,1.0,8/19,25.02%,GSK3B;BMI1;CCND1;GLI1;CD40LG;TNFSF13B;ING1;FMOD
prerank,Elsevier_Pathway_Collection__MTOR/TORC in Cancer Cell Motility and Invasion,-0.3563520448793067,-0.5888396262710321,0.5887096774193549,0.8853122531112226,1.0,8/25,12.93%,SGK1;MAPK3;CDC42;PIK3CA;MMP9;RHEB;RAF1;PIK3R1
prerank,Elsevier_Pathway_Collection__Leptin in Insulin Synthesis and Secretion,0.2956608787434608,0.5878859887864895,0.6015037593984962,0.8660618667358182,1.0,5/17,18.97%,SH2B1;PDPK1;JAK2;PDE3B;IAPP
prerank,Elsevier_Pathway_Collection__SERPINA1 Associated Liver Damage,0.3665971248182262,0.5862698103710868,0.5683453237410072,0.8663875913266769,1.0,12/25,25.51%,EIF2AK3;CYCS;TRAF2;CASP9;BBC3;CASP12;XBP1;HSP90B1;EIF2S1;MAP2K7;ATF4;SERPINA1
prerank,GO_Biological_Process_2021__nuclear membrane organization (GO:0071763),0.33661537106480877,0.5856712757865044,0.5925925925925926,0.8663174630137865,1.0,5/19,9.98%,TARDBP;TOR1A;TOR1AIP1;GPER1;UBXN2B
prerank,GO_Biological_Process_2021__positive regulation of cell development (GO:0010720),-0.35084581403545556,-0.5846566525027549,0.608,0.8874210344627113,1.0,16/28,34.92%,RGS14;TYROBP;SERPINF1;ATP6AP1;PDE3A;CLEC7A;NUMBL;FAIM;CX3CR1;LRP2;TRIM32;SNW1;IFNG;SPEN;BMP4;LIG4
prerank,TRRUST_Transcription_Factors_2019__ESR2 human,0.3067352020300299,0.5839890510714932,0.6134453781512605,0.8667054384812041,1.0,4/16,19.56%,BRCA2;JUN;TERT;CDKN1A
prerank,Reactome_2022__Insulin Receptor Recycling R-HSA-77387,0.32758945568385694,0.583605884051795,0.5524475524475524,0.8665556123968132,1.0,9/22,25.21%,ATP6V1G1;ATP6V0A1;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;ATP6V0A2;ATP6V1E1;ATP6V0E2
prerank,Reactome_2022__MAP3K8 (TPL2)-dependent MAPK1/3 Activation R-HSA-5684264,-0.29039516599734927,-0.5823329654490813,0.7327586206896551,0.8884824105739777,1.0,8/16,29.45%,MAP2K4;SKP1;RPS27A;TNIP2;CHUK;UBC;CUL1;FBXW11
prerank,Elsevier_Pathway_Collection__Proteins Involved in Graves Disease,-0.3280087445491735,-0.5822142323953264,0.5663716814159292,0.8881888051919181,1.0,5/18,16.74%,TNF;IFIH1;IGF1;FAS;CTLA4
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress (GO:0070059),-0.340467210267794,-0.5821884918263405,0.5423728813559322,0.8878479409766751,1.0,12/29,25.16%,AIFM1;ATP2A3;MAP3K5;PPP1R15A;ERN1;CHAC1;BAK1;ERN2;DAB2IP;DNAJC10;ITPR1;DDIT3
prerank,GO_Biological_Process_2021__tRNA 5'-end processing (GO:0099116),-0.28810340528973166,-0.5821265266564022,0.6339285714285714,0.8875293920781434,1.0,6/15,24.71%,RPP14;TRMT10C;PRORP;POP1;RPP21;RPP25L
prerank,Reactome_2022__IL-6-type Cytokine Receptor Ligand Interactions R-HSA-6788467,-0.28005095169593663,-0.581505994882944,0.6666666666666666,0.8875195638977627,1.0,5/16,25.28%,CCM2;CNTF;TYK2;IL6ST;LIFR
prerank,GO_Biological_Process_2021__regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045091),0.3178324866119833,0.581082165350884,0.6062992125984252,0.8672715638628479,1.0,5/17,12.23%,RESF1;SETDB1;TOP2A;MORC2;APOBEC3G
prerank,WikiPathway_2021_Human__Mammary gland development pathway - Embryonic development (Stage 1 of 4) WP2813,-0.30676670576199183,-0.5806678857195781,0.6283185840707964,0.8876961041002662,1.0,6/15,18.02%,TNF;CDH1;NRG3;ITGB1;SFRP1;ERBB4
prerank,GO_Biological_Process_2021__positive regulation of cell communication (GO:0010647),-0.3520901767230604,-0.5804605545230864,0.5603448275862069,0.8874626739621176,1.0,6/20,13.77%,TNF;HOMER1;CLSTN3;KCTD13;SYT1;EDN1
prerank,Elsevier_Pathway_Collection__IL6/IL12 Signaling Activates Immune System in Multiple Sclerosis,0.33335505665282156,0.5793909190537297,0.6377952755905512,0.8676999530835446,1.0,6/18,22.80%,IL12B;IL23A;CXCL16;JAK2;STAT1;IL12A
prerank,WikiPathway_2021_Human__Estrogen signaling pathway WP712,0.3588161254377006,0.5790654982350162,0.5897435897435898,0.8675144132743109,1.0,13/22,32.91%,ELK1;JUN;MAPK1;GPER1;GNB1;IKBKB;PRKACA;SP1;CREB1;MAP2K1;IKBKG;BCL2;GNAS
prerank,GO_Biological_Process_2021__error-free translesion synthesis (GO:0070987),0.35044130926030137,0.574795930868753,0.6178861788617886,0.8690342622079799,1.0,7/22,10.29%,RFC2;RCHY1;POLD1;PCNA;SPRTN;VCP;UBB
prerank,GO_Biological_Process_2021__dopaminergic neuron differentiation (GO:0071542),0.2806475083142431,0.5739119420461177,0.6363636363636364,0.869069777252084,1.0,8/15,35.54%,CDNF;EN1;WNT9B;CTNNB1;LMX1B;FOXA2;NR4A2;FOXA1
prerank,GO_Biological_Process_2021__response to interferon-alpha (GO:0035455),-0.30887148303784895,-0.5728977583878561,0.6159420289855072,0.8917306671314817,1.0,9/18,37.39%,KLHL20;TPR;AXL;IFITM3;IFITM2;IFITM1;RO60;GAS6;IFNAR1
prerank,GO_Biological_Process_2021__regulation of cellular response to growth factor stimulus (GO:0090287),-0.2872741959537622,-0.5726417741322887,0.6875,0.8915431902085207,1.0,5/15,21.52%,FSTL1;SULF1;LRIT3;TWSG1;TMEM204
prerank,GO_Biological_Process_2021__negative regulation of cell-matrix adhesion (GO:0001953),0.3696040573494881,0.5726232261519424,0.6097560975609756,0.8693351108255288,1.0,17/29,35.38%,MAP4K4;RASA1;ACER2;APOD;ARHGAP6;NEXMIF;RCC2;PTEN;CASK;DLC1;SEMA3E;DMTN;MMP12;SRC;PHLDB2;ITGB1BP1;CLASP2
prerank,GO_Biological_Process_2021__DNA methylation (GO:0006306),-0.383684637092462,-0.5724680582073483,0.6551724137931034,0.8912949700405952,1.0,9/23,23.64%,DNMT3B;SPOCD1;BAZ2A;KMT2E;METTL4;ZFP57;DNMT3A;N6AMT1;GATAD2A
prerank,Reactome_2022__RNA Polymerase III Transcription Termination R-HSA-73980,0.32601001959155684,0.5715127097371047,0.5193798449612403,0.8695676259607588,1.0,8/21,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;POLR2H;POLR3F;CRCP
prerank,GO_Biological_Process_2021__neuronal action potential (GO:0019228),0.31256869675079596,0.5710382909742723,0.5703125,0.8694568750732297,1.0,5/19,8.77%,SCN1A;SCN2A;ANK3;GPER1;CACNA1G
prerank,GO_Biological_Process_2021__resolution of meiotic recombination intermediates (GO:0000712),0.3175843640087512,0.5701631343977216,0.6290322580645161,0.8695205234093812,1.0,9/16,29.27%,RMI1;EME2;TOP2A;SHOC1;CENPX;CORT;MSH4;FANCM;MEIOB
prerank,Elsevier_Pathway_Collection__mTOR Hyperactivation after Status Epilepticus,-0.29650732198266216,-0.5698698366345961,0.680672268907563,0.8926464458452409,1.0,8/16,30.23%,HOMER1;RHEB;RPS6KB1;GNAQ;ITPR1;AKT1;SHANK2;EIF4E
prerank,Reactome_2022__Protein Methylation R-HSA-8876725,0.33036278105248956,0.5695589918110064,0.5748031496062992,0.869448123101797,1.0,7/17,25.75%,METTL21A;RPS2;VCP;METTL22;HSPA8;EEF1A1;PRMT3
prerank,Elsevier_Pathway_Collection__ER Stress in Huntington Disease,0.350902855247103,0.5694916947637642,0.6,0.8691576897554806,1.0,12/23,32.15%,EIF2AK3;CYCS;TRAF2;CASP9;CASP12;XBP1;EIF2S1;MAP2K7;ATF4;ATG5;MAPK8;BCL2
prerank,GO_Biological_Process_2021__regulation of B cell activation (GO:0050864),-0.34274027158669307,-0.5694796602841694,0.5294117647058824,0.8925044611352971,1.0,9/26,16.76%,IL4I1;TNFAIP3;CD22;BANK1;ZFP36L1;TNIP2;NOD2;SLAMF8;TNFSF4
prerank,GO_Biological_Process_2021__negative regulation of striated muscle cell differentiation (GO:0051154),-0.2990682635392954,-0.569296026080919,0.6363636363636364,0.8922679806138403,1.0,11/18,33.41%,GSK3A;TMEM119;HDAC5;HDAC1;DKK1;HDAC3;HDAC4;BMP2;FRS2;NOTCH1;BDNF
prerank,Elsevier_Pathway_Collection__Glutamate Mediated Excitotoxicity in Amyotrophic Lateral Sclerosis,-0.2934341438538174,-0.5689016504045177,0.6854838709677419,0.892146525659513,1.0,6/15,28.93%,SLC1A1;SLC1A2;SLC1A3;HNRNPK;AKT1;CASP3
prerank,GO_Biological_Process_2021__response to exogenous dsRNA (GO:0043330),-0.3063971208816329,-0.5673532718868268,0.5948275862068966,0.8927594920039605,1.0,14/19,37.20%,IFIH1;DHX9;RALB;IRAK3;RFTN1;TICAM1;PQBP1;MUL1;SLC3A2;IFIT1;STING1;FLOT1;COLEC12;ZCCHC3
prerank,WikiPathway_2021_Human__Proteoglycan biosynthesis WP4784,-0.31452593623916625,-0.5673080191557079,0.5873015873015873,0.8924286967354944,1.0,9/17,31.66%,CANT1;CSGALNACT1;EXT2;SLC35B2;CHST3;XYLT1;EXTL3;B3GAT3;SLC35B3
prerank,Elsevier_Pathway_Collection__Find me Signal: Apoptotic Cell Attracts Phagocyte,-0.29791251433543275,-0.5671984449468037,0.6198347107438017,0.8921352738871549,1.0,7/16,23.32%,RPS19;ANXA1;ADAM17;PANX1;CXCR3;CXCL8;CX3CR1
prerank,TRRUST_Transcription_Factors_2019__GLI1 human,0.28946990107075427,0.5664962571117506,0.6339285714285714,0.8702293010300408,1.0,7/16,33.81%,JUN;S100A9;CDK2;TNFRSF10B;SMAD4;BCL2;PDGFRA
prerank,GO_Biological_Process_2021__positive regulation of vascular associated smooth muscle cell proliferation (GO:1904707),-0.29557972537946103,-0.5662666387640006,0.5862068965517241,0.8924052368368192,1.0,7/21,14.82%,MEF2D;P2RY6;HTR1B;IGF1;MMP9;ERN1;FGF9
prerank,GO_Biological_Process_2021__mitotic cytokinetic process (GO:1902410),0.3503717209605607,0.5662473344233003,0.5655737704918032,0.8700222835281474,1.0,11/20,31.31%,VPS4B;CHMP1A;CNTROB;RHOA;KIF20A;CHMP1B;MITD1;CHMP4B;CHMP5;CHMP2A;PDCD6IP
prerank,GO_Biological_Process_2021__negative regulation of viral entry into host cell (GO:0046597),-0.300114560955938,-0.5660148364895573,0.65,0.8922148672574158,1.0,8/16,35.46%,TRIM31;IFITM3;IFITM2;TRIM11;IFITM1;SNX3;CIITA;APCS
prerank,GO_Biological_Process_2021__regulation of neuron projection arborization (GO:0150011),0.32103108331852337,0.5651445413990804,0.6068376068376068,0.8701945241200102,1.0,4/15,15.62%,NTNG1;MYO9A;MAP3K13;DLG4
prerank,GO_Biological_Process_2021__diol biosynthetic process (GO:0034312),0.2991439089106144,0.5649804179319348,0.6194029850746269,0.8699509088141024,1.0,5/17,25.48%,ACER2;GBA;ACER3;ASAH2;SPHK1
prerank,GO_Biological_Process_2021__peptidyl-lysine methylation (GO:0018022),-0.29505523208796836,-0.5639808834639717,0.5648854961832062,0.893200598231604,1.0,11/25,28.32%,SMYD3;SMYD2;SETD7;SUV39H1;N6AMT1;EEF1AKMT3;EEF2KMT;EEF1AKMT1;TRMT112;SUV39H2;SETD4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Ichthyosis,-0.28878333163146563,-0.5628701420795572,0.5655737704918032,0.8935927517821478,1.0,5/21,10.18%,PNPLA2;LBR;ST14;ABCA12;CLDN1
prerank,GO_Biological_Process_2021__membrane depolarization during cardiac muscle cell action potential (GO:0086012),-0.2929061420073507,-0.5619670385246758,0.5826771653543307,0.893833087254356,1.0,8/17,24.77%,SCN4B;SCN5A;SLC8A1;SCN1B;SCN2B;CACNA2D1;CACNA1D;KCNJ2
prerank,Elsevier_Pathway_Collection__TNFRSF6 -> HSF1 Signaling,-0.30859298556070996,-0.561917599001344,0.648854961832061,0.8935078341984676,1.0,7/15,19.32%,TRADD;MAP3K1;MAPK3;MAP2K4;MAP3K5;FAS;MAP2K2
prerank,Reactome_2022__NOTCH2 Activation And Transmission Of Signal To Nucleus R-HSA-2979096,0.3361138270646803,0.5615685388164541,0.5365853658536586,0.8712114524285405,1.0,9/21,25.05%,DLL1;PSEN2;UBB;UBA52;NEURL1;PSENEN;CNTN1;NOTCH2;ADAM10
prerank,GO_Biological_Process_2021__regulation of cellular respiration (GO:0043457),-0.31387258950385605,-0.5603288321720753,0.6578947368421053,0.894181984070175,1.0,11/15,39.83%,CBFA2T3;PRELID1;PNPT1;SHMT2;IDE;IFNG;IFNLR1;NOP53;NOS2;IFNAR1;IL10RB
prerank,"GO_Biological_Process_2021__RNA splicing, via endonucleolytic cleavage and ligation (GO:0000394)",-0.3164742846937224,-0.5601263695933165,0.6554621848739496,0.8939644600125071,1.0,7/15,30.02%,TRPT1;ERN1;RTRAF;TSEN54;CPSF4;CSTF2;DDX1
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator (GO:1902254),0.31797925394722865,0.5599468951148048,0.648854961832061,0.8717320655554984,1.0,8/16,34.42%,KDM1A;TAF9;TAF9B;CD74;ING2;PRKN;BCL2;TRIAP1
prerank,Reactome_2022__GRB2 Events In ERBB2 Signaling R-HSA-1963640,-0.26833395983194636,-0.5589047925639448,0.7165354330708661,0.894410994981079,1.0,5/15,18.02%,EGFR;NRG3;BTC;GRB2;ERBB4
prerank,GO_Biological_Process_2021__cardiac muscle cell differentiation (GO:0055007),-0.31128166684790515,-0.5584626763347814,0.5583333333333333,0.8943548382238656,1.0,9/22,29.76%,SLC8A1;CXADR;TCAP;ALPK3;SHOX2;TTN;BMP2;AKAP13;VEGFA
prerank,GO_Biological_Process_2021__autophagy of nucleus (GO:0044804),-0.28740280028861775,-0.5582875710812327,0.6507936507936508,0.8941425427762857,1.0,5/16,21.08%,ULK1;WDR45;ATG7;ATG13;WDR45B
prerank,TRRUST_Transcription_Factors_2019__NFKBIA human,-0.2932911727667443,-0.5571808821359092,0.6086956521739131,0.8945666520803994,1.0,6/18,19.25%,MMP9;FAS;CD58;S100A6;MMP3;CXCL8
prerank,GO_Biological_Process_2021__negative regulation of receptor signaling pathway via JAK-STAT (GO:0046426),0.2743173807602107,0.5569801731154735,0.6774193548387096,0.8728864859575038,1.0,5/16,23.97%,SH2B3;CAV1;ADIPOR1;SOCS3;HGS
prerank,GO_Biological_Process_2021__negative regulation of response to biotic stimulus (GO:0002832),-0.3471041684132584,-0.5566520754399025,0.5905511811023622,0.8945541299073597,1.0,14/29,27.21%,RNF26;SIRT2;C1QBP;TNFAIP3;TRIB1;TRAFD1;IRAK3;LTF;TRIM21;MAPKBP1;DHX58;ITCH;PPM1B;MUL1
prerank,Reactome_2022__Signaling By EGFR In Cancer R-HSA-1643713,-0.318331390122809,-0.5555042678573131,0.6293103448275862,0.894976062292625,1.0,8/23,17.20%,PIK3CA;EGFR;BTC;RPS27A;PIK3R1;GRB2;SHC1;TGFA
prerank,GO_Biological_Process_2021__protein quality control for misfolded or incompletely synthesized proteins (GO:0006515),-0.34929403706317197,-0.5541421479844963,0.616822429906542,0.8955569493259169,1.0,11/25,23.57%,RNF185;ATXN3;UGGT1;DERL1;UBE2W;YME1L1;KLHL15;RNF5;UGGT2;POMT2;LONP1
prerank,GO_Biological_Process_2021__negative regulation of nervous system development (GO:0051961),0.3083713703104462,0.553624183334297,0.6153846153846154,0.8742207751041983,1.0,7/17,18.29%,PCM1;ROBO2;DYNLT1;TLR2;B2M;HOOK3;REST
prerank,TRRUST_Transcription_Factors_2019__REL human,0.33891352470594416,0.5530797703722976,0.5801526717557252,0.8741821813372657,1.0,7/21,19.56%,IL12B;BIRC3;EPHB2;SELE;CD40LG;BCL2A1;CDKN1A
prerank,GO_Biological_Process_2021__mammary gland epithelium development (GO:0061180),0.32768946839361074,0.5529412166278839,0.647887323943662,0.8739206963871686,1.0,6/15,27.24%,ID2;JAK2;SCRIB;IRF6;WNT4;AKT2
prerank,GO_Biological_Process_2021__heparan sulfate proteoglycan biosynthetic process (GO:0015012),-0.3053080344356437,-0.552913832171906,0.6412213740458015,0.8960653053494032,1.0,9/17,27.87%,NDST3;CSGALNACT1;EXT2;GLCE;HS2ST1;HS6ST1;XYLT1;EXTL3;B3GAT3
prerank,TRRUST_Transcription_Factors_2019__BCL3 mouse,-0.27981537966894443,-0.5516707558998158,0.6259541984732825,0.8965799603124307,1.0,4/15,12.30%,TNF;TRIM63;TNFAIP3;FBXO32
prerank,TRRUST_Transcription_Factors_2019__PGR human,-0.31016491960787884,-0.5512779253759212,0.6134453781512605,0.8964427354143055,1.0,15/24,39.21%,ATP1B1;PTGS2;EGFR;E2F1;DUSP1;KLK3;KLK4;ABCG2;VEGFA;RLN2;MYC;CYP19A1;PLD1;ESR1;RELA
prerank,GO_Biological_Process_2021__endocardial cushion development (GO:0003197),-0.2591628027976531,-0.550878468736745,0.6065573770491803,0.8963709079875259,1.0,11/20,38.42%,ENG;MDM4;BMP2;NOS3;ACVRL1;BMPR1A;NOTCH1;GATA4;BMP4;CRELD1;ACVR1
prerank,GO_Biological_Process_2021__tetrapyrrole metabolic process (GO:0033013),-0.31941710502801335,-0.550783952245056,0.6031746031746031,0.8960933078045702,1.0,9/18,33.59%,AMN;TCN2;MMACHC;MTR;CUBN;MMUT;PRSS3;MMADHC;TCN1
prerank,GO_Biological_Process_2021__negative regulation of fibroblast proliferation (GO:0048147),-0.29416950050773083,-0.5507703265502341,0.6260162601626016,0.895745671674315,1.0,10/18,33.01%,GSTP1;FTH1;MORC3;SFRP1;DAB2IP;EMD;TP53;TRIM32;MYC;NLRC3
prerank,GO_Biological_Process_2021__regulation of smooth muscle cell migration (GO:0014910),-0.3150805374195875,-0.5507056286467218,0.5619047619047619,0.8954417846530677,1.0,9/20,31.29%,IGF1;TRIB1;CCN4;S100A11;LRP1;BMPR1A;SORL1;NDRG4;PDGFA
prerank,Reactome_2022__Defective Pyroptosis R-HSA-9710421,-0.3286775581756557,-0.5506068267293052,0.5785123966942148,0.8951498377579459,1.0,11/32,19.70%,DNMT3B;RBBP7;H2BC13;H2AZ2;H2BC15;H2AC6;SUZ12;H2BC5;POLA1;DNMT3A;RBBP4
prerank,GO_Biological_Process_2021__protein-DNA complex disassembly (GO:0032986),-0.2862538783572034,-0.5494553914774923,0.6290322580645161,0.8955631854014683,1.0,8/18,32.85%,NFE2;SUPT16H;SMARCB1;SMARCC1;SMARCA4;RPL23;MYC;GRWD1
prerank,GO_Biological_Process_2021__nuclear transport (GO:0051169),-0.31765087393263025,-0.5492795440142596,0.6283185840707964,0.8953449058459922,1.0,4/15,8.00%,NXT1;RGS14;NPM1;ANP32A
prerank,GO_Biological_Process_2021__error-prone translesion synthesis (GO:0042276),0.31650181823880724,0.5488801469386614,0.6349206349206349,0.8756367319026863,1.0,10/21,25.09%,RFC2;POLE2;PCNA;PRIMPOL;UBB;POLK;UBA52;RPA2;REV3L;REV1
prerank,Elsevier_Pathway_Collection__Single Strand Nucleotide Excision DNA Repair Suppression in Cancer,0.3228822261988865,0.5488518023079684,0.6120689655172413,0.8753156877394134,1.0,5/19,10.62%,ERCC6;DDB1;GTF2H5;PCNA;ERCC3
prerank,GO_Biological_Process_2021__phagosome maturation (GO:0090382),0.3581482458023986,0.5488265364924564,0.6356589147286822,0.8750005192590796,1.0,15/34,25.36%,RAB39A;ATP6V1G1;MCOLN1;ATP6V0A1;RAB20;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;RAB34;ATP6V0A2;PIKFYVE;ATP6V1E1;ATP6V0E2;RAB31
prerank,Elsevier_Pathway_Collection__P2RY1/2/4/6 -> Potassium Channels,-0.27984331854817146,-0.5472800921338918,0.680327868852459,0.8963922408626779,1.0,7/16,26.01%,KCNJ1;KCNQ1;P2RY6;GNAQ;ITPR1;KCNJ2;PLCB1
prerank,WikiPathway_2021_Human__ACE Inhibitor Pathway WP554,-0.2643952818123079,-0.5470578467377263,0.7016129032258065,0.896192163170405,1.0,7/15,32.21%,KNG1;AGTR1;CTSG;MAS1;NOS3;ACE2;TGFB1
prerank,TRRUST_Transcription_Factors_2019__HMGA1 human,-0.27522731493826136,-0.5470182919960608,0.7007874015748031,0.8958621289461116,1.0,7/16,31.73%,CDH1;PTGS2;CRYAB;TP53;CXCL1;KL;INSR
prerank,GO_Biological_Process_2021__negative regulation of proteolysis (GO:0045861),-0.3694899024815746,-0.5466945537977854,0.6756756756756757,0.895719112077492,1.0,17/37,26.57%,EPHA4;KNG1;PTPN3;ECM1;F2;TIMP2;EFNA1;SERPINE2;CHAC1;TRIM21;TIMP1;CSTA;CST3;CST7;PRNP;AKT1;GAS1
prerank,Reactome_2022__Mitochondrial Calcium Ion Transport R-HSA-8949215,-0.32672982442734727,-0.5466292308510564,0.6016260162601627,0.8954028588572648,1.0,10/21,23.43%,MCU;LETM1;PMPCA;PARL;YME1L1;AKAP1;SLC8A3;SPG7;MICU1;AFG3L2
prerank,Reactome_2022__Formation Of ATP By Chemiosmotic Coupling R-HSA-163210,-0.29032723954503853,-0.546382926490637,0.6379310344827587,0.8952268123044705,1.0,10/16,35.65%,ATP5ME;ATP5MF;ATP5F1E;ATP5PB;DMAC2L;ATP5F1D;ATP5MG;ATP5PD;ATP5PF;ATP5F1A
prerank,GO_Biological_Process_2021__negative regulation of reproductive process (GO:2000242),0.3157070969882181,0.5462380947619359,0.6124031007751938,0.8759901247083587,1.0,9/16,23.73%,NKX3-1;WEE2;ACVR1C;GJA1;ARHGDIB;PAEP;NPPC;CALR;ZP3
prerank,Elsevier_Pathway_Collection__Adherens Junction Assembly (Cadherins),-0.32831829611365554,-0.5459306877496551,0.6186440677966102,0.8951741517671509,1.0,17/30,30.93%,CDH1;FER;CDC42;APC;MAGI2;CDH2;PTPN1;FYN;SNAI2;CDH3;EPB41;CLIP1;AKT1;CTNND1;IQGAP1;MET;NOTCH1
prerank,GO_Biological_Process_2021__positive regulation of mitochondrial fission (GO:0090141),-0.2907669763526935,-0.5457967626317909,0.6260162601626016,0.8949267452401387,1.0,10/19,29.06%,MCU;RALA;MARCHF5;SPIRE1;FIS1;PINK1;VPS35;MIEF2;MUL1;RALBP1
prerank,Elsevier_Pathway_Collection__MTHFR Activity Regulation,-0.28587651209365544,-0.5454594329687938,0.6859504132231405,0.8947677357012109,1.0,5/19,9.79%,TNF;TRADD;TNFRSF1A;MAP2K4;MAP3K5
prerank,Elsevier_Pathway_Collection__Telomere Maintenance,-0.31543375146444813,-0.5434310659456689,0.6071428571428571,0.8959047493008472,1.0,10/20,28.35%,TNKS;MRE11;TERF2;TEP1;ABL1;XRCC6;TP53;AKT1;TERF1;TINF2
prerank,Reactome_2022__Abortive Elongation Of HIV-1 Transcript In Absence Of Tat R-HSA-167242,0.32232658970904265,0.5419698568186485,0.584,0.8778619796058009,1.0,6/22,14.89%,NCBP2;GTF2F2;POLR2A;POLR2F;POLR2C;POLR2L
prerank,GO_Biological_Process_2021__negative regulation of catalytic activity (GO:0043086),-0.31528610605847995,-0.5417961025163226,0.5983606557377049,0.8967581782940607,1.0,13/25,35.88%,NOSIP;NES;ATP5IF1;PPP1R12A;PLN;TIMP1;TP53;MT3;NOTCH1;IFIT1;CAMK2A;HDAC6;CCAR2
prerank,WikiPathway_2021_Human__Farnesoid X receptor pathway WP2879,-0.2620992489579343,-0.5411647575098044,0.6535433070866141,0.8969111364218731,1.0,11/19,39.89%,ABCB4;SLC27A5;FGF19;CYP7A1;BAAT;SLCO2B1;RXRA;FKBP5;SLC10A1;PPARGC1A;CYP3A4
prerank,"Reactome_2022__Synthesis, Secretion, And Inactivation Of Glucagon-like Peptide-1 (GLP-1) R-HSA-381771",-0.3152839925140705,-0.541049745002635,0.664179104477612,0.8966419329825339,1.0,4/16,8.31%,SEC11A;SPCS2;TCF7L2;SEC11C
prerank,GO_Biological_Process_2021__nuclear envelope organization (GO:0006998),0.3158812052595445,0.5408099676595827,0.6422764227642277,0.8781628098242252,1.0,8/20,24.77%,REEP4;TOR1A;TOR1AIP1;CTDNEP1;SUN3;SUN1;TOR1B;NUP155
prerank,GO_Biological_Process_2021__neural tube development (GO:0021915),-0.2798102506635617,-0.5404636736429153,0.6283185840707964,0.8967117702423414,1.0,3/15,12.29%,HES5;SOX4;GRHL2
prerank,GO_Biological_Process_2021__apoptotic nuclear changes (GO:0030262),0.32250149119094385,0.5399566442385086,0.5704225352112676,0.8783044007155798,1.0,9/23,17.54%,DEDD2;BLCAP;TOP2A;GPER1;CDK5RAP3;ACVR1C;CECR2;ENDOG;DFFA
prerank,GO_Biological_Process_2021__membrane depolarization during action potential (GO:0086010),-0.3080009299718917,-0.539438930390159,0.5793650793650794,0.897108627083839,1.0,7/25,10.05%,SCN4B;CACNA1H;SCN5A;SLC8A1;SCN1B;SCN2B;SCN9A
prerank,KEGG_2021_Human__Ascorbate and aldarate metabolism,0.348817422967015,0.5390776867535124,0.6230769230769231,0.878455733559647,1.0,13/27,26.59%,ALDH7A1;UGT1A5;UGT2B11;UGT1A4;UGT2A3;UGT2B15;UGT2B4;UGT2B17;MIOX;ALDH2;UGT2B10;RGN;UGT1A6
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transmembrane transporter activity (GO:1901021),-0.30079612438424974,-0.5384613932083195,0.6097560975609756,0.8974869166702354,1.0,11/20,38.14%,ATP1B1;P2RY6;STAC3;CALM2;AKAP6;JPH2;ANK2;CASQ1;CALM3;RYR2;PKD2
prerank,GO_Biological_Process_2021__nucleotide-sugar biosynthetic process (GO:0009226),0.2878130360154316,0.5370930152426081,0.6617647058823529,0.8791623956033906,1.0,5/19,14.50%,GNPDA1;MPI;PGM3;RENBP;NANS
prerank,GO_Biological_Process_2021__histone methylation (GO:0016571),-0.2908419435882065,-0.5365031947739692,0.6065573770491803,0.8986214016845503,1.0,10/24,25.44%,SMYD3;SIRT7;SMYD2;FBL;PRMT6;SUV39H1;N6AMT1;NTMT1;TRMT112;SUV39H2
prerank,GO_Biological_Process_2021__endoplasmic reticulum to cytosol transport (GO:1903513),-0.29709045354614905,-0.5361597953747937,0.6268656716417911,0.8985394460297772,1.0,4/15,9.54%,SELENOS;OS9;DERL1;SYVN1
prerank,GO_Biological_Process_2021__N-acetylglucosamine metabolic process (GO:0006044),-0.2665021639587216,-0.5358346575765603,0.6115702479338843,0.8984393201915165,1.0,6/15,24.05%,CHST4;AMDHD2;MGAT3;OGA;EXTL2;CHST3
prerank,GO_Biological_Process_2021__sterol transport (GO:0015918),-0.3274635227144691,-0.5356812167308487,0.6048387096774194,0.8982133389275926,1.0,6/21,16.95%,APOA2;CD36;OSBPL2;NPC2;NPC1L1;ARV1
prerank,GO_Biological_Process_2021__negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902236),-0.3147447252481295,-0.5341270735542776,0.676923076923077,0.8989565144244142,1.0,5/15,17.51%,SELENOS;SYVN1;TXNDC12;OPA1;CREB3L1
prerank,GO_Biological_Process_2021__positive regulation of phosphoprotein phosphatase activity (GO:0032516),-0.27302619710537623,-0.5329251907578394,0.7083333333333334,0.8995699614392072,1.0,5/17,19.23%,MAGI2;PPP1R12A;PPP1R15A;PTPA;CALM2
prerank,GO_Biological_Process_2021__vasculature development (GO:0001944),-0.29082899679417706,-0.5327097731041702,0.6129032258064516,0.899405041010825,1.0,3/17,9.41%,PIK3CA;APLNR;NOTCH4
prerank,GO_Biological_Process_2021__regulation of triglyceride biosynthetic process (GO:0010866),0.2928790250510831,0.5324211863417995,0.6829268292682927,0.8815215901173721,1.0,6/15,30.24%,SREBF1;CNEP1R1;CTDNEP1;SIK1;PLIN5;GPLD1
prerank,Reactome_2022__Assembly Of Active LPL And LIPC Lipase Complexes R-HSA-8963889,-0.28242819309012823,-0.531965534900028,0.6142857142857143,0.8995628638919181,1.0,5/19,18.48%,ANGPTL4;ANGPTL8;LIPC;PCSK5;LMF1
prerank,GO_Biological_Process_2021__positive regulation of B cell proliferation (GO:0030890),0.3249214999456094,0.5315886746232727,0.5909090909090909,0.8816982614137733,1.0,9/25,27.09%,CD320;EPHB2;NFATC2;CD81;CD74;FCRL3;TNFSF13B;SASH3;NCKAP1L
prerank,GO_Biological_Process_2021__midbody abscission (GO:0061952),0.32043053593697507,0.5314068078958165,0.6347826086956522,0.8814758900467942,1.0,9/17,31.31%,VPS4B;CHMP1A;KIF20A;CHMP1B;MITD1;CHMP4B;CHMP5;CHMP2A;PDCD6IP
prerank,GO_Biological_Process_2021__maturation of SSU-rRNA (GO:0030490),-0.3365602054968886,-0.5309209328023458,0.6541353383458647,0.8999752463618385,1.0,9/34,17.22%,NOB1;UTP4;RPS19;WDR3;RPS28;BMS1;WDR46;SNU13;NOL11
prerank,TRRUST_Transcription_Factors_2019__TCF3 mouse,-0.33280518757358224,-0.5305060398514586,0.6377952755905512,0.8999426120468387,1.0,7/31,6.29%,CDH1;VCAM1;CD5;ATXN3;EPB42;CD7;COL2A1
prerank,GO_Biological_Process_2021__cell migration involved in sprouting angiogenesis (GO:0002042),0.31970301584551386,0.5298731971373963,0.6165413533834586,0.8820273421447359,1.0,9/18,30.24%,SRF;FGF2;MIA3;KDR;ADTRP;EGR3;SLIT2;GREM1;GPLD1
prerank,Elsevier_Pathway_Collection__Skeletal Muscle Wasting in Cancer Cachexia,-0.34917933286491065,-0.5294976744354473,0.7232142857142857,0.9004057513052048,1.0,13/42,12.93%,TNF;TRADD;MAP1LC3B;TNFRSF1A;PIK3CA;TRIM63;CAPN1;IGF1;CAPN2;FBXO32;SMAD2;ACVR1B;PIK3R1
prerank,"Reactome_2022__TICAM1, RIP1-mediated IKK Complex Recruitment R-HSA-168927",0.309726056503442,0.5291762969530875,0.6299212598425197,0.8820801153146004,1.0,6/19,18.53%,BIRC3;BIRC2;TLR3;UBB;IKBKB;UBA52
prerank,TRRUST_Transcription_Factors_2019__ATF3 human,0.2973820938759065,0.5291537124214328,0.635036496350365,0.8817652473428236,1.0,6/15,28.12%,SELE;ADIPOR2;ADIPOR1;CD82;GDF15;ASNS
prerank,GO_Biological_Process_2021__negative regulation of phosphoprotein phosphatase activity (GO:0032515),0.33233114614822934,0.5289557176551778,0.6231884057971014,0.8815670231614736,1.0,8/22,16.85%,GSK3B;BOD1L1;STYXL1;BOD1;CRY2;FKBP1A;PPP1R14D;IKBKB
prerank,GO_Biological_Process_2021__morphogenesis of an epithelium (GO:0002009),-0.3183169916959331,-0.5285120638122397,0.5344827586206896,0.9008206252754658,1.0,6/27,13.34%,KRT6A;SOX8;FLG2;TBX18;LAMA5;LRP6
prerank,KEGG_2021_Human__Porphyrin and chlorophyll metabolism,0.37971170988710984,0.5282981900612748,0.7165354330708661,0.8816002795448852,1.0,21/40,28.69%,UGT1A5;UGT2B11;UGT1A4;ALAS1;COX15;ALAS2;UGT2A3;HMBS;HMOX1;FXN;CPOX;UGT2B15;UGT2B4;UGT2B17;UGT2B10;COX10;FECH;UGT1A6;HCCS;HEPH;HMOX2
prerank,Elsevier_Pathway_Collection__Fatty Acids in Hypertension and Atherosclerosis Development,-0.2832222368815671,-0.5279429963222717,0.75,0.900891725031762,1.0,6/15,31.73%,TNF;CD36;PIK3R1;SLC27A1;NOS3;INSR
prerank,GO_Biological_Process_2021__negative regulation of release of cytochrome c from mitochondria (GO:0090201),-0.27195883203317794,-0.5277725912866328,0.7372881355932204,0.900657415827851,1.0,4/15,12.02%,PRELID1;IGF1;OPA1;PSMD10
prerank,GO_Biological_Process_2021__positive regulation of cardiac muscle hypertrophy (GO:0010613),-0.2815206423006933,-0.5277269428765835,0.6666666666666666,0.9003407936124513,1.0,6/18,22.99%,IGF1;PDE9A;EDN1;AKAP6;NR4A3;IL6ST
prerank,GO_Biological_Process_2021__positive regulation of exosomal secretion (GO:1903543),0.29778651803826117,0.5273358092333351,0.6935483870967742,0.881856351009145,1.0,2/15,2.18%,VPS4B;SDC4
prerank,GO_Biological_Process_2021__regulation of non-canonical Wnt signaling pathway (GO:2000050),-0.25594002306805075,-0.5269473527639472,0.7591240875912408,0.9005587825198403,1.0,15/15,74.42%,LBX2;DAAM2;SFRP1;TIAM1;CSNK1E;DACT1;RSPO3;GPC3;CSNK1D;SFRP4;WNT5B;NPHP3;RNF213;ZNRF3;SPEF1
prerank,GO_Biological_Process_2021__natural killer cell mediated immunity (GO:0002228),-0.29903569873222563,-0.5269373736327919,0.6016260162601627,0.9002111215629718,1.0,5/18,14.79%,RAET1G;KLRD1;MICA;SLAMF7;CEBPG
prerank,Reactome_2022__Downregulation Of SMAD2/3:SMAD4 Transcriptional Activity R-HSA-2173795,0.33778112192530174,0.526674656349309,0.656,0.881914693854578,1.0,12/30,21.21%,SKIL;MAPK1;PPM1A;TGIF1;RNF111;UBB;SMAD7;SMAD3;SKI;STAT1;UBA52;WWTR1
prerank,GO_Biological_Process_2021__tRNA metabolic process (GO:0006399),0.3066415940748332,0.5262224595118671,0.6923076923076923,0.8818455506120771,1.0,5/18,11.93%,DTD2;THG1L;ADAT1;POP7;SARS1
prerank,GO_Biological_Process_2021__positive regulation of oxidoreductase activity (GO:0051353),-0.2694759060971142,-0.5261349687209348,0.6557377049180327,0.9004339351080806,1.0,6/17,18.39%,TNF;GDNF;AGTR1;NOD2;EDN1;ABL1
prerank,GO_Biological_Process_2021__filopodium assembly (GO:0046847),-0.2987249589975749,-0.5258356498882739,0.7401574803149606,0.9003254586492385,1.0,6/16,23.28%,RAB17;FGD1;VSTM5;ARHGEF4;FGD4;PPP1R9B
prerank,Elsevier_Pathway_Collection__ECL-cell: CHGA and Histamine Synthesis,-0.2629228698205356,-0.5255217592576445,0.7416666666666667,0.9002187133451318,1.0,8/17,34.70%,PCSK2;GNAO1;CXCL8;GNAQ;ITPR1;PLCB1;SSTR2;PIEZO2
prerank,Elsevier_Pathway_Collection__Acetaminophen Induced Hepatotoxicity,-0.2739722204816901,-0.5249831060960423,0.7543859649122807,0.9002684271586715,1.0,5/15,18.95%,AIFM1;DNASE1L3;BID;BAK1;ATP2B1
prerank,WikiPathway_2021_Human__Type 2 papillary renal cell carcinoma WP4241,-0.3000301381968498,-0.5235433228780025,0.5692307692307692,0.9011605590874135,1.0,18/34,32.52%,EP300;RBX1;EGLN2;VHL;TFE3;ELOB;TGFA;SLC2A1;TFEB;PRCC;FH;ARNT2;CADM2;VEGFA;CTSK;TGFB1;ARNT;SFPQ
prerank,Reactome_2022__PIWI-interacting RNA (piRNA) Biogenesis R-HSA-5601884,0.32565345084468084,0.523469423436321,0.5950413223140496,0.8832086136466899,1.0,11/26,25.99%,TDRD6;HENMT1;POLR2A;POLR2F;TDRD1;POLR2C;TDRD9;POLR2L;POLR2H;MOV10L1;MAEL
prerank,Reactome_2022__mRNA Decay By 5 To 3 Exoribonuclease R-HSA-430039,0.2865329177466979,0.5231665109959476,0.7131782945736435,0.8830298879606149,1.0,7/15,25.15%,EDC4;LSM1;EDC3;LSM6;XRN1;DCP1B;PATL1
prerank,GO_Biological_Process_2021__heme biosynthetic process (GO:0006783),0.32504412600882354,0.5231465189736583,0.6176470588235294,0.8827100026815397,1.0,11/22,26.58%,ALAS1;COX15;ALAS2;HMBS;NFE2L1;FXN;CPOX;ABCB6;COX10;FECH;TSPO
prerank,GO_Biological_Process_2021__sodium ion homeostasis (GO:0055078),0.2930101093105483,0.5231241725350119,0.6571428571428571,0.8823917515410107,1.0,15/22,35.44%,SCNN1A;ATP4A;ATP1A4;SCNN1G;SLC9A1;ATP12A;SCNN1B;CYP4F2;CYP4A11;ATP1B3;ATP1B2;ATP1A2;SLC12A2;ATP1A3;TMPRSS3
prerank,GO_Biological_Process_2021__axon extension (GO:0048675),0.32325328039913714,0.5229890380141538,0.6461538461538462,0.8821562105692697,1.0,12/23,31.64%,NRP2;SLC9A6;SPG11;SEMA3F;SEMA5A;NLGN3;PPP3CB;SLIT3;AUTS2;ULK2;SLIT2;CYFIP1
prerank,TRRUST_Transcription_Factors_2019__IRF1 mouse,0.3165003608445679,0.5227114765956411,0.6461538461538462,0.8820004936494458,1.0,9/22,25.77%,IL12B;TAP1;TAP2;PIGR;SELL;CDKN1A;GBP2;IL12A;MYD88
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881),0.2966566332335083,0.522321878407966,0.6935483870967742,0.8819524499375896,1.0,11/17,38.47%,CACNA1C;HRC;CLIC2;PRKACA;FKBP1B;GSTO1;ATP1A2;CALM1;DMD;CASQ2;GSTM2
prerank,GO_Biological_Process_2021__negative regulation of DNA binding (GO:0043392),-0.34122549962609083,-0.5219138093239342,0.6612903225806451,0.9020240359675512,1.0,8/30,9.05%,HEY2;SUMO1;HABP4;TFAP4;TNKS;CPNE1;E2F1;HMGA2
prerank,GO_Biological_Process_2021__ribosomal small subunit assembly (GO:0000028),-0.2985534860310221,-0.5206448142284267,0.7022900763358778,0.902689544334111,1.0,3/16,9.86%,RPS19;ERAL1;RPS28
prerank,Elsevier_Pathway_Collection__AGE Related Insulin Resistance in Skeletal Muscles,0.31154983280259435,0.5205651378533767,0.6239316239316239,0.8826877943732474,1.0,5/22,9.16%,GSK3B;BIRC3;MAPK1;BIRC2;PDPK1
prerank,GO_Biological_Process_2021__dermatan sulfate proteoglycan biosynthetic process (GO:0050651),-0.30281946842732715,-0.5205369952520125,0.6810344827586207,0.9024275984016789,1.0,7/15,27.87%,NCAN;VCAN;CSGALNACT1;CSPG5;CSPG4;DSE;B3GAT3
prerank,Elsevier_Pathway_Collection__Reperfusion Injury in Myocardial ischemia,0.3268242991128509,0.5192445410732898,0.6222222222222222,0.8831825139102221,1.0,10/27,17.48%,CACNA1C;CYCS;CACNB2;CTSA;VDAC1;CASP9;PPID;NOS1;BBC3;ENDOG
prerank,Elsevier_Pathway_Collection__GALR1/2/3 -> POMC/NPY Production,-0.26882455901433455,-0.5187616216608718,0.6956521739130435,0.9034801498555372,1.0,9/20,26.50%,GALR1;MAPK3;RAF1;RASGRP1;MAP2K2;GNAQ;GAL;ITPR1;AKT1
prerank,Reactome_2022__RHO GTPases Activate CIT R-HSA-5625900,-0.2693964954028696,-0.518653182340778,0.7361111111111112,0.9031868980217055,1.0,5/19,19.08%,PRC1;PPP1R12A;PPP1CB;MYH10;RHOC
prerank,TRRUST_Transcription_Factors_2019__VHL human,0.282666113888195,0.5184705600234272,0.5895522388059702,0.8833085041296275,1.0,6/19,15.34%,CDKN1C;CXCR4;COL4A2;CA9;HIF1A;CCND1
prerank,Reactome_2022__Glucuronidation R-HSA-156588,0.2888214721237324,0.5183258267821194,0.644927536231884,0.8830787248701505,1.0,9/22,22.76%,UGT1A5;UGT2B11;UGT1A4;UGT3A1;UGT2A3;UGT2B15;UGT2B4;UGT2B17;UGT2B10
prerank,Elsevier_Pathway_Collection__Circadian Clock Genes Mutations Cause Insomnia,-0.26706422618703324,-0.5170369294464174,0.7394957983193278,0.9037956925580107,1.0,3/18,3.83%,NPAS2;CLOCK;RORB
prerank,Elsevier_Pathway_Collection__Circadian Clock and Sleep Regulation by Melatonin,-0.26706422618703324,-0.5170369294464174,0.7394957983193278,0.9037956925580107,1.0,3/18,3.83%,NPAS2;CLOCK;RORB
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Asthma,-0.26277131987642177,-0.5168633782188641,0.7333333333333333,0.9035649916313122,1.0,5/17,15.90%,TNF;PHF11;HLA-DQB1;DPP10;IRAK3
prerank,GO_Biological_Process_2021__regulation of exosomal secretion (GO:1903541),0.2945858648004311,0.5168163557819836,0.6617647058823529,0.8836508362779917,1.0,19/19,70.56%,VPS4B;SDC4;ATP9A;HGS;CHMP2A;PRKN;PDCD6IP;STAM;SDC1;VPS4A;CHMP3;CHMP6;SNF8;SMPD3;RAB7A;SDCBP;ATP13A2;TSG101;IFNG
prerank,Reactome_2022__CTNNB1 S33 Mutants Not Phosphorylated R-HSA-5358747,0.27781656639841096,0.5167445432770956,0.6904761904761905,0.883366742383751,1.0,4/15,23.18%,GSK3B;PPP2CB;CTNNB1;AXIN1
prerank,Elsevier_Pathway_Collection__Conventional Dendritic Cell Role in Diabetes Mellitus Type 1,-0.29435705863698286,-0.5162379273860498,0.6271186440677966,0.9037181554967142,1.0,6/21,13.71%,TNF;IL18;PYCARD;NLRP3;CTSB;IRAK1
prerank,Elsevier_Pathway_Collection__Mineralcorticoids Secretion Regulation,-0.3047650445645446,-0.5161622085172494,0.6030534351145038,0.9034155452560418,1.0,20/34,33.21%,MAPKAPK3;MAPK3;STAR;AGTR1;EDN1;RASGRP1;CACNA2D1;HSD3B2;MAP2K2;GNAQ;ATF1;AVPR2;NR4A1;ITPR1;PLCB1;BRAF;CYP21A2;EDNRA;CAMK1;PRKD1
prerank,GO_Biological_Process_2021__regulation of androgen receptor signaling pathway (GO:0060765),-0.3325570147934875,-0.5159699106138503,0.672,0.9032032821564743,1.0,18/36,34.09%,NODAL;EP300;H3C1;TRIM68;NCOR2;KDM4C;KLK3;SFRP1;RNF6;HDAC1;RNF14;FOXH1;SMARCA4;ZBTB7A;PHB;DAB2;PIAS2;HDAC6
prerank,GO_Biological_Process_2021__chromatin disassembly (GO:0031498),-0.2522877551628675,-0.5158338797030608,0.7338709677419355,0.9026351800370742,1.0,5/16,26.22%,NFE2;SUPT16H;SMARCB1;SMARCC1;SMARCA4
prerank,GO_Biological_Process_2021__nucleosome disassembly (GO:0006337),-0.2522877551628675,-0.5158338797030608,0.7338709677419355,0.9026351800370742,1.0,5/16,26.22%,NFE2;SUPT16H;SMARCB1;SMARCC1;SMARCA4
prerank,GO_Biological_Process_2021__homologous chromosome segregation (GO:0045143),0.2965008964625886,0.5150318575852377,0.627906976744186,0.8841208470480424,1.0,6/17,29.27%,IHO1;RNF212B;CENPC;FANCD2;RNF212;MEIOB
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to NOTCH Signaling Pathway,-0.32457956083790906,-0.5144450192667605,0.6017699115044248,0.9034004628416074,1.0,10/31,14.16%,CDH1;SGK1;EP300;EGFR;MMP9;CDK4;CTSB;NOTCH4;SMAD2;ADAM17
prerank,GO_Biological_Process_2021__leukocyte tethering or rolling (GO:0050901),-0.24615122374079956,-0.5144023981913397,0.7603305785123967,0.9030887452700281,1.0,7/18,24.16%,TNF;ADD2;VCAM1;ITGB1;GOLPH3;CX3CR1;SELP
prerank,Elsevier_Pathway_Collection__FOXA2 Signaling in Prostate Cancer,-0.3007187733797285,-0.5127770408221237,0.7070707070707071,0.9040445849937888,1.0,4/18,9.40%,HIPK2;EP300;EGLN2;VHL
prerank,Elsevier_Pathway_Collection__EGFR Nuclear Signaling in Colorectal Cancer,0.29943325227298717,0.5119600968716773,0.6030534351145038,0.8856682736284094,1.0,10/22,23.13%,CAV1;STAT5A;PCNA;AURKA;MDC1;EGF;CCND1;XPO1;PIKFYVE;PRKDC
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, preincision complex assembly (GO:0006294)",-0.3007770886002749,-0.5115362444214245,0.6090909090909091,0.9047544937982906,1.0,8/29,12.12%,CDK7;RPA1;CUL4A;CHD1L;CCNH;RBX1;RPS27A;RPA3
prerank,GO_Biological_Process_2021__positive regulation of ERBB signaling pathway (GO:1901186),-0.2890575523287204,-0.5105400249686864,0.6213592233009708,0.9052187566556305,1.0,12/24,29.14%,MMP9;PTK6;HIP1;PLAUR;DGKD;HIP1R;NEU3;SHKBP1;NUP62;AKT1;PDE6G;CNOT9
prerank,GO_Biological_Process_2021__positive regulation of smooth muscle cell migration (GO:0014911),0.2769591171466386,0.5104952223418836,0.689922480620155,0.8862720096732954,1.0,4/17,12.28%,AIF1;IGFBP5;DOCK5;PDGFB
prerank,GO_Biological_Process_2021__calcium-mediated signaling using intracellular calcium source (GO:0035584),0.320221508254245,0.5103521764613447,0.6587301587301587,0.8860249483428712,1.0,11/20,29.90%,CCL20;DEFB1;TRPM2;PTPRJ;KDR;PRKACA;STIMATE;AZU1;ADGRL1;FKBP1B;DMTN
prerank,Elsevier_Pathway_Collection__WNT Signaling in Melanoma,-0.2879267579443332,-0.5097745819110867,0.6724137931034483,0.9055111589711053,1.0,6/23,18.82%,CDH1;WNT5A;CAPN1;LRP6;TCF4;FZD2
prerank,GO_Biological_Process_2021__regulation of protein autophosphorylation (GO:0031952),-0.3196322179134995,-0.5096360796316332,0.6290322580645161,0.9052759662628226,1.0,14/35,33.90%,TOM1L1;MRE11;PPP2R5C;NLRP12;ENG;CALM2;TESK1;PPP2R5B;ENPP1;VEGFA;PDGFA;TAOK2;CALM3;RAP2A
prerank,WikiPathway_2021_Human__GABA receptor Signaling WP4159,0.3314805084846219,0.5095408462648386,0.6859504132231405,0.8862149150550561,1.0,12/25,29.69%,GAD1;AP2B1;GABRQ;GABRB2;GABRG3;GABRB1;AP2M1;AP2S1;GABBR2;SLC6A11;GABRA3;GABRE
prerank,GO_Biological_Process_2021__ribosomal small subunit biogenesis (GO:0042274),-0.3264159499522463,-0.5094212973014518,0.664179104477612,0.9050899178035117,1.0,12/39,18.05%,NOB1;UTP4;RPS19;ERAL1;NPM1;WDR3;RPS28;RPS17;SNU13;SURF6;NOL11;EMG1
prerank,GO_Biological_Process_2021__regulation of receptor recycling (GO:0001919),-0.2626828881633212,-0.5093893553669453,0.6974789915966386,0.9047686014145223,1.0,6/17,28.69%,SNCA;ECE1;AP1AR;ANXA2;VAMP3;TRAT1
prerank,Reactome_2022__Synthesis Of Prostaglandins (PG) And Thromboxanes (TX) R-HSA-2162123,0.28516510549720636,0.5091555471717738,0.6742424242424242,0.8861349423989262,1.0,5/15,17.92%,PTGIS;HPGDS;PTGES2;PTGES;PTGES3
prerank,GO_Biological_Process_2021__positive regulation of muscle hypertrophy (GO:0014742),-0.27483214691253754,-0.5090928662405783,0.680672268907563,0.9046774803686308,1.0,5/17,22.99%,IGF1;PDE9A;EDN1;NR4A3;IL6ST
prerank,GO_Biological_Process_2021__regulation of cell killing (GO:0031341),-0.2441852852538299,-0.508900329010717,0.8203125,0.9044706849515194,1.0,5/16,23.29%,WNT5A;CYBA;CR1L;NOX1;CFH
prerank,TRRUST_Transcription_Factors_2019__RUNX3 human,-0.2986066208898595,-0.5086882199701774,0.6147540983606558,0.9042917516730783,1.0,13/29,31.41%,ING4;HSPD1;MMP9;FADD;CD36;TCF4;ICAM3;TIMP1;CD6;HES1;CASP3;TIAL1;MYC
prerank,GO_Biological_Process_2021__positive regulation of signaling (GO:0023056),-0.3180241027110704,-0.5086007933842117,0.6218487394957983,0.9040298797358364,1.0,8/29,13.77%,TNF;HOMER1;CLSTN3;KCTD13;SNCA;SYT1;ECE1;EDN1
prerank,WikiPathway_2021_Human__Overview of interferons-mediated signaling pathway WP4558,-0.2642784664931845,-0.5084532966475745,0.7435897435897436,0.9037730943631316,1.0,5/19,17.64%,IRF9;PIK3CA;STAT2;PIK3R1;TYK2
prerank,GO_Biological_Process_2021__mitotic cell cycle checkpoint signaling (GO:0007093),-0.2840308241141348,-0.5079895345467909,0.6509433962264151,0.9038453013172439,1.0,6/22,13.96%,SETMAR;BUB1;BUB1B;PLK2;WEE1;ZW10
prerank,WikiPathway_2021_Human__Mitochondrial Gene Expression WP391,0.2847892046673982,0.5068152751002395,0.6564885496183206,0.8873298536408233,1.0,8/19,34.34%,PPARGC1B;MTERF1;SP1;TFAM;CREB1;POLRMT;MTERF3;HCFC1
prerank,GO_Biological_Process_2021__dendritic cell migration (GO:0036336),0.30554456460916357,0.5068011002345197,0.6583333333333333,0.8870160610366551,1.0,6/18,20.89%,TRPM2;CXCR4;TRPM4;EPS8;PIK3CG;ALOX5
prerank,Elsevier_Pathway_Collection__Circadian Clock in Sleep Regulation,-0.2698535988564259,-0.5053478140857626,0.6754385964912281,0.9057576695923671,1.0,9/18,32.96%,NPAS2;CLOCK;GNAQ;PER3;ITPR1;PER2;ARNTL;NR1D1;CSNK1E
prerank,GO_Biological_Process_2021__leukocyte adhesion to vascular endothelial cell (GO:0061756),-0.2416884206247089,-0.5052501825973681,0.7310924369747899,0.905487504557026,1.0,7/19,24.16%,TNF;ADD2;VCAM1;ITGB1;GOLPH3;CX3CR1;SELP
prerank,TRRUST_Transcription_Factors_2019__DDIT3 human,-0.2651475476224686,-0.5046759674470205,0.6612903225806451,0.9056093697972489,1.0,3/18,3.86%,ANKRD1;MAP1LC3B;SIRT2
prerank,Reactome_2022__DNA Methylation R-HSA-5334118,-0.3031405972774893,-0.5046507956513367,0.6311475409836066,0.9052858378664622,1.0,7/24,18.07%,DNMT3B;H2BC13;H2AZ2;H2BC15;H2AC6;H2BC5;DNMT3A
prerank,GO_Biological_Process_2021__positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742),-0.32552941042993083,-0.5045062717981046,0.6434782608695652,0.9050892709834675,1.0,18/32,30.45%,MMP9;BTC;PTK6;HIP1;ADAM17;PLAUR;NCF1;TGFA;DGKD;HIP1R;NEU3;SHKBP1;NUP62;ADRA2A;AKT1;PDE6G;CNOT9;AREG
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Interleukins Production,-0.2628064682706386,-0.5043307949667951,0.7540983606557377,0.9048814873820792,1.0,6/17,26.50%,KNG1;ITGAM;GNA12;CXCL8;GNAQ;AKT1
prerank,GO_Biological_Process_2021__negative regulation of small molecule metabolic process (GO:0062014),-0.2746613327476055,-0.5040927777351624,0.6909090909090909,0.9047631460926839,1.0,6/18,17.43%,GSK3A;EP300;DKKL1;ERFE;GCK;BCKDK
prerank,GO_Biological_Process_2021__mitochondrial calcium ion homeostasis (GO:0051560),-0.2917433413602371,-0.5036610822735804,0.640625,0.9047828252437753,1.0,8/21,23.43%,MCU;PDZD8;LETM1;FIS1;BCAP31;SLC8A3;MICU1;AFG3L2
prerank,WikiPathway_2021_Human__Blood Clotting Cascade WP272,0.30228779968038066,0.5025703997722463,0.7007299270072993,0.889390590981899,1.0,9/22,26.47%,VWF;FGA;F5;SERPINB2;F7;F12;F9;FGG;PLAT
prerank,Elsevier_Pathway_Collection__Androgen Receptor non-Genomic Signaling,-0.32173484736370206,-0.5021987490584207,0.6982758620689655,0.9057270746756004,1.0,11/28,19.79%,MAPK3;RHEB;RPS6KB1;NCOA4;RAF1;PIK3R1;GRB2;TCF4;SHC1;MAP2K2;MDM2
prerank,TRRUST_Transcription_Factors_2019__SMAD1 mouse,0.32541520925432876,0.5008742460446564,0.6496350364963503,0.8901441742608245,1.0,11/21,31.14%,ID2;COL4A2;OVOL2;DSG4;TBX20;CDKN1A;MSX2;TNFRSF11B;SPP1;TNFSF11;CRELD2
prerank,GO_Biological_Process_2021__response to ATP (GO:0033198),0.2799690746746437,0.5006345041951867,0.7074829931972789,0.8899768435775277,1.0,5/18,19.07%,ABCC9;TRPV1;P2RY2;TRPC3;HSP90B1
prerank,GO_Biological_Process_2021__detection of visible light (GO:0009584),-0.2551647944073056,-0.5002942887418419,0.8288288288288288,0.9070419141208087,1.0,5/15,23.32%,REEP6;GNAT1;ABCA4;GNAQ;GNAT2
prerank,GO_Biological_Process_2021__regulation of autophagy of mitochondrion (GO:1903146),0.2898750385106293,0.5001075284456478,0.6231884057971014,0.8899761558325258,1.0,9/19,30.32%,VDAC1;SREBF1;USP36;PARK7;HTRA2;FZD5;SREBF2;DNM1L;PRKN
prerank,GO_Biological_Process_2021__negative regulation of cell junction assembly (GO:1901889),0.307836060981187,0.4997667144727052,0.6692307692307692,0.8898742055981635,1.0,16/25,39.19%,ROBO2;APOD;ARHGAP6;TLR2;IKBKB;RCC2;PTEN;DLC1;DMTN;SRC;PHLDB2;IL1B;ITGB1BP1;CLASP2;THBS1;DUSP22
prerank,GO_Biological_Process_2021__calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules (GO:0016338),-0.2704273227083027,-0.4995061929186004,0.7441860465116279,0.9072746479957932,1.0,7/18,28.02%,CLDN12;CLDN5;CLDN1;CLDN9;CLDN10;CLDN18;CLDN8
prerank,Elsevier_Pathway_Collection__Spindle Assembly,-0.25927802489429247,-0.49947693782058517,0.7747747747747747,0.9069530897765519,1.0,7/16,31.09%,CDC20;BUB1B;ZW10;MAD2L1;AURKB;ESPL1;KIF2C
prerank,KEGG_2021_Human__Renin-angiotensin system,0.3237356874009588,0.49909349288806704,0.6541353383458647,0.890048274695355,1.0,8/20,22.50%,CTSA;AGT;MME;PREP;LNPEP;CPA3;ATP6AP2;ANPEP
prerank,GO_Biological_Process_2021__response to cholesterol (GO:0070723),-0.28521952627873143,-0.49824215678798967,0.6944444444444444,0.9076731777171485,1.0,6/19,17.26%,SMAD2;LRP6;PMVK;CCR5;CYP7A1;ABCA2
prerank,GO_Biological_Process_2021__negative regulation of GTPase activity (GO:0034260),-0.2973974938881998,-0.49800541655400504,0.6410256410256411,0.9075217055539472,1.0,7/22,20.43%,RRP1B;SH3BP4;FICD;TMED2;ARFGEF1;DAB2IP;LRCH1
prerank,Elsevier_Pathway_Collection__Contraction Due Vasospasm,-0.3014179603125556,-0.497949196798786,0.6090909090909091,0.90722307885248,1.0,16/36,27.90%,MAPK3;TBXA2R;CALD1;ACTG2;RAF1;EDN1;GNAO1;RASGRP1;MYLK;MAP2K2;GNAQ;ADRA1B;ITPR1;PLCB1;BRAF;ACTA2
prerank,GO_Biological_Process_2021__establishment of vesicle localization (GO:0051650),0.2865149637171867,0.4978939570820886,0.7196969696969697,0.8904828130313225,1.0,6/18,20.88%,TMEM230;SPG11;TOR1A;LIMK2;KIF5A;SNAPIN
prerank,GO_Biological_Process_2021__regulation of interferon-gamma-mediated signaling pathway (GO:0060334),0.28896769032395914,0.4977693671341837,0.6339285714285714,0.8902519245048757,1.0,8/21,25.16%,TXK;NLRC5;JAK2;PPARG;STAT1;IFNGR1;SOCS3;IFNGR2
prerank,Elsevier_Pathway_Collection__FXN Role in Friedreich Ataxia Progression,0.26869301750513364,0.49749303483169516,0.6846153846153846,0.8901347859260738,1.0,7/17,25.82%,LYRM4;SRF;NFS1;HIF1A;FXN;PMPCB;FECH
prerank,GO_Biological_Process_2021__positive regulation of embryonic development (GO:0040019),0.2747363542713455,0.49705886548295575,0.7241379310344828,0.8900883491464248,1.0,8/15,30.72%,TLE6;NIBAN2;SCX;B4GALT5;WNT4;FOXA2;RBM19;WNT1
prerank,WikiPathway_2021_Human__IL-9 signaling pathway WP22,-0.28459740426484864,-0.4969973007611847,0.7235772357723578,0.9077125187151749,1.0,6/16,19.32%,MAPK3;JAK3;IL9R;PIK3R1;GRB2;MAP2K2
prerank,GO_Biological_Process_2021__regulation of cellular amine metabolic process (GO:0033238),-0.3440987803912821,-0.49626343352136626,0.7478260869565218,0.9079978273802459,1.0,18/48,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD1;PSMD2;PSMB8;PSMD11;PSMD10;OAZ2;PSMD13;PSMC1;PSME1;PSMA1;OAZ1;PSMD5;PSMD12;PSMB3
prerank,KEGG_2021_Human__African trypanosomiasis,-0.3173370930997514,-0.49602756699259176,0.6258992805755396,0.9078545451891411,1.0,7/34,6.77%,TNF;THOP1;VCAM1;IDO1;IDO2;IL18;KNG1
prerank,GO_Biological_Process_2021__negative regulation of interleukin-1 beta production (GO:0032691),-0.2667645750985787,-0.49468342923148456,0.725925925925926,0.9087116044843254,1.0,9/21,26.62%,GSTP1;TNFAIP3;IGF1;NLRP3;CPTP;CX3CR1;GHRL;APOA1;FFAR4
prerank,WikiPathway_2021_Human__ERK Pathway in Huntington's Disease WP3853,0.278237415664056,0.4946755811246626,0.712,0.8915146593923324,1.0,5/15,24.63%,ELK1;MAPK1;EGF;MAP2K7;CREB1
prerank,GO_Biological_Process_2021__positive regulation of interleukin-17 production (GO:0032740),0.2810805189944646,0.49462557531499546,0.6581196581196581,0.8912228519171526,1.0,4/20,4.45%,IL12B;NR1H4;SLC7A5;IL23A
prerank,Reactome_2022__EPHA-mediated Growth Cone Collapse R-HSA-3928663,0.2705699165328041,0.4942702271853019,0.7857142857142857,0.8911525563399723,1.0,6/15,31.66%,YES1;MYL12B;RHOA;MYL6;MYH14;SRC
prerank,GO_Biological_Process_2021__regulation of activin receptor signaling pathway (GO:0032925),-0.2667766307701109,-0.49386384030107067,0.744,0.9090705071294313,1.0,4/15,12.86%,NODAL;MAGI2;LEMD3;ACVR1B
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Methylation R-HSA-6804760,-0.25508602530281077,-0.4934774223075319,0.7642276422764228,0.909065839501758,1.0,8/19,25.96%,EP300;SMYD2;RPS27A;MDM2;TP53;UBC;TTC5;MDM4
prerank,GO_Biological_Process_2021__histone H4-K8 acetylation (GO:0043982),0.24299134929915728,0.49197500246732945,0.8032786885245902,0.8920708171046645,1.0,11/15,37.41%,PHF20;KANSL1;JADE3;OGT;KANSL2;MCRS1;JADE1;JADE2;MEAF6;HCFC1;KANSL3
prerank,GO_Biological_Process_2021__histone H4-K5 acetylation (GO:0043981),0.24299134929915728,0.49197500246732945,0.8032786885245902,0.8920708171046645,1.0,11/15,37.41%,PHF20;KANSL1;JADE3;OGT;KANSL2;MCRS1;JADE1;JADE2;MEAF6;HCFC1;KANSL3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Photoaging,0.30534359064261246,0.4914714075656706,0.6821705426356589,0.8920790413544255,1.0,7/21,11.93%,JUN;PPARD;ESR2;HSPB1;MMP1;SMAD7;MC1R
prerank,GO_Biological_Process_2021__activation of adenylate cyclase activity (GO:0007190),-0.2810418557953485,-0.49143034031910066,0.6272727272727273,0.9106122622870007,1.0,13/30,32.56%,LGR5;ADCY8;ADRB1;ADCY3;RAF1;ADCY5;AVPR2;ACR;GIPR;CAP1;EDNRA;ADRB2;ADCY9
prerank,Elsevier_Pathway_Collection__Disorders of Phenylalanine and Tyrosine Metabolism,0.2918260845076605,0.49113368143202457,0.6692913385826772,0.8920002498908289,1.0,4/15,15.39%,HGD;SLC45A2;DBH;DCT
prerank,"Reactome_2022__Tristetraprolin (TTP, ZFP36) Binds And Destabilizes mRNA R-HSA-450513",0.2905945429308462,0.4907736355219489,0.6746031746031746,0.8919242769597321,1.0,7/17,25.30%,EXOSC9;EXOSC6;DIS3;EXOSC3;XRN1;MAPKAPK2;ZFP36
prerank,GO_Biological_Process_2021__pore complex assembly (GO:0046931),-0.2588363871288857,-0.4907180529335794,0.7338709677419355,0.9108974255623062,1.0,5/19,23.23%,TSPAN33;TPR;GSDMD;P2RX7;NUP205
prerank,Elsevier_Pathway_Collection__Ca2+ Toxicity in Lens Cells,-0.2693875096127728,-0.49025918396273604,0.6532258064516129,0.9109872221804167,1.0,7/24,18.95%,MCU;CAPN2;SLC8A1;ATP2A3;CASR;CRYAB;ATP2B1
prerank,WikiPathway_2021_Human__Interactome of polycomb repressive complex 2 (PRC2)  WP2916,-0.26281374976223953,-0.49000560696373346,0.7155963302752294,0.9108802633137308,1.0,6/16,22.58%,RBBP7;SUZ12;MORC3;TRIM35;RBBP4;ELL
prerank,GO_Biological_Process_2021__regulation of actin polymerization or depolymerization (GO:0008064),-0.3005487842647493,-0.4894859378799445,0.6086956521739131,0.910986113800407,1.0,10/29,21.92%,ARHGAP28;DBNL;PLEKHG2;PFN3;ESAM;BRK1;GBA2;FCHSD1;TMSB4Y;NAA80
prerank,GO_Biological_Process_2021__regulation of centrosome cycle (GO:0046605),0.30947077030310216,0.4893889211466301,0.6825396825396826,0.8926018951637342,1.0,11/21,34.25%,VPS4B;MARK4;CHMP1A;AURKA;CHMP1B;CHMP4B;CHMP5;CHMP2A;PDCD6IP;GEN1;NAT10
prerank,Elsevier_Pathway_Collection__Leptin Role in Endometriosis,-0.282267328722979,-0.48918359462906835,0.6956521739130435,0.9108872916222587,1.0,6/17,20.83%,TNF;MAPK3;RAF1;GRB2;MAP2K2;LEP
prerank,Reactome_2022__Platelet Sensitization By LDL R-HSA-432142,-0.28919067326003134,-0.4889567667446509,0.7647058823529411,0.9107370135511689,1.0,5/17,22.87%,FGR;PPP2R5C;MAPK14;PTPN6;PPP2R5B
prerank,GO_Biological_Process_2021__ATP synthesis coupled proton transport (GO:0015986),-0.27503112145874226,-0.4887529394396379,0.7477477477477478,0.910572362231893,1.0,11/18,35.65%,ATP5ME;ATP5MF;ATP5F1E;ATP5PB;DMAC2L;ATP5F1D;ATP5MG;VPS9D1;ATP5PD;ATP5PF;ATP5F1A
prerank,WikiPathway_2021_Human__Cholesterol Biosynthesis Pathway WP197,-0.26348071142857105,-0.4883316770530138,0.7768595041322314,0.9105928852817029,1.0,5/15,19.37%,MVD;NSDHL;PMVK;DHCR7;HMGCR
prerank,TRRUST_Transcription_Factors_2019__SPI1 mouse,-0.2827275715549618,-0.48817448726770846,0.6386554621848739,0.9103672905609863,1.0,13/32,28.15%,TNF;DCSTAMP;TAL1;BCL2L11;ITGA2B;ELF1;CSF1R;NCF1;PTPRO;PTGDS;IGHM;SCN8A;NCF4
prerank,GO_Biological_Process_2021__medium-chain fatty acid metabolic process (GO:0051791),0.28258362168396767,0.48813387845023,0.6910569105691057,0.8931162278539728,1.0,15/15,71.76%,ACOT7;ABHD3;GLYATL2;CYP4A11;ACADM;CES1;ACAD9;ABHD2;CYP4Z1;CYP4A22;CRAT;OLAH;ABHD1;OXSM;CROT
prerank,GO_Biological_Process_2021__lymphocyte proliferation (GO:0046651),-0.26786863566515495,-0.4868854138549889,0.7155172413793104,0.9111484124200286,1.0,6/22,21.66%,CTPS1;HSPD1;MS4A1;RASGRP1;LMBR1L;TNFSF14
prerank,GO_Biological_Process_2021__membrane depolarization (GO:0051899),-0.2845746177491543,-0.4866980083625619,0.6666666666666666,0.9109517092521441,1.0,10/28,20.94%,CACNA1H;SCN5A;CACNB3;ATP5IF1;CHRNB2;SCN1B;SCN9A;ABL1;P2RX7;CHRNA4
prerank,GO_Biological_Process_2021__regulation of protein localization to membrane (GO:1905475),-0.2996602420562053,-0.48639099882695047,0.625,0.9109222500267034,1.0,10/29,27.26%,STX8;GPC6;NECAB2;FYN;PDZK1;ZDHHC7;CRIPT;MMP14;APPL1;ZDHHC2
prerank,Elsevier_Pathway_Collection__Hedgehog Family -> ARRB1/ARRB2 Canonical Signaling,0.2777832158975676,0.48608077923745435,0.7603305785123967,0.894315599141186,1.0,5/16,15.80%,GSK3B;SMO;PDPK1;GLI1;PTCH1
prerank,GO_Biological_Process_2021__protein kinase B signaling (GO:0043491),-0.2656690729691959,-0.4857255563062861,0.7027027027027027,0.9112413299656752,1.0,5/24,9.78%,TNF;SIRT2;IGF1;PIK3R3;ZFP36L1
prerank,WikiPathway_2021_Human__Regucalcin in proximal tubule epithelial kidney cells WP4838,-0.28710386606885696,-0.48566579771198637,0.6209677419354839,0.9109420661305161,1.0,14/30,28.93%,MCU;TNFRSF1A;PIK3CA;PDE1B;MAP3K5;RAF1;SMAD2;PPP3R1;BAK1;BRAF;SEC16B;AKT1;ACTA2;CASP3
prerank,TRRUST_Transcription_Factors_2019__MYB mouse,0.2861050897569094,0.48561615554204335,0.703125,0.8943160970797149,1.0,6/15,22.50%,IGFBP5;PPM1A;CSF3R;NOL3;CDKN1A;ANPEP
prerank,GO_Biological_Process_2021__negative regulation of phagocytosis (GO:0050765),-0.24768930983573006,-0.48516045370579436,0.7983870967741935,0.9110137496165422,1.0,8/16,36.47%,PLSCR1;HMGB1;APPL1;SNX3;PRTN3;CD47;RACK1;FCGR2B
prerank,Reactome_2022__Synthesis Of PC R-HSA-1483191,0.29681078960528,0.48508765127786174,0.6461538461538462,0.8943345099285808,1.0,7/27,10.53%,CHKB;PHOSPHO1;BCHE;CHPT1;CHKA;STARD7;SLC44A5
prerank,GO_Biological_Process_2021__stem cell differentiation (GO:0048863),-0.287618439805568,-0.48507844727979305,0.6363636363636364,0.9107613220469657,1.0,15/37,25.61%,EPCAM;HMGA2;ZNF281;BATF;EPOP;PSMD11;LRP6;SFRP1;KIT;WNT7A;LMBR1L;OSR1;TP53;MEOX1;MLLT3
prerank,Reactome_2022__Response Of Mtb To Phagocytosis R-HSA-9637690,-0.28475771863607946,-0.48489392701784356,0.6486486486486487,0.9105940783992221,1.0,9/21,23.67%,GSK3A;MAPK3;RAB5A;RPS27A;TRIM27;CORO1A;CTSG;KPNA1;UBC
prerank,GO_Biological_Process_2021__regulation of ryanodine-sensitive calcium-release channel activity (GO:0060314),0.3231096328593412,0.48450788047580207,0.6776859504132231,0.8943942373393412,1.0,15/24,38.47%,HRC;CLIC2;SRI;NOS1;FKBP1A;SELENON;PRKACA;JPH4;FKBP1B;GSTO1;CALM1;PDE4D;DMD;CASQ2;GSTM2
prerank,Elsevier_Pathway_Collection__AHR in Intestinal Cell Antimicrobial Barrier Maintenance,0.2653352774735962,0.4835509231398442,0.6916666666666667,0.8947486203295758,1.0,8/16,35.60%,S100A9;LCN2;BCL2L1;IL7R;S100A8;AHR;BCL2;IL22RA1
prerank,GO_Biological_Process_2021__DNA alkylation (GO:0006305),-0.2954260157065963,-0.48331242563552457,0.6717557251908397,0.911397688003721,1.0,6/19,23.64%,DNMT3B;SPOCD1;BAZ2A;KMT2E;DNMT3A;GATAD2A
prerank,GO_Biological_Process_2021__DNA methylation or demethylation (GO:0044728),-0.2954260157065963,-0.48331242563552457,0.6717557251908397,0.911397688003721,1.0,6/19,23.64%,DNMT3B;SPOCD1;BAZ2A;KMT2E;DNMT3A;GATAD2A
prerank,Elsevier_Pathway_Collection__Postsynaptic Neuron Activation,0.3014078637423161,0.48297777594754576,0.6544117647058824,0.8948577117473143,1.0,11/25,30.01%,GRIA1;MAPK1;PDPK1;TRPV1;NOS1;DLG4;NOS1AP;CASK;CREB1;KCNMA1;NFKBIA
prerank,GO_Biological_Process_2021__positive regulation of transcription from RNA polymerase II promoter in response to stress (GO:0036003),-0.2862667435245643,-0.4826903681016265,0.71900826446281,0.9116004117834521,1.0,12/24,35.41%,ATF3;CREB3L1;NFE2L2;TP53;HSPA5;DDIT3;MT3;GCN1;VEGFA;NOTCH1;MUC1;SESN2
prerank,GO_Biological_Process_2021__mitochondrial calcium ion transmembrane transport (GO:0006851),-0.29573833870094846,-0.48237446140174084,0.712,0.9115579977365577,1.0,9/21,23.43%,MCU;LETM1;PMPCA;PARL;YME1L1;SLC8A3;SPG7;MICU1;AFG3L2
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Cataract,-0.25645030907775734,-0.4821909691041305,0.8407079646017699,0.9113811654550513,1.0,6/16,23.63%,SLC16A12;CRYBB3;BFSP1;CRYAB;MAF;CRYBB2
prerank,Reactome_2022__Listeria Monocytogenes Entry Into Host Cells R-HSA-8876384,-0.24334175439053435,-0.48201684770882985,0.7583333333333333,0.9111884669967637,1.0,6/19,23.67%,RNMT;EPS15;RPS27A;GRB2;SH3GL2;UBC
prerank,GO_Biological_Process_2021__histone H4-K16 acetylation (GO:0043984),0.2509337800560666,0.48201270928313583,0.7109375,0.8952790985631532,1.0,12/19,34.34%,PHF20;MSL3;KMT2A;KANSL1;JADE3;OGT;KANSL2;MCRS1;JADE1;JADE2;MEAF6;HCFC1
prerank,GO_Biological_Process_2021__aerobic respiration (GO:0009060),0.2959021787687293,0.48193617971689884,0.6717557251908397,0.8950137553243345,1.0,4/21,7.38%,UQCRHL;UQCRC1;NDUFS8;ME3
prerank,GO_Biological_Process_2021__histone ubiquitination (GO:0016574),0.26356578222744154,0.4812972027211205,0.6923076923076923,0.8951240072030182,1.0,6/20,19.13%,RAG1;WAC;CDC73;UBE2A;RNF20;PHC1
prerank,GO_Biological_Process_2021__establishment of skin barrier (GO:0061436),-0.2612696172946619,-0.4811712149326478,0.7478991596638656,0.9112511666780688,1.0,5/18,16.57%,FLG2;HRNR;ABCA12;CLDN1;UGCG
prerank,GO_Biological_Process_2021__regulation of water loss via skin (GO:0033561),-0.2612696172946619,-0.4811712149326478,0.7478991596638656,0.9112511666780688,1.0,5/18,16.57%,FLG2;HRNR;ABCA12;CLDN1;UGCG
prerank,GO_Biological_Process_2021__mitochondrial ATP synthesis coupled proton transport (GO:0042776),-0.259645873039947,-0.48109078287661544,0.7631578947368421,0.9109660412630413,1.0,10/17,35.65%,ATP5ME;ATP5MF;ATP5F1E;ATP5PB;DMAC2L;ATP5F1D;ATP5MG;ATP5PD;ATP5PF;ATP5F1A
prerank,GO_Biological_Process_2021__positive regulation of mRNA processing (GO:0050685),0.26270230141953277,0.480936432004006,0.676923076923077,0.8950664775382244,1.0,5/21,18.72%,THRAP3;NCBP2;CDC73;CELF4;RBMX
prerank,GO_Biological_Process_2021__oligodendrocyte differentiation (GO:0048709),-0.2981808324052303,-0.4804685737094646,0.6869565217391305,0.9111763800345658,1.0,6/20,17.37%,HES5;SOX8;PRDM8;MYRF;SLC8A3;SOX13
prerank,GO_Biological_Process_2021__regulation of transport (GO:0051049),-0.3327832647444432,-0.48045396463524265,0.6916666666666667,0.910848379829182,1.0,16/35,28.69%,ICA1;REEP6;SNCA;DISP3;USP6;CLDN3;SCFD1;RAB25;PINK1;CLDN10;EPB41;WWC1;ARL6IP5;MUL1;TMEM102;TRAT1
prerank,GO_Biological_Process_2021__response to glucagon (GO:0033762),0.26532515498013953,0.4804188469956732,0.7142857142857143,0.895167011749938,1.0,12/20,35.27%,PRKAR2B;CRY1;PRKACA;GCGR;GCG;ADCY2;CREB1;ADCY4;ADCY7;PRKAR1A;PRKAR1B;ADCY1
prerank,GO_Biological_Process_2021__positive regulation of histone modification (GO:0031058),-0.2992341110268653,-0.4802798990642138,0.6111111111111112,0.9106387586376133,1.0,16/32,31.40%,MAPK3;ARRB1;APLNR;RPS6KA4;TADA2A;PAXIP1;SART3;ZBTB7B;CHTOP;PAF1;UBE2N;GLYR1;FAM47E;FMR1;TADA2B;AKAP8
prerank,WikiPathway_2021_Human__Kallmann's Syndrome WP5074,-0.23649315759644815,-0.48010708377490946,0.753968253968254,0.9104771686607948,1.0,8/19,29.39%,PIK3CA;MYRF;PROK2;GRB2;MAP2K2;AKT1;GNRH1;FRS2
prerank,GO_Biological_Process_2021__cellular response to interleukin-7 (GO:0098761),0.2822316394974936,0.47927400718294705,0.7142857142857143,0.8953761006087753,1.0,4/19,16.06%,BRWD1;STAT5A;STAT5B;IL7R
prerank,GO_Biological_Process_2021__interleukin-7-mediated signaling pathway (GO:0038111),0.2822316394974936,0.47927400718294705,0.7142857142857143,0.8953761006087753,1.0,4/19,16.06%,BRWD1;STAT5A;STAT5B;IL7R
prerank,GO_Biological_Process_2021__atrioventricular valve morphogenesis (GO:0003181),-0.25116258307404754,-0.47915405646667203,0.773109243697479,0.9110446919886199,1.0,8/19,33.12%,HEY2;SOX4;EFNA1;MDM4;BMP2;BMPR1A;NOTCH1;GATA4
prerank,Reactome_2022__Pyroptosis R-HSA-5620971,-0.2639417034066995,-0.47901386611836677,0.7317073170731707,0.9108320447074248,1.0,7/24,17.03%,CHMP7;IL18;HMGB1;GSDMD;CHMP2B;BAK1;IRF2
prerank,"Reactome_2022__Sensory Perception Of Sweet, Bitter, And Umami (Glutamate) Taste R-HSA-9717207",-0.29156225719344464,-0.47886370617459,0.7280701754385965,0.9106163697424949,1.0,5/20,10.05%,SCN4B;TRPM5;SCN1B;SCN2B;SCN9A
prerank,GO_Biological_Process_2021__negative regulation of phosphate metabolic process (GO:0045936),0.28213339669355136,0.47846388354463487,0.728,0.8956507359124835,1.0,7/22,21.79%,INHA;CDKN1C;ANKLE2;CDKN1A;BMP7;DYNLL1;PLEK
prerank,GO_Biological_Process_2021__negative regulation of interleukin-1 production (GO:0032692),-0.27023417264708743,-0.4776105137045063,0.7480314960629921,0.9114476979313691,1.0,10/25,26.62%,GSTP1;TNFAIP3;IGF1;NLRP3;NLRP12;CPTP;CX3CR1;GHRL;APOA1;FFAR4
prerank,GO_Biological_Process_2021__positive chemotaxis (GO:0050918),0.2644735821436349,0.4772593401931976,0.7777777777777778,0.8961323626223516,1.0,4/17,13.00%,FPR2;PTPRJ;SEMA5A;CX3CL1
prerank,GO_Biological_Process_2021__regulation of protein modification by small protein conjugation or removal (GO:1903320),0.2912358341424384,0.47700561343025766,0.746031746031746,0.8960060121226125,1.0,11/20,35.54%,DCUN1D2;DAXX;UBQLN1;HIF1A;DCUN1D3;HSPA1B;WASHC1;EPAS1;PRKN;ZMIZ1;HSP90AB1
prerank,Elsevier_Pathway_Collection__GDNF -> HSF1 Signaling,-0.2794520777003926,-0.47698056667695476,0.6728971962616822,0.9116412941566537,1.0,11/29,19.32%,MAP3K1;MAPK3;CDC42;MAP2K4;GDNF;RAF1;GRB2;SHC1;RASGRP1;RET;MAP2K2
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882),0.2821527767686314,0.4767615981756822,0.674074074074074,0.8958578148734817,1.0,6/21,17.08%,CACNA1C;HRC;CLIC2;ATP2A2;SLC9A1;PRKACA
prerank,GO_Biological_Process_2021__porphyrin-containing compound biosynthetic process (GO:0006779),0.29767597911475846,0.4765708093605804,0.6811594202898551,0.8956864239117199,1.0,11/24,26.58%,ALAS1;COX15;ALAS2;HMBS;NFE2L1;FXN;CPOX;ABCB6;COX10;FECH;TSPO
prerank,WikiPathway_2021_Human__Matrix Metalloproteinases WP129,-0.2886840872562309,-0.4761652775338468,0.6379310344827587,0.9121054127827998,1.0,10/26,24.21%,TNF;MMP9;TCF20;TIMP2;MMP21;MMP15;MMP3;TIMP1;MMP14;MMP8
prerank,GO_Biological_Process_2021__cellular monovalent inorganic cation homeostasis (GO:0030004),-0.25243813859063824,-0.47582196205710375,0.7479674796747967,0.9121028532181036,1.0,6/18,18.74%,ATP1B1;ATP1A1;SLC8A1;ATP6AP1;LACC1;NEDD4L
prerank,Elsevier_Pathway_Collection__SCF/FBXW7 Complex,0.2739524432376344,0.4756261508403175,0.75,0.8960248479261392,1.0,6/20,20.03%,JUN;AURKA;TRIM17;CSF3R;MTOR;CCNE1
prerank,Elsevier_Pathway_Collection__SELE -> ELK-SRF Signaling,0.2708753517422664,0.4756126103388873,0.72,0.8957138167768031,1.0,4/17,7.16%,ELK1;MAPK1;SELE;SRF
prerank,"Elsevier_Pathway_Collection__Oxidative Stress, All-Trans-Retinal and Lipofuscin Toxicity in AMD",-0.238793920742271,-0.47542879763223755,0.7589285714285714,0.912095522674971,1.0,8/18,29.76%,CHRM3;ABCA4;GCLM;NFE2L2;GNAQ;ITPR1;ALOX15;VEGFA
prerank,GO_Biological_Process_2021__mitochondrion localization (GO:0051646),-0.2648531821436938,-0.4752834777457816,0.743801652892562,0.9119100762289022,1.0,9/18,33.40%,MARK1;NECTIN2;ALB;MSTO1;MUL1;MFN1;MARK2;ZBED3;TRAK2
prerank,GO_Biological_Process_2021__activin receptor signaling pathway (GO:0032924),0.25631468078486214,0.4752027732930698,0.7569444444444444,0.8956987462541136,1.0,6/17,27.93%,GDF7;ACVR1C;SMAD3;ACVR2B;GDF2;GDF6
prerank,GO_Biological_Process_2021__positive regulation of RNA splicing (GO:0033120),0.3116817648985702,0.4747361100635691,0.6984126984126984,0.8957042164320749,1.0,9/29,18.72%,THRAP3;SLC38A2;POLR2A;U2AF2;RBM22;CELF4;HNRNPLL;DYRK1A;RBMX
prerank,KEGG_2021_Human__Asthma,-0.2520873709484545,-0.474196675494999,0.646551724137931,0.912605502915412,1.0,5/23,12.79%,TNF;HLA-DQB1;HLA-DQA1;CCL11;FCER1A
prerank,Reactome_2022__VLDLR Internalisation And Degradation R-HSA-8866427,0.2601798594014698,0.4735365171891489,0.7737226277372263,0.8962815743925797,1.0,5/16,18.84%,AP2B1;UBB;AP2M1;UBA52;AP2S1
prerank,Reactome_2022__Interleukin-7 Signaling R-HSA-1266695,0.28874114234447656,0.47352875030819297,0.6825396825396826,0.8959654283864152,1.0,4/23,8.03%,BRWD1;RAG1;STAT5A;STAT5B
prerank,GO_Biological_Process_2021__cytosolic calcium ion transport (GO:0060401),-0.2852437037219049,-0.47296144101958637,0.6875,0.9133878117373379,1.0,12/28,25.83%,CACNB3;MCU;SLC8A1;ATP2A3;ATP2B3;JPH3;CACNA2D1;ATP2B1;MICU1;AFG3L2;ADRA1A;JPH2
prerank,WikiPathway_2021_Human__Differentiation of white and brown adipocyte WP2895,0.2889103627226869,0.4728662473220434,0.675,0.8960911081016864,1.0,8/23,21.22%,CEBPA;EBF3;PPARGC1B;ZNF423;PPARG;CIDEA;SMAD5;BMP7
prerank,GO_Biological_Process_2021__hyaluronan catabolic process (GO:0030214),0.2667800107690722,0.47282737329776525,0.7109375,0.8957943919474142,1.0,5/17,24.19%,FGF2;HEXB;SLC9A1;HEXA;HYAL2
prerank,GO_Biological_Process_2021__cellular response to dsRNA (GO:0071359),-0.25024010916441536,-0.4726856605877187,0.7868852459016393,0.9132894607280422,1.0,11/17,37.20%,IFIH1;NPM1;DHX9;RALB;PQBP1;MUL1;IFIT1;STING1;FLOT1;COLEC12;ZCCHC3
prerank,Elsevier_Pathway_Collection__Coagulation Factors and PAR1/2 Receptors (F2R/F2RL1) in Endometriosis,-0.2906755684844035,-0.4725896216968456,0.625,0.9130498531728979,1.0,13/32,26.50%,TNF;MAPK3;PTGS2;RAF1;F2;RASGRP1;F2R;CXCL8;MAP2K2;GNAQ;ITPR1;PLCB1;AKT1
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Early Diabetic Nephropathy,-0.2666891864142804,-0.47230247921449814,0.6904761904761905,0.9130056739095275,1.0,4/24,3.14%,VCAM1;MAP3K1;MAPK3;CDC42
prerank,Elsevier_Pathway_Collection__ActivinR -> SMAD2/3 Signaling,0.29412642581385506,0.47213182830138734,0.7021276595744681,0.8959992818864179,1.0,11/22,27.88%,INHA;SMAD7;ACVR1C;SMAD3;ACVR2B;BMP7;BMP6;SMAD4;MSTN;GDF5;INHBC
prerank,GO_Biological_Process_2021__positive regulation of interleukin-4 production (GO:0032753),0.28034158839871054,0.4720703752830468,0.6991869918699187,0.8957328577258784,1.0,9/18,37.11%,SLC7A5;PRKCQ;CD40LG;CD86;ZP3;SYK;FCER1G;LGALS9;GATA3
prerank,Elsevier_Pathway_Collection__InsulinR -> ELK/SRF/SREBF Signaling,0.28934440406200324,0.47193810201793696,0.6528925619834711,0.8954884685839136,1.0,6/20,11.68%,GSK3B;ELK1;MAPK1;SRF;PDPK1;SREBF1
prerank,GO_Biological_Process_2021__regulation of lymphocyte activation (GO:0051249),0.2571945491511686,0.4717533900891354,0.782258064516129,0.8952879261822996,1.0,5/15,19.67%,IKZF3;CRTAM;FCRL3;THEMIS2;LAT
prerank,Reactome_2022__Spry Regulation Of FGF Signaling R-HSA-1295596,0.25308710559311653,0.47165559495280507,0.7622950819672131,0.8950452368934205,1.0,5/16,18.53%,MAPK1;UBB;PPP2CB;MKNK1;UBA52
prerank,GO_Biological_Process_2021__negative regulation of viral life cycle (GO:1903901),-0.25949297981371583,-0.47156511640571935,0.7288135593220338,0.9133613990066387,1.0,8/19,35.46%,TRIM31;IFITM3;IFITM2;TRIM11;IFITM1;SNX3;CIITA;APCS
prerank,GO_Biological_Process_2021__proteasomal ubiquitin-independent protein catabolic process (GO:0010499),-0.26846482798178406,-0.47147272403361296,0.7076923076923077,0.9131029996559263,1.0,9/20,30.41%,PSMB7;PSMA5;PSMB8;PSMA1;NFE2L2;PSMB3;PSMB2;PSMB10;PSMA7
prerank,GO_Biological_Process_2021__regulation of protein sumoylation (GO:0033233),-0.2544312607539067,-0.4713846679193219,0.7293233082706767,0.9128447940078755,1.0,7/16,31.68%,RWDD3;RASD2;UBA2;GNL3;HDAC4;MUL1;PIAS4
prerank,GO_Biological_Process_2021__negative regulation of osteoclast differentiation (GO:0045671),0.2799199007150587,0.4712651706413131,0.7099236641221374,0.8949991002126702,1.0,3/18,9.99%,TCTA;TLR3;FSTL3
prerank,MSigDB_Oncogenic_Signatures__SINGH KRAS DEPENDENCY SIGNATURE ,-0.23664111856777287,-0.4701781073325059,0.7819548872180451,0.9136962867222825,1.0,4/16,17.49%,LAMC2;FAM83A;TGFA;SH2D3A
prerank,TRRUST_Transcription_Factors_2019__SREBF1 human,0.31474986329436244,0.46944428420752277,0.6893939393939394,0.8960504110342365,1.0,10/26,25.66%,CAV1;APOA5;FASN;HMOX1;BCL2L1;PPARG;CIC;HK2;PCK1;FDFT1
prerank,WikiPathway_2021_Human__Physiological and pathological hypertrophy of the heart WP1528,0.28921634847296496,0.4694063626183517,0.656934306569343,0.8957518363030837,1.0,8/25,20.26%,MAPK11;JUN;MAPK1;AGT;CTF1;PPP3CB;RHOA;PRKCB
prerank,GO_Biological_Process_2021__positive regulation of heart contraction (GO:0045823),0.25192670180320376,0.4693988394713344,0.7669172932330827,0.8954330418761675,1.0,5/17,15.49%,APELA;HRC;TRPM4;ATP2A2;EDN2
prerank,GO_Biological_Process_2021__ribosomal large subunit assembly (GO:0000027),-0.27332771797925554,-0.468848878446684,0.6491228070175439,0.9146247778677153,1.0,6/24,10.40%,TRAF7;NOP2;BOP1;RPL3L;MDN1;RPL3
prerank,Elsevier_Pathway_Collection__EGFR/ERBB -> STAT Signaling,0.2746327490265918,0.46850078811914664,0.75,0.8958334961748643,1.0,7/20,17.16%,STAT5A;HBEGF;STAT5B;ERBB2;EGF;JAK2;STAT1
prerank,GO_Biological_Process_2021__blood vessel endothelial cell migration (GO:0043534),0.28349833208316294,0.4684780741912313,0.6690140845070423,0.8955244301909836,1.0,10/23,30.24%,SRF;FGF2;CDH5;MIA3;KDR;ADTRP;EGR3;SLIT2;GREM1;GPLD1
prerank,GO_Biological_Process_2021__snRNA 3'-end processing (GO:0034472),0.248283536130006,0.46843127539971285,0.7368421052631579,0.8952373586980614,1.0,5/20,16.36%,EXOSC9;EXOSC6;INTS5;USB1;EXOSC3
prerank,Reactome_2022__Regulation Of Ornithine Decarboxylase (ODC) R-HSA-350562,-0.3264808679469473,-0.4681043716656926,0.7522123893805309,0.914976063243135,1.0,17/48,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;PSMD11;PSMD10;OAZ2;PSMD13;PSMC1;PSME1;PSMA1;OAZ1;PSMD5;PSMD12;PSMB3
prerank,WikiPathway_2021_Human__Nanomaterial induced apoptosis WP2507,0.27523128810634234,0.4680269403955096,0.6796875,0.8952470418648767,1.0,6/20,17.48%,FASLG;CYCS;CASP9;CFLAR;HTRA2;ENDOG
prerank,WikiPathway_2021_Human__Imatinib and Chronic Myeloid Leukemia WP3640,-0.2957809002428803,-0.4678358214684078,0.725,0.9148901149196014,1.0,6/20,18.39%,PIM1;NOP2;PIM2;CSF1R;KIT;ABL1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hirschsprung Disease,-0.2561677279445469,-0.4675829257180087,0.75,0.9147852392834899,1.0,7/20,24.58%,GSTP1;GDNF;ITGB1;ECE1;RET;ARNT2;DCX
prerank,Reactome_2022__Depolymerisation Of Nuclear Lamina R-HSA-4419969,0.24045585093396354,0.46731684946330004,0.8174603174603174,0.89548924877331,1.0,5/15,20.26%,LMNA;CNEP1R1;CTDNEP1;CCNB1;PRKCB
prerank,Elsevier_Pathway_Collection__Telogen Maintenance in Androgenic Alopecia,0.2655021925710701,0.4670441913356002,0.7459016393442623,0.8953955248315437,1.0,11/22,36.27%,CD34;DLL1;NOG;WNT10B;CTNNB1;CREB1;CD200;FGF18;ITGA6;SMAD1;SFRP4
prerank,GO_Biological_Process_2021__cellular response to catecholamine stimulus (GO:0071870),-0.2860619824309992,-0.4665758618508959,0.6417910447761194,0.9154065999310093,1.0,5/22,9.44%,MAPK3;SIRT2;PDE4B;KCNQ1;SNCA
prerank,GO_Biological_Process_2021__regulation of lymphocyte proliferation (GO:0050670),0.2512725100489743,0.46653336283157776,0.7272727272727273,0.8954744425628723,1.0,4/18,10.07%,IL12B;TNFRSF1B;IKZF3;TNFSF18
prerank,GO_Biological_Process_2021__positive regulation of cell cycle G2/M phase transition (GO:1902751),-0.251907361233409,-0.46585012189200276,0.6923076923076923,0.9157317645209629,1.0,5/22,11.45%,FBXO5;NPM1;CDK4;RAD51C;DBF4B
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> NF-kB Signaling,-0.25720616705152843,-0.46548285804376,0.7317073170731707,0.9156899263740886,1.0,9/19,35.20%,BTK;CD22;BCL10;PTPN6;CARD11;ITPR1;CD19;CD79A;TRAF6
prerank,Elsevier_Pathway_Collection__Transcription Factors in beta-Cell Neogenesis (Rodent Model),-0.2495249311073242,-0.46531964396674763,0.8503937007874016,0.9155295992120843,1.0,7/15,34.02%,GATA6;ONECUT1;NEUROD1;HES1;MYT1;NOTCH1;HNF1B
prerank,"Elsevier_Pathway_Collection__Myocarditis, Acute Viral Overiew",0.26579863374124457,0.46467034351047914,0.7559055118110236,0.8965435544054661,1.0,5/20,15.34%,GSK3B;CAV1;PDPK1;CD55;CCND1
prerank,GO_Biological_Process_2021__ureteric bud morphogenesis (GO:0060675),0.2340409599815006,0.4643649021736532,0.8347107438016529,0.8964522696154376,1.0,3/16,9.29%,WNT11;FGF2;PAX2
prerank,Reactome_2022__Processing Of Intronless Pre-mRNAs R-HSA-77595,0.27242899091872635,0.4640890419284582,0.646551724137931,0.8963447613604923,1.0,6/20,23.08%,NCBP2;CSTF3;SYMPK;CPSF1;CSTF2T;FIP1L1
prerank,WikiPathway_2021_Human__Follicle Stimulating Hormone (FSH) signaling pathway WP2035,-0.2748310822167663,-0.46405989203140846,0.6984126984126984,0.9164467336884954,1.0,13/24,34.17%,SGK1;MAPK3;RHEB;RPS6KB1;RAF1;MAPK14;CGA;APPL1;AKT1;AREG;BDNF;CYP19A1;TSC2
prerank,WikiPathway_2021_Human__Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,-0.24539601720543436,-0.46318679154241016,0.7767857142857143,0.9169778853852532,1.0,7/19,24.70%,MAPK3;ELK4;RAF1;RASGRP1;MAP2K2;GNAQ;ITPR1
prerank,GO_Biological_Process_2021__cellular response to epidermal growth factor stimulus (GO:0071364),0.2859611450859662,0.46309467686753736,0.6846153846153846,0.8968140173657697,1.0,8/28,12.84%,KNSTRN;SYAP1;PDE8A;STAT5B;PDPK1;ERBB2;ZFP36L2;MARS1
prerank,GO_Biological_Process_2021__cellular response to unfolded protein (GO:0034620),-0.2578304534924225,-0.46239822217213494,0.717741935483871,0.9174123521182688,1.0,11/27,26.53%,HSPA6;HSPD1;PTPN1;HSPA14;ERN1;BAK1;DAB2IP;PACRG;HSPA5;TM7SF3;HSPA1L
prerank,WikiPathway_2021_Human__Canonical and non-canonical TGF-B signaling WP3874,0.29559514215582183,0.4623014385172992,0.7578125,0.8971120282046339,1.0,8/17,30.11%,LOXL4;BMP1;LOX;SMAD3;TGFBR2;SMAD4;GREM1;MAPK8
prerank,GO_Biological_Process_2021__positive regulation of protein autophosphorylation (GO:0031954),-0.2343198991391683,-0.461360035106529,0.7580645161290323,0.9181068503171879,1.0,9/22,36.92%,TOM1L1;MRE11;CALM2;VEGFA;PDGFA;TAOK2;CALM3;RAP2A;ACE
prerank,Reactome_2022__SCF-beta-TrCP Mediated Degradation Of Emi1 R-HSA-174113,-0.3371964787864752,-0.4611356564143587,0.8275862068965517,0.917968003424471,1.0,19/52,20.00%,PSMB7;PSMD7;FBXO5;PSMF1;CDC20;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__histone H2A acetylation (GO:0043968),0.2521417828281845,0.46112781881076037,0.8174603174603174,0.897732540281493,1.0,8/16,34.55%,MORF4L2;YEATS4;DMAP1;MSL3;RUVBL1;TRRAP;MEAF6;BRD8
prerank,"Reactome_2022__Incretin Synthesis, Secretion, And Inactivation R-HSA-400508",-0.27271819524137564,-0.46104564608784865,0.7786259541984732,0.9177015443895272,1.0,4/18,8.31%,SEC11A;SPCS2;TCF7L2;SEC11C
prerank,GO_Biological_Process_2021__positive regulation of DNA replication (GO:0045740),0.26355549327680633,0.4609823718269663,0.7375886524822695,0.8975298463338143,1.0,6/17,17.12%,NPM2;PCNA;EGF;DNA2;GLI1;BCAR3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Antiphospholipid Syndrome,-0.25428224781076914,-0.460437974473555,0.6916666666666667,0.9179585653368376,1.0,6/18,22.63%,TNF;F2;EDN1;MAPK14;ANXA2;TICAM1
prerank,Reactome_2022__Recycling Pathway Of L1 R-HSA-437239,0.2868967117440039,0.46005575881656635,0.6842105263157895,0.8979167106945255,1.0,12/27,31.66%,AP2B1;MAPK1;SHTN1;DNM1;RPS6KA6;AP2M1;AP2S1;EZR;CLTC;RPS6KA3;DNM3;SRC
prerank,GO_Biological_Process_2021__regulation of protein processing (GO:0070613),-0.22602700027376968,-0.4598109404879291,0.8508771929824561,0.918232726015126,1.0,6/20,26.57%,ANGPTL8;NKD2;SERPINE2;CHAC1;PRNP;GAS1
prerank,Reactome_2022__VEGFR2 Mediated Cell Proliferation R-HSA-5218921,0.255069696541983,0.45942031765396585,0.7361111111111112,0.8980838715131968,1.0,8/18,35.85%,PDPK1;KDR;PRKCB;SPHK1;HRAS;SRC;ITPR3;CALM1
prerank,WikiPathway_2021_Human__16p11.2 distal deletion syndrome WP4950,0.3011807918843594,0.4592035364263947,0.6861313868613139,0.8979327214278037,1.0,12/29,24.14%,SH2B1;NFATC2;CD81;TRAF2;KDR;JAK2;RAB4A;LAT;ATXN2L;CD82;CR2;RABGEF1
prerank,GO_Biological_Process_2021__regulation of oligodendrocyte differentiation (GO:0048713),-0.24967216520901792,-0.4589002839448653,0.7596899224806202,0.9188090778063418,1.0,6/17,24.78%,HES5;DAAM2;TENM4;SLC45A3;ZNF365;HES1
prerank,GO_Biological_Process_2021__positive regulation of cell cycle phase transition (GO:1901989),0.2771111437531556,0.4588735365804225,0.7741935483870968,0.8978574764999632,1.0,5/16,15.57%,EZH2;CDC73;PAGR1;FAM83D;GLI1
prerank,GO_Biological_Process_2021__ribosomal large subunit biogenesis (GO:0042273),-0.3422269018047141,-0.45837712821732346,0.8571428571428571,0.9189819569870294,1.0,26/56,25.67%,PES1;TRAF7;RPL7A;NOP2;NPM1;RPL7;BOP1;RPL3L;RPL26L1;MDN1;RPL3;RPL14;NOC2L;NSA2;NHP2;RSL1D1;SNU13;SURF6;ZNF622;EIF6;BRIX1;RPLP0;RSL24D1;MAK16;MRTO4;PAK1IP1
prerank,Elsevier_Pathway_Collection__Microangiopathy in Diabetic Neuropathy,-0.25573288239172975,-0.45836711629281496,0.7372881355932204,0.9186432214253508,1.0,11/23,32.21%,VCAM1;MAP3K1;MAPK3;RAF1;EDN1;SLC2A1;MAP2K2;AGER;AKT1;VEGFA;TGFB1
prerank,GO_Biological_Process_2021__positive regulation of T cell cytokine production (GO:0002726),0.2561848709644799,0.4581564431508873,0.7130434782608696,0.8981164864775761,1.0,6/20,18.17%,CD81;TRAF2;DENND1B;CD55;B2M;FZD5
prerank,WikiPathway_2021_Human__Glucuronidation WP698,0.2812344387581656,0.4580367312811113,0.7307692307692307,0.897874864894555,1.0,9/23,22.76%,UGT1A5;UGT2B11;UGT1A4;UGT2A3;PGM3;UGT2B15;UGT2B4;UGT2B17;UGT2B10
prerank,GO_Biological_Process_2021__keratinocyte differentiation (GO:0030216),-0.3080728119225367,-0.4577750345264164,0.7107438016528925,0.9188695231201058,1.0,9/29,18.81%,ST14;WNT5A;AKR1C3;ANXA1;ADAM9;TGM3;ACER1;UGCG;CSTA
prerank,GO_Biological_Process_2021__fatty acid beta-oxidation using acyl-CoA oxidase (GO:0033540),0.2557914250772802,0.45766382746431533,0.8110236220472441,0.8978686769477037,1.0,2/15,3.62%,HSD17B4;ACOX3
prerank,Reactome_2022__Diseases Associated With Glycosylation Precursor Biosynthesis R-HSA-5609975,-0.2447268387413831,-0.4575929269538987,0.8074074074074075,0.9187135066670801,1.0,3/15,11.02%,DPM2;SRD5A3;PMM2
prerank,Reactome_2022__PKA-mediated Phosphorylation Of CREB R-HSA-111931,0.24577641991271573,0.4574678648669553,0.7560975609756098,0.8977057082767969,1.0,10/18,35.85%,PRKX;PRKAR2B;ADCY2;CREB1;ADCY4;ADCY7;PRKAR1A;PRKAR1B;ADCY1;CALM1
prerank,Elsevier_Pathway_Collection__AHR Signaling in M1 Macrophages Function,0.272572221164022,0.45742025944972137,0.7054263565891473,0.8974239575372193,1.0,11/22,32.41%,IL12B;JAK2;STAT1;ITGB7;IFNGR1;IFNGR2;MYD88;NFKBIA;IKBKG;AHR;HDC
prerank,GO_Biological_Process_2021__positive regulation of protein targeting to membrane (GO:0090314),-0.2250557958464967,-0.45699750657449806,0.7441860465116279,0.9189396140516788,1.0,9/24,26.24%,TCAF1;TCAF2;ITGAM;FIS1;FYN;PDZK1;MTCL1;MIEF2;PRNP
prerank,GO_Biological_Process_2021__cardiac atrium morphogenesis (GO:0003209),-0.21510578237700817,-0.4565220026839767,0.9292035398230089,0.9190948375296476,1.0,7/17,33.12%,HEY2;DLL4;ENG;SHOX2;BMP2;NOTCH1;GATA4
prerank,Reactome_2022__Chondroitin Sulfate Biosynthesis R-HSA-2022870,-0.2585541686029878,-0.4558850533566659,0.7596899224806202,0.9193771871214023,1.0,8/20,25.05%,NCAN;VCAN;CSGALNACT1;CHST13;CSPG5;CSPG4;CHST3;CHST15
prerank,Reactome_2022__PKA Activation R-HSA-163615,-0.22533774086301617,-0.4551051388365985,0.8359375,0.9197535449969926,1.0,3/16,13.96%,ADCY8;PRKAR2A;ADCY5
prerank,Elsevier_Pathway_Collection__IL17F Signaling in Bronchial Epithelial Cell in Asthma,-0.2530532191275945,-0.4550064722523532,0.7007299270072993,0.919519004195367,1.0,6/20,19.77%,MAPK3;IL17RC;IGF1;RAF1;MAP2K2;IL33
prerank,Elsevier_Pathway_Collection__APC/C-FZR1 Complex,-0.2470821027817526,-0.4549123176672089,0.7410714285714286,0.9192595312513253,1.0,6/23,15.50%,CDC20;ANAPC16;CDC26;CDC23;ANAPC5;ANAPC13
prerank,GO_Biological_Process_2021__peptidyl-lysine trimethylation (GO:0018023),0.27877014091654634,0.4547938374189091,0.6875,0.8992345393523619,1.0,10/28,27.58%,KMT5C;ATPSCKMT;TET3;PRDM7;SETD1B;KMT2A;SMYD5;OGT;KMT5B;ANTKMT
prerank,WikiPathway_2021_Human__LTF danger signal response pathway WP4478,-0.23546871079821113,-0.4545024278531393,0.8547008547008547,0.9192998440740509,1.0,8/16,35.20%,TNF;IRAK1;LTF;CXCL8;AGER;TLR4;TREM1;TRAF6
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Ion Channels,0.2260632898857268,0.4544752624861474,0.8307692307692308,0.8991806211409518,1.0,3/16,10.24%,TRPC1;GNAI1;TRPV1
prerank,Reactome_2022__RA Biosynthesis Pathway R-HSA-5365859,-0.2640260148004619,-0.45424602084069754,0.7194244604316546,0.9191943057847699,1.0,5/20,16.39%,CYP26A1;CYP26C1;AKR1C3;ALDH1A1;ADH7
prerank,KEGG_2021_Human__Intestinal immune network for IgA production,0.31644641940889323,0.4535261788768331,0.7430555555555556,0.8996733589845242,1.0,14/42,22.00%,TNFRSF17;HLA-DMB;CCL28;CXCR4;PIGR;HLA-DQA2;CD40LG;ITGB7;IL15;IL5;TNFSF13B;CD86;HLA-DOA;MADCAM1
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA duplex unwinding (GO:0000717)",0.2586383080085144,0.4531399941784654,0.7205882352941176,0.8996651956918262,1.0,5/22,11.08%,DDB1;GTF2H5;UBB;ERCC3;DDB2
prerank,GO_Biological_Process_2021__positive regulation of vasoconstriction (GO:0045907),0.24203060154405792,0.4530595196779617,0.8099173553719008,0.8994061773797739,1.0,4/15,12.08%,CAV1;AVPR1A;TRPM4;FGA
prerank,Reactome_2022__Butyrate Response Factor 1 Binds And Destabilizes mRNA R-HSA-450385,0.263973781904954,0.4529745137102105,0.753968253968254,0.8991513877998693,1.0,6/17,22.77%,EXOSC9;EXOSC6;DIS3;EXOSC3;XRN1;MAPKAPK2
prerank,TRRUST_Transcription_Factors_2019__PAX3 mouse,0.2630920489458856,0.4527543035808062,0.7175572519083969,0.899027511529806,1.0,8/15,34.26%,POU3F2;DCT;MSX2;TYRP1;FGFR4;WNT1;MBP;ITM2A
prerank,GO_Biological_Process_2021__insulin secretion (GO:0030073),-0.2470009456783995,-0.4527374763559836,0.8308823529411765,0.9203443244936395,1.0,6/18,22.71%,ANXA1;SNX19;PTPRN2;RAB11B;NEUROD1;GAL
prerank,Reactome_2022__PKA Activation In Glucagon Signaling R-HSA-164378,-0.2294002802039361,-0.45142388771725767,0.8837209302325582,0.9213007738618112,1.0,3/15,13.96%,ADCY8;PRKAR2A;ADCY5
prerank,Reactome_2022__Cross-presentation Of Soluble Exogenous Antigens (Endosomes) R-HSA-1236978,-0.30672422973792857,-0.4513382074907409,0.7631578947368421,0.9210270255170581,1.0,15/46,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,"GO_Biological_Process_2021__retrograde protein transport, ER to cytosol (GO:0030970)",-0.26107903687571,-0.45102640666697236,0.7633587786259542,0.920967973711727,1.0,4/17,9.54%,SELENOS;OS9;DERL1;SYVN1
prerank,Reactome_2022__Regulation Of RUNX3 Expression And Activity R-HSA-8941858,-0.32385979816233257,-0.45092947652285553,0.831858407079646,0.9207446332737266,1.0,19/54,20.00%,PSMB7;PSMD7;PSMF1;EP300;SMURF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;MDM2;PSMB3
prerank,Reactome_2022__Formation Of Incision Complex In GG-NER R-HSA-5696395,-0.27663858438103484,-0.4498509455608884,0.6859504132231405,0.9214726685413583,1.0,10/42,12.12%,SUMO1;CDK7;CUL4A;CHD1L;CCNH;RBX1;ERCC1;POLR1B;RPS27A;RPA3
prerank,WikiPathway_2021_Human__Sleep regulation WP3591,-0.2880376083993623,-0.4495276847586714,0.6910569105691057,0.9214275926934273,1.0,11/28,26.34%,NPAS2;STAR;IL18;CHRNB2;ADORA2A;ADORA1;CST3;PER3;GHRL;PTGDS;DLAT
prerank,GO_Biological_Process_2021__pyroptosis (GO:0070269),-0.2322727101429849,-0.4486172638643323,0.8442622950819673,0.922070417412571,1.0,4/19,13.63%,NLRP9;DHX9;ZBP1;GSDMD
prerank,Reactome_2022__Defective CFTR Causes Cystic Fibrosis R-HSA-5678895,-0.3263041633776515,-0.44837118815361754,0.825,0.921982959608858,1.0,21/58,20.00%,PSMB7;RNF185;PSMD7;PSMF1;OS9;CFTR;PSMA5;DERL1;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;RNF5;PSMB3
prerank,Elsevier_Pathway_Collection__GNRH Signaling Impairment in Hypogonadotrophic Hypogonadism,-0.2602685471697248,-0.44743946059393463,0.6747967479674797,0.9225907365231663,1.0,12/30,24.70%,MAP3K1;MAPK3;MAP2K4;GNRHR;ELK4;RAF1;RASGRP1;MAP2K2;CGA;GNAQ;GNRH2;ITPR1
prerank,Reactome_2022__Aggrephagy R-HSA-9646399,0.28197819668645246,0.4472959649927121,0.689922480620155,0.9030856733839363,1.0,9/23,21.43%,ARL13B;HSF1;VCP;UBB;DYNC1LI2;PARK7;UBA52;DYNC1LI1;DYNLL1
prerank,GO_Biological_Process_2021__negative regulation of signal transduction by p53 class mediator (GO:1901797),0.2402677131885111,0.44642437190047773,0.7938931297709924,0.9034803535757098,1.0,4/17,16.64%,KDM1A;RFFL;CD74;DYRK1A
prerank,GO_Biological_Process_2021__prostaglandin biosynthetic process (GO:0001516),0.26870193569000445,0.44605203533057874,0.7404580152671756,0.9034722035028141,1.0,8/18,22.33%,PTGIS;HPGDS;PTGES2;PTGES;CD74;EDN2;PTGES3;PNPLA8
prerank,Elsevier_Pathway_Collection__WNT Planar Cell Polarity (PCP) non-Canonical Signaling,0.26180904294396523,0.44595453587032835,0.7483443708609272,0.9032218072022021,1.0,10/22,30.11%,WNT11;JUN;MAPK10;PRICKLE1;RHOA;MAP2K7;RAC1;WNT4;DVL3;MAPK8
prerank,GO_Biological_Process_2021__positive regulation of isotype switching (GO:0045830),-0.22205840143134167,-0.44566802291036794,0.9007633587786259,0.9240522617851638,1.0,7/15,35.52%,SHLD3;TFRC;PAXIP1;MAD2L2;TGFB1;SHLD2;HMCES
prerank,Elsevier_Pathway_Collection__Myeloid Progenitor Cell -> GEMM - CFU Surface Expression Markers,-0.24006551899642697,-0.4454403585111248,0.819672131147541,0.9239423151101136,1.0,9/17,30.93%,CD7;MPO;CSF1R;FAS;KIT;CX3CR1;FCGR1A;CCR2;NOTCH1
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Taste Sensor Receptors (Rodent Model),-0.2760124898912017,-0.44494512119839047,0.7589285714285714,0.9240774404078133,1.0,12/29,24.70%,ULK1;TRPM5;RHEB;RPS6KB1;SLC1A5;RAF1;CASR;ATG13;SLC2A2;STK11;RPS6KA1;ITPR1
prerank,GO_Biological_Process_2021__regulation of ruffle assembly (GO:1900027),-0.24373383021346107,-0.4445021806937493,0.8214285714285714,0.9241828284123921,1.0,5/23,16.61%,EVL;P2RY12;EPS8L1;FAM98A;EPS8L2
prerank,Elsevier_Pathway_Collection__Golgi Transport,-0.2537363196553557,-0.44438743209664383,0.7798165137614679,0.9239809564299911,1.0,7/20,22.56%,RAB1A;RAB6A;RAB2A;ERGIC3;GBF1;SEC31B;SEC16A
prerank,Elsevier_Pathway_Collection__Methylases in Histone Methylation Cancer,-0.24948011918398966,-0.44436248824425906,0.7863247863247863,0.9236576525475815,1.0,5/17,18.67%,SMYD3;PRDM1;SUZ12;SUV39H1;NSD2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Celiac Disease,-0.26389674292587667,-0.4440718200621828,0.7672413793103449,0.9236399846846318,1.0,4/19,9.26%,TNF;CD226;HLA-DQB1;MICA
prerank,Reactome_2022__Gastrin-CREB Signaling Pathway Via PKC And MAPK R-HSA-881907,-0.2430760809951683,-0.44403633773603046,0.8217054263565892,0.9233295050468057,1.0,5/15,23.46%,MAPK3;EGFR;GRB2;MMP3;RPS6KA1
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA damage recognition (GO:0000715)",0.27731422650591975,0.44360945354701964,0.75,0.9048012880992028,1.0,6/23,11.08%,COPS5;DDB1;UBB;COPS3;COPS6;DDB2
prerank,GO_Biological_Process_2021__chondrocyte differentiation (GO:0002062),-0.26623497132345403,-0.4429384452019459,0.7024793388429752,0.9241683239198651,1.0,10/31,22.54%,HES5;OSR2;CREB3L2;SULF1;HMGA2;SNX19;BMPR1B;WNT7A;SOX5;OSR1
prerank,GO_Biological_Process_2021__mRNA modification (GO:0016556),-0.2522949799841804,-0.4429272396042892,0.728,0.9238345318707368,1.0,5/22,13.20%,PCIF1;METTL3;CMTR1;TRMT10C;ZC3H13
prerank,GO_Biological_Process_2021__positive regulation of viral transcription (GO:0050434),0.26474469646880455,0.44271503020158387,0.7272727272727273,0.905201525368157,1.0,6/25,14.89%,GTF2F2;POLR2A;POLR2F;CDK9;POLR2C;POLR2L
prerank,GO_Biological_Process_2021__positive regulation of leukocyte adhesion to vascular endothelial cell (GO:1904996),0.24572183138050427,0.4420216214559984,0.7642276422764228,0.9054791373848446,1.0,5/16,20.89%,SELE;ITGB2;FUT7;RHOA;ALOX5
prerank,GO_Biological_Process_2021__activation of protein kinase A activity (GO:0034199),-0.2450969848956703,-0.4419368016083165,0.837037037037037,0.9245014033880508,1.0,4/16,13.96%,ADCY8;ADCY3;PRKAR2A;ADCY5
prerank,Reactome_2022__Transferrin Endocytosis And Recycling R-HSA-917977,0.27474174604566665,0.44130886085347015,0.7014925373134329,0.905729674028594,1.0,8/28,17.87%,ATP6V1G1;MCOLN1;ATP6V0A1;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;ATP6V0A2
prerank,Reactome_2022__Regulation Of KIT Signaling R-HSA-1433559,-0.23331315621039828,-0.44129143082368066,0.8728813559322034,0.9248333976199044,1.0,5/16,21.58%,SOCS6;FYN;GRB2;KIT;PTPN6
prerank,Reactome_2022__Activation Of Matrix Metalloproteinases R-HSA-1592389,-0.2817631889339574,-0.4411532722698302,0.6837606837606838,0.924636544217968,1.0,16/28,36.44%,MMP9;TIMP2;MMP15;MMP3;TIMP1;PLG;CTSG;MMP14;MMP8;MMP24;CTSK;MMP17;KLKB1;CTSV;FURIN;KLK2
prerank,GO_Biological_Process_2021__energy derivation by oxidation of organic compounds (GO:0015980),0.2615462391443147,0.44079987653662994,0.7058823529411765,0.9058510609048444,1.0,11/24,30.22%,COQ10B;CYCS;COX15;ACSM1;SLC25A13;COX10;NDUFS4;PID1;GFPT2;COQ10A;MTLN
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Endometriosis,-0.29166892152032237,-0.4406158538034372,0.6822429906542056,0.9248952000374902,1.0,15/40,20.96%,TNF;CDH1;NR2F2;PTGS2;STAR;CYP26A1;ANGPT2;HSD17B2;MMP9;ITGB1;MMP3;TIMP1;HSD3B2;LEP;SNAI2
prerank,Elsevier_Pathway_Collection__IGF1R -> ELK/SRF/HIF1A/MYC/SREBF Signaling,0.2408926213353695,0.4405629389497899,0.7398373983739838,0.9057279382273183,1.0,6/20,14.95%,ELK1;MAPK1;IGF2;SRF;SREBF1;HIF1A
prerank,Reactome_2022__Regulation Of TLR By Endogenous Ligand R-HSA-5686938,-0.23324433236924555,-0.44044916161694336,0.8188976377952756,0.924735754314849,1.0,5/18,14.24%,HMGB1;CD36;NDUFA2;GSDMD;LBP
prerank,GO_Biological_Process_2021__global genome nucleotide-excision repair (GO:0070911),0.27120521317054125,0.4396895350088533,0.7426470588235294,0.9061526475554217,1.0,8/26,18.53%,DDB1;GTF2H5;RNF111;UBB;ERCC3;DDB2;USP45;UBA52
prerank,GO_Biological_Process_2021__positive regulation of dendrite morphogenesis (GO:0050775),-0.24560191474268112,-0.43940710485214224,0.8253968253968254,0.925444555039466,1.0,4/19,12.77%,DBNL;CAPRIN1;CUX1;CUX2
prerank,WikiPathway_2021_Human__Extracellular vesicles in the crosstalk of cardiac cells WP4300,-0.23940929551193993,-0.4392355476263158,0.7652173913043478,0.9252989966521713,1.0,5/19,15.90%,EGFR;IGF1;MMP9;PDLIM5;SOD1
prerank,Reactome_2022__MyD88 Deficiency (TLR2/4) R-HSA-5602498,0.24133097026789138,0.4390566526392061,0.7727272727272727,0.9063609885195667,1.0,7/17,25.77%,S100A9;TLR2;FGA;LY96;S100A8;FGG;MYD88
prerank,Reactome_2022__Formation Of Early Elongation Complex R-HSA-113418,0.31026494849293035,0.4390276627590712,0.7222222222222222,0.9060634129791828,1.0,9/32,14.89%,MNAT1;NCBP2;GTF2F2;GTF2H5;POLR2A;POLR2F;ERCC3;POLR2C;POLR2L
prerank,WikiPathway_2021_Human__Eicosanoid Synthesis WP167,0.2538913035134754,0.43816308646457114,0.7096774193548387,0.9064741426545269,1.0,11/25,28.63%,PTGIS;PTGES2;GGT1;PTGES;PLA2G4B;PLA2G6;ALOX5;PNPLA3;PNPLA8;GGTLC1;LTA4H
prerank,Reactome_2022__Infection With Mycobacterium Tuberculosis R-HSA-9635486,-0.2559323092052723,-0.4379654447884183,0.6896551724137931,0.9262833026726546,1.0,10/25,23.67%,GSK3A;MAPK3;RAB5A;RPS27A;TRIM27;CORO1A;LTF;CTSG;KPNA1;UBC
prerank,TRRUST_Transcription_Factors_2019__CREB1 mouse,-0.29631990112041356,-0.4374963772802911,0.7317073170731707,0.9264121228206962,1.0,9/28,26.83%,NECTIN2;PTGS2;CFTR;ETV2;ETV3;ENTPD1;HSPA5;PRKCE;NMNAT2
prerank,"GO_Biological_Process_2021__mitochondrial electron transport, cytochrome c to oxygen (GO:0006123)",0.23575761401860132,0.4374176406757918,0.8181818181818182,0.9067679486470268,1.0,3/17,5.42%,COX7C;CYCS;COX15
prerank,GO_Biological_Process_2021__release of sequestered calcium ion into cytosol (GO:0051209),0.25584521917042097,0.4373270992497115,0.7244094488188977,0.9065308510134472,1.0,4/25,7.24%,FASLG;TRPM2;SLC8B1;FGF2
prerank,GO_Biological_Process_2021__dendritic cell chemotaxis (GO:0002407),0.25466818134662267,0.43706134661012574,0.7851239669421488,0.9064520016704511,1.0,4/16,17.61%,TRPM2;CXCR4;TRPM4;PIK3CG
prerank,Reactome_2022__Negative Regulation Of NOTCH4 Signaling R-HSA-9604323,-0.31971581311648367,-0.43689223231865654,0.8508771929824561,0.9267191821452012,1.0,19/53,20.00%,PSMB7;PSMD7;PSMF1;RBX1;SKP1;PSMA5;NOTCH4;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,TRRUST_Transcription_Factors_2019__SIRT1 mouse,-0.26410581742154726,-0.4368795644364382,0.7321428571428571,0.926388901133636,1.0,9/22,24.78%,MMP9;CRP;RICTOR;SHC1;NOX1;TIMP1;NR1I2;DKK1;HES1
prerank,Elsevier_Pathway_Collection__Myostatin in Skeletal Muscles in Muscular Dystrophies,-0.22811779404057309,-0.43676773794614343,0.8529411764705882,0.9261626846872876,1.0,4/17,12.86%,TRIM63;FBXO32;SMAD2;ACVR1B
prerank,Reactome_2022__Interaction Between L1 And Ankyrins R-HSA-445095,-0.2605595495241014,-0.4365050195657104,0.7205882352941176,0.9261147716267248,1.0,6/27,10.05%,SCN4B;SCN5A;NFASC;SCN1B;SCN2B;SCN9A
prerank,Elsevier_Pathway_Collection__Sarcomere Disorganization and Intracellular Calcium Overload,-0.24178354274721275,-0.4363891625635877,0.7024793388429752,0.9258965634089219,1.0,9/23,26.92%,ANKRD1;SLC8A1;PLN;TCAP;MYL3;TTN;MYOZ2;JPH2;TLN1
prerank,Reactome_2022__GSK3B And BTRC:CUL1-mediated-degradation Of NFE2L2 R-HSA-9762114,-0.32066806989280733,-0.43618209025971283,0.8376068376068376,0.9257806756206309,1.0,19/51,20.00%,PSMB7;PSMD7;PSMF1;RBX1;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;NFE2L2;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__positive regulation of reactive oxygen species metabolic process (GO:2000379),-0.29088826924691064,-0.43606732427816813,0.72,0.9255967903551257,1.0,14/49,16.00%,GSTP1;GRIN1;AKR1C3;TYROBP;AGTR1;ITGAM;CBR1;CRP;CD36;CYBA;F2;GRB2;SOD1;CLEC7A
prerank,GO_Biological_Process_2021__negative regulation of interleukin-6 production (GO:0032715),-0.2754350133687359,-0.4354617701630997,0.6810344827586207,0.9259080021724958,1.0,10/28,24.48%,TNF;SELENOS;ARRB1;TNFAIP3;SLAMF1;IRAK3;NLRP12;PTPN6;GHRL;CD200R1
prerank,Reactome_2022__Beta-catenin Phosphorylation Cascade R-HSA-196299,0.24440238935607467,0.43411017660951307,0.7952755905511811,0.908631092424708,1.0,4/17,23.18%,GSK3B;PPP2CB;CTNNB1;AXIN1
prerank,GO_Biological_Process_2021__microtubule nucleation (GO:0007020),-0.23288682181131248,-0.4338504830076448,0.8235294117647058,0.9271977265605715,1.0,5/20,18.38%,CENPJ;NDE1;TUBG2;SLAIN2;TUBGCP4
prerank,GO_Biological_Process_2021__pulmonary valve development (GO:0003177),-0.22502743410976345,-0.4337123028527539,0.8828125,0.9270166163670616,1.0,2/18,3.70%,HEY2;TNFRSF1A
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Endometrial Cancer,0.2732620519192641,0.43369427381233866,0.7555555555555555,0.9086773979015554,1.0,7/22,15.22%,IGF2;PGR;CLDN4;FGF2;ERBB2;KDR;WNT10B
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced NF-kB survival signaling WP3617,0.2765807976255605,0.4336814323201272,0.7021276595744681,0.9083676958048545,1.0,11/33,17.01%,BIRC3;CSF2;SELE;CXCL2;BIRC2;CFLAR;MMP1;CCND1;CD40LG;IKBKB;BCL2A1
prerank,GO_Biological_Process_2021__heparan sulfate proteoglycan metabolic process (GO:0030201),-0.2453120317707364,-0.4333065749555533,0.7407407407407407,0.9270843936752137,1.0,10/21,30.88%,NDST3;SULF1;EXT2;GLCE;HS2ST1;HS6ST1;XYLT1;EXTL3;B3GAT3;SGSH
prerank,Reactome_2022__Eicosanoid Ligand-Binding Receptors R-HSA-391903,-0.23752024604223687,-0.4328998494899758,0.8648648648648649,0.9271752889823959,1.0,3/15,11.41%,PTGDR2;TBXA2R;PTGFR
prerank,Elsevier_Pathway_Collection__SIRT6 Signaling in Aging,-0.23234804076324964,-0.432795541680932,0.7833333333333333,0.9269434353981734,1.0,6/20,22.81%,POLB;SHC1;SLC2A1;MDM2;XRCC6;TP53
prerank,GO_Biological_Process_2021__negative regulation of immune effector process (GO:0002698),0.23734319027449843,0.43276066648293815,0.8709677419354839,0.9088421510356629,1.0,4/15,16.50%,GRN;RC3H1;CD55;ENPP3
prerank,GO_Biological_Process_2021__regulation of hematopoietic stem cell differentiation (GO:1902036),-0.32855073989280253,-0.43273776659049484,0.890625,0.9266608197010207,1.0,25/68,21.69%,PSMB7;PSMD7;PSMF1;METTL3;FOXC1;TAL1;PSMA5;PSMD1;PSMD2;PSMB8;OSM;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;N4BP2L2;PSMD5;ABL1;TCF3;PSMD12;PSMB3;TCF15;ITCH
prerank,Reactome_2022__Signaling By KIT In Disease R-HSA-9669938,-0.25042322236249615,-0.4326293742934142,0.7520661157024794,0.9264246944266663,1.0,6/19,17.53%,PIK3CA;PIK3R3;FYN;PIK3R1;GRB2;KIT
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-serine phosphorylation (GO:0033137),0.2690463326047823,0.43256276354903855,0.75,0.9086930861574011,1.0,5/20,14.92%,CAV1;MLXIPL;PAQR3;SMAD7;GPD1L
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 2 Promoter R-HSA-76066,0.28184557727818715,0.4324599658386201,0.7153846153846154,0.9084679265580027,1.0,9/26,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;TBP;POLR2H;POLR3F;CRCP
prerank,Reactome_2022__Degradation Of GLI1 By Proteasome R-HSA-5610780,-0.3121388048554067,-0.43215122969156705,0.8389830508474576,0.9265758453220051,1.0,20/56,21.69%,PSMB7;PSMD7;PSMF1;RBX1;SKP1;PSMA5;PSMD2;PSMB8;SUFU;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;ITCH
prerank,GO_Biological_Process_2021__regulation of intracellular steroid hormone receptor signaling pathway (GO:0033143),-0.27662968560157253,-0.4320589874426069,0.7043478260869566,0.9263322146930376,1.0,12/36,24.12%,EP300;H3C1;TRIM68;GPAM;UBA5;KDM4C;KLK3;DNAAF4;RNF6;RNF14;UFM1;DDRGK1
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA gap filling (GO:0006297)",0.2691950674374498,0.43198772499858756,0.751937984496124,0.9085329170978373,1.0,9/24,20.43%,RFC2;POLD1;PCNA;UBB;XRCC1;POLK;UBA52;LIG3;RPA2
prerank,Elsevier_Pathway_Collection__NOTCH -> RBPJ/HES/HEY Signaling,0.24877932650234852,0.4317073498482171,0.8278688524590164,0.9084709517349905,1.0,3/16,13.59%,DLL1;MFNG;CIR1
prerank,Reactome_2022__FBXL7 Down-Regulates AURKA During Mitotic Entry And In Early Mitosis R-HSA-8854050,-0.3153835657411613,-0.4311671843353974,0.8290598290598291,0.9268932279617179,1.0,19/52,20.00%,PSMB7;PSMD7;PSMF1;RBX1;SKP1;PSMA5;FBXL7;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__intermediate filament organization (GO:0045109),0.2633509522391333,0.43062713378049394,0.8151260504201681,0.9091769000838418,1.0,3/15,14.97%,GFAP;BFSP2;PKP2
prerank,Elsevier_Pathway_Collection__Androgens in Adipocyte Activation,0.23215242892719395,0.43049863094368807,0.8442622950819673,0.9089572269249286,1.0,7/16,29.95%,CEBPA;PPARG;HIF1A;CTNNB1;CEBPD;SHBG;SRD5A2
prerank,GO_Biological_Process_2021__positive regulation of myeloid leukocyte differentiation (GO:0002763),0.2940891836047467,0.4303797011011359,0.6717557251908397,0.908744380683598,1.0,9/33,15.39%,IL12B;CTNNBIP1;IL23A;ID2;FES;HCLS1;HSF1;POU4F1;CD74
prerank,GO_Biological_Process_2021__positive regulation of striated muscle cell differentiation (GO:0051155),-0.2193660296143775,-0.4302199728838223,0.8095238095238095,0.9274661571234214,1.0,6/22,21.77%,IGF1;RBM24;EDN1;MAPK14;AKAP6;MMP14
prerank,Reactome_2022__Signaling By Activin R-HSA-1502540,0.23840535794283194,0.43011203319329455,0.8439716312056738,0.9086344034632482,1.0,5/15,20.35%,MAPK1;FSTL3;ACVR1C;SMAD3;ACVR2B
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 3 Promoter R-HSA-76071,0.283524841784655,0.4300092213147314,0.7213114754098361,0.9083818137476473,1.0,10/27,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;ZNF143;TBP;POLR2H;POLR3F;CRCP
prerank,TRRUST_Transcription_Factors_2019__PTTG1 human,0.23169832608508847,0.42974553767149254,0.8540145985401459,0.9082960365931939,1.0,5/15,24.88%,FGF2;KDR;CCNB1;RHOA;RAC1
prerank,Reactome_2022__IRAK4 Deficiency (TLR2/4) R-HSA-5603041,-0.2314693647019979,-0.4295050142616368,0.8676470588235294,0.9278939090312227,1.0,4/18,12.23%,BTK;HMGB1;CD36;NDUFA2
prerank,Elsevier_Pathway_Collection__FAS Mediated Apoptosis in Systemic Scleroderma,0.22965748294233518,0.42949516403604654,0.8115942028985508,0.9082383045458022,1.0,3/15,8.94%,FASLG;CYCS;DAXX
prerank,Reactome_2022__Interleukin-20 Family Signaling R-HSA-8854691,-0.21911077109474497,-0.42916374435440385,0.8392857142857143,0.9279210949859268,1.0,5/20,18.94%,IL20RA;JAK3;STAT2;TYK2;IL20RB
prerank,Reactome_2022__Vif-mediated Degradation Of APOBEC3G R-HSA-180585,-0.3070220369382928,-0.42909864573728895,0.7863247863247863,0.9276681848378239,1.0,19/51,21.43%,PSMB7;PSMD7;PSMF1;RBX1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;ELOB;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;CUL5
prerank,GO_Biological_Process_2021__chaperone-mediated protein complex assembly (GO:0051131),-0.2161852666703583,-0.4288951352304568,0.8461538461538461,0.9275446776142551,1.0,7/21,23.57%,MKKS;HSPD1;HSPA4;CCT2;BBS12;PTGES3L;LONP1
prerank,Elsevier_Pathway_Collection__Advanced Glycation End Products Pathway in Diabetic Microangiopathy,-0.22226109671069066,-0.4287095075110116,0.7906976744186046,0.9273828161284234,1.0,8/22,26.50%,VCAM1;HMGB1;RAF1;EDN1;NOX1;MAP2K2;AGER;AKT1
prerank,Elsevier_Pathway_Collection__GCG and PPY Regulate Metabolism and Satiety,-0.22576623254670372,-0.42856388453614463,0.8083333333333333,0.927202625834381,1.0,5/15,26.01%,PCSK2;GLP2R;GNAQ;ITPR1;PLCB1
prerank,GO_Biological_Process_2021__anterograde synaptic vesicle transport (GO:0048490),0.2265927090945934,0.4284467231625527,0.8387096774193549,0.9085064851710094,1.0,3/15,12.20%,AP3S2;BLOC1S2;AP3D1
prerank,GO_Biological_Process_2021__synaptic vesicle transport along microtubule (GO:0099517),0.2265927090945934,0.4284467231625527,0.8387096774193549,0.9085064851710094,1.0,3/15,12.20%,AP3S2;BLOC1S2;AP3D1
prerank,Reactome_2022__Pyruvate Metabolism R-HSA-70268,0.26660806333402537,0.4283107050404987,0.7333333333333333,0.9083076317322096,1.0,7/30,9.16%,PDP2;LDHAL6A;PDK2;SLC16A8;PPARD;VDAC1;PDPK1
prerank,GO_Biological_Process_2021__regulation of adenylate cyclase activity (GO:0045761),0.23458757371840316,0.4276773605589938,0.8646616541353384,0.9085560476750769,1.0,6/17,25.24%,CACNA1C;CAP2;GRM2;GABBR2;STIM1;EDNRB
prerank,Reactome_2022__Vpu Mediated Degradation Of CD4 R-HSA-180534,-0.3108820886667227,-0.4275079698319229,0.8103448275862069,0.9280229223192796,1.0,17/49,20.00%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__regulation of ceramide biosynthetic process (GO:2000303),-0.2199183581124713,-0.42744509841911177,0.8547008547008547,0.9277642900175884,1.0,3/16,12.67%,TNF;TNFRSF1A;ORMDL2
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in Pyelonephritis,-0.22635945174998917,-0.4272798128778164,0.775,0.9276133325312925,1.0,4/18,19.25%,TNF;TLR5;IRAK1;CXCL8
prerank,Elsevier_Pathway_Collection__Protein Nuclear Import and Export,-0.23881769905393013,-0.42679375499920535,0.8360655737704918,0.9278109233002788,1.0,6/17,21.96%,NXT1;RANGAP1;TNPO1;XPOT;CSE1L;KPNA1
prerank,Elsevier_Pathway_Collection__Actin Cytoskeleton,0.2301735866835517,0.4266114256590765,0.8759124087591241,0.9091860790916021,1.0,4/15,22.06%,ACTN1;LIMK2;CAPZA1;LIMK1
prerank,GO_Biological_Process_2021__cellular response to cadmium ion (GO:0071276),-0.2731645552866406,-0.4264834350422303,0.7016129032258065,0.9278150343758313,1.0,9/26,17.76%,SUMO1;MAPK3;AKR1C3;EGFR;MMP9;MT1F;MT1A;NCF1;MT1B
prerank,Elsevier_Pathway_Collection__Toll-like Receptor Independent Sterile Inflammation,-0.2955637919454935,-0.4263237121175013,0.8090909090909091,0.9276718919896395,1.0,26/65,26.53%,TNF;BTK;CLEC4E;MAP3K1;MAPK3;CDC42;IL18;PYCARD;VCAN;NLRP3;HMGB1;RAF1;BCL10;GRB2;IRAK1;PANX1;SHC1;NF2;P2RX7;MAP2K2;IL33;TXNIP;AGER;CXCL1;AKT1;PRKCE
prerank,Elsevier_Pathway_Collection__CR3 Mediated Phagocytosis in Neutrophils and Macrophages,0.23823438941864028,0.4263097875136369,0.7878787878787878,0.9091148584440749,1.0,17/17,76.19%,RHOA;PRKCB;RAC1;C3AR1;ROCK2;PRKCA;RASGRF1;VIM;DIAPH1;PLCG1;ROCK1;PRKCD;IQGAP1;PLCB1;C3;ITPR1;CLIP1
prerank,Elsevier_Pathway_Collection__Gluconeogenesis Impairment in non-Alcoholic Fatty Liver Disease,-0.21511004729702704,-0.42568304895941433,0.9016393442622951,0.9279980441542064,1.0,8/15,37.23%,LPIN1;G6PC;PIK3R1;LEP;AKT1;INSR;RETN;FOXO1
prerank,GO_Biological_Process_2021__regulation of B cell receptor signaling pathway (GO:0050855),0.2534814777883777,0.425609919868768,0.7372262773722628,0.9094318565800199,1.0,8/23,24.40%,CD81;GPS2;PAX5;PTPN22;FCRL3;FOXP1;PRKCB;PRKCH
prerank,Elsevier_Pathway_Collection__SOCS in Negative Feedback Regulation in Myocarditis,-0.20920989446418709,-0.42539037461120904,0.924812030075188,0.9279744935055445,1.0,2/17,3.70%,TNF;TNFRSF1A
prerank,Elsevier_Pathway_Collection__Mitochondrial DNA Replication and Transcription,0.24634715139581637,0.42536005863523224,0.8142857142857143,0.909351297589918,1.0,8/16,33.39%,PTCD3;MTERF1;MT-RNR1;ENDOG;TFAM;POLRMT;DHX30;MTERF3
prerank,Elsevier_Pathway_Collection__MHC1 Causes Antigen Presentation Failure in Cancer Immune Escape,0.2489558267744772,0.425275774722439,0.7,0.9091073999574418,1.0,10/25,26.45%,TAP1;PDIA3;TAP2;NLRC5;B2M;TAPBP;CALR;KLRK1;PSMB9;TPP2
prerank,Reactome_2022__Constitutive Signaling By NOTCH1 HD Domain Mutants R-HSA-2691232,0.22457359201475569,0.42512645547779176,0.9097744360902256,0.9089685810619806,1.0,5/15,25.05%,DLL1;UBB;UBA52;NEURL1;ADAM10
prerank,GO_Biological_Process_2021__chondroitin sulfate biosynthetic process (GO:0030206),-0.2435466422418335,-0.42493645925325996,0.7938931297709924,0.9280735353194254,1.0,8/21,25.05%,NCAN;VCAN;CSGALNACT1;CHST13;CSPG5;CSPG4;CHST3;CHST15
prerank,GO_Biological_Process_2021__regulation of early endosome to late endosome transport (GO:2000641),-0.2460691079411812,-0.4244767352768345,0.7674418604651163,0.9282215178253722,1.0,4/18,12.05%,DNAJC13;MAPK3;MTMR2;RAB21
prerank,Reactome_2022__Degradation Of GLI2 By Proteasome R-HSA-5610783,-0.30778391942348843,-0.42350683520530225,0.8559322033898306,0.928902210257792,1.0,19/56,20.00%,PSMB7;PSMD7;PSMF1;RBX1;SKP1;PSMA5;PSMD2;PSMB8;SUFU;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Elsevier_Pathway_Collection__NOTCH1 Signaling in Breast Cancer,-0.28747686200654576,-0.423384475368204,0.717948717948718,0.9286793977309982,1.0,10/35,14.16%,CDH1;EP300;EGFR;MMP9;CDK4;CTSB;DLL4;TADA2A;SMAD2;ADAM17
prerank,GO_Biological_Process_2021__cellular response to radiation (GO:0071478),0.2931959785444764,0.4232276799096797,0.7265625,0.9102476139448114,1.0,11/36,19.91%,SWI5;RAD1;NET1;EEF1D;HUS1;NSMCE3;RHO;ECT2;KDM4D;CDKN1A;BLM
prerank,GO_Biological_Process_2021__regulation of vacuole organization (GO:0044088),-0.24663486358240383,-0.4228452300182378,0.7835820895522388,0.9289478686616308,1.0,3/21,3.99%,TBC1D12;LAPTM4B;RAB5A
prerank,GO_Biological_Process_2021__positive regulation of telomere capping (GO:1904355),0.2349447095935673,0.42283749307069163,0.8487394957983193,0.9102863143287472,1.0,8/17,30.01%,HNRNPD;MAPK1;PRKCQ;NEK2;MAP2K7;NABP2;TNKS2;PNKP
prerank,TRRUST_Transcription_Factors_2019__REL mouse,0.26445442537878855,0.42257710529489134,0.7540983606557377,0.9102016177968171,1.0,5/21,14.40%,IL12B;BIRC3;IL23A;EZH2;RC3H1
prerank,Reactome_2022__PRC2 Methylates Histones And DNA R-HSA-212300,-0.2756918248337591,-0.4223398162996159,0.7,0.9291427331734161,1.0,10/32,19.70%,DNMT3B;RBBP7;H2BC13;H2AZ2;H2BC15;H2AC6;SUZ12;H2BC5;DNMT3A;RBBP4
prerank,Reactome_2022__Activated PKN1 Stimulates Transcription Of Androgen Receptor Regulated KLK2 And KLK3 R-HSA-5625886,-0.2688003877898309,-0.42133601034151463,0.7478991596638656,0.9299138408681272,1.0,6/26,13.33%,H2BC13;H2AZ2;H2BC15;H2AC6;KDM4C;H2BC5
prerank,Reactome_2022__Attenuation Phase R-HSA-3371568,0.2722795122838938,0.4212611613540141,0.752,0.9110837030871795,1.0,7/24,18.98%,SERPINH1;DEDD2;HSF1;CREBBP;UBB;PTGES3;HSPA8
prerank,GO_Biological_Process_2021__negative regulation of insulin secretion (GO:0046676),0.2239036037964931,0.42108399942358593,0.889763779527559,0.9109391338129262,1.0,7/16,30.32%,PIM3;CCN3;REST;FAM3D;MIDN;PSMD9;PRKN
prerank,GO_Biological_Process_2021__hematopoietic progenitor cell differentiation (GO:0002244),-0.2603088252783565,-0.4208732366879987,0.6846846846846847,0.930036384668098,1.0,17/30,36.92%,PLD4;BATF;MLF1;CSF1R;SFRP1;KIT;LMBR1L;TP53;MEOX1;MLLT3;PRRC2C;TGFB1;BMP4;UFL1;INHBA;SHH;ACE
prerank,Elsevier_Pathway_Collection__Somatostatin Receptors Signaling,-0.21497262252244242,-0.42002227779176465,0.9,0.9306018920490059,1.0,8/18,31.29%,TNF;PTGS2;GNAO1;ATF1;TP53;VEGFA;SSTR2;SSTR3
prerank,Reactome_2022__Phase 0 - Rapid Depolarisation R-HSA-5576892,-0.2658123936836514,-0.4199443721896183,0.7265625,0.930348404259188,1.0,6/28,10.05%,SCN4B;SCN5A;FGF12;SCN1B;SCN2B;SCN9A
prerank,GO_Biological_Process_2021__positive regulation of protein export from nucleus (GO:0046827),-0.21223583419583375,-0.4199101519115493,0.9029850746268657,0.9300416662166364,1.0,9/15,37.03%,TCF7L2;TPR;EMD;TP53;GTSE1;CAMK1;RAPGEF3;YWHAE;GAS6
prerank,GO_Biological_Process_2021__regulation of ubiquitin-protein transferase activity (GO:0051438),0.28304348342626917,0.41990283316385424,0.7163120567375887,0.9116984301435594,1.0,10/27,23.18%,UBE2L3;RPS2;DCUN1D2;BMI1;SMAD7;PARK7;DCUN1D3;FEM1B;LIMK1;AXIN1
prerank,GO_Biological_Process_2021__neuromuscular junction development (GO:0007528),-0.2485779377019583,-0.4197983887565575,0.7301587301587301,0.9298221378931075,1.0,9/23,25.61%,CACNB3;UNC13C;ZC4H2;PPFIBP1;F2R;LRP4;MUSK;UNC13B;DCTN1
prerank,Reactome_2022__NIK To Noncanonical NF-kB Signaling R-HSA-5676590,-0.3002078490609892,-0.4197686027500861,0.8067226890756303,0.9295158108647826,1.0,25/56,30.41%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;UBA3;PSMD5;PSMD12;PSMB3;CHUK;UBC;PSMB2;CUL1;FBXW11;PSMB10;PSMA7
prerank,Elsevier_Pathway_Collection__MTOR/TP53 Regulates Cell Metabolism,0.2749896190851209,0.4192473481320375,0.7482014388489209,0.9119524836023343,1.0,14/27,31.67%,PDK2;FASN;H6PD;MTOR;HK2;CPT1C;PFKFB3;SIRT6;PCK1;MLST8;RPTOR;PRKN;GLS2;PGAM1
prerank,Reactome_2022__RHO GTPases Activate ROCKs R-HSA-5627117,-0.21571731507657899,-0.41757470270610525,0.8702290076335878,0.9314697726415201,1.0,5/19,19.08%,PPP1R12A;PPP1CB;VPS72;MYH10;RHOC
prerank,Elsevier_Pathway_Collection__Tamoxifen Induced Endometrial Cancer,0.2574128509839593,0.4175656338492196,0.796875,0.9131359786089367,1.0,5/16,21.17%,CASP9;PDPK1;EGF;CCND1;PTEN
prerank,GO_Biological_Process_2021__dendritic spine morphogenesis (GO:0060997),-0.21654773407552053,-0.4163409394807449,0.8571428571428571,0.932400936243937,1.0,7/16,24.45%,CDC42;EPHB3;CTNND2;WNT7A;EPHB1;SHANK3;ZNF365
prerank,KEGG_2021_Human__Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,-0.22337460944985033,-0.4159997133914967,0.8278688524590164,0.9324307961600417,1.0,8/25,28.15%,DPM2;PIGB;PIGA;PIGN;PIGV;PIGP;GPAA1;PIGL
prerank,Elsevier_Pathway_Collection__AHR Signaling in Treg and Dendritic Cells Function,-0.23693418299686542,-0.41590099631932087,0.8320610687022901,0.9321909990302142,1.0,3/21,3.92%,IDO1;IDO2;JAK3
prerank,GO_Biological_Process_2021__positive regulation of smooth muscle cell proliferation (GO:0048661),-0.27969759354837403,-0.41589289584303557,0.7610619469026548,0.9318660968294046,1.0,15/46,17.09%,TNF;HES5;MEF2D;IL18;P2RY6;HTR1B;IGF1;RBPMS2;MMP9;CCN4;CDH13;EDN1;ERN1;FGF9;NOX1
prerank,KEGG_2021_Human__Folate biosynthesis,-0.23036966045640445,-0.4158628477161318,0.8099173553719008,0.9315612179431565,1.0,6/24,23.60%,AKR1B10;AKR1C3;CBR1;MOCS2;TPH2;MOCS1
prerank,GO_Biological_Process_2021__response to cadmium ion (GO:0046686),-0.2476911102439818,-0.4156189469056763,0.7246376811594203,0.931504598871344,1.0,9/28,17.76%,SUMO1;MAPK3;AKR1C3;EGFR;MMP9;MT1F;MT1A;NCF1;MT1B
prerank,GO_Biological_Process_2021__regulation of intracellular transport (GO:0032386),-0.24291007338077364,-0.4153173792760059,0.708029197080292,0.931473880468103,1.0,14/37,30.81%,MYLK2;REEP6;LCP1;TTC21B;PTPN1;SCFD1;NEFH;CRYAB;RAB11B;GAS1;WWC1;GRIPAP1;RBM4;ATP13A2
prerank,Reactome_2022__Dectin-1 Mediated Noncanonical NF-kB Signaling R-HSA-5607761,-0.29960190000363157,-0.4151470358721268,0.8205128205128205,0.9313321783963517,1.0,26/59,30.41%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;CCL17;UBA3;PSMD5;PSMD12;PSMB3;CHUK;UBC;PSMB2;CUL1;FBXW11;PSMB10;PSMA7
prerank,Elsevier_Pathway_Collection__Genes with Susceptibility for Crohn's Disease and Ulcerative Colitis,0.24274657467521266,0.41501318972895807,0.7872340425531915,0.9151870486577244,1.0,5/19,17.81%,HNF4A;ITLN1;ATG16L1;IL7R;XBP1
prerank,WikiPathway_2021_Human__Unfolded protein response WP4925,-0.235166983134334,-0.4145323576518373,0.7207207207207207,0.9315751584856705,1.0,9/24,25.16%,BCL2L11;PPP1R15A;ERN1;BID;NFE2L2;TP53;HSPA5;TXNIP;DDIT3
prerank,Elsevier_Pathway_Collection__N2 Neutrophils in Tumor-Promoting Inflammation and Tumor Progression,-0.2459220623496269,-0.4137710151494196,0.7024793388429752,0.9320382964993531,1.0,16/34,34.17%,PREX1;MMP9;RHEB;SMAD2;PIK3R1;TYK2;EIF4EBP3;EIF4G1;PREX2;AKT1;ARG1;VEGFA;EIF4E;MYC;TGFB1;TSC2
prerank,Reactome_2022__Diseases Associated With N-glycosylation Of Proteins R-HSA-3781860,0.2551001868392081,0.4137334935593434,0.7674418604651163,0.915983504452636,1.0,7/20,24.61%,ALG12;CTSA;MOGS;MPDU1;ALG8;ALG13;ALG2
prerank,GO_Biological_Process_2021__regulation of transposition (GO:0010528),-0.23131175184861488,-0.41366831830691125,0.8135593220338984,0.9318069240713878,1.0,5/18,18.89%,SIRT7;APOBEC3H;SPOCD1;PIWIL4;APOBEC3A
prerank,GO_Biological_Process_2021__cyclic purine nucleotide metabolic process (GO:0052652),-0.22973331118518436,-0.41280756059821877,0.8405797101449275,0.9324306014316962,1.0,6/19,22.75%,ADCY8;ADCY3;GUCY2C;ADCY5;NPR1;GUCY1B1
prerank,Elsevier_Pathway_Collection__SIRT2 Signaling in Aging,-0.2151527860437984,-0.41257567696262804,0.8823529411764706,0.9323525620440072,1.0,3/22,5.18%,EP300;SIRT2;CDC20
prerank,Reactome_2022__Hh Mutants Are Degraded By ERAD R-HSA-5362768,-0.29308662746151487,-0.41238968153904937,0.8174603174603174,0.9322229885947929,1.0,18/53,20.00%,PSMB7;PSMD7;PSMF1;OS9;PSMA5;SYVN1;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway (GO:0043162),0.2634662103947071,0.4123603889034733,0.7384615384615385,0.9169619595258716,1.0,4/22,7.50%,VPS4B;VPS25;VPS28;RNF115
prerank,TRRUST_Transcription_Factors_2019__CEBPD human,0.24697776674519725,0.4113324211877892,0.8770491803278688,0.9175562374099956,1.0,6/16,23.25%,CCL20;IL23A;GAPDH;PPARG;POU5F1;TNFAIP6
prerank,GO_Biological_Process_2021__positive regulation of immune effector process (GO:0002699),0.2649575501345899,0.41123825106707584,0.7251908396946565,0.9173106712393915,1.0,6/30,9.51%,IL12B;HLA-DMB;CD46;IL23A;CD81;PTPRJ
prerank,KEGG_2021_Human__Proteasome,-0.29406530090817806,-0.41113830563938947,0.8035714285714286,0.9332371829402203,1.0,14/44,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD1;PSMD2;PSMB8;PSMD11;PSMD13;PSMC1;PSME1;PSMA1;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__negative regulation of small GTPase mediated signal transduction (GO:0051058),-0.2390274792033166,-0.41045288047507195,0.8225806451612904,0.9336441436556809,1.0,12/21,34.86%,STAMBP;MAPKAP1;ARHGAP25;SPRY4;DAB2IP;ARHGAP12;SYNGAP1;CGNL1;SPRY1;SPRY3;FBP1;SPRY2
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 1 Promoter R-HSA-76061,0.27595233473711334,0.4101993619039458,0.7380952380952381,0.9179096997705726,1.0,9/27,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;TBP;POLR2H;POLR3F;CRCP
prerank,GO_Biological_Process_2021__regulation of lipid catabolic process (GO:0050994),-0.24131540840938595,-0.41019461291581233,0.8434782608695652,0.9335748756463188,1.0,4/20,9.16%,TNF;APOA2;SCT;ABCD1
prerank,GO_Biological_Process_2021__positive regulation of T cell mediated immunity (GO:0002711),0.2602492022431262,0.4093775135379559,0.6581196581196581,0.9183431841878589,1.0,12/35,23.73%,IL12B;CD1C;IL23A;STX7;TRAF2;CD55;B2M;CD1D;CD1B;FZD5;IL12A;ZP3
prerank,GO_Biological_Process_2021__modulation by host of symbiont process (GO:0051851),-0.24896536464850672,-0.40874340945649573,0.7256637168141593,0.9347844694894397,1.0,18/32,36.45%,RRP1B;EP300;TFAP4;HMGA2;CHD1;SMARCB1;HDAC1;CX3CR1;INPP5K;TAF11;SMARCA4;SNW1;CCL3;CCL4;ZNF639;LRRC19;LEF1;CTDP1
prerank,Reactome_2022__RMTs Methylate Histone Arginines R-HSA-3214858,-0.2771507482422168,-0.4087018661780791,0.7768595041322314,0.9344740153784721,1.0,16/40,26.22%,COPRS;RBBP7;H2AZ2;CDK4;H2AC6;WDR5;ACTL6B;PRMT6;SMARCA2;ACTL6A;SMARCB1;DNMT3A;PBRM1;WDR77;SMARCC1;SMARCA4
prerank,WikiPathway_2021_Human__Proteasome Degradation WP183,-0.2908693129697352,-0.40816677071811835,0.8461538461538461,0.9347012874970176,1.0,25/59,30.41%,PSMB7;PSMD7;HLA-A;UBA7;PSMA5;PSMD1;PSMD2;PSMB8;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;RPN1;PSMD5;PSMD12;PSMB3;HLA-F;UBC;UBA1;PSMB2;IFNG;PSMB10;PSMA7
prerank,GO_Biological_Process_2021__positive regulation of telomerase RNA localization to Cajal body (GO:1904874),-0.21167747480196075,-0.4079655695796548,0.9112903225806451,0.934548494918906,1.0,4/15,15.97%,SHQ1;NHP2;CCT2;TCP1
prerank,"GO_Biological_Process_2021__RNA splicing, via transesterification reactions (GO:0000375)",0.2528612625794403,0.4078511752581683,0.7244094488188977,0.9194855061742858,1.0,9/25,28.88%,PRPF3;MPHOSPH10;SF3A3;DBR1;LSM1;SCAF11;SNRNP40;SF3B3;PRPF4
prerank,GO_Biological_Process_2021__negative regulation of transposition (GO:0010529),0.2440401782561844,0.40745000066494214,0.7910447761194029,0.9195194713653709,1.0,6/23,14.56%,TEX19;ZNF91;TUT7;APOBEC3G;TEX15;TDRD9
prerank,TRRUST_Transcription_Factors_2019__ETS2 mouse,0.24309057651065055,0.4073832438379804,0.752,0.9192564941857104,1.0,10/23,28.83%,JUN;SETDB1;DUSP6;HMOX1;BCL2L1;CSF3R;KRT8;ETV4;HMOX2;FLT4
prerank,GO_Biological_Process_2021__regulation of programmed necrotic cell death (GO:0062098),0.22671657777802318,0.40675953139225995,0.7815126050420168,0.9195332445244289,1.0,3/20,10.71%,BIRC3;BIRC2;CFLAR
prerank,GO_Biological_Process_2021__cilium-dependent cell motility (GO:0060285),0.2645453174231234,0.40657510262230423,0.7538461538461538,0.9193680307252536,1.0,6/21,17.88%,CCDC65;CFAP54;CFAP44;TEKT4;DNAH8;RSPH9
prerank,GO_Biological_Process_2021__regulation of mRNA processing (GO:0050684),-0.2871924941728651,-0.4065655335388827,0.7310924369747899,0.9357075936726998,1.0,14/34,29.85%,IWS1;SRPK2;SON;SAFB;ZFP36L1;DHX9;SRSF3;HNRNPK;KHDRBS1;QKI;CPSF4;SRPK3;RBM39;PTCD2
prerank,WikiPathway_2021_Human__Simplified Depiction of MYD88 Distinct Input-Output Pathway WP3877,0.22906416460992113,0.4065388554009856,0.864,0.919075060109908,1.0,6/16,26.88%,JUN;TLR2;TIFA;MYD88;TLR10;TLR7
prerank,GO_Biological_Process_2021__positive regulation of reproductive process (GO:2000243),-0.23781330360352199,-0.4065093006253852,0.7461538461538462,0.9354169156357492,1.0,13/28,32.89%,CACNA1H;SIRT2;C1QBP;AGO2;ACVR1B;PDE3A;CFAP69;PGAM4;PLCB1;VEGFA;HYAL3;ANKRD31;TACR2
prerank,Elsevier_Pathway_Collection__Goblet-Cell Related Mucus Secretion in Asthma,-0.25020801029200174,-0.40622149019490916,0.711864406779661,0.9353789378907288,1.0,13/44,19.32%,TNF;TRADD;PTGS2;TNFRSF1A;EGFR;PEBP1;RAF1;GRB2;SHC1;TGFA;ERN2;TYK2;MAP2K2
prerank,Elsevier_Pathway_Collection__Blood-Brain Barrier Disruption in Epileptiform Disorders,-0.2445607705437937,-0.40587712018754224,0.8275862068965517,0.9354044657071864,1.0,9/24,26.50%,RHEB;RPS6KB1;ALB;F2;SLC1A2;SLC1A3;GNAQ;ITPR1;AKT1
prerank,Elsevier_Pathway_Collection__SOD1 Mutation,0.27868795027709814,0.40586941937982673,0.7426470588235294,0.9193713522558898,1.0,8/28,14.45%,CYCS;TARDBP;HSPB1;VDAC1;CASP9;RNF19A;HSPB8;BCL2L1
prerank,Reactome_2022__Signaling By FLT3 Fusion Proteins R-HSA-9703465,0.24537479496583287,0.4051505458759702,0.8524590163934426,0.9196648040175582,1.0,3/18,8.03%,GOLGB1;STAT5A;STAT5B
prerank,Elsevier_Pathway_Collection__NOTCH Signaling in Hepatocellular Carcinoma,-0.24422145905631576,-0.40494016608974176,0.8114754098360656,0.9360690653829372,1.0,6/24,14.72%,EP300;DLL4;TADA2A;SMAD2;ADAM17;TCF4
prerank,GO_Biological_Process_2021__mesenchyme development (GO:0060485),-0.2178250868104472,-0.4048929002674919,0.8760330578512396,0.9357816940248984,1.0,8/15,38.17%,HMGA2;SFRP2;MEOX1;BMP2;GATA4;BMP4;PKD2;CRELD1
prerank,GO_Biological_Process_2021__sphingolipid catabolic process (GO:0030149),0.2260382772325945,0.4048535152010788,0.9044117647058824,0.9196248785716595,1.0,8/16,37.91%,ACER2;SMPD4;ACER3;ASAH2;SPHK1;SMPD1;SMPDL3A;PDXDC1
prerank,Reactome_2022__ROS And RNS Production In Phagocytes R-HSA-1222556,0.26507450415472006,0.40483392610112956,0.7164179104477612,0.9193151116939727,1.0,9/31,18.52%,RAC2;ATP6V1G1;ATP6V0A1;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;ATP6V0A2;HVCN1
prerank,Reactome_2022__NRIF Signals Cell Death From Nucleus R-HSA-205043,-0.17985841192592464,-0.40459140259411713,0.9661016949152542,0.9357768553133298,1.0,9/16,35.74%,RPS27A;APH1B;NGFR;UBC;NGF;NCSTN;TRAF6;APH1A;ITGB3BP
prerank,Reactome_2022__WNT Ligand Biogenesis And Trafficking R-HSA-3238698,0.23675076157208683,0.40442756911419336,0.7368421052631579,0.9193556098653098,1.0,10/24,33.89%,WNT11;WNT2B;WNT10B;WNT9B;PORCN;WNT16;WNT4;WNT1;VPS29;WNT5B
prerank,WikiPathway_2021_Human__Intraflagellar transport proteins binding to dynein WP4532,-0.26392125313542253,-0.40440286034037803,0.743801652892562,0.9356286428007196,1.0,7/25,15.07%,IFT27;IFT22;DYNLRB2;DYNLL2;DYNC1I2;DYNLT3;IFT140
prerank,GO_Biological_Process_2021__dolichol-linked oligosaccharide biosynthetic process (GO:0006488),0.22539425552792047,0.4042601840250634,0.8854961832061069,0.9192132223801822,1.0,6/17,24.61%,ALG12;NUS1;MPDU1;ALG8;ALG13;ALG2
prerank,"Elsevier_Pathway_Collection__L-cell: GCG, PYY and 5-HT Release",-0.24620342116588734,-0.4042239153246805,0.8151260504201681,0.9355046751392441,1.0,7/19,27.60%,PCSK2;GPBAR1;CASR;GNAQ;ITPR1;FFAR4;PLCB2
prerank,Reactome_2022__TP53 Regulates Transcription Of Additional Cell Cycle Genes With Uncertain Roles In P53 Pathway R-HSA-6804115,-0.21922325403344695,-0.4041612781770049,0.856,0.9352179147885762,1.0,4/21,10.67%,NPM1;CENPJ;PLK2;CNOT6
prerank,GO_Biological_Process_2021__superoxide metabolic process (GO:0006801),-0.25798396499939485,-0.40405729811422264,0.7661290322580645,0.934987140793504,1.0,13/28,31.30%,SH3PXD2B;PREX1;CCS;CYBA;SOD1;NCF1;NOX1;NCF2;MT3;NOS3;NCF4;ATP7A;DUOX1
prerank,GO_Biological_Process_2021__positive regulation of signaling receptor activity (GO:2000273),-0.24510139495278205,-0.40349338683346697,0.7391304347826086,0.935217698800128,1.0,16/36,31.99%,ADRA2B;BTC;ITGB1;EDN1;ADAM17;NCF1;TGFA;HDAC1;ADRA2A;BUD31;SHANK3;IFNG;CCR2;ARC;AREG;ADRB2
prerank,GO_Biological_Process_2021__cellular response to alkaloid (GO:0071312),-0.2157295340701892,-0.40314019239545357,0.8740157480314961,0.9352914117176738,1.0,3/17,14.19%,HTR1B;SLC8A1;CRHBP
prerank,Reactome_2022__TNFR1-induced NFkappaB Signaling Pathway R-HSA-5357956,-0.23036755983350868,-0.40311733984902937,0.811965811965812,0.9349750154228544,1.0,4/26,5.98%,TNF;TRADD;TNFRSF1A;TNFAIP3
prerank,GO_Biological_Process_2021__negative regulation of lipid catabolic process (GO:0050995),-0.2096625239218208,-0.40306918874645625,0.8782608695652174,0.934696481185872,1.0,7/17,29.86%,TNF;APOA2;PRKAA1;ADRA2A;AKT1;APOC1;SORL1
prerank,GO_Biological_Process_2021__organelle transport along microtubule (GO:0072384),-0.23959185992761567,-0.40274921526879887,0.7478260869565218,0.9347597662818885,1.0,7/31,14.29%,CDC42;RAB1A;RAB6A;LRPPRC;NDE1;RHOT1;BICDL1
prerank,KEGG_2021_Human__Graft-versus-host disease,-0.2521647979035012,-0.40244296838875265,0.7454545454545455,0.9348094667326103,1.0,15/35,30.43%,TNF;HLA-A;HLA-DQB1;KLRD1;HLA-DQA1;FAS;HLA-F;HLA-DMA;KIR3DL2;CD80;KIR2DL3;GZMB;PRF1;IFNG;HLA-DRB5
prerank,Reactome_2022__ABC Transporter Disorders R-HSA-5619084,-0.302328678821739,-0.4023642942124633,0.8947368421052632,0.9345418154805488,1.0,25/75,20.00%,PSMB7;RNF185;PSMD7;PSMF1;OS9;CFTR;ABCA12;PSMA5;DERL1;ABCB4;ABCD1;PSMD2;PSMB8;RPS27A;PSMD11;ABCC6;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;RNF5;PSMB3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Helicobacter Infections,-0.26943445735557237,-0.4023212815064955,0.7647058823529411,0.9342503011030244,1.0,19/55,20.83%,TNF;PTGS2;IL18;TP53BP2;HLA-DQB1;SCT;IL1RN;HLA-DQA1;CXCL13;MS4A1;IRAK3;OLFM4;LTF;CAMP;F2R;MMP3;CXCL8;NOD1;LEP
prerank,KEGG_2021_Human__Fat digestion and absorption,-0.2587879632383884,-0.40228650330940624,0.696969696969697,0.9339544854388084,1.0,12/35,26.57%,MOGAT3;PLA2G12B;PLA2G1B;CD36;NPC1L1;ACAT2;ACAT1;DGAT2;PLPP1;SLC27A1;PLA2G2C;APOA1
prerank,GO_Biological_Process_2021__regulation of mitochondrial translation (GO:0070129),-0.236629262398163,-0.4017634848556941,0.796875,0.9341696506177769,1.0,5/21,21.15%,C1QBP;TRMT10C;TSFM;MPV17L2;SHMT2
prerank,Elsevier_Pathway_Collection__Apoptosis of Mantle Cell Deregulation,0.23128724350945942,0.40172913676361705,0.8412698412698413,0.9212223821019278,1.0,4/17,14.45%,CASP10;CASP9;CFLAR;BCL2L1
prerank,GO_Biological_Process_2021__retina homeostasis (GO:0001895),0.23700171842478532,0.40166509721137533,0.7835820895522388,0.9209545586155166,1.0,11/25,33.35%,OPRPN;HSPB1;PRDX1;PIGR;JCHAIN;B2M;ZG16B;CNGB1;ATP1B2;CCDC66;SLC28A2
prerank,GO_Biological_Process_2021__regulation of protein localization to cell surface (GO:2000008),-0.2522683817893435,-0.40165775256086017,0.7540983606557377,0.9339656793558501,1.0,10/32,18.74%,TNF;COMMD1;TYROBP;RIC3;TM9SF4;KCNAB2;GBF1;ABCA2;RAB11B;NEDD4L
prerank,GO_Biological_Process_2021__multivesicular body organization (GO:0036257),0.26462617777951775,0.40111503022242406,0.6962962962962963,0.9211573883177028,1.0,13/31,31.35%,VPS4B;VPS25;CHMP1A;VPS28;VTA1;CHMP1B;HGS;CHMP4B;CHMP5;CHMP2A;RAB11A;PDCD6IP;VPS37C
prerank,Reactome_2022__Chemokine Receptors Bind Chemokines R-HSA-380108,-0.28901296504110463,-0.401092479502345,0.8113207547169812,0.9342587502916617,1.0,26/51,32.67%,CXCL5;XCR1;CXCL13;CCL11;CCL21;CXCR6;CNOT6;CXCL3;CCR5;ACKR2;CCR8;CCL17;CXCR3;CXCL8;CX3CR1;XCL1;CXCL1;CCRL2;XCL2;CCR2;CCL3;CCR3;CCL4;CXCL10;CCL25;CXCL11
prerank,GO_Biological_Process_2021__mitochondrial fission (GO:0000266),-0.2132679046610596,-0.40105642618944615,0.9016393442622951,0.9339663527121078,1.0,7/18,29.31%,FIS1;OPA1;MTFR1;DNM2;GDAP1;MUL1;SLC25A46
prerank,WikiPathway_2021_Human__Translation Factors WP107,0.2962848845523318,0.40070290745847936,0.7846153846153846,0.9212011198143744,1.0,15/50,21.36%,EIF2AK1;EIF2AK3;EIF2B3;EIF2B5;EIF2B4;EIF4G3;EIF3C;EEF1A2;EEF1D;EIF4EBP2;EIF3G;EIF4A2;EIF5A;EIF3A;EIF2S1
prerank,TRRUST_Transcription_Factors_2019__REST human,0.2226442334654699,0.40034775363191755,0.8943089430894309,0.9212027971693072,1.0,5/20,17.16%,VIP;KCNN4;CD59;DYRK1A;STAT1
prerank,GO_Biological_Process_2021__receptor signaling pathway via JAK-STAT (GO:0007259),-0.26627001499931685,-0.39982853360342513,0.8016528925619835,0.9349837812586514,1.0,6/30,12.76%,FER;JAK3;SOCS6;STAMBP;PTK6;STAT2
prerank,GO_Biological_Process_2021__regulation of blood circulation (GO:1903522),-0.24186851616987776,-0.3997093309770642,0.8114754098360656,0.9347858090356455,1.0,15/33,34.16%,CACNA1H;KCNQ1;AGTR1;PLN;ECE1;CELF2;CYP2J2;KCNE5;AGER;PER2;KCNJ12;ACE2;KCNMB2;DES;TPM1
prerank,GO_Biological_Process_2021__ventricular septum morphogenesis (GO:0060412),-0.25754783849292673,-0.3994040087070986,0.7310924369747899,0.9347888528815563,1.0,5/26,8.76%,HEY2;SOX4;ZFPM2;APLNR;CITED2
prerank,"GO_Biological_Process_2021__alternative mRNA splicing, via spliceosome (GO:0000380)",0.23919004799244914,0.39930273938207694,0.8721804511278195,0.9218674332863299,1.0,7/16,24.44%,RSRC1;DDX5;CELF4;RBM17;DDX17;HNRNPM;SRSF1
prerank,Reactome_2022__SCF(Skp2)-mediated Degradation Of P27/P21 R-HSA-187577,-0.28283592615252623,-0.39916769101228533,0.8461538461538461,0.9347064776864692,1.0,19/58,20.00%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;PTK6;CDK4;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__positive regulation of insulin secretion (GO:0032024),-0.25945378167158695,-0.3990822529409065,0.6904761904761905,0.9344518895440383,1.0,7/36,7.00%,NNAT;MCU;ADCY8;SOX4;CFTR;C2CD2L;TCF7L2
prerank,Reactome_2022__Autodegradation Of E3 Ubiquitin Ligase COP1 R-HSA-349425,-0.2797470424490775,-0.3990369234766093,0.7796610169491526,0.9341630395798544,1.0,18/49,23.67%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;TP53;UBC
prerank,GO_Biological_Process_2021__protein K48-linked deubiquitination (GO:0071108),-0.21211945318353398,-0.39877268348223616,0.8823529411764706,0.9340839671823897,1.0,13/23,38.47%,ATXN3;TNFAIP3;MINDY1;YOD1;OTUD4;OTUD3;BAP1;OTUB1;MINDY2;USP5;USP33;OTUD7A;USP20
prerank,GO_Biological_Process_2021__poly(A)+ mRNA export from nucleus (GO:0016973),-0.23162721190099766,-0.39859070192026713,0.8220338983050848,0.933913669013917,1.0,3/19,3.37%,IWS1;HHEX;DDX19B
prerank,GO_Biological_Process_2021__mononuclear cell differentiation (GO:1903131),0.2355904509876542,0.3983862896634151,0.768595041322314,0.9223977512910175,1.0,7/24,24.37%,CSF2;TRPM2;MT1G;PPARG;BATF3;FLT3;IRF8
prerank,Elsevier_Pathway_Collection__Androgen Induced Sebocyte Hyperfunction,0.22331770310650484,0.39823066109975347,0.905982905982906,0.9222140375816521,1.0,5/16,21.17%,PDPK1;HSD17B1;SREBF1;FADS2;PTEN
prerank,WikiPathway_2021_Human__Cytokines and Inflammatory Response WP530,0.24262394524608716,0.3978819653802963,0.852112676056338,0.9222179854741548,1.0,5/20,19.72%,IL12B;CSF2;CXCL2;IL15;IL5
prerank,Elsevier_Pathway_Collection__FOXO1 and SREBP-1C Role in beta-Cell Suppression (Rodent Model),0.26464071353382346,0.3975094746264967,0.75,0.9222874795418137,1.0,8/31,15.34%,SH2B1;MAPK1;PDPK1;SYTL4;HMOX1;SREBF1;JAK2;CCND1
prerank,GO_Biological_Process_2021__positive regulation of transcription initiation from RNA polymerase II promoter (GO:0060261),0.24147623928868095,0.39703068809315273,0.7878787878787878,0.9223975519026494,1.0,8/22,34.96%,MED12;SRF;MED13;MED30;SUB1;MED14;MED16;DHX36
prerank,Reactome_2022__Regulation Of Activated PAK-2p34 By Proteasome Mediated Degradation R-HSA-211733,-0.2858903380951991,-0.39661213204294815,0.8050847457627118,0.9358033350639051,1.0,16/47,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__cytoplasmic translational initiation (GO:0002183),0.23289845282275845,0.39652466065162456,0.8181818181818182,0.9225507806816305,1.0,5/19,20.40%,EIF2B3;EIF2S3B;EIF2D;EIF4A2;EIF3A
prerank,Elsevier_Pathway_Collection__Ethanol Induced Efects in Hyperprolactinemia,0.2255756441484144,0.3962501946008912,0.9069767441860465,0.9225179375404985,1.0,3/18,7.24%,JUN;MAPK1;FGF2
prerank,Reactome_2022__Hh Mutants Abrogate Ligand Secretion R-HSA-5387390,-0.2932451789036236,-0.3962492049174499,0.8666666666666667,0.9358777891536195,1.0,19/56,20.00%,PSMB7;PSMD7;PSMF1;OS9;PSMA5;SYVN1;PSMD2;PSMB8;DHH;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Elsevier_Pathway_Collection__IL2R -> ELK/SRF/MYC Signaling,0.22501530441122927,0.39623501258731664,0.8290598290598291,0.9222049548527748,1.0,4/19,9.16%,ELK1;MAPK1;SRF;PDPK1
prerank,WikiPathway_2021_Human__Extracellular vesicle-mediated signaling in recipient cells WP2870,-0.23265313216795258,-0.3958700387940898,0.8090909090909091,0.9359222939217351,1.0,9/29,22.22%,WNT5A;APC;EGFR;MFGE8;RAF1;SMAD2;TGFA;TSPAN8;PROM1
prerank,GO_Biological_Process_2021__multivesicular body assembly (GO:0036258),0.26685436094743925,0.3956074130984839,0.7218045112781954,0.9224798022821825,1.0,13/30,31.35%,VPS4B;VPS25;CHMP1A;VPS28;VTA1;CHMP1B;HGS;CHMP4B;CHMP5;CHMP2A;RAB11A;PDCD6IP;VPS37C
prerank,Reactome_2022__Degradation Of DVL R-HSA-4641258,-0.28965973374978315,-0.39560619011454334,0.8166666666666667,0.9358666486684605,1.0,17/53,20.00%,PSMB7;PSMD7;PSMF1;RBX1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Reactome_2022__Ubiquitin-dependent Degradation Of Cyclin D R-HSA-75815,-0.28916426427631803,-0.3955048998552584,0.847457627118644,0.9356422456270549,1.0,17/49,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;CDK4;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Apoptosis in COPD,0.2557924130528603,0.3954656909699046,0.8014184397163121,0.92229525864425,1.0,9/25,17.54%,FASLG;CYCS;CAV1;CASP9;MMP7;BCL2L1;BBC3;CASP12;DFFA
prerank,GO_Biological_Process_2021__antibacterial humoral response (GO:0019731),-0.249576500452036,-0.39507722581559623,0.7603305785123967,0.9357883275620739,1.0,8/28,19.06%,HLA-A;WFDC2;PLA2G1B;TF;LTF;CAMP;ANG;CTSG
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - apoptosis WP4864,0.24845435781946812,0.3948077334348855,0.751937984496124,0.922563346457553,1.0,6/21,18.12%,FASLG;MAPK11;CASP9;BCL2L1;BBC3;MAPK13
prerank,Elsevier_Pathway_Collection__BMP Signaling Impairment in Granulosa Cell in POF,-0.2207546378099584,-0.39445276694678444,0.8,0.9361791133595085,1.0,5/20,17.24%,PTGS2;VCAN;GDF9;SMAD2;BMPR1B
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - autophagy WP4863,-0.2141255067925096,-0.394394434415536,0.9180327868852459,0.9359190247936224,1.0,4/19,14.74%,ULK1;ATG7;ATG13;MAP1LC3A
prerank,WikiPathway_2021_Human__Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.2599695507507251,0.3942231356006259,0.796875,0.9228325569390717,1.0,8/30,15.62%,PTGIS;ACOX3;AKR1B1;PTGDR;PPARD;PTGES;PLA2G4B;PLA2G6
prerank,Elsevier_Pathway_Collection__IL6R -> CEBP/ELK/SRF Signaling,-0.21511870657707854,-0.3938001479155509,0.8712121212121212,0.9361812050698323,1.0,6/17,22.99%,MAPK3;ELK4;RAF1;GRB2;MAP2K2;IL6ST
prerank,GO_Biological_Process_2021__negative regulation of Rho protein signal transduction (GO:0035024),0.22335101988265532,0.3937543830529157,0.8732394366197183,0.9230244740228837,1.0,9/17,33.33%,KANK1;FLCN;ITGA3;ABL2;RASIP1;CCDC125;DLC1;SCAI;CUL3
prerank,Elsevier_Pathway_Collection__Wolfram Syndrome Progression (Hypothesis),0.21097616455627752,0.39267887977161375,0.8870967741935484,0.923766280834522,1.0,5/17,17.81%,EIF2AK3;CISD2;ABCC8;WFS1;XBP1
prerank,Elsevier_Pathway_Collection__TNFR/NF-kB Classical Pathway in Multiple Myeloma Plasma Cells,-0.2623658694022063,-0.39260948487955655,0.7889908256880734,0.9370724644850991,1.0,4/29,3.70%,TNF;TRADD;VCAM1;TNFRSF1A
prerank,TRRUST_Transcription_Factors_2019__JUND human,-0.23737990982460994,-0.39249399155584824,0.7647058823529411,0.9368838859006232,1.0,8/30,19.79%,PTGS2;SOX4;ITGAV;NTS;PLAUR;TIMP1;CSTA;MDM2
prerank,Reactome_2022__Signaling By NOTCH4 R-HSA-9013694,-0.29170470708436697,-0.3918013783402496,0.9065420560747663,0.9373019093877454,1.0,26/80,20.00%,PSMB7;HES5;HEY2;PSMD7;PSMF1;EP300;RBX1;SKP1;PSMA5;NOTCH4;PSMD2;DLL4;PSMB8;RPS27A;PSMD11;PSMD10;MAMLD1;PSMD13;PSMC1;PSME1;PSMA1;APH1B;PSMD5;PSMD12;MAML2;PSMB3
prerank,GO_Biological_Process_2021__artery morphogenesis (GO:0048844),-0.23306668562015287,-0.3917281695402593,0.7739130434782608,0.9370374146584823,1.0,10/29,30.93%,HEY2;ADAMTS9;ENG;TBX1;LRP1;LRP2;HES1;BMPR1A;VEGFA;NOTCH1
prerank,GO_Biological_Process_2021__neuromuscular process (GO:0050905),-0.2004839481922248,-0.3917264823089539,0.9180327868852459,0.9367075880429743,1.0,4/15,25.61%,UBA5;CHRND;MYCBP2;DCTN1
prerank,GO_Biological_Process_2021__endosome organization (GO:0007032),-0.27854862160741295,-0.39119752023965165,0.7967479674796748,0.9369525635815075,1.0,13/41,22.38%,DNAJC13;SNX10;RNF26;LAPTM4B;PHETA2;PI4K2B;RAB22A;HOOK1;CHMP2B;RILP;PLEKHF1;TMEM9;WASHC4
prerank,GO_Biological_Process_2021__mitochondrial translational termination (GO:0070126),-0.2849513360040619,-0.390325215403527,0.944954128440367,0.9375172867536462,1.0,38/88,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL22;MRPL43;MRPL54;GFM2;MRPL27;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPL2;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRRF;MRPL14;DAP3;MRPS15;MRPL16
prerank,GO_Biological_Process_2021__mitochondrial translational elongation (GO:0070125),-0.2841483699082549,-0.38965180361320767,0.940677966101695,0.937952202324059,1.0,38/88,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL22;MRPL43;MRPL54;GFM2;MRPL27;TSFM;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPL2;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRPL14;DAP3;MRPS15;MRPL16
prerank,Elsevier_Pathway_Collection__SIRT3 Signaling in Aging,-0.25576067762252214,-0.3896215372181002,0.832,0.9376522569706748,1.0,11/26,27.94%,ACADL;SDHA;NDUFS1;OTC;IDH2;XRCC6;STK11;TP53;PDHA1;ACSL1;SIRT3
prerank,GO_Biological_Process_2021__regulation of regulatory T cell differentiation (GO:0045589),-0.2257701312914019,-0.38893849894310767,0.8,0.9380793873269822,1.0,5/25,16.76%,IL4I1;SOX12;DUSP10;CTLA4;TNFSF4
prerank,GO_Biological_Process_2021__regulation of rhodopsin mediated signaling pathway (GO:0022400),0.2290814814955428,0.3885132446754847,0.8064516129032258,0.9274004017597846,1.0,7/20,26.66%,GUCY2D;RHO;GUCA1B;PDE6A;NMT2;GRK4;CNGB1
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> AP-1 Signaling,-0.20722785822676615,-0.3884575320574165,0.8360655737704918,0.9382298385087868,1.0,7/21,26.36%,BTK;MAPK3;CD22;RASGRP1;MAP2K2;ITPR1;BRAF
prerank,WikiPathway_2021_Human__7-oxo-C and 7beta-HC pathways WP5064,-0.2494507588722788,-0.38841177151425194,0.773109243697479,0.9379523924369458,1.0,8/27,20.07%,ACOT1;HSD11B1;NPC2;THEM5;SLC27A5;DHCR7;CYP7A1;EBP
prerank,GO_Biological_Process_2021__stress-activated protein kinase signaling cascade (GO:0031098),-0.23135416839791367,-0.3882749232835243,0.8130081300813008,0.9377746271629852,1.0,7/27,13.05%,MAPK3;SKP1;KAT7;MAP3K5;RPS27A;TNIP2;CCM2
prerank,GO_Biological_Process_2021__positive regulation of G2/M transition of mitotic cell cycle (GO:0010971),0.22493141626365978,0.3882279630937717,0.8785714285714286,0.9273268250525964,1.0,9/19,31.03%,VPS4B;CCND1;DTL;CCNB1;BRD4;RCC2;STOX1;RAB11A;CDC25B
prerank,WikiPathway_2021_Human__Prostaglandin Synthesis and Regulation WP98,-0.2729786563741908,-0.38768463631732497,0.7692307692307693,0.9381016639780169,1.0,11/43,13.77%,ABCC4;PTGS2;TBXA2R;AKR1C3;ANXA1;HSD11B1;CBR1;ANXA4;PTGFR;ANXA3;EDN1
prerank,GO_Biological_Process_2021__membrane protein ectodomain proteolysis (GO:0006509),0.24822420094435274,0.38758436931674106,0.8538461538461538,0.9275913243601408,1.0,7/22,25.05%,HM13;PSEN2;MMP7;PRKCQ;RBMX;PSENEN;ADAM10
prerank,Reactome_2022__Meiotic Recombination R-HSA-912446,-0.26600287191343025,-0.38751015311165504,0.7948717948717948,0.9379580990133318,1.0,11/42,13.33%,MLH3;H2BC13;POLR1B;H2AZ2;H2BC15;CDK4;RAD51C;H2AC6;MRE11;RPA3;H2BC5
prerank,GO_Biological_Process_2021__regulation of calcium ion transmembrane transporter activity (GO:1901019),0.25282331314665574,0.38743074660306204,0.768,0.9274498898306895,1.0,7/27,17.08%,CACNB2;HPCA;HRC;NOS1;FKBP1A;SELENON;PRKACA
prerank,Reactome_2022__Ubiquitin Mediated Degradation Of Phosphorylated Cdc25A R-HSA-69601,-0.2869739627189085,-0.38742071916028936,0.8173913043478261,0.937721186560323,1.0,16/49,20.00%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Reactome_2022__Initiation Of Nuclear Envelope (NE) Reformation R-HSA-2995383,-0.20685153384551952,-0.3872781626575545,0.9333333333333333,0.9375541310487719,1.0,3/19,8.90%,LBR;SIRT2;LEMD3
prerank,GO_Biological_Process_2021__negative regulation of cell development (GO:0010721),0.23302419423292126,0.38699735654415707,0.7874015748031497,0.9275602670504852,1.0,7/23,18.29%,PCM1;GSK3B;RFLNA;DYNLT1;B2M;HOOK3;REST
prerank,Elsevier_Pathway_Collection__Insulin Influence on Protein Synthesis,-0.23427479218477051,-0.38678284910693367,0.7804878048780488,0.9377370070859186,1.0,16/31,34.17%,MAPK3;IGF1;RHEB;RPS6KB1;RAF1;GRB2;SHC1;MAP2K2;AKT1;IDE;EIF4E;SOS1;MYC;INSR;EIF2S3;TSC2
prerank,Elsevier_Pathway_Collection__OPTN Effects on NF-kB Signaling in Glaucoma,0.2453029084279512,0.3866606968063996,0.7619047619047619,0.9275962534088922,1.0,6/26,9.61%,FASLG;TNFRSF1B;CYCS;TRAF2;CASP9;TAX1BP1
prerank,Elsevier_Pathway_Collection__TGFB2 Signaling Impairement in Osteoarthritis,-0.22767071351566626,-0.3864438195627196,0.8596491228070176,0.9377582447468206,1.0,5/22,19.85%,SMURF1;COL2A1;SMAD2;TIMP1;MAPK14
prerank,GO_Biological_Process_2021__positive regulation of lipid storage (GO:0010884),0.2193238074530201,0.38619293563427953,0.8852459016393442,0.9277195378047025,1.0,8/19,33.58%,IKBKE;PLA2G10;CIDEA;SREBF2;PLIN5;APOB;ZC3H12A;MSR1
prerank,Elsevier_Pathway_Collection__Doxorubicin Induced Cardiotoxicity,0.2199284328559919,0.38615741042931734,0.8292682926829268,0.9274258168331554,1.0,4/22,12.13%,FASLG;SRF;PDPK1;ATP2A2
prerank,GO_Biological_Process_2021__integrated stress response signaling (GO:0140467),0.2173200795732616,0.38541405474216545,0.9302325581395349,0.927801746551715,1.0,5/15,23.61%,EIF2AK1;EIF2AK3;QRICH1;EIF2S1;ATF4
prerank,GO_Biological_Process_2021__translational termination (GO:0006415),-0.2797827439480671,-0.3853102473123361,0.9333333333333333,0.9386296916897684,1.0,40/95,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL22;MRPL43;MRPL54;GFM2;MRPL27;MRPS18A;MRPS36;N6AMT1;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPL2;MRPS23;TRMT112;MRPS2;MRPS14;MRPS5;MRPL30;MRRF;MRPL14;DAP3;MRPS15;MRPL16
prerank,GO_Biological_Process_2021__phosphatidylinositol dephosphorylation (GO:0046856),-0.24260799544938141,-0.3851821101140423,0.7815126050420168,0.938434418617338,1.0,4/24,6.21%,MTMR1;MTMR2;MTMR4;OCRL
prerank,"GO_Biological_Process_2021__regulation of alternative mRNA splicing, via spliceosome (GO:0000381)",0.2669311216317064,0.3848343319428207,0.7557251908396947,0.9280472200077832,1.0,18/48,23.47%,THRAP3;RBM15B;NOVA1;HNRNPU;MBNL3;MAGOH;SRSF12;DDX5;CELF4;SAP18;REST;RBMX;WTAP;RBM25;KHDRBS3;YTHDC1;DDX17;RBM15
prerank,WikiPathway_2021_Human__Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,-0.20897429913877535,-0.38481434145175086,0.9292035398230089,0.9384672314861698,1.0,4/18,15.35%,MAPK3;RAB5A;RAF1;MRAS
prerank,Elsevier_Pathway_Collection__V(D)J Recombination Activation,0.2405557776570305,0.3848028148002057,0.7916666666666666,0.9277680057497962,1.0,8/34,16.25%,RAG1;MAPK1;STAT5A;STAT5B;PRKCQ;PAX5;IL7R;CD40LG
prerank,GO_Biological_Process_2021__positive regulation of histone methylation (GO:0031062),-0.2327670673397395,-0.3845649558486892,0.7698412698412699,0.9384304767947325,1.0,10/26,28.64%,DNMT3B;H1-5;WDR61;WDR5;PAXIP1;CHTOP;PAF1;PHF1;SNW1;FAM47E
prerank,GO_Biological_Process_2021__autophagy of mitochondrion (GO:0000422),-0.25006780680423196,-0.384468820498916,0.8099173553719008,0.938205895107675,1.0,12/40,21.08%,ULK1;FBXO7;MAP1LC3B;WDR45;ATG7;FIS1;MAP1LC3C;ATG13;MAP1LC3A;USP30;PINK1;WDR45B
prerank,Elsevier_Pathway_Collection__Apoptosis of Renal Tubule Epithelial Cell in Pyelonephritis,0.25057343781942604,0.38408573561479503,0.7323943661971831,0.9281395282614843,1.0,10/30,19.07%,EIF2AK3;CYCS;TRAF2;VDAC1;CASP9;MAPK10;BCL2L1;CASP12;XBP1;HSP90B1
prerank,Reactome_2022__Mitochondrial Translation Termination R-HSA-5419276,-0.27439990148864035,-0.3835307487667525,0.8938053097345132,0.9388538668934509,1.0,34/81,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL43;MRPL54;GFM2;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRRF;MRPL14;MRPS15;MRPL16
prerank,GO_Biological_Process_2021__negative regulation of mitotic cell cycle (GO:0045930),-0.24880369685163856,-0.38337659322355205,0.78,0.9387076346487176,1.0,15/46,20.80%,BRINP2;BUB1;FOXC1;PTPN3;TOM1L1;BUB1B;TOM1L2;PLK2;ZFP36L1;WEE1;ZW10;TRIM35;MAD2L1;AURKAIP1;PRCC
prerank,Reactome_2022__Signaling By NODAL R-HSA-1181150,-0.22087996920681904,-0.38331813764795286,0.8211382113821138,0.9384373857229913,1.0,5/21,12.86%,NODAL;MAPK3;CERS1;SMAD2;ACVR1B
prerank,GO_Biological_Process_2021__regulation of stem cell population maintenance (GO:2000036),-0.20185392268563804,-0.3831663544428974,0.8974358974358975,0.9382692446764775,1.0,9/19,35.77%,NODAL;HMGA2;ZC3H13;WDR43;LOXL2;ZNF706;MYC;TAF5L;PTN
prerank,Reactome_2022__Sensory Perception Of Taste R-HSA-9717189,0.24443505346860128,0.38308139961649124,0.8,0.9287969379820733,1.0,6/25,11.25%,SCNN1A;TAS1R3;SCN2A;GNB1;SCNN1G;TRPM4
prerank,"GO_Biological_Process_2021__regulation of DNA-templated transcription, initiation (GO:2000142)",0.26714190727220727,0.3830435585331955,0.84,0.9285112528496475,1.0,22/61,28.08%,JUN;MED12;AGO4;MED6;MED25;MED26;MED13;MED15;MED8;FOSL1;CCND1;CCNB1;MED30;CDKN1A;MED10;PTEN;CTNNB1;TNRC6C;MED27;MED20;MED14;TWIST1
prerank,Elsevier_Pathway_Collection__Golgi to Endosome Transport,-0.2650822066788755,-0.38246731021197566,0.7345132743362832,0.9387154756573864,1.0,15/41,24.39%,PACS1;NAPA;RAB5A;GOSR1;GGA2;IGF2R;BET1L;YKT6;CPD;DNM2;STX6;GOLGA4;GOLGA1;ARFRP1;VPS35
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,-0.23421244661317858,-0.38246150860864553,0.8396946564885496,0.9383953208919745,1.0,9/22,28.34%,ABCC4;GSTP1;ABCC6;GCLM;NFE2L2;MAPK14;MAPK12;ABCC3;ABCG2
prerank,Elsevier_Pathway_Collection__Alcoholic Dilated Cardiomyopathy (Mouse Model),-0.2288206997113122,-0.3823985034899923,0.8629032258064516,0.9381299845788228,1.0,8/26,24.24%,ANKRD1;ADRB1;SLC8A1;PLN;TCAP;MYL3;TTN;LAMA4
prerank,TRRUST_Transcription_Factors_2019__NFIC human,0.24242070976835234,0.38239081400435126,0.803030303030303,0.9288275494586509,1.0,5/25,8.70%,GFAP;JUN;ALAS1;POLE2;VWF
prerank,GO_Biological_Process_2021__response to zinc ion (GO:0010043),-0.20201114841021214,-0.3822175074888485,0.85,0.938004961067055,1.0,7/25,19.42%,PAM;MT1F;CRIP1;MT1A;SLC30A3;MT1B;ZNF658
prerank,GO_Biological_Process_2021__regulation of viral transcription (GO:0046782),-0.2534501479652835,-0.3820423541820387,0.7735849056603774,0.9378888718001835,1.0,13/40,21.58%,TRIM14;POLR2G;HEXIM1;TRIM31;DHX9;NELFE;TRIM27;TRIM21;IFITM3;POLR2D;NELFCD;TRIM11;TRIM62
prerank,GO_Biological_Process_2021__ganglioside metabolic process (GO:0001573),0.22011825004620267,0.38121975257814217,0.8549618320610687,0.9295866938539279,1.0,5/18,18.18%,ST8SIA6;HEXB;ST3GAL5;NEU4;HEXA
prerank,GO_Biological_Process_2021__regulation of mitochondrial membrane permeability (GO:0046902),0.22074973047862076,0.3809666678510352,0.8099173553719008,0.9295205398186278,1.0,7/18,26.75%,PPIF;BCL2L1;NAIF1;ARHGAP11B;THEM4;BNIP3;SLC25A4
prerank,Elsevier_Pathway_Collection__Corneodesmosomes in Atopic Dermatitis,0.20888819919222584,0.3809131145229283,0.9590163934426229,0.9292440870190429,1.0,4/15,21.39%,DSC3;JUP;PKP2;CTNNB1
prerank,Elsevier_Pathway_Collection__Histone Methylation,-0.22298267337749922,-0.38077652453981903,0.8108108108108109,0.9389461684294714,1.0,8/28,19.70%,DNMT3B;ZBTB33;RBBP7;MBD1;SUV39H1;DNMT3A;HDAC1;RBBP4
prerank,Reactome_2022__Peroxisomal Lipid Metabolism R-HSA-390918,0.23975606294356006,0.38075964665428286,0.8169014084507042,0.9290573836470059,1.0,4/28,5.97%,HSD17B4;NUDT7;ACOX3;NUDT19
prerank,GO_Biological_Process_2021__phosphatidylglycerol metabolic process (GO:0046471),-0.2099077627829069,-0.3807215502803448,0.835820895522388,0.9386677485375458,1.0,4/21,12.33%,GPAM;SERAC1;PLA2G1B;LPCAT1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Amyotrophic Lateral Sclerosis,-0.21349209006671535,-0.38033176332831753,0.8620689655172413,0.9387666040776151,1.0,8/19,29.76%,TNF;SLC1A2;HNRNPK;NFE2L2;TP53;HSPA5;CASP3;VEGFA
prerank,GO_Biological_Process_2021__mitochondrion disassembly (GO:0061726),-0.25253365462436894,-0.3802845128546807,0.8455284552845529,0.9384958028150393,1.0,11/36,21.08%,ULK1;FBXO7;MAP1LC3B;WDR45;ATG7;FIS1;MAP1LC3C;MAP1LC3A;USP30;PINK1;WDR45B
prerank,WikiPathway_2021_Human__PDGFR-beta pathway WP3972,-0.25304198330872346,-0.3801351720303112,0.7642276422764228,0.938320866735605,1.0,8/29,15.15%,MAP3K1;MAPK3;PIK3CA;MAP2K4;RAF1;PIK3R1;GRB2;SHC1
prerank,GO_Biological_Process_2021__negative regulation of ubiquitin-protein transferase activity (GO:0051444),0.20909273881895876,0.3798964271272754,0.9071428571428571,0.9296091037128904,1.0,6/15,26.22%,SMAD7;RPS7;PARK7;USP44;LIMK1;RPL5
prerank,GO_Biological_Process_2021__natural killer cell mediated cytotoxicity (GO:0042267),-0.22647138467077021,-0.37927261771759785,0.8849557522123894,0.9389053142416878,1.0,5/20,14.84%,RAET1G;MICA;SLAMF7;CEBPG;CORO1A
prerank,GO_Biological_Process_2021__peptidyl-proline modification (GO:0018208),0.24306768522006594,0.37867491564172934,0.7478260869565218,0.9304937984521798,1.0,5/25,11.85%,PPIF;PPID;PPWD1;OGFOD1;FKBP1A
prerank,GO_Biological_Process_2021__GPI anchor metabolic process (GO:0006505),-0.20499304721912148,-0.3782762693084173,0.8852459016393442,0.9396055584825319,1.0,6/26,22.12%,DPM2;PIGB;PIGA;PIGN;PIGV;PIGP
prerank,Reactome_2022__Class C/3 (Metabotropic Glutamate/Pheromone Receptors) R-HSA-420499,-0.1985645315346721,-0.37766584689276933,0.9586776859504132,0.9399494755356714,1.0,4/16,19.64%,TAS2R19;CASR;GRM8;GRM7
prerank,GO_Biological_Process_2021__histone deubiquitination (GO:0016578),-0.21122629434073642,-0.37754879151125376,0.8803418803418803,0.9397536988381813,1.0,9/19,33.42%,USP49;EPOP;USP15;USP7;USP3;USP51;ENY2;SUPT3H;USP21
prerank,WikiPathway_2021_Human__Cori Cycle WP1946,-0.18884223015452453,-0.3772626159368734,0.9145299145299145,0.9397490792858952,1.0,7/15,30.28%,ALDOA;HK1;SLC2A1;SLC2A2;TPI1;TALDO1;PFKP
prerank,GO_Biological_Process_2021__regulation of rRNA processing (GO:2000232),-0.20585525695352405,-0.37705970591007293,0.9712230215827338,0.9396548610668279,1.0,5/16,24.00%,SIRT7;SHQ1;WDR43;UTP15;TRMT112
prerank,GO_Biological_Process_2021__regulation of mitochondrial fission (GO:0090140),-0.2313983675805654,-0.3770566726753722,0.8103448275862069,0.9393301736397297,1.0,11/25,29.06%,MCU;RALA;MARCHF5;SPIRE1;FIS1;STAT2;PINK1;VPS35;MIEF2;MUL1;RALBP1
prerank,GO_Biological_Process_2021__regulation of release of cytochrome c from mitochondria (GO:0090199),-0.23467379744301795,-0.3765756966642021,0.7946428571428571,0.9395590962025808,1.0,13/37,23.82%,PRELID1;PYCARD;IGF1;MMP9;BCL2L11;OPA1;PSMD10;PLAUR;BID;PINK1;TP53;MLLT11;GPX1
prerank,GO_Biological_Process_2021__negative regulation of peptide hormone secretion (GO:0090278),-0.1925228986708599,-0.37625660023292196,0.9264705882352942,0.9395457464315161,1.0,5/16,26.62%,BMP8A;CRHBP;SFRP1;ADRA2A;FFAR4
prerank,GO_Biological_Process_2021__response to fatty acid (GO:0070542),0.20845586540484978,0.3757174139407856,0.9384615384615385,0.9330855708442617,1.0,5/15,29.42%,NR1H4;GLDC;PDK3;PID1;FOXO3
prerank,GO_Biological_Process_2021__cellular response to glucagon stimulus (GO:0071377),-0.21818284647485928,-0.3754769759699277,0.9117647058823529,0.94003993460227,1.0,4/18,13.96%,ADCY8;ADCY3;PRKAR2A;ADCY5
prerank,GO_Biological_Process_2021__response to hexose (GO:0009746),-0.24002936346907072,-0.37495204196757703,0.7874015748031497,0.9402713057746681,1.0,4/23,7.22%,SELENOS;APOA2;TCF7L2;PFKL
prerank,Elsevier_Pathway_Collection__TGFBR Signaling in Pancreatic Neoplasms,0.26977859720102304,0.3747628815122635,0.8175182481751825,0.9336664587406036,1.0,21/47,32.15%,BRCA2;ELK1;CYCS;JUN;MAPK1;DAXX;CASP9;CDK2;MAPK10;BRCA1;SMAD3;CDKN1A;SP1;MAP2K7;TGFBR2;CREB1;SMAD4;MAP2K1;MAPK8;HRAS;BCL2
prerank,GO_Biological_Process_2021__neuron cell-cell adhesion (GO:0007158),0.19824486897388088,0.37451575175238594,0.9426229508196722,0.9336107317611163,1.0,3/16,15.98%,NLGN2;NLGN3;CEL
prerank,Elsevier_Pathway_Collection__Neutrophil Recruitment in Sinovium in Gout,-0.2358227446575229,-0.3742794601987977,0.7345132743362832,0.9406461678861479,1.0,10/36,19.85%,TNF;TRADD;VCAM1;TNFRSF1A;MAP2K4;C5;MAP3K5;IRAK1;CXCL8;MAPK14
prerank,GO_Biological_Process_2021__regulation of transcription from RNA polymerase II promoter in response to hypoxia (GO:0061418),-0.2883242372024995,-0.3741512097214164,0.9203539823008849,0.9404405029353656,1.0,26/73,20.00%,PSMB7;PSMD7;PSMF1;EP300;SIRT2;RBX1;HIF3A;EGLN2;PSMA5;PSMD1;CITED2;VHL;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;ELOB;PSME1;PSMA1;PSMD5;NFE2L2;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__positive regulation of release of cytochrome c from mitochondria (GO:0090200),-0.22039924540175287,-0.37401369964057757,0.8504672897196262,0.9402569526258094,1.0,8/23,22.95%,PYCARD;MMP9;BCL2L11;PLAUR;BID;PINK1;TP53;MLLT11
prerank,GO_Biological_Process_2021__histone lysine methylation (GO:0034968),0.240484934223248,0.3737995386715723,0.7633587786259542,0.9339747258212567,1.0,10/31,17.96%,SETDB1;EZH2;DOT1L;MEN1;PAGR1;RBBP5;SETD1B;PRDM5;SETD6;KMT2A
prerank,GO_Biological_Process_2021__secondary alcohol biosynthetic process (GO:1902653),-0.25867925892954324,-0.37375490462559446,0.7777777777777778,0.9401833524271623,1.0,12/33,22.13%,MVD;LBR;TM7SF2;NSDHL;NPC1L1;ACAT2;PMVK;DHCR7;ARV1;HMGCR;EBP;INSIG2
prerank,Reactome_2022__Nef-mediated Downmodulation Of Cell Surface Receptors By Recruitment To Clathrin Adapters R-HSA-164938,0.2121313260789776,0.37279853709835453,0.856,0.9345741389319259,1.0,9/20,31.47%,AP2B1;ATP6V1H;B2M;AP2M1;AP2S1;CD8B;AP1M1;LCK;AP1S3
prerank,GO_Biological_Process_2021__histone H3-K4 methylation (GO:0051568),0.25136221283268617,0.37261431815732754,0.7777777777777778,0.9344016603049605,1.0,11/28,27.60%,TET3;MEN1;PAGR1;PRDM7;KMT2C;RBBP5;SETD1B;KMT2A;DPY30;OGT;KMT2B
prerank,GO_Biological_Process_2021__transferrin transport (GO:0033572),0.23388431140149024,0.37257811224552895,0.7586206896551724,0.9341193098857645,1.0,12/33,26.46%,ATP6V1G1;MCOLN1;ATP6V0A1;ATP6V0C;ATP6V1E2;ATP6V0D2;ATP6V1H;ATP6V0A2;REP15;ATP6V1E1;ATP6V0E2;CLTC
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Autophagy in COPD,0.24724453727720538,0.3724590062346815,0.8492063492063492,0.9339070037404369,1.0,10/24,26.27%,EIF2AK3;HMOX1;ATG4B;BCL2L1;XBP1;EIF2S1;ATF4;E2F4;ATG5;ATG14
prerank,GO_Biological_Process_2021__proton transmembrane transport (GO:1902600),0.2544779432205145,0.371666806391357,0.8137931034482758,0.9343517427714554,1.0,9/29,18.52%,COX15;ATP4A;ATP6V0C;ATP1A4;SLC36A1;SLC9A1;ATP6V1H;ATP12A;HVCN1
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell Vasodilation in Brain,-0.2028649980058161,-0.3713343392066274,0.8739495798319328,0.9425031170665666,1.0,9/28,26.01%,HTR1B;KNG1;AGTR1;CALCRL;EDN1;MYLK;GNAQ;ITPR1;PLCB1
prerank,Reactome_2022__Signaling By FLT3 ITD And TKD Mutants R-HSA-9703648,0.2116892969763402,0.3713248460124434,0.9416666666666667,0.9343683048132323,1.0,5/15,24.31%,STAT5A;STAT5B;BCL2L1;CDKN1A;FLT3
prerank,WikiPathway_2021_Human__miRNA regulation of p53 pathway in prostate cancer WP3982,0.2526561403866049,0.3713225950430775,0.8309859154929577,0.9340514600657498,1.0,8/24,29.63%,TP53AIP1;CASP9;DDB2;BBC3;PTEN;TNFRSF10B;CHEK2;PERP
prerank,GO_Biological_Process_2021__respiratory chain complex IV assembly (GO:0008535),0.21291025615192652,0.37101070560866994,0.8529411764705882,0.9340384018505851,1.0,3/23,5.42%,COA1;SCO1;COX15
prerank,Reactome_2022__TBC/RABGAPs R-HSA-8854214,-0.25839032515164057,-0.3705402110302129,0.7863247863247863,0.9430536174670201,1.0,8/43,6.79%,RAB8B;ULK1;MAP1LC3B;RAB5A;RAB6A;TBC1D25;TBC1D13;GGA2
prerank,GO_Biological_Process_2021__mesonephric tubule development (GO:0072164),0.1856984585952317,0.3704962612511223,0.9538461538461539,0.9341958108925784,1.0,2/15,6.92%,WNT11;ROBO2
prerank,GO_Biological_Process_2021__central nervous system neuron differentiation (GO:0021953),-0.23446672363539525,-0.3703097547600869,0.7560975609756098,0.9429367057232254,1.0,9/29,22.35%,SOX4;DRAXIN;LRP6;GBA2;ZC4H2;MDGA2;RYK;OPHN1;CBLN1
prerank,GO_Biological_Process_2021__dendritic cell differentiation (GO:0097028),-0.22269364348409884,-0.3699291381693746,0.896551724137931,0.9429982732820082,1.0,4/22,12.68%,DCSTAMP;DHRS2;BATF;AXL
prerank,Reactome_2022__Regulation Of TNFR1 Signaling R-HSA-5357905,-0.220149084072718,-0.3694994325246105,0.8440366972477065,0.9431211929402966,1.0,7/35,12.35%,TNF;TRADD;TNFRSF1A;TNFAIP3;FADD;RPS27A;USP2
prerank,Reactome_2022__HSF1-dependent Transactivation R-HSA-3371571,0.2679340890902709,0.36944231641169656,0.8074074074074075,0.934967586994289,1.0,14/34,30.84%,SERPINH1;DEDD2;HSF1;CREBBP;UBB;HSPB8;MTOR;PTGES3;HSPA8;MLST8;COL4A6;RPTOR;HSPA1B;HSPH1
prerank,Elsevier_Pathway_Collection__MYOC Associated Glaucoma,0.23689688415724314,0.3692752542329625,0.8102189781021898,0.9347929214569753,1.0,9/26,23.61%,EIF2AK3;CYCS;TRAF2;BBC3;XBP1;RHOA;EIF2S1;MAP2K7;ATF4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pulmonary Emphysema,-0.2117318992493908,-0.3691799088490253,0.7837837837837838,0.9431373547948132,1.0,18/35,36.04%,TNF;ELN;IL18;MPO;ITGB6;TGFA;NFE2L2;CTSG;LYZ;MMP8;KL;IFNG;VEGFA;EDNRA;TGFB1;TLR4;CTSS;NOS2
prerank,GO_Biological_Process_2021__acidic amino acid transport (GO:0015800),-0.19755335739108423,-0.3688972603398675,0.9285714285714286,0.9430892317038915,1.0,6/17,26.99%,SLC1A1;SLC1A2;SLC1A3;SLC25A12;SLC6A6;ARL6IP5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Atopic Dermatitis,-0.23106771712791263,-0.36797350633807346,0.8245614035087719,0.9436953399204494,1.0,10/39,17.53%,TNF;IL18;LTA;CTSE;CCL11;FCER1A;TAC1;FAS;CAMP;CCL17
prerank,GO_Biological_Process_2021__transcription by RNA polymerase III (GO:0006383),-0.22528275802630576,-0.36774715949484704,0.832,0.9435828280727213,1.0,8/28,22.58%,GTF3C2;GTF3C4;SNAPC4;SNAPC5;ICE2;POLR3H;IVNS1ABP;ELL
prerank,Elsevier_Pathway_Collection__TRPM7/8 in Pancreatic Adenocarcinoma,-0.21770240141554997,-0.3676321169062459,0.8495575221238938,0.9433565718659407,1.0,10/21,33.21%,TNF;MAPK3;RAF1;CXCL8;MAP2K2;ITPR1;TRPM7;MYC;TRPM8;PRKD1
prerank,WikiPathway_2021_Human__Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds WP3664,-0.1919115734351819,-0.36739503558236447,0.905511811023622,0.9433040633007087,1.0,5/17,23.09%,APC;TNKS;TCF4;LRP1;DKK3
prerank,GO_Biological_Process_2021__inner ear morphogenesis (GO:0042472),-0.21152990694271145,-0.3665590195162839,0.9230769230769231,0.9438946792385917,1.0,7/20,25.08%,TFAP2A;TBX18;PAX8;TMIE;ZIC1;TBX1;TTC39C
prerank,GO_Biological_Process_2021__protein K63-linked deubiquitination (GO:0070536),-0.22418422062152735,-0.36643058951673496,0.864406779661017,0.9437166551393801,1.0,9/31,24.62%,ATXN3;STAMBP;TNFAIP3;SPATA2;USP7;YOD1;SHMT2;OTUD4;USP13
prerank,Elsevier_Pathway_Collection__Lipids Enhance Apoptotic Cell Engulfment and Reduce Inflammation,-0.21653125028412418,-0.3660861617208805,0.847457627118644,0.9437821136818998,1.0,7/25,23.19%,TNF;IL18;MFGE8;CD36;ALDH1A1;CXCL8;NR4A1
prerank,KEGG_2021_Human__Fatty acid elongation,-0.20006015400609634,-0.3656952027348959,0.9145299145299145,0.9439189075822646,1.0,7/27,19.63%,HADHA;ACOT1;THEM5;ELOVL6;ELOVL1;MECR;PPT1
prerank,GO_Biological_Process_2021__dendritic spine organization (GO:0097061),-0.22613436157073818,-0.36561944853474593,0.8660714285714286,0.9436682468786087,1.0,11/27,26.24%,CDC42;MTMR2;EPHB3;FYN;LGMN;CTNND2;WNT7A;EPHB1;SHANK3;ZNF365;PRNP
prerank,Reactome_2022__Miscellaneous Transport And Binding Events R-HSA-5223345,-0.2149184109104064,-0.36561553065269026,0.8303571428571429,0.943346427374244,1.0,6/23,23.40%,ADD2;SLC66A1;CTNS;NIPAL3;TUSC3;ANKH
prerank,WikiPathway_2021_Human__EPO Receptor Signaling WP581,0.23049314955047823,0.3649069765803488,0.816793893129771,0.9387026238410546,1.0,7/26,17.61%,RASA1;MAPK1;STAT5A;STAT5B;JAK2;STAT1;PIK3CG
prerank,GO_Biological_Process_2021__protein peptidyl-prolyl isomerization (GO:0000413),0.22612468527604035,0.3648650078282114,0.8448275862068966,0.9384184818007913,1.0,4/20,11.85%,PPIF;PPID;PPWD1;FKBP1A
prerank,KEGG_2021_Human__Biosynthesis of unsaturated fatty acids,0.2316540168484611,0.3647858960722206,0.8151260504201681,0.9381628942700864,1.0,11/27,30.90%,HSD17B4;ACOT7;ACOX3;ELOVL5;ACOT4;FADS2;HACD2;ACOX1;SCP2;ELOVL7;TECR
prerank,GO_Biological_Process_2021__ear morphogenesis (GO:0042471),-0.21458974381234736,-0.3647447332807507,0.9230769230769231,0.9439605488028227,1.0,7/20,22.54%,TFAP2A;OSR2;PAX8;TMIE;ZIC1;TBX1;OSR1
prerank,GO_Biological_Process_2021__receptor signaling pathway via STAT (GO:0097696),-0.22108135823199915,-0.36402526647642297,0.8524590163934426,0.9443836769390693,1.0,4/25,12.76%,SOCS6;STAMBP;THPO;STAT2
prerank,GO_Biological_Process_2021__base conversion or substitution editing (GO:0016553),0.18915903182351024,0.36398517841457895,0.9672131147540983,0.9386265862735779,1.0,6/15,29.70%,APOBEC2;APOBEC3G;ADARB2;APOBEC3D;NUDT16;ADAR
prerank,GO_Biological_Process_2021__calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0016339),-0.24323094599040157,-0.36372652201205635,0.8017241379310345,0.9443498828663704,1.0,12/32,28.08%,CDH8;CDH11;CDH20;PCDHB16;CDHR3;CDH13;ATP2C1;PCDHB11;PCDHB14;SELP;CDH24;PCDHB4
prerank,GO_Biological_Process_2021__regulation of innate immune response (GO:0045088),-0.25800662447628897,-0.3636945174193958,0.8083333333333333,0.9440500775874315,1.0,18/61,21.58%,PLSCR1;TNFAIP3;POLR3B;RNF135;TRAFD1;USP18;DHX9;SH2D1B;PTPN1;RNASEL;IFI35;FGR;IRAK3;TRIM21;AKIRIN2;APPL2;DHX58;PTPN6
prerank,Elsevier_Pathway_Collection__G-Proteins Signaling in Insulin Secretion in beta-Cell,-0.18899723396225837,-0.36363759784954514,0.9658119658119658,0.9437998884723077,1.0,6/19,26.01%,TRPV4;CHRM3;GNAQ;ITPR1;GIPR;PLCB1
prerank,TRRUST_Transcription_Factors_2019__ETS1 mouse,-0.2448916278667752,-0.36361692883126984,0.8016528925619835,0.9435077416833888,1.0,22/54,29.97%,ERG;NR2F1;PRDM1;NR2F2;PTGS2;SH2D1A;ANGPT2;MMP9;CD3D;ITGA2B;CSF1R;MMP3;TIMP1;NPR1;LTBR;IGHM;ZEB1;TBX21;OPRD1;NOS3;VEGFA;MET
prerank,TRRUST_Transcription_Factors_2019__USF1 mouse,0.22448969559767112,0.36357178155199177,0.928,0.9387266677017292,1.0,3/15,10.91%,APOA5;FASN;PIGR
prerank,GO_Biological_Process_2021__mucosal immune response (GO:0002385),-0.21335635143125437,-0.3634476010614122,0.8442622950819673,0.9433682809814227,1.0,9/20,36.04%,RAB17;PLA2G1B;LTF;CAMP;RPL39;IFNLR1;H2BC21;IFNL2;NOS2
prerank,Elsevier_Pathway_Collection__BDNF Upregulation Triggered by Seizures,-0.21528000930120011,-0.3634268464671675,0.8990825688073395,0.9430706758420162,1.0,7/22,24.70%,MAPK3;RAF1;RASGRP1;MAP2K2;CREM;GABRA4;ITPR1
prerank,Reactome_2022__RIP-mediated NFkB Activation Via ZBP1 R-HSA-1810476,-0.18386034175627114,-0.36299050655402815,0.9776119402985075,0.9432115513395433,1.0,5/17,22.94%,DHX9;ZBP1;NKIRAS1;TICAM1;CHUK
prerank,Reactome_2022__AUF1 (hnRNP D0) Binds And Destabilizes mRNA R-HSA-450408,-0.24899168408638458,-0.36286262026755495,0.8130081300813008,0.9430636311968589,1.0,17/52,21.60%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;EIF4G1
prerank,Reactome_2022__Asymmetric Localization Of PCP Proteins R-HSA-4608870,-0.26849922206183396,-0.3628598011767685,0.8611111111111112,0.9427417822946994,1.0,19/60,20.00%,PSMB7;PSMD7;PSMF1;WNT5A;SMURF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;FZD2;PSMD12;PSMB3
prerank,Reactome_2022__RHO GTPases Activate NADPH Oxidases R-HSA-5668599,0.2390068358462702,0.3625742071387897,0.8203125,0.9393920454980099,1.0,4/22,6.71%,RAC2;MAPK11;MAPK1;S100A9
prerank,GO_Biological_Process_2021__positive regulation of glial cell differentiation (GO:0045687),0.24407049422688634,0.3623744585975058,0.8455284552845529,0.9392652154069763,1.0,3/18,8.03%,TNFRSF1B;ID2;CXCR4
prerank,Elsevier_Pathway_Collection__Sister Chromatid Cohesion,0.19588601936923056,0.36205130311134825,0.9185185185185185,0.9392491509536183,1.0,3/18,9.92%,MAU2;PCNA;AURKA
prerank,GO_Biological_Process_2021__snRNA metabolic process (GO:0016073),0.20335435264681898,0.3618199714263631,0.8870967741935484,0.9391456129374854,1.0,3/17,12.96%,ZCCHC8;INTS4;INTS5
prerank,GO_Biological_Process_2021__rRNA modification (GO:0000154),-0.20044857574410874,-0.36169693266295994,0.8461538461538461,0.9436698423571284,1.0,4/21,13.55%,GAR1;FBL;MRM2;NHP2
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision (GO:0033683)",0.24415553625577013,0.36159426011752205,0.8267716535433071,0.9390678670952518,1.0,9/39,11.08%,RFC2;DDB1;GTF2H5;POLD1;FAN1;PCNA;UBB;ERCC3;DDB2
prerank,Elsevier_Pathway_Collection__Keratinocyte Activation in Psoriatic Arthritis,-0.22326449225646,-0.3611908290439237,0.7413793103448276,0.9438740868884942,1.0,11/40,19.32%,TNF;MAP3K1;MAPK3;IL17RC;TNFRSF1A;MAP2K4;MMP9;TYK2;MMP3;CXCL8;MAP2K2
prerank,GO_Biological_Process_2021__regulation of stem cell differentiation (GO:2000736),-0.2682241215094411,-0.3611305958609609,0.9285714285714286,0.9436044465139092,1.0,27/86,21.69%,PSMB7;HES5;PSMD7;SLC4A11;PSMF1;METTL3;RBM24;GDNF;TAL1;PSMA5;PSMD1;PSMD2;PSMB8;OSM;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;ABL1;TCF3;PSMD12;PSMB3;TCF15;ITCH
prerank,Reactome_2022__Metalloprotease DUBs R-HSA-5689901,-0.21697598260809653,-0.36086928825998155,0.8608695652173913,0.9435594719175948,1.0,5/24,11.32%,EP300;STAMBP;NLRP3;H2AC6;RPS27A
prerank,Elsevier_Pathway_Collection__Insulin Resistance in Myocytes Induced by Obesity,-0.23703812145743303,-0.3606881700780443,0.8174603174603174,0.9434102886731587,1.0,20/39,35.20%,CXCL5;SOCS6;MAP2K4;RPS6KB1;ACACB;CD36;PIK3R1;IRAK1;SLC2A1;STK11;APPL1;AKT1;FABP3;ACSL1;CPT2;INSR;MAPK9;TLR4;SLC2A4;TRAF6
prerank,GO_Biological_Process_2021__positive regulation of T cell mediated cytotoxicity (GO:0001916),0.22011520579648758,0.36041750448847115,0.8264462809917356,0.9398695684103509,1.0,4/25,4.60%,IL12B;CD1C;IL23A;STX7
prerank,WikiPathway_2021_Human__Cannabinoid receptor signaling WP3869,0.2249911412234973,0.36037668835536824,0.8103448275862069,0.9396001309321813,1.0,15/28,35.27%,MAPK11;MAPK1;CYP2C19;PRKAR2B;MAPK10;PRKACA;MAPK13;DAGLA;ADCY7;MAPK8;CYP2C9;AHR;PRKAR1A;PRKAR1B;ADCY1
prerank,Reactome_2022__Mitochondrial Translation Elongation R-HSA-5389840,-0.26131884373484354,-0.3602767484572361,0.8991596638655462,0.9435202696539717,1.0,33/81,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL43;MRPL54;TSFM;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRPL14;MRPS15;MRPL16
prerank,GO_Biological_Process_2021__in utero embryonic development (GO:0001701),-0.21375820499585238,-0.3602227789477842,0.8947368421052632,0.9432496723693782,1.0,10/24,34.92%,SOX8;HINFP;EGFL8;FUT8;ARNT2;BMP2;VEGFA;PTPRR;MBNL1;LIG4
prerank,GO_Biological_Process_2021__cholesterol biosynthetic process (GO:0006695),-0.2512631801482737,-0.3598613775909718,0.7936507936507936,0.943306120516428,1.0,14/34,26.57%,MVD;LBR;TM7SF2;NSDHL;NPC1L1;ACAT2;PMVK;DHCR7;ARV1;HMGCR;EBP;INSIG2;SC5D;APOA1
prerank,GO_Biological_Process_2021__sarcomere organization (GO:0045214),-0.23342230266112626,-0.3598561645720184,0.8181818181818182,0.9429895160782438,1.0,6/25,15.29%,ANKRD1;MYOM2;OBSCN;CSRP1;TCAP;TNNT3
prerank,GO_Biological_Process_2021__regulation of cellular carbohydrate metabolic process (GO:0010675),-0.19602529854987216,-0.3598018757538074,0.9435483870967742,0.9427164868764091,1.0,4/15,17.43%,FOXK1;FOXK2;SCARB2;BCKDK
prerank,Reactome_2022__Mitochondrial Translation R-HSA-5368287,-0.25602376364304763,-0.3594342636451101,0.8983050847457628,0.9427961761363717,1.0,35/87,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL43;MRPL54;GFM2;TSFM;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRRF;MRPL14;MRPS15;MRPL16
prerank,TRRUST_Transcription_Factors_2019__SMAD4 human,0.22723321350421855,0.3591405500349249,0.88,0.9404756273244819,1.0,13/26,34.51%,JUN;SKIL;FSTL3;SMAD7;GLI1;CDKN1A;ZFP36;EPO;AHR;UCP2;BCL2;BTRC;BAMBI
prerank,TRRUST_Transcription_Factors_2019__ESR2 mouse,0.19060322802996083,0.35865339370153987,0.9365079365079365,0.9406094559016827,1.0,3/17,14.74%,MAPK1;STAT5A;PPARG
prerank,GO_Biological_Process_2021__epidermal cell differentiation (GO:0009913),-0.24552044220579752,-0.35854704832021034,0.8412698412698413,0.943384208055169,1.0,11/39,18.81%,ST14;WNT5A;GATA6;AKR1C3;ANXA1;ADAM9;TGM3;ACER1;UGCG;HDAC1;CSTA
prerank,GO_Biological_Process_2021__positive regulation of heart rate (GO:0010460),0.2050744849600365,0.35825587142935145,0.8974358974358975,0.9406764298466334,1.0,5/16,20.05%,HRC;TRPM4;ATP2A2;EDN2;ADRA1D
prerank,Elsevier_Pathway_Collection__SOCS3 and PTPN1 in Hypothalamic Neuron Insensitivity to Insulin and Leptin,-0.19740914925001535,-0.357937655866924,0.976,0.9437899176541381,1.0,4/15,20.83%,RPS6KB1;PTPN1;PIK3R1;LEP
prerank,"GO_Biological_Process_2021__positive regulation of mRNA splicing, via spliceosome (GO:0048026)",0.1986422603146374,0.3576176360341329,0.9426229508196722,0.9409743867859756,1.0,3/16,18.72%,THRAP3;CELF4;RBMX
prerank,GO_Biological_Process_2021__negative regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032435),0.22682859973830763,0.3571258534408111,0.8248175182481752,0.9411361382661062,1.0,14/29,35.54%,TAF9;WAC;PARK7;BAG6;N4BP1;MAP1A;CAMLG;OGT;SVIP;SGTA;FHIT;RYBP;GIPC1;HSP90AB1
prerank,Elsevier_Pathway_Collection__Rett Syndrome,-0.19475599887882117,-0.3568729912509232,0.9180327868852459,0.944577831358902,1.0,7/19,33.41%,PTPN1;GRB2;SHC1;HDAC1;MECP2;SOS1;BDNF
prerank,Reactome_2022__Regulation Of NF-kappa B Signaling R-HSA-9758274,0.20646147449451807,0.35670321362917123,0.9242424242424242,0.9412695627117592,1.0,5/18,18.53%,UBB;NLRC5;IKBKB;N4BP1;UBA52
prerank,Reactome_2022__Hedgehog Ligand Biogenesis R-HSA-5358346,-0.26009379300156144,-0.3566771643948939,0.875,0.9444230382708825,1.0,20/62,20.00%,PSMB7;PSMD7;PSMF1;OS9;PSMA5;SYVN1;PSMD2;PSMB8;DHH;RPS27A;PSMD11;PSMD10;ADAM17;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Elsevier_Pathway_Collection__Leptin and CCK8 Activate Nodose Ganglia Neuron,0.20849819595834268,0.35647973700054614,0.8846153846153846,0.9411605631559553,1.0,10/23,31.66%,MAPK1;JAK2;IPO7;RHOA;SOCS3;CREB1;MAP2K1;GNA11;HRAS;SRC
prerank,GO_Biological_Process_2021__cellular response to zinc ion (GO:0071294),0.19113628334541105,0.3558872638727916,0.9274193548387096,0.9414054020605747,1.0,4/15,18.52%,MT1G;MT1X;MT1E;HVCN1
prerank,Elsevier_Pathway_Collection__Angiotensin-Aldosterone System Activation Scheme,0.21839567089624295,0.35587722984380826,0.9534883720930233,0.9411003876826246,1.0,7/17,28.21%,SCNN1A;AGT;SCNN1G;SCNN1B;NR3C2;CREB1;POMC
prerank,Reactome_2022__Postmitotic Nuclear Pore Complex (NPC) Reformation R-HSA-9615933,-0.2149174701290041,-0.3557049692255887,0.8699186991869918,0.9451020233299515,1.0,9/27,26.48%,SUMO1;SEH1L;RANGAP1;TNPO1;NUP85;NUP62;NUP205;UBE2I;NUP35
prerank,GO_Biological_Process_2021__regulation of intracellular estrogen receptor signaling pathway (GO:0033146),0.23256853031130714,0.3556490407458514,0.7906976744186046,0.940976184885582,1.0,10/31,23.18%,VPS11;ZNF366;CNOT2;BRCA1;PAGR1;SRARP;CARM1;CNOT1;KCTD6;AXIN1
prerank,WikiPathway_2021_Human__Leptin Insulin Overlap WP3935,0.18547037607376127,0.3556280747030025,0.9420289855072463,0.9406843257237262,1.0,4/15,21.96%,PDPK1;JAK2;PIK3CG;SOCS3
prerank,GO_Biological_Process_2021__response to endoplasmic reticulum stress (GO:0034976),-0.2671671401694331,-0.3555004287110856,0.9586776859504132,0.9449860870078939,1.0,42/110,25.54%,SELENOS;RNF185;AIFM1;PDIA4;GORASP2;OS9;UFC1;FICD;PDIA2;CREB3L2;CFTR;ATP2A3;BCL2L11;DERL1;UBA5;SYVN1;MAP3K5;ANKS4B;PIK3R1;PPP1R15A;ERN1;ERP27;BCAP31;ATF3;CHAC1;BAK1;CREB3L1;ERN2;DAB2IP;CXCL8;RNF5;SEC16A;DNAJC10;UFM1;TP53;DNAJB9;HSPA5;DDRGK1;ITPR1;ERLEC1;DDIT3;ALOX15
prerank,GO_Biological_Process_2021__glycosphingolipid biosynthetic process (GO:0006688),0.20579290986979593,0.3551780705494186,0.937007874015748,0.9408726737338077,1.0,5/15,28.57%,ST8SIA6;ST3GAL5;LARGE1;ST8SIA5;ST6GALNAC5
prerank,WikiPathway_2021_Human__Galanin receptor pathway WP4970,-0.19951798413343946,-0.3550381070846428,0.890625,0.9451152604249106,1.0,3/18,10.41%,TFAP2A;BCL2L11;CRP
prerank,WikiPathway_2021_Human__Glycosaminoglycan degradation WP4815,0.18587396861749,0.35502677424375456,0.9557522123893806,0.9406987690977586,1.0,6/17,31.29%,HEXB;IDUA;HEXA;HYAL2;IDS;GNS
prerank,TRRUST_Transcription_Factors_2019__SMAD4 mouse,0.25375379764821065,0.35488863930060266,0.8142857142857143,0.9405121900413184,1.0,10/34,20.04%,SCNN1A;JUN;SKIL;ID2;MMP7;DSG4;SMAD7;PPARG;CDKN1A;TNFSF13B
prerank,KEGG_2021_Human__Phototransduction,0.2079349904497022,0.35354567125997177,0.8705035971223022,0.9415034503987066,1.0,6/19,21.67%,GNB1;GUCY2D;RHO;GUCA1B;RGS9;PDE6A
prerank,TRRUST_Transcription_Factors_2019__SRF human,-0.212320728068295,-0.353293102062747,0.8842975206611571,0.9466880939296836,1.0,8/25,22.93%,CFTR;TAGLN;MMP9;HMGXB4;PLG;MMP14;KPNA1;FHL2
prerank,Reactome_2022__ERCC6 (CSB) And EHMT2 (G9a) Positively Regulate rRNA Expression R-HSA-427389,-0.23784421461768568,-0.3531858379103784,0.8203125,0.9464694693212652,1.0,10/35,19.70%,MTA1;RBBP7;H2BC13;H2AZ2;H2BC15;H2AC6;H2BC5;CHD3;HDAC1;RBBP4
prerank,GO_Biological_Process_2021__regulation of interleukin-17 production (GO:0032660),0.2249820448713068,0.35309810367697064,0.808,0.9415851696187352,1.0,11/29,27.09%,IL12B;NR1H4;SLC7A5;IL23A;PRKCQ;IL15;VSIR;IL12A;SPHK1;MYD88;NCKAP1L
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> NFATC Signaling,-0.1885440647042827,-0.3530426116909756,0.9672131147540983,0.946288430561297,1.0,5/18,24.70%,BTK;CD22;NFATC4;PTPN6;ITPR1
prerank,TRRUST_Transcription_Factors_2019__HDAC1 mouse,0.23641770526018227,0.35289655082793925,0.8064516129032258,0.9414828201625735,1.0,7/25,20.22%,IL12B;JUN;CSN2;PPARG;CDKN1A;SP1;AKAP12
prerank,KEGG_2021_Human__Thyroid cancer,-0.23156287032259337,-0.3519820931687514,0.784,0.9470359251452458,1.0,17/37,35.54%,CDH1;MAPK3;TCF7L2;NCOA4;TPR;PAX8;BAK1;RET;MAP2K2;TP53;BRAF;RXRB;MYC;RXRA;TCF7;NTRK1;LEF1
prerank,GO_Biological_Process_2021__negative regulation of response to DNA damage stimulus (GO:2001021),-0.2212514294958327,-0.3516378678887566,0.8956521739130435,0.9470720916726543,1.0,10/30,27.29%,THOC5;FBXO5;TMEM161A;PSMD10;YJU2;MDM2;SNAI2;SFRP2;TRIM32;CDKN2D
prerank,GO_Biological_Process_2021__iron-sulfur cluster assembly (GO:0016226),0.21711460930302717,0.3514116582221545,0.8920863309352518,0.9425251280219994,1.0,8/23,27.40%,GLRX3;LYRM4;NFS1;NUBP2;FXN;ISCA2;GLRX5;NFU1
prerank,GO_Biological_Process_2021__regulation of phosphoprotein phosphatase activity (GO:0043666),0.24828554401983646,0.3512130879454926,0.8346456692913385,0.9424084840316787,1.0,11/34,22.05%,GSK3B;BOD1L1;STYXL1;BOD1;PPP6R3;CRY2;FKBP1A;MTOR;PPP1R15B;HSP90B1;ITGA1
prerank,TRRUST_Transcription_Factors_2019__SREBF2 human,0.18586363158871688,0.35107860673455776,0.9435483870967742,0.9422280893569038,1.0,2/19,3.33%,HNF4A;ACOT7
prerank,Reactome_2022__Oxygen-dependent Proline Hydroxylation Of Hypoxia-inducible Factor Alpha R-HSA-1234176,-0.2645390330016299,-0.35101459355453407,0.8861788617886179,0.9473729022833154,1.0,20/62,20.00%,PSMB7;PSMD7;PSMF1;RBX1;HIF3A;PSMA5;VHL;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;ELOB;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,GO_Biological_Process_2021__pulmonary valve morphogenesis (GO:0003184),0.19029481668735923,0.35090371639754314,0.9338842975206612,0.942088652918841,1.0,6/17,33.45%,ROBO2;TBX20;GJA5;NOTCH2;SLIT2;NFATC1
prerank,Elsevier_Pathway_Collection__PTGER2/3 -> Inflammation-Related Expression Targets,-0.21827556675070048,-0.3506675018441813,0.875968992248062,0.9473657918501146,1.0,7/24,19.32%,MAP3K1;MAPK3;MAP2K4;RAF1;GNA12;CXCL8;MAP2K2
prerank,Elsevier_Pathway_Collection__Nitric Oxide Effects on beta-Cell,0.21743603850572507,0.35016148908775496,0.8870967741935484,0.9425297650306693,1.0,8/25,23.61%,TRAF2;ATP2A2;ABCC8;STAT1;XBP1;IFNGR1;EIF2S1;ATF4
prerank,GO_Biological_Process_2021__positive regulation of interferon-alpha production (GO:0032727),-0.18853057778342625,-0.34989241864674964,0.923728813559322,0.9478819141217323,1.0,3/19,11.08%,IFIH1;HSPD1;DHX9
prerank,Elsevier_Pathway_Collection__Sarcomere in Cardiomyocyte in Dilated Cardiomyopathy,-0.20038206807924203,-0.3496095219104738,0.9453125,0.9478803834247466,1.0,5/19,24.24%,ANKRD1;TCAP;MYL3;TTN;LAMA4
prerank,Reactome_2022__HSF1 Activation R-HSA-3371511,0.22792351017409263,0.3495973286203278,0.8359375,0.9427869380450287,1.0,11/27,30.84%,SERPINH1;DEDD2;HSF1;VCP;UBB;PTGES3;EEF1A1;POLR1A;COL4A6;HSPA1B;HSPH1
prerank,GO_Biological_Process_2021__regulation of DNA binding (GO:0051101),-0.26801208361787165,-0.34924674892030266,0.8173913043478261,0.94794924045532,1.0,13/47,14.79%,SUMO1;SIRT2;HABP4;TFAP4;FOXC1;IGF1;MMP9;CPNE1;E2F1;HMGA2;HMGB1;PLAUR;CEBPG
prerank,GO_Biological_Process_2021__negative regulation of signal transduction in absence of ligand (GO:1901099),-0.19132363050211604,-0.34890185940426005,0.8879310344827587,0.9476877486181869,1.0,8/22,27.38%,TNF;GDNF;IFI6;SNAI2;EYA4;GATA1;AKT1;UNC5B
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001240),-0.19132363050211604,-0.34890185940426005,0.8879310344827587,0.9476877486181869,1.0,8/22,27.38%,TNF;GDNF;IFI6;SNAI2;EYA4;GATA1;AKT1;UNC5B
prerank,Elsevier_Pathway_Collection__Eicosanoids in Myeloid Cell Activation,-0.18674331982725362,-0.3485333250904387,0.923728813559322,0.9477035058762415,1.0,9/23,26.89%,PTGDR2;MAPK3;RAF1;MAP2K2;ITPR1;PLCB1;AKT1;PRKCE;LTB4R2
prerank,GO_Biological_Process_2021__positive regulation of protein ubiquitination (GO:0031398),0.25557822358629023,0.3484422823204454,0.9014084507042254,0.9436635240396353,1.0,23/79,17.19%,KDM1A;BIRC3;UBE2L3;RPS2;CAV1;DCUN1D2;RCHY1;BMI1;BIRC2;CDK5RAP3;SPRTN;UBB;LAPTM5;UBQLN1;SMAD7;FKBP1A;BRCA1;NSMCE3;NDFIP2;WFS1;CRY1;PRICKLE1;DCUN1D3
prerank,Reactome_2022__Mitochondrial Fatty Acid Beta-Oxidation R-HSA-77289,-0.21215470236061898,-0.3480439805059184,0.8032786885245902,0.947922953523004,1.0,8/36,15.92%,ACADL;HADHA;PCTP;ACOT1;ACADS;DECR1;THEM5;MECR
prerank,GO_Biological_Process_2021__early endosome to late endosome transport (GO:0045022),-0.19911324135560518,-0.34800719918451245,0.9310344827586207,0.9476403424733784,1.0,7/20,26.55%,STX8;RAB5A;HOOK1;RILP;EMP2;PIK3C3;LMTK2
prerank,GO_Biological_Process_2021__regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880),0.2115384182027331,0.3479111309285914,0.8582677165354331,0.9438729893579045,1.0,13/22,38.47%,CACNA1C;HRC;CLIC2;SRI;PRKACA;FKBP1B;GSTO1;ATP1A2;CALM1;PDE4D;DMD;CASQ2;GSTM2
prerank,GO_Biological_Process_2021__sterol biosynthetic process (GO:0016126),-0.2415776156612508,-0.34776686807121465,0.7716535433070866,0.9475457170128221,1.0,15/37,26.57%,MVD;LBR;TM7SF2;NSDHL;FAXDC2;NPC1L1;ACAT2;PMVK;DHCR7;ARV1;HMGCR;EBP;INSIG2;SC5D;APOA1
prerank,GO_Biological_Process_2021__positive regulation of macrophage derived foam cell differentiation (GO:0010744),-0.1855555368833438,-0.34766999813864935,0.9291338582677166,0.9473379441764986,1.0,3/17,10.80%,IL18;AGTR1;CD36
prerank,Reactome_2022__Activation Of NF-kappaB In B Cells R-HSA-1169091,-0.25842005230618603,-0.34545925458105764,0.905982905982906,0.9493250115761125,1.0,22/64,23.67%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;NFKBIE;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;BCL10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;CHUK;CARD11;UBC
prerank,GO_Biological_Process_2021__tube closure (GO:0060606),0.22828224711187614,0.3451077846907746,0.8394160583941606,0.9463526032583116,1.0,16/31,36.22%,PAX2;VANGL2;GRHL3;PRICKLE1;SKI;SCRIB;PLXNB2;FUZ;MTHFD1;DLC1;CELSR1;MTHFD1L;STIL;FOLR1;PHACTR4;SEMA4C
prerank,Elsevier_Pathway_Collection__NF-kB Signaling Activation in Huntington Disease,0.19402618893650525,0.3451022848042382,0.96,0.9460375824394043,1.0,6/15,33.70%,CASP9;BCL2L1;IKBKB;NFKBIA;IKBKG;IL1B
prerank,"GO_Biological_Process_2021__base-excision repair, gap-filling (GO:0006287)",0.22343108091608324,0.3439972210500674,0.8642857142857143,0.9468304196914289,1.0,7/35,12.35%,ADPRS;RFC2;POLD1;UNG;PCNA;XRCC1;MBD4
prerank,Elsevier_Pathway_Collection__IGF1 Role in Muscle Hypertrophy,0.23689309341392123,0.34371085952552616,0.782608695652174,0.9468145415176118,1.0,15/31,34.70%,GSK3B;JUN;MAPK1;SRF;PDPK1;CCND1;CDKN1A;PTEN;GATA2;RPS6KB2;MEF2A;FOXO3;NFATC1;RPS6;IRS1
prerank,WikiPathway_2021_Human__Platelet-mediated interactions with vascular and circulating cells WP4462,0.21222335505247406,0.3436373810646149,0.9124087591240876,0.9465785654772989,1.0,5/17,26.88%,SELE;TLR2;CD40LG;PF4;TLR7
prerank,GO_Biological_Process_2021__calcium ion import (GO:0070509),0.25082075397271575,0.3434724975096524,0.8217054263565892,0.9464216039820365,1.0,7/27,12.33%,CACNA1C;CACNB2;CACNA1E;CACNA1G;MCUR1;ATP2A2;MAIP1
prerank,"Elsevier_Pathway_Collection__Apoptosis of Cochlear Hair Cells (Noise-Induced, Mouse Model)",-0.19472808975962058,-0.3431044462355918,0.9090909090909091,0.9514138438654373,1.0,5/22,22.81%,GSTP1;AIFM1;BAK1;NOX1;TP53
prerank,Reactome_2022__Cytosolic tRNA Aminoacylation R-HSA-379716,-0.203273805180093,-0.3428349805073626,0.8739495798319328,0.9513739019787371,1.0,8/24,22.98%,HARS1;AIMP2;IARS1;AARS1;DARS1;KARS1;NARS1;LARS1
prerank,GO_Biological_Process_2021__positive regulation of CREB transcription factor activity (GO:0032793),0.1725269229310628,0.342300989123554,0.9465648854961832,0.9472145216062238,1.0,9/17,41.06%,CRTC2;CRTC1;CRTC3;CAMK1D;CD200;ADCY1;TSSK4;RPS6KA5;LPAR5
prerank,GO_Biological_Process_2021__activation of phospholipase C activity (GO:0007202),0.19823528218060502,0.3418801060551256,0.8958333333333334,0.9473091152668213,1.0,9/29,24.23%,TXK;LPAR1;SELE;AVPR1A;ARHGAP6;LPAR2;GNA15;CD86;C5AR1
prerank,GO_Biological_Process_2021__purine ribonucleoside monophosphate biosynthetic process (GO:0009168),0.18654900717446357,0.34153261971268944,0.9658119658119658,0.9473324920044434,1.0,5/16,29.81%,PFAS;ADSS2;NUDT2;ADSS1;LHPP
prerank,Reactome_2022__RHOBTB2 GTPase Cycle R-HSA-9013418,0.19388973924526226,0.3409656578921592,0.9191176470588235,0.9475628915412811,1.0,10/23,35.54%,CCT7;PHIP;ACTN1;MYO6;RBMX;HNRNPC;TXNL1;CUL3;CCT6A;HSP90AB1
prerank,KEGG_2021_Human__Ribosome,-0.22897680525264444,-0.34008181416394745,0.9469026548672567,0.9539371900132975,1.0,53/129,31.22%,RPL34;MRPS9;RPL37;RPL35;RPS19;MRPL21;MRPL33;MRPL3;RPL12;MRPS18C;MRPS21;RPL7A;RPL8;RPL22L1;MRPL23;RPL7;MRPS10;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;MRPL22;RPS17;MRPL27;RPL21;RPS10;MRPS18A;RPL36;RPS9;MRPL2;RPLP1;RPLP0;RSL24D1;MRPS2;MRPS14;MRPS5;MRPL30;MRPL14;RPL23;RPL4;MRPS15;MRPL16;RPS8;RPL39;RPS3A;MRPL4;RPL17;RPS20;RPS4X;RPL36AL
prerank,GO_Biological_Process_2021__regulation of myotube differentiation (GO:0010830),0.20677800510554864,0.3398814946964478,0.8951612903225806,0.9482629442531308,1.0,7/22,22.02%,ATP11A;CEACAM5;FBXO22;PIEZO1;CCN3;XBP1;SIK1
prerank,Reactome_2022__Stabilization Of P53 R-HSA-69541,-0.2588898180807516,-0.3397457533181137,0.9210526315789473,0.9539579390404659,1.0,19/54,23.67%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;MDM2;PSMB3;TP53;UBC
prerank,GO_Biological_Process_2021__gene silencing by miRNA (GO:0035195),-0.20235357397011766,-0.33884708647672745,0.8362068965517241,0.9545149802755212,1.0,12/31,29.08%,AGO2;NOTCH4;CNOT6;SNIP1;AGO1;ZC3H7A;EIF6;ZC3H7B;AJUBA;WTIP;PRKRA;RBM4
prerank,GO_Biological_Process_2021__protein exit from endoplasmic reticulum (GO:0032527),-0.21465124674770686,-0.3388406221631463,0.8306451612903226,0.9541981186851575,1.0,9/24,26.32%,SELENOS;OS9;DERL1;SYVN1;MAP1LC3C;SURF4;SEC16A;TMED9;DERL2
prerank,GO_Biological_Process_2021__regulation of fibroblast growth factor receptor signaling pathway (GO:0040036),0.2078209709763954,0.33809562717124414,0.9512195121951219,0.9497393555423767,1.0,4/19,13.96%,NOG;FGF2;GPC1;NPTN
prerank,Reactome_2022__FLT3 Signaling In Disease R-HSA-9682385,0.22472204506255422,0.3363060387246964,0.9105691056910569,0.9511716369780202,1.0,7/27,19.56%,GOLGB1;STAT5A;STAT5B;UBB;BCL2L1;UBA52;CDKN1A
prerank,Elsevier_Pathway_Collection__Neurogenic Transcription Factors Role in Hirschsprung Disease,0.1884359981829757,0.3362307614868228,0.9435483870967742,0.9509184243167039,1.0,5/17,26.04%,ZEB2;SIM2;SMAD5;EDNRB;SMAD4
prerank,GO_Biological_Process_2021__DNA double-strand break processing (GO:0000729),0.18462056206886152,0.33566600855199485,0.9453125,0.9511218797976978,1.0,7/18,32.43%,BARD1;BRCA1;DNA2;BLM;RBBP8;RNF138;RAD52
prerank,GO_Biological_Process_2021__negative regulation of response to endoplasmic reticulum stress (GO:1903573),0.204329705310193,0.335523966368343,0.9206349206349206,0.9509525164211784,1.0,7/25,20.89%,BCL2L1;TMBIM6;AQP11;WFS1;PARK7;XBP1;ALOX5
prerank,Reactome_2022__Phosphorylation Of CD3 And TCR Zeta Chains R-HSA-202427,0.20037141230051547,0.3353727636686078,0.9328358208955224,0.9507946709945314,1.0,4/17,16.99%,PTPRJ;HLA-DQA2;HLA-DQB2;PTPN22
prerank,GO_Biological_Process_2021__positive regulation of tyrosine phosphorylation of STAT protein (GO:0042531),-0.2552773075868618,-0.3348961946634769,0.8813559322033898,0.958000378463231,1.0,13/48,18.02%,TNF;HES5;TNFRSF1A;IL18;IGF1;PTK6;PARP14;OSM;ARL2BP;CSF1R;CNTF;KIT;ERBB4
prerank,GO_Biological_Process_2021__regulation of tumor necrosis factor-mediated signaling pathway (GO:0010803),-0.22621099087811142,-0.33474970056203385,0.8148148148148148,0.9578339960982324,1.0,12/55,14.16%,TNF;TRADD;GSTP1;TNFRSF1A;PELI3;PYCARD;TNFAIP3;SPATA2;CPNE1;FADD;HIPK1;ADAM17
prerank,GO_Biological_Process_2021__metallo-sulfur cluster assembly (GO:0031163),-0.19176788831357136,-0.33445774269198886,0.9210526315789473,0.9578119761599913,1.0,6/22,22.17%,ISCA1;CIAPIN1;CIAO3;MMS19;NUBP1;NUBPL
prerank,Reactome_2022__Mitochondrial Translation Initiation R-HSA-5368286,-0.24452646489395646,-0.3344260996045688,0.9122807017543859,0.9575229843375732,1.0,32/81,28.29%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL43;MRPL54;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRPL14;MRPS15;MRPL16
prerank,WikiPathway_2021_Human__nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell WP5027,-0.16910225237071166,-0.3343222852620778,0.968,0.9573241045766511,1.0,8/17,33.84%,EIF5;EIF3E;EIF3J;EIF1;EIF3H;EIF3I;EIF3B;EIF2S3
prerank,Reactome_2022__Formation Of Cornified Envelope R-HSA-6809371,0.21396781537913584,0.33383660600474624,0.864,0.9519176484130569,1.0,8/33,15.48%,DSC3;FLG;EVPL;DSG4;JUP;TGM1;PKP2;LIPJ
prerank,Elsevier_Pathway_Collection__Translation,0.2063205680061404,0.3338160784330048,0.8527131782945736,0.9516139548687181,1.0,4/24,11.07%,GSPT1;FARSA;EEF1A2;EEF1D
prerank,Elsevier_Pathway_Collection__RAS/RAF/MAPK Signaling Activation in Cancer,-0.2092153957179908,-0.3334591088815582,0.896551724137931,0.9578687079906734,1.0,5/29,5.84%,MAP3K1;RALGDS;MAPK3;RALA;MAP2K4
prerank,GO_Biological_Process_2021__chondroitin sulfate proteoglycan biosynthetic process (GO:0050650),-0.201573819467495,-0.3332063984696798,0.9007633587786259,0.9577796702974722,1.0,10/27,27.87%,NCAN;VCAN;CSGALNACT1;CHST13;CSPG5;CSPG4;CHST3;CHST15;XYLT1;B3GAT3
prerank,GO_Biological_Process_2021__organelle fission (GO:0048285),-0.19154433805060414,-0.3330775802794092,0.9389312977099237,0.9575809051146839,1.0,9/26,27.56%,FIS1;OPA1;MTFR1;PEX11G;DNM2;GDAP1;SEC16B;MUL1;PEX11A
prerank,GO_Biological_Process_2021__primary neural tube formation (GO:0014020),0.22140649031872442,0.33286800457887644,0.8518518518518519,0.9522270028727916,1.0,13/30,31.94%,PAX2;VANGL2;GRHL3;PRICKLE1;SKI;SCRIB;PLXNB2;FUZ;MTHFD1;DLC1;CELSR1;MTHFD1L;STIL
prerank,GO_Biological_Process_2021__regulation of tyrosine phosphorylation of STAT protein (GO:0042509),-0.24070812559093474,-0.33278841724875774,0.8416666666666667,0.9575647162899881,1.0,14/56,18.02%,TNF;HES5;TNFRSF1A;IL18;IGF1;PTK6;PARP14;OSM;ARL2BP;CSF1R;CNTF;KIT;NF2;ERBB4
prerank,GO_Biological_Process_2021__negative regulation of intracellular steroid hormone receptor signaling pathway (GO:0033144),0.21144530796321212,0.3326976337337656,0.8484848484848485,0.9520790671316777,1.0,9/30,21.64%,VPS11;ZNF366;CRY2;CNOT2;BRCA1;CRY1;FOXP1;CNOT1;CALR
prerank,GO_Biological_Process_2021__ureteric bud development (GO:0001657),0.16133797273961276,0.33240152899448866,0.9922480620155039,0.9520425582704705,1.0,2/17,6.92%,WNT11;ROBO2
prerank,Reactome_2022__Viral mRNA Translation R-HSA-192823,-0.24341448756049855,-0.3322637676761037,0.9134615384615384,0.9577850636912268,1.0,29/88,23.04%,RPL34;RPL37;RPL35;RPS19;RPL12;DNAJC3;RPL7A;RPL8;RPL22L1;XK;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;GNL3;RPL21;RPS10;RPL36;PBRM1;RPS9;GRSF1;RPLP1;RPLP0;RSL24D1
prerank,GO_Biological_Process_2021__regulation of T cell mediated cytotoxicity (GO:0001914),0.22028941312572292,0.3321548804030507,0.8333333333333334,0.9519453694718338,1.0,4/29,4.60%,IL12B;CD1C;IL23A;STX7
prerank,TRRUST_Transcription_Factors_2019__CIITA human,-0.19819510596706774,-0.3316886505724932,0.8416666666666667,0.957999565224051,1.0,9/28,25.12%,HLA-A;HLA-DQB1;MMP9;COL1A1;RAB4B;IRF2;HLA-F;S100A4;HLA-DMA
prerank,Elsevier_Pathway_Collection__Apoptosis of Thyroid Cell in Hashimoto's Thyroiditis,0.1851011744287811,0.3309606234060555,0.9323308270676691,0.9527332211121294,1.0,4/19,15.77%,FASLG;CYCS;DAXX;BBC3
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced HIF-1 survival signaling WP3614,-0.22040007352946034,-0.3307118881550369,0.8623853211009175,0.9587293713207102,1.0,12/37,25.12%,PTGS2;ANGPT2;PFKL;EDN1;BID;HK1;BAK1;TGFA;SLC2A1;TP53;ANGPT1;PDHA1
prerank,Elsevier_Pathway_Collection__beta-Cell Recovery in Diabetes Mellitus,0.1788325837959851,0.33057490777633175,0.9603174603174603,0.9528026926089018,1.0,10/22,33.58%,ATP2A2;ABCC8;PPARG;GCGR;CREB1;CAT;CYP2E1;UCP2;GNAS;PFKFB2
prerank,Elsevier_Pathway_Collection__IL22 Induces Keratinocyte Proliferation in Psoriasis,0.22881218858403538,0.330441545235965,0.8409090909090909,0.9526118555426955,1.0,7/33,11.12%,JUN;MAPK1;CEBPA;S100A9;PDPK1;FLG;MMP1
prerank,KEGG_2021_Human__Salivary secretion,-0.23316745289783622,-0.3296057592799172,0.875,0.9594330648611967,1.0,26/73,24.70%,ATP1B1;AQP5;ADCY8;ATP1A1;ADRB1;CD38;CHRM3;ADCY3;CST5;FXYD2;CALML6;ADCY5;ATP2B3;CAMP;TRPV6;ATP2B1;PRH2;CALM2;GNAQ;CST3;LYZ;ADRA1B;GUCY1B1;MUC7;ADRA1A;ITPR1
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision, 5'-to lesion (GO:0006296)",0.2192869691129663,0.32939351471791656,0.8604651162790697,0.9533077636535688,1.0,8/37,11.08%,RFC2;DDB1;GTF2H5;POLD1;PCNA;UBB;ERCC3;DDB2
prerank,GO_Biological_Process_2021__clathrin-dependent endocytosis (GO:0072583),0.2095888797629596,0.32914652391543475,0.8943089430894309,0.9532166284630149,1.0,10/25,28.80%,AP2B1;DLL1;ITSN1;GPR107;FCHSD2;AP2M1;AP2S1;CLTC;FCHO1;PICALM
prerank,GO_Biological_Process_2021__positive regulation of BMP signaling pathway (GO:0030513),-0.20107012946798186,-0.3290675255917568,0.8925619834710744,0.9596467956218149,1.0,6/25,18.79%,HES5;SULF1;SMAD2;ELAPOR2;BMPR1B;ENG
prerank,Reactome_2022__Interleukin-6 Family Signaling R-HSA-6783589,0.1982693383295152,0.32841823291025957,0.8467153284671532,0.9536013839873813,1.0,5/23,21.96%,CTF1;JAK2;STAT1;OSMR;SOCS3
prerank,Reactome_2022__DNA Damage Recognition In GG-NER R-HSA-5696394,0.20650651248804247,0.32837506385348264,0.8888888888888888,0.9533360931482057,1.0,11/36,25.06%,COPS5;DDB1;UBB;COPS3;COPS6;DDB2;UBA52;COPS8;ACTR5;RUVBL1;NFRKB
prerank,Reactome_2022__IKK Complex Recruitment Mediated By RIP1 R-HSA-937041,0.20435686404895995,0.32803330020759486,0.8925619834710744,0.9533257632382569,1.0,6/22,21.75%,BIRC3;BIRC2;UBB;IKBKB;UBA52;LY96
prerank,Reactome_2022__mRNA Splicing - Minor Pathway R-HSA-72165,0.228241969054593,0.32716558228236076,0.8098591549295775,0.9538424925671626,1.0,15/49,25.81%,NCBP2;SNRPE;RNPC3;GTF2F2;POLR2A;POLR2F;ZCRB1;POLR2C;POLR2L;SNRNP200;SNRPG;POLR2H;SRSF1;SNRNP40;SF3B3
prerank,GO_Biological_Process_2021__positive regulation of intracellular transport (GO:0032388),0.21433543777452166,0.3268885975083586,0.8536585365853658,0.9537853638682676,1.0,16/39,32.65%,PCM1;TBC1D20;ICE1;RAB29;VAMP2;RUFY3;ZFAND1;MLC1;ACTN2;KIF20B;RIPOR1;STRIT1;PDCD10;CAPN10;DYNC1H1;EIPR1
prerank,GO_Biological_Process_2021__eye morphogenesis (GO:0048592),0.18941782665538703,0.3266262908852467,0.9212598425196851,0.9537282731034354,1.0,19/19,81.07%,SKI;COL5A2;NIPBL;TENM3;MFAP2;FBN1;COL5A1;NF1;IFT122;AGTPBP1;ALDH1A3;NKD1;STAT3;MFAP5;RARG;FBN2;VEGFA;EFEMP1;SHROOM2
prerank,Elsevier_Pathway_Collection__IL6 and Insulin Resistance in Muscular Dystrophies,0.1936074273375098,0.32628030878378456,0.9296875,0.9537379809110442,1.0,6/23,21.96%,GSK3B;PDPK1;MTOR;PDE3B;CPT1B;SOCS3
prerank,Reactome_2022__Metabolism Of Angiotensinogen To Angiotensins R-HSA-2022377,0.19067943246049138,0.3262501429285006,0.9398496240601504,0.9534479885187719,1.0,18/18,80.95%,AOPEP;ATP6AP2;ANPEP;MMP12;CTSZ;CPB1;GZMH;CES1;CPA4;ENPEP;CTSD;CMA1;ACE;AGXT;ACE2;CPB2;KCTD11;CTSG
prerank,GO_Biological_Process_2021__ribonucleoprotein complex biogenesis (GO:0022613),-0.24900131271449305,-0.32615105411769846,0.8991596638655462,0.9622145470253368,1.0,18/60,19.42%,RPS19;CUL4A;PES1;NPM1;RPL7;BOP1;RPS28;URB2;RPL26L1;RPL14;TGS1;NOC2L;SHQ1;RPS17;SURF6;EMG1;ZNF622;ZNF658
prerank,GO_Biological_Process_2021__late endosome to vacuole transport via multivesicular body sorting pathway (GO:0032511),0.19349992854107612,0.326043499267484,0.9637681159420289,0.9533306440682668,1.0,5/16,26.36%,VPS25;VPS28;VTA1;CHMP4B;CHMP5
prerank,GO_Biological_Process_2021__negative regulation of fat cell differentiation (GO:0045599),-0.2140060113969241,-0.32579728780275763,0.8514851485148515,0.9621982607429804,1.0,6/35,8.83%,TNF;WNT5A;ANKRD26;SIRT2;ZFPM2;E2F1
prerank,Reactome_2022__Activated NOTCH1 Transmits Signal To Nucleus R-HSA-2122948,0.21403870745738215,0.32576919826451023,0.8682170542635659,0.9532511289057654,1.0,13/31,32.17%,DLL1;PSEN2;UBB;DTX1;UBA52;NEURL1;PSENEN;CNTN1;ADAM10;DTX2;ARRB2;DNER;DTX4
prerank,Elsevier_Pathway_Collection__Androgen Deficiency in Male Obesity,0.1954011701361284,0.3257063629534442,0.926829268292683,0.9529980672365431,1.0,8/22,29.95%,CEBPA;GAPDH;PPARG;HIF1A;CTNNB1;CEBPD;SHBG;SRD5A2
prerank,TRRUST_Transcription_Factors_2019__RFX5 human,0.18592442824507335,0.3256752580250062,0.9424460431654677,0.9527061892645257,1.0,6/16,31.50%,HLA-DMB;HLA-DQA2;HLA-DQB2;HLA-DOA;HLA-DRA;HLA-DOB
prerank,GO_Biological_Process_2021__cellular response to vascular endothelial growth factor stimulus (GO:0035924),-0.18243634723090565,-0.3254621394837374,0.912,0.9621962004043529,1.0,14/34,34.86%,PIK3CA;FOXC1;ANXA1;DLL4;ERN1;DAB2IP;RAMP2;MAPK14;NR4A1;GAS1;VEGFA;NOTCH1;PRKD1;SPRY2
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Progressive Diabetic Nephropathy,0.19716936758595105,0.3250152706619455,0.9166666666666666,0.9530015852893553,1.0,6/26,14.95%,JUN;MAPK1;KDR;JAK2;SMAD3;HIF1A
prerank,GO_Biological_Process_2021__amyloid-beta metabolic process (GO:0050435),0.1985241545166319,0.3249531938818772,0.9279279279279279,0.9527551412148055,1.0,5/17,22.95%,PSEN2;MME;DYRK1A;PSENEN;ABCA7
prerank,TRRUST_Transcription_Factors_2019__IRF1 human,0.23207537650105123,0.3248440958562069,0.8652482269503546,0.9525390114875323,1.0,15/48,24.01%,IL12B;FASLG;TAP1;TAP2;CDK2;PIGR;TNFSF10;CCNB1;CDKN1A;TAPBP;CCNE1;DDX58;IL12A;SLPI;PSMB9
prerank,WikiPathway_2021_Human__Parkinson's disease pathway WP2371,0.23895657196821707,0.324485158799127,0.8396946564885496,0.9525880163224483,1.0,10/36,20.03%,UBE2L3;MAPK11;CYCS;CASP9;UBB;PARK7;UBE2G1;HTRA2;MAPK13;CCNE1
prerank,Reactome_2022__Response Of EIF2AK4 (GCN2) To Amino Acid Deficiency R-HSA-9633012,-0.2238987327539024,-0.3242507430686672,0.8807339449541285,0.963099332699972,1.0,43/96,33.88%,RPL34;EIF2AK4;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;GDNF;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;CEBPG;ATF3;RPL21;RPS10;RPL36;RPS9;RPLP1;RPLP0;RSL24D1;DDIT3;GCN1;RPL23;RPL4;RPS8;RPL39;RPS3A;RPS20;RPS4X;RPL39L;RPL36AL;RPL22;RPL11;EIF2S3;RPSA
prerank,KEGG_2021_Human__Mitophagy,0.2373974558887184,0.3242002915479696,0.8805970149253731,0.9525177192228261,1.0,31/67,32.56%,BNIP3L;EIF2AK3;MFN2;GABARAPL1;JUN;RAB7B;TAX1BP1;UBB;MAPK10;TBC1D17;AMBRA1;BCL2L1;HIF1A;USP8;UBA52;SP1;CSNK2A1;ATF4;BNIP3;GABARAP;ATG5;FOXO3;NBR1;CSNK2B;MAPK8;PRKN;RRAS;HRAS;SRC;SQSTM1;RHOT2
prerank,GO_Biological_Process_2021__neural tube closure (GO:0001843),0.22653642314485545,0.3240720832583618,0.8529411764705882,0.9523257284369755,1.0,17/34,36.22%,PAX2;VANGL2;GRHL3;PRICKLE1;SKI;SCRIB;PLXNB2;FUZ;MTHFD1;DLC1;CELSR1;DVL3;MTHFD1L;STIL;FOLR1;PHACTR4;SEMA4C
prerank,GO_Biological_Process_2021__mitochondrial cytochrome c oxidase assembly (GO:0033617),0.18469583723827065,0.3235870284410725,0.9465648854961832,0.9525002190286753,1.0,2/20,3.31%,COA1;SCO1
prerank,Reactome_2022__p75NTR Signals Via NF-kB R-HSA-193639,-0.16918870177921028,-0.32350283545131203,0.9829059829059829,0.9634776772816921,1.0,6/16,30.08%,RPS27A;IRAK1;NGFR;UBC;NGF;PRKCI
prerank,"WikiPathway_2021_Human__Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304",-0.19939249123431946,-0.3230181182257641,0.9130434782608695,0.9635887950069318,1.0,9/25,26.93%,TNF;SOX8;IGF1;CNTF;SOX5;MAG;MYT1;CXCL1;BMP2
prerank,GO_Biological_Process_2021__regulation of actin filament bundle assembly (GO:0032231),0.20585143736605405,0.3228217201316952,0.9105691056910569,0.9529128968297915,1.0,8/26,24.88%,SYNPO2L;CX3CL1;SHANK1;SLC9A1;PLEK;LIMK1;ASAP3;RAC1
prerank,Reactome_2022__Cargo Concentration In ER R-HSA-5694530,0.21124467021655915,0.32275021469305365,0.9142857142857143,0.9526494986279144,1.0,10/30,25.51%,GRIA1;CNIH3;MIA3;CD59;F5;STX5;CNIH2;LMAN1;SEC23A;SERPINA1
prerank,WikiPathway_2021_Human__Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,-0.20666097401926992,-0.3227363356546606,0.8602941176470589,0.9635252283637431,1.0,11/39,22.94%,NDUFA13;PRDM1;IL18;PYCARD;ACAP1;NLRP3;NOD2;NLRP12;NOD1;ERBIN;CHUK
prerank,Elsevier_Pathway_Collection__IGF1R/AKT Signaling in Breast Cancer,0.24413077111846598,0.3225494561491454,0.864406779661017,0.9525354284609834,1.0,11/42,17.20%,GSK3B;CYCS;JUN;MAPK1;IGF2;STAT5A;CASP9;PDPK1;JAK2;BCL2L1;MTOR
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Acute Myeloid Leukemia Cell,-0.202896307464436,-0.32194979377699495,0.8992248062015504,0.9639328507469168,1.0,8/32,17.53%,PIM1;NPM1;PPP1R15A;GRB2;MLF1;PIM2;SHC1;KIT
prerank,Reactome_2022__Role Of GTSE1 In G2/M Progression After G2 Checkpoint R-HSA-8852276,-0.23476844389327045,-0.3213027383752728,0.868421052631579,0.9642281272048888,1.0,19/57,23.67%,PSMB7;PSMD7;PSMF1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;PSME1;PSMA1;PSMD5;PSMD12;PSMB3;TP53;GTSE1;UBC
prerank,Reactome_2022__Zinc Transporters R-HSA-435354,0.17773406348774753,0.32103841199767674,0.9552238805970149,0.9536029953209664,1.0,6/16,33.54%,SLC30A1;SLC39A1;SLC39A4;SLC30A2;SLC39A7;SLC30A5
prerank,GO_Biological_Process_2021__regulation of B cell proliferation (GO:0030888),0.22065275954648025,0.31985994756341557,0.8549618320610687,0.9543492000731025,1.0,9/41,20.04%,CD320;EPHB2;NFATC2;CD81;IKZF3;RC3H1;CD74;FCRL3;TNFSF13B
prerank,GO_Biological_Process_2021__regulation of cell cycle G1/S phase transition (GO:1902806),0.2243834269801065,0.3190397805065156,0.8345864661654135,0.9547831258769178,1.0,10/34,21.17%,SUSD2;ID2;EZH2;CDC73;PAGR1;FAM83D;GLI1;PSME2;CDKN1A;PTEN
prerank,WikiPathway_2021_Human__Eukaryotic Transcription Initiation WP405,0.22338898237072644,0.31856868255916476,0.8923076923076924,0.9549113404250678,1.0,10/42,14.69%,MNAT1;TAF9;GTF2F2;POLR2A;POLR2F;POLR3K;ERCC3;GTF2E1;POLR2C;POLR3D
prerank,GO_Biological_Process_2021__endocardial cushion morphogenesis (GO:0003203),0.18791094705271671,0.3183367855534014,0.9491525423728814,0.9548229904756241,1.0,18/18,81.22%,NOG;TBX20;TGFBR2;TBX2;GATA5;SOX9;TGFB2;HEY1;HEYL;ACVR1;BMP4;NOTCH1;BMPR1A;ACVRL1;NOS3;BMP2;MDM4;ENG
prerank,GO_Biological_Process_2021__RNA transport (GO:0050658),-0.22630455627174978,-0.31797683916048247,0.8648648648648649,0.9672134630430637,1.0,30/71,33.57%,THOC5;UPF3B;CASC3;ATXN2;SRSF9;SLU7;NUP62CL;SRSF2;ZFP36L1;TPR;THOC2;SRSF3;TST;RFTN1;RTRAF;NUP62;PNPT1;CHTOP;SRRM1;KIF5C;SRSF5;CDC40;FMR1;POLDIP3;ARC;EIF4E;XPO5;FLOT1;SRSF6;MAGOHB
prerank,Elsevier_Pathway_Collection__Extraocular Muscles Weakness in Myasthenia Gravis,0.16705872256390158,0.31764576841783165,0.9767441860465116,0.9551324902965516,1.0,5/15,27.33%,CD46;CD59;CD55;RAC1;DOK7
prerank,GO_Biological_Process_2021__negative regulation of epithelial to mesenchymal transition (GO:0010719),0.19935112710793373,0.3170688171312799,0.9147286821705426,0.9553392447866268,1.0,8/28,23.82%,USF3;ZNF750;OVOL2;SMAD7;HPN;ADIPOR1;PTEN;FUZ
prerank,Reactome_2022__Cellular Response To Hypoxia R-HSA-1234174,-0.24296545806988268,-0.3167639189687098,0.940677966101695,0.9680915300093708,1.0,22/71,20.00%,PSMB7;PSMD7;PSMF1;EP300;RBX1;HIF3A;PSMA5;CITED2;VHL;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;ELOB;PSME1;PSMA1;PSMD5;PSMD12;PSMB3
prerank,Elsevier_Pathway_Collection__Glutamate Toxiicity Effects on Striatum Medium Spiny Neurons in Hantington's Disease,-0.19107994803980424,-0.31628729660363036,0.9133858267716536,0.9682193024842539,1.0,9/27,28.93%,MCU;ADORA2A;HIP1;SLC1A2;KMO;GNAQ;ITPR1;AKT1;CASP3
prerank,GO_Biological_Process_2021__post-transcriptional gene silencing by RNA (GO:0035194),-0.18059702852320889,-0.3162798275248427,0.9603174603174603,0.9679035499722309,1.0,6/20,25.53%,AGO2;CNOT6;AGO1;EIF6;AJUBA;WTIP
prerank,Elsevier_Pathway_Collection__Endosomal Recycling,0.22077541556640864,0.3161853892402391,0.8582677165354331,0.9558871383837011,1.0,17/32,32.92%,ARF1;DNM1;RAB11FIP2;SNX4;EPN3;ARF6;RAB4A;EEA1;PIK3CG;PARD3;EHD4;RBSN;ARF3;RAB11FIP3;RAB11A;PDCD6IP;RAB11FIP1
prerank,GO_Biological_Process_2021__regulation of interleukin-4 production (GO:0032673),0.20267757373378792,0.3161152750263441,0.8842975206611571,0.9556348752735526,1.0,10/23,37.11%,SLC7A5;PRKCQ;CD40LG;CD86;ZP3;SYK;FCER1G;LGALS9;ZFPM1;GATA3
prerank,Elsevier_Pathway_Collection__TRRAP/TIP60 in Chromatin Remodeling,-0.17123257324420355,-0.31610143782211286,0.9609375,0.9677537118846832,1.0,7/22,26.10%,VPS72;ACTL6A;EPC1;MAD2L1;ING3;ITPR1;EPC2
prerank,GO_Biological_Process_2021__regulation of macrophage activation (GO:0043030),-0.1924229487811624,-0.3153614050814576,0.9327731092436975,0.9681051641149454,1.0,9/27,28.63%,WNT5A;HSPD1;TNIP2;LBP;KARS1;IL33;MMP8;NR1H3;TLR6
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Pyelonephritis,0.21265433823696944,0.31478613197076405,0.8582089552238806,0.9565845757210399,1.0,10/37,17.29%,TNFRSF1B;TRAF2;SELE;CXCL2;PDGFB;JAK2;HIF1A;IKBKB;STAT1;IL1RAP
prerank,GO_Biological_Process_2021__regulation of transcription initiation from RNA polymerase II promoter (GO:0060260),0.22843917717454373,0.313642730792277,0.8843537414965986,0.957396276707786,1.0,20/63,25.17%,MED12;AGO4;MED6;SRF;MED25;MED26;MED13;MED15;MED8;CCND1;CCNB1;MED30;CDKN1A;MED10;PTEN;CTNNB1;SUB1;TNRC6C;MED27;MED20
prerank,GO_Biological_Process_2021__renal system development (GO:0072001),-0.19673642516760742,-0.31352542449704374,0.8762886597938144,0.9694754096826412,1.0,13/55,20.65%,IFT27;TFAP2A;TBX18;FOXC1;SULF1;AGTR1;PYGO1;GREB1L;SALL1;PAX8;PCSK5;LRP4;SIX2
prerank,"GO_Biological_Process_2021__maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000462)",0.2022128260544921,0.3134678415999006,0.8278688524590164,0.9572336543594562,1.0,12/29,32.49%,UTP20;TSR2;NOP9;KRI1;RPS21;RPS16;RRS1;UTP6;MRPS11;RPP40;UTP3;RPS14
prerank,WikiPathway_2021_Human__Ebstein-Barr virus LMP1 signaling WP262,-0.17039740082040847,-0.31292410024524553,0.96,0.9697623830285766,1.0,2/22,1.94%,TNF;TRADD
prerank,Reactome_2022__Endosomal Sorting Complex Required For Transport (ESCRT) R-HSA-917729,0.21523263368474835,0.3127661560480853,0.8439716312056738,0.9575815862237909,1.0,12/29,31.35%,VPS4B;VPS25;VPS28;UBB;UBA52;VTA1;HGS;CHMP4B;MVB12B;CHMP5;CHMP2A;VPS37C
prerank,GO_Biological_Process_2021__translational elongation (GO:0006414),-0.22893821836239336,-0.31194423607792854,0.9642857142857143,0.9703560829856525,1.0,41/102,29.51%,MRPS18B;MRPS9;MRPS30;MRPL21;MRPL33;MRPL3;ERAL1;MRPS18C;MRPL47;MRPS21;MRPL40;MRPL23;MRPL50;MRPS10;MRPL48;MRPL22;MRPL43;MRPL54;GFM2;MRPL27;TSFM;MRPS18A;MRPS36;AURKAIP1;MRPS31;CHCHD1;MRPL37;MRPS22;MRPL2;MRPS23;MRPS2;MRPS14;MRPS5;MRPL30;MRPL14;DAP3;MRPS15;MRPL16;MTRES1;MRPL4;EEFSEC
prerank,GO_Biological_Process_2021__positive regulation of immunoglobulin production (GO:0002639),-0.19592396380313226,-0.31180722848537235,0.8538461538461538,0.9701660864478038,1.0,14/31,35.52%,SHLD3;TFRC;PAXIP1;TNFSF4;VAMP3;DNAJB9;MZB1;XCL1;MAD2L2;STX4;PHB;RBP4;SHLD2;HMCES
prerank,GO_Biological_Process_2021__GPI anchor biosynthetic process (GO:0006506),-0.17294342677886737,-0.31170098981251615,0.957983193277311,0.9699380543723505,1.0,8/30,28.15%,DPM2;PIGB;PIGA;PIGN;PIGV;PIGP;GPAA1;PIGL
prerank,GO_Biological_Process_2021__negative regulation of response to wounding (GO:1903035),0.19112571466483558,0.31126514113541437,0.9629629629629629,0.9586317033598892,1.0,5/20,21.48%,FGF2;GIT1;CERS2;ALOX5;CASK
prerank,GO_Biological_Process_2021__positive regulation of nervous system development (GO:0051962),-0.21142217729794904,-0.31084707948779977,0.85,0.9703883924341219,1.0,20/40,34.92%,RGS14;CLSTN3;EPHB3;LRRC4B;SERPINF1;CUX2;NUMBL;WNT7A;FAIM;EPHB1;CX3CR1;GHRL;LRP2;TRIM32;SNW1;IFNG;BDNF;SPEN;DLG5;LIG4
prerank,TRRUST_Transcription_Factors_2019__XBP1 human,0.1898802180869621,0.31074150296444036,0.9571428571428572,0.9588093255985534,1.0,3/18,14.72%,GAD1;ERP29;WFS1
prerank,GO_Biological_Process_2021__regulation of smooth muscle cell proliferation (GO:0048660),-0.2186526408443389,-0.31065828606550755,0.9076923076923077,0.9702268250622534,1.0,14/49,17.47%,TNF;HES5;ELN;IL18;TNFAIP3;IGF1;TCF7L2;RBPMS2;TRIB1;CCN4;CDH13;EDN1;NOX1;ANG
prerank,TRRUST_Transcription_Factors_2019__MITF mouse,-0.1740973253912012,-0.309931560430736,0.940677966101695,0.970548273152674,1.0,8/24,30.37%,DCSTAMP;PIK3R1;NGFR;SLC2A2;DKK3;BEST1;MET;CTSK
prerank,WikiPathway_2021_Human__BDNF-TrkB Signaling WP3676,-0.19348047032317217,-0.3098304278835147,0.9145299145299145,0.9702935986525454,1.0,14/33,34.17%,GRIN1;HOMER1;RHEB;RPS6KB1;GRB2;SHC1;RPS6KA1;BRAF;AKT1;TRPC6;ARC;SOS1;BDNF;TSC2
prerank,Reactome_2022__rRNA Modification In Nucleus And Cytosol R-HSA-6790901,-0.2203120586904847,-0.30971573088292875,0.8692307692307693,0.9700588490087751,1.0,21/59,26.70%,UTP4;RCL1;NOP2;WDR3;BMS1;GAR1;FBL;NHP2;WDR46;WDR43;SNU13;UTP14A;NOL11;DDX47;EMG1;UTP15;RPS9;TBL3;TRMT112;NOL6;NOP14
prerank,GO_Biological_Process_2021__non-motile cilium assembly (GO:1905515),0.2139489932201544,0.3096783155335105,0.8848920863309353,0.959469345563722,1.0,12/29,32.39%,PCM1;CEP89;ARL13B;VANGL2;TBC1D32;FUZ;IFT88;CEP250;BBS10;TOGARAM1;TMEM80;CCDC13
prerank,GO_Biological_Process_2021__regulation of megakaryocyte differentiation (GO:0045652),-0.20764485272796876,-0.3095951348186034,0.8760330578512396,0.9698327195053421,1.0,16/54,23.25%,NFE2;EP300;H3C1;ITGA2B;WDR5;THPO;KMT2E;FAXDC2;PRMT6;AGO1;HDAC1;SCIN;EIF6;TESC;NR4A3;GATA1
prerank,GO_Biological_Process_2021__rRNA methylation (GO:0031167),0.1920697593534268,0.3095196825301424,0.9398496240601504,0.9592950918557109,1.0,8/22,27.42%,FDXACB1;FBLL1;MRM1;NSUN4;MRM3;METTL16;NSUN5;METTL5
prerank,WikiPathway_2021_Human__Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex WP3657,-0.17821461884459058,-0.309442833555958,0.9571428571428572,0.9696363534400924,1.0,7/20,29.30%,DNMT3B;EP300;TERF2;DNMT3A;SMARCA4;GZMB;GABPB1
prerank,GO_Biological_Process_2021__DNA biosynthetic process (GO:0071897),0.17565703971784424,0.3091846091188277,1.0,0.9592916530088486,1.0,2/17,10.19%,POLD1;TERT
prerank,Reactome_2022__RNA Polymerase III Abortive And Retractive Initiation R-HSA-749476,-0.2039333324850774,-0.3089082743133204,0.8898305084745762,0.9698164969225294,1.0,6/39,11.46%,GTF3C2;NFIA;GTF3C4;POLR3B;SNAPC4;SNAPC5
prerank,GO_Biological_Process_2021__nucleic acid metabolic process (GO:0090304),0.23327356276707142,0.307876354283409,0.9264705882352942,0.9600754228126845,1.0,20/69,19.60%,HNRNPR;NCBP2;HNRNPD;HNRNPH1;HNRNPU;PCBP2;DDX54;GTF2F2;KPNA2;PDE12;POLR2A;POLR2F;HNRNPA3;POLR2C;POLR2L;DNA2;LSM1;RBMX;WTAP;DXO
prerank,GO_Biological_Process_2021__regulation of mitochondrion organization (GO:0010821),-0.20939506044737502,-0.30765948461011183,0.8813559322033898,0.970664475694157,1.0,19/47,28.24%,GSK3A;SIRT7;EP300;PARL;MARCHF5;FIS1;PRMT6;STAT2;RHOT1;PISD;PDE2A;GOLPH3;PINK1;VPS35;MIEF2;MUL1;TMEM102;OMA1;MGARP
prerank,GO_Biological_Process_2021__energy reserve metabolic process (GO:0006112),0.1852226759860286,0.30745406001584547,0.9432624113475178,0.960121537051461,1.0,7/18,32.28%,GSK3B;PRKAG2;PYGM;PID1;GBE1;GFPT2;UGP2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Systemic Lupus Erythematosus,-0.22238446256618885,-0.307159528816766,0.9017857142857143,0.9708004865423165,1.0,14/61,16.75%,TNF;PDCD1;PTGS2;IL18;IL1RN;MMP9;TLR5;CRP;HMGB1;F2;CORO1A;FAS;CTLA4;TRIM21
prerank,GO_Biological_Process_2021__aggrephagy (GO:0035973),0.20754167432556442,0.30667205348008275,0.9111111111111111,0.9604949936302768,1.0,13/28,32.18%,ARL13B;UBB;UBQLN1;DYNC1LI2;PARK7;UBA52;DYNC1LI1;DYNLL1;ATG5;IFT88;PRKN;DYNC1H1;SQSTM1
prerank,KEGG_2021_Human__RNA polymerase,-0.2010122218821236,-0.30664965389242127,0.8739495798319328,0.9709223243353263,1.0,5/31,8.18%,POLR2G;POLR1C;POLR3B;POLR1B;POLR2J2
prerank,Reactome_2022__N-glycan Antennae Elongation In medial/trans-Golgi R-HSA-975576,0.204995120022803,0.3059790980651776,0.8968253968253969,0.9608047432361492,1.0,4/24,8.98%,MGAT4C;ST8SIA6;FUT3;B4GALT2
prerank,GO_Biological_Process_2021__chordate embryonic development (GO:0043009),-0.21605775768389757,-0.3055000205385304,0.8487394957983193,0.9715917080663597,1.0,23/53,34.92%,HES5;SOX8;WNT5A;HINFP;SULF1;EGFL8;COL1A1;GRHL2;FUT8;KIAA1217;PCSK5;TBX1;BMP5;ARNT2;XYLT1;BMP2;VEGFA;PTPRR;TGFB1;RBP4;DACT1;MBNL1;LIG4
prerank,GO_Biological_Process_2021__vasculogenesis (GO:0001570),0.2065063826663859,0.30443618977915876,0.8854961832061069,0.961839510734636,1.0,11/32,24.81%,RASA1;CAV1;APELA;KDR;CUL7;TGFBR3L;TBX20;SOX17;RASIP1;TGFBR2;TGFBR3
prerank,Elsevier_Pathway_Collection__Dectin-1 (CLEC7A) Signaling,-0.16779058545462222,-0.3043141715931602,0.9606299212598425,0.9723099023956774,1.0,5/26,16.00%,PYCARD;NLRP3;RAF1;BCL10;CLEC7A
prerank,GO_Biological_Process_2021__positive regulation of interleukin-2 production (GO:0032743),-0.18628377610952612,-0.30392052353536514,0.9682539682539683,0.9723664017867227,1.0,9/25,38.21%,PDE4B;ANXA1;CLEC7A;CARD11;CD80;CCR2;TRAF6;RPS3;CD4
prerank,GO_Biological_Process_2021__response to peptide (GO:1901652),0.20314922986716943,0.3033337985766729,0.9448818897637795,0.9625714201305314,1.0,7/35,11.92%,EIF2B3;EIF2B5;STAT5A;EIF2B4;STAT5B;GNAI1;CALCR
prerank,GO_Biological_Process_2021__regulation of intracellular protein transport (GO:0033157),-0.19983842179267414,-0.30309254023737925,0.8661417322834646,0.9727843026357871,1.0,7/31,16.15%,SIRT7;GCC2;LCP1;TPR;PTPN1;OAZ2;OAZ1
prerank,GO_Biological_Process_2021__hydrogen peroxide catabolic process (GO:0042744),0.1650869965757244,0.3027785253048045,0.984,0.9627260368913277,1.0,5/16,26.45%,PRDX1;PRDX4;GPX3;HBA1;CAT
prerank,GO_Biological_Process_2021__outflow tract septum morphogenesis (GO:0003148),0.18973892865738634,0.30227899830418264,0.953125,0.9628308434059513,1.0,3/22,6.92%,SEMA3C;NRP2;ROBO2
prerank,TRRUST_Transcription_Factors_2019__PPARA human,-0.2253073945915412,-0.30210993160035016,0.9173553719008265,0.973353764012206,1.0,7/37,10.80%,ACADL;PTGS2;G0S2;ANGPTL4;MMP9;CPT1A;CD36
prerank,GO_Biological_Process_2021__positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900740),0.19825257563001022,0.30209313183744935,0.9172932330827067,0.9623907309635912,1.0,6/26,19.66%,YWHAQ;PPP3CC;TFDP1;BBC3;TP63;SFN
prerank,GO_Biological_Process_2021__regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900739),0.19825257563001022,0.30209313183744935,0.9172932330827067,0.9623907309635912,1.0,6/26,19.66%,YWHAQ;PPP3CC;TFDP1;BBC3;TP63;SFN
prerank,Elsevier_Pathway_Collection__Lactate as a Signaling Molecule in Cancer Cells,-0.16485873494880277,-0.3020285180225332,0.954954954954955,0.9731020682645148,1.0,5/24,19.25%,MAPK3;VHL;RAF1;SLC16A3;CXCL8
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometrioid Ovarian Carcinoma,0.23548595907718053,0.30150367419557783,0.90625,0.9626259023586189,1.0,15/47,21.39%,GSK3B;JUN;MAPK1;HBEGF;FGF2;CASP9;ERBB2;EGF;BRCA1;BCL2L1;LPAR2;MTOR;CCNE1;PTEN;CTNNB1
prerank,Reactome_2022__Downstream Signaling Events Of B Cell Receptor (BCR) R-HSA-1168372,-0.2208616236350733,-0.30129549961527946,0.9230769230769231,0.9733830257133924,1.0,24/77,23.67%,PSMB7;PSMD7;PSMF1;SKP1;PSMA5;NFKBIE;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;BCL10;PSMD13;PSMC1;PSME1;PSMA1;PPP3R1;RASGRP1;PSMD5;PSMD12;PSMB3;CHUK;CARD11;UBC
prerank,Reactome_2022__Membrane Binding And Targetting Of GAG Proteins R-HSA-174490,0.17992603906468652,0.3008141601086728,0.9652173913043478,0.9629217338087857,1.0,5/15,25.96%,VPS28;UBB;UBA52;NMT2;MVB12B
prerank,GO_Biological_Process_2021__organelle disassembly (GO:1903008),-0.19706474246553338,-0.3006395727379655,0.8584070796460177,0.9735879530729105,1.0,16/34,36.05%,ULK1;UFC1;MCTS1;UBA5;GFM2;GBF1;KIF9;UFM1;DDRGK1;MRRF;DYRK3;STING1;DENR;UFL1;RETREG1;PLK3
prerank,GO_Biological_Process_2021__positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus (GO:1901522),-0.17580403604023398,-0.3005525430816325,0.9739130434782609,0.9733504706455496,1.0,2/21,3.44%,CARF;EP300
prerank,GO_Biological_Process_2021__cellular respiration (GO:0045333),0.21933145998729806,0.30045637357655486,0.84251968503937,0.962920846092171,1.0,7/42,7.38%,COQ10B;CYCS;UQCRHL;COX15;UQCRC1;NDUFS8;ME3
prerank,Reactome_2022__Synthesis Of IP3 And IP4 In Cytosol R-HSA-1855204,-0.1730180609606197,-0.3004348732052954,0.9495798319327731,0.9731327958941068,1.0,9/26,31.90%,PLD4;OCRL;SYNJ1;PLCH2;INPP5J;PLCB1;PLCB2;PLCD4;PLCZ1
prerank,Elsevier_Pathway_Collection__Proteins Involved in T-Cell Acute Lymphoblastic Leukemia,0.2074472431317647,0.3003528410632455,0.9007633587786259,0.9627252337306691,1.0,10/37,25.11%,CXCR4;JAK2;PAX5;MTOR;KMT2A;SET;PTEN;LYL1;TGFBR2;CCND3
prerank,GO_Biological_Process_2021__membrane assembly (GO:0071709),-0.19255908964309706,-0.30030346475942626,0.8582677165354331,0.9729110562002796,1.0,17/36,32.63%,CHMP7;DMKN;GAK;UGCG;RFTN1;LRP4;NRXN2;EMP2;STX2;ANXA2;S100A10;NLGN4X;STX4;SPAST;FLOT2;UBXN2A;FLOT1
prerank,GO_Biological_Process_2021__ventricular septum development (GO:0003281),-0.2005878276443421,-0.2995704047551072,0.8728813559322034,0.9732070403217005,1.0,6/35,10.83%,HEY2;SOX4;ZFPM2;APLNR;CITED2;SALL1
prerank,GO_Biological_Process_2021__ATP-dependent chromatin remodeling (GO:0043044),-0.1970452824611548,-0.2972862378345103,0.8809523809523809,0.9748811733022179,1.0,10/42,19.70%,SMARCA5;ACTL6B;VPS72;SMARCA2;ACTL6A;CHD3;SMARCB1;HDAC1;PBRM1;RBBP4
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902230),0.2016308900976097,0.2968221015280342,0.9022556390977443,0.9655426645465105,1.0,5/25,15.39%,KDM1A;TAF9;TAF9B;BCL2L1;CD74
prerank,GO_Biological_Process_2021__regulation of necroptotic process (GO:0060544),0.1791501170149835,0.2951441590980497,0.9322033898305084,0.966613070165277,1.0,3/23,10.71%,BIRC3;BIRC2;CFLAR
prerank,GO_Biological_Process_2021__exonucleolytic catabolism of deadenylated mRNA (GO:0043928),0.20616554199175643,0.2949491659495764,0.9029850746268657,0.9664672459698732,1.0,11/33,25.15%,EXOSC9;EDC4;EXOSC6;DIS3;NT5C3B;EXOSC3;LSM1;EDC3;LSM6;DCP1B;PATL1
prerank,GO_Biological_Process_2021__G protein-coupled acetylcholine receptor signaling pathway (GO:0007213),0.17471963253391629,0.2935107621850344,0.9915254237288136,0.967384294861517,1.0,6/15,29.48%,GNB1;GNA15;HRH4;HRH3;CHRM5;GNA11
prerank,WikiPathway_2021_Human__STING pathway in Kawasaki-like disease and COVID-19 WP4961,-0.1634301095943088,-0.2934710733313517,0.9669421487603306,0.9779741367393606,1.0,20/20,83.67%,NLRP3;NFKBIE;GSDMD;CHUK;ITPR1;F3;FCGR2C;RELA;FCGR2A;TBK1;NFKB1;IRF3;NLRX1;IL1B;IKBKG;NFKBIA;CGAS;REL;IKBKB;IKBKE
prerank,Elsevier_Pathway_Collection__Myostatin-IGF1 Crosstalk in Skeletal Muscles in Muscular Dystrophies,0.18947722139459153,0.29336928206243634,0.9440559440559441,0.9671776392247721,1.0,11/29,29.42%,GSK3B;PDPK1;SMAD7;SMAD3;CDKN1A;ACVR2B;SMAD4;RPS6KB2;MSTN;MEF2A;FOXO3
prerank,GO_Biological_Process_2021__regulation of RNA splicing (GO:0043484),-0.21104894389807702,-0.29325961733596656,0.8947368421052632,0.9778309586496989,1.0,15/70,14.17%,RRP1B;PTBP3;SRPK2;HABP4;HNRNPL;SON;CLK4;HNRNPH2;PTBP1;METTL4;PIK3R1;PTBP2;SRSF3;FAM50A;ERN1
prerank,GO_Biological_Process_2021__homologous chromosome pairing at meiosis (GO:0007129),-0.1717926187817893,-0.29316378322220454,0.9097744360902256,0.9775884193417496,1.0,9/24,32.19%,SIRT7;REC8;SYCP2;SYCE2;ZCWPW1;SYCE3;P3H4;ANKRD31;RAD21
prerank,GO_Biological_Process_2021__positive regulation of antigen receptor-mediated signaling pathway (GO:0050857),0.17031408625228164,0.2922937321538105,0.9603174603174603,0.9678017230430469,1.0,8/21,31.20%,CD81;KCNN4;RAB29;FOXP1;PRKCB;PRKCH;IKBKG;LCK
prerank,GO_Biological_Process_2021__positive regulation of microtubule polymerization or depolymerization (GO:0031112),-0.18099487971736292,-0.2921080977363253,0.923728813559322,0.9782240447455242,1.0,14/25,36.75%,TRPV4;NAV3;SLAIN2;STMN2;CLIP1;OCLN;DCTN1;ANKRD53;MET;CDK5R1;DRG1;CDK5RAP2;RPS3;AKAP9
prerank,GO_Biological_Process_2021__rRNA processing (GO:0006364),-0.19324466819756325,-0.2918628209256452,0.981651376146789,0.9781131229262134,1.0,52/173,24.45%,RPL34;NOB1;RRP1B;UTP4;RPL37;RCL1;RPL35;RPS19;PES1;RPL12;RPL7A;NOP2;RPL8;HELQ;WDR3;RPL7;BOP1;RPS28;MDN1;RPL3;BMS1;RPL14;FBL;RPS17;MRM2;NSA2;NHP2;WDR46;RSL1D1;WDR43;EXOSC5;SNU13;UTP14A;DDX10;RPL21;NOL11;DDX47;EMG1;RPL36;UTP15;EIF6;RPS9;WDR55;EXOSC8;RPLP1;RPLP0;MAK16;C1D;MPHOSPH6;TBL3;EXOSC7;MRTO4
prerank,MSigDB_Hallmark_2020__Cholesterol Homeostasis,-0.21045717868480604,-0.29178563919624856,0.9173553719008265,0.9778567369817025,1.0,21/74,20.07%,MVD;GPX8;CD9;TM7SF2;CBS;PLSCR1;ATXN2;NSDHL;SEMA3B;S100A11;PNRC1;ACAT2;PMVK;DHCR7;PLAUR;LGMN;ATF3;ABCA2;HMGCR;SCD;EBP
prerank,Reactome_2022__Peptide Chain Elongation R-HSA-156902,-0.2051563782054207,-0.2916772304047173,0.897196261682243,0.9776145099683631,1.0,17/84,12.43%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17
prerank,GO_Biological_Process_2021__regulation of protein export from nucleus (GO:0046825),0.17912249671582792,0.2915406879336266,0.905511811023622,0.9681197479478627,1.0,8/23,25.05%,GSK3B;BARD1;RBM22;PARK7;IFI27;BAG3;XPO4;UHMK1
prerank,GO_Biological_Process_2021__regulation of transcription from RNA polymerase II promoter in response to stress (GO:0043618),-0.22495379720352357,-0.29114066059688365,0.9369369369369369,0.9777444371668933,1.0,25/85,20.00%,PSMB7;PSMD7;PSMF1;EP300;RBX1;HIF3A;EGLN2;PSMA5;PSMD1;VHL;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;PSMD13;PSMC1;ELOB;PSME1;ATF3;PSMA1;PSMD5;NFE2L2;PSMD12;PSMB3
prerank,KEGG_2021_Human__Glycosaminoglycan degradation,0.1597444923513887,0.2911337782295776,0.9908256880733946,0.9681493319695791,1.0,6/18,31.29%,HEXB;IDUA;HEXA;HYAL2;IDS;GNS
prerank,KEGG_2021_Human__Cytosolic DNA-sensing pathway,0.214948126385445,0.29111523766327807,0.8442622950819673,0.9678462376335097,1.0,18/47,30.17%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;MAVS;NFKBIB;IKBKE;IKBKB;DDX58;POLR2H;POLR3F;CGAS;CASP1;IRF7;ADAR;NFKBIA;IKBKG
prerank,Reactome_2022__ZBP1(DAI) Mediated Induction Of Type I IFNs R-HSA-1606322,-0.15403947962433817,-0.2910418231725753,0.9852941176470589,0.9775052033858855,1.0,5/20,22.94%,DHX9;ZBP1;NKIRAS1;TICAM1;CHUK
prerank,Elsevier_Pathway_Collection__CD157 -> cADPR/Calcium Signaling,0.18169694282023943,0.29059176540508286,0.9538461538461539,0.9679723188200261,1.0,9/21,31.65%,TRPM2;MAPK1;LIMK2;RHOA;LIMK1;PECAM1;MAP2K1;LCK;RYR3
prerank,Reactome_2022__RUNX1 Regulates Genes Involved In Megakaryocyte Differentiation And Platelet Function R-HSA-8936459,-0.20311531299317442,-0.2905457622998433,0.8769230769230769,0.9776183102504277,1.0,12/56,15.84%,NFE2;EP300;H2BC13;H2AZ2;H2BC15;H2AC6;ITGA2B;WDR5;KMT2E;PRMT6;H2BC5;AGO1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle hypertrophy (GO:0010611),-0.15456498560005252,-0.2891918006762504,0.952755905511811,0.978420106976177,1.0,7/23,30.93%,IGF1;PDE9A;EDN1;NR4A3;IL6ST;RGS2;NOTCH1
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor production (GO:0032720),-0.17623883618654404,-0.2891262284043844,0.9186991869918699,0.9781641275459009,1.0,11/41,23.48%,SELENOS;GSTP1;TNFAIP3;IGF1;SLAMF1;LBP;TRIM27;IRAK3;LILRA4;PTPN6;GHRL
prerank,Reactome_2022__rRNA Processing In Nucleus And Cytosol R-HSA-8868773,-0.19896793828129802,-0.28864188408517016,1.0,0.9782601509622842,1.0,55/186,24.44%,RPL34;NOB1;RRP1B;UTP4;RPL37;RCL1;RPL35;RPS19;PES1;RPL12;RPL7A;NOP2;RPL8;RPP14;RPL22L1;WDR3;RPL7;BOP1;RPL3L;RPS28;RPL26L1;RPL3;BMS1;RPL14;GAR1;RPS27A;FBL;FAU;RPS17;DDX56;NHP2;WDR46;WDR43;EXOSC5;SNU13;UTP14A;GNL3;RPL21;RPS10;NOL11;DDX47;EMG1;RPL36;UTP15;RPS9;EXOSC8;RPLP1;RPP21;RPLP0;RSL24D1;C1D;MPHOSPH6;TBL3;TRMT112;EXOSC7
prerank,Reactome_2022__rRNA Processing R-HSA-72312,-0.1955753173759852,-0.2883744807649073,1.0,0.9781439637704126,1.0,58/196,24.44%,RPL34;NOB1;RRP1B;UTP4;RPL37;RCL1;RPL35;RPS19;PES1;RPL12;RPL7A;NOP2;RPL8;RPP14;RPL22L1;WDR3;RPL7;BOP1;RPL3L;RPS28;RPL26L1;RPL3;BMS1;RPL14;TRMT10C;PRORP;GAR1;RPS27A;FBL;FAU;RPS17;MRM2;DDX56;NHP2;WDR46;WDR43;EXOSC5;SNU13;UTP14A;GNL3;RPL21;RPS10;NOL11;DDX47;EMG1;RPL36;UTP15;RPS9;EXOSC8;RPLP1;RPP21;RPLP0;RSL24D1;C1D;MPHOSPH6;TBL3;TRMT112;EXOSC7
prerank,GO_Biological_Process_2021__positive regulation of cation channel activity (GO:2001259),0.1944602231655822,0.28777835249432204,0.8962962962962963,0.9700583688208803,1.0,7/36,15.24%,EPHB2;KCNIP2;ANK3;ATPSCKMT;LRRC26;NLGN3;LRRC55
prerank,TRRUST_Transcription_Factors_2019__POU2F1 human,0.18615429376183976,0.2874116981707445,0.8947368421052632,0.9700279819874832,1.0,11/32,29.78%,SDC4;VWF;LGALS4;HPGDS;CCND1;IL5;TWIST1;GCM1;RPTOR;SPP1;TXNRD1
prerank,Reactome_2022__TNF Signaling R-HSA-75893,-0.18385734581349344,-0.2873191299525994,0.9074074074074074,0.9786264134313184,1.0,8/44,14.16%,TNF;TRADD;TNFRSF1A;TNFAIP3;FADD;RPS27A;USP2;ADAM17
prerank,Reactome_2022__Eukaryotic Translation Termination R-HSA-72764,-0.2048957738190378,-0.2865220678558649,0.9223300970873787,0.978948144657338,1.0,35/88,31.22%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;RPL21;RPS10;N6AMT1;RPL36;RPS9;RPLP1;RPLP0;RSL24D1;TRMT112;RPL23;RPL4;RPS8;RPL39;RPS3A;RPS20;RPS4X;RPL39L;RPL36AL
prerank,GO_Biological_Process_2021__nucleocytoplasmic transport (GO:0006913),0.21016781220551173,0.28648867569044756,0.9022556390977443,0.9705237424611012,1.0,5/39,4.02%,RSRC1;NCBP2;NUTF2;RBM15B;SNRPE
prerank,Reactome_2022__Selenocysteine Synthesis R-HSA-2408557,-0.20894668232393848,-0.285946677626583,0.9345794392523364,0.9791121050168625,1.0,36/88,31.22%,RPL34;RPL37;RPL35;RPS19;RPL12;PSTK;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;RPL21;RPS10;RPL36;RPS9;RPLP1;RPLP0;SEPHS2;RSL24D1;RPL23;RPL4;RPS8;RPL39;RPS3A;EEFSEC;RPS20;RPS4X;RPL39L;RPL36AL
prerank,GO_Biological_Process_2021__positive regulation of protein modification by small protein conjugation or removal (GO:1903322),0.21578635765359322,0.2857699629452685,0.9180327868852459,0.9707364479657347,1.0,21/76,17.19%,BIRC3;UBE2L3;CAV1;DCUN1D2;RCHY1;BIRC2;CDK5RAP3;SPRTN;UBB;LAPTM5;UBQLN1;SMAD7;FKBP1A;BRCA1;NSMCE3;NDFIP2;WFS1;SAE1;CRY1;PRICKLE1;DCUN1D3
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation R-HSA-76046,0.19127034060830045,0.2855541667562786,0.917910447761194,0.970582446477258,1.0,10/35,24.88%,POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;ZNF143;TBP;POLR2H;POLR3F;CRCP
prerank,GO_Biological_Process_2021__neuron projection extension (GO:1990138),0.1971404761878293,0.28407738197765764,0.9047619047619048,0.9714526295182018,1.0,7/32,16.10%,NRP2;SLC9A6;SPG11;SEMA3F;SEMA5A;NLGN3;PPP3CB
prerank,GO_Biological_Process_2021__positive regulation of Notch signaling pathway (GO:0045747),-0.2015417205261863,-0.28403802246777893,0.8907563025210085,0.9803325078297735,1.0,16/44,30.93%,AAK1;EP300;EPN2;NOTCH4;DLL4;NOD2;MAML2;ENHO;POGLUT1;IL6ST;ROBO1;NOS3;SNW1;PRKCI;NOTCH2NLA;NOTCH1
prerank,GO_Biological_Process_2021__erythrocyte differentiation (GO:0030218),0.1944326787003054,0.2832299966432964,0.8947368421052632,0.9718066708577435,1.0,8/46,8.39%,SH2B3;ALAS1;ID2;ALAS2;TSPO2;INHA;HCLS1;CDK5RAP3
prerank,Elsevier_Pathway_Collection__BMPR2 Signaling,0.20779739655525314,0.2830296948503969,0.9043478260869565,0.9716512387325276,1.0,9/30,26.04%,JUN;CREBBP;SMAD7;ZNF423;SMAD5;BMP7;LIMK1;BMP6;SMAD4
prerank,WikiPathway_2021_Human__Vitamin A and carotenoid metabolism WP716,0.1880478157505846,0.2824774212180912,0.8898305084745762,0.9717683197824668,1.0,17/38,36.54%,SULT1A1;MAPK1;LRAT;DGAT1;BCO1;BCO2;DHRS3;RDH10;CRABP2;RBP2;RETSAT;CYP2E1;RBP1;AWAT2;RDH5;CYP26B1;ALDH1A2
prerank,WikiPathway_2021_Human__Glycosylation and related congenital defects WP4521,0.17662377066437027,0.2823092713644896,0.96,0.9715735695431904,1.0,8/25,24.61%,ALG12;MOGS;MPI;MPDU1;MGAT2;ALG8;ALG13;ALG2
prerank,Elsevier_Pathway_Collection__IL6/IGF1/VEGFA Signaling in Multiple Myeloma,-0.20451250943522617,-0.28171741715861515,0.8938053097345132,0.9818544760033517,1.0,14/47,22.99%,TNF;VCAM1;MAPK3;IGF1;MMP9;RPS6KB1;RAF1;GRB2;SHC1;TYK2;CXCL8;MAP2K2;TP53;IL6ST
prerank,GO_Biological_Process_2021__snRNA processing (GO:0016180),-0.15463459995326248,-0.28171399121890617,1.0,0.9815339644100661,1.0,4/16,24.81%,TOE1;INTS14;INTS6L;INTS1
prerank,Elsevier_Pathway_Collection__Adiponectin Synthesis Declines in Insulin Resistance,-0.20707903781656306,-0.28134229427056184,0.8666666666666667,0.9815269739927439,1.0,15/42,26.50%,TNF;MAPK3;TNFRSF1A;IGF1;RAF1;PIK3R1;GRB2;NFATC4;SHC1;ATF3;MAP2K2;IL6ST;HSPA5;DDIT3;AKT1
prerank,GO_Biological_Process_2021__positive regulation of growth (GO:0045927),-0.2023227204219092,-0.2806915569950304,0.8990825688073395,0.9817315769573312,1.0,24/67,26.50%,CDC42;DNPH1;H1-5;EGFR;H3-5;SLC44A4;PSMD10;ADNP2;ADAM17;SFRP1;RFTN1;N6AMT1;LEP;AKAP6;EIF4G1;MMP14;CSNK2A3;RPS6KA1;SFRP2;CEP43;PLCB1;DERL2;TRIM32;AKT1
prerank,GO_Biological_Process_2021__antigen processing and presentation of peptide antigen via MHC class I (GO:0002474),0.18173501518092006,0.2803228780036091,0.9117647058823529,0.9729187385905238,1.0,8/33,21.64%,TAP1;PDIA3;TAP2;TAPBPL;SEC13;B2M;TAPBP;CALR
prerank,Reactome_2022__CLEC7A (Dectin-1) Signaling R-HSA-5607764,-0.2067805418642253,-0.27990099223314563,0.9661016949152542,0.9820306723162233,1.0,28/97,24.70%,PSMB7;PSMD7;PSMF1;PYCARD;SKP1;PSMA5;PSMD2;PSMB8;RPS27A;PSMD11;PSMD10;BCL10;PSMD13;PSMC1;PSME1;PSMA1;CLEC7A;PPP3R1;CCL17;UBA3;PSMD5;PSMD12;PSMB3;UBE2N;CHUK;CARD11;UBC;ITPR1
prerank,WikiPathway_2021_Human__Cytosolic DNA-sensing pathway WP4655,0.19768648852234766,0.27923601433120093,0.9185185185185185,0.9734428992703601,1.0,21/57,30.17%,CASP10;TRIM25;POLR2F;POLR3K;POLR3G;POLR3D;POLR2L;MAVS;NFKBIB;IKBKE;IKBKB;DDX58;POLR2H;POLR3F;ATG5;CGAS;CASP1;IRF7;ADAR;NFKBIA;IKBKG
prerank,GO_Biological_Process_2021__negative regulation of protein-containing complex assembly (GO:0031333),0.1914926260560864,0.2787545613407131,0.9290780141843972,0.9734927713733553,1.0,11/47,18.97%,RPL13A;GSK3B;PPM1A;HSF1;PRRT2;GBA;PYDC1;PARK7;TFIP11;JAM3;IAPP
prerank,KEGG_2021_Human__Renin secretion,-0.19415325960336355,-0.2786484664938386,0.9196428571428571,0.9827051722724683,1.0,20/59,27.60%,ADRB1;PDE1B;AGTR1;CTSB;CALML6;EDN1;ADCY5;PDE3A;ADORA1;PPP3R1;CALM2;GNAQ;ORAI1;CACNA1D;NPR1;GUCY1B1;ITPR1;KCNJ2;PLCB1;PLCB2
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Vasodilation in Brain,0.17340733068484931,0.27800372166628917,0.9416666666666667,0.9737395128955962,1.0,11/29,30.01%,PDPK1;AGT;TRPV1;PRKCQ;MME;PTGES;PLCB3;PRKCH;CRCP;GNA11;NFKBIA
prerank,Elsevier_Pathway_Collection__I-cell: CCK-8 Secretion and Regulation of Eating Behavior,-0.16798286513596997,-0.27781120408004967,0.96,0.9829912350086095,1.0,7/24,27.60%,TLR5;CASR;IRAK1;GNAQ;ITPR1;FFAR4;PLCB2
prerank,Reactome_2022__Major Pathway Of rRNA Processing In Nucleolus And Cytosol R-HSA-6791226,-0.1925231270125627,-0.2764330970646795,0.9906542056074766,0.9836913898205049,1.0,51/176,24.44%,RPL34;NOB1;RRP1B;UTP4;RPL37;RCL1;RPL35;RPS19;PES1;RPL12;RPL7A;RPL8;RPP14;RPL22L1;WDR3;RPL7;BOP1;RPL3L;RPS28;RPL26L1;RPL3;BMS1;RPL14;RPS27A;FBL;FAU;RPS17;DDX56;WDR46;WDR43;EXOSC5;SNU13;UTP14A;GNL3;RPL21;RPS10;NOL11;DDX47;EMG1;RPL36;UTP15;RPS9;EXOSC8;RPLP1;RPP21;RPLP0;RSL24D1;C1D;MPHOSPH6;TBL3;EXOSC7
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Glomerulonephritis,-0.19174291636956856,-0.27605012902021786,0.8947368421052632,0.9836711967306195,1.0,15/54,20.28%,TNF;VCAM1;MAPK3;MAP2K4;KNG1;MAP3K5;RAF1;F2;IRAK1;EDN1;F2R;CXCL8;MAP2K2;MAPK14;GNAQ
prerank,GO_Biological_Process_2021__lysosome localization (GO:0032418),0.18328183921915533,0.2745999072594393,0.9583333333333334,0.975983999508124,1.0,8/35,23.48%,BLOC1S2;SYTL4;HPS6;PIK3CG;RAB34;FLCN;SNAPIN;PIP4P1
prerank,GO_Biological_Process_2021__positive regulation of neural precursor cell proliferation (GO:2000179),-0.16507741386286845,-0.27458406488979337,0.9916666666666667,0.9844109577339686,1.0,8/20,31.03%,NES;DLL4;DISP3;DISC1;CX3CR1;LRP2;VEGFA;FZD3
prerank,GO_Biological_Process_2021__IRE1-mediated unfolded protein response (GO:0036498),-0.19473800155392396,-0.2744899522636486,0.9150943396226415,0.984161384317331,1.0,17/52,27.45%,GSK3A;DNAJC3;SYVN1;PDIA6;ERN1;SHC1;ERN2;EXTL2;GOSR2;PPP2R5B;ZBTB17;DNAJB9;HSPA5;DCTN1;HYOU1;TLN1;EXTL3
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001239),-0.161679903867284,-0.2743621791615601,0.9516129032258065,0.983948072508952,1.0,9/27,27.38%,TNF;GDNF;IFI6;RET;SNAI2;EYA4;GATA1;AKT1;UNC5B
prerank,GO_Biological_Process_2021__polyol metabolic process (GO:0019751),-0.17908765672075808,-0.27398101348183707,0.925,0.9839208821000655,1.0,16/47,30.14%,PLD4;IMPA2;OCRL;IMPA1;INPP4A;SYNJ1;PLCH2;NUDT3;IP6K2;INPP5J;PPIP5K1;NUDT10;PLCB1;PLCB2;PLCD4;NUDT4
prerank,GO_Biological_Process_2021__tRNA methylation (GO:0030488),-0.16976606661892862,-0.27377840248600593,0.9774436090225563,0.9837854871848586,1.0,10/34,25.99%,FTSJ1;TRMT10C;PRORP;BCDIN3D;THADA;TYW3;TRMT112;METTL6;NSUN6;TRDMT1
prerank,GO_Biological_Process_2021__chondroitin sulfate metabolic process (GO:0030204),0.16721269890182092,0.2732782677972049,0.967479674796748,0.9767622939013344,1.0,7/30,18.18%,CHSY1;CSGALNACT2;HEXB;IDUA;BGN;CHST11;HEXA
prerank,KEGG_2021_Human__Vascular smooth muscle contraction,-0.1875229058470488,-0.27186703737753615,0.9741379310344828,0.9849567454298087,1.0,41/120,28.82%,KCNMB1;MYLK2;MAPK3;ADCY8;PLA2G12B;PPP1R12A;AGTR1;ADCY3;PPP1CB;CALD1;ACTG2;PLA2G1B;CALCRL;RAF1;ADORA2A;CALML6;MYL6B;EDN1;ADCY5;MYH10;RAMP2;MYLK;GNA12;CALM2;MAP2K2;GNAQ;CACNA1D;ADRA1B;NPR1;GUCY1B1;ADRA1A;ITPR1;PLA2G4C;PLA2G2C;PLCB1;BRAF;PRKCE;PLCB2;ACTA2;ARHGEF11;ADM
prerank,KEGG_2021_Human__Long-term depression,0.1880939375377144,0.2704829334498148,0.948905109489051,0.9785445365814864,1.0,13/53,21.10%,GRIA1;MAPK1;JMJD7-PLA2G4B;GUCY1A1;GNAI1;NOS1;PLA2G4F;PPP2CB;PLA2G4B;PRKG2;PRKCB;PLCB3;ARAF
prerank,GO_Biological_Process_2021__positive regulation of peptide hormone secretion (GO:0090277),-0.18628018644356983,-0.27030137802615556,0.9024390243902439,0.9857736640045527,1.0,5/36,7.21%,NNAT;MCU;SOX4;TCF7L2;SCT
prerank,GO_Biological_Process_2021__internal peptidyl-lysine acetylation (GO:0018393),-0.17765487155013795,-0.2701657346070078,0.9339622641509434,0.9855407679592773,1.0,5/28,15.63%,NAT8B;EP300;KAT7;NAA50;PHF20L1
prerank,Elsevier_Pathway_Collection__IL6 Expression Targets -> Nociception,-0.16313886877075381,-0.2701214560142686,0.957983193277311,0.9852553698554998,1.0,7/26,22.99%,PTGS2;RAF1;GRB2;TYK2;CXCL8;MAP2K2;IL6ST
prerank,Reactome_2022__Eukaryotic Translation Elongation R-HSA-156842,-0.1904813291496442,-0.27005231327082774,0.8909090909090909,0.9849715438472709,1.0,17/87,12.43%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17
prerank,Reactome_2022__Nonsense Mediated Decay (NMD) Independent Of Exon Junction Complex (EJC) R-HSA-975956,-0.1961387924494647,-0.2698491372085068,0.9439252336448598,0.9847654491429583,1.0,26/90,23.04%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;RPL21;RPS10;UPF1;RPL36;RPS9;EIF4G1;RPLP1;RPLP0;RSL24D1
prerank,GO_Biological_Process_2021__positive regulation of microtubule polymerization (GO:0031116),0.19533629500283814,0.2696697927198385,0.9347826086956522,0.9788200486040948,1.0,6/27,18.32%,FES;ARL2;GIT1;MAPRE1;PSRC1;MAPT
prerank,GO_Biological_Process_2021__base-excision repair (GO:0006284),-0.18572409494599051,-0.2688283496624874,0.9038461538461539,0.985168575960968,1.0,9/48,12.59%,RPA1;POLG;RFC1;POLB;HMGA2;NEIL1;APEX2;RPA3;PRMT6
prerank,"Reactome_2022__Antigen Presentation: Folding, Assembly, Peptide Loading Of Class I MHC R-HSA-983170",-0.1634719517325844,-0.26764804315726975,0.9661016949152542,0.9856558529738743,1.0,8/28,25.85%,HLA-A;CANX;SEC24A;SEC14L3;HLA-F;HSPA5;PIK3C3;ERAP1
prerank,GO_Biological_Process_2021__regulation of NLRP3 inflammasome complex assembly (GO:1900225),-0.13426667243471285,-0.26583982167981957,1.0,0.9866795636956501,1.0,5/15,34.49%,CD36;CPTP;TLR6;NLRC3;TLR4
prerank,KEGG_2021_Human__Amino sugar and nucleotide sugar metabolism,0.17585410961798534,0.26539221007575553,0.9763779527559056,0.9816730774519772,1.0,20/48,33.16%,GNPDA1;HEXB;MPI;PGM3;CYB5R3;RENBP;NANP;NANS;GNE;HEXA;CYB5R4;HK2;GALK1;CHIA;UAP1;GMPPA;GFPT2;CMAS;UGP2;UGDH
prerank,KEGG_2021_Human__Autoimmune thyroid disease,-0.1670305822150144,-0.2641828104202882,0.9658119658119658,0.9875034631524854,1.0,12/33,30.43%,HLA-A;HLA-DQB1;HLA-DQA1;FAS;CTLA4;CGA;HLA-F;HLA-DMA;CD80;GZMB;PRF1;HLA-DRB5
prerank,GO_Biological_Process_2021__membrane protein intracellular domain proteolysis (GO:0031293),0.16524618641193473,0.26394001552030083,0.9854014598540146,0.9823711436939502,1.0,3/21,11.13%,HM13;PSEN2;MMP7
prerank,GO_Biological_Process_2021__mitotic nuclear membrane organization (GO:0101024),-0.18277795979761347,-0.2637673183191175,0.9487179487179487,0.9870862813057842,1.0,6/51,5.33%,SUMO1;CHMP7;LBR;SIRT2;SEH1L;RANGAP1
prerank,GO_Biological_Process_2021__mitotic nuclear membrane reassembly (GO:0007084),-0.18277795979761347,-0.2637673183191175,0.9487179487179487,0.9870862813057842,1.0,6/51,5.33%,SUMO1;CHMP7;LBR;SIRT2;SEH1L;RANGAP1
prerank,GO_Biological_Process_2021__response to unfolded protein (GO:0006986),0.18690904477745313,0.26319951212051046,0.9090909090909091,0.9826242768980682,1.0,19/47,30.84%,SERPINH1;HSPA4L;ERP44;HSPB1;DAXX;HSF1;HSPB8;TMBIM6;DNAJA1;HSPA8;STT3B;BAG3;HSPA13;TOR1B;DNAJC4;HSPA1B;HERPUD1;PRKN;HSPH1
prerank,Elsevier_Pathway_Collection__Eosinophil Survival by Cytokine Signaling,-0.19138214924087196,-0.26256200775368005,0.9074074074074074,0.987594241547674,1.0,18/68,20.85%,TNF;TRADD;MAPK3;TNFRSF1A;JAK3;PIM1;SOX4;MAP2K4;RAF1;IL9R;GRB2;IRAK1;CXCL8;MAP2K2;CSF2RB;IL33;LEP;IL15RA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cholesteatoma,-0.16310088725043256,-0.26230186553965623,0.940677966101695,0.9874568850868478,1.0,16/34,34.49%,TNF;MMP9;CAMP;TGFA;ERBB4;CXCL8;HSPA5;TNFRSF11A;BMP2;VEGFA;CTSK;AREG;MYC;TGFB1;TCN1;TLR4
prerank,Reactome_2022__GTP Hydrolysis And Joining Of 60S Ribosomal Subunit R-HSA-72706,-0.18556105547092977,-0.2622406135100424,0.9553571428571429,0.9871801702610069,1.0,45/107,33.88%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;EIF5;RPL21;RPS10;RPL36;RPS9;EIF4G1;RPLP1;RPLP0;RSL24D1;EIF3E;EIF3J;RPL23;RPL4;RPS8;RPL39;RPS3A;EIF3H;EIF4E;RPS20;RPS4X;RPL39L;RPL36AL;EIF3I;EIF3B;RPL22;RPL11;EIF2S3;RPSA
prerank,Reactome_2022__Signaling By NOTCH2 R-HSA-1980145,0.17356428369771168,0.26223539195478596,0.9689922480620154,0.9830257680549414,1.0,10/31,25.05%,DLL1;PSEN2;UBB;UBA52;NEURL1;PSENEN;CNTN1;NOTCH2;CREB1;ADAM10
prerank,GO_Biological_Process_2021__nucleic acid phosphodiester bond hydrolysis (GO:0090305),0.1970448474118232,0.2613800137300692,0.9344262295081968,0.9833067481981954,1.0,19/73,20.43%,RNASE4;RFC2;EDC4;DDB1;GTF2H5;POLD1;PDE12;FAN1;PCNA;IHO1;UBB;ERCC3;DDB2;DNA2;POLK;EDC3;UBA52;DXO;RPA2
prerank,KEGG_2021_Human__Cardiac muscle contraction,0.20085249553664405,0.2610620792294272,0.9523809523809523,0.9832011492789667,1.0,11/70,8.21%,CACNA1C;COX7C;SLC9A6;UQCRHL;CACNB2;UQCRQ;UQCRC1;SLC9A7;CACNA2D4;HRC;ATP1A4
prerank,GO_Biological_Process_2021__regulation of neurogenesis (GO:0050767),-0.18390908707320983,-0.2609723135594438,0.9435483870967742,0.9876323937611112,1.0,22/53,31.70%,TNF;HES5;HEY2;RGS14;CCL11;ASCL2;SERPINF1;NUMBL;APPL2;WNT7A;FAIM;CX3CR1;LRP2;HES1;TRIM32;PER2;SNW1;HES2;IFNG;SORL1;NOTCH1;ARNTL
prerank,WikiPathway_2021_Human__Peptide GPCRs WP24,-0.18609151354269537,-0.2608426145397413,0.9098360655737705,0.9874082335659535,1.0,21/50,33.91%,GALR1;FPR1;GRPR;GNRHR;NPY1R;AGTR1;CXCR6;CCR5;CCR8;CXCR3;NPY5R;AVPR2;CX3CR1;OPRD1;CCR2;CCR3;SSTR2;SSTR3;EDNRA;TACR2;NTSR1
prerank,GO_Biological_Process_2021__sulfur compound transport (GO:0072348),-0.15724940244271146,-0.26051469700772034,0.9836065573770492,0.9873055999690847,1.0,11/28,33.54%,SLC44A4;SLC26A8;SLC25A10;MGST1;SLC35B2;SLC27A1;SLC6A6;SLC25A19;ABCG2;SLC13A1;SLC13A4
prerank,Reactome_2022__Inositol Phosphate Metabolism R-HSA-1483249,-0.17392711006030198,-0.26044389103400445,0.952,0.9870334318496368,1.0,18/48,31.90%,PLD4;IMPA2;OCRL;IMPA1;INPP4A;SYNJ1;PLCH2;NUDT3;IP6K2;INPP5J;PPIP5K1;NUDT10;PLCB1;PLCB2;PLCD4;NUDT4;MTMR9;PLCZ1
prerank,Reactome_2022__RHO GTPases Activate PKNs R-HSA-5625740,0.17899198461142757,0.26033568135128576,0.953125,0.9833837902112059,1.0,8/52,11.50%,YWHAQ;PKN2;KDM1A;MYL12B;REXO2;H2AJ;PDPK1;PKN3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Rheumatoid Arthritis,-0.19513960053259305,-0.2599839562452039,0.9607843137254902,0.9869957731950887,1.0,24/83,22.81%,TNF;PTGS2;IL18;TNFSF12;COL2A1;IL1RN;MMP9;HLA-DQA1;CTSB;HMGB1;ALB;F2;ADAM17;CCR5;FAS;CTLA4;MMP3;CXCR3;CXCL8;IL33;MAPK14;LEP;TNFSF14;TP53
prerank,GO_Biological_Process_2021__ventricular cardiac muscle tissue morphogenesis (GO:0055010),0.173287529171959,0.25978817469054005,0.9470198675496688,0.9834253385564139,1.0,5/28,14.97%,NOG;MYBPC3;SMAD7;FKBP1A;PKP2
prerank,WikiPathway_2021_Human__ATM Signaling Pathway WP2516,0.1712750240141711,0.259234807969323,0.9541984732824428,0.983463183659432,1.0,19/39,38.06%,JUN;CDK2;MDC1;BRCA1;CCNB1;CDKN1A;CCNE1;FANCD2;CREB1;CHEK2;NFKBIA;IKBKG;TP53BP1;ATF2;RIPK1;CDK1;CASP2;CDC25A;RAD9A
prerank,Reactome_2022__Budding And Maturation Of HIV Virion R-HSA-162588,0.1746372489385656,0.2589818578056328,0.950354609929078,0.9833294938708357,1.0,11/27,31.35%,VPS4B;VPS28;UBB;UBA52;VTA1;CHMP4B;MVB12B;CHMP5;CHMP2A;PDCD6IP;VPS37C
prerank,Reactome_2022__EGR2 And SOX10-mediated Initiation Of Schwann Cell Myelination R-HSA-9619665,-0.17413822619652852,-0.2589414706087991,0.968503937007874,0.9872847191756768,1.0,4/29,8.50%,TEAD1;LAMC1;PLPPR3;MPZ
prerank,TRRUST_Transcription_Factors_2019__MYCN human,-0.1668439401010341,-0.2588075966629802,0.9310344827586207,0.9870293540481919,1.0,19/44,35.21%,MCM4;MCM7;HLA-A;NES;NGFR;MXI1;EFNB3;MDM2;TP53;HLA-F;DKK3;MCM6;IFNG;MYBL2;GRHL1;CIITA;TP53INP1;NTRK1;BIRC5
prerank,Reactome_2022__COPII-mediated Vesicle Transport R-HSA-204005,0.19102283186549712,0.2583137614549777,0.9712230215827338,0.983453073035321,1.0,21/65,26.08%,GRIA1;CNIH3;TRAPPC6A;TBC1D20;PPP6R3;CD59;SEC13;SEC22C;SEC23IP;F5;TRAPPC5;STX5;NAPSA;CNIH2;LMAN1;TRAPPC10;SEC22A;SEC23A;SERPINA1;ANKRD28;TRAPPC3
prerank,Elsevier_Pathway_Collection__RAGE/AGER and S100 Proteins in Cardiovascular Injury,0.17149655814047277,0.2582068515038546,0.9603174603174603,0.9832068386003163,1.0,4/30,9.16%,JUN;MAPK1;S100A9;PDPK1
prerank,Reactome_2022__Formation Of A Pool Of Free 40S Subunits R-HSA-72689,-0.18847054192464863,-0.25708406629690966,0.963302752293578,0.9878551613992648,1.0,40/96,33.11%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;RPL21;RPS10;RPL36;RPS9;RPLP1;RPLP0;RSL24D1;EIF3E;EIF3J;RPL23;RPL4;RPS8;RPL39;RPS3A;EIF3H;RPS20;RPS4X;RPL39L;RPL36AL;EIF3I;EIF3B;RPL22;RPL11
prerank,TRRUST_Transcription_Factors_2019__PPARA mouse,-0.17973024212622762,-0.25663249971856317,0.9478260869565217,0.9877993881720853,1.0,14/42,27.56%,PTGS2;ANGPTL4;ACOT1;CPT1A;CD36;UCP3;MPO;SERPINE2;CYP7A1;NR1I2;IL6ST;SLC27A1;TBX21;PEX11A
prerank,WikiPathway_2021_Human__IL-5 signaling pathway WP127,-0.18548922653358285,-0.25649286326048587,0.9292035398230089,0.9875647475665087,1.0,11/39,19.65%,BTK;GSK3A;MAPK3;RPS6KB1;RAF1;PIK3R1;GRB2;SHC1;SPRED1;MAP2K2;CSF2RB
prerank,TRRUST_Transcription_Factors_2019__RXRA human,-0.1417938463119375,-0.2564156046630491,1.0,0.9873054963516508,1.0,10/18,40.70%,HSD17B2;CYP7A1;GNRH2;ABCC3;NOL7;PLD1;HNF1A;CYP3A4;SERPINC1;IL2RG
prerank,TRRUST_Transcription_Factors_2019__ETS1 human,-0.18374812196286253,-0.2563313579104194,0.9666666666666667,0.9870491642751621,1.0,20/70,22.94%,TFAP2A;ERG;GP6;TNC;TBXA2R;GRPR;ANGPT2;ATXN2;MMP9;CTSB;COL1A1;ECE1;TMEM158;MMP3;RHOC;MDM2;TNFSF14;CD6;TP53;CHUK
prerank,GO_Biological_Process_2021__inositol phosphate metabolic process (GO:0043647),-0.1637002803110613,-0.2561814575681735,0.9576271186440678,0.9868122465745315,1.0,16/47,30.14%,PLD4;IMPA2;OCRL;IMPA1;INPP4A;SYNJ1;PLCH2;NUDT3;IP6K2;INPP5J;PPIP5K1;NUDT10;PLCB1;PLCB2;PLCD4;NUDT4
prerank,GO_Biological_Process_2021__positive regulation of phosphatase activity (GO:0010922),-0.1520106986682852,-0.25605080223827514,1.0,0.9865644876674755,1.0,8/20,33.46%,MAGI2;PPP1R15A;PTPA;CALM2;BMP2;IFNG;MTMR9;CALM3
prerank,KEGG_2021_Human__Leishmaniasis,0.1997432705419706,0.2552618500245067,0.9432624113475178,0.9848063883982712,1.0,24/72,25.77%,IL12B;HLA-DMB;MAPK11;ELK1;JUN;MAPK1;ITGB2;EEF1A2;TAB2;TLR2;HLA-DQA2;JAK2;NFKBIB;FCGR3B;STAT1;MAPK13;PRKCB;IFNGR1;FCGR3A;HLA-DOA;IL12A;IFNGR2;EEF1A1;MYD88
prerank,GO_Biological_Process_2021__regulation of interferon-alpha production (GO:0032647),-0.14833862054755953,-0.2548947888035529,0.9821428571428571,0.9869736364828359,1.0,3/24,11.08%,IFIH1;HSPD1;DHX9
prerank,GO_Biological_Process_2021__myofibril assembly (GO:0030239),-0.18323584806429483,-0.25473045387969195,0.9478260869565217,0.9867713115974086,1.0,5/38,6.71%,ANKRD1;MYOM2;LMOD1;OBSCN;CSRP1
prerank,GO_Biological_Process_2021__negative regulation of sequestering of calcium ion (GO:0051283),-0.1380199056625208,-0.25412438690469186,0.992,0.9868176410712416,1.0,6/23,27.93%,CCL21;IBTK;F2R;ITPR1;XCL1;RYR1
prerank,Reactome_2022__L13a-mediated Translational Silencing Of Ceruloplasmin Expression R-HSA-156827,-0.1775741744619911,-0.2531306635159082,0.9736842105263158,0.9870753223994014,1.0,44/106,33.88%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;RPL21;RPS10;RPL36;RPS9;EIF4G1;RPLP1;RPLP0;RSL24D1;EIF3E;EIF3J;RPL23;RPL4;RPS8;RPL39;RPS3A;EIF3H;EIF4E;RPS20;RPS4X;RPL39L;RPL36AL;EIF3I;EIF3B;RPL22;RPL11;EIF2S3;RPSA
prerank,KEGG_2021_Human__Allograft rejection,0.17230312209791296,0.2526452308495459,0.9389312977099237,0.9861651018760398,1.0,9/33,22.80%,IL12B;FASLG;HLA-DMB;HLA-DQA2;CD40LG;IL5;CD86;HLA-DOA;IL12A
prerank,Elsevier_Pathway_Collection__Proerythroblast -> Erythrocyte Surface Expression Markers,0.17247898425944025,0.25203089469181106,0.9452054794520548,0.9862252297743368,1.0,10/47,18.67%,CD34;G6PD;VPS13A;KCNN4;ABCC5;KDR;RHD;CD55;CNP;PDE3B
prerank,Reactome_2022__Ca-dependent Events R-HSA-111996,0.15706850672481773,0.25180000032565486,0.9523809523809523,0.9860493365460077,1.0,14/33,37.27%,MAPK1;KPNA2;PRKX;PRKAR2B;CAMKK1;ADCY2;CREB1;ADCY4;ADCY7;PRKAR1A;PRKAR1B;ADCY1;CALM1;PLA2G4A
prerank,Reactome_2022__mRNA 3-End Processing R-HSA-72187,-0.17293575952466816,-0.2517971982947643,0.9285714285714286,0.9875194509564211,1.0,10/57,13.31%,THOC5;PCF11;UPF3B;CASC3;SRSF9;SLU7;CSTF1;SRSF2;THOC2;SRSF3
prerank,Elsevier_Pathway_Collection__IL23A and IL17A Provoke Cancer-Associated Inflammation,-0.14465113509883554,-0.25120279380693955,0.991304347826087,0.9875874402907523,1.0,2/25,3.31%,TNF;PTGS2
prerank,GO_Biological_Process_2021__RNA methylation (GO:0001510),-0.18992243176538104,-0.2506389383508288,0.9307692307692308,0.9876046483700529,1.0,18/60,25.99%,PCIF1;METTL3;NOP2;FTSJ1;CMTR1;TGS1;TRMT10C;FBL;MRM2;ZC3H13;MEPCE;BCDIN3D;THADA;TYW3;TRMT112;METTL6;NSUN6;TRDMT1
prerank,"GO_Biological_Process_2021__Wnt signaling pathway, calcium modulating pathway (GO:0007223)",0.16170530877933334,0.25016995999621405,0.9833333333333333,0.986701062426541,1.0,10/36,22.32%,WNT11;AGO4;GNB1;GNG2;PPP3CB;FZD5;PLCB3;CTNNB1;PDE6A;TNRC6C
prerank,GO_Biological_Process_2021__rRNA metabolic process (GO:0016072),-0.17206699847952234,-0.2501651327047094,0.990909090909091,0.9875820912061651,1.0,48/162,24.45%,RPL34;NOB1;RRP1B;UTP4;RPL37;RCL1;RPL35;RPS19;PES1;RPL12;RPL7A;RPL8;HELQ;WDR3;RPL7;BOP1;RPS28;MDN1;RPL3;BMS1;RPL14;FBL;RPS17;MRM2;WDR46;WDR43;EXOSC5;SNU13;UTP14A;DDX10;RPL21;NOL11;ERN2;DDX47;EMG1;RPL36;UTP15;RPS9;WDR55;DIS3L;EXOSC8;RPLP1;RPLP0;C1D;MPHOSPH6;TBL3;EXOSC7;MRTO4
prerank,GO_Biological_Process_2021__regulation of calcium-mediated signaling (GO:0050848),-0.145212562905568,-0.24965053858928415,1.0,0.9875746229097532,1.0,8/25,31.12%,CD22;CDH13;CLEC7A;P2RX2;ITPR1;TRAT1;CCL3;CCL4
prerank,WikiPathway_2021_Human__Cytoplasmic Ribosomal Proteins WP477,-0.17832232974625625,-0.2484417869386168,0.9642857142857143,0.9879206047120116,1.0,16/88,12.43%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPS6KB1;RPL7;RPL3L;RPS28;RPL3;RPL14;RPS27A;FAU;RPS17
prerank,KEGG_2021_Human__Taste transduction,-0.1745021878833911,-0.24843546039843986,0.9615384615384616,0.9876076333016116,1.0,8/50,10.91%,ADCY8;TAS2R19;HTR1B;TRPM5;PDE1B;CHRM3;SCN9A;GABBR1
prerank,Reactome_2022__Iron Uptake And Transport R-HSA-917937,0.18600495272879133,0.24833055474074392,0.9117647058823529,0.9875356565513842,1.0,28/55,37.72%,GLRX3;ATP6V1G1;MCOLN1;ATP6V0A1;ATP6V0C;ATP6V1E2;UBB;HMOX1;LCN2;ATP6V0D2;ATP6V1H;ATP6V0A2;UBA52;ATP6V1E1;ATP6V0E2;ACO1;HEPH;HMOX2;IREB2;CP;SLC22A17;TCIRG1;TFR2;ALAD;CAND1;ATP6V1G2;CYBRD1;FBXL5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Clear Cell Ovarian Carcinoma,0.1822444435376929,0.24785015515798006,0.937984496124031,0.9875097590978058,1.0,12/46,21.39%,GSK3B;JUN;MAPK1;CASP9;PDGFB;BRCA1;BCL2L1;HIF1A;MTOR;CCNE1;PTEN;CTNNB1
prerank,GO_Biological_Process_2021__nucleotide metabolic process (GO:0009117),0.1633598474297268,0.24498662165610766,0.9927536231884058,0.9888771910964904,1.0,4/23,16.50%,DCTD;REXO2;PARK7;ENPP3
prerank,GO_Biological_Process_2021__positive regulation of myeloid cell differentiation (GO:0045639),-0.17149433495771466,-0.2445451269392468,0.9435483870967742,0.9893511868445943,1.0,11/37,23.25%,FAM210B;TAL1;ETS1;THPO;FAXDC2;ACVR1B;SCIN;MAPK14;BRD1;TESC;GATA1
prerank,Reactome_2022__Assembly Of HIV Virion R-HSA-175474,0.15187748027184927,0.24390301490587643,0.9916666666666667,0.9891804786714808,1.0,5/17,25.96%,VPS28;UBB;UBA52;NMT2;MVB12B
prerank,Elsevier_Pathway_Collection__Eosinophil Survival in Asthma,-0.15995651648402037,-0.24298352771297393,0.9545454545454546,0.9898687033682753,1.0,19/47,33.41%,TRADD;MAPK3;PIM1;SOX4;TYK2;NGFR;CXCL8;MAP2K2;CSF2RB;IL33;ITPR1;BRAF;VEGFA;CCR3;IL17RA;SDCBP;TGFB1;IL5RA;BDNF
prerank,GO_Biological_Process_2021__cytoplasmic translation (GO:0002181),-0.1764136778183994,-0.2428083926878923,0.9903846153846154,0.989655282028437,1.0,16/93,12.43%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;FTSJ1;RPL8;RPL22L1;RPL7;RPS28;RPL26L1;RPL3;RPL14;RPS27A;RPS17
prerank,GO_Biological_Process_2021__dendrite morphogenesis (GO:0048813),-0.16504218157068512,-0.24237912987367172,0.9754098360655737,0.989558255595954,1.0,13/36,30.11%,DCDC2;CDC42;PHACTR1;EPHB3;CTNND2;LRP4;WNT7A;EPHB1;SHANK3;ZNF365;BTBD3;MAP6;ARC
prerank,GO_Biological_Process_2021__nuclear membrane reassembly (GO:0031468),-0.1681559959003603,-0.24159482141879476,0.9739130434782609,0.9896527119548367,1.0,6/54,5.33%,SUMO1;CHMP7;LBR;SIRT2;SEH1L;RANGAP1
prerank,Elsevier_Pathway_Collection__Hereditary Hemorrhagic Telangiectasia,-0.14612175882546435,-0.24129000656742158,1.0,0.9895024421177154,1.0,13/25,39.22%,PIK3CA;SMAD2;PIK3R1;ATF3;ENG;AKT1;ACVRL1;ID1;TGFB1;SMAD9;ACVR1;ACVR2A;BMP10
prerank,GO_Biological_Process_2021__cotranslational protein targeting to membrane (GO:0006613),0.18767741122372983,0.24012699899323198,0.9861111111111112,0.9910126669187505,1.0,37/94,32.61%,RPL13A;RPL6;RPLP2;RPS2;RPL19;SRP14;RPS25;SRPRA;RPL37A;RPL41;RPS4Y1;SRP9;SRP19;RPL28;RPS7;RPS26;RPS21;RPL24;RPS18;UBA52;RPL26;SRP68;RPL35A;RPS16;TRAM1;SEC63;RPL5;RPS15;SRP72;RPL27A;RPL18;RPL30;RPL15;SRP54;RPS14;RPL31;SSR2
prerank,Reactome_2022__Ion Homeostasis R-HSA-5578775,-0.15508577715191216,-0.2400850731512393,0.9829059829059829,0.9897867854988154,1.0,11/45,24.70%,ATP1B1;SLC8A1;ATP2A3;FXYD2;PLN;ATP2B3;SLC8A3;ATP2B1;ORAI1;ORAI2;ITPR1
prerank,KEGG_2021_Human__Legionellosis,0.18577686248811623,0.2376087111293307,0.9642857142857143,0.9920653457008248,1.0,11/56,11.60%,IL12B;ARF1;CYCS;CXCL2;NLRC4;ITGB2;CASP9;HSF1;EEF1A2;VCP;TLR2
prerank,GO_Biological_Process_2021__negative regulation of cell death (GO:0060548),0.17691609848770443,0.23757477703782884,0.9527027027027027,0.9917575347070635,1.0,32/90,30.32%,BNIP3L;VPS4B;GSK3B;WNT11;TNFRSF1B;CD34;PDE8A;TRAF2;CCN2;FGF2;PDE12;PAX2;GBA;POU4F1;WFS1;PARK7;HTRA2;CCN3;BMP7;WNT16;DUS2;ZBED6;BNIP3;SPEF1;CHMP4B;ATG5;SRGAP2;CD200;CHMP2A;HSPA1B;IKBKG;PRKN
prerank,WikiPathway_2021_Human__Allograft Rejection WP2328,-0.1808022091672396,-0.23622894594323643,0.9693877551020408,0.9912743575729894,1.0,12/80,9.95%,TNF;C6;GNLY;HLA-A;HLA-DQB1;GDNF;HLA-DQA1;AGTR1;C5;MICA;CXCL13;CCL21
prerank,GO_Biological_Process_2021__snRNA transcription by RNA polymerase II (GO:0042795),0.17749933186746,0.23550811763893054,0.967479674796748,0.9925569293622494,1.0,20/70,26.28%,NCBP2;TAF9;GTF2F2;NABP1;POLR2A;ICE1;POLR2F;INTS4;GTF2E1;INTS5;CDK9;POLR2C;POLR2L;ZNF143;SP1;TBP;POLR2H;INTS11;NABP2;CCNT2
prerank,GO_Biological_Process_2021__mesenchymal cell differentiation (GO:0048762),-0.16009993106415596,-0.23539360690816893,0.944954128440367,0.9913394620974774,1.0,7/49,9.41%,HEY2;WNT5A;FOXF2;FOXC1;TRIM28;HMGA2;NOTCH4
prerank,WikiPathway_2021_Human__AGE/RAGE pathway WP2324,0.17404421148308302,0.23439419944292808,0.9473684210526315,0.9928207661018785,1.0,28/64,34.70%,CYCS;JUN;MAPK1;STAT5A;STAT5B;CASP9;MMP7;JAK2;SMAD3;HIF1A;IKBKB;STAT1;RHOA;SP1;PRKCB;EZR;ALPL;RAC1;FOXO4;MYD88;MAP2K1;NFKBIA;MAPK8;SRC;ATF2;MSR1;MMP2;IRS1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diffuse Large-B-Cell Lymphoma,-0.1588110706448886,-0.2340900409936731,0.981651376146789,0.991606556477838,1.0,9/54,13.37%,IDO1;PRDM1;PDE4B;MTA1;RPS6KB1;HGFAC;BCL10;CKAP2;MS4A1
prerank,TRRUST_Transcription_Factors_2019__FOXA1 human,-0.12486060373005191,-0.23287787811225738,1.0,0.9918107051052193,1.0,20/20,87.53%,CFTR;RET;TFF1;SFTPB;MYC;NKX2-1;ESR1;SERPINC1;KRT7;HSPA1A;ABCA1;NF1;AGR2;CCNG2;BCL2;APOB;UGT2B17;UGT2B15;GCG;BRCA1
prerank,Reactome_2022__Keratinization R-HSA-6805567,-0.17317328419478673,-0.23261606199791152,0.9830508474576272,0.9915986411255613,1.0,8/59,7.70%,SPINK9;KRT6A;ST14;KRT4;KRT6C;CAPN1;RCAN1;LCE2D
prerank,Reactome_2022__Cytosolic Sensors Of Pathogen-Associated DNA R-HSA-1834949,0.1761774667402724,0.23150340762748017,0.9444444444444444,0.9939567999040801,1.0,22/61,30.17%,TLR3;POLR2F;CREBBP;POLR3K;UBB;POLR3G;POLR3D;POLR2L;NFKBIB;IKBKB;UBA52;CTNNB1;LRRFIP1;POLR2H;PRKDC;POLR3F;CRCP;MYD88;CGAS;IRF7;NFKBIA;IKBKG
prerank,Reactome_2022__Signaling By Retinoic Acid R-HSA-5362517,0.15056818038979902,0.2311087389121866,1.0,0.9938217327346773,1.0,8/38,17.99%,PDK2;PPARD;PDPK1;RDH13;PDK3;DHRS4;DHRS3;RDH10
prerank,GO_Biological_Process_2021__snRNA transcription (GO:0009301),0.17555488211036002,0.23097357379570238,0.9682539682539683,0.993564991516065,1.0,20/71,26.28%,NCBP2;TAF9;GTF2F2;NABP1;POLR2A;ICE1;POLR2F;INTS4;GTF2E1;INTS5;CDK9;POLR2C;POLR2L;ZNF143;SP1;TBP;POLR2H;INTS11;NABP2;CCNT2
prerank,GO_Biological_Process_2021__regulation of protein localization to nucleus (GO:1900180),0.17525831415379498,0.23048294145148737,0.9621212121212122,0.993500735208512,1.0,20/46,37.65%,GSK3B;EIF2AK3;LAMTOR5;CDK5RAP3;LIMK2;PARK7;MFHAS1;FLCN;ORMDL3;WWTR1;GLUL;ILRUN;PYHIN1;SUMO4;PARP9;CDK1;LILRB4;LATS1;BYSL;PLK1
prerank,GO_Biological_Process_2021__regulation of immunoglobulin production (GO:0002637),0.15441211062860552,0.23031377743971643,1.0,0.9932795495019945,1.0,6/24,25.20%,EPHB2;FCRL3;XBP1;CD86;SUPT6H;SASH3
prerank,Reactome_2022__CaM Pathway R-HSA-111997,-0.13307481849960184,-0.2298835925301936,1.0,0.9924422641324486,1.0,6/31,21.30%,ADCY8;PDE1B;PRKAR2A;ADCY5;GRK2;CAMK4
prerank,GO_Biological_Process_2021__autophagosome assembly (GO:0000045),-0.17188497425242172,-0.2298353961843117,0.9919354838709677,0.9921347008672996,1.0,11/56,15.81%,ULK1;MAP1LC3B;RAB1A;WDR45;SMURF1;ATG7;PACS2;MAP1LC3C;ATG13;MAP1LC3A;RAB19
prerank,Elsevier_Pathway_Collection__Insulin Influence on Glycogenesis,0.14615212013537743,0.2271553276870482,1.0,0.9944561909640016,1.0,3/23,9.16%,GSK3B;MAPK1;PDPK1
prerank,GO_Biological_Process_2021__protein export from nucleus (GO:0006611),0.15452811326276658,0.22623743794998816,0.9863945578231292,0.9945364204183479,1.0,11/27,34.13%,NUTF2;DESI1;STRADB;XPO1;CALR;XPO4;DUSP16;RAN;ANKLE1;RANBP3L;CHP1
prerank,KEGG_2021_Human__Antigen processing and presentation,-0.15842413600622826,-0.2257535000297509,0.9622641509433962,0.9934491645374947,1.0,9/65,8.74%,TNF;HSPA6;HLA-A;CANX;HLA-DQB1;KLRD1;HLA-DQA1;HSPA4;CTSB
prerank,GO_Biological_Process_2021__import into nucleus (GO:0051170),0.16731002678059936,0.2238231763525598,0.9642857142857143,0.9952876411941213,1.0,14/74,16.30%,HEATR3;NUTF2;IPO8;SNRPE;TNPO3;NUP133;RANBP6;PPP1R10;FAM53A;RPAIN;SEC13;IPO7;GEMIN5;PRICKLE1
prerank,Reactome_2022__mTORC1-mediated Signaling R-HSA-166208,0.14465925781595498,0.22296163856174145,0.9928571428571429,0.9953505392845418,1.0,11/24,37.05%,LAMTOR5;FKBP1A;RRAGB;MTOR;MLST8;RPTOR;SLC38A9;RRAGA;RPS6;LAMTOR4;LAMTOR1
prerank,GO_Biological_Process_2021__nuclear export (GO:0051168),-0.16363574887011748,-0.22249019394771566,0.9805825242718447,0.9943867474346806,1.0,22/81,24.95%,THOC5;SMURF1;UPF3B;CASC3;SRSF9;SLU7;NUP62CL;SRSF2;TPR;THOC2;SRSF3;CSE1L;CCHCR1;NUP62;CHTOP;WASHC4;SRRM1;ATXN1;XPO6;NUP42;SRSF5;CDC40
prerank,Reactome_2022__PCP/CE Pathway R-HSA-4086400,0.17570367196246672,0.22204145003022815,0.9930555555555556,0.9954024631978509,1.0,22/85,20.58%,RAC2;WNT11;AP2B1;PSMD14;PSMD3;FZD1;PSMA6;UBB;PSMA2;VANGL2;RORA;PSMD6;PSMB6;PRICKLE1;PSME2;PSMB4;AP2M1;RHOA;UBA52;AP2S1;PRKCB;SCRIB
prerank,GO_Biological_Process_2021__COPII-coated vesicle budding (GO:0090114),-0.16576118140029725,-0.2213473350740388,0.9523809523809523,0.9944629402483885,1.0,16/70,17.77%,NAPA;RAB1A;CNIH1;TRAPPC6B;SCAP;GORASP1;TMED2;TRAPPC1;SEC22B;PEF1;SCFD1;VAPA;SEC24A;TGFA;BET1;SEC31B
prerank,GO_Biological_Process_2021__positive regulation of erythrocyte differentiation (GO:0045648),-0.1476528718390517,-0.21994801809800987,0.9834710743801653,0.9946044391538388,1.0,7/27,23.25%,FAM210B;TAL1;ETS1;ACVR1B;MAPK14;BRD1;GATA1
prerank,GO_Biological_Process_2021__negative regulation of proteasomal protein catabolic process (GO:1901799),0.15122495567617877,0.21993680556638603,0.9858156028368794,0.995982657058705,1.0,14/35,35.54%,TAF9;WAC;AQP11;PARK7;BAG6;N4BP1;MAP1A;CAMLG;OGT;FHIT;RYBP;GIPC1;ALAD;HSP90AB1
prerank,GO_Biological_Process_2021__glycolipid biosynthetic process (GO:0009247),0.16215371052499888,0.21944440274238178,0.96875,0.995832804680426,1.0,13/38,30.65%,ST8SIA6;ST3GAL5;PIGQ;PIGM;LARGE1;PIGU;SCCPDH;B3GNT5;ST8SIA5;ST6GALNAC5;PGAP4;DPM3;PIGH
prerank,Reactome_2022__Cap-dependent Translation Initiation R-HSA-72737,-0.15355112877837734,-0.2192793128749294,0.9823008849557522,0.9945144553664474,1.0,45/114,33.88%,RPL34;RPL37;RPL35;RPS19;RPL12;RPL7A;RPL8;RPL22L1;RPL7;RPL3L;RPS28;RPL26L1;RPL3;RPL14;RPS27A;FAU;RPS17;EIF5;RPL21;RPS10;RPL36;RPS9;EIF4G1;RPLP1;RPLP0;RSL24D1;EIF3E;EIF3J;RPL23;RPL4;RPS8;RPL39;RPS3A;EIF3H;EIF4E;RPS20;RPS4X;RPL39L;RPL36AL;EIF3I;EIF3B;RPL22;RPL11;EIF2S3;RPSA
prerank,Elsevier_Pathway_Collection__IDO1 in Cancer Immune Escape,0.1622845378216936,0.2183300841126831,0.9452054794520548,0.9959330730840307,1.0,22/61,31.51%,TDO2;DOK1;TRAF2;PDPK1;TNFSF18;JAK2;CD40LG;IKBKB;STAT1;MTOR;CD86;PTEN;IFNGR1;BIN1;IFNGR2;MYD88;CD200;FOXO3;NFKBIA;AHR;DOK2;IL6R
prerank,Reactome_2022__SARS-CoV-2 Modulates Host Translation Machinery R-HSA-9754678,0.15018123976610603,0.21729987054062136,0.9923076923076923,0.99601750414884,1.0,8/46,15.66%,RPS2;SNRPE;RPS25;RPS27L;RPS4Y1;RPS7;RPS21;GEMIN5
prerank,GO_Biological_Process_2021__autophagosome organization (GO:1905037),-0.1575756116033849,-0.21636805088837538,1.0,0.9951320879953209,1.0,10/54,15.81%,ULK1;MAP1LC3B;RAB1A;WDR45;ATG7;PACS2;MAP1LC3C;ATG13;MAP1LC3A;RAB19
prerank,Reactome_2022__Late Endosomal Microautophagy R-HSA-9615710,0.1468526274387267,0.21472612139404013,0.9851851851851852,0.9966695359998001,1.0,11/29,31.35%,ARL13B;VPS28;UBB;PARK7;UBA52;HSPA8;CHMP4B;MVB12B;IFT88;CHMP2A;VPS37C
prerank,Reactome_2022__RNA Polymerase II Transcribes snRNA Genes R-HSA-6807505,0.162294674154336,0.21401712740323878,0.9763779527559056,0.9966118094749787,1.0,14/73,16.82%,NCBP2;TAF9;GTF2F2;NABP1;POLR2A;ICE1;POLR2F;INTS4;GTF2E1;INTS5;CDK9;POLR2C;POLR2L;ZNF143
prerank,GO_Biological_Process_2021__regulation of G protein-coupled receptor signaling pathway (GO:0008277),0.1617861327004702,0.2122469492763555,1.0,0.9969165564757942,1.0,25/73,29.02%,GIT1;GPER1;DYNLT1;RGS16;GUCY2D;CALCR;SYP;RHO;RGS12;CRY1;FRMPD1;GUCA1B;RGS20;MGLL;PDE6A;PLEK;RGS3;RAMP3;NMT2;GRK4;CNGB1;GRK6;GRK5;RGS6;MRAP
prerank,GO_Biological_Process_2021__neuron migration (GO:0001764),-0.1419680036109433,-0.211592832780294,0.9913793103448276,0.9961560387689957,1.0,15/49,32.06%,DCDC2;MARK1;DDIT4;DNAAF4;SH3RF1;TUBB2B;MAP1B;DISC1;DCX;ASTN2;LRP12;VEGFA;NDNF;MARK2;CDK5R1
prerank,Elsevier_Pathway_Collection__Adipokines Production by Adipocyte Impaired in Obesity,0.15547610855001073,0.21131197553014366,0.9767441860465116,0.9969133178494884,1.0,7/42,14.95%,ITLN1;JUN;CEBPA;TRAF2;JAK2;PPARG;HIF1A
prerank,GO_Biological_Process_2021__RNA 3'-end processing (GO:0031123),-0.15663507475482413,-0.2107208163084422,0.9747899159663865,0.9960738018968508,1.0,11/67,13.31%,THOC5;PCF11;UPF3B;CASC3;SRSF9;SLU7;CSTF1;SRSF2;RPRD2;THOC2;SRSF3
prerank,GO_Biological_Process_2021__positive regulation of neurogenesis (GO:0050769),-0.15102660364428452,-0.20706552560997393,0.9911504424778761,0.996693056801681,1.0,27/66,31.46%,SOX8;RGS14;CAPRIN1;CHODL;SERPINF1;CUX1;CUX2;PLXNB1;NUMBL;NGFR;FAIM;DISC1;CX3CR1;SHANK3;LRP2;TIAM1;CAPRIN2;NGF;ROBO1;TRIM32;SNW1;MAP6;IFNG;VEGFA;CDKL3;FZD3;METRN
prerank,GO_Biological_Process_2021__vesicle coating (GO:0006901),0.15604449685864516,0.2063118927141851,0.9862068965517241,0.9974665508513166,1.0,19/63,26.08%,GRIA1;CNIH3;TRAPPC6A;TBC1D20;PPP6R3;CD59;TMED10;SEC13;SEC23IP;F5;TRAPPC5;STX5;CNIH2;LMAN1;TRAPPC10;SEC23A;SERPINA1;ANKRD28;TRAPPC3
prerank,"GO_Biological_Process_2021__vesicle targeting, rough ER to cis-Golgi (GO:0048207)",0.15604449685864516,0.2063118927141851,0.9862068965517241,0.9974665508513166,1.0,19/63,26.08%,GRIA1;CNIH3;TRAPPC6A;TBC1D20;PPP6R3;CD59;TMED10;SEC13;SEC23IP;F5;TRAPPC5;STX5;CNIH2;LMAN1;TRAPPC10;SEC23A;SERPINA1;ANKRD28;TRAPPC3
prerank,GO_Biological_Process_2021__COPII vesicle coating (GO:0048208),0.15604449685864516,0.2063118927141851,0.9862068965517241,0.9974665508513166,1.0,19/63,26.08%,GRIA1;CNIH3;TRAPPC6A;TBC1D20;PPP6R3;CD59;TMED10;SEC13;SEC23IP;F5;TRAPPC5;STX5;CNIH2;LMAN1;TRAPPC10;SEC23A;SERPINA1;ANKRD28;TRAPPC3
prerank,Reactome_2022__EPH-ephrin Mediated Repulsion Of Cells R-HSA-3928665,0.15270516977143037,0.20529590710708445,0.9850746268656716,0.9974062601623955,1.0,7/47,10.58%,YES1;AP2B1;EPHB2;EPHA6;DNM1;PSEN2;EFNB1
prerank,GO_Biological_Process_2021__blood vessel diameter maintenance (GO:0097746),0.14372947043563972,0.20399083991544203,1.0,0.9974367462317378,1.0,6/31,19.24%,CPS1;GPER1;AGT;NOS1;EDN2;SCPEP1
prerank,Reactome_2022__DAG And IP3 Signaling R-HSA-1489509,-0.1268513530817204,-0.20398335886015123,1.0,0.9970781759890219,1.0,11/37,32.56%,ADCY8;PDE1B;PRKAR2A;ADCY5;GRK2;CAMK4;ITPR1;PRKCE;CAMK2A;PRKCD;ADCY9
prerank,"Reactome_2022__Formation Of Ternary Complex, And Subsequently, 43S Complex R-HSA-72695",0.15096473721334577,0.20140139169490123,0.9918032786885246,0.9977308748713613,1.0,11/49,22.15%,RPS2;RPS25;EIF3C;RPS27L;RPS4Y1;RPS7;RPS21;EIF3G;EIF3A;EIF2S1;RPS16
prerank,GO_Biological_Process_2021__spliceosomal snRNP assembly (GO:0000387),-0.13659632046052803,-0.20054707827908547,1.0,0.9974739158669228,1.0,16/38,34.85%,TGS1;SNUPN;CD2BP2;SNRPB;SART3;LSM2;PRPF19;WDR77;LSM4;SNRPF;GEMIN6;SRSF10;SNRPC;GEMIN2;STRAP;PRMT7
prerank,GO_Biological_Process_2021__cellular iron ion homeostasis (GO:0006879),-0.13350413639709732,-0.1994240015202822,0.9829059829059829,0.9973777808356824,1.0,20/56,33.70%,SKP1;FTH1;ERFE;SLC40A1;ATP6AP1;TF;TFRC;SLC11A2;SOD1;NEDD8;NUBP1;CCDC115;SLC46A1;ABCG2;HAMP;CUL1;ATP13A2;MYC;SCARA5;ATP6V0D1
prerank,GO_Biological_Process_2021__response to amino acid starvation (GO:1990928),0.15375805581869872,0.19901659839865748,0.9921875,0.9979764531715233,1.0,27/72,33.28%,EIF2AK3;LAMTOR5;MAPK1;ATP6V1G1;ATP6V0C;ATP6V1E2;LARP1;SEC13;ATP6V0D2;ATP6V1H;RRAGB;MTOR;WDR24;FLCN;CDKN1A;EIF2S1;ATP6V1E1;ATF4;ATP6V0E2;MLST8;RPTOR;MAPK8;SLC38A9;RNF152;ATF2;TCIRG1;RRAGA
prerank,Elsevier_Pathway_Collection__Adipokines Production by Adipocyte,-0.14590754902036984,-0.1985320785191184,0.992,0.9972355479956342,1.0,4/44,4.51%,TNF;TRADD;TNFRSF1A;SERPINA12
prerank,GO_Biological_Process_2021__RNA splicing (GO:0008380),0.14880560757391195,0.19848646508026366,1.0,0.9977758690467404,1.0,21/97,20.96%,RSRC1;USP39;NCBP2;PRPF3;NOVA1;TARDBP;RNPC3;MPHOSPH10;MAGOH;SF3A3;ZCRB1;DBR1;USB1;LSM1;SYNCRIP;NOL3;SCAF11;LSM6;U2AF1;SRPK1;SNRPG
prerank,GO_Biological_Process_2021__positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862),0.14824631765465485,0.19694872807845967,1.0,0.9977904906741515,1.0,15/43,30.12%,TTK;GDF7;INHA;LEFTY1;BMP7;BMP6;GDF2;SMAD4;GDF15;MSTN;GDF5;INHBC;GDF6;CSNK2B;GDF10
prerank,GO_Biological_Process_2021__positive regulation of protein transport (GO:0051222),-0.14402805528838086,-0.196083806771918,0.9916666666666667,0.9973282015296671,1.0,13/68,17.47%,TNF;ANKRD1;IGF1;ADAM9;TPR;PLA2G1B;OAZ2;ATP2C1;ARHGEF5;OAZ1;MYH10;APBB1;ANG
prerank,Reactome_2022__Translation Initiation Complex Formation R-HSA-72649,0.14305405245676275,0.19055575357218266,0.9831932773109243,0.9987170818295608,1.0,12/56,22.15%,RPS2;RPS25;EIF3C;RPS27L;RPS4Y1;RPS7;RPS21;EIF3G;EIF4A2;EIF3A;EIF2S1;RPS16
prerank,"Reactome_2022__mRNA Activation Upon Binding Of Cap-Binding Complex And eIFs, Subsequent Binding To 43S R-HSA-72662",0.1402401814649822,0.1877986962455126,0.9836065573770492,0.9988654310375373,1.0,12/57,22.15%,RPS2;RPS25;EIF3C;RPS27L;RPS4Y1;RPS7;RPS21;EIF3G;EIF4A2;EIF3A;EIF2S1;RPS16
prerank,GO_Biological_Process_2021__cellular response to amino acid starvation (GO:0034198),0.14206664470497696,0.18615167687366552,1.0,0.9988084702753647,1.0,26/71,33.28%,EIF2AK3;LAMTOR5;MAPK1;ATP6V1G1;ATP6V0C;ATP6V1E2;SEC13;ATP6V0D2;ATP6V1H;RRAGB;MTOR;WDR24;FLCN;CDKN1A;EIF2S1;ATP6V1E1;ATF4;ATP6V0E2;MLST8;RPTOR;MAPK8;SLC38A9;RNF152;ATF2;TCIRG1;RRAGA
prerank,GO_Biological_Process_2021__positive regulation of protein secretion (GO:0050714),0.13560859423134772,0.1842382792686191,1.0,0.9987334442348663,1.0,10/69,12.08%,NLGN2;AACS;GPER1;C1QTNF3;PPID;TMED10;SYTL4;TLR2;ARF6;FGA
prerank,GO_Biological_Process_2021__regulation of pathway-restricted SMAD protein phosphorylation (GO:0060393),0.13995467708613746,0.18277951537769632,0.9926470588235294,0.9985872892834026,1.0,18/54,30.12%,TTK;GDF7;NOG;INHA;SMAD7;LEFTY1;BMP7;BMP6;GDF2;SMAD4;GDF15;MSTN;GDF5;INHBC;GDF6;GREM1;CSNK2B;GDF10
prerank,KEGG_2021_Human__Melanogenesis,0.14264540715015833,0.18219463073136097,1.0,0.9983350992323724,1.0,31/93,31.06%,GSK3B;WNT11;MAPK1;FZD10;WNT2B;FZD1;CREBBP;GNAI1;MC1R;KITLG;WNT10B;DCT;PRKACA;FZD5;WNT9B;PRKCB;PLCB3;CTNNB1;WNT16;ADCY2;TYRP1;CREB1;EDNRB;ADCY4;WNT4;POMC;DVL3;MAP2K1;ADCY7;WNT1;HRAS
prerank,Reactome_2022__Ribosomal Scanning And Start Codon Recognition R-HSA-72702,0.13581518061499503,0.18035548160369058,1.0,0.9982578838291833,1.0,12/56,22.15%,RPS2;RPS25;EIF3C;RPS27L;RPS4Y1;RPS7;RPS21;EIF3G;EIF4A2;EIF3A;EIF2S1;RPS16
prerank,GO_Biological_Process_2021__synapse assembly (GO:0007416),-0.12450366100204574,-0.17008253337442386,1.0,0.9994125220982594,1.0,19/61,30.50%,CDH1;WNT5A;DBNL;PCDHB16;CDH2;PLXNB1;FLRT3;GABRB3;RYK;WNT7A;NRXN2;PCDHB11;PCDHB14;SHANK3;DSCAM;PCDHB4;NLGN4X;SHANK2;IGFN1
